Paclitaxel
Based on 365 publication(s) in Google Scholar
Paclitaxel is a naturally occurring antineoplastic agent and stabilizes tubulin polymerization. Paclitaxel can cause both mitotic arrest and apoptotic cell death. Paclitaxel also induces autophagy.
For research use only. We do not sell to patients.
- Purity: 99.97%
- CAS No.: 33069-62-4
- Formula: C47H51NO14
- Molecular Weight:853.91
-
Storage:
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Publications Citing Use of MedChemExpress (MCE) Paclitaxel
More- Signal Transduct Target Ther. 2025 Dec 15;10(1):406. [Abstract]
- Signal Transduct Target Ther. 2022 Sep 12;7(1):317. [Abstract]
- Nat Med. 2024 Mar;30(3):749-761. [Abstract]
- Cell. 2022 Sep 1;185(18):3356-3374.e22. [Abstract]
- Cell. 2021 Sep 2;184(18):4753-4771.e27. [Abstract]
- Nat Nanotechnol. 2021 Oct;16(10):1150-1160. [Abstract]
- Mol Cancer. 2024 Mar 22;23(1):60. [Abstract]
- Cell Res. 2023 Mar;33(3):215-228. [Abstract]
- Gastroenterology. 2021 Nov;161(5):1601-1614.e23. [Abstract]
- Mater Today. 2025 Sep 2.
- Drug Resist Updat. 2023 Feb 13;68:100951. [Abstract]
- Bioact Mater. 2024 Jun 24:40:445-459. [Abstract]
- Bioact Mater. 2024 May 11:38:384-398. [Abstract]
- Cell Mol Immunol. 2020 May;17(5):496-506. [Abstract]
- Adv Funct Mater. 04 August 2021.
- Mol Cell. 2025 Jun 19;85(12):2320-2336.e9. [Abstract]
- ACS Nano. 2024 Jun 18;18(24):15864-15877. [Abstract]
- ACS Nano. 2024 Mar 19;18(11):8337-8349. [Abstract]
- ACS Nano. 2023 Dec 12;17(23):23535-23544. [Abstract]
- Nat Commun. 2026 Jun 17.
- Nat Commun. 2025 Jul 26;16(1):6911. [Abstract]
- Nat Commun. 2025 May 23;16(1):4793. [Abstract]
- Nat Commun. 2025 Mar 14;16(1):2526. [Abstract]
- Nat Commun. 2024 Feb 6;15(1):1118. [Abstract]
- Nat Commun. 2024 Jan 5;15(1):296. [Abstract]
- Acta Pharm Sin B. 2026 Feb.
- Autophagy. 2021 Dec;17(12):3976-3991. [Abstract]
- Adv Sci (Weinh). 2026 Feb 3:e16660. [Abstract]
- Adv Sci (Weinh). 2025 Nov 21:e12508. [Abstract]
- Adv Sci (Weinh). 2025 Oct 29:e12652. [Abstract]
- Adv Sci (Weinh). 2025 Aug 28:e04922. [Abstract]
- Adv Sci (Weinh). 2025 May 13:e2500362. [Abstract]
- Adv Sci (Weinh). 2025 Apr 24:e2501934. [Abstract]
- Adv Sci (Weinh). 2024 Dec 24:e2409790. [Abstract]
- Adv Sci (Weinh). 2024 Dec 16:e2407387. [Abstract]
- Adv Sci (Weinh). 2024 Dec;11(45):e2405441. [Abstract]
- Adv Sci (Weinh). 2023 Mar;10(9):e2206912. [Abstract]
- J Clin Invest. 2024 Mar 7;134(10):e172716. [Abstract]
- Theranostics. 2024 Jun 17;14(10):3909-3926. [Abstract]
- Theranostics. 2021 Mar 24;11(12):5650-5674. [Abstract]
- Chem Eng J. 2023 Oct 21, 146685.
- Nucleic Acids Res. 2020 Apr 6;48(6):2912-2923. [Abstract]
- J Adv Res. 2025 Mar 17:S2090-1232(25)00186-9. [Abstract]
- Biomaterials. 2022 Oct:289:121800. [Abstract]
- J Exp Clin Cancer Res. 2024 Jun 26;43(1):177. [Abstract]
- J Exp Clin Cancer Res. 2024 Apr 16;43(1):115. [Abstract]
- J Exp Clin Cancer Res. 2023 Sep 4;42(1):228. [Abstract]
- J Exp Clin Cancer Res. 2021 Apr 30;40(1):150. [Abstract]
- Carbohydr Polym. 2024 Dec 15:346:122645. [Abstract]
- Small. 2026 Apr;22(20):e12540. [Abstract]
- J Control Release. 2018 May 10;277:23-34. [Abstract]
- MedComm (2020). 2025 Nov 29;6(12):e70517. [Abstract]
- Research (Wash D C). 2025 Apr 14:29:0177. [Abstract]
- Cell Rep Med. 2026 May 19;7(5):102757. [Abstract]
- Cell Rep Med. 2026 Apr 21;7(4):102691. [Abstract]
- Cell Rep Med. 2025 Apr 2:102053. [Abstract]
- Cell Rep Med. 2023 Feb 21;4(2):100911. [Abstract]
- J Immunother Cancer. 2021 Jul;9(7):e001758. [Abstract]
- Pharmacol Res. 2024 May:203:107174. [Abstract]
- Mater Today Bio. 2026 Feb 24:37:102967. [Abstract]
- Mater Today Bio. 2025 May 10:32:101838. [Abstract]
- Clin Cancer Res. 2023 Dec 15;29(24):5227-5243. [Abstract]
- Cancer Lett. 2024 Sep 12:217232. [Abstract]
- Int J Biol Sci. 2024 Apr 29;20(7):2748-2762. [Abstract]
- Adv Healthc Mater. 2025 Aug 11:e00602. [Abstract]
- Acta Biomater. 2025 Aug:202:248-261. [Abstract]
- Cell Death Dis. 2025 Mar 12;16(1):170. [Abstract]
- Cell Death Dis. 2025 Jan 18;16(1):28. [Abstract]
- Cell Death Dis. 2021 Apr 1;12(4):338. [Abstract]
- Sci China Life Sci. 2025 Aug;68(8):2348-2362. [Abstract]
- Nano Res. 13, 273-281(2020).
- Cell Commun Signal. 2025 Jul 1;23(1):306. [Abstract]
- Cell Commun Signal. 2025 Jun 4;23(1):263. [Abstract]
- Cell Commun Signal. 2025 Jan 13;23(1):22. [Abstract]
- Cell Commun Signal. 2024 Jun 13;22(1):325. [Abstract]
- Dev Cell. 2021 Sep 13;56(17):2440-2454.e6. [Abstract]
- Acta Pharmacol Sin. 2025 Oct 13. [Abstract]
- Acta Pharmacol Sin. 2024 Oct;45(10):2061-2076. [Abstract]
- Acta Pharmacol Sin. 2022 Jul;43(7):1843-1856. [Abstract]
- EMBO Mol Med. 2025 Nov 19. [Abstract]
- Phytomedicine. 2024 Dec:135:156143. [Abstract]
- Phytomedicine. 2024 Dec:135:156155. [Abstract]
- Phytomedicine. 2024 Jan:123:155180. [Abstract]
- Phytomedicine. 2023 Jul 25:116:154909. [Abstract]
- Phytomedicine. 2023 Mar:111:154673. [Abstract]
- Phytomedicine. 2022: 154560.
- Phytomedicine. 2023 Jan:109:154550. [Abstract]
- EMBO J. 2022 Mar 15;41(6):e108946. [Abstract]
- ACS Appl Mater Interfaces. 2026 Mar 11;18(9):13670-13689. [Abstract]
- ACS Appl Mater Interfaces. 2026 Feb 11;18(5):7845-7862. [Abstract]
- ACS Appl Mater Interfaces. 2026 Jan 25. [Abstract]
- Free Radic Biol Med. 2025 Sep 24:241:367-383. [Abstract]
- Cancer Immunol Res. 2023 May 3;11(5):583-599. [Abstract]
- ACS Appl Mater Interfaces. 2021 Aug 4;13(30):35248-35265. [Abstract]
- Food Res Int. 2025 Dec;222(Pt 1):117620. [Abstract]
- NPJ Precis Oncol. 2024 Jun 5;8(1):128. [Abstract]
- NPJ Precis Oncol. 2023 Dec 8;7(1):128. [Abstract]
- Br J Pharmacol. 2025 May 13. [Abstract]
- Br J Pharmacol. 2022 Jul;179(13):3346-3362. [Abstract]
- Cell Syst. 2019 Jul 24;9(1):35-48.e5. [Abstract]
- Biomed Pharmacother. 2024 Oct 28:180:117603. [Abstract]
- J Transl Med. 2024 Sep 27;22(1):871. [Abstract]
- Biomed Pharmacother. 2024 Nov:180:117452. [Abstract]
- Biomed Pharmacother. 2024 Jun 10:176:116871. [Abstract]
- Biomed Pharmacother. 2023 Jul:163:114751. [Abstract]
- J Transl Med. 2022 Oct 2;20(1):444. [Abstract]
- Biomed Pharmacother. 2021 Dec:144:112331. [Abstract]
- Biomed Pharmacother. 2020 Sep;129:110356. [Abstract]
- J Transl Int Med. 2026 Mar 26;14(2):237-258. [Abstract]
- Chin Med J (Engl). 2026 Mar 5;139(5):699-709. [Abstract]
- Stem Cell Res Ther. 2022 May 12;13(1):197. [Abstract]
- Oncogene. 2022 Jan;41(3):427-443. [Abstract]
- Oncogene. 2021 Dec;40(49):6666-6679. [Abstract]
- Cell Chem Biol. 2026 Jan 15;33(1):74-90.e19. [Abstract]
- Cell Chem Biol. 2024 Jul 9:S2451-9456(24)00273-3. [Abstract]
- Cell Chem Biol. 2020 Nov 19;27(11):1359-1370.e8. [Abstract]
- Cell Death Discov. 2026 Jan 9;12(1):11. [Abstract]
- Cell Death Discov. 2025 Nov 10;11(1):520. [Abstract]
- Cell Rep. 2026 Mar 12;45(3):117087. [Abstract]
- Cell Rep. 2023 Nov 12;42(11):113420. [Abstract]
- Cell Rep. 2023 Jan 31;42(1):111916. [Abstract]
- Clin Transl Med. 2025 Jan;15(1):e70193. [Abstract]
- Neural Regen Res. 2023 Dec;18(12):2727-2732. [Abstract]
- Anal Chem. 2023 Apr 11;95(14):6191. [Abstract]
- Thyroid. 2019 Jun;29(6):809-823. [Abstract]
- J Cell Biol. 2026 Jan 5;225(1):e202503083. [Abstract]
- J Cell Biol. 2025 Dec 1;224(12):e202412005. [Abstract]
- Mol Med. 2025 May 6;31(1):172. [Abstract]
- Elife. 2022 May 3;11:e69255. [Abstract]
- Fundam Res. 2023 Mar 17.
- Phytother Res. 2022 Aug;36(8):3313-3324. [Abstract]
- Cell Mol Life Sci. 2025 Feb 27;82(1):96. [Abstract]
- Cell Biosci. 2022 Aug 21;12(1):135. [Abstract]
- J Agric Food Chem. 2019 Feb 13;67(6):1656-1665. [Abstract]
- Ecotoxicol Environ Saf. 2025 Nov 15:307:119433. [Abstract]
- Cancer Cell Int. 2025 Oct 15;25(1):357. [Abstract]
- Cancer Cell Int. 2023 Oct 11;23(1):237. [Abstract]
- Eur J Med Chem. 2024 Sep 18:279:116882. [Abstract]
- Int J Mol Med. 2021 Oct;48(4):193. [Abstract]
- Biochem Pharmacol. 2026 Mar 15:249:117903. [Abstract]
- Breast Cancer Res. 2025 Oct 27;27(1):189. [Abstract]
- Biochem Pharmacol. 2025 Jul 12:241:117159. [Abstract]
- Breast Cancer Res. 2025 Jul 6;27(1):124. [Abstract]
- Biochem Pharmacol. 2023 Aug:214:115634. [Abstract]
- Biochem Pharmacol. 2022 Dec:206:115329. [Abstract]
- Cell Prolif. 2021 May;54(5):e13038. [Abstract]
- Breast Cancer Res. 2021 Mar 4;23(1):29. [Abstract]
- Biochem Pharmacol. 2018 Nov:157:285-293. [Abstract]
- J Gastroenterol. 2026 May 14. [Abstract]
- Mol Cancer Ther. 2026 Mar 24. [Abstract]
- Mol Cancer Ther. 2021 Dec;20(12):2483-2494. [Abstract]
- J Enzyme Inhib Med Chem. 2023 Dec;38(1):2230388. [Abstract]
- Mar Drugs. 2023 Apr 23;21(5):259. [Abstract]
- Biomacromolecules. 2023 Feb 13;24(2):849-857. [Abstract]
- Mol Ther Oncol. 2024 Jun 07.
- Cells. 2026 Feb 23;15(4):383. [Abstract]
- Int J Pharm. 2024 Sep 23:124753. [Abstract]
- J Funct Biomater. 2023 Jul 11;14(7):362. [Abstract]
- Int J Pharm. 2023 Apr 5:636:122846. [Abstract]
- Microchem J. 2025 Oct 15;218:115702.
- Commun Biol. 2025 Jul 3;8(1):989. [Abstract]
- Food Hydrocoll Health. 2025 Jun.
- Commun Biol. 2024 Dec 3;7(1):1612. [Abstract]
- Cancer Immunol Immunother. 2024 Jul 2;73(9):177. [Abstract]
- Gastric Cancer. 2023 Nov;26(6):863-877. [Abstract]
- Commun Biol. 2022 Nov 26;5(1):1295. [Abstract]
- Drug Des Devel Ther. 2021 Feb 15:15:577-588. [Abstract]
- Int J Mol Sci. 2026 Jun 2;27(11):5039. [Abstract]
- Int J Mol Sci. 2025 Nov 28;26(23):11540. [Abstract]
- Int J Oncol. 2026 Jan;68(1):10. [Abstract]
- Biol Direct. 2024 Sep 11;19(1):79. [Abstract]
- Int J Mol Sci. 2023 Sep 13;24(18):14030. [Abstract]
- Eng Comput. 2024;40(3):1469-1499. [Abstract]
- Int J Oncol. 2023 Sep;63(3):103. [Abstract]
- Int J Oncol. 2022 Dec;61(6):148. [Abstract]
- Int J Mol Sci. 2020 Jan 29;21(3):876. [Abstract]
- Biomolecules. 2026 Feb 9;16(2):269. [Abstract]
- Cell Oncol (Dordr). 2024 Dec;47(6):2201-2215. [Abstract]
- Pharmaceuticals (Basel). 2022 Sep 6;15(9):1111. [Abstract]
- Cell Oncol (Dordr). 2022 Feb;45(1):41-56. [Abstract]
- Front Pharmacol. 2021 Apr 15:12:621181. [Abstract]
- ACS Appl Bio Mater. 2026 Jun 1;9(11):4723-4739. [Abstract]
- Eur J Pharmacol. 2026 Mar 28:1019:178674. [Abstract]
- Int Immunopharmacol. 2025 Jul 30:163:115273. [Abstract]
- Int J Cancer. 2024 Jul 15;155(2):324-338. [Abstract]
- Bioorg Chem. 2024 Jun 17:150:107569. [Abstract]
- Eur J Pharmacol. 2024 Jun 15:973:176592. [Abstract]
- J Mol Cell Cardiol. 2022 Dec:173:101-114. [Abstract]
- Eur J Pharmacol. 2022 Aug 5:928:175130. [Abstract]
- Eur J Pharmacol. 2022 May 12;174982. [Abstract]
- Eur J Pharmacol. 2020 Oct 5;884:173359. [Abstract]
- Microbiologyopen. 2025 Dec;14(6):e70193. [Abstract]
- RSC Adv. 2023 Oct 12;13(43):29847-29861. [Abstract]
- Molecules. 2022 Sep 9;27(18):5841. [Abstract]
- Molecules. 2020 Mar 5;25(5):1162. [Abstract]
- Cell Rep Methods. 2026 Jun 15;6(6):101339. [Abstract]
- Cell Rep Methods. 2023 Oct 23;3(10):100599. [Abstract]
- J Biomed Inform. 2023 Jun:142:104383. [Abstract]
- Gene Ther. 2023 Feb;30(1-2):88-100. [Abstract]
- Mol Pharm. 2018 Nov 5;15(11):4884-4897. [Abstract]
- BJU Int. 2025 Nov 3. [Abstract]
- Cancers (Basel). 2023 Oct 18;15(20):5033. [Abstract]
- Cancers. 2020 Aug 4;12(8):2169. [Abstract]
- Cancer Sci. 2025 Dec 5. [Abstract]
- ACS Omega. 2025 Nov 3;10(44):52202-52214. [Abstract]
- ACS Omega. 2025 Oct 29;10(44):52562-52575. [Abstract]
- Biol Proced Online. 2025 Jun 16;27(1):21. [Abstract]
- Mol Neurobiol. 2022 Aug;59(8):5056-5069. [Abstract]
- Front Cell Dev Biol. 2021 Sep 14:9:729965. [Abstract]
- Biochim Biophys Acta Mol Basis Dis. 2025 Jul 4;1871(7):167971. [Abstract]
- FASEB J. 2024 May 31;38(10):e23661. [Abstract]
- J Cell Mol Med. 2023 Aug;27(16):2385-2397. [Abstract]
- Exp Neurol. 2023 Mar:361:114315. [Abstract]
- J Cell Mol Med. 2020 Jan;24(1):385-397. [Abstract]
- FASEB J. 2019 Apr;33(4):5520-5534. [Abstract]
- iScience. 2025 Apr 23;28(6):112509. [Abstract]
- iScience. 2024 Nov 28;27(12):111488. [Abstract]
- iScience. 2024 Jul 1;27(8):110434. [Abstract]
- iScience. 2024 Feb 9;27(3):109160. [Abstract]
- Transl Oncol. 2023 Oct:36:101746. [Abstract]
- Transl Oncol. 2022 Dec:26:101540. [Abstract]
- iScience. 2022 Sep 6;25(10):105081. [Abstract]
- Adv Ther. 2024 Jul 18.
- Sci Rep. 2026 Jan 21;16(1):5921. [Abstract]
- Sci Rep. 2025 Jun 4;15(1):19590. [Abstract]
- Sci Rep. 2024 Nov 29;14(1):29661. [Abstract]
- Oncol Rep. 2024 Jul;52(1):94. [Abstract]
- J Biol Chem. 2022 Nov;298(11):102588. [Abstract]
- Biomedicines. 2021 Dec 10;9(12):1873. [Abstract]
- Aging. 2020 Mar 22;12(6):5336-5351. [Abstract]
- Bioconjug Chem. 2020 Mar 18;31(3):781-793. [Abstract]
- Sci Rep. 2019 Oct 22;9(1):15099. [Abstract]
- Sci Rep. 2019 Sep 24;9(1):13786. [Abstract]
- Sci Rep. 2019 Aug 12;9(1):11677. [Abstract]
- Sci Rep. 2019 Apr 15;9(1):6032. [Abstract]
- J Pharmacol Exp Ther. 2025 Sep 3;392(10):103692. [Abstract]
- J Pharm Sci. 2019 Nov;108(11):3592-3598. [Abstract]
- PLoS Genet. 2026 Jun 3;22(6):e1012191. [Abstract]
- ACS Pharmacol Transl Sci. 2025 Jul 7;8(8):2612-2629. [Abstract]
- Cell Signal. 2024 Dec 3:111534. [Abstract]
- Cell Signal. 2024 Mar:115:111034. [Abstract]
- Brain Res Bull. 2022 Dec:191:30-39. [Abstract]
- Biochim Biophys Acta. 2018 May;1862(5):1134-1147. [Abstract]
- Heliyon. 2024 May 20;10(11):e31431. [Abstract]
- Exp Cell Res. 2026 Aug 1;461(1):115103. [Abstract]
- Transl Lung Cancer Res. 2025 Jun 30;14(6):2159-2179. [Abstract]
- Transl Lung Cancer Res. 2024 Oct 31;13(10):2698-2712. [Abstract]
- Exp Cell Res. 2023 Nov 15;432(2):113793. [Abstract]
- Exp Cell Res. 2020 Aug 1;393(1):112054. [Abstract]
- Food Chem Toxicol. 2019 Apr:126:56-66. [Abstract]
- Phytochemistry. 2025 Dec 2:243:114735. [Abstract]
- Eur J Med Res. 2025 Aug 4;30(1):704. [Abstract]
- BMC Cancer. 2025 Jan 7;25(1):24. [Abstract]
- Toxicol Appl Pharmacol. 2024 Aug 9:117066. [Abstract]
- Toxicol Appl Pharmacol. 2024 Feb:483:116807. [Abstract]
- Cell Cycle. 2022 May;21(10):1058-1076. [Abstract]
- Int J Med Sci. 2026 Jan 1;23(1):161-176. [Abstract]
- Mol Carcinog. 2024 Aug;63(8):1449-1466. [Abstract]
- Mol Carcinog. 2020 May;59(5):512-519. [Abstract]
- Environ Toxicol. 2020 May;35(5):561-569. [Abstract]
- Hum Cell. 2025 Jun 2;38(4):115. [Abstract]
- Hum Cell. 2023 Jul;36(4):1485-1500. [Abstract]
- Hum Cell. 2021 Jul;34(4):1244-1254. [Abstract]
- Cancer Med. 2019 May;8(5):2462-2473. [Abstract]
- Curr Issues Mol Biol. 2024 Dec 11;46(12):13951-13969. [Abstract]
- Mol Immunol. 2021 Oct:138:1-9. [Abstract]
- Micromachines. 2021 Jun 10;12(6):681. [Abstract]
- 3 Biotech. 2025 Jan;15(1):7. [Abstract]
- Plasma Process Polym. 2021 Feb 12.
- Am J Cancer Res. 2019 Oct 1;9(10):2233-2248. [Abstract]
- Am J Cancer Res. 2017 Apr 1;7(4):903-912. [Abstract]
- J Biochem Mol Toxicol. 2023 Aug;37(8):e23380. [Abstract]
- Onco Targets Ther. 2020 May 4;13:3777-3788. [Abstract]
- Neuroscience. 2020 Feb 1;426:168-178. [Abstract]
- Onco Targets Ther. 2019 Sep 26;12:7897-7909. [Abstract]
- S Afr J Bot. 2026 Feb 9.
- BMC Pregnancy Childbirth. 2024 Oct 28;24(1):705. [Abstract]
- Invest New Drugs. 2022 Apr;40(2):274-289. [Abstract]
- Invest New Drugs. 2021 Aug;39(4):949-960. [Abstract]
- SLAS Discov. 2018 Aug;23(7):687-696. [Abstract]
- Cancer Manag Res. 2020 Dec 8:12:12623-12633. [Abstract]
- J Nat Med. 2025 Apr 8. [Abstract]
- Mol Biotechnol. 2024 Sep;66(9):2558-2568. [Abstract]
- Clin Transl Oncol. 2022 Nov;24(11):2231-2240. [Abstract]
- Tissue Cell. 2022 Aug:77:101815. [Abstract]
- Clin Exp Pharmacol Physiol. 2020 Apr;47(4):677-686. [Abstract]
- Eur J Neurosci. 2021 Aug;54(4):5341-5356. [Abstract]
- Behav Brain Res. 2024 May 28:115075. [Abstract]
- Thorac Cancer. 2020 Oct;11(10):2858-2866. [Abstract]
- FEBS Open Bio. 2020 Aug;10(8):1655-1667. [Abstract]
- Cancer Chemother Pharmacol. 2019 Nov;84(5):1133-1143. [Abstract]
- Anticancer Drugs. 2026 Jan 14. [Abstract]
- Oncol Lett. 2025 Oct 21;30(6):607. [Abstract]
- J Gene Med. 2024 Sep;26(9):e3737. [Abstract]
- Biochem Biophys Res Commun. 2024 Jan 8:691:149314. [Abstract]
- Biochem Biophys Res Commun. 2023 Aug 20:669:61-67. [Abstract]
- Oncol Lett. 2023 Feb 15;25(4):134. [Abstract]
- Bioorg Med Chem Lett. 2022 Jul 1;67:128731. [Abstract]
- Biochem Biophys Res Commun. 2020 Jan 15;521(3):596-602. [Abstract]
- Biochem Biophys Res Commun. 2018 May 23;499(4):927-933. [Abstract]
- Mol Cell Oncol. 2025 Dec 31;13(1):2604899. [Abstract]
- Biomed Chromatogr. 2024 Aug 17:e5984. [Abstract]
- Anticancer Res. 2022 Jan;42(1):599-608. [Abstract]
- Biochem Genet. 2025 Nov 22. [Abstract]
- Am J Transl Res. 2024 May 15;16(5):2132-2146. [Abstract]
- Curr Med Sci. 2025 Feb;45(1):104-113. [Abstract]
- Braz J Med Biol Res. 2024 Jul 1:57:e13357. [Abstract]
- J Asian Nat Prod Res. 2025 Jun 18:1-17. [Abstract]
- STAR Protoc. 2025 Jan 7;6(1):103539. [Abstract]
- J Asthma. 2024 Oct;61(10):1328-1336. [Abstract]
- Eur J Inflamm. 2021 Mar 11.
- bioRxiv. 2026 Jun 3.
- medRxiv. 2026 Apr 18.
- bioRxiv. 2026 Apr 29.
- University of Califomia San Francisco. 2026.
- Res Sq. 2026 Mar 26.
- bioRxiv. 2026 Mar 15.
- bioRxiv. 2026 Mar 27.
- Res Sq. 2026 Feb 26.
- bioRxiv. 2026 Feb 18:2026.02.16.706212. [Abstract]
- Res Sq. 2026 Jan 9.
- Res Sq. 2025 Dec 10.
- chemRxiv. 2025 Oct 22.
- Patent. US20250319053A1.
- SSRN. 2025 Sep 26.
- bioRxiv. 2025 Sep 21.
- Res Sq. 2025 Sep 7.
- Ursinus College. 2025.
- SSRN. 2025 Aug 27.
- bioRxiv. 2025 Aug 27:2025.08.22.671824. [Abstract]
- bioRxiv. 2025 Jul 12:2025.07.08.663754. [Abstract]
- bioRxiv. 2025 May 24.
- Complutense University of Madrid. 2025.
- bioRxiv. 2025 April 17.
- SSRN. 2025 Mar 17.
- Patent. US20240344020A1
- Res Sq. 2024 Oct 14.
- Patent. US20240344020A1.
- Res Sq. 2024 Sep 11.
- bioRxiv. 2024 Aug 21:2024.08.20.608802. [Abstract]
- bioRxiv. 2024 August 26.
- bioRxiv. 2024 June 12.
- SSRN. 2024 Mar 20.
- Research Square Preprint. 2024 Jan 7.
- Preprints. 2024 Jan 26.
- Universitat de València. 2023 May.
- Research Square Preprint. 2023 Jul 20.
- University of Gothenburg. 2023 Jun 27.
- bioRxiv. 2023 May 12.
- bioRxiv. 2023 Feb 28.
- Arch Cancer Res. 2023 Jan 30.
- AfricArXiv Preprints. 2212.
- Research Square Print. September 27th, 2022.
- Research Square Preprint. 2022 Feb.
- Research Square Preprint. 2021 Nov.
- Research Square Preprint. 2021 Jul.
- Health Sci J. (2021): 1-7.
- South Dakota State University. 2021 Apr.
- Research Square Preprint. 2021 Feb.
- Adıyaman University Journal of Science. 2020; 10(2): 427-440.
- Universitat Politècnica de València. 2020 Jul.
- bioRxiv. 2020 Jun.
- bioRxiv. September 11, 2018.
- Universidade do Porto. 2015-11-16.
- Universidade do Porto. 2015 Sep.
-
Cell Proliferation/Viability Assay
-
Cell Proliferation/Viability Assay
-
RT-PCR
-
Cell Proliferation/Viability Assay
-
WB
Biological Activity
|
Traditional Cytotoxic Agents |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| 143B | IC50 |
5.56 μM
Compound: Paclitaxel
|
Antiproliferative activity against human 143B cells after 48 hrs by MTT assay
Antiproliferative activity against human 143B cells after 48 hrs by MTT assay
|
[PMID: 29223717] |
| 184B5 | IC50 |
2.32 μM
Compound: Paclitaxel
|
Antiproliferative activity against human 184B5 cells after 72 hrs by SRB assay
Antiproliferative activity against human 184B5 cells after 72 hrs by SRB assay
|
[PMID: 26602827] |
| 1A9 | ED50 |
0.002 μg/mL
Compound: Paclitaxel
|
Effective dose required for inhibitory activity against 1A9 human tumor cell line.
Effective dose required for inhibitory activity against 1A9 human tumor cell line.
|
[PMID: 12852747] |
| 1A9 | ED50 |
0.002 μg/mL
Compound: paclitaxel
|
Cytotoxicity against human 1A9 cells after 3 days by SRB assay
Cytotoxicity against human 1A9 cells after 3 days by SRB assay
|
[PMID: 14640511] |
| 1A9 | ED50 |
0.041 μg/mL
Compound: paclitaxel
|
Cytotoxicity against human 1A9 cells after 6 days by SRB assay
Cytotoxicity against human 1A9 cells after 6 days by SRB assay
|
[PMID: 14640511] |
| 1A9 | IC50 |
0.002 μM
Compound: Paclitaxel
|
Cytotoxicity against human 1A9 cells after 3 days by SRB assay
Cytotoxicity against human 1A9 cells after 3 days by SRB assay
|
[PMID: 16038545] |
| 1A9 | IC50 |
21.5 nM
Compound: 1a, PTX
|
Inhibition of growth in epothilone A resistant 1A9-A8 T-beta-274I mutant cell line after 72 hrs by SRB assay
Inhibition of growth in epothilone A resistant 1A9-A8 T-beta-274I mutant cell line after 72 hrs by SRB assay
|
[PMID: 17263521] |
| 1A9 | IC50 |
4.8 nM
Compound: 1a, PTX
|
Inhibition of growth in 1A9 cell line after 72 hrs
Inhibition of growth in 1A9 cell line after 72 hrs
|
[PMID: 17263521] |
| 1A9 | ED50 |
1 nM
Compound: 1
|
Cytotoxicity against human 1A9 cells by sulforhodamine B assay
Cytotoxicity against human 1A9 cells by sulforhodamine B assay
|
[PMID: 17350834] |
| 1A9 | GI50 |
0.71 nM
Compound: paclitaxel
|
Growth inhibition of human 1A9 cells after 72 hrs
Growth inhibition of human 1A9 cells after 72 hrs
|
[PMID: 17542572] |
| 1A9 | ED50 |
0.001 μg/mL
Compound: 1
|
Cytotoxicity against human 1A9 cells by sulforhodamine B assay
Cytotoxicity against human 1A9 cells by sulforhodamine B assay
|
[PMID: 17643301] |
| 1A9 | ED50 |
2.09 nM
Compound: Paclitaxel
|
Antiproliferative activity against human 1A9 cells after 3 days by sulforhodamine B assay
Antiproliferative activity against human 1A9 cells after 3 days by sulforhodamine B assay
|
[PMID: 21296579] |
| 1A9 | IC50 |
3.9 nM
Compound: Paclitaxel, Taxol
|
Cytotoxicity against human 1A9 cells by MTT assay
Cytotoxicity against human 1A9 cells by MTT assay
|
[PMID: 25047938] |
| 1A9 | IC50 |
3.71 nM
Compound: 7
|
Cytotoxicity against human 1A9 cells
Cytotoxicity against human 1A9 cells
|
[PMID: 28850227] |
| 1A9 | GI50 |
5.2 nM
Compound: Taxol
|
Induction of microtubule stabilization in human 1A9 cells assessed as inhibition of cell growth incubated for 72 hrs by Celltiter reagent-based assay
Induction of microtubule stabilization in human 1A9 cells assessed as inhibition of cell growth incubated for 72 hrs by Celltiter reagent-based assay
|
[PMID: 31191870] |
| 1A9/ptx-10 | ED50 |
0.041 μg/mL
Compound: Paclitaxel
|
Effective dose required for inhibitory activity against PTX10 human tumor cell line
Effective dose required for inhibitory activity against PTX10 human tumor cell line
|
[PMID: 12852747] |
| 1A9/ptx-10 | IC50 |
30 nM
Compound: 6
|
Cytotoxicity against human 1A9PTX10 cells
Cytotoxicity against human 1A9PTX10 cells
|
[PMID: 17206139] |
| 1A9/ptx-10 | IC50 |
157 nM
Compound: 1a, PTX
|
Inhibition of growth in paclitaxel resistant 1A9-PTX10 F-beta-270V mutant cell line after 72 hrs by SRB assay
Inhibition of growth in paclitaxel resistant 1A9-PTX10 F-beta-270V mutant cell line after 72 hrs by SRB assay
|
[PMID: 17263521] |
| 1A9/ptx-10 | GI50 |
64 nM
Compound: paclitaxel
|
Growth inhibition of beta tubulin Phe270Val mutant expressing human 1A9/Ptx10 cells after 72 hrs
Growth inhibition of beta tubulin Phe270Val mutant expressing human 1A9/Ptx10 cells after 72 hrs
|
[PMID: 17542572] |
| 1A9/ptx-10 | IC50 |
532.95 nM
Compound: paclitaxel
|
Cytotoxicity against paclitaxel resistant human 1A9PTX10 cells expressing class 1 beta-tubulin mutant after 72 hrs
Cytotoxicity against paclitaxel resistant human 1A9PTX10 cells expressing class 1 beta-tubulin mutant after 72 hrs
|
[PMID: 18465846] |
| 1A9/ptx-10 | IC50 |
532.95 nM
Compound: paclitaxel
|
Cytotoxicity against paclitaxel-resistant human 1A9PTX10 cells harboring point mutation in beta-tubulin after 72 hrs
Cytotoxicity against paclitaxel-resistant human 1A9PTX10 cells harboring point mutation in beta-tubulin after 72 hrs
|
[PMID: 19239240] |
| 1A9/ptx-10 | IC50 |
532.95 nM
Compound: Taxol
|
Cytotoxicity against paclitaxel-resistant human 1A9PTX10 cells
Cytotoxicity against paclitaxel-resistant human 1A9PTX10 cells
|
[PMID: 24680057] |
| 1A9/ptx-10 | IC50 |
81.4 nM
Compound: Paclitaxel, Taxol
|
Cytotoxicity against human 1A9PTX10 cells by MTT assay
Cytotoxicity against human 1A9PTX10 cells by MTT assay
|
[PMID: 25047938] |
| 1A9/ptx-22 | IC50 |
19 nM
Compound: 6
|
Cytotoxicity against human 1A9PTX22 cells
Cytotoxicity against human 1A9PTX22 cells
|
[PMID: 17206139] |
| 1A9/ptx-22 | GI50 |
51 nM
Compound: paclitaxel
|
Growth inhibition of beta tubulin A364T mutant expressing human 1A9/Ptx22 cells after 72 hrs
Growth inhibition of beta tubulin A364T mutant expressing human 1A9/Ptx22 cells after 72 hrs
|
[PMID: 17542572] |
| 1A9/ptx-22 | IC50 |
160.7 nM
Compound: paclitaxel
|
Cytotoxicity against paclitaxel resistant human 1A9PTX22 cells expressing class 1 beta-tubulin mutant after 72 hrs
Cytotoxicity against paclitaxel resistant human 1A9PTX22 cells expressing class 1 beta-tubulin mutant after 72 hrs
|
[PMID: 18465846] |
| 1A9/ptx-22 | IC50 |
160.7 nM
Compound: paclitaxel
|
Cytotoxicity against paclitaxel-resistant human 1A9PTX22 cells harboring point mutation in beta-tubulin after 72 hrs
Cytotoxicity against paclitaxel-resistant human 1A9PTX22 cells harboring point mutation in beta-tubulin after 72 hrs
|
[PMID: 19239240] |
| 1A9/ptx-22 | IC50 |
160.7 nM
Compound: Taxol
|
Cytotoxicity against paclitaxel-resistant human 1A9PTX22 cells
Cytotoxicity against paclitaxel-resistant human 1A9PTX22 cells
|
[PMID: 24680057] |
| 1A9/ptx-22 | IC50 |
32.8 nM
Compound: Paclitaxel, Taxol
|
Cytotoxicity against human 1A9PTX22 cells by MTT assay
Cytotoxicity against human 1A9PTX22 cells by MTT assay
|
[PMID: 25047938] |
| 2008 | GI50 |
0.0092 nM
Compound: Paclitaxel
|
Inhibitory concentration against 2008 (ovarian) cells
Inhibitory concentration against 2008 (ovarian) cells
|
[PMID: 12825928] |
| 2008 | GI50 |
3 nM
Compound: PTX, Taxol
|
Growth inhibition of human 2008 cells
Growth inhibition of human 2008 cells
|
[PMID: 23750455] |
| 4T1 | IC50 |
0.2 μM
Compound: Taxol
|
Cytotoxicity against mouse 4T1 cells by MTT assay
Cytotoxicity against mouse 4T1 cells by MTT assay
|
[PMID: 16539377] |
| 4T1 | IC50 |
0.094 μM
Compound: Paclitaxel
|
Cytotoxicity activity against mouse 4T1 cells assessed as cell growth inhibition after 48 hrs by MTT assay
Cytotoxicity activity against mouse 4T1 cells assessed as cell growth inhibition after 48 hrs by MTT assay
|
[PMID: 30433783] |
| 4T1 | IC50 |
0.001 mM
Compound: Taxol
|
Antiproliferative activity against mouse 4T1 cells incubated for 24 hrs by MTT assay
Antiproliferative activity against mouse 4T1 cells incubated for 24 hrs by MTT assay
|
[PMID: 31857837] |
| 4T1 | IC50 |
0.8 μM
Compound: Paclitaxel
|
Cytotoxicity against mouse 4T1 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
Cytotoxicity against mouse 4T1 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
|
[PMID: 34018743] |
| 4T1 | IC50 |
0.094 μM
Compound: Taxol
|
Cytotoxicity against mouse 4T1 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay
Cytotoxicity against mouse 4T1 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay
|
[PMID: 34704758] |
| 4T1 | IC50 |
3.84 μM
Compound: Taxol
|
Antiproliferative activity against mouse 4T1 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
Antiproliferative activity against mouse 4T1 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
|
[PMID: 39044437] |
| 5637 | IC50 |
0.002 μM
Compound: PTX
|
Cytotoxicity against human 5637 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay
Cytotoxicity against human 5637 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay
|
[PMID: 38547648] |
| 769-P | IC50 |
7.1 μM
Compound: Paclitaxel
|
Cytotoxicity against human 769-P cells by MTT assay
Cytotoxicity against human 769-P cells by MTT assay
|
[PMID: 20122764] |
| 769-P | IC50 |
7.1 μM
Compound: Paclitaxel
|
Cytotoxicity against human 769-P cells by MTT assay
Cytotoxicity against human 769-P cells by MTT assay
|
[PMID: 20627721] |
| 769-P | IC50 |
7.1 μM
Compound: Paclitaxel
|
Cytotoxicity against human 769-P cells by MTT assay
Cytotoxicity against human 769-P cells by MTT assay
|
[PMID: 20716468] |
| 769-P | IC50 |
7.1 μM
Compound: Paclitaxel
|
Cytotoxicity against human 769-P cells by MTT assay
Cytotoxicity against human 769-P cells by MTT assay
|
[PMID: 21875764] |
| 786-0 | IC50 |
<0.08 μM
Compound: Paclitaxel
|
Cytotoxicity against human 786-0 cells by MTT assay
Cytotoxicity against human 786-0 cells by MTT assay
|
[PMID: 20122764] |
| 786-0 | IC50 |
<0.08 μM
Compound: Paclitaxel
|
Cytotoxicity against human 786-0 cells by MTT assay
Cytotoxicity against human 786-0 cells by MTT assay
|
[PMID: 20627721] |
| 786-0 | IC50 |
<0.08 μM
Compound: Paclitaxel
|
Cytotoxicity against human 786-0 cells by MTT assay
Cytotoxicity against human 786-0 cells by MTT assay
|
[PMID: 20716468] |
| 786-0 | IC50 |
31 nM
Compound: Paclitaxel
|
Antiproliferative activity against MDR-1 overexpressing human 786-0 cells
Antiproliferative activity against MDR-1 overexpressing human 786-0 cells
|
[PMID: 21774499] |
| 786-0 | IC50 |
4 nM
Compound: Paclitaxel
|
Antiproliferative activity against MDR-1 overexpressing human 786-0 cells in presence of MDR1 inhibitor verapamil
Antiproliferative activity against MDR-1 overexpressing human 786-0 cells in presence of MDR1 inhibitor verapamil
|
[PMID: 21774499] |
| 786-0 | IC50 |
<0.08 μM
Compound: Paclitaxel
|
Cytotoxicity against human 786-0 cells by MTT assay
Cytotoxicity against human 786-0 cells by MTT assay
|
[PMID: 21875764] |
| 786-0 | GI50 |
0.02 μM
Compound: PCT
|
Growth inhibition of human 786-0 cells after 48 hrs by sulforhodamine B assay
Growth inhibition of human 786-0 cells after 48 hrs by sulforhodamine B assay
|
[PMID: 24727464] |
| 786-0 | GI50 |
39 nM
Compound: Paclitaxel
|
Growth inhibition of human 786-0 cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human 786-0 cells incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 29655610] |
| 786-0 | GI50 |
39 nM
Compound: Paclitaxel
|
Cytotoxicity against human 786-0 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay
Cytotoxicity against human 786-0 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay
|
[PMID: 33310545] |
| 786-0 | IC50 |
<0.01 μM
Compound: Taxol
|
Anticancer activity against human 786-0 cells assessed as inhibition of cell proliferation measured after 72 hrs by CCK8 reagent assay
Anticancer activity against human 786-0 cells assessed as inhibition of cell proliferation measured after 72 hrs by CCK8 reagent assay
|
[PMID: 34399390] |
| 786-0 | IC50 |
2.55 nM
Compound: PTX
|
Antiproliferative activity against human 786-O cells incubated for 72 hrs by MTT assay
Antiproliferative activity against human 786-O cells incubated for 72 hrs by MTT assay
|
[PMID: 34648295] |
| A 172 | GI50 |
0.01 μM
Compound: taxol
|
Cytotoxicity against human A172 cells after 72 hrs by MTT colorimetric assay
Cytotoxicity against human A172 cells after 72 hrs by MTT colorimetric assay
|
[PMID: 19081249] |
| A 172 | GI50 |
0.01 μM
Compound: Taxol
|
Cytotoxicity against human A172 cells after 72 hrs by MTT assay
Cytotoxicity against human A172 cells after 72 hrs by MTT assay
|
[PMID: 20538462] |
| A 172 | GI50 |
0.01 μM
Compound: Paclitaxel
|
Cytotoxicity against human A-172 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
Cytotoxicity against human A-172 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
|
[PMID: 31945642] |
| A10 | IC50 |
38 nM
Compound: Paclitaxel
|
Growth inhibition of rat A10 cells
Growth inhibition of rat A10 cells
|
[PMID: 19601594] |
| A121 | IC50 |
6.1 nM
Compound: paclitaxel
|
In vitro cytotoxicity against human ovarian carcinoma A21
In vitro cytotoxicity against human ovarian carcinoma A21
|
[PMID: 8182698] |
| A121 | IC50 |
6.3 nM
Compound: paclitaxel
|
Concentration required to inhibit growth of human tumor A121 (ovarian) cell line.
Concentration required to inhibit growth of human tumor A121 (ovarian) cell line.
|
[PMID: 8831755] |
| A121 | IC50 |
6.1 nM
Compound: Paclitaxel
|
Growth inhibition of human ovarian carcinoma (A121) cell line
Growth inhibition of human ovarian carcinoma (A121) cell line
|
[PMID: 9022793] |
| A121 | IC50 |
6.1 nM
Compound: Paclitaxel
|
Inhibition of the growth against human Ovarian Carcinoma (A121) cell line after 72 hr exposure
Inhibition of the growth against human Ovarian Carcinoma (A121) cell line after 72 hr exposure
|
[PMID: 9022794] |
| A121 | IC50 |
6.1 nM
Compound: Paclitaxel
|
Cytotoxicity against human A121 ovarian cells
Cytotoxicity against human A121 ovarian cells
|
10.1016/S0960-894X(01)80298-5 |
| A121 | IC50 |
6.1 nM
Compound: Paclitaxel
|
Cytotoxicity was evaluated in vitro against A121 (ovarian carcinoma) human tumor cell lines
Cytotoxicity was evaluated in vitro against A121 (ovarian carcinoma) human tumor cell lines
|
10.1016/S0960-894X(01)80568-0 |
| A121 | IC50 |
6.3 nM
Compound: Paclitaxel
|
Cytotoxicity was evaluated against A121 ovarian carcinoma human cancer cell line
Cytotoxicity was evaluated against A121 ovarian carcinoma human cancer cell line
|
10.1016/S0960-894X(96)00595-1 |
| A2058 | IC50 |
0.0047 μM
Compound: Taxol
|
Cytotoxicity against human A2058 cells after 96 hrs by CellTire-Glo luminescent assay
Cytotoxicity against human A2058 cells after 96 hrs by CellTire-Glo luminescent assay
|
[PMID: 23623678] |
| A2780 | IC50 |
0.136 μg/mL
Compound: 1
|
Cytotoxicity against human A2780 cells
Cytotoxicity against human A2780 cells
|
[PMID: 12193017] |
| A2780 | IC50 |
2688 nM
Compound: Taxol
|
In vitro cytotoxicity against A2780ADR cell line
In vitro cytotoxicity against A2780ADR cell line
|
[PMID: 14584931] |
| A2780 | IC50 |
4.6 nM
Compound: Taxol
|
In vitro cytotoxicity against A2780CIS cell line
In vitro cytotoxicity against A2780CIS cell line
|
[PMID: 14584931] |
| A2780 | IC50 |
4498 nM
Compound: Taxol
|
In vitro cytotoxicity against A2780TAX cell line
In vitro cytotoxicity against A2780TAX cell line
|
[PMID: 14584931] |
| A2780 | IC50 |
5.3 nM
Compound: Taxol
|
In vitro cytotoxicity against A2780 cell line
In vitro cytotoxicity against A2780 cell line
|
[PMID: 14584931] |
| A2780 | IC50 |
25 nM
Compound: 1
|
Cytotoxicity against human A2780 cells after 48 hrs by MTS method
Cytotoxicity against human A2780 cells after 48 hrs by MTS method
|
[PMID: 14987051] |
| A2780 | IC50 |
0.00676 μg/mL
Compound: Paclitaxel
|
Inhibitory concentration against A2780 proliferation after 72 hr
Inhibitory concentration against A2780 proliferation after 72 hr
|
[PMID: 15664868] |
| A2780 | IC50 |
1.1 nM
Compound: Paclitaxel
|
Inhibitory concentration of compound required for exhibiting cytotoxic effect on human A2780 cells; no. of experiment=4
Inhibitory concentration of compound required for exhibiting cytotoxic effect on human A2780 cells; no. of experiment=4
|
[PMID: 15837302] |
| A2780 | IC50 |
1 nM
Compound: 6
|
Cytotoxicity against human A2780 cells
Cytotoxicity against human A2780 cells
|
[PMID: 17206139] |
| A2780 | IC50 |
0.7 nM
Compound: taxol
|
Cytotoxicity againt human A2780 cells
Cytotoxicity againt human A2780 cells
|
[PMID: 17239597] |
| A2780 | IC50 |
15 nM
Compound: 1a, PTX
|
Cytotoxicity against A2780 cell line
Cytotoxicity against A2780 cell line
|
[PMID: 17263521] |
| A2780 | IC50 |
0.0016 μM
Compound: 1
|
Cytotoxicity against A2780 cells by MTT assay
Cytotoxicity against A2780 cells by MTT assay
|
[PMID: 17395465] |
| A2780 | IC50 |
25 nM
Compound: 1
|
Cytotoxicity against ERbeta negative human A2780 cells
Cytotoxicity against ERbeta negative human A2780 cells
|
[PMID: 17419065] |
| A2780 | IC50 |
2.8 nM
Compound: Paclitaxel
|
Growth inhibition of human A2780 cells
Growth inhibition of human A2780 cells
|
[PMID: 17490878] |
| A2780 | IC50 |
0.0063 μM
Compound: paclitaxel
|
Cytotoxicity against human A2780 cells by MTT assay
Cytotoxicity against human A2780 cells by MTT assay
|
[PMID: 18001087] |
| A2780 | IC50 |
23.4 nM
Compound: paclitaxel
|
Antiproliferative activity against human A2780 cells after 96 hrs by CellTiter-Glo luminescent cell viability assay
Antiproliferative activity against human A2780 cells after 96 hrs by CellTiter-Glo luminescent cell viability assay
|
[PMID: 18177014] |
| A2780 | IC50 |
1.38 nM
Compound: paclitaxel
|
Cytotoxicity against human A2780 cells after 72 hrs
Cytotoxicity against human A2780 cells after 72 hrs
|
[PMID: 18465846] |
| A2780 | EC50 |
>10 μM
Compound: paclitaxel
|
Induction of mitotic arrest in human A2780 cells expressing MDR1 after 16 hrs
Induction of mitotic arrest in human A2780 cells expressing MDR1 after 16 hrs
|
[PMID: 18578472] |
| A2780 | IC50 |
23.4 nM
Compound: Paclitaxel
|
Antiproliferative activity against human A2780 cells after 2 days by alamar-blue assay
Antiproliferative activity against human A2780 cells after 2 days by alamar-blue assay
|
[PMID: 19028102] |
| A2780 | IC50 |
1.3 nM
Compound: 1a
|
Cytotoxicity against human A2780 cells after 48 hrs by MTT assay
Cytotoxicity against human A2780 cells after 48 hrs by MTT assay
|
[PMID: 19128972] |
| A2780 | IC50 |
980 nM
Compound: 1a
|
Cytotoxicity against p-glycoprotein expressing drug-resistant human A2780 cells after 48 hrs by MTT assay
Cytotoxicity against p-glycoprotein expressing drug-resistant human A2780 cells after 48 hrs by MTT assay
|
[PMID: 19128972] |
| A2780 | IC50 |
0.13 ng/mL
Compound: paclitaxel
|
Cytotoxicity against human A2780 cells after 72 hrs by MTT assay
Cytotoxicity against human A2780 cells after 72 hrs by MTT assay
|
[PMID: 19136258] |
| A2780 | IC50 |
1.38 nM
Compound: paclitaxel
|
Cytotoxicity against human A2780 cells after 72 hrs
Cytotoxicity against human A2780 cells after 72 hrs
|
[PMID: 19239240] |
| A2780 | IC50 |
1.7 nM
Compound: paclitaxel
|
Cytotoxicity against human wild type A2780 cells after 72 hrs
Cytotoxicity against human wild type A2780 cells after 72 hrs
|
[PMID: 19239240] |
| A2780 | IC50 |
2.2 nM
Compound: paclitaxel
|
Cytotoxicity against human cisplatin-resistant A2780 cells after 72 hrs
Cytotoxicity against human cisplatin-resistant A2780 cells after 72 hrs
|
[PMID: 19239240] |
| A2780 | IC50 |
386 nM
Compound: paclitaxel
|
Resistance factor, ratio of IC50 for human A2780 cells to IC50 for paclitaxel-resistant human 1A9PTX10 cells harboring point mutation in beta-tubulin
Resistance factor, ratio of IC50 for human A2780 cells to IC50 for paclitaxel-resistant human 1A9PTX10 cells harboring point mutation in beta-tubulin
|
[PMID: 19239240] |
| A2780 | IC50 |
7.2 nM
Compound: paclitaxel
|
Cytotoxicity against human topotecan-resistant A2780 cells after 72 hrs
Cytotoxicity against human topotecan-resistant A2780 cells after 72 hrs
|
[PMID: 19239240] |
| A2780 | IC50 |
0.014 μM
Compound: Paclitaxel
|
Cytotoxicity against human A2780 cells
Cytotoxicity against human A2780 cells
|
[PMID: 19282186] |
| A2780 | IC50 |
14.9 nM
Compound: 1,PTX
|
Cytotoxicity against human A2780 cells after 4 days by sulforhodamine B assay
Cytotoxicity against human A2780 cells after 4 days by sulforhodamine B assay
|
[PMID: 19359169] |
| A2780 | IC50 |
1.7 nM
Compound: Paclitaxel
|
Growth inhibition of human wild type A2780 cells after 72 hrs
Growth inhibition of human wild type A2780 cells after 72 hrs
|
[PMID: 19423340] |
| A2780 | IC50 |
1239 nM
Compound: Paclitaxel
|
Growth inhibition of human adriamycin and doxorubicin-resistant A2780 cells after 72 hrs
Growth inhibition of human adriamycin and doxorubicin-resistant A2780 cells after 72 hrs
|
[PMID: 19423340] |
| A2780 | IC50 |
2.2 nM
Compound: Paclitaxel
|
Growth inhibition of human cisplatin-resistant A2780 cells after 72 hrs
Growth inhibition of human cisplatin-resistant A2780 cells after 72 hrs
|
[PMID: 19423340] |
| A2780 | IC50 |
5898 nM
Compound: Paclitaxel
|
Resistant factor, IC50 for human paclitaxel-resistant A2780TC1 cells overexpressing class 3 beta-tubulin to IC50 for human wild type A2780 cells
Resistant factor, IC50 for human paclitaxel-resistant A2780TC1 cells overexpressing class 3 beta-tubulin to IC50 for human wild type A2780 cells
|
[PMID: 19423340] |
| A2780 | IC50 |
7.2 nM
Compound: Paclitaxel
|
Growth inhibition of human topotecan-resistant A2780 cells after 72 hrs
Growth inhibition of human topotecan-resistant A2780 cells after 72 hrs
|
[PMID: 19423340] |
| A2780 | IC50 |
7.9 nM
Compound: paclitaxel
|
Cytotoxicity against human A2780 cells by MTT assay
Cytotoxicity against human A2780 cells by MTT assay
|
[PMID: 19708679] |
| A2780 | IC50 |
2.8 nM
Compound: Paclitaxel
|
Cytotoxicity against human A2780 cells by MTT cell proliferation assay
Cytotoxicity against human A2780 cells by MTT cell proliferation assay
|
[PMID: 19877653] |
| A2780 | IC50 |
0.9 μM
Compound: paclitaxel
|
Cytotoxicity against human A2780 cells after 96 hrs by MTT assay
Cytotoxicity against human A2780 cells after 96 hrs by MTT assay
|
[PMID: 20560647] |
| A2780 | IC50 |
0.65 μM
Compound: paclitaxel
|
Cytotoxicity against human A2780 cells after 3 days by MTT assay
Cytotoxicity against human A2780 cells after 3 days by MTT assay
|
[PMID: 20593839] |
| A2780 | IC50 |
<1 x 10-9 M
Compound: Taxol
|
Cytotoxicity against human A2780 cells after 72 hrs by MTT assay
Cytotoxicity against human A2780 cells after 72 hrs by MTT assay
|
[PMID: 20719510] |
| A2780 | IC50 |
0.02 μM
Compound: Paclitaxel
|
Cytotoxicity against human A2780 cells after 72 hrs by SRB assay
Cytotoxicity against human A2780 cells after 72 hrs by SRB assay
|
[PMID: 20800500] |
| A2780 | IC50 |
0.01 μM
Compound: Paclitaxel
|
Cytotoxicity against human A2780 cells after 48 to 72 hrs by WAT-1 assay
Cytotoxicity against human A2780 cells after 48 to 72 hrs by WAT-1 assay
|
[PMID: 21126027] |
| A2780 | IC50 |
0.00082 μM
Compound: Taxol
|
Cytotoxicity against compound-sensitive human A2780 cells after 24 hrs by MTT assay
Cytotoxicity against compound-sensitive human A2780 cells after 24 hrs by MTT assay
|
[PMID: 21396747] |
| A2780 | IC50 |
<1 x 10-9 M
Compound: Taxol
|
Cytotoxicity against human A2780 cells after 72 hrs by MTT assay
Cytotoxicity against human A2780 cells after 72 hrs by MTT assay
|
[PMID: 21530251] |
| A2780 | IC50 |
0.62 nM
Compound: 1a
|
Cytotoxicity against human A2780 cells after 48 hrs by MTT assay
Cytotoxicity against human A2780 cells after 48 hrs by MTT assay
|
[PMID: 21764308] |
| A2780 | IC50 |
14 nM
Compound: 2
|
Cytotoxicity against human A2780 cells after 2 days by Alamar blue assay
Cytotoxicity against human A2780 cells after 2 days by Alamar blue assay
|
[PMID: 21802957] |
| A2780 | GI50 |
0.27 nM
Compound: Paclitaxel
|
Growth inhibition of human A2780 cells
Growth inhibition of human A2780 cells
|
[PMID: 21986585] |
| A2780 | IC50 |
0.017 μM
Compound: Paclitaxel
|
Antiproliferative activity against human A2780 cells
Antiproliferative activity against human A2780 cells
|
[PMID: 21995542] |
| A2780 | IC50 |
0.015 μM
Compound: 1a, Taxol
|
Antiproliferative activity against human A2780 cells after 2 days by alamar blue assay
Antiproliferative activity against human A2780 cells after 2 days by alamar blue assay
|
[PMID: 22071526] |
| A2780 | IC50 |
0.02 μM
Compound: paclitaxel
|
Antiproliferative activity against human A2780 cells after 2 days by Alamar blue assay
Antiproliferative activity against human A2780 cells after 2 days by Alamar blue assay
|
[PMID: 22136523] |
| A2780 | IC50 |
<0.001 μM
Compound: paclitaxel
|
Cytotoxicity against human A2780 cells after 72 hrs by MTT assay
Cytotoxicity against human A2780 cells after 72 hrs by MTT assay
|
[PMID: 22583079] |
| A2780 | IC50 |
1.1 μM
Compound: Paclitaxel
|
Cytotoxicity against human A2780 cells assessed as growth inhibition
Cytotoxicity against human A2780 cells assessed as growth inhibition
|
[PMID: 23103097] |
| A2780 | IC50 |
0.028 μM
Compound: Paclitaxel
|
Antiproliferative activity against human A2780 cells after 2 days by alamar blue assay
Antiproliferative activity against human A2780 cells after 2 days by alamar blue assay
|
[PMID: 23149304] |
| A2780 | IC50 |
0.02 μM
Compound: Taxol
|
Cytotoxicity against human A2780S cells by MTT assay
Cytotoxicity against human A2780S cells by MTT assay
|
[PMID: 23425970] |
| A2780 | IC50 |
8.25 μM
Compound: Taxol
|
Cytotoxicity against taxol-resistant human A2780 cells by MTT assay
Cytotoxicity against taxol-resistant human A2780 cells by MTT assay
|
[PMID: 23425970] |
| A2780 | IC50 |
<0.001 μM
Compound: Paclitaxel
|
Cytotoxicity against human A2780 cells by MTT assay
Cytotoxicity against human A2780 cells by MTT assay
|
[PMID: 23547884] |
| A2780 | IC50 |
0.012 μM
Compound: Taxol
|
Cytotoxicity against human A2780 cells after 2 days by alamar Blue assay
Cytotoxicity against human A2780 cells after 2 days by alamar Blue assay
|
[PMID: 23623678] |
| A2780 | IC50 |
0.028 μM
Compound: Taxol
|
Cytotoxicity against human A2780 cells assessed as growth inhibition
Cytotoxicity against human A2780 cells assessed as growth inhibition
|
[PMID: 23659371] |
| A2780 | IC50 |
0.024 μM
Compound: Paclitaxel
|
Antiproliferative activity against human A2780 cells after 2 days by Alamar Blue assay
Antiproliferative activity against human A2780 cells after 2 days by Alamar Blue assay
|
[PMID: 24239390] |
| A2780 | IC50 |
0.59 μM
Compound: Taxol
|
Cytotoxicity against human A2780 cells after 96 hrs by MTT assay
Cytotoxicity against human A2780 cells after 96 hrs by MTT assay
|
[PMID: 24467317] |
| A2780 | IC50 |
1.38 nM
Compound: Taxol
|
Cytotoxicity against human A2780 cells
Cytotoxicity against human A2780 cells
|
[PMID: 24680057] |
| A2780 | IC50 |
0.4 nM
Compound: Paclitaxel, Taxol
|
Cytotoxicity against human A2780 cells by MTT assay
Cytotoxicity against human A2780 cells by MTT assay
|
[PMID: 25047938] |
| A2780 | IC50 |
0.015 μM
Compound: TAX, Taxol
|
Antiproliferative activity against human A2780 cells after 48 hrs by SRB method
Antiproliferative activity against human A2780 cells after 48 hrs by SRB method
|
[PMID: 25061803] |
| A2780 | IC50 |
2.9 μM
Compound: TAX, Taxol
|
Antiproliferative activity against taxol-resistant human A2780 cells after 48 hrs by SRB method
Antiproliferative activity against taxol-resistant human A2780 cells after 48 hrs by SRB method
|
[PMID: 25061803] |
| A2780 | IC50 |
107 nM
Compound: taxol
|
Antiproliferative activity against taxol resistant human A2780S cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay
Antiproliferative activity against taxol resistant human A2780S cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay
|
[PMID: 25208345] |
| A2780 | IC50 |
4 nM
Compound: taxol
|
Antiproliferative activity against human A2780S cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay
Antiproliferative activity against human A2780S cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay
|
[PMID: 25208345] |
| A2780 | IC50 |
0.006 μM
Compound: 6
|
Antiproliferative activity against human A2780 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
Antiproliferative activity against human A2780 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
|
[PMID: 25682561] |
| A2780 | IC50 |
0.028 μM
Compound: taxol, Paclitaxel
|
Antiproliferative activity against human A2780 cells assessed as inhibition of cell growth incubated for 2 days by alamar blue assay
Antiproliferative activity against human A2780 cells assessed as inhibition of cell growth incubated for 2 days by alamar blue assay
|
[PMID: 26042470] |
| A2780 | IC50 |
5.87 x 10-7 mg/mL
Compound: Taxol
|
Cytotoxicity against human A2780 cells after 72 hrs by MTT assay
Cytotoxicity against human A2780 cells after 72 hrs by MTT assay
|
[PMID: 26920798] |
| A2780 | IC50 |
0.005 μM
Compound: TAX
|
Cytotoxicity against human A2780 cells assessed as cell viability after 48 hrs by MTT assay
Cytotoxicity against human A2780 cells assessed as cell viability after 48 hrs by MTT assay
|
[PMID: 27149641] |
| A2780 | IC50 |
3.8 x 10-2 μM
Compound: Paclitaxel
|
Cytotoxicity against human A2780 cells by MTT assay
Cytotoxicity against human A2780 cells by MTT assay
|
[PMID: 27441892] |
| A2780 | IC50 |
0.028 μM
Compound: Paclitaxel
|
Antiproliferative activity against human A2780 cells after 2 days by alamar blue assay
Antiproliferative activity against human A2780 cells after 2 days by alamar blue assay
|
[PMID: 28463001] |
| A2780 | IC50 |
1.07 nM
Compound: 1
|
Cytotoxicity against human A2780 cells assessed as decrease in cell viability after 48 hrs by MTT assay
Cytotoxicity against human A2780 cells assessed as decrease in cell viability after 48 hrs by MTT assay
|
[PMID: 28624703] |
| A2780 | IC50 |
0.03 μM
Compound: Taxol
|
Growth inhibition of human A2780 cells incubated for 3 days by SRB assay
Growth inhibition of human A2780 cells incubated for 3 days by SRB assay
|
[PMID: 28625363] |
| A2780 | IC50 |
13.7 nM
Compound: Taxol
|
Antiproliferative activity against human A2780 cells after 2 days by Alamar blue assay
Antiproliferative activity against human A2780 cells after 2 days by Alamar blue assay
|
[PMID: 28648491] |
| A2780 | IC50 |
164.2 nM
Compound: Paclitaxel
|
Cytotoxicity against human A2780 cells after 48 hrs by MTT assay
Cytotoxicity against human A2780 cells after 48 hrs by MTT assay
|
[PMID: 28719204] |
| A2780 | IC50 |
0.0204 μM
Compound: Taxol
|
Growth inhibition of human A2780 cells after 96 hrs by MTT assay
Growth inhibition of human A2780 cells after 96 hrs by MTT assay
|
[PMID: 28737396] |
| A2780 | IC50 |
0.013 μM
Compound: Paclitaxel
|
Cytotoxicity against human A2780 cells after 2 days by Alamar blue assay
Cytotoxicity against human A2780 cells after 2 days by Alamar blue assay
|
[PMID: 29048892] |
| A2780 | IC50 |
0.001 μM
Compound: PTX
|
Antiproliferative activity against human A2780 cells after 48 hrs by MTT assay
Antiproliferative activity against human A2780 cells after 48 hrs by MTT assay
|
[PMID: 29306206] |
| A2780 | IC50 |
13.4 nM
Compound: 1a
|
Cytotoxicity against human A2780 cells assessed as decrease in cell viability after 48 hrs by MTT assay
Cytotoxicity against human A2780 cells assessed as decrease in cell viability after 48 hrs by MTT assay
|
[PMID: 29359935] |
| A2780 | IC50 |
0.009 μM
Compound: Paclitaxel
|
Growth inhibition of human A2780 cells after 72 hrs by SRB assay
Growth inhibition of human A2780 cells after 72 hrs by SRB assay
|
[PMID: 29519737] |
| A2780 | IC50 |
0.05 μM
Compound: Paclitaxel
|
Growth inhibition of human A2780 cells after 48 hrs by MTT assay
Growth inhibition of human A2780 cells after 48 hrs by MTT assay
|
[PMID: 29519737] |
| A2780 | IC50 |
0.013 μM
Compound: Paclitaxel
|
Cytotoxicity against human A2780 cells assessed as inhibition of cell growth after 2 days by Alamar blue assay
Cytotoxicity against human A2780 cells assessed as inhibition of cell growth after 2 days by Alamar blue assay
|
[PMID: 29738243] |
| A2780 | IC50 |
0.013 μM
Compound: Paclitaxel
|
Antiproliferative activity against human A2780 cells assessed as reduction in cell viability incubated for 48 hrs by Alamar blue assay
Antiproliferative activity against human A2780 cells assessed as reduction in cell viability incubated for 48 hrs by Alamar blue assay
|
[PMID: 30354100] |
| A2780 | IC50 |
3.3 nM
Compound: 1
|
Cytotoxicity against human A2780 cells after 48 hrs by MTT assay
Cytotoxicity against human A2780 cells after 48 hrs by MTT assay
|
[PMID: 30448418] |
| A2780 | IC50 |
2.8 nM
Compound: Paclitaxel
|
Cytotoxicity against human A2780 cells after 48 hrs by MTT assay
Cytotoxicity against human A2780 cells after 48 hrs by MTT assay
|
[PMID: 30455148] |
| A2780 | IC50 |
0.0015 μM
Compound: PTX
|
Growth inhibition human A2780 cells after 72 hrs by MTS assay
Growth inhibition human A2780 cells after 72 hrs by MTS assay
|
[PMID: 30633861] |
| A2780 | IC50 |
2.85 μM
Compound: PTX
|
Cytotoxicity against human A2780 cells incubated for 48 hrs by MTT assay
Cytotoxicity against human A2780 cells incubated for 48 hrs by MTT assay
|
[PMID: 30913525] |
| A2780 | EC50 |
2.4 nM
Compound: Paclitaxel
|
Antiproliferative activity against D4-9-31 resistance human A2780 cells incubated for 72 hrs by ATPlite reagent based assay
Antiproliferative activity against D4-9-31 resistance human A2780 cells incubated for 72 hrs by ATPlite reagent based assay
|
[PMID: 31047749] |
| A2780 | EC50 |
2.5 nM
Compound: Paclitaxel
|
Antiproliferative activity against human A2780 cells incubated for 72 hrs by ATPlite reagent based assay
Antiproliferative activity against human A2780 cells incubated for 72 hrs by ATPlite reagent based assay
|
[PMID: 31047749] |
| A2780 | IC50 |
0.41 μM
Compound: Paclitaxel
|
Antiproliferative activity against human A2780 cells incubated for 48 hrs by MTT assay
Antiproliferative activity against human A2780 cells incubated for 48 hrs by MTT assay
|
[PMID: 31279299] |
| A2780 | IC50 |
0.018 μM
Compound: Paclitaxel
|
Antiproliferative activity against human A2780 cells measured after 72 hrs by sulforhodamine B assay
Antiproliferative activity against human A2780 cells measured after 72 hrs by sulforhodamine B assay
|
[PMID: 31465222] |
| A2780 | IC50 |
0.013 μM
Compound: Paclitaxel
|
Cytotoxicity against human A2780 cells assessed as reduction in cell viability after 2 days by AlamarBlue assay
Cytotoxicity against human A2780 cells assessed as reduction in cell viability after 2 days by AlamarBlue assay
|
[PMID: 31577436] |
| A2780 | IC50 |
0.013 μM
Compound: Paclitaxel
|
Antiproliferative activity against human A2780 cells assessed as reduction in cell viability after 2 days hrs by AlamarBlue assay
Antiproliferative activity against human A2780 cells assessed as reduction in cell viability after 2 days hrs by AlamarBlue assay
|
[PMID: 32227943] |
| A2780 | IC50 |
2 nM
Compound: Paclitaxel
|
Antiproliferative activity against human A2780 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay
Antiproliferative activity against human A2780 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay
|
[PMID: 32339854] |
| A2780 | IC50 |
15.2 nM
Compound: PTX
|
Cytotoxicity against human A2780 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay
Cytotoxicity against human A2780 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay
|
[PMID: 33280896] |
| A2780 | IC50 |
0.019 μM
Compound: Taxol
|
Anticancer activity against human A2780 cells by MTT assay
Anticancer activity against human A2780 cells by MTT assay
|
[PMID: 33316408] |
| A2780 | IC50 |
0.021 μM
Compound: TAX
|
Antiproliferative activity against human A2780 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
Antiproliferative activity against human A2780 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
|
[PMID: 34649064] |
| A2780 | IC50 |
0.002 μM
Compound: PTX
|
Antiproliferative activity against human A2780 cells after 48 hrs by MTT assay
Antiproliferative activity against human A2780 cells after 48 hrs by MTT assay
|
[PMID: 35065411] |
| A2780 | IC50 |
0.02 μM
Compound: TAX
|
Antiproliferative activity against human A2780 cells assessed as cell viability incubated for 48 hrs by MTT assay
Antiproliferative activity against human A2780 cells assessed as cell viability incubated for 48 hrs by MTT assay
|
[PMID: 35282680] |
| A2780 | IC50 |
0.27 μM
Compound: TAX
|
Antiproliferative activity against human paclitaxel-resistant A2780/TAX cells assessed as cell viability incubated for 48 hrs by MTT assay
Antiproliferative activity against human paclitaxel-resistant A2780/TAX cells assessed as cell viability incubated for 48 hrs by MTT assay
|
[PMID: 35282680] |
| A2780 | IC50 |
0.006 μM
Compound: Paclitaxel
|
Antiproliferative activity against human A2780 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
Antiproliferative activity against human A2780 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
|
[PMID: 36621138] |
| A2780 | IC50 |
2.3 nM
Compound: 1a; PTX
|
Antiproliferative activity against human A2780 cells assessed as inhibition of cell viability by MTT assay
Antiproliferative activity against human A2780 cells assessed as inhibition of cell viability by MTT assay
|
[PMID: 37490800] |
| A2780 | IC50 |
0.028 μM
Compound: 2
|
Antiproliferative activity against human A2780 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay
Antiproliferative activity against human A2780 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay
|
[PMID: 37856840] |
| A2780 | IC50 |
3.4 nM
Compound: Paclitaxel
|
Antiproliferative activity against human A2780 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
Antiproliferative activity against human A2780 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
|
[PMID: 38294341] |
| A2780 | IC50 |
0.008 μM
Compound: PTX
|
Cytotoxicity against human A2780 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay
Cytotoxicity against human A2780 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay
|
[PMID: 38547648] |
| A2780 | IC50 |
1.31 nM
Compound: Paclitaxel
|
Antiproliferative activity against human A2780 cells incubated for 48 hrs by CCK8 assay
Antiproliferative activity against human A2780 cells incubated for 48 hrs by CCK8 assay
|
[PMID: 38972078] |
| A2780 | IC50 |
2.7 nM
Compound: paclitaxel
|
Cytotoxicity against A2780-WT, human ovarian carcinoma cell line
Cytotoxicity against A2780-WT, human ovarian carcinoma cell line
|
[PMID: 8831755] |
| A2780 | IC50 |
3.4 nM
Compound: paclitaxel
|
Cytotoxicity against A2780-C25, oxaliplatin-resistant Ovarian carcinoma cell line
Cytotoxicity against A2780-C25, oxaliplatin-resistant Ovarian carcinoma cell line
|
[PMID: 8831755] |
| A2780 | IC50 |
4.1 nM
Compound: paclitaxel
|
Cytotoxicity against A2780-CP3, cisplatin-resistant Ovarian carcinoma cell line
Cytotoxicity against A2780-CP3, cisplatin-resistant Ovarian carcinoma cell line
|
[PMID: 8831755] |
| A2780 | IC50 |
547 nM
Compound: paclitaxel
|
Cytotoxicity against A2780-DX5, Doxorubicin-resistant Ovarian carcinoma cell line
Cytotoxicity against A2780-DX5, Doxorubicin-resistant Ovarian carcinoma cell line
|
[PMID: 8831755] |
| A2780 | IC50 |
3.4 nM
Compound: taxol
|
Concentration of compound to inhibit the growth of human A2780 ovarian carcinoma cells(in vitro)
Concentration of compound to inhibit the growth of human A2780 ovarian carcinoma cells(in vitro)
|
[PMID: 9288161] |
| A2780 ADR | IC50 |
1500 nM
Compound: Paclitaxel
|
Inhibitory concentration measured in term of cytotoxicity against human A2780/AD10 cells
Inhibitory concentration measured in term of cytotoxicity against human A2780/AD10 cells
|
[PMID: 15837302] |
| A2780 ADR | IC50 |
900 nM
Compound: 6
|
Cytotoxicity against human A2780AD cells
Cytotoxicity against human A2780AD cells
|
[PMID: 17206139] |
| A2780 ADR | IC50 |
535 nM
Compound: taxol
|
Cytotoxicity againt multidrug-resistant human 2780AD cells
Cytotoxicity againt multidrug-resistant human 2780AD cells
|
[PMID: 17239597] |
| A2780 ADR | IC50 |
0.92 μM
Compound: 1
|
Cytotoxicity against A2780/AD cells by MTT assay
Cytotoxicity against A2780/AD cells by MTT assay
|
[PMID: 17395465] |
| A2780 ADR | IC50 |
183 nM
Compound: Paclitaxel
|
Growth inhibition of multidrug-resistant human 2780AD cells
Growth inhibition of multidrug-resistant human 2780AD cells
|
[PMID: 17490878] |
| A2780 ADR | IC50 |
1239 nM
Compound: paclitaxel
|
Cytotoxicity against human A2780/ADR cells after 72 hrs
Cytotoxicity against human A2780/ADR cells after 72 hrs
|
[PMID: 19239240] |
| A2780 ADR | IC50 |
415 nM
Compound: Paclitaxel
|
Cytotoxicity against p-glycoprotein overexpressing human A2780AD cells by MTT cell proliferation assay
Cytotoxicity against p-glycoprotein overexpressing human A2780AD cells by MTT cell proliferation assay
|
[PMID: 19877653] |
| A2780 ADR | IC50 |
0.949 μM
Compound: Taxol
|
Cytotoxicity against compound-resistant human A2780AD cells after 24 hrs by MTT assay
Cytotoxicity against compound-resistant human A2780AD cells after 24 hrs by MTT assay
|
[PMID: 21396747] |
| A2780 ADR | IC50 |
1900 nM
Compound: 1a
|
Cytotoxicity against multidrug-resistant human A2780AD cells overexpressing p-gp after 48 hrs by MTT assay
Cytotoxicity against multidrug-resistant human A2780AD cells overexpressing p-gp after 48 hrs by MTT assay
|
[PMID: 21764308] |
| A2780 ADR | IC50 |
>1000 μM
Compound: Paclitaxel
|
Cytotoxicity against multidrug-resistant human A2780AD cells overexpressing p-gp assessed as growth inhibition
Cytotoxicity against multidrug-resistant human A2780AD cells overexpressing p-gp assessed as growth inhibition
|
[PMID: 23103097] |
| A2780 ADR | IC50 |
>1000 nM
Compound: paclitaxel
|
Cytotoxicity against human A2780AD cells expressing p-gp after 96 hrs by MTT assay
Cytotoxicity against human A2780AD cells expressing p-gp after 96 hrs by MTT assay
|
[PMID: 23176628] |
| A2780 ADR | IC50 |
1244 nM
Compound: Paclitaxel, Taxol
|
Cytotoxicity against human A2780AD cells by MTT assay
Cytotoxicity against human A2780AD cells by MTT assay
|
[PMID: 25047938] |
| A2780/Taxol | IC50 |
56600 nM
Compound: Paclitaxel
|
Cytotoxicity against beta-tubulin 3 overexpressing human A2780T cells assessed as reduction in cell growth after 24 hrs by MTT assay
Cytotoxicity against beta-tubulin 3 overexpressing human A2780T cells assessed as reduction in cell growth after 24 hrs by MTT assay
|
[PMID: 27213819] |
| A2780/Taxol | IC50 |
25120 nM
Compound: Paclitaxel
|
Antiproliferative activity against human A2780T cells after 48 hrs by MTT assay
Antiproliferative activity against human A2780T cells after 48 hrs by MTT assay
|
[PMID: 28763646] |
| A2780/Taxol | IC50 |
72967.4 nM
Compound: Taxol
|
Antiproliferative activity against human A2780T cells after 48 to 72 hrs by MTT assay
Antiproliferative activity against human A2780T cells after 48 to 72 hrs by MTT assay
|
[PMID: 29754076] |
| A2780/Taxol | IC50 |
>500 nM
Compound: Paclitaxel
|
Antiproliferative activity against paclitaxel-resistant human A2780T cells assessed as reduction in cell viability measured after 48 hrs by MTT assay
Antiproliferative activity against paclitaxel-resistant human A2780T cells assessed as reduction in cell viability measured after 48 hrs by MTT assay
|
[PMID: 32339854] |
| A2780/Taxol | IC50 |
3164 nM
Compound: Paclitaxel
|
Antiproliferative activity against human A2780T cells assessed as reduction in cell viability measured after 48 hrs by MTT assay
Antiproliferative activity against human A2780T cells assessed as reduction in cell viability measured after 48 hrs by MTT assay
|
[PMID: 33788562] |
| A2780/Taxol | IC50 |
3422 nM
Compound: PTX
|
Antiproliferative activity against human A2780T cells incubated for 72 hrs by MTT assay
Antiproliferative activity against human A2780T cells incubated for 72 hrs by MTT assay
|
[PMID: 34648295] |
| A2780/Taxol | IC50 |
58855 nM
Compound: PTX
|
Cytotoxicity in human A2780T assessed as inhibition in cell growth measured after 24 hrs by MTT assay
Cytotoxicity in human A2780T assessed as inhibition in cell growth measured after 24 hrs by MTT assay
|
[PMID: 35084853] |
| A2780/Taxol | IC50 |
17.938 μM
Compound: Paclitaxel
|
Antiproliferative activity against paclitaxel resistant human A2780/Taxol cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
Antiproliferative activity against paclitaxel resistant human A2780/Taxol cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
|
[PMID: 36621138] |
| A2780/Taxol | IC50 |
4.42 μM
Compound: PTX
|
Reversal of multi-drug resistance in human A2780/Taxol cells incubated for 48 hrs by MTT assay
Reversal of multi-drug resistance in human A2780/Taxol cells incubated for 48 hrs by MTT assay
|
[PMID: 36871374] |
| A2780/Taxol | IC50 |
2015.6 nM
Compound: Paclitaxel
|
Antiproliferative activity against paclitaxel resistant human A2780/Taxol cells assessed as inhibition of cell proliferation incubated for 48 hrs by MTT assay
Antiproliferative activity against paclitaxel resistant human A2780/Taxol cells assessed as inhibition of cell proliferation incubated for 48 hrs by MTT assay
|
[PMID: 37145846] |
| A2780/Taxol | IC50 |
0.319 μM
Compound: 2
|
Antiproliferative activity against human A2780T cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay
Antiproliferative activity against human A2780T cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay
|
[PMID: 37856840] |
| A2780/Taxol | IC50 |
55857 nM
Compound: PTX
|
Antiproliferative activity against human A2780T cells assessed as reduction in cell viability measured after 72 hrs
Antiproliferative activity against human A2780T cells assessed as reduction in cell viability measured after 72 hrs
|
[PMID: 38430854] |
| A2780/Taxol | IC50 |
>500 nM
Compound: PTX
|
Antiproliferative activity against paclitaxel resistant human A2780/Taxol cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay
Antiproliferative activity against paclitaxel resistant human A2780/Taxol cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay
|
[PMID: 38996194] |
| A2780cis | IC50 |
0.003 μM
Compound: Paclitaxel
|
Growth inhibition of human A2780cis cells after 72 hrs by MTT assay
Growth inhibition of human A2780cis cells after 72 hrs by MTT assay
|
[PMID: 29519737] |
| A2780S | IC50 |
58.1 nM
Compound: Paclitaxel
|
Antiproliferative activity against human A2780S cells after 24 hrs by MTT assay
Antiproliferative activity against human A2780S cells after 24 hrs by MTT assay
|
[PMID: 27213819] |
| A2780S | IC50 |
12.3 nM
Compound: Paclitaxel
|
Antiproliferative activity against human A2780S cells after 48 hrs by MTT assay
Antiproliferative activity against human A2780S cells after 48 hrs by MTT assay
|
[PMID: 28763646] |
| A2780S | IC50 |
18.94 nM
Compound: Taxol
|
Antiproliferative activity against human A2780S cells after 48 to 72 hrs by MTT assay
Antiproliferative activity against human A2780S cells after 48 to 72 hrs by MTT assay
|
[PMID: 29754076] |
| A2780S | IC50 |
7.5 nM
Compound: Paclitaxel
|
Antiproliferative activity against human A2780S cells assessed as reduction in cell viability measured after 48 hrs by MTT assay
Antiproliferative activity against human A2780S cells assessed as reduction in cell viability measured after 48 hrs by MTT assay
|
[PMID: 33788562] |
| A2780S | IC50 |
5.62 nM
Compound: PTX
|
Antiproliferative activity against human A2780S cells incubated for 72 hrs by MTT assay
Antiproliferative activity against human A2780S cells incubated for 72 hrs by MTT assay
|
[PMID: 34648295] |
| A2780S | IC50 |
60.4 nM
Compound: PTX
|
Cytotoxicity in human A2780S assessed as inhibition in cell growth measured after 24 hrs by MTT assay
Cytotoxicity in human A2780S assessed as inhibition in cell growth measured after 24 hrs by MTT assay
|
[PMID: 35084853] |
| A2780S | IC50 |
2.7 nM
Compound: Paclitaxel
|
Antiproliferative activity against parental human A2780S cells assessed as inhibition of cell proliferation incubated for 48 hrs by MTT assay
Antiproliferative activity against parental human A2780S cells assessed as inhibition of cell proliferation incubated for 48 hrs by MTT assay
|
[PMID: 37145846] |
| A2780S | IC50 |
58.3 nM
Compound: PTX
|
Antiproliferative activity against human A2780S cells assessed as reduction in cell viability measured after 72 hrs
Antiproliferative activity against human A2780S cells assessed as reduction in cell viability measured after 72 hrs
|
[PMID: 38430854] |
| A-375 | IC50 |
0.81 μM
Compound: Paclitaxel
|
Cytotoxicity against human A375 cells by MTT assay
Cytotoxicity against human A375 cells by MTT assay
|
[PMID: 20122764] |
| A-375 | IC50 |
0.81 μM
Compound: Paclitaxel
|
Cytotoxicity against human A375 cells by MTT assay
Cytotoxicity against human A375 cells by MTT assay
|
[PMID: 20627721] |
| A-375 | IC50 |
0.81 μM
Compound: Paclitaxel
|
Cytotoxicity against human A375 cells by MTT assay
Cytotoxicity against human A375 cells by MTT assay
|
[PMID: 20716468] |
| A-375 | IC50 |
4.6 nM
Compound: Taxol
|
Antiproliferative activity against human A375 cells after 96 hrs by MTT assay
Antiproliferative activity against human A375 cells after 96 hrs by MTT assay
|
[PMID: 21296467] |
| A-375 | IC50 |
8.9 x 10-3 μM
Compound: Paclitaxel
|
Cytotoxicity against human A375 cells after 72 hrs by MTS assay
Cytotoxicity against human A375 cells after 72 hrs by MTS assay
|
[PMID: 21812410] |
| A-375 | IC50 |
0.81 μM
Compound: Paclitaxel
|
Cytotoxicity against human A375 cells by MTT assay
Cytotoxicity against human A375 cells by MTT assay
|
[PMID: 21875764] |
| A-375 | IC50 |
4.9 x 10-3 μM
Compound: Paclitaxel
|
Cytotoxicity against human A375 cells by MTT assay
Cytotoxicity against human A375 cells by MTT assay
|
[PMID: 21928797] |
| A-375 | IC50 |
9.2 x 10-3 μM
Compound: Paclitaxel
|
Cytotoxicity against human A375 cells assessed as reduction in cell viability after 72 hrs by MTT assay
Cytotoxicity against human A375 cells assessed as reduction in cell viability after 72 hrs by MTT assay
|
[PMID: 22871217] |
| A-375 | IC50 |
8 μM
Compound: Pacli
|
Cytotoxicity against human A375 cells after 48 hrs by MTT assay
Cytotoxicity against human A375 cells after 48 hrs by MTT assay
|
[PMID: 25563891] |
| A-375 | IC50 |
8.9 x 10-3 μM
Compound: paclitaxel
|
Cytotoxicity against human A375 cells assessed as reduction in cell viability by MTS assay
Cytotoxicity against human A375 cells assessed as reduction in cell viability by MTS assay
|
[PMID: 25760674] |
| A-375 | IC50 |
2.2 x 10-2 μM
Compound: Paclitaxel
|
Cytotoxicity against human A375 cells by MTT assay
Cytotoxicity against human A375 cells by MTT assay
|
[PMID: 27441892] |
| A-375 | IC50 |
11.26 μM
Compound: Paclitaxel
|
Cytotoxicity against human A375 cells measured after 24 hrs by MTT assay
Cytotoxicity against human A375 cells measured after 24 hrs by MTT assay
|
[PMID: 27769031] |
| A-375 | IC50 |
0.01 μM
Compound: Paclitaxel
|
Antiproliferative activity against human A375 cells after 72 hrs by CellTiter96 AQueous nonradioactive cell proliferation assay
Antiproliferative activity against human A375 cells after 72 hrs by CellTiter96 AQueous nonradioactive cell proliferation assay
|
[PMID: 28335606] |
| A-375 | IC50 |
0.7 μM
Compound: Paclitaxel
|
Antiproliferative activity against human A375 cells after 48 hrs by MTT assay
Antiproliferative activity against human A375 cells after 48 hrs by MTT assay
|
[PMID: 28667872] |
| A-375 | IC50 |
47.8 nM
Compound: Paclitaxel
|
Antiproliferative activity against human A375 cells after 72 hrs by MTS assay
Antiproliferative activity against human A375 cells after 72 hrs by MTS assay
|
[PMID: 30099258] |
| A-375 | IC50 |
0.1 μM
Compound: Paclitaxel
|
Cytotoxicity activity against human A375 cells assessed as cell growth inhibition after 48 hrs by MTT assay
Cytotoxicity activity against human A375 cells assessed as cell growth inhibition after 48 hrs by MTT assay
|
[PMID: 30433783] |
| A-375 | IC50 |
15.8 μM
Compound: Paclitaxel
|
Cytotoxicity against human A375 spheroid cells assessed as reduction in spheroid cell viability after 48 hrs by MTT assay
Cytotoxicity against human A375 spheroid cells assessed as reduction in spheroid cell viability after 48 hrs by MTT assay
|
[PMID: 30433783] |
| A-375 | IC50 |
0.002 μM
Compound: PTX
|
Cytotoxicity against human A375 cells assessed as cell growth inhibition after 48 hrs by sulforhodamine B assay
Cytotoxicity against human A375 cells assessed as cell growth inhibition after 48 hrs by sulforhodamine B assay
|
[PMID: 30633861] |
| A-375 | GI50 |
0.01 μM
Compound: Taxol
|
Antiproliferative activity against human A375 cells assessed as inhibition of cell growth after 48 hrs by sulforhodamine B colorimetric assay
Antiproliferative activity against human A375 cells assessed as inhibition of cell growth after 48 hrs by sulforhodamine B colorimetric assay
|
[PMID: 32199690] |
| A-375 | IC50 |
1.6 nM
Compound: Paclitaxel
|
Cytotoxicity against human A-375 cells measured after 72 hrs by western blot
Cytotoxicity against human A-375 cells measured after 72 hrs by western blot
|
[PMID: 34378386] |
| A-375 | IC50 |
1.7 nM
Compound: Paclitaxel
|
Antiproliferative activity against human A-375 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTS assay
Antiproliferative activity against human A-375 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTS assay
|
[PMID: 34406768] |
| A-375 | IC50 |
0.1 μM
Compound: Taxol
|
Cytotoxicity against human A-375 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay
Cytotoxicity against human A-375 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay
|
[PMID: 34704758] |
| A-375 | IC50 |
0.059 μM
Compound: Taxol
|
Antiproliferative activity against human A-375 cells assessed as reduction in cell viability incubated for 48 hrs by CCk-8 assay
Antiproliferative activity against human A-375 cells assessed as reduction in cell viability incubated for 48 hrs by CCk-8 assay
|
[PMID: 37329677] |
| A-375 | IC50 |
5.1 nM
Compound: PT
|
Antiproliferative activity against human A-375 cells assessed as reduction in cell viability incubated for 72 hrs by CelltiterGlo luminescent assay
Antiproliferative activity against human A-375 cells assessed as reduction in cell viability incubated for 72 hrs by CelltiterGlo luminescent assay
|
[PMID: 38959729] |
| A-375 | EC50 |
0.002 x 10-3 μM
Compound: Paclitaxel
|
Cytotoxicity against human A-375 cells incubated for 48 to 72 hrs by MTT assay
Cytotoxicity against human A-375 cells incubated for 48 to 72 hrs by MTT assay
|
[PMID: 39038808] |
| A-375 | IC50 |
0.013 μM
Compound: Paclitaxel
|
Antiproliferative activity against human A-375 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
Antiproliferative activity against human A-375 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
|
[PMID: 39163776] |
| A-375 | IC50 |
0.68 μM
Compound: Paclitaxel
|
Antiproliferative activity against human A375 cells after 48 hrs by MTT assay
Antiproliferative activity against human A375 cells after 48 hrs by MTT assay
|
10.1039/C6MD00256K |
| A375/TxR | IC50 |
112.1 nM
Compound: Paclitaxel
|
Cytotoxicity against paclitaxel resistant human A-375/TxR cells measured after 72 hrs by western blot
Cytotoxicity against paclitaxel resistant human A-375/TxR cells measured after 72 hrs by western blot
|
[PMID: 34378386] |
| A375/TxR | IC50 |
103.8 nM
Compound: Paclitaxel
|
Antiproliferative activity against human A375/TxR cells assessed as inhibition of cell proliferation measured after 72 hrs by MTS assay
Antiproliferative activity against human A375/TxR cells assessed as inhibition of cell proliferation measured after 72 hrs by MTS assay
|
[PMID: 34406768] |
| A-431 | EC50 |
0.009 μM
Compound: Taxol
|
Cell cycle arrest in A431 cells by accumulation at G2/M phase
Cell cycle arrest in A431 cells by accumulation at G2/M phase
|
[PMID: 16377187] |
| A-431 | ED50 |
0.01 μg/mL
Compound: 1
|
Cytotoxicity against human A431 cells
Cytotoxicity against human A431 cells
|
[PMID: 17643301] |
| A-431 | IC50 |
25.1 nM
Compound: Paclitaxel
|
Cytotoxicity against human A431 cells after 72 hrs by SRB method
Cytotoxicity against human A431 cells after 72 hrs by SRB method
|
[PMID: 18990574] |
| A-431 | GI50 |
<0.00001 μM
Compound: Paclitaxel
|
Antiproliferative activity against human A431 cells by SRB assay
Antiproliferative activity against human A431 cells by SRB assay
|
[PMID: 19394218] |
| A-431 | IC50 |
9.2 nM
Compound: Paclitaxel
|
Antiproliferative activity against human A431 cells after 72 hrs by sulforhodamine B assay
Antiproliferative activity against human A431 cells after 72 hrs by sulforhodamine B assay
|
[PMID: 21480626] |
| A-431 | GI50 |
2.355 nM
Compound: 1, Taxol
|
Growth inhibition of human A431 cells by MTT assay
Growth inhibition of human A431 cells by MTT assay
|
[PMID: 24405702] |
| A-431 | IC50 |
0.007 μM
Compound: Taxol
|
Cytotoxicity against human A431 cells assessed as growth inhibition after 72 hrs by CCK-8 assay
Cytotoxicity against human A431 cells assessed as growth inhibition after 72 hrs by CCK-8 assay
|
[PMID: 25091926] |
| A-431 | GI50 |
0.0023 μg/mL
Compound: Paclitaxel
|
Cytotoxicity against human A431 cells assessed as growth inhibition after 48 hrs by MTT assay
Cytotoxicity against human A431 cells assessed as growth inhibition after 48 hrs by MTT assay
|
[PMID: 26642768] |
| A-431 | IC50 |
0.002 μM
Compound: Taxol
|
Antiproliferative activity against human A431 wild type cells measured after 72 hrs by Sulforhodamine B assay
Antiproliferative activity against human A431 wild type cells measured after 72 hrs by Sulforhodamine B assay
|
[PMID: 31889606] |
| A-431 | IC50 |
0.001 μM
Compound: Taxol
|
Anticancer activity against human A431 cells by MTT assay
Anticancer activity against human A431 cells by MTT assay
|
[PMID: 33316408] |
| A498 | IC50 |
<3 ng/mL
Compound: 1 (paclitaxel)
|
Cytotoxicity against A498 Tumor cell line in SRB Cell viability test
Cytotoxicity against A498 Tumor cell line in SRB Cell viability test
|
[PMID: 10956217] |
| A498 | GI50 |
3.5 μM
Compound: Paclitaxel
|
Compound was tested for growth inhibition of multidrug resistant tumor A498 cell line
Compound was tested for growth inhibition of multidrug resistant tumor A498 cell line
|
[PMID: 15546733] |
| A498 | IC50 |
0.017 μM
Compound: paclitaxel
|
Antitumor activity against human A498 cell line
Antitumor activity against human A498 cell line
|
[PMID: 16884301] |
| A498 | IC50 |
0.061 μM
Compound: paclitaxel
|
Cytotoxicity against human A498 cells
Cytotoxicity against human A498 cells
|
[PMID: 17113288] |
| A498 | IC50 |
<3 ng/mL
Compound: 1
|
Cytotoxicity against human A498 cells
Cytotoxicity against human A498 cells
|
[PMID: 17419065] |
| A498 | IC50 |
8.81 μM
Compound: paclitaxel
|
Cytotoxicity against human A498 cells after 72 hrs by MTT assay
Cytotoxicity against human A498 cells after 72 hrs by MTT assay
|
[PMID: 19053781] |
| A498 | IC50 |
>150 ng/mL
Compound: Paclitaxel
|
Antiproliferative activity against human A498 cells assessed as cell growth inhibition incubated for 1 days by MTS assay
Antiproliferative activity against human A498 cells assessed as cell growth inhibition incubated for 1 days by MTS assay
|
[PMID: 20068177] |
| A498 | IC50 |
>150 ng/mL
Compound: Paclitaxel
|
Antiproliferative activity against human A498 cells assessed as cell growth inhibition incubated for 2 days by MTS assay
Antiproliferative activity against human A498 cells assessed as cell growth inhibition incubated for 2 days by MTS assay
|
[PMID: 20068177] |
| A498 | IC50 |
30 ng/mL
Compound: Paclitaxel
|
Antiproliferative activity against human A498 cells assessed as cell growth inhibition incubated for 3 days by MTS assay
Antiproliferative activity against human A498 cells assessed as cell growth inhibition incubated for 3 days by MTS assay
|
[PMID: 20068177] |
| A498 | IC50 |
7.53 μg/mL
Compound: Paclitaxel
|
Anticancer activity against human A498 cells after 24 hrs by MTT assay
Anticancer activity against human A498 cells after 24 hrs by MTT assay
|
[PMID: 25305717] |
| A498 | GI50 |
7.9 nM
Compound: Paclitaxel
|
Growth inhibition of human A498 cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human A498 cells incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 29655610] |
| A498 | GI50 |
7.9 nM
Compound: Paclitaxel
|
Cytotoxicity against human A498 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay
Cytotoxicity against human A498 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay
|
[PMID: 33310545] |
| A498 | IC50 |
0.02 μM
Compound: PTX
|
Cytotoxicity against human A498 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay
Cytotoxicity against human A498 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay
|
[PMID: 38547648] |
| A549 | IC50 |
0.012 μM
Compound: 1a (Paclitaxel)
|
Inhibitory activity against A549 lung cancer cell line
Inhibitory activity against A549 lung cancer cell line
|
[PMID: 12031338] |
| A549 | IC50 |
0.96 μM
Compound: 1a (Paclitaxel)
|
Inhibitory activity against Taxol-resistant A549 lung cancer cell line
Inhibitory activity against Taxol-resistant A549 lung cancer cell line
|
[PMID: 12031338] |
| A549 | IC50 |
1.4 nM
Compound: Paclitaxel
|
Antiproliferative potency determined as inhibitory concentration against A549 cells
Antiproliferative potency determined as inhibitory concentration against A549 cells
|
[PMID: 12825928] |
| A549 | ED50 |
0.005 μg/mL
Compound: Paclitaxel
|
Effective dose required for inhibitory activity against A549 human tumor cell line.
Effective dose required for inhibitory activity against A549 human tumor cell line.
|
[PMID: 12852747] |
| A549 | ED50 |
0.005 μg/mL
Compound: paclitaxel
|
Cytotoxicity against human A549 cells after 3 days by SRB assay
Cytotoxicity against human A549 cells after 3 days by SRB assay
|
[PMID: 14640511] |
| A549 | IC50 |
3 nM
Compound: 1a Paclitaxel
|
Compound was tested for its cytotoxicity by inhibiting the growth of A-549 cell line after 72 h
Compound was tested for its cytotoxicity by inhibiting the growth of A-549 cell line after 72 h
|
[PMID: 15225730] |
| A549 | IC50 |
0.0029 μM
Compound: Taxol
|
Concentration required for growth inhibition of human lung carcinoma cell line (CCRF-CEM) was determined
Concentration required for growth inhibition of human lung carcinoma cell line (CCRF-CEM) was determined
|
[PMID: 15324894] |
| A549 | IC50 |
1.7 μM
Compound: 1
|
inhibitory concentration against the growth of Non-small-cell lung carcinoma A549 cell line after 72 hr of exposure
inhibitory concentration against the growth of Non-small-cell lung carcinoma A549 cell line after 72 hr of exposure
|
[PMID: 15501062] |
| A549 | GI50 |
0.01 μM
Compound: Paclitaxel
|
Inhibition of human non-small cell lung cancer A549 cell proliferation
Inhibition of human non-small cell lung cancer A549 cell proliferation
|
[PMID: 15546733] |
| A549 | IC50 |
0.002 μg/mL
Compound: Paclitaxel
|
Inhibitory concentration required to inhibit A549 Cell line growth on continuous exposure time of 72 h
Inhibitory concentration required to inhibit A549 Cell line growth on continuous exposure time of 72 h
|
[PMID: 15664868] |
| A549 | IC50 |
1.25 μM
Compound: taxol
|
Cytotoxicity against human A549 cells after 48 hrs by SRB assay
Cytotoxicity against human A549 cells after 48 hrs by SRB assay
|
[PMID: 15787460] |
| A549 | IC50 |
0.013 μM
Compound: Taxol
|
Antiproliferative activity against A549 cell line by MTS assay
Antiproliferative activity against A549 cell line by MTS assay
|
[PMID: 16257201] |
| A549 | IC50 |
0.028 μM
Compound: paclitaxel
|
Cytotoxicity against human A549 cell line
Cytotoxicity against human A549 cell line
|
[PMID: 16420032] |
| A549 | IC50 |
<0.015 μM
Compound: 1
|
Antiproliferative activity against human A549 cell line by MTT assay after 72 hrs
Antiproliferative activity against human A549 cell line by MTT assay after 72 hrs
|
[PMID: 16513344] |
| A549 | IC50 |
0.028 μM
Compound: 1
|
Antiproliferative activity against human A549 cell line by MTT assay after 1 hr
Antiproliferative activity against human A549 cell line by MTT assay after 1 hr
|
[PMID: 16513344] |
| A549 | IC50 |
0.006 μM
Compound: Taxol
|
Cytotoxicity against human A549 cells by MTT assay
Cytotoxicity against human A549 cells by MTT assay
|
[PMID: 16539377] |
| A549 | IC50 |
0.0021 μM
Compound: taxol
|
Antiproliferative activity against human A549 cell line
Antiproliferative activity against human A549 cell line
|
[PMID: 16759114] |
| A549 | IC50 |
0.0049 μM
Compound: paclitaxel
|
Antitumor activity against human A549 cell line
Antitumor activity against human A549 cell line
|
[PMID: 16884301] |
| A549 | IC50 |
3.6 nM
Compound: 6
|
Cytotoxicity against human A549 cells
Cytotoxicity against human A549 cells
|
[PMID: 17206139] |
| A549 | ED50 |
2.3 nM
Compound: 1
|
Cytotoxicity against human A549 cells by sulforhodamine B assay
Cytotoxicity against human A549 cells by sulforhodamine B assay
|
[PMID: 17350834] |
| A549 | ED50 |
0.02 μg/mL
Compound: 1
|
Cytotoxicity against human A549 cells
Cytotoxicity against human A549 cells
|
[PMID: 17419065] |
| A549 | ED50 |
0.02 μg/mL
Compound: 1
|
Cytotoxicity against human A549 cells
Cytotoxicity against human A549 cells
|
[PMID: 17643301] |
| A549 | GI50 |
0.004 μM
Compound: paclitaxel
|
Cytotoxicity against human A549 cells
Cytotoxicity against human A549 cells
|
[PMID: 17696332] |
| A549 | IC50 |
12.6 nM
Compound: Paclitaxel
|
Cytotoxicity against human A549 cells by MTT assay
Cytotoxicity against human A549 cells by MTT assay
|
[PMID: 17764148] |
| A549 | IC50 |
0.006 μM
Compound: taxol
|
Cytotoxicity against human A549 cells after 72 hrs by MTT assay
Cytotoxicity against human A549 cells after 72 hrs by MTT assay
|
[PMID: 17915851] |
| A549 | IC50 |
0.06 μM
Compound: taxol
|
Cytotoxicity againat taxol-resistant human A549T12 cells after 72 hrs by MTT assay
Cytotoxicity againat taxol-resistant human A549T12 cells after 72 hrs by MTT assay
|
[PMID: 17915851] |
| A549 | IC50 |
0.102 μM
Compound: taxol
|
Cytotoxicity againat taxol-resistant human A549T24 cells after 72 hrs by MTT assay
Cytotoxicity againat taxol-resistant human A549T24 cells after 72 hrs by MTT assay
|
[PMID: 17915851] |
| A549 | IC50 |
0.019 μM
Compound: paclitaxel
|
Cytotoxicity against human A549 cells by MTT assay
Cytotoxicity against human A549 cells by MTT assay
|
[PMID: 18001087] |
| A549 | IC50 |
0.93 μM
Compound: paclitaxel
|
Cytotoxicity against human A549 cells after 24 hrs by SRB assay
Cytotoxicity against human A549 cells after 24 hrs by SRB assay
|
[PMID: 18281952] |
| A549 | IC50 |
7 x 10-3 μM
Compound: paclitaxel
|
Cytotoxicity against human A549 cells after 3 days by MTT assay
Cytotoxicity against human A549 cells after 3 days by MTT assay
|
[PMID: 18419154] |
| A549 | IC50 |
<2 μg/mL
Compound: paclitaxel
|
Cytotoxicity against human A549 cells after 48 hrs by MTT assay
Cytotoxicity against human A549 cells after 48 hrs by MTT assay
|
[PMID: 18553923] |
| A549 | IC50 |
23.1 nM
Compound: paclitaxel
|
Cytotoxicity against human A549 cells
Cytotoxicity against human A549 cells
|
[PMID: 18606540] |
| A549 | EC50 |
<0.005 μg/mL
Compound: Paclitaxel
|
Cytotoxicity against human A549 cells
Cytotoxicity against human A549 cells
|
[PMID: 18640035] |
| A549 | IC50 |
13.05 μM
Compound: Taxol
|
Antiproliferative activity against human A549 cells after 48 hrs by MTT assay
Antiproliferative activity against human A549 cells after 48 hrs by MTT assay
|
[PMID: 18701301] |
| A549 | IC50 |
0.002 μM
Compound: 1a
|
Cytotoxicity against human A549 cells
Cytotoxicity against human A549 cells
|
[PMID: 18715782] |
| A549 | IC50 |
0.1 μM
Compound: Paclitaxel
|
Cytotoxicity against human A549 cells after 48 hrs by WST-8 assay
Cytotoxicity against human A549 cells after 48 hrs by WST-8 assay
|
[PMID: 19072209] |
| A549 | IC50 |
0.29 ng/mL
Compound: paclitaxel
|
Cytotoxicity against human A549 cells after 72 hrs by MTT assay
Cytotoxicity against human A549 cells after 72 hrs by MTT assay
|
[PMID: 19136258] |
| A549 | IC50 |
19.64 ng/mL
Compound: taxol
|
Cytotoxicity against human A549 cells after 24 hrs by propidium iodide assay
Cytotoxicity against human A549 cells after 24 hrs by propidium iodide assay
|
[PMID: 19138858] |
| A549 | IC50 |
19.64 ng/mL
Compound: taxol
|
Cytotoxicity against human A549 cells after 24 hrs by YO-PRO-1 assay
Cytotoxicity against human A549 cells after 24 hrs by YO-PRO-1 assay
|
[PMID: 19138858] |
| A549 | EC50 |
<0.005 μg/mL
Compound: Palitaxel
|
Cytotoxicity against human A549 cells after 3 days by sulforhodamine B assay
Cytotoxicity against human A549 cells after 3 days by sulforhodamine B assay
|
[PMID: 19193043] |
| A549 | IC50 |
0.0052 μM
Compound: paclitaxel
|
Cytotoxicity against human A549 cells after 24 hrs by MTT assay
Cytotoxicity against human A549 cells after 24 hrs by MTT assay
|
[PMID: 19245261] |
| A549 | IC50 |
2.46 μM
Compound: Taxol
|
Cytotoxicity against human A549 cells after 48 hrs by MTT assay
Cytotoxicity against human A549 cells after 48 hrs by MTT assay
|
[PMID: 19359185] |
| A549 | IC50 |
0.1 μM
Compound: paclitaxel
|
Cytotoxicity against human A549 cells after 48 hrs by SRB method
Cytotoxicity against human A549 cells after 48 hrs by SRB method
|
[PMID: 19425589] |
| A549 | IC50 |
2.3 nM
Compound: paclitaxel
|
Cytotoxicity against human A549 cells by MTT assay
Cytotoxicity against human A549 cells by MTT assay
|
[PMID: 19708679] |
| A549 | IC50 |
2.28 μM
Compound: Taxol
|
Antiproliferative activity against human A549 cells after 48 hrs by MTT assay
Antiproliferative activity against human A549 cells after 48 hrs by MTT assay
|
[PMID: 19815316] |
| A549 | IC50 |
2.7 μM
Compound: paclitaxel
|
Growth inhibition of human A549 cells after 48 hrs by sulforhodamine B assay
Growth inhibition of human A549 cells after 48 hrs by sulforhodamine B assay
|
[PMID: 19939522] |
| A549 | IC50 |
1.93 x 10-3 μM
Compound: Paclitaxel
|
Cytotoxicity against human A549 cells
Cytotoxicity against human A549 cells
|
[PMID: 20036537] |
| A549 | IC50 |
>=0.0049 μM
Compound: Taxol
|
Antiproliferative activity human A549 cells after 20 hrs by MTT assay
Antiproliferative activity human A549 cells after 20 hrs by MTT assay
|
[PMID: 20149494] |
| A549 | IC50 |
0.002 μg/mL
Compound: paclitaxel
|
Cytotoxicity against human A549 cells after 3 days by SRB assay
Cytotoxicity against human A549 cells after 3 days by SRB assay
|
[PMID: 20232858] |
| A549 | IC50 |
1.4 μM
Compound: Paclitaxel
|
Cytotoxicity against human A549 cells after 48 hrs by MTT assay
Cytotoxicity against human A549 cells after 48 hrs by MTT assay
|
[PMID: 20521771] |
| A549 | IC50 |
1 x 10-3 μM
Compound: paclitaxel
|
Cytotoxicity against human A549 cells after 96 hrs by MTT assay
Cytotoxicity against human A549 cells after 96 hrs by MTT assay
|
[PMID: 20560647] |
| A549 | IC50 |
1.6 x 10-8 M
Compound: Taxol
|
Cytotoxicity against human A549 cells after 72 hrs by MTT assay
Cytotoxicity against human A549 cells after 72 hrs by MTT assay
|
[PMID: 20719510] |
| A549 | IC50 |
0.0038 μM
Compound: Paclitaxel
|
Cytotoxicity against human A549 cells after 72 hrs by alamar blue assay
Cytotoxicity against human A549 cells after 72 hrs by alamar blue assay
|
[PMID: 20732809] |
| A549 | ED50 |
0.008 μM
Compound: paclitaxel
|
Cytotoxicity against human A549 cells
Cytotoxicity against human A549 cells
|
[PMID: 20738103] |
| A549 | IC50 |
0.0049 μM
Compound: Taxol
|
Antiproliferative activity against human A549 cells after 96 hrs by MTT assay
Antiproliferative activity against human A549 cells after 96 hrs by MTT assay
|
[PMID: 20974505] |
| A549 | IC50 |
0.001 μM
Compound: taxol
|
Cytotoxicity against human A549 after 48 hrs by SRB assay
Cytotoxicity against human A549 after 48 hrs by SRB assay
|
[PMID: 21044847] |
| A549 | IC50 |
2.46 μM
Compound: Taxol
|
Cytotoxicity against human A549 cells after 48 hrs by MTT assay
Cytotoxicity against human A549 cells after 48 hrs by MTT assay
|
[PMID: 21067933] |
| A549 | IC50 |
4.4 nM
Compound: Taxol
|
Antiproliferative activity against human A549 cells after 96 hrs by MTT assay
Antiproliferative activity against human A549 cells after 96 hrs by MTT assay
|
[PMID: 21296467] |
| A549 | ED50 |
2.56 nM
Compound: Paclitaxel
|
Antiproliferative activity against human A549 cells after 3 days by sulforhodamine B assay
Antiproliferative activity against human A549 cells after 3 days by sulforhodamine B assay
|
[PMID: 21296579] |
| A549 | GI50 |
0.00558 μM
Compound: Paclitaxel
|
Cytotoxicity activity against human A549 cells assessed as growth inhibition at 10 ug/ml after 72 hrs sulforhodamine B assay
Cytotoxicity activity against human A549 cells assessed as growth inhibition at 10 ug/ml after 72 hrs sulforhodamine B assay
|
[PMID: 21316977] |
| A549 | IC50 |
2.46 μM
Compound: Taxol
|
Cytotoxicity against human A549 cells after 48 hrs by MTT assay
Cytotoxicity against human A549 cells after 48 hrs by MTT assay
|
[PMID: 21342735] |
| A549 | GI50 |
7.6 nM
Compound: Paclitaxel
|
Cytotoxicity against human A549 cells after 3 days
Cytotoxicity against human A549 cells after 3 days
|
[PMID: 21377368] |
| A549 | IC50 |
2.3 nM
Compound: Paclitaxel
|
Antiproliferative activity against human A549 cells after 72 hrs by sulforhodamine B assay
Antiproliferative activity against human A549 cells after 72 hrs by sulforhodamine B assay
|
[PMID: 21480626] |
| A549 | IC50 |
1.6 x 10-8 M
Compound: Taxol
|
Cytotoxicity against human A549 cells after 72 hrs by MTT assay
Cytotoxicity against human A549 cells after 72 hrs by MTT assay
|
[PMID: 21530251] |
| A549 | IC50 |
<0.008 μM
Compound: paclitaxel
|
Cytotoxicity against human A549 cells after 48 hrs by MTT method
Cytotoxicity against human A549 cells after 48 hrs by MTT method
|
[PMID: 21534539] |
| A549 | IC50 |
7.2 nM
Compound: taxol
|
Antiproliferative activity against human A549 cells assessed as growth inhibition after 72 hrs by MTT assay
Antiproliferative activity against human A549 cells assessed as growth inhibition after 72 hrs by MTT assay
|
[PMID: 21663319] |
| A549 | IC50 |
75.2 nM
Compound: taxol
|
Antiproliferative activity against human taxol-resistant A549-T12 cells assessed as growth inhibition after 72 hrs by MTT assay
Antiproliferative activity against human taxol-resistant A549-T12 cells assessed as growth inhibition after 72 hrs by MTT assay
|
[PMID: 21663319] |
| A549 | IC50 |
9.265 μM
Compound: Paclitaxel
|
Cytotoxicity against human A549 cells
Cytotoxicity against human A549 cells
|
[PMID: 21784631] |
| A549 | IC50 |
3 x 10-2 μM
Compound: Paclitaxel
|
Cytotoxicity against human A549 cells after 72 hrs by MTS assay
Cytotoxicity against human A549 cells after 72 hrs by MTS assay
|
[PMID: 21812410] |
| A549 | GI50 |
0.004 μM
Compound: Paclitaxel
|
Cytotoxicity against human A549 cells by sulforhodamine B assay
Cytotoxicity against human A549 cells by sulforhodamine B assay
|
[PMID: 21839640] |
| A549 | IC50 |
3.14 nM
Compound: (+)-2, 2, taxol
|
Antiproliferative activity against human A549 cells after 72 hrs by SRB method
Antiproliferative activity against human A549 cells after 72 hrs by SRB method
|
[PMID: 21870795] |
| A549 | EC50 |
4.6 nM
Compound: Taxol
|
Cytotoxicity against human A549 cells after 24 hrs by MTT assay
Cytotoxicity against human A549 cells after 24 hrs by MTT assay
|
[PMID: 21873068] |
| A549 | IC50 |
4.49 x 10-2 μM
Compound: Paclitaxel
|
Cytotoxicity against human A549 cells by MTT assay
Cytotoxicity against human A549 cells by MTT assay
|
[PMID: 21928797] |
| A549 | IC50 |
0.01 μM
Compound: paclitaxel
|
Cytotoxicity against human A549 cells after 48 hrs by SRB assay
Cytotoxicity against human A549 cells after 48 hrs by SRB assay
|
[PMID: 21973054] |
| A549 | IC50 |
0.0072 μM
Compound: Taxol
|
Antiproliferative activity against human A549 cells after 72 hrs by MTT assay
Antiproliferative activity against human A549 cells after 72 hrs by MTT assay
|
[PMID: 22027100] |
| A549 | IC50 |
0.075 μM
Compound: Taxol
|
Antiproliferative activity against human taxol-resistant A549-T12 cells after 72 hrs by MTT assay
Antiproliferative activity against human taxol-resistant A549-T12 cells after 72 hrs by MTT assay
|
[PMID: 22027100] |
| A549 | EC50 |
0.0064 μM
Compound: Paclitaxel
|
Cytotoxicity against human A549 cells by sulforhodamine B assay
Cytotoxicity against human A549 cells by sulforhodamine B assay
|
[PMID: 22142543] |
| A549 | IC50 |
0.0052 μg/mL
Compound: Paclitaxel
|
Cytotoxicity against human A549 cells by SRB assay
Cytotoxicity against human A549 cells by SRB assay
|
[PMID: 22204911] |
| A549 | GI50 |
5.46 nM
Compound: Paclitaxel
|
Antiproliferative activity against human A549 cells after 72 hrs by SRB assay
Antiproliferative activity against human A549 cells after 72 hrs by SRB assay
|
[PMID: 22265685] |
| A549 | IC50 |
0.19 μM
Compound: Paclitaxel
|
Cytotoxicity against human A549 cells after 72 hrs by MTT assay
Cytotoxicity against human A549 cells after 72 hrs by MTT assay
|
[PMID: 22472043] |
| A549 | IC50 |
1.16 μM
Compound: Paclitaxel
|
Cytotoxicity against human A549 cells after 48 hrs by MTT assay
Cytotoxicity against human A549 cells after 48 hrs by MTT assay
|
[PMID: 22472043] |
| A549 | IC50 |
3.46 μM
Compound: Taxol
|
Cytotoxicity against human A549 cells after 72 hrs by MTT assay
Cytotoxicity against human A549 cells after 72 hrs by MTT assay
|
[PMID: 22483090] |
| A549 | IC50 |
0.016 μM
Compound: paclitaxel
|
Cytotoxicity against human A549 cells by MTT assay
Cytotoxicity against human A549 cells by MTT assay
|
[PMID: 22506620] |
| A549 | IC50 |
0.016 μM
Compound: paclitaxel
|
Cytotoxicity against human A549 cells after 72 hrs by MTT assay
Cytotoxicity against human A549 cells after 72 hrs by MTT assay
|
[PMID: 22583079] |
| A549 | IC50 |
0.0019 μg/mL
Compound: Paclitaxel
|
Cytotoxicity against human A549 cells by MTT assay
Cytotoxicity against human A549 cells by MTT assay
|
[PMID: 22595179] |
| A549 | IC50 |
0.72 μM
Compound: Paclitaxel
|
Cytotoxicity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay
Cytotoxicity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay
|
[PMID: 22871217] |
| A549 | GI50 |
0.00489 μM
Compound: Paclitaxel
|
Cytotoxicity against human A549 cells after 72 hrs by SRB assay
Cytotoxicity against human A549 cells after 72 hrs by SRB assay
|
[PMID: 22932313] |
| A549 | IC50 |
0.02 μg/mL
Compound: Taxol
|
Cytotoxicity against human A549 cells
Cytotoxicity against human A549 cells
|
[PMID: 22989532] |
| A549 | IC50 |
7.2 nM
Compound: Taxol
|
Antiproliferative activity against human A549 cells after 72 hrs by MTT assay
Antiproliferative activity against human A549 cells after 72 hrs by MTT assay
|
[PMID: 23117171] |
| A549 | IC50 |
75.2 nM
Compound: Taxol
|
Antiproliferative activity against human taxol-resistant A549-T12 cells expressing tubulin mutant gene after 72 hrs by MTT assay
Antiproliferative activity against human taxol-resistant A549-T12 cells expressing tubulin mutant gene after 72 hrs by MTT assay
|
[PMID: 23117171] |
| A549 | IC50 |
0.056 μM
Compound: Taxol
|
Cytotoxicity against human A549 cells after 72 hrs by crystal violet staining based microplate reader analysis
Cytotoxicity against human A549 cells after 72 hrs by crystal violet staining based microplate reader analysis
|
[PMID: 23153397] |
| A549 | GI50 |
0.06 μM
Compound: paclitaxel
|
Growth inhibition of human A549 cells
Growth inhibition of human A549 cells
|
[PMID: 23167614] |
| A549 | IC50 |
7 nM
Compound: PTX
|
Cytotoxicity against human A549 cells assessed as growth inhibition after 48 hrs by MTT assay
Cytotoxicity against human A549 cells assessed as growth inhibition after 48 hrs by MTT assay
|
[PMID: 23214452] |
| A549 | GI50 |
8.18 nM
Compound: Paclitaxel
|
Growth inhibition of human A549 cells by SRB assay
Growth inhibition of human A549 cells by SRB assay
|
[PMID: 23274123] |
| A549 | IC50 |
<0.008 μM
Compound: Paclitaxel
|
Cytotoxicity against human A549 cells assessed as inhibition of cell viability after 48 hrs by MTT assay
Cytotoxicity against human A549 cells assessed as inhibition of cell viability after 48 hrs by MTT assay
|
[PMID: 23327668] |
| A549 | IC50 |
1037.8 nM
Compound: paclitaxel
|
Cytotoxicity against paclitaxel-resistant human A549 cells after 48 hrs by MTT assay
Cytotoxicity against paclitaxel-resistant human A549 cells after 48 hrs by MTT assay
|
[PMID: 23356786] |
| A549 | IC50 |
8.2 nM
Compound: paclitaxel
|
Cytotoxicity against human A549 cells after 48 hrs by MTT assay
Cytotoxicity against human A549 cells after 48 hrs by MTT assay
|
[PMID: 23356786] |
| A549 | IC50 |
3.5 nM
Compound: paclitaxel
|
Cytotoxicity against human A549 cells after 72 hrs by MTT assay
Cytotoxicity against human A549 cells after 72 hrs by MTT assay
|
[PMID: 23445496] |
| A549 | IC50 |
92.3 nM
Compound: paclitaxel
|
Cytotoxicity against human A549-T12 cells after 72 hrs by MTT assay
Cytotoxicity against human A549-T12 cells after 72 hrs by MTT assay
|
[PMID: 23445496] |
| A549 | IC50 |
0.016 μM
Compound: Paclitaxel
|
Cytotoxicity against human A549 cells by MTT assay
Cytotoxicity against human A549 cells by MTT assay
|
[PMID: 23547884] |
| A549 | IC50 |
<0.008 μM
Compound: paclitaxel
|
Cytotoxicity against human A549 assessed as cell viability measured after 48 hrs by MTT assay
Cytotoxicity against human A549 assessed as cell viability measured after 48 hrs by MTT assay
|
[PMID: 23586920] |
| A549 | IC50 |
0.02 μM
Compound: Paclitaxel
|
Cytotoxicity against human A549 cells after 3 days by MTT assay
Cytotoxicity against human A549 cells after 3 days by MTT assay
|
[PMID: 23738539] |
| A549 | IC50 |
3.6 nM
Compound: Taxol
|
Cytotoxicity against human A549 cells by MTT assay
Cytotoxicity against human A549 cells by MTT assay
|
[PMID: 23806112] |
| A549 | IC50 |
1.4 μM
Compound: paclitaxel
|
Cytotoxicity against human A549 cells after 48 hrs by MTT assay
Cytotoxicity against human A549 cells after 48 hrs by MTT assay
|
[PMID: 23819871] |
| A549 | GI50 |
0.0076 μM
Compound: Paclitaxel
|
Cytotoxicity against human A549 cells by SRB method
Cytotoxicity against human A549 cells by SRB method
|
[PMID: 23867604] |
| A549 | IC50 |
14 nM
Compound: paclitaxel
|
Cytotoxicity against human A549 cells after 72 hrs by MTT assay
Cytotoxicity against human A549 cells after 72 hrs by MTT assay
|
[PMID: 23886686] |
| A549 | IC50 |
0.01 μM
Compound: Taxol
|
Cytotoxicity against human A549 cells
Cytotoxicity against human A549 cells
|
[PMID: 23937981] |
| A549 | IC50 |
0.1 μM
Compound: paclitaxel
|
Antimicrobial activity against human A549 cells after 48 hrs by MTT assay
Antimicrobial activity against human A549 cells after 48 hrs by MTT assay
|
[PMID: 23957453] |
| A549 | IC50 |
0.02 μM
Compound: paclitaxel
|
Cytotoxicity against human A549 cells assessed as growth inhibition after 72 hrs by MTT assay
Cytotoxicity against human A549 cells assessed as growth inhibition after 72 hrs by MTT assay
|
[PMID: 24063567] |
| A549 | IC50 |
0.02 μM
Compound: Paclitaxel
|
Cytotoxicity against human A549 cells after 48 hrs by MTT assay
Cytotoxicity against human A549 cells after 48 hrs by MTT assay
|
[PMID: 24063582] |
| A549 | IC50 |
4.4 nM
Compound: Taxol
|
Antiproliferative against human A549 cells assessed as cell viability after 96 hrs by MTT assay
Antiproliferative against human A549 cells assessed as cell viability after 96 hrs by MTT assay
|
[PMID: 24211639] |
| A549 | IC50 |
<0.008 μM
Compound: paclitaxel
|
Cytotoxicity against human A549 cells after 48 hrs by MTS assay
Cytotoxicity against human A549 cells after 48 hrs by MTS assay
|
[PMID: 24219809] |
| A549 | IC50 |
<0.008 μM
Compound: paclitaxel
|
Cytotoxicity against human A549 cells after 48 hrs by MTS assay
Cytotoxicity against human A549 cells after 48 hrs by MTS assay
|
[PMID: 24256484] |
| A549 | IC50 |
930 nM
Compound: 1, Taxol
|
Cytotoxicity against human A549 cells after 48 hrs by MTT assay
Cytotoxicity against human A549 cells after 48 hrs by MTT assay
|
[PMID: 24269481] |
| A549 | GI50 |
0.0076 μM
Compound: Paclitaxel
|
Cytotoxicity against human A549 cells by SRB assay
Cytotoxicity against human A549 cells by SRB assay
|
[PMID: 24315191] |
| A549 | GI50 |
18.73 nM
Compound: 1, Taxol
|
Growth inhibition of human A549 cells by MTT assay
Growth inhibition of human A549 cells by MTT assay
|
[PMID: 24405702] |
| A549 | IC50 |
<0.008 μM
Compound: Paclitaxel
|
Cytotoxicity against human A549 cells after 48 hrs by MTT assay
Cytotoxicity against human A549 cells after 48 hrs by MTT assay
|
[PMID: 24417634] |
| A549 | IC50 |
0.032 μM
Compound: Taxol
|
Cytotoxicity against human A549 cells after 96 hrs by MTT assay
Cytotoxicity against human A549 cells after 96 hrs by MTT assay
|
[PMID: 24467317] |
| A549 | GI50 |
0.0076 μM
Compound: paclitaxel
|
Cytotoxicity against human A549 cells by SRB assay
Cytotoxicity against human A549 cells by SRB assay
|
[PMID: 24502232] |
| A549 | IC50 |
<0.008 μM
Compound: paclitaxel
|
Cytotoxicity against human A549 cells assessed as growth inhibition after 48 hrs by MTS assay
Cytotoxicity against human A549 cells assessed as growth inhibition after 48 hrs by MTS assay
|
[PMID: 24697496] |
| A549 | IC50 |
1.525 μM
Compound: Paclitaxel
|
Antiproliferative against human A549 cells after 48 hrs by MTT assay
Antiproliferative against human A549 cells after 48 hrs by MTT assay
|
[PMID: 24996136] |
| A549 | IC50 |
0.0057 μM
Compound: Paclitaxel
|
Cytotoxicity against human A549 cells after 72 hrs sulforhodamine B colorimetric assay
Cytotoxicity against human A549 cells after 72 hrs sulforhodamine B colorimetric assay
|
[PMID: 25008456] |
| A549 | IC50 |
0.005 μM
Compound: TAX, Taxol
|
Antiproliferative activity against human A549 cells after 48 hrs by SRB method
Antiproliferative activity against human A549 cells after 48 hrs by SRB method
|
[PMID: 25061803] |
| A549 | IC50 |
0.009 μM
Compound: TAX, Taxol
|
Antiproliferative activity against cis-platinum-resistant human A549 cells after 48 hrs by SRB method
Antiproliferative activity against cis-platinum-resistant human A549 cells after 48 hrs by SRB method
|
[PMID: 25061803] |
| A549 | IC50 |
0.082 μM
Compound: 1, TAX
|
Cytotoxicity against human A549 cells after 48 hrs by SRB assay
Cytotoxicity against human A549 cells after 48 hrs by SRB assay
|
[PMID: 25084144] |
| A549 | IC50 |
1.04 μM
Compound: Taxol
|
Cytotoxicity against human A549 cells after 24 hrs by MTT assay
Cytotoxicity against human A549 cells after 24 hrs by MTT assay
|
[PMID: 25226363] |
| A549 | IC50 |
2.4 nM
Compound: PXL
|
Antiproliferative activity against human A549 cells after 3 days by SRB assay
Antiproliferative activity against human A549 cells after 3 days by SRB assay
|
[PMID: 25241925] |
| A549 | IC50 |
<0.008 μM
Compound: paclitaxel
|
Cytotoxicity against human A549 cells after 48 hrs by MTT assay
Cytotoxicity against human A549 cells after 48 hrs by MTT assay
|
[PMID: 25375202] |
| A549 | IC50 |
0.006 μM
Compound: Paclitaxel
|
Cytotoxicity against human A549 cells after 72 hrs by MTT assay
Cytotoxicity against human A549 cells after 72 hrs by MTT assay
|
[PMID: 25462279] |
| A549 | IC50 |
4.9 μM
Compound: Pacli
|
Cytotoxicity against human A549 cells after 48 hrs by MTT assay
Cytotoxicity against human A549 cells after 48 hrs by MTT assay
|
[PMID: 25563891] |
| A549 | IC50 |
0.025 μM
Compound: Paclitaxel
|
Cytotoxicity against human A549 cells after 48 hrs by MTT assay
Cytotoxicity against human A549 cells after 48 hrs by MTT assay
|
[PMID: 25647428] |
| A549 | IC50 |
0.003 μM
Compound: 6
|
Antiproliferative activity against human A549 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
Antiproliferative activity against human A549 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
|
[PMID: 25682561] |
| A549 | IC50 |
0.006 μM
Compound: 6
|
Antiproliferative activity against human A549/CDDP cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
Antiproliferative activity against human A549/CDDP cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
|
[PMID: 25682561] |
| A549 | IC50 |
3 x 10-2 μM
Compound: paclitaxel
|
Cytotoxicity against human A549 cells assessed as reduction in cell viability by MTS assay
Cytotoxicity against human A549 cells assessed as reduction in cell viability by MTS assay
|
[PMID: 25760674] |
| A549 | GI50 |
0.0071 μM
Compound: Paclitaxel
|
Antiproliferative activity against human A549 cells by sulforhodamine B assay
Antiproliferative activity against human A549 cells by sulforhodamine B assay
|
[PMID: 25770782] |
| A549 | IC50 |
0.058 μM
Compound: Taxol
|
Antiproliferative activity against human A549 cells after 72 hrs by MTT assay
Antiproliferative activity against human A549 cells after 72 hrs by MTT assay
|
[PMID: 25771484] |
| A549 | IC50 |
<0.008 μM
Compound: paclitaxel
|
Cytotoxicity against human A549 cells incubated for 48 hrs by MTT assay
Cytotoxicity against human A549 cells incubated for 48 hrs by MTT assay
|
[PMID: 25798528] |
| A549 | IC50 |
4.4 nM
Compound: Taxol
|
Cytotoxicity against human A549 cells assessed as cell viability after 72 hrs by CCK8 assay
Cytotoxicity against human A549 cells assessed as cell viability after 72 hrs by CCK8 assay
|
[PMID: 25819096] |
| A549 | GI50 |
<0.01 μM
Compound: Paclitaxel
|
Antiproliferative activity against human A549 cells after 48 hrs by SRB assay
Antiproliferative activity against human A549 cells after 48 hrs by SRB assay
|
[PMID: 25827522] |
| A549 | IC50 |
<0.008 μM
Compound: Taxol
|
Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay
|
[PMID: 25871261] |
| A549 | IC50 |
2.3 nM
Compound: taxol
|
Antiproliferative activity against human A549 cells after 48 hrs by MTT assay
Antiproliferative activity against human A549 cells after 48 hrs by MTT assay
|
[PMID: 25937236] |
| A549 | IC50 |
520 nM
Compound: taxol
|
Antiproliferative activity against human taxol-resistant A549 cells after 48 hrs by MTT assay
Antiproliferative activity against human taxol-resistant A549 cells after 48 hrs by MTT assay
|
[PMID: 25937236] |
| A549 | IC50 |
2.82 μM
Compound: Paclitaxel
|
Antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation incubated for 48 hrs by CCK8 assay
Antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation incubated for 48 hrs by CCK8 assay
|
[PMID: 25959813] |
| A549 | IC50 |
<0.008 μM
Compound: Taxol
|
Cytotoxicity against human A549 cells assessed as cell viability after 48 hrs by MTS assay
Cytotoxicity against human A549 cells assessed as cell viability after 48 hrs by MTS assay
|
[PMID: 26068802] |
| A549 | IC50 |
7 nM
Compound: PTX
|
Cytotoxicity against human A549 cells assessed as growth inhibition after 72 hrs by CellTiter-Fluor assay
Cytotoxicity against human A549 cells assessed as growth inhibition after 72 hrs by CellTiter-Fluor assay
|
[PMID: 26132075] |
| A549 | GI50 |
0.0076 μM
Compound: Paclitaxel
|
Antiproliferative activity against human A549 cells assessed as cell growth inhibition by SRB assay
Antiproliferative activity against human A549 cells assessed as cell growth inhibition by SRB assay
|
[PMID: 26242242] |
| A549 | GI50 |
0.0035 μg/mL
Compound: Paclitaxel
|
Cytotoxicity against human A549 cells after 48 hrs by MTT assay
Cytotoxicity against human A549 cells after 48 hrs by MTT assay
|
[PMID: 26299346] |
| A549 | IC50 |
2.1 μM
Compound: taxol
|
Cytotoxicity against human A549 cells after 72 hrs by CCK8 assay
Cytotoxicity against human A549 cells after 72 hrs by CCK8 assay
|
[PMID: 26316467] |
| A549 | IC50 |
0.0063 μM
Compound: 1
|
Cytotoxicity against human A549 cells
Cytotoxicity against human A549 cells
|
[PMID: 26448037] |
| A549 | GI50 |
<0.0023 μg/mL
Compound: Paclitaxel
|
Cytotoxicity against human A549 cells assessed as growth inhibition after 48 hrs by MTT assay
Cytotoxicity against human A549 cells assessed as growth inhibition after 48 hrs by MTT assay
|
[PMID: 26642768] |
| A549 | IC50 |
2.12 nM
Compound: Taxol
|
Cytotoxicity against human A549 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay
Cytotoxicity against human A549 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay
|
[PMID: 26697718] |
| A549 | IC50 |
0.03 nM
Compound: PXL
|
Antiproliferative activity against human A549 cells after 3 days by SRB assay
Antiproliferative activity against human A549 cells after 3 days by SRB assay
|
[PMID: 26865176] |
| A549 | IC50 |
10 μM
Compound: Paclitaxel
|
Cytotoxicity against human A549 cells assessed as reduction in viable cells after 48 hrs by MTT assay
Cytotoxicity against human A549 cells assessed as reduction in viable cells after 48 hrs by MTT assay
|
[PMID: 26916436] |
| A549 | GI50 |
0.12 μg/mL
Compound: Paclitaxel
|
Cytotoxicity against human A549 cells after 48 hrs by MTT assay
Cytotoxicity against human A549 cells after 48 hrs by MTT assay
|
[PMID: 26920799] |
| A549 | GI50 |
0.039 μg/mL
Compound: Paclitaxel
|
Cytotoxicity against human A549 cells after 48 and 72 hrs by MTT assay
Cytotoxicity against human A549 cells after 48 and 72 hrs by MTT assay
|
[PMID: 26927426] |
| A549 | IC50 |
13.2 nM
Compound: Paclitaxel
|
Cytotoxicity against human A549 cells after 48 hrs by Celltiter-Glo luminescent cell viability assay
Cytotoxicity against human A549 cells after 48 hrs by Celltiter-Glo luminescent cell viability assay
|
[PMID: 26985296] |
| A549 | GI50 |
<0.01 μM
Compound: Paclitaxel
|
Antiproliferative activity against human A549 cells after 48 hrs by SRB assay
Antiproliferative activity against human A549 cells after 48 hrs by SRB assay
|
[PMID: 26994690] |
| A549 | GI50 |
<0.004 μg/mL
Compound: Paclitaxel
|
Cytotoxicity against human A549 cells after 48 hrs by MTT assay
Cytotoxicity against human A549 cells after 48 hrs by MTT assay
|
[PMID: 27013391] |
| A549 | IC50 |
0.009 μM
Compound: TAX
|
Cytotoxicity against human A549 cells assessed as cell viability after 48 hrs by MTT assay
Cytotoxicity against human A549 cells assessed as cell viability after 48 hrs by MTT assay
|
[PMID: 27149641] |
| A549 | IC50 |
0.023 μM
Compound: TAX
|
Cytotoxicity against human A549/CDDP cells assessed as growth inhibition after 48 hrs by MTT assay
Cytotoxicity against human A549/CDDP cells assessed as growth inhibition after 48 hrs by MTT assay
|
[PMID: 27149641] |
| A549 | GI50 |
2.6 μM
Compound: Paclitaxel
|
Antiproliferative activity against human A549 cells after 48 hrs by SRB method
Antiproliferative activity against human A549 cells after 48 hrs by SRB method
|
[PMID: 27238842] |
| A549 | IC50 |
0.08 μM
Compound: Paclitaxel
|
Cytotoxicity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay
Cytotoxicity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay
|
[PMID: 27329938] |
| A549 | IC50 |
2.3 x 10-2 μM
Compound: Paclitaxel
|
Cytotoxicity against human A549 cells by MTT assay
Cytotoxicity against human A549 cells by MTT assay
|
[PMID: 27441892] |
| A549 | IC50 |
1.92 μM
Compound: Taxol
|
Cytotoxicity against human A549 cells after 72 hrs by CCK8 assay
Cytotoxicity against human A549 cells after 72 hrs by CCK8 assay
|
[PMID: 27623549] |
| A549 | IC50 |
0.03 μM
Compound: Paclitaxel
|
Cytotoxicity activity against human A549 cells assessed as growth inhibition measured after 48 hrs by MTT assay
Cytotoxicity activity against human A549 cells assessed as growth inhibition measured after 48 hrs by MTT assay
|
[PMID: 27627130] |
| A549 | GI50 |
0.04 μg/mL
Compound: Paclitaxel
|
Cytotoxicity against human A549 cells measured after 48 hrs by MTT assay
Cytotoxicity against human A549 cells measured after 48 hrs by MTT assay
|
[PMID: 27688192] |
| A549 | IC50 |
<0.008 μM
Compound: Paclitaxel
|
Cytotoxicity against human A549 cells assessed as decrease in cell viability after 48 hrs by MTS assay
Cytotoxicity against human A549 cells assessed as decrease in cell viability after 48 hrs by MTS assay
|
[PMID: 27704807] |
| A549 | IC50 |
0.02 μM
Compound: Paclitaxel
|
Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay
|
[PMID: 27704822] |
| A549 | IC50 |
0.7 μM
Compound: PXL
|
Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
|
[PMID: 27707623] |
| A549 | IC50 |
5.5 μM
Compound: Paclitaxel
|
Cytotoxicity against human A549 cells after 72 hrs by MTT assay
Cytotoxicity against human A549 cells after 72 hrs by MTT assay
|
[PMID: 27748595] |
| A549 | IC50 |
0.99 nM
Compound: Paclitaxel
|
Cytotoxicity against human A549 cells assessed as growth inhibition after 48 hrs by SRB assay
Cytotoxicity against human A549 cells assessed as growth inhibition after 48 hrs by SRB assay
|
[PMID: 27797192] |
| A549 | IC50 |
6.2 nM
Compound: PXL
|
Antiproliferative activity against human A549 cells after 72 hrs by SRB assay
Antiproliferative activity against human A549 cells after 72 hrs by SRB assay
|
[PMID: 28099003] |
| A549 | GI50 |
0.0035 μg/mL
Compound: Paclitaxel
|
Cytotoxicity against human A549 cells assessed as growth inhibition by MTT assay
Cytotoxicity against human A549 cells assessed as growth inhibition by MTT assay
|
[PMID: 28103537] |
| A549 | GI50 |
0.0035 μg/mL
Compound: Paclitaxel
|
Cytotoxicity against human A549 cells assessed as growth inhibition after 48 hrs by MTT assay
Cytotoxicity against human A549 cells assessed as growth inhibition after 48 hrs by MTT assay
|
[PMID: 28110868] |
| A549 | IC50 |
6.195 μM
Compound: Paclitaxel
|
Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay
|
[PMID: 28237662] |
| A549 | IC50 |
6.2 nM
Compound: Paclitaxel
|
Antiproliferative activity against human A549 cells incubated for 72 hrs by SRB assay
Antiproliferative activity against human A549 cells incubated for 72 hrs by SRB assay
|
[PMID: 28290698] |
| A549 | IC50 |
9.52 nM
Compound: Paclitaxel
|
Cytotoxicity against human A549 cells after 48 hrs by MTT assay
Cytotoxicity against human A549 cells after 48 hrs by MTT assay
|
[PMID: 28340411] |
| A549 | IC50 |
0.023 μM
Compound: Taxol
|
Antiproliferative activity against human A549 cells expressing NQO1 after 72 hrs by MTT assay
Antiproliferative activity against human A549 cells expressing NQO1 after 72 hrs by MTT assay
|
[PMID: 28395199] |
| A549 | GI50 |
0.0035 μg/mL
Compound: Paclitaxel
|
Growth inhibition of human A549 cells by MTT assay
Growth inhibition of human A549 cells by MTT assay
|
[PMID: 28411559] |
| A549 | IC50 |
6.85 nM
Compound: PXL
|
Antiproliferative activity against human A549 cells by sulforhodamine B assay
Antiproliferative activity against human A549 cells by sulforhodamine B assay
|
[PMID: 28457756] |
| A549 | IC50 |
2.1 nM
Compound: Paclitaxel
|
Cytotoxicity against human A549 cells assessed as reduction in cell viability after 72 hrs by CCK-8 assay
Cytotoxicity against human A549 cells assessed as reduction in cell viability after 72 hrs by CCK-8 assay
|
[PMID: 28598633] |
| A549 | GI50 |
7.03 nM
Compound: Paclitaxel
|
Cytotoxicity against human A549 cells assessed as growth inhibition after 48 hrs by SRB assay
Cytotoxicity against human A549 cells assessed as growth inhibition after 48 hrs by SRB assay
|
[PMID: 28653846] |
| A549 | IC50 |
<0.008 μM
Compound: Paclitaxel
|
Antiproliferative activity against human A549 cells after 48 hrs by MTS assay
Antiproliferative activity against human A549 cells after 48 hrs by MTS assay
|
[PMID: 28654256] |
| A549 | GI50 |
3.7 nM
Compound: Paclitaxel
|
Growth inhibition of human A549 cells after 4 days by SRB assay
Growth inhibition of human A549 cells after 4 days by SRB assay
|
[PMID: 28740601] |
| A549 | IC50 |
4.1 nM
Compound: PTX
|
Cytotoxicity against human A549 cells measured after 24 hrs
Cytotoxicity against human A549 cells measured after 24 hrs
|
[PMID: 28835794] |
| A549 | IC50 |
6.2 nM
Compound: Paclitaxel
|
Cytotoxicity against human A549 cells after 72 hrs by sulforhodamine B assay
Cytotoxicity against human A549 cells after 72 hrs by sulforhodamine B assay
|
[PMID: 29131631] |
| A549 | IC50 |
<0.008 μM
Compound: Paclitaxel
|
Cytotoxicity against human A549 cells after 48 hrs by MTS assay
Cytotoxicity against human A549 cells after 48 hrs by MTS assay
|
[PMID: 29286250] |
| A549 | IC50 |
4.5 nM
Compound: PXL
|
Antiproliferative activity against human A549 cells after 72 hrs by sulforhodamine B assay
Antiproliferative activity against human A549 cells after 72 hrs by sulforhodamine B assay
|
[PMID: 29319316] |
| A549 | IC50 |
<0.008 μM
Compound: Paclitaxel
|
Cytotoxicity against human A549 cells after 48 hrs by MTS assay
Cytotoxicity against human A549 cells after 48 hrs by MTS assay
|
[PMID: 29338226] |
| A549 | IC50 |
<0.008 μM
Compound: Paclitaxel
|
Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTS assay
Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTS assay
|
[PMID: 29338260] |
| A549 | IC50 |
6.8 nM
Compound: Paclitaxel
|
Cytotoxicity against human A549 cells after 48 hrs by MTT assay
Cytotoxicity against human A549 cells after 48 hrs by MTT assay
|
[PMID: 29373791] |
| A549 | IC50 |
5.82 μM
Compound: Paclitaxel
|
Antiproliferative activity against human A549 cells after 72 hrs by SRB assay
Antiproliferative activity against human A549 cells after 72 hrs by SRB assay
|
[PMID: 29391939] |
| A549 | IC50 |
<0.008 μM
Compound: Paclitaxel
|
Growth inhibition of human A549 cells after 48 hrs by MTS assay
Growth inhibition of human A549 cells after 48 hrs by MTS assay
|
[PMID: 29412669] |
| A549 | IC50 |
7.1 nM
Compound: Taxol
|
Growth inhibition of human A549 cells
Growth inhibition of human A549 cells
|
[PMID: 29439899] |
| A549 | IC50 |
0.007 μM
Compound: Taxol
|
Antiproliferative activity against human A549 cells after 72 hrs by MTT assay
Antiproliferative activity against human A549 cells after 72 hrs by MTT assay
|
[PMID: 29501947] |
| A549 | IC50 |
3.2 x 10-3 μM
Compound: Paclitaxel
|
Cytotoxicity against human A549 cells assessed as reduction in cell viability after 72 hrs by CCK-8 assay
Cytotoxicity against human A549 cells assessed as reduction in cell viability after 72 hrs by CCK-8 assay
|
[PMID: 29648818] |
| A549 | GI50 |
6.3 nM
Compound: Paclitaxel
|
Growth inhibition of human A549/ATCC cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human A549/ATCC cells incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 29655610] |
| A549 | IC50 |
23.18 nM
Compound: Taxol
|
Antiproliferative activity against human A549 cells after 48 to 72 hrs by MTT assay
Antiproliferative activity against human A549 cells after 48 to 72 hrs by MTT assay
|
[PMID: 29754076] |
| A549 | IC50 |
>30 μM
Compound: Taxol
|
Antiproliferative activity against human A549 cells after 72 hrs by MTS assay
Antiproliferative activity against human A549 cells after 72 hrs by MTS assay
|
[PMID: 29843103] |
| A549 | IC50 |
<0.008 μM
Compound: Taxol
|
Cytotoxicity against human A549 cells assessed as decrease in cell viability after 4 days by MTT assay
Cytotoxicity against human A549 cells assessed as decrease in cell viability after 4 days by MTT assay
|
[PMID: 29884535] |
| A549 | IC50 |
6.3 nM
Compound: PXL
|
Antiproliferative activity against human A549 cells after 72 hrs by SRB assay
Antiproliferative activity against human A549 cells after 72 hrs by SRB assay
|
[PMID: 30010341] |
| A549 | IC50 |
>10 nM
Compound: PXL
|
Antiproliferative activity against human A549 cells after 24 hrs by SRB assay
Antiproliferative activity against human A549 cells after 24 hrs by SRB assay
|
[PMID: 30106296] |
| A549 | IC50 |
10 nM
Compound: PXL
|
Antiproliferative activity against human A549 cells after 48 hrs by SRB assay
Antiproliferative activity against human A549 cells after 48 hrs by SRB assay
|
[PMID: 30106296] |
| A549 | IC50 |
8.76 nM
Compound: PXL
|
Antiproliferative activity against human A549 cells after 72 hrs by SRB assay
Antiproliferative activity against human A549 cells after 72 hrs by SRB assay
|
[PMID: 30106296] |
| A549 | IC50 |
6.8 μM
Compound: Paclitaxel
|
Antiproliferative activity against human A549 cells assessed as reduction in cell growth after 72 hrs by sulforhodamine B assay
Antiproliferative activity against human A549 cells assessed as reduction in cell growth after 72 hrs by sulforhodamine B assay
|
[PMID: 30189396] |
| A549 | IC50 |
0.051 μM
Compound: Taxol
|
Antiproliferative activity against human A549 cells after 72 hrs by MTT assay
Antiproliferative activity against human A549 cells after 72 hrs by MTT assay
|
[PMID: 30212198] |
| A549 | IC50 |
0.004 μM
Compound: Paclitaxel
|
Cytotoxicity activity against human A549 cells assessed as cell growth inhibition after 48 hrs by MTT assay
Cytotoxicity activity against human A549 cells assessed as cell growth inhibition after 48 hrs by MTT assay
|
[PMID: 30433783] |
| A549 | IC50 |
0.7 μM
Compound: Taxol
|
Cytotoxicity against human A549 cells expressing NQO1 assessed as reduction in cell viability after 72 hrs by MTT assay
Cytotoxicity against human A549 cells expressing NQO1 assessed as reduction in cell viability after 72 hrs by MTT assay
|
[PMID: 30508483] |
| A549 | IC50 |
58.5 nM
Compound: Taxol
|
Cytotoxicity against human A549 cells after 48 hrs by sulforhodamine B assay
Cytotoxicity against human A549 cells after 48 hrs by sulforhodamine B assay
|
[PMID: 30528697] |
| A549 | IC50 |
0.018 μM
Compound: PTX
|
Antiproliferative activity against human A549 cells after 72 hrs by MTT assay
Antiproliferative activity against human A549 cells after 72 hrs by MTT assay
|
[PMID: 30530194] |
| A549 | IC50 |
0.0034 μM
Compound: PTX
|
Cytotoxicity against human A549 cells assessed as cell growth inhibition after 48 hrs by sulforhodamine B assay
Cytotoxicity against human A549 cells assessed as cell growth inhibition after 48 hrs by sulforhodamine B assay
|
[PMID: 30633861] |
| A549 | IC50 |
0.54 μM
Compound: TAX
|
Cytotoxicity against human A549 cells after 72 hrs by MTT assay
Cytotoxicity against human A549 cells after 72 hrs by MTT assay
|
[PMID: 30677614] |
| A549 | IC50 |
0.11 μM
Compound: Paclitaxel
|
Cytotoxicity against human A549 cells assessed as inhibition of cell viability after 48 hrs by SRB assay
Cytotoxicity against human A549 cells assessed as inhibition of cell viability after 48 hrs by SRB assay
|
[PMID: 30798081] |
| A549 | IC50 |
<0.008 μM
Compound: Paclitaxel
|
Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay
Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay
|
[PMID: 30822712] |
| A549 | GI50 |
0.0035 μg/mL
Compound: Paclitaxel
|
Growth inhibition of human A549 cells by MTT assay
Growth inhibition of human A549 cells by MTT assay
|
[PMID: 30910461] |
| A549 | IC50 |
13.7 nM
Compound: Taxol
|
Cytotoxicity against human A549 cells measured after 48 hrs by MTT assay
Cytotoxicity against human A549 cells measured after 48 hrs by MTT assay
|
[PMID: 31050424] |
| A549 | IC50 |
6.2 nM
Compound: Paclitaxel
|
Antiproliferative activity against human A549 cells assessed as cell growth inhibition after 72 hrs by sulforhodamine B assay
Antiproliferative activity against human A549 cells assessed as cell growth inhibition after 72 hrs by sulforhodamine B assay
|
[PMID: 31126820] |
| A549 | GI50 |
6 nM
Compound: Taxol
|
Induction of microtubule stabilization in human A549 cells assessed as inhibition of cell growth incubated for 72 hrs by Celltiter reagent-based assay
Induction of microtubule stabilization in human A549 cells assessed as inhibition of cell growth incubated for 72 hrs by Celltiter reagent-based assay
|
[PMID: 31191870] |
| A549 | IC50 |
0.39 μM
Compound: PTX
|
Antiproliferative activity against human A549 cells incubated for 72 hrs by CCK8 cells
Antiproliferative activity against human A549 cells incubated for 72 hrs by CCK8 cells
|
[PMID: 31200238] |
| A549 | CC50 |
<20 nM
Compound: Ptxl; PTX
|
Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
|
[PMID: 31248772] |
| A549 | IC50 |
<0.008 μM
Compound: Paclitaxel
|
Cytotoxicity in human A549 cells assessed as reduction in cell viability incubated for 3 days by MTT assay
Cytotoxicity in human A549 cells assessed as reduction in cell viability incubated for 3 days by MTT assay
|
[PMID: 31390200] |
| A549 | IC50 |
0.0033 μM
Compound: Paclitaxel
|
Cytotoxicity against human A549 cells assessed as reduction in cell viability after 68 hrs by MTT assay
Cytotoxicity against human A549 cells assessed as reduction in cell viability after 68 hrs by MTT assay
|
[PMID: 31404864] |
| A549 | IC50 |
0.35 μM
Compound: Paclitaxel
|
Anticancer activity against human A549 cells by MTT assay
Anticancer activity against human A549 cells by MTT assay
|
[PMID: 31404864] |
| A549 | IC50 |
7.52 nM
Compound: PXL
|
Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
|
[PMID: 31541869] |
| A549 | IC50 |
6.3 nM
Compound: Paclitaxel
|
Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 72 hrs by SRB assay
Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 72 hrs by SRB assay
|
[PMID: 31550158] |
| A549 | IC50 |
6.2 μM
Compound: Paclitaxel
|
Antiproliferative activity against human A549 cells harbouring wild type EGFR incubated for 72 hrs by SRB assay
Antiproliferative activity against human A549 cells harbouring wild type EGFR incubated for 72 hrs by SRB assay
|
[PMID: 31718182] |
| A549 | GI50 |
2.4 nM
Compound: Paclitaxel
|
Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
|
[PMID: 31938468] |
| A549 | IC50 |
2.2 x 10-3 μM
Compound: Taxol
|
Cytotoxicity against human A549 cells assessed as reduction in cell viability
Cytotoxicity against human A549 cells assessed as reduction in cell viability
|
[PMID: 32273216] |
| A549 | IC50 |
<0.008 μM
Compound: Paclitaxel
|
Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay
|
[PMID: 32628478] |
| A549 | IC50 |
854 μM
Compound: Paclitaxel
|
Antiproliferative activity against human A549 cells assessed as cell growth inhibition by CCK8 assay
Antiproliferative activity against human A549 cells assessed as cell growth inhibition by CCK8 assay
|
[PMID: 32631533] |
| A549 | IC50 |
0.005 μM
Compound: Paclitaxel
|
Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
|
[PMID: 32633512] |
| A549 | IC50 |
0.012 μM
Compound: PTX
|
Antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation measured after 48 hrs by CCK-8 assay
Antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation measured after 48 hrs by CCK-8 assay
|
[PMID: 32650183] |
| A549 | IC50 |
6.5 nM
Compound: Paclitaxel
|
Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 72 hrs by SRB assay
Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 72 hrs by SRB assay
|
[PMID: 32946697] |
| A549 | IC50 |
<0.001 μM
Compound: Taxol
|
Antiproliferative activity against human A549 cells assessed as reduction in cell growth by MTT assay
Antiproliferative activity against human A549 cells assessed as reduction in cell growth by MTT assay
|
[PMID: 32949719] |
| A549 | IC50 |
3.8 nM
Compound: Taxol
|
Antiproliferative activity against human A549 cells assessed as cell growth inhibition measured for 72 hrs
Antiproliferative activity against human A549 cells assessed as cell growth inhibition measured for 72 hrs
|
[PMID: 33038665] |
| A549 | IC50 |
0.013 μM
Compound: 1; PTX
|
Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay
Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay
|
[PMID: 33065439] |
| A549 | GI50 |
6.3 nM
Compound: Paclitaxel
|
Cytotoxicity against human A549 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay
Cytotoxicity against human A549 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay
|
[PMID: 33310545] |
| A549 | IC50 |
5.4 μM
Compound: PTX
|
Cytotoxicity against human A549 cells assessed as cell growth inhibition measured after 24 hrs by MTT assay
Cytotoxicity against human A549 cells assessed as cell growth inhibition measured after 24 hrs by MTT assay
|
[PMID: 33381964] |
| A549 | IC50 |
0.7 μM
Compound: Paclitaxel
|
Cytotoxicity against human A549 cells assessed as cell growth inhibition after 48 hrs by MTT assay
Cytotoxicity against human A549 cells assessed as cell growth inhibition after 48 hrs by MTT assay
|
[PMID: 33459007] |
| A549 | IC50 |
0.0057 μM
Compound: Paclitaxel
|
Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
|
[PMID: 34171512] |
| A549 | IC50 |
0.015 μM
Compound: Paclitaxel
|
Antiproliferative activity against human A549 assessed as reduction in cell viability measured after 48 hrs by MTT assay
Antiproliferative activity against human A549 assessed as reduction in cell viability measured after 48 hrs by MTT assay
|
[PMID: 34175541] |
| A549 | IC50 |
0.003 μM
Compound: Paclitaxel
|
Anticancer activity against human A549 cells assessed as cell growth inhibition measured for 72 hrs by MTT assay
Anticancer activity against human A549 cells assessed as cell growth inhibition measured for 72 hrs by MTT assay
|
[PMID: 34303874] |
| A549 | IC50 |
<0.008 μM
Compound: Paclitaxel
|
Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay
Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay
|
[PMID: 34355562] |
| A549 | IC50 |
2.4 μM
Compound: Taxol
|
Anticancer activity against human A549 cells assessed as inhibition of cell proliferation measured after 72 hrs by CCK8 reagent assay
Anticancer activity against human A549 cells assessed as inhibition of cell proliferation measured after 72 hrs by CCK8 reagent assay
|
[PMID: 34399390] |
| A549 | IC50 |
0.006 μM
Compound: Paclitaxel
|
Antiproliferative activity against human A549 cells assessed as reduction in cell viability measured after 72 hrs by SRB assay
Antiproliferative activity against human A549 cells assessed as reduction in cell viability measured after 72 hrs by SRB assay
|
[PMID: 34403728] |
| A549 | IC50 |
9.8 nM
Compound: Paclitaxel
|
Antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTS assay
Antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTS assay
|
[PMID: 34406768] |
| A549 | IC50 |
4.7 nM
Compound: Taxol
|
Antiproliferative activity against human A549 cells assessed as inhibition of cell growth by secondary round CCK8 assay
Antiproliferative activity against human A549 cells assessed as inhibition of cell growth by secondary round CCK8 assay
|
[PMID: 34508844] |
| A549 | IC50 |
4.97 nM
Compound: PTX
|
Antiproliferative activity against human A549 cells incubated for 72 hrs by MTT assay
Antiproliferative activity against human A549 cells incubated for 72 hrs by MTT assay
|
[PMID: 34648295] |
| A549 | IC50 |
0.29 μM
Compound: Paclitaxel
|
Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay
|
[PMID: 34671737] |
| A549 | IC50 |
<0.008 μM
Compound: Taxol
|
Cytotoxicity against human A549 cells assessed as inhibition of cell growth measured after 48 hrs by MTS assay
Cytotoxicity against human A549 cells assessed as inhibition of cell growth measured after 48 hrs by MTS assay
|
[PMID: 34781083] |
| A549 | IC50 |
29.5 x 10-3 μM
Compound: Taxol
|
Cytotoxicity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay
Cytotoxicity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay
|
[PMID: 34883453] |
| A549 | GI50 |
0.6 nM
Compound: Paclitaxel
|
Antiproliferative activity against human A549 cells assessed as cell growth inhibition measured after 72 hrs by SRB assay
Antiproliferative activity against human A549 cells assessed as cell growth inhibition measured after 72 hrs by SRB assay
|
[PMID: 34917259] |
| A549 | IC50 |
3.76 μM
Compound: Paclitaxel
|
Antiproliferative activity against human A549 cells by CCK8 assay
Antiproliferative activity against human A549 cells by CCK8 assay
|
[PMID: 34922028] |
| A549 | IC50 |
0.006 μM
Compound: PTX
|
Antiproliferative activity against human A549 cells after 48 hrs by MTT assay
Antiproliferative activity against human A549 cells after 48 hrs by MTT assay
|
[PMID: 35065411] |
| A549 | IC50 |
24.2 nM
Compound: PTX
|
Cytotoxicity in human A549 assessed as inhibition in cell growth measured after 24 hrs by MTT assay
Cytotoxicity in human A549 assessed as inhibition in cell growth measured after 24 hrs by MTT assay
|
[PMID: 35084853] |
| A549 | IC50 |
0.05 μM
Compound: PTX
|
Cytotoxicity against human A549 cells assessed as reduction in cell viability by MTT assay
Cytotoxicity against human A549 cells assessed as reduction in cell viability by MTT assay
|
[PMID: 35213164] |
| A549 | IC50 |
0.03 μM
Compound: TAX
|
Antiproliferative activity against human A549 cells assessed as cell viability incubated for 48 hrs by MTT assay
Antiproliferative activity against human A549 cells assessed as cell viability incubated for 48 hrs by MTT assay
|
[PMID: 35282680] |
| A549 | IC50 |
0.07 μM
Compound: TAX
|
Antiproliferative activity against human adriamycin-resistant A549/ADR cells assessed as cell viability incubated for 48 hrs by MTT assay
Antiproliferative activity against human adriamycin-resistant A549/ADR cells assessed as cell viability incubated for 48 hrs by MTT assay
|
[PMID: 35282680] |
| A549 | IC50 |
67.5 nM
Compound: Paclitaxel
|
Cytotoxicity against human A549 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
Cytotoxicity against human A549 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
|
[PMID: 35324187] |
| A549 | IC50 |
<0.008 μM
Compound: taxol
|
Antitumor activity against human A549 cells assessed as inhibition of cell growth incubated for 48 hrs by MTS assay
Antitumor activity against human A549 cells assessed as inhibition of cell growth incubated for 48 hrs by MTS assay
|
[PMID: 35413617] |
| A549 | IC50 |
0.058 μM
Compound: PTX
|
Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay
Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay
|
[PMID: 35447432] |
| A549 | IC50 |
0.1 μM
Compound: Paclitaxel; Taxol
|
Antiproliferative activity against human A549 cells measured after 48 hrs by MTT assay
Antiproliferative activity against human A549 cells measured after 48 hrs by MTT assay
|
[PMID: 35551039] |
| A549 | IC50 |
1.1 nM
Compound: PTX
|
Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay
Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay
|
[PMID: 35635956] |
| A549 | IC50 |
15 nM
Compound: Paclitaxel
|
Antiproliferative activity against human A549 cells assessed as cell growth inhibition incubated for 48 hr by MTT assay
Antiproliferative activity against human A549 cells assessed as cell growth inhibition incubated for 48 hr by MTT assay
|
[PMID: 36092142] |
| A549 | IC50 |
<0.008 μM
Compound: Taxol
|
Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
|
[PMID: 36274275] |
| A549 | IC50 |
0.003 μM
Compound: Paclitaxel
|
Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
|
[PMID: 36511661] |
| A549 | IC50 |
0.39 μM
Compound: Paclitaxel
|
Antiproliferative activity against paclitaxel-resistant human A549 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
Antiproliferative activity against paclitaxel-resistant human A549 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
|
[PMID: 36511661] |
| A549 | IC50 |
3.8 nM
Compound: Paclitaxel
|
Antiproliferative activity against human A549 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay
Antiproliferative activity against human A549 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay
|
[PMID: 36621138] |
| A549 | IC50 |
18 nM
Compound: Paclitaxel
|
Anticancer activity against human A549 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
Anticancer activity against human A549 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
|
[PMID: 37146221] |
| A549 | IC50 |
0.014 μM
Compound: Taxol
|
Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by CCk-8 assay
Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by CCk-8 assay
|
[PMID: 37329677] |
| A549 | IC50 |
0.014 μM
Compound: 2
|
Antiproliferative activity against human A549 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay
Antiproliferative activity against human A549 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay
|
[PMID: 37856840] |
| A549 | IC50 |
0.022 μM
Compound: Paclitaxel
|
Antiproliferative activity against human A549 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay
Antiproliferative activity against human A549 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay
|
[PMID: 37883897] |
| A549 | IC50 |
0.02 μM
Compound: Taxol
|
Inhibition of cell growth in human A549 cells incubated for 72 hrs by SRB method
Inhibition of cell growth in human A549 cells incubated for 72 hrs by SRB method
|
[PMID: 38171146] |
| A549 | IC50 |
0.5 nM
Compound: PXL
|
Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay
Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay
|
[PMID: 38251859] |
| A549 | IC50 |
0.1 μM
Compound: PTX
|
Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
|
[PMID: 38280356] |
| A549 | IC50 |
5 nM
Compound: Paclitaxel
|
Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
|
[PMID: 38294341] |
| A549 | IC50 |
23.6 nM
Compound: PTX
|
Antiproliferative activity against human A549 cells assessed as reduction in cell viability measured after 72 hrs
Antiproliferative activity against human A549 cells assessed as reduction in cell viability measured after 72 hrs
|
[PMID: 38430854] |
| A549 | IC50 |
5.4 μM
Compound: PXL
|
Antiproliferative activity against human A549 cells assessed as cell growth inhibition incubated for 72 hrs by sulforhodamine B assay
Antiproliferative activity against human A549 cells assessed as cell growth inhibition incubated for 72 hrs by sulforhodamine B assay
|
[PMID: 38438305] |
| A549 | IC50 |
0.4 μM
Compound: Paciitaxel
|
Cytotoxicity against human A549 cells incubated for 72 hrs by CCK8 assay
Cytotoxicity against human A549 cells incubated for 72 hrs by CCK8 assay
|
[PMID: 38493728] |
| A549 | IC50 |
6.5 nM
Compound: PXL
|
Antiproliferative activity against human A549 cells assessed as reduction in cell viability by SRB assay
Antiproliferative activity against human A549 cells assessed as reduction in cell viability by SRB assay
|
[PMID: 38970504] |
| A549 | IC50 |
3.12 nM
Compound: Paclitaxel
|
Antiproliferative activity against human A549 cells incubated for 48 hrs by CCK8 assay
Antiproliferative activity against human A549 cells incubated for 48 hrs by CCK8 assay
|
[PMID: 38972078] |
| A549 | IC50 |
0.131 μM
Compound: Paclitaxel
|
Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
|
[PMID: 39163776] |
| A549 | IC50 |
3.6 nM
Compound: paclitaxel
|
In vitro cytotoxicity against human non-small cell lung carcinoma A549
In vitro cytotoxicity against human non-small cell lung carcinoma A549
|
[PMID: 8182698] |
| A549 | IC50 |
3.6 nM
Compound: paclitaxel
|
Concentration required to inhibit growth of human tumor A549 (NSCL) cell line.
Concentration required to inhibit growth of human tumor A549 (NSCL) cell line.
|
[PMID: 8831755] |
| A549 | IC50 |
3.6 nM
Compound: Paclitaxel
|
Growth inhibition of human non-small-lung carcinoma (A549) cell line
Growth inhibition of human non-small-lung carcinoma (A549) cell line
|
[PMID: 9022793] |
| A549 | IC50 |
3.6 nM
Compound: Paclitaxel
|
Inhibition of the growth against human non-small-lung carcinoma (A549) cell line after 72 hr exposure
Inhibition of the growth against human non-small-lung carcinoma (A549) cell line after 72 hr exposure
|
[PMID: 9022794] |
| A549 | IC50 |
2.7 μM
Compound: Paclitaxel
|
Cytotoxicity against Homo sapiens (human) A549 cells after 48 hr by SRB assay
Cytotoxicity against Homo sapiens (human) A549 cells after 48 hr by SRB assay
|
10.1007/s00044-012-0424-0 |
| A549 | IC50 |
3.6 nM
Compound: Paclitaxel
|
Cytotoxicity against human A549 non small cell lung cell lines
Cytotoxicity against human A549 non small cell lung cell lines
|
10.1016/S0960-894X(01)80298-5 |
| A549 | IC50 |
0.0034 μg/mL
Compound: 3
|
In vitro cytotoxicity against A549-human lung carcinoma cells.
In vitro cytotoxicity against A549-human lung carcinoma cells.
|
10.1016/S0960-894X(01)80507-2 |
| A549 | IC50 |
3.6 nM
Compound: Paclitaxel
|
Cytotoxicity was evaluated in vitro against A549 (non-small cell lung carcinoma) human tumor cell lines
Cytotoxicity was evaluated in vitro against A549 (non-small cell lung carcinoma) human tumor cell lines
|
10.1016/S0960-894X(01)80568-0 |
| A549 | IC50 |
3.6 nM
Compound: Paclitaxel
|
Cytotoxicity was evaluated against A549 non-small cell lung carcinoma human cancer cell line
Cytotoxicity was evaluated against A549 non-small cell lung carcinoma human cancer cell line
|
10.1016/S0960-894X(96)00595-1 |
| A549 | IC50 |
<0.02 μg/mL
Compound: 1
|
Cytotoxicity against human A549/VP cells
Cytotoxicity against human A549/VP cells
|
10.1021/np50078a018 |
| A549 | IC50 |
4.79 μg/mL
Compound: 1
|
Cytotoxicity against human A549 cells
Cytotoxicity against human A549 cells
|
10.1021/np50078a018 |
| A549 | IC50 |
2.7 μM
Compound: Paclitaxel
|
Cytotoxicity against human A549 cells assessed as inhibition of cell proliferation after 48 hrs by sulforhodamine-B assay
Cytotoxicity against human A549 cells assessed as inhibition of cell proliferation after 48 hrs by sulforhodamine-B assay
|
10.1039/C3MD00055A |
| A549 | IC50 |
0.74 μM
Compound: Paclitaxel
|
Cytotoxicity against human A549 cells assessed as inhibition of cell proliferation after 96 hrs by MTT assay
Cytotoxicity against human A549 cells assessed as inhibition of cell proliferation after 96 hrs by MTT assay
|
10.1039/C4MD00573B |
| A549 | GI50 |
0.13 μg/mL
Compound: Paclitaxel
|
Cytotoxicity against human A549 cells assessed as growth inhibition after 48 hrs by MTT assay
Cytotoxicity against human A549 cells assessed as growth inhibition after 48 hrs by MTT assay
|
10.1039/C5MD00057B |
| A549 | GI50 |
0.0035 μg/mL
Compound: Paclitaxel
|
Cytotoxicity against human A549 cells incubated for 1 to 11 days by MTT assay
Cytotoxicity against human A549 cells incubated for 1 to 11 days by MTT assay
|
10.1039/C5MD00404G |
| A549 | IC50 |
21.02 μM
Compound: Taxol
|
Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay
|
10.1039/C6MD00234J |
| A549 | IC50 |
0.4 μM
Compound: Paclitaxel
|
Antiproliferative activity against human A549 cells after 48 hrs by MTT assay
Antiproliferative activity against human A549 cells after 48 hrs by MTT assay
|
10.1039/C6MD00256K |
| A549 | GI50 |
0.08 mM
Compound: Paclitaxel
|
Cytotoxicity against human A549 cells by MTT assay
Cytotoxicity against human A549 cells by MTT assay
|
10.1039/C6MD00278A |
| A549/TR | IC50 |
1.51 μM
Compound: Paclitaxel
|
Cytotoxicity against human A549/TR cells after 48 hrs by MTT assay
Cytotoxicity against human A549/TR cells after 48 hrs by MTT assay
|
[PMID: 28340411] |
| A549/TR | IC50 |
28 μM
Compound: Taxol
|
Cytotoxicity against human A549/TR cells assessed as cell growth inhibition preincubated for 24 hrs followed by compound washout measured after 72 hrs by MTT assay
Cytotoxicity against human A549/TR cells assessed as cell growth inhibition preincubated for 24 hrs followed by compound washout measured after 72 hrs by MTT assay
|
[PMID: 28710963] |
| A549/TR | EC50 |
10.3 μM
Compound: Paclitaxel
|
Cytotoxicity against human A549/TR cells assessed as reduction in cell viability after 72 hrs by MTT assay
Cytotoxicity against human A549/TR cells assessed as reduction in cell viability after 72 hrs by MTT assay
|
[PMID: 29288939] |
| A549/TR | IC50 |
3.112 μM
Compound: Taxol
|
Antiproliferative activity against human A549/TR cells after 72 hrs by MTT assay
Antiproliferative activity against human A549/TR cells after 72 hrs by MTT assay
|
[PMID: 29501947] |
| A549/TR | IC50 |
759.39 nM
Compound: Taxol
|
Antiproliferative activity against human A549/TR cells after 48 to 72 hrs by MTT assay
Antiproliferative activity against human A549/TR cells after 48 to 72 hrs by MTT assay
|
[PMID: 29754076] |
| A549/TR | IC50 |
27 μM
Compound: Taxol
|
Cytotoxicity against human A549/TR cells expressing NQO1 assessed as reduction in cell viability after 72 hrs by MTT assay
Cytotoxicity against human A549/TR cells expressing NQO1 assessed as reduction in cell viability after 72 hrs by MTT assay
|
[PMID: 30508483] |
| A549/TR | IC50 |
1.83 μM
Compound: PTX
|
Antiproliferative activity against human taxol-resistant A549/TR cells after 72 hrs by MTT assay
Antiproliferative activity against human taxol-resistant A549/TR cells after 72 hrs by MTT assay
|
[PMID: 30530194] |
| A549/TR | IC50 |
24.53 μM
Compound: TAX
|
Cytotoxicity against human A549/TAX cells after 72 hrs by MTT assay
Cytotoxicity against human A549/TAX cells after 72 hrs by MTT assay
|
[PMID: 30677614] |
| A549/TR | IC50 |
>1000 nM
Compound: Paclitaxel
|
Antiproliferative activity against human A549/Taxol cells assessed as inhibition of cell proliferation measured after 72 hrs by MTS assay
Antiproliferative activity against human A549/Taxol cells assessed as inhibition of cell proliferation measured after 72 hrs by MTS assay
|
[PMID: 34406768] |
| A549/TR | IC50 |
4863 nM
Compound: PTX
|
Antiproliferative activity against human A549/T cells incubated for 72 hrs by MTT assay
Antiproliferative activity against human A549/T cells incubated for 72 hrs by MTT assay
|
[PMID: 34648295] |
| A549/TR | IC50 |
802 nM
Compound: PTX
|
Cytotoxicity in human A549T assessed as inhibition in cell growth measured after 24 hrs by MTT assay
Cytotoxicity in human A549T assessed as inhibition in cell growth measured after 24 hrs by MTT assay
|
[PMID: 35084853] |
| A549/TR | IC50 |
34.3 μM
Compound: Taxol
|
Antiproliferative activity against human A549/Taxol cells assessed as inhibition of cell growth measured after 72 hrs by cell titer glo luminescent assay
Antiproliferative activity against human A549/Taxol cells assessed as inhibition of cell growth measured after 72 hrs by cell titer glo luminescent assay
|
[PMID: 35640078] |
| A549/TR | IC50 |
0.602 μM
Compound: Paclitaxel
|
Antiproliferative activity against human A549/Taxol cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay
Antiproliferative activity against human A549/Taxol cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay
|
[PMID: 37883897] |
| A549/TR | IC50 |
5653 nM
Compound: Paclitaxel
|
Antiproliferative activity against human A549/Taxol cells assessed as cell growth inhibition incubated for72 hrs by MTT assay
Antiproliferative activity against human A549/Taxol cells assessed as cell growth inhibition incubated for72 hrs by MTT assay
|
[PMID: 37890199] |
| A549/TR | IC50 |
1.029 μM
Compound: Taxol
|
Inhibition of cell growth in human A549/Taxol cells incubated for 72 hrs by SRB method
Inhibition of cell growth in human A549/Taxol cells incubated for 72 hrs by SRB method
|
[PMID: 38171146] |
| A549/TR | IC50 |
834 nM
Compound: PTX
|
Antiproliferative activity against paclitaxel resistant human A549T cells assessed as reduction in cell viability measured after 72 hrs
Antiproliferative activity against paclitaxel resistant human A549T cells assessed as reduction in cell viability measured after 72 hrs
|
[PMID: 38430854] |
| A549/TR | IC50 |
>500 nM
Compound: PTX
|
Antiproliferative activity against paclitaxel resistant human A549/Taxol cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay
Antiproliferative activity against paclitaxel resistant human A549/Taxol cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay
|
[PMID: 38996194] |
| ACHN | IC50 |
31.5 μM
Compound: Paclitaxel
|
Cytotoxicity against multidrug-resistant human ACHN cells after 72 hrs by fluorometric microculture cytotoxicity assay
Cytotoxicity against multidrug-resistant human ACHN cells after 72 hrs by fluorometric microculture cytotoxicity assay
|
[PMID: 16562840] |
| ACHN | IC50 |
25 nM
Compound: paclitaxel
|
Antiproliferative activity against drug resistant ACHN cell line expressing MDR1 by Alamar Blue assay
Antiproliferative activity against drug resistant ACHN cell line expressing MDR1 by Alamar Blue assay
|
[PMID: 17286393] |
| ACHN | IC50 |
31.5 μM
Compound: paclitaxel
|
Cytotoxicity against ACHN cells
Cytotoxicity against ACHN cells
|
[PMID: 17442577] |
| ACHN | GI50 |
0.398 μM
Compound: paclitaxel
|
Cytotoxicity against human ACHN cells
Cytotoxicity against human ACHN cells
|
[PMID: 17696332] |
| ACHN | GI50 |
0.398 μM
Compound: Paclitaxel
|
Cytotoxicity against human ACHN cells by sulforhodamine B assay
Cytotoxicity against human ACHN cells by sulforhodamine B assay
|
[PMID: 21839640] |
| ACHN | IC50 |
2.33 μM
Compound: 1
|
Cytotoxicity against human ACHN cells assessed as inhibition of cell proliferation
Cytotoxicity against human ACHN cells assessed as inhibition of cell proliferation
|
[PMID: 25466201] |
| ACHN | IC50 |
0.066 μM
Compound: Paclitaxel
|
Antiproliferative activity against human ACHN cells after 72 hrs by CellTiter96 AQueous nonradioactive cell proliferation assay
Antiproliferative activity against human ACHN cells after 72 hrs by CellTiter96 AQueous nonradioactive cell proliferation assay
|
[PMID: 28335606] |
| ACHN | GI50 |
158 nM
Compound: Paclitaxel
|
Growth inhibition of human ACHN cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human ACHN cells incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 29655610] |
| ACHN | IC50 |
80 μM
Compound: Paclitaxel
|
Antiproliferative activity against taxane-resistant human ACHN cells after 72 hrs by CellTiter 96 aqueous nonradioactive cell proliferation assay
Antiproliferative activity against taxane-resistant human ACHN cells after 72 hrs by CellTiter 96 aqueous nonradioactive cell proliferation assay
|
[PMID: 29995409] |
| ACHN | GI50 |
158 nM
Compound: Paclitaxel
|
Cytotoxicity against human ACHN cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay
Cytotoxicity against human ACHN cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay
|
[PMID: 33310545] |
| AGS | IC50 |
<10 μM
Compound: Taxol
|
Cytotoxicity against human AGS cells after 48 hrs by MTT assay
Cytotoxicity against human AGS cells after 48 hrs by MTT assay
|
[PMID: 22370266] |
| AGS | IC50 |
1.6 μM
Compound: Paclitaxel
|
Cytotoxicity against human AGS cells assessed as reduction in cell viability after 72 hrs by MTT assay
Cytotoxicity against human AGS cells assessed as reduction in cell viability after 72 hrs by MTT assay
|
[PMID: 22871217] |
| AGS | IC50 |
15.4 μM
Compound: Paclitaxol
|
Cytotoxicity against human AGS cells assessed as cell viability after 24 hrs by MTT assay
Cytotoxicity against human AGS cells assessed as cell viability after 24 hrs by MTT assay
|
[PMID: 22901410] |
| AGS | IC50 |
15.4 μM
Compound: Paclitaxol
|
Cytotoxicity against human AGS cells after 24 hrs by MTT assay
Cytotoxicity against human AGS cells after 24 hrs by MTT assay
|
[PMID: 22921966] |
| AGS | IC50 |
8 nM
Compound: taxol
|
Antiproliferative activity against human AGS cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay
Antiproliferative activity against human AGS cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay
|
[PMID: 25208345] |
| AGS | IC50 |
53 μM
Compound: Paclitaxel
|
Cytotoxicity against human AGS cells assessed as reduction in cell viability measured after 72 hrs by CCK8 assay
Cytotoxicity against human AGS cells assessed as reduction in cell viability measured after 72 hrs by CCK8 assay
|
[PMID: 32193933] |
| AGS | IC50 |
53 nM
Compound: Paclitaxel
|
Cytotoxicity against human AGS cells after 72 hrs by CCK8 assay
Cytotoxicity against human AGS cells after 72 hrs by CCK8 assay
|
[PMID: 32489099] |
| ARO | IC50 |
0.0002 μM
Compound: Taxol
|
Cytotoxicity against human Aro cells by MTT assay
Cytotoxicity against human Aro cells by MTT assay
|
[PMID: 16539377] |
| ARO | IC50 |
0.0002 μM
Compound: taxol
|
Cytotoxicity against human Aro cells after 72 hrs by MTT assay
Cytotoxicity against human Aro cells after 72 hrs by MTT assay
|
[PMID: 17915851] |
| ASPC1 | IC50 |
20 nM
Compound: 2
|
Cytotoxicity against human AsPC1 cells after 72 hrs by MTT assay
Cytotoxicity against human AsPC1 cells after 72 hrs by MTT assay
|
[PMID: 18081257] |
| ASPC1 | IC50 |
89 nM
Compound: 1,paclitaxel
|
Cytotoxicity against taxol-sensitive human AsPC1 cells after 72 hrs by MTT assay
Cytotoxicity against taxol-sensitive human AsPC1 cells after 72 hrs by MTT assay
|
[PMID: 18951787] |
| ASPC1 | IC50 |
89 nM
Compound: 1
|
Growth inhibition of human AsPC1 cells after 72 hrs by MTT assay
Growth inhibition of human AsPC1 cells after 72 hrs by MTT assay
|
[PMID: 19022679] |
| Astrocyte | ED50 |
<0.01 μg/mL
Compound: 5
|
Astrocyte reversal activity in astrocytes
Astrocyte reversal activity in astrocytes
|
[PMID: 7130988] |
| B16 | IC50 |
19 nM
Compound: 1 (taxol)
|
Concentration required to inhibit the proliferation of B16 melanoma cells was determined
Concentration required to inhibit the proliferation of B16 melanoma cells was determined
|
[PMID: 1346275] |
| B16 | ED50 |
28 nM
Compound: 1
|
Cytotoxicity against B16 melanoma cell line.
Cytotoxicity against B16 melanoma cell line.
|
[PMID: 1359143] |
| B16 | IC50 |
<0.1 μg/mL
Compound: paclitaxel
|
Cytotoxicity against B16 cancer cell line
Cytotoxicity against B16 cancer cell line
|
[PMID: 16384699] |
| B16 | IC50 |
0.08 μM
Compound: Paclitaxel
|
Antiproliferative activity against mouse B16 cell line
Antiproliferative activity against mouse B16 cell line
|
[PMID: 16793260] |
| B16 | GI50 |
0.01 μM
Compound: taxol
|
Cytotoxicity against mouse B16 cells after 72 hrs by MTT colorimetric assay
Cytotoxicity against mouse B16 cells after 72 hrs by MTT colorimetric assay
|
[PMID: 19081249] |
| B16 | IC50 |
0.63 μg/mL
Compound: paclitaxel
|
Cytotoxicity against mouse B16 cells after 44 hrs by MTT assay
Cytotoxicity against mouse B16 cells after 44 hrs by MTT assay
|
[PMID: 19928884] |
| B16 | GI50 |
0.01 μM
Compound: Taxol
|
Cytotoxicity against mouse B16 cells after 72 hrs by MTT assay
Cytotoxicity against mouse B16 cells after 72 hrs by MTT assay
|
[PMID: 20538462] |
| B16 | IC50 |
0.04 μM
Compound: taxol
|
Cytotoxicity against mouse B16 after 48 hrs by SRB assay
Cytotoxicity against mouse B16 after 48 hrs by SRB assay
|
[PMID: 21044847] |
| B16 | IC50 |
56 μM
Compound: Paclitaxel
|
Cytotoxicity against mouse B16 cells assessed as cell viability after 48 hrs by MTT assay
Cytotoxicity against mouse B16 cells assessed as cell viability after 48 hrs by MTT assay
|
[PMID: 25875311] |
| B16 | GI50 |
0.01 μM
Compound: Paclitaxel
|
Cytotoxicity against mouse B16 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
Cytotoxicity against mouse B16 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
|
[PMID: 31945642] |
| B16 | ED50 |
1 μM
Compound: Taxol
|
Effective dose against B16 melanoma cells in microtubule assembly assay
Effective dose against B16 melanoma cells in microtubule assembly assay
|
10.1016/S0960-894X(00)80346-7 |
| B16 | ED50 |
27 nM
Compound: Taxol
|
Effective dose against B16 melanoma cells in cytotoxicity assay
Effective dose against B16 melanoma cells in cytotoxicity assay
|
10.1016/S0960-894X(00)80346-7 |
| B16 | ED50 |
0.7 μM
Compound: 1 (Taxol)
|
Compound was evaluated for the in vitro concentration required to produce 50% stimulation of the microtubule assembly
Compound was evaluated for the in vitro concentration required to produce 50% stimulation of the microtubule assembly
|
10.1016/S0960-894X(00)80402-3 |
| B16 | ED50 |
31.5 nM
Compound: 1 (Taxol)
|
Compound was evaluated for the concentration which inhibits B16 melanoma cell proliferation by 50%
Compound was evaluated for the concentration which inhibits B16 melanoma cell proliferation by 50%
|
10.1016/S0960-894X(00)80402-3 |
| B16 | ED50 |
28 nM
Compound: 1
|
The compound was tested for cytotoxicity against B16 melanoma cells
The compound was tested for cytotoxicity against B16 melanoma cells
|
10.1016/S0960-894X(01)80203-1 |
| B16 | IC50 |
8 nM
Compound: Paclitaxel
|
In vitro antiproliferative activity against B16 cell lines
In vitro antiproliferative activity against B16 cell lines
|
10.1016/S0960-894X(97)10152-4 |
| B16 | IC50 |
<0.02 μg/mL
Compound: 1
|
Cytotoxicity against mouse B16 cells grown in PRIM medium
Cytotoxicity against mouse B16 cells grown in PRIM medium
|
10.1021/np50078a018 |
| B16-F0 | IC50 |
0.021 μM
Compound: PTX
|
Antiproliferative activity against mouse B16-F0 cells assessed as inhibition of cell proliferation measured after 48 hrs by CCK-8 assay
Antiproliferative activity against mouse B16-F0 cells assessed as inhibition of cell proliferation measured after 48 hrs by CCK-8 assay
|
[PMID: 32650183] |
| B16-F1 | GI50 |
0.02 μM
Compound: Taxol
|
Antiproliferative activity against mouse B16-F1 cells assessed as inhibition of cell growth after 48 hrs by sulforhodamine B colorimetric assay
Antiproliferative activity against mouse B16-F1 cells assessed as inhibition of cell growth after 48 hrs by sulforhodamine B colorimetric assay
|
[PMID: 32199690] |
| B16-F10 | IC50 |
19.14 μM
Compound: Taxol
|
Cytotoxicity against mouse B16F10 cells after 24 hrs by MTT assay
Cytotoxicity against mouse B16F10 cells after 24 hrs by MTT assay
|
[PMID: 21964182] |
| B16-F10 | IC50 |
0.53 μM
Compound: Paclitaxel
|
Cytotoxicity activity against mouse B16F10 cells assessed as cell growth inhibition after 48 hrs by MTT assay
Cytotoxicity activity against mouse B16F10 cells assessed as cell growth inhibition after 48 hrs by MTT assay
|
[PMID: 30433783] |
| B16-F10 | IC50 |
8.01 μM
Compound: Paclitaxel
|
Cytotoxicity against mouse B16F10 spheroid cells assessed as reduction in spheroid cell viability after 48 hrs by MTT assay
Cytotoxicity against mouse B16F10 spheroid cells assessed as reduction in spheroid cell viability after 48 hrs by MTT assay
|
[PMID: 30433783] |
| B16-F10 | IC50 |
0.53 μM
Compound: Taxol
|
Cytotoxicity against mouse B16-F10 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay
Cytotoxicity against mouse B16-F10 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay
|
[PMID: 34704758] |
| B16-F10 | IC50 |
<0.001 μM
Compound: Paclitaxel
|
Antiproliferative activity against mouse B16-F10 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
Antiproliferative activity against mouse B16-F10 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
|
[PMID: 36511661] |
| B16-F10 | IC50 |
>1000 nM
Compound: Paclitaxel
|
Antiproliferative activity against mouse B16-F10 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay
Antiproliferative activity against mouse B16-F10 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay
|
[PMID: 36621138] |
| B16-F10 | IC50 |
0.0041 μg/mL
Compound: 3
|
In vitro cytotoxicity against B16F10-mouse melanoma cells.
In vitro cytotoxicity against B16F10-mouse melanoma cells.
|
10.1016/S0960-894X(01)80507-2 |
| BC1 cell line | IC50 |
0.02 μM
Compound: 1
|
Cytotoxicity against human BC1 cells after 72 hrs by SRB assay
Cytotoxicity against human BC1 cells after 72 hrs by SRB assay
|
[PMID: 12088425] |
| BEAS-2B | IC50 |
0.58 μM
Compound: paclitaxel
|
Cytotoxicity against human BEAS2B cells after 48 hrs by MTS assay
Cytotoxicity against human BEAS2B cells after 48 hrs by MTS assay
|
[PMID: 24256484] |
| BEAS-2B | IC50 |
0.58 μM
Compound: Taxol
|
Cytotoxicity against human BEAS2B cells assessed as cell viability after 48 hrs by MTS assay
Cytotoxicity against human BEAS2B cells assessed as cell viability after 48 hrs by MTS assay
|
[PMID: 26068802] |
| BEAS-2B | IC50 |
0.007 μM
Compound: Paclitaxel
|
Antiproliferative activity against human BEAS2B cells after 24 hrs by CCK8 assay
Antiproliferative activity against human BEAS2B cells after 24 hrs by CCK8 assay
|
[PMID: 30392953] |
| BEAS-2B | IC50 |
<0.1 μM
Compound: Paclitaxel
|
Anticancer activity against human BEAS-2B cells assessed as cell growth inhibition measured for 72 hrs by MTT assay
Anticancer activity against human BEAS-2B cells assessed as cell growth inhibition measured for 72 hrs by MTT assay
|
[PMID: 34303874] |
| BEAS-2B | IC50 |
0.008 μM
Compound: PTX
|
Cytotoxicity against human BEAS-2B cells reduction in cell viability measured after 96 hrs by MTT assay
Cytotoxicity against human BEAS-2B cells reduction in cell viability measured after 96 hrs by MTT assay
|
[PMID: 34600241] |
| Bel-7402 | IC50 |
0.93 μM
Compound: paclitaxel
|
Cytotoxicity against human BEL-7402 cells after 24 hrs by SRB assay
Cytotoxicity against human BEL-7402 cells after 24 hrs by SRB assay
|
[PMID: 17896816] |
| Bel-7402 | IC50 |
0.1 μM
Compound: paclitaxel
|
Cytotoxicity against human Bel7402 cells by MTT assay
Cytotoxicity against human Bel7402 cells by MTT assay
|
[PMID: 18001087] |
| Bel-7402 | IC50 |
0.93 μM
Compound: paclitaxel
|
Cytotoxicity against human Bel7402 cells after 24 hrs by SRB assay
Cytotoxicity against human Bel7402 cells after 24 hrs by SRB assay
|
[PMID: 18281952] |
| Bel-7402 | IC50 |
0.095 μM
Compound: paclitaxel
|
Cytotoxicity against human Bel7402 cells after 24 hrs by MTT assay
Cytotoxicity against human Bel7402 cells after 24 hrs by MTT assay
|
[PMID: 19245261] |
| Bel-7402 | IC50 |
6.3 μM
Compound: paclitaxel
|
Cytotoxicity against human Bel7402 cells after 96 hrs by MTT assay
Cytotoxicity against human Bel7402 cells after 96 hrs by MTT assay
|
[PMID: 20560647] |
| Bel-7402 | IC50 |
1.8 μM
Compound: paclitaxel
|
Cytotoxicity against human Bel7402 cells after 3 days by MTT assay
Cytotoxicity against human Bel7402 cells after 3 days by MTT assay
|
[PMID: 20593839] |
| Bel-7402 | IC50 |
6 x 10-8 M
Compound: Taxol
|
Cytotoxicity against human Bel7402 cells after 72 hrs by MTT assay
Cytotoxicity against human Bel7402 cells after 72 hrs by MTT assay
|
[PMID: 20719510] |
| Bel-7402 | IC50 |
1.07 μM
Compound: taxol
|
Cytotoxicity against human Bel7402 after 48 hrs by SRB assay
Cytotoxicity against human Bel7402 after 48 hrs by SRB assay
|
[PMID: 21044847] |
| Bel-7402 | IC50 |
578.2 nM
Compound: Taxol
|
Antiproliferative activity against human Bel7402 cells after 96 hrs by MTT assay
Antiproliferative activity against human Bel7402 cells after 96 hrs by MTT assay
|
[PMID: 21296467] |
| Bel-7402 | IC50 |
6 x 10-9 M
Compound: Taxol
|
Cytotoxicity against human Bel7402 cells after 72 hrs by MTT assay
Cytotoxicity against human Bel7402 cells after 72 hrs by MTT assay
|
[PMID: 21530251] |
| Bel-7402 | IC50 |
1.25 μM
Compound: Taxol
|
Cytotoxicity against human Bel7402 cells after 72 hrs by MTT assay
Cytotoxicity against human Bel7402 cells after 72 hrs by MTT assay
|
[PMID: 22153338] |
| Bel-7402 | IC50 |
1.89 μM
Compound: Taxol
|
Cytotoxicity against human Bel7402 cells after 72 hrs by MTT assay
Cytotoxicity against human Bel7402 cells after 72 hrs by MTT assay
|
[PMID: 22483090] |
| Bel-7402 | IC50 |
0.006 μM
Compound: paclitaxel
|
Cytotoxicity against human Bel7402 cells after 72 hrs by MTT assay
Cytotoxicity against human Bel7402 cells after 72 hrs by MTT assay
|
[PMID: 22583079] |
| Bel-7402 | IC50 |
1.89 μM
Compound: Taxol
|
Antiproliferative activity against human Bel7402 cells assessed as growth inhibition by MTT assay
Antiproliferative activity against human Bel7402 cells assessed as growth inhibition by MTT assay
|
[PMID: 23274570] |
| Bel-7402 | IC50 |
>2 μM
Compound: Taxol
|
Cytotoxicity against human Bel7402 cells by MTT assay
Cytotoxicity against human Bel7402 cells by MTT assay
|
[PMID: 23425970] |
| Bel-7402 | IC50 |
0.006 μM
Compound: Paclitaxel
|
Cytotoxicity against human Bel7402 cells by MTT assay
Cytotoxicity against human Bel7402 cells by MTT assay
|
[PMID: 23547884] |
| Bel-7402 | IC50 |
1.89 μM
Compound: Taxol
|
Cytotoxicity against human Bel7402 cells after 72 hrs by MTT assay
Cytotoxicity against human Bel7402 cells after 72 hrs by MTT assay
|
[PMID: 23644204] |
| Bel-7402 | GI50 |
1.792 nM
Compound: 1, Taxol
|
Growth inhibition of human Bel7402 cells by MTT assay
Growth inhibition of human Bel7402 cells by MTT assay
|
[PMID: 24405702] |
| Bel-7402 | IC50 |
0.011 μM
Compound: Taxol
|
Cytotoxicity against human Bel7402 cells after 96 hrs by MTT assay
Cytotoxicity against human Bel7402 cells after 96 hrs by MTT assay
|
[PMID: 24467317] |
| Bel-7402 | IC50 |
>25 μM
Compound: Taxol
|
Cytotoxicity against human Bel7402 cells assessed as growth inhibition by MTT assay
Cytotoxicity against human Bel7402 cells assessed as growth inhibition by MTT assay
|
[PMID: 24684840] |
| Bel-7402 | IC50 |
1.95 μM
Compound: PTX
|
Antiproliferative activity against human Bel7402 cells after 24 hrs by MTT assay
Antiproliferative activity against human Bel7402 cells after 24 hrs by MTT assay
|
[PMID: 27491707] |
| Bel-7402 | IC50 |
<0.1 μM
Compound: Taxol
|
Cytotoxicity against human Bel7402 cells assessed as cell growth inhibition after 48 hrs by MTT assay
Cytotoxicity against human Bel7402 cells assessed as cell growth inhibition after 48 hrs by MTT assay
|
[PMID: 27887843] |
| Bel-7402 | IC50 |
1.9 μM
Compound: Taxol
|
Cytotoxicity against human Bel7402 cells incubated for 48 hrs by MTT assay
Cytotoxicity against human Bel7402 cells incubated for 48 hrs by MTT assay
|
[PMID: 31042380] |
| Bel-7402 | IC50 |
0.013 μM
Compound: Taxol
|
Anticancer activity against human H7402 cells by MTT assay
Anticancer activity against human H7402 cells by MTT assay
|
[PMID: 33316408] |
| Bel-7402 | IC50 |
>10 μM
Compound: Paclitaxel
|
Cytotoxicity against human Bel7402 cells assessed as inhibition of cell proliferation after 96 hrs by MTT assay
Cytotoxicity against human Bel7402 cells assessed as inhibition of cell proliferation after 96 hrs by MTT assay
|
10.1039/C4MD00573B |
| Bel7402/5-FU | IC50 |
10.54 μM
Compound: TAX
|
Cytotoxicity against human Bel7402/5-FU cells after 72 hrs by MTT assay
Cytotoxicity against human Bel7402/5-FU cells after 72 hrs by MTT assay
|
[PMID: 30677614] |
| BEL-7404 tumor cell line | IC50 |
0.82 μM
Compound: Taxol
|
Cytotoxicity against human Bel7404 cells after 72 hrs by MTT assay
Cytotoxicity against human Bel7404 cells after 72 hrs by MTT assay
|
[PMID: 22153338] |
| BeWo | IC50 |
7.39 μg/mL
Compound: (22) taxol
|
In vitro cytotoxicity of compound against Bewo, human choriocarcinoma was defined by microculture tetrazolium assay
In vitro cytotoxicity of compound against Bewo, human choriocarcinoma was defined by microculture tetrazolium assay
|
[PMID: 12620075] |
| BeWo | IC50 |
0.0001 μM
Compound: Taxol
|
Antiproliferative activity against human BeWo cells assessed as reduction in cell viability after 72 hrs by MTT assay
Antiproliferative activity against human BeWo cells assessed as reduction in cell viability after 72 hrs by MTT assay
|
[PMID: 27010926] |
| BGC-823 | IC50 |
1.15 μM
Compound: taxol
|
Cytotoxicity against human BGC823 cells
Cytotoxicity against human BGC823 cells
|
[PMID: 17911017] |
| BGC-823 | IC50 |
0.007 μM
Compound: paclitaxel
|
Cytotoxicity against human BGC823 cells by MTT assay
Cytotoxicity against human BGC823 cells by MTT assay
|
[PMID: 18001087] |
| BGC-823 | IC50 |
0.0189 μM
Compound: Paclitaxol
|
Antiproliferative activity against human BGC823 cells after 96 hrs by MTT assay
Antiproliferative activity against human BGC823 cells after 96 hrs by MTT assay
|
[PMID: 19091579] |
| BGC-823 | IC50 |
3.3 nM
Compound: paclitaxel
|
Cytotoxicity against human BGC823 cells by MTT assay
Cytotoxicity against human BGC823 cells by MTT assay
|
[PMID: 19708679] |
| BGC-823 | IC50 |
0.04 μM
Compound: paclitaxel
|
Cytotoxicity against human BGC823 cells after 96 hrs by MTT assay
Cytotoxicity against human BGC823 cells after 96 hrs by MTT assay
|
[PMID: 20560647] |
| BGC-823 | IC50 |
1.5 μM
Compound: Paclitaxel
|
Cytotoxicity against human BGC823 cells by MTT assay
Cytotoxicity against human BGC823 cells by MTT assay
|
[PMID: 20716468] |
| BGC-823 | IC50 |
<1 x 10-9 M
Compound: Taxol
|
Cytotoxicity against human BGC823 cells after 72 hrs by MTT assay
Cytotoxicity against human BGC823 cells after 72 hrs by MTT assay
|
[PMID: 20719510] |
| BGC-823 | IC50 |
0.02 μM
Compound: taxol
|
Cytotoxicity against human BGC823 after 48 hrs by SRB assay
Cytotoxicity against human BGC823 after 48 hrs by SRB assay
|
[PMID: 21044847] |
| BGC-823 | IC50 |
9.24 μM
Compound: Paclitaxel
|
Cytotoxicity against human BGC823 cells after 24 hrs by MTT assay
Cytotoxicity against human BGC823 cells after 24 hrs by MTT assay
|
[PMID: 21514015] |
| BGC-823 | IC50 |
<1 x 10-9 M
Compound: Taxol
|
Cytotoxicity against human BGC823 cells after 72 hrs by MTT assay
Cytotoxicity against human BGC823 cells after 72 hrs by MTT assay
|
[PMID: 21530251] |
| BGC-823 | IC50 |
33.09 μM
Compound: Taxol
|
Cytotoxicity against human BGC823 cells by MTT assay
Cytotoxicity against human BGC823 cells by MTT assay
|
[PMID: 21664827] |
| BGC-823 | IC50 |
1.5 μM
Compound: Paclitaxel
|
Cytotoxicity against human BGC823 cells by MTT assay
Cytotoxicity against human BGC823 cells by MTT assay
|
[PMID: 21875764] |
| BGC-823 | IC50 |
3.29 x 10-3 μM
Compound: Paclitaxel
|
Cytotoxicity against human BGC823 cells by MTT assay
Cytotoxicity against human BGC823 cells by MTT assay
|
[PMID: 21928797] |
| BGC-823 | IC50 |
0.0033 μM
Compound: paclitaxel
|
Cytotoxicity against human BGC823 cells by MTT assay
Cytotoxicity against human BGC823 cells by MTT assay
|
[PMID: 22506620] |
| BGC-823 | IC50 |
<0.001 μM
Compound: paclitaxel
|
Cytotoxicity against human BGC823 cells after 72 hrs by MTT assay
Cytotoxicity against human BGC823 cells after 72 hrs by MTT assay
|
[PMID: 22583079] |
| BGC-823 | IC50 |
0.01 μg/mL
Compound: Taxol
|
Cytotoxicity against human BGC823 cells
Cytotoxicity against human BGC823 cells
|
[PMID: 22989532] |
| BGC-823 | IC50 |
<0.001 μM
Compound: Paclitaxel
|
Cytotoxicity against human BGC823 cells by MTT assay
Cytotoxicity against human BGC823 cells by MTT assay
|
[PMID: 23547884] |
| BGC-823 | IC50 |
3.5 nM
Compound: Taxol
|
Cytotoxicity against human BGC823 cells by MTT assay
Cytotoxicity against human BGC823 cells by MTT assay
|
[PMID: 23806112] |
| BGC-823 | GI50 |
3.605 nM
Compound: 1, Taxol
|
Growth inhibition of human BGC823 cells by MTT assay
Growth inhibition of human BGC823 cells by MTT assay
|
[PMID: 24405702] |
| BGC-823 | IC50 |
0.026 μM
Compound: Taxol
|
Cytotoxicity against human BGC823 cells after 96 hrs by MTT assay
Cytotoxicity against human BGC823 cells after 96 hrs by MTT assay
|
[PMID: 24467317] |
| BGC-823 | IC50 |
3.3 x 10-3 μM
Compound: Paclitaxel
|
Cytotoxicity against human BGC823 cells by MTT assay
Cytotoxicity against human BGC823 cells by MTT assay
|
[PMID: 27441892] |
| BGC-823 | IC50 |
9.26 μM
Compound: Paclitaxel
|
Cytotoxicity against human BGC823 cells measured after 24 hrs by MTT assay
Cytotoxicity against human BGC823 cells measured after 24 hrs by MTT assay
|
[PMID: 27769031] |
| BGC-823 | IC50 |
0.8 nM
Compound: Paclitaxel
|
Cytotoxicity against human BGC823 cells assessed as reduction in cell viability after 96 hrs by MTT assay
Cytotoxicity against human BGC823 cells assessed as reduction in cell viability after 96 hrs by MTT assay
|
[PMID: 28530828] |
| BGC-823 | IC50 |
0.001 μM
Compound: Taxol
|
Growth inhibition of human BGC823 cells incubated for 3 days by SRB assay
Growth inhibition of human BGC823 cells incubated for 3 days by SRB assay
|
[PMID: 28625363] |
| BGC-823 | IC50 |
0.0006 μM
Compound: Taxol
|
Growth inhibition of human BGC823 cells after 96 hrs by MTT assay
Growth inhibition of human BGC823 cells after 96 hrs by MTT assay
|
[PMID: 28737396] |
| BGC-823 | IC50 |
0.002 μM
Compound: Paclitaxel
|
Cytotoxicity against human BGC823 cells after 96 hrs by MTT assay
Cytotoxicity against human BGC823 cells after 96 hrs by MTT assay
|
[PMID: 29279273] |
| BGC-823 | IC50 |
0.4 nM
Compound: Taxol
|
Cytotoxicity against human BGC823 cells measured after 48 hrs by MTT assay
Cytotoxicity against human BGC823 cells measured after 48 hrs by MTT assay
|
[PMID: 31050424] |
| BGC-823 | IC50 |
1.3 nM
Compound: Paclitaxel
|
Cytotoxicity against human BGC823 cells after 72 hrs by CCK8 assay
Cytotoxicity against human BGC823 cells after 72 hrs by CCK8 assay
|
[PMID: 32489099] |
| BGC-823 | IC50 |
umol/L μM
Compound: Taxol
|
Antiproliferation activity against human BGC823 cells assessed as reduction in cell viability incubated for 96 hrs by MTT assay
Antiproliferation activity against human BGC823 cells assessed as reduction in cell viability incubated for 96 hrs by MTT assay
|
[PMID: 32546298] |
| BGC-823 | IC50 |
0.004 μM
Compound: Taxol
|
Anticancer activity against human BGC-823 cells by MTT assay
Anticancer activity against human BGC-823 cells by MTT assay
|
[PMID: 33316408] |
| BGC-823 | IC50 |
<0.001 μM
Compound: Paclitaxel
|
Antiproliferative activity against human BGC-823 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
Antiproliferative activity against human BGC-823 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
|
[PMID: 36511661] |
| BGC-823 | IC50 |
0.011 nM
Compound: Paclitaxel
|
Cytotoxicity against human BGC-823 cells assessed as reduction in cell growth measured after 72 hrs by MTT assay
Cytotoxicity against human BGC-823 cells assessed as reduction in cell growth measured after 72 hrs by MTT assay
|
[PMID: 37336771] |
| BNL | IC50 |
0.2 μM
Compound: Taxol
|
Cytotoxicity against mouse BNL cells by MTT assay
Cytotoxicity against mouse BNL cells by MTT assay
|
[PMID: 16539377] |
| Breast carcinoma cell | IC50 |
7.8 μM
Compound: Taxol
|
Cytotoxicity against patient derived inflammatory breast cancer cell spheroids assessed as increase in spheroid dissolution incubated for 24 hrs by propidium iodide/Acridine orange staining based dual-fluorescence viability assay
Cytotoxicity against patient derived inflammatory breast cancer cell spheroids assessed as increase in spheroid dissolution incubated for 24 hrs by propidium iodide/Acridine orange staining based dual-fluorescence viability assay
|
[PMID: 30831408] |
| BT-474 | IC50 |
8.36 nM
Compound: Paclitaxel
|
Cytotoxicity against human BT474 cells after 4 days by MTS/cell proliferation assay
Cytotoxicity against human BT474 cells after 4 days by MTS/cell proliferation assay
|
[PMID: 25098528] |
| BT-474 | IC50 |
13.7 nM
Compound: PT
|
Antiproliferative activity against human BT-474 cells assessed as reduction in cell viability incubated for 72 hrs by CelltiterGlo luminescent assay
Antiproliferative activity against human BT-474 cells assessed as reduction in cell viability incubated for 72 hrs by CelltiterGlo luminescent assay
|
[PMID: 38959729] |
| BT-549 | IC50 |
0.02 μM
Compound: paclitaxel
|
Cytotoxicity against human BT549 cells after 48 hrs by neutral red assay
Cytotoxicity against human BT549 cells after 48 hrs by neutral red assay
|
[PMID: 19879765] |
| BT-549 | IC50 |
0.006 μM
Compound: paclitaxel
|
Antiproliferative activity against human BT549 cells after 48 hrs by alamar blue assay
Antiproliferative activity against human BT549 cells after 48 hrs by alamar blue assay
|
[PMID: 21563750] |
| BT-549 | IC50 |
0.0001 μM
Compound: Taxol
|
Antiproliferative activity against human BT-549 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
Antiproliferative activity against human BT-549 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
|
[PMID: 27010926] |
| BT-549 | GI50 |
4 nM
Compound: Paclitaxel
|
Growth inhibition of human BT549 cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human BT549 cells incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 29655610] |
| BT-549 | GI50 |
4 nM
Compound: Paclitaxel
|
Cytotoxicity against human BT-549 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay
Cytotoxicity against human BT-549 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay
|
[PMID: 33310545] |
| BT-549 | GI50 |
1.5 nM
Compound: 1a; PTX
|
Antiproliferative activity against human BT-549 cells assessed as inhibition of cell growth by SRB assay
Antiproliferative activity against human BT-549 cells assessed as inhibition of cell growth by SRB assay
|
[PMID: 37490800] |
| BXPC-3 | IC50 |
0.09 μM
Compound: Paclitaxel
|
Cytotoxicity against human BxPC3 cells assessed as reduction in cell viability after 72 hrs by MTT assay
Cytotoxicity against human BxPC3 cells assessed as reduction in cell viability after 72 hrs by MTT assay
|
[PMID: 22871217] |
| BXPC-3 | IC50 |
0.011 μM
Compound: 2
|
Antiproliferative activity against human BXPC-3 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay
Antiproliferative activity against human BXPC-3 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay
|
[PMID: 37856840] |
| BXPC-3 | IC50 |
0.005 μM
Compound: PTX
|
Cytotoxicity against human BXPC-3 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay
Cytotoxicity against human BXPC-3 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay
|
[PMID: 38547648] |
| C6 | IC50 |
3.1 nM
Compound: paclitaxel
|
Cytotoxicity against Pgp deficient human LCC6 cells after 72 hrs by sulforhodamine B test
Cytotoxicity against Pgp deficient human LCC6 cells after 72 hrs by sulforhodamine B test
|
[PMID: 18465846] |
| Ca9-22 | IC50 |
>100 μM
Compound: Paclitaxel
|
Cytotoxicity against human Ca9-22 cells
Cytotoxicity against human Ca9-22 cells
|
[PMID: 31945642] |
| Caco-2 | IC50 |
0.007 μg/mL
Compound: taxol
|
Cytotoxicity against human Caco-2 cell line by MTT assay
Cytotoxicity against human Caco-2 cell line by MTT assay
|
[PMID: 16297622] |
| Caco-2 | IC50 |
0.0078 μg/mL
Compound: Paclitaxel
|
Cytotoxicity against human Caco-2 cells after 48 hrs by MTT assay
Cytotoxicity against human Caco-2 cells after 48 hrs by MTT assay
|
[PMID: 17950495] |
| Caco-2 | IC50 |
0.008 μM
Compound: taxol
|
Cytotoxicity against human CaCO2 cells after 24 hrs by MTT assay
Cytotoxicity against human CaCO2 cells after 24 hrs by MTT assay
|
[PMID: 18586491] |
| Caco-2 | IC50 |
0.02 μM
Compound: Taxol
|
Antiproliferative activity against human Caco-2 cells after 72 hrs by imaging analysis
Antiproliferative activity against human Caco-2 cells after 72 hrs by imaging analysis
|
[PMID: 19665384] |
| Caco-2 | IC50 |
0.008 μM
Compound: Taxol
|
Cytotoxicity against human Caco2 cells compound treated for 6 hrs measured 48 hrs post washout by MTT assay
Cytotoxicity against human Caco2 cells compound treated for 6 hrs measured 48 hrs post washout by MTT assay
|
[PMID: 23584542] |
| Caco-2 | IC50 |
0.31 μM
Compound: Paclitaxel
|
Antiproliferative activity against human Caco2 cells after 24 and 72 hrs by MTT assay
Antiproliferative activity against human Caco2 cells after 24 and 72 hrs by MTT assay
|
[PMID: 24941130] |
| Caco-2 | IC50 |
0.014 μM
Compound: Paclitaxel
|
Cytotoxicity against human Caco2 cells assessed as cell growth inhibition
Cytotoxicity against human Caco2 cells assessed as cell growth inhibition
|
[PMID: 26934105] |
| Caco-2 | IC50 |
0.02 μM
Compound: Taxol
|
Antiproliferative activity against human Caco2 cells after 48 hrs by Hoechst 33342 staining-based assay
Antiproliferative activity against human Caco2 cells after 48 hrs by Hoechst 33342 staining-based assay
|
[PMID: 30655216] |
| Caco-2 | IC50 |
0.014 μM
Compound: Taxol
|
Cytotoxicity against human CaCo-2 cells assessed as reduction in cell viability incubated for 48 hrs by Hoechst-33342 staining based cell counting method (Rvb > 25 microM)
Cytotoxicity against human CaCo-2 cells assessed as reduction in cell viability incubated for 48 hrs by Hoechst-33342 staining based cell counting method (Rvb > 25 microM)
|
[PMID: 33422908] |
| Caco-2 | IC50 |
2.1 μM
Compound: Paclitaxel
|
Antiproliferative activity against human Caco-2 cells measured after 72 hrs by SRB method
Antiproliferative activity against human Caco-2 cells measured after 72 hrs by SRB method
|
[PMID: 38340509] |
| Caco-2 | IC50 |
2.8 μM
Compound: Paclitaxel
|
Antiproliferative activity against human Caco2 cells after 48 hrs by MTT assay
Antiproliferative activity against human Caco2 cells after 48 hrs by MTT assay
|
10.1039/C6MD00256K |
| CAKI-1 | GI50 |
158 nM
Compound: Paclitaxel
|
Growth inhibition of human Caki1 cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human Caki1 cells incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 29655610] |
| CAKI-1 | GI50 |
158 nM
Compound: Paclitaxel
|
Cytotoxicity against human CAKI-1 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay
Cytotoxicity against human CAKI-1 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay
|
[PMID: 33310545] |
| CAKI-1 | IC50 |
0.9 nM
Compound: PT
|
Antiproliferative activity against human CAKI-1 cells assessed as reduction in cell viability incubated for 72 hrs by CelltiterGlo luminescent assay
Antiproliferative activity against human CAKI-1 cells assessed as reduction in cell viability incubated for 72 hrs by CelltiterGlo luminescent assay
|
[PMID: 38959729] |
| CAKI-2 | IC50 |
0.01 μM
Compound: PTX
|
Cytotoxicity against human CAKI-2 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay
Cytotoxicity against human CAKI-2 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay
|
[PMID: 38547648] |
| Calu-1 | IC50 |
1.33 μM
Compound: 1
|
Cytotoxicity against human Calu1 cells assessed as inhibition of cell proliferation
Cytotoxicity against human Calu1 cells assessed as inhibition of cell proliferation
|
[PMID: 25466201] |
| CAPAN-1 | IC50 |
3.3 nM
Compound: Taxol
|
Cytotoxicity against human Capan1 cells after 48 hrs by sulforhodamine B assay
Cytotoxicity against human Capan1 cells after 48 hrs by sulforhodamine B assay
|
[PMID: 30528697] |
| Capan-2 | IC50 |
1.7 x 10-2 μM
Compound: Paclitaxel
|
Cytotoxicity against human Capan2 cells by MTT assay
Cytotoxicity against human Capan2 cells by MTT assay
|
[PMID: 27441892] |
| Ca-Ski | IC50 |
2.9 μM
Compound: Paclitaxel
|
Antiproliferative activity against human CaSki cells after 24 hrs by MTT assay
Antiproliferative activity against human CaSki cells after 24 hrs by MTT assay
|
[PMID: 24487193] |
| Ca-Ski | IC50 |
2.9 μM
Compound: Paclitaxel
|
Antiproliferative activity against human CaSki cells after 24 hrs by crystal violet staining-based assay
Antiproliferative activity against human CaSki cells after 24 hrs by crystal violet staining-based assay
|
[PMID: 29407986] |
| CCD 19Lu | IC50 |
2 μg/mL
Compound: Taxol (TAX)
|
Tested for the cytostatic activity as inhibitory concentration against CCD-19Lu (human normal pulmonary) cells
Tested for the cytostatic activity as inhibitory concentration against CCD-19Lu (human normal pulmonary) cells
|
10.1016/S0960-894X(97)00071-1 |
| CCRF-CEM | IC50 |
0.0015 μM
Compound: Taxol
|
Concentration required for growth inhibition of human lymphoblastic leukemic cell line (CCRF-CEM) was determined
Concentration required for growth inhibition of human lymphoblastic leukemic cell line (CCRF-CEM) was determined
|
[PMID: 15324894] |
| CCRF-CEM | IC50 |
0.14 μM
Compound: Taxol
|
Concentration required for growth inhibition of taxol resistant human lymphoblastic leukemic cell line (CCRF-CEM/taxol) was determined
Concentration required for growth inhibition of taxol resistant human lymphoblastic leukemic cell line (CCRF-CEM/taxol) was determined
|
[PMID: 15324894] |
| CCRF-CEM | IC50 |
1.62 μM
Compound: Taxol
|
Concentration required for growth inhibition of vinblastine resistant human lymphoblastic leukemic cell line (CCRF-CEM/VBL) was determined
Concentration required for growth inhibition of vinblastine resistant human lymphoblastic leukemic cell line (CCRF-CEM/VBL) was determined
|
[PMID: 15324894] |
| CCRF-CEM | IC50 |
0.0011 μM
Compound: taxol
|
Antiproliferative activity against human CCRF-CEM cell line
Antiproliferative activity against human CCRF-CEM cell line
|
[PMID: 16759114] |
| CCRF-CEM | IC50 |
0.4843 μM
Compound: taxol
|
Antiproliferative activity against human taxol resistant CCRF-CEM cell line
Antiproliferative activity against human taxol resistant CCRF-CEM cell line
|
[PMID: 16759114] |
| CCRF-CEM | IC50 |
1.731 μM
Compound: taxol
|
Antiproliferative activity against human vinblastine resistant CCRF-CEM cell line
Antiproliferative activity against human vinblastine resistant CCRF-CEM cell line
|
[PMID: 16759114] |
| CCRF-CEM | IC50 |
1.274 nM
Compound: taxol
|
Cytotoxicity against vinblastine-resistant human CCRF-CEM cells after 72 hrs by XTT assay
Cytotoxicity against vinblastine-resistant human CCRF-CEM cells after 72 hrs by XTT assay
|
[PMID: 18450456] |
| CCRF-CEM | IC50 |
1.3 nM
Compound: taxol
|
Cytotoxicity against human CCRF-CEM cells after 72 hrs by XTT assay
Cytotoxicity against human CCRF-CEM cells after 72 hrs by XTT assay
|
[PMID: 18450456] |
| CCRF-CEM | IC50 |
429 nM
Compound: taxol
|
Cytotoxicity against taxol-resistant human CCRF-CEM cells after 72 hrs by XTT assay
Cytotoxicity against taxol-resistant human CCRF-CEM cells after 72 hrs by XTT assay
|
[PMID: 18450456] |
| CCRF-CEM | IC50 |
1.1 nM
Compound: Taxol
|
Cytotoxicity against human CCRF-CEM cells after 72 hrs by XTT-tetrazolium assay
Cytotoxicity against human CCRF-CEM cells after 72 hrs by XTT-tetrazolium assay
|
[PMID: 18752869] |
| CCRF-CEM | IC50 |
0.0031 μM
Compound: taxol
|
Cytotoxicity against human CCRF-CEM cells after 72 hrs by XTT assay
Cytotoxicity against human CCRF-CEM cells after 72 hrs by XTT assay
|
[PMID: 19124250] |
| CCRF-CEM | IC50 |
0.429 μM
Compound: taxol
|
Cytotoxicity against taxol-resistant human CCRF-CEM cells after 72 hrs by XTT assay
Cytotoxicity against taxol-resistant human CCRF-CEM cells after 72 hrs by XTT assay
|
[PMID: 19124250] |
| CCRF-CEM | IC50 |
1.274 μM
Compound: taxol
|
Cytotoxicity against vinblastine-resistant human CCRF-CEM cells after 72 hrs by XTT assay
Cytotoxicity against vinblastine-resistant human CCRF-CEM cells after 72 hrs by XTT assay
|
[PMID: 19124250] |
| CCRF-CEM | IC50 |
0.0012 μM
Compound: Taxol
|
Cytotoxicity against human CCRF-CEM cells after 72 hrs by XTT assay
Cytotoxicity against human CCRF-CEM cells after 72 hrs by XTT assay
|
[PMID: 19576785] |
| CCRF-CEM | IC50 |
0.4 μM
Compound: Taxol
|
Cytotoxicity against human vinblastine-resistant CCRF-CEM cells after 72 hrs by XTT assay
Cytotoxicity against human vinblastine-resistant CCRF-CEM cells after 72 hrs by XTT assay
|
[PMID: 19576785] |
| CCRF-CEM | IC50 |
1.2 μM
Compound: Taxol
|
Cytotoxicity against human taxol-resistant CCRF-CEM cells after 72 hrs by XTT assay
Cytotoxicity against human taxol-resistant CCRF-CEM cells after 72 hrs by XTT assay
|
[PMID: 19576785] |
| CCRF-CEM | IC50 |
0.002 μM
Compound: paclitaxel
|
Antiproliferative activity against human CEM cells after 72 hrs by MTT assay
Antiproliferative activity against human CEM cells after 72 hrs by MTT assay
|
[PMID: 19743863] |
| CCRF-CEM | IC50 |
0.0031 μM
Compound: Taxol
|
Cytotoxicity against human CCRF-CEM cells after 72 hrs by XTT assay
Cytotoxicity against human CCRF-CEM cells after 72 hrs by XTT assay
|
[PMID: 20181487] |
| CCRF-CEM | IC50 |
0.429 μM
Compound: Taxol
|
Cytotoxicity against taxol-resistant human CCRF-CEM cells after 72 hrs by XTT assay
Cytotoxicity against taxol-resistant human CCRF-CEM cells after 72 hrs by XTT assay
|
[PMID: 20181487] |
| CCRF-CEM | IC50 |
1.274 μM
Compound: Taxol
|
Cytotoxicity against vinblastine-resistant human CCRF-CEM cells after 72 hrs by XTT assay
Cytotoxicity against vinblastine-resistant human CCRF-CEM cells after 72 hrs by XTT assay
|
[PMID: 20181487] |
| CCRF-CEM | IC50 |
0.003 μM
Compound: Taxol
|
Cytotoxicity against human CCRF-CEM cells after 72 hrs by XTT assay
Cytotoxicity against human CCRF-CEM cells after 72 hrs by XTT assay
|
[PMID: 21106377] |
| CCRF-CEM | IC50 |
0.43 μM
Compound: Taxol
|
Cytotoxicity against taxol-resistant human CCRF-CEM cells after 72 hrs by XTT assay
Cytotoxicity against taxol-resistant human CCRF-CEM cells after 72 hrs by XTT assay
|
[PMID: 21106377] |
| CCRF-CEM | IC50 |
1.27 μM
Compound: Taxol
|
Cytotoxicity against vinblastine-resistant human CCRF-CEM cells after 72 hrs by XTT assay
Cytotoxicity against vinblastine-resistant human CCRF-CEM cells after 72 hrs by XTT assay
|
[PMID: 21106377] |
| CCRF-CEM | IC50 |
0.003 μM
Compound: Taxol
|
Cytotoxicity against human CCRF-CEM cells after 72 hrs by XTT assay
Cytotoxicity against human CCRF-CEM cells after 72 hrs by XTT assay
|
[PMID: 21144756] |
| CCRF-CEM | IC50 |
0.43 μM
Compound: Taxol
|
Cytotoxicity against Taxol-resistant human CCRF-CEM cells after 72 hrs by XTT assay
Cytotoxicity against Taxol-resistant human CCRF-CEM cells after 72 hrs by XTT assay
|
[PMID: 21144756] |
| CCRF-CEM | IC50 |
1.27 μM
Compound: Taxol
|
Cytotoxicity against vinblastine-resistant human CCRF-CEM cells after 72 hrs by XTT assay
Cytotoxicity against vinblastine-resistant human CCRF-CEM cells after 72 hrs by XTT assay
|
[PMID: 21144756] |
| CCRF-CEM | IC50 |
0.003 μM
Compound: Taxol
|
Cytotoxicity against human CCRF-CEM cells after 72 hrs by XTT assay
Cytotoxicity against human CCRF-CEM cells after 72 hrs by XTT assay
|
[PMID: 21356592] |
| CCRF-CEM | IC50 |
0.43 μM
Compound: Taxol
|
Cytotoxicity against human taxol-resistant CCRF-CEM cells after 72 hrs by XTT assay
Cytotoxicity against human taxol-resistant CCRF-CEM cells after 72 hrs by XTT assay
|
[PMID: 21356592] |
| CCRF-CEM | IC50 |
1.27 μM
Compound: Taxol
|
Cytotoxicity against human vinblastine-resistant CCRF-CEM cells after 72 hrs by XTT assay
Cytotoxicity against human vinblastine-resistant CCRF-CEM cells after 72 hrs by XTT assay
|
[PMID: 21356592] |
| CCRF-CEM | IC50 |
0.27 nM
Compound: Pac
|
Antiproliferative activity against human CEM cells after 48 hrs by sulforhodamine B assay
Antiproliferative activity against human CEM cells after 48 hrs by sulforhodamine B assay
|
[PMID: 21604746] |
| CCRF-CEM | IC50 |
0.27 nM
Compound: Pac
|
Antiproliferative activity against human CEM after 48 hrs by SRB assay
Antiproliferative activity against human CEM after 48 hrs by SRB assay
|
[PMID: 21920638] |
| CCRF-CEM | IC50 |
0.0012 μM
Compound: Taxol
|
Cytotoxicity against human CCRF-CEM cells after 72 hrs by XTT assay
Cytotoxicity against human CCRF-CEM cells after 72 hrs by XTT assay
|
[PMID: 22507893] |
| CCRF-CEM | IC50 |
0.43 μM
Compound: Taxol
|
Cytotoxicity against human taxol-resistant CCRF-CEM cells after 72 hrs by XTT assay
Cytotoxicity against human taxol-resistant CCRF-CEM cells after 72 hrs by XTT assay
|
[PMID: 22507893] |
| CCRF-CEM | IC50 |
1.27 μM
Compound: Taxol
|
Cytotoxicity against human vinblastine-resistant CCRF-CEM cells after 72 hrs by XTT assay
Cytotoxicity against human vinblastine-resistant CCRF-CEM cells after 72 hrs by XTT assay
|
[PMID: 22507893] |
| CCRF-CEM | GI50 |
5 nM
Compound: Paclitaxel
|
Growth inhibition of human CCRF-CEM cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human CCRF-CEM cells incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 29655610] |
| CCRF-CEM | IC50 |
4 nM
Compound: Paclitaxel
|
Antiproliferative activity against human CCRF-CEM cells assessed as reduction in cell viability after 72 hrs by MTS assay
Antiproliferative activity against human CCRF-CEM cells assessed as reduction in cell viability after 72 hrs by MTS assay
|
[PMID: 31419740] |
| CCRF-CEM | GI50 |
5 nM
Compound: Paclitaxel
|
Cytotoxicity against human CCRF-CEM cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay
Cytotoxicity against human CCRF-CEM cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay
|
[PMID: 33310545] |
| CCRF-CEM | IC50 |
0.001 μg/mL
Compound: Taxol (TAX)
|
Tested for the cytostatic activity as inhibitory concentration against CCRF-CEM human leukemia cells
Tested for the cytostatic activity as inhibitory concentration against CCRF-CEM human leukemia cells
|
10.1016/S0960-894X(97)00071-1 |
| CEM-VLB | IC50 |
3340 nM
Compound: Pac
|
Antiproliferative activity against multidrug-resistant human CEM/VLB cells after 48 hrs by sulforhodamine B assay
Antiproliferative activity against multidrug-resistant human CEM/VLB cells after 48 hrs by sulforhodamine B assay
|
[PMID: 21604746] |
| CEM-VLB | IC50 |
3340 nM
Compound: Pac
|
Antiproliferative activity against human multidrug-resistant CEM/VLB cells after 48 hrs by SRB assay
Antiproliferative activity against human multidrug-resistant CEM/VLB cells after 48 hrs by SRB assay
|
[PMID: 21920638] |
| CFPAC-1 | IC50 |
0.047 μM
Compound: Paclitaxel
|
Cytotoxicity against human CFPAC-1 cells after 72 hrs by SRB assay
Cytotoxicity against human CFPAC-1 cells after 72 hrs by SRB assay
|
[PMID: 20800500] |
| CHO | ED50 |
0.35 μM
Compound: taxol
|
Concentration that inhibits cell division by 50% after 72 hr for CHO cells was determined
Concentration that inhibits cell division by 50% after 72 hr for CHO cells was determined
|
[PMID: 1672157] |
| CHO | IC50 |
170 nM
Compound: Pac
|
Antiproliferative activity against CHO cells after 48 hrs by sulforhodamine B assay
Antiproliferative activity against CHO cells after 48 hrs by sulforhodamine B assay
|
[PMID: 21604746] |
| CHO | IC50 |
170 nM
Compound: Pac
|
Antiproliferative activity against human CHO after 48 hrs by SRB assay
Antiproliferative activity against human CHO after 48 hrs by SRB assay
|
[PMID: 21920638] |
| CHO-K1 | IC50 |
15.99 μM
Compound: paclitaxel
|
Cytotoxicity against CHOK1 cells after 72 hrs by MTT assay
Cytotoxicity against CHOK1 cells after 72 hrs by MTT assay
|
[PMID: 19053781] |
| CHO-K1 | GI50 |
5.9 μM
Compound: Paclitaxel
|
Cytotoxicity against human CHOK1 cells after 48 hrs by SRB assay
Cytotoxicity against human CHOK1 cells after 48 hrs by SRB assay
|
[PMID: 21513294] |
| CHO-M19 | IC50 |
<3 ng/mL
Compound: 1
|
Cytotoxicity against Chinese hamster M19 cells
Cytotoxicity against Chinese hamster M19 cells
|
[PMID: 17419065] |
| CHO-TAX 5-6 | IC50 |
520 nM
Compound: Pac
|
Antiproliferative activity against paclitaxel-resistant CHO-TAX 5-6 cells after 48 hrs by sulforhodamine B assay
Antiproliferative activity against paclitaxel-resistant CHO-TAX 5-6 cells after 48 hrs by sulforhodamine B assay
|
[PMID: 21604746] |
| CHO-TAX 5-6 | IC50 |
520 nM
Compound: Pac
|
Antiproliferative activity against paclitaxel-resistant CHO-TAX 5-6 cells after 48 hrs by SRB assay
Antiproliferative activity against paclitaxel-resistant CHO-TAX 5-6 cells after 48 hrs by SRB assay
|
[PMID: 21920638] |
| CHO-VV 3-2 | IC50 |
140 nM
Compound: Pac
|
Antiproliferative activity against paclitaxel-resistant CHO-VV 3-2 cells after 48 hrs by sulforhodamine B assay
Antiproliferative activity against paclitaxel-resistant CHO-VV 3-2 cells after 48 hrs by sulforhodamine B assay
|
[PMID: 21604746] |
| CHO-VV 3-2 | IC50 |
140 nM
Compound: Pac
|
Antiproliferative activity against colchicine and vinblastine-resistant CHO-VV 3-2 cells after 48 hrs by SRB assay
Antiproliferative activity against colchicine and vinblastine-resistant CHO-VV 3-2 cells after 48 hrs by SRB assay
|
[PMID: 21920638] |
| CNE-2 | IC50 |
0.003 μM
Compound: TAX, Taxol
|
Antiproliferative activity against human CNE2 cells after 48 hrs by SRB method
Antiproliferative activity against human CNE2 cells after 48 hrs by SRB method
|
[PMID: 25061803] |
| Col2 | IC50 |
0.02 μM
Compound: 1
|
Cytotoxicity against human Col2 cells after 72 hrs by SRB assay
Cytotoxicity against human Col2 cells after 72 hrs by SRB assay
|
[PMID: 12088425] |
| Col2 | ED50 |
46 nM
Compound: paclitaxel
|
Cytotoxicity against human Col2 cells
Cytotoxicity against human Col2 cells
|
[PMID: 15043407] |
| COLO 205 | IC50 |
3.3 nM
Compound: Paclitaxel
|
Cytotoxicity against COLO205 cells
Cytotoxicity against COLO205 cells
|
[PMID: 17228873] |
| COLO 205 | IC50 |
3.3 nM
Compound: paclitaxel
|
Cytotoxicity against COLO205 cells
Cytotoxicity against COLO205 cells
|
[PMID: 17416524] |
| COLO 205 | GI50 |
0.003 μM
Compound: paclitaxel
|
Cytotoxicity against human COLO205 cells
Cytotoxicity against human COLO205 cells
|
[PMID: 17696332] |
| COLO 205 | IC50 |
3.3 nM
Compound: Paclitaxel
|
Antiproliferative activity against human COLO205 cells after 24 hrs by MTS assay
Antiproliferative activity against human COLO205 cells after 24 hrs by MTS assay
|
[PMID: 19041247] |
| COLO 205 | IC50 |
0.005 μM
Compound: paclitaxel
|
Antiproliferative activity against human COLO205 cells after 48 hrs by alamar blue assay
Antiproliferative activity against human COLO205 cells after 48 hrs by alamar blue assay
|
[PMID: 21563750] |
| COLO 205 | IC50 |
3.31 nM
Compound: Paclitaxel
|
Cytotoxicity against human COLO205 cells after 48 hrs by Alamar blue assay
Cytotoxicity against human COLO205 cells after 48 hrs by Alamar blue assay
|
[PMID: 21779519] |
| COLO 205 | GI50 |
0.003 μM
Compound: Paclitaxel
|
Cytotoxicity against human COLO205 cells by sulforhodamine B assay
Cytotoxicity against human COLO205 cells by sulforhodamine B assay
|
[PMID: 21839640] |
| COLO 205 | IC50 |
0.003 μM
Compound: Taxol
|
Cytotoxicity against human COLO205 cells assessed as growth inhibition by MTT assay
Cytotoxicity against human COLO205 cells assessed as growth inhibition by MTT assay
|
[PMID: 25091926] |
| COLO 205 | GI50 |
7.9 nM
Compound: Paclitaxel
|
Growth inhibition of human COLO205 cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human COLO205 cells incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 29655610] |
| COLO 205 | GI50 |
7.9 nM
Compound: Paclitaxel
|
Cytotoxicity against human COLO 205 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay
Cytotoxicity against human COLO 205 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay
|
[PMID: 33310545] |
| COLO 205 | IC50 |
0.01 μM
Compound: PTX
|
Cytotoxicity against human COLO 205 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay
Cytotoxicity against human COLO 205 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay
|
[PMID: 38547648] |
| COLO 205 | GI50 |
1.76 x 10-9 M
Compound: 5
|
Cytotoxicity against human COLO205 cells
Cytotoxicity against human COLO205 cells
|
[PMID: 7908950] |
| COLO 320DM | IC50 |
0.0045 μg/mL
Compound: taxol
|
Cytotoxicity against human COLO320DM cell line by MTT assay
Cytotoxicity against human COLO320DM cell line by MTT assay
|
[PMID: 16297622] |
| Coronary artery smooth muscle cell line | IC50 |
~~ 1 μM
Compound: paclitaxel
|
In vitro antiproliferative effect on cultured human coronary artery smooth muscle cells (hCASMC)
In vitro antiproliferative effect on cultured human coronary artery smooth muscle cells (hCASMC)
|
[PMID: 15084126] |
| CT26 | IC50 |
>10 μM
Compound: Taxol
|
Cytotoxicity against mouse CT26 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay
Cytotoxicity against mouse CT26 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay
|
[PMID: 34704758] |
| CWR22R | IC50 |
0.08 μM
Compound: Paclitaxel
|
Cytotoxicity against human 22Rv1 cells by MTT assay
Cytotoxicity against human 22Rv1 cells by MTT assay
|
[PMID: 20627721] |
| CWR22R | IC50 |
0.08 μM
Compound: Paclitaxel
|
Cytotoxicity against human 22Rv1 cells by MTT assay
Cytotoxicity against human 22Rv1 cells by MTT assay
|
[PMID: 20716468] |
| CWR22R | IC50 |
0.08 μM
Compound: Paclitaxel
|
Cytotoxicity against human 22Rv1 cells by MTT assay
Cytotoxicity against human 22Rv1 cells by MTT assay
|
[PMID: 21875764] |
| CWR22R | CC50 |
3.9 nM
Compound: Ptxl; PTX
|
Cytotoxicity against PSMA-positive human 22Rv1 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
Cytotoxicity against PSMA-positive human 22Rv1 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
|
[PMID: 31248772] |
| Daoy | IC50 |
0.002 μM
Compound: Paclitaxel
|
Cytotoxicity against human DaOY cells after 96 hrs by MTT assay
Cytotoxicity against human DaOY cells after 96 hrs by MTT assay
|
[PMID: 29279273] |
| DG-75 | IC50 |
10 nM
Compound: Taxol
|
Antiproliferative activity against human DG75 cells after 24 to 72 hrs by alamar blue assay
Antiproliferative activity against human DG75 cells after 24 to 72 hrs by alamar blue assay
|
[PMID: 19717215] |
| DG-75 | IC50 |
10 nM
Compound: Taxol
|
Cytotoxicity against human chemoresistant DG75 cells expressing SERT assessed as decrease in cell viability 10 or 50 uM after 72 hrs Alamar blue assay
Cytotoxicity against human chemoresistant DG75 cells expressing SERT assessed as decrease in cell viability 10 or 50 uM after 72 hrs Alamar blue assay
|
[PMID: 21227702] |
| DLD-1 | IC50 |
27 nM
Compound: Paclitaxel
|
The compound was tested for cell growth inhibition against DLD-1 human colon cancer cells under continuous exposure conditions for 3-4 days
The compound was tested for cell growth inhibition against DLD-1 human colon cancer cells under continuous exposure conditions for 3-4 days
|
[PMID: 10843209] |
| DLD-1 | EC50 |
0.075 μM
Compound: paclitaxel
|
Induction of apoptosis in human DLD1 cells assessed as caspase activation after 24 hrs
Induction of apoptosis in human DLD1 cells assessed as caspase activation after 24 hrs
|
[PMID: 15566300] |
| DLD-1 | IC50 |
0.09 μM
Compound: Paclitaxel
|
Antiproliferative activity against human DLD1 cell line
Antiproliferative activity against human DLD1 cell line
|
[PMID: 16793260] |
| DLD-1 | IC50 |
11 nM
Compound: 2
|
Cytotoxicity against human DLD1 cells after 72 hrs by MTT assay
Cytotoxicity against human DLD1 cells after 72 hrs by MTT assay
|
[PMID: 18081257] |
| DLD-1 | IC50 |
22 nM
Compound: 1,paclitaxel
|
Cytotoxicity against taxol-sensitive human DLD1 cells after 72 hrs by MTT assay
Cytotoxicity against taxol-sensitive human DLD1 cells after 72 hrs by MTT assay
|
[PMID: 18951787] |
| DLD-1 | IC50 |
22 nM
Compound: 1
|
Growth inhibition of human DLD1 cells after 72 hrs by MTT assay
Growth inhibition of human DLD1 cells after 72 hrs by MTT assay
|
[PMID: 19022679] |
| DLD-1 | GI50 |
0.01 μM
Compound: taxol
|
Cytotoxicity against human DLD1 cells after 72 hrs by MTT colorimetric assay
Cytotoxicity against human DLD1 cells after 72 hrs by MTT colorimetric assay
|
[PMID: 19081249] |
| DLD-1 | EC50 |
0.054 μM
Compound: Taxol
|
Induction of apoptosis in human DLD1 cells assessed as caspase activation after 48 hrs
Induction of apoptosis in human DLD1 cells assessed as caspase activation after 48 hrs
|
[PMID: 19500976] |
| DLD-1 | GI50 |
0.01 μM
Compound: Taxol
|
Cytotoxicity against human DLD1 cells after 72 hrs by MTT assay
Cytotoxicity against human DLD1 cells after 72 hrs by MTT assay
|
[PMID: 20538462] |
| DLD-1 | IC50 |
0.05 μM
Compound: paclitaxel
|
Antiproliferative activity against human DLD1 cells after 48 hrs by alamar blue assay
Antiproliferative activity against human DLD1 cells after 48 hrs by alamar blue assay
|
[PMID: 21563750] |
| DLD-1 | IC50 |
39 μM
Compound: Paclitaxel
|
Anticancer activity against human DLD1 cells after 72 hrs by SRB assay
Anticancer activity against human DLD1 cells after 72 hrs by SRB assay
|
[PMID: 21707046] |
| DLD-1 | IC50 |
16 nM
Compound: taxol
|
Antiproliferative activity against human DLD1 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay
Antiproliferative activity against human DLD1 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay
|
[PMID: 25208345] |
| DLD-1 | GI50 |
0.01 μM
Compound: Paclitaxel
|
Cytotoxicity against human DLD-1 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
Cytotoxicity against human DLD-1 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
|
[PMID: 31945642] |
| DLD-1 | IC50 |
0.031 μg/mL
Compound: Paclitaxel
|
Cytotoxicity against human DLD-1 cells assessed as reduction in cell viability incubated for 48 hrs by sulforhodamine B assay
Cytotoxicity against human DLD-1 cells assessed as reduction in cell viability incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 39052090] |
| DLD-1 | GI50 |
0.02 μM
Compound: Paclitaxel
|
Inhibition of cell growth in human DLD-1 cells incubated for 48 hrs by SRB method
Inhibition of cell growth in human DLD-1 cells incubated for 48 hrs by SRB method
|
[PMID: 39093920] |
| DMS-114 | GI50 |
1.23 x 10-8 M
Compound: 5
|
Cytotoxicity against human DMS114 cells
Cytotoxicity against human DMS114 cells
|
[PMID: 7908950] |
| DU-145 | IC50 |
0.00489 μM
Compound: paclitaxel
|
In vitro cytotoxic activity against prostate carcinoma (DU-145) cells assayed by inhibition of [3H]-labeled thymidine incorporation
In vitro cytotoxic activity against prostate carcinoma (DU-145) cells assayed by inhibition of [3H]-labeled thymidine incorporation
|
[PMID: 11728191] |
| DU-145 | IC50 |
2.7 nM
Compound: Paclitaxel
|
Antiproliferative activity against prostate cancer DU-145 cell line using sulforhodamine B(SRB) assay
Antiproliferative activity against prostate cancer DU-145 cell line using sulforhodamine B(SRB) assay
|
[PMID: 15801848] |
| DU-145 | IC50 |
0.005 μM
Compound: Taxol
|
Cytotoxicity against human DU145 cell line by MTS assay
Cytotoxicity against human DU145 cell line by MTS assay
|
[PMID: 16870446] |
| DU-145 | ED50 |
1.3 nM
Compound: 1
|
Cytotoxicity against human DU145 cells by sulforhodamine B assay
Cytotoxicity against human DU145 cells by sulforhodamine B assay
|
[PMID: 17350834] |
| DU-145 | GI50 |
0.005 μM
Compound: paclitaxel
|
Cytotoxicity against human DU145 cells
Cytotoxicity against human DU145 cells
|
[PMID: 17696332] |
| DU-145 | IC50 |
0.005 μM
Compound: Taxol
|
Cytotoxicity against human DU145 cells after 72 hrs by MTT assay
Cytotoxicity against human DU145 cells after 72 hrs by MTT assay
|
[PMID: 18308566] |
| DU-145 | EC50 |
<0.005 μg/mL
Compound: Paclitaxel
|
Cytotoxicity against human DU145 cells
Cytotoxicity against human DU145 cells
|
[PMID: 18640035] |
| DU-145 | EC50 |
<0.005 μg/mL
Compound: Palitaxel
|
Cytotoxicity against human DU145 cells after 3 days by sulforhodamine B assay
Cytotoxicity against human DU145 cells after 3 days by sulforhodamine B assay
|
[PMID: 19193043] |
| DU-145 | IC50 |
4.84 μM
Compound: taxol
|
Cytotoxicity against human DU145 cells after 72 hrs by XTT assay
Cytotoxicity against human DU145 cells after 72 hrs by XTT assay
|
[PMID: 19754130] |
| DU-145 | IC50 |
2.35 x 10-3 μM
Compound: Paclitaxel
|
Cytotoxicity against human DU145 cells
Cytotoxicity against human DU145 cells
|
[PMID: 20036537] |
| DU-145 | IC50 |
0.002 μg/mL
Compound: paclitaxel
|
Cytotoxicity against human DU145 cells after 3 days by SRB assay
Cytotoxicity against human DU145 cells after 3 days by SRB assay
|
[PMID: 20232858] |
| DU-145 | ED50 |
0.003 μM
Compound: paclitaxel
|
Cytotoxicity against human DU145 cells
Cytotoxicity against human DU145 cells
|
[PMID: 20738103] |
| DU-145 | IC50 |
0.01 μM
Compound: taxol
|
Cytotoxicity against human DU145 after 48 hrs by SRB assay
Cytotoxicity against human DU145 after 48 hrs by SRB assay
|
[PMID: 21044847] |
| DU-145 | GI50 |
0.00555 μM
Compound: Paclitaxel
|
Cytotoxicity activity against human DU145 cells assessed as growth inhibition at 10 ug/ml after 72 hrs sulforhodamine B assay
Cytotoxicity activity against human DU145 cells assessed as growth inhibition at 10 ug/ml after 72 hrs sulforhodamine B assay
|
[PMID: 21316977] |
| DU-145 | GI50 |
5.23 nM
Compound: Paclitaxel
|
Cytotoxicity against human DU145 cells after 3 days
Cytotoxicity against human DU145 cells after 3 days
|
[PMID: 21377368] |
| DU-145 | IC50 |
1.3 nM
Compound: Pac
|
Antiproliferative activity against human DU145 cells after 48 hrs by sulforhodamine B assay
Antiproliferative activity against human DU145 cells after 48 hrs by sulforhodamine B assay
|
[PMID: 21604746] |
| DU-145 | IC50 |
>3000 nM
Compound: Paclitaxel
|
Antiproliferative activity against human paclitaxel-resistant DU145 cells by sulforhodamine B assay
Antiproliferative activity against human paclitaxel-resistant DU145 cells by sulforhodamine B assay
|
[PMID: 21775150] |
| DU-145 | IC50 |
2.3 nM
Compound: Paclitaxel
|
Antiproliferative activity against human DU145 cells by sulforhodamine B assay
Antiproliferative activity against human DU145 cells by sulforhodamine B assay
|
[PMID: 21775150] |
| DU-145 | IC50 |
8.626 μM
Compound: Paclitaxel
|
Cytotoxicity against human DU145 cells
Cytotoxicity against human DU145 cells
|
[PMID: 21784631] |
| DU-145 | GI50 |
0.005 μM
Compound: Paclitaxel
|
Cytotoxicity against human DU145 cells by sulforhodamine B assay
Cytotoxicity against human DU145 cells by sulforhodamine B assay
|
[PMID: 21839640] |
| DU-145 | IC50 |
1.3 nM
Compound: Pac
|
Antiproliferative activity against human DU145 after 48 hrs by SRB assay
Antiproliferative activity against human DU145 after 48 hrs by SRB assay
|
[PMID: 21920638] |
| DU-145 | EC50 |
0.0059 μM
Compound: Paclitaxel
|
Cytotoxicity against human DU145 cells by sulforhodamine B assay
Cytotoxicity against human DU145 cells by sulforhodamine B assay
|
[PMID: 22142543] |
| DU-145 | IC50 |
0.0037 μg/mL
Compound: Paclitaxel
|
Cytotoxicity against human DU145 cells by SRB assay
Cytotoxicity against human DU145 cells by SRB assay
|
[PMID: 22204911] |
| DU-145 | GI50 |
3.86 nM
Compound: Paclitaxel
|
Antiproliferative activity against human DU145 cells after 72 hrs by SRB assay
Antiproliferative activity against human DU145 cells after 72 hrs by SRB assay
|
[PMID: 22265685] |
| DU-145 | IC50 |
0.0024 μg/mL
Compound: Paclitaxel
|
Cytotoxicity against human DU145 cells by MTT assay
Cytotoxicity against human DU145 cells by MTT assay
|
[PMID: 22595179] |
| DU-145 | GI50 |
0.00255 μM
Compound: Paclitaxel
|
Cytotoxicity against human DU145 cells after 72 hrs by SRB assay
Cytotoxicity against human DU145 cells after 72 hrs by SRB assay
|
[PMID: 22932313] |
| DU-145 | GI50 |
6.5 nM
Compound: Paclitaxel
|
Growth inhibition of human DU145 cells by SRB assay
Growth inhibition of human DU145 cells by SRB assay
|
[PMID: 23274123] |
| DU-145 | IC50 |
0.03 μM
Compound: Taxol
|
Cytotoxicity against human DU145 cells by MTT assay
Cytotoxicity against human DU145 cells by MTT assay
|
[PMID: 23425970] |
| DU-145 | GI50 |
0.032 μM
Compound: 1a, PXL, Taxol
|
Cytotoxicity against human DU145 cells
Cytotoxicity against human DU145 cells
|
[PMID: 23725535] |
| DU-145 | GI50 |
0.006 μM
Compound: Paclitaxel
|
Cytotoxicity against human DU145 cells by SRB method
Cytotoxicity against human DU145 cells by SRB method
|
[PMID: 23867604] |
| DU-145 | IC50 |
0.005 μM
Compound: Taxol
|
Cytotoxicity against human DU145 cells
Cytotoxicity against human DU145 cells
|
[PMID: 23937981] |
| DU-145 | IC50 |
0.04 μM
Compound: paclitaxel
|
Cytotoxicity against human DU145 cells after 72 hrs by MTT assay
Cytotoxicity against human DU145 cells after 72 hrs by MTT assay
|
[PMID: 24033131] |
| DU-145 | GI50 |
0.006 μM
Compound: Paclitaxel
|
Cytotoxicity against human DU145 cells by SRB assay
Cytotoxicity against human DU145 cells by SRB assay
|
[PMID: 24315191] |
| DU-145 | GI50 |
5.568 nM
Compound: 1, Taxol
|
Growth inhibition of human DU145 cells by MTT assay
Growth inhibition of human DU145 cells by MTT assay
|
[PMID: 24405702] |
| DU-145 | GI50 |
0.006 μM
Compound: paclitaxel
|
Cytotoxicity against human DU145 cells by SRB assay
Cytotoxicity against human DU145 cells by SRB assay
|
[PMID: 24502232] |
| DU-145 | IC50 |
1.5 μM
Compound: Paclitaxel
|
Cytotoxicity against human DU145 cells assessed as reduction in cell viability
Cytotoxicity against human DU145 cells assessed as reduction in cell viability
|
[PMID: 25105722] |
| DU-145 | IC50 |
1.79 μM
Compound: Taxol
|
Cytotoxicity against human DU145 cells after 24 hrs by MTT assay
Cytotoxicity against human DU145 cells after 24 hrs by MTT assay
|
[PMID: 25226363] |
| DU-145 | IC50 |
4.88 nM
Compound: PXL
|
Antiproliferative activity against human DU145 cells after 3 days by SRB assay
Antiproliferative activity against human DU145 cells after 3 days by SRB assay
|
[PMID: 25241925] |
| DU-145 | IC50 |
0.004 μM
Compound: paclitaxel
|
Growth inhibition of human DU145 cells by sulforhodamine B assay
Growth inhibition of human DU145 cells by sulforhodamine B assay
|
[PMID: 25685941] |
| DU-145 | GI50 |
0.0057 μM
Compound: Paclitaxel
|
Antiproliferative activity against human DU145 cells by sulforhodamine B assay
Antiproliferative activity against human DU145 cells by sulforhodamine B assay
|
[PMID: 25770782] |
| DU-145 | IC50 |
3.4 nM
Compound: Taxol
|
Cytotoxicity against human DU145 cells assessed as cell viability after 72 hrs by CCK8 assay
Cytotoxicity against human DU145 cells assessed as cell viability after 72 hrs by CCK8 assay
|
[PMID: 25819096] |
| DU-145 | GI50 |
0.006 μM
Compound: Paclitaxel
|
Antiproliferative activity against human DU145 cells assessed as cell growth inhibition by SRB assay
Antiproliferative activity against human DU145 cells assessed as cell growth inhibition by SRB assay
|
[PMID: 26242242] |
| DU-145 | IC50 |
3.1 μM
Compound: taxol
|
Cytotoxicity against human DU145 cells after 72 hrs by CCK8 assay
Cytotoxicity against human DU145 cells after 72 hrs by CCK8 assay
|
[PMID: 26316467] |
| DU-145 | IC50 |
2.3 nM
Compound: Taxol
|
Cytotoxicity against human DU145 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay
Cytotoxicity against human DU145 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay
|
[PMID: 26697718] |
| DU-145 | IC50 |
0.0038 μM
Compound: Paclitaxel
|
Antiproliferative activity against human DU145 cells after 48 hrs by sulforhodamine B assay
Antiproliferative activity against human DU145 cells after 48 hrs by sulforhodamine B assay
|
[PMID: 26785306] |
| DU-145 | IC50 |
17.2 μM
Compound: PXL
|
Cytotoxicity against human DU-145 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
Cytotoxicity against human DU-145 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
|
[PMID: 27707623] |
| DU-145 | IC50 |
0.011 μM
Compound: Taxol
|
Antiproliferative activity against human DU145 cells after 48 hrs by MTT assay
Antiproliferative activity against human DU145 cells after 48 hrs by MTT assay
|
[PMID: 27979593] |
| DU-145 | IC50 |
2.3 nM
Compound: Paclitaxel
|
Cytotoxicity against human DU145 cells assessed as reduction in cell viability after 72 hrs by CCK-8 assay
Cytotoxicity against human DU145 cells assessed as reduction in cell viability after 72 hrs by CCK-8 assay
|
[PMID: 28598633] |
| DU-145 | IC50 |
1.1 nM
Compound: Paclitaxel
|
Cytotoxicity against human DU145 cells after 72 hrs by MTS assay
Cytotoxicity against human DU145 cells after 72 hrs by MTS assay
|
[PMID: 29406710] |
| DU-145 | GI50 |
6.3 nM
Compound: Paclitaxel
|
Growth inhibition of human DU145 cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human DU145 cells incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 29655610] |
| DU-145 | IC50 |
1.5 nM
Compound: Paclitaxel
|
Cytotoxicity in human DU145 cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay
Cytotoxicity in human DU145 cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay
|
[PMID: 30122035] |
| DU-145 | GI50 |
0.00147 μM
Compound: Paclitaxel
|
Cytotoxicity against human DU145 cells assessed as growth inhibition measured after 48 hrs by SRB assay
Cytotoxicity against human DU145 cells assessed as growth inhibition measured after 48 hrs by SRB assay
|
[PMID: 31059248] |
| DU-145 | IC50 |
0.004 μM
Compound: Paclitaxel
|
Cytotoxicity against human DU145 cells assessed as reduction in cell viability measured after 72 hrs by SRB assay
Cytotoxicity against human DU145 cells assessed as reduction in cell viability measured after 72 hrs by SRB assay
|
[PMID: 31120251] |
| DU-145 | IC50 |
1.15 nM
Compound: Paclitaxel
|
Antiproliferative activity against human DU145 cells
Antiproliferative activity against human DU145 cells
|
[PMID: 31251599] |
| DU-145 | IC50 |
0.001 μM
Compound: Paclitaxel
|
Antiproliferative activity against human DU145 cells measured after 72 hrs by sulforhodamine B assay
Antiproliferative activity against human DU145 cells measured after 72 hrs by sulforhodamine B assay
|
[PMID: 31465222] |
| DU-145 | GI50 |
0.00152 μM
Compound: Paclitaxel
|
Cytotoxicity against human DU145 cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay
Cytotoxicity against human DU145 cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay
|
[PMID: 31534659] |
| DU-145 | GI50 |
<0.016 μM
Compound: Paciltaxel
|
Antiproliferative activity against human DU145 cells by SRB assay
Antiproliferative activity against human DU145 cells by SRB assay
|
[PMID: 31546197] |
| DU-145 | IC50 |
1.5 nM
Compound: Paclitaxel
|
Antiproliferative activity against human DU145 cells measured after 72 hrs by MTS assay
Antiproliferative activity against human DU145 cells measured after 72 hrs by MTS assay
|
[PMID: 31860298] |
| DU-145 | GI50 |
6.3 nM
Compound: Paclitaxel
|
Cytotoxicity against human DU-145 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay
Cytotoxicity against human DU-145 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay
|
[PMID: 33310545] |
| DU-145 | IC50 |
<0.001 μM
Compound: Paclitaxel
|
Antiproliferative activity against human DU-145 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
Antiproliferative activity against human DU-145 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
|
[PMID: 36511661] |
| DU-145 | IC50 |
0.03 μM
Compound: Taxol
|
Antiproliferative activity against human DU-145 cells assessed as reduction in cell viability incubated for 48 hrs by CCk-8 assay
Antiproliferative activity against human DU-145 cells assessed as reduction in cell viability incubated for 48 hrs by CCk-8 assay
|
[PMID: 37329677] |
| ECa-109 cell line | IC50 |
0.14 μM
Compound: paclitaxel
|
Cytotoxicity against human EC109 cells assessed as reduction in cell viability by MTS assay
Cytotoxicity against human EC109 cells assessed as reduction in cell viability by MTS assay
|
[PMID: 25760674] |
| EKVX | GI50 |
79 nM
Compound: Paclitaxel
|
Growth inhibition of human EKVX cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human EKVX cells incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 29655610] |
| EKVX | IC50 |
150 μM
Compound: Paclitaxel
|
Antiproliferative activity against taxane-resistant human EKVX cells after 72 hrs by CellTiter 96 aqueous nonradioactive cell proliferation assay
Antiproliferative activity against taxane-resistant human EKVX cells after 72 hrs by CellTiter 96 aqueous nonradioactive cell proliferation assay
|
[PMID: 29995409] |
| EKVX | GI50 |
79 nM
Compound: Paclitaxel
|
Cytotoxicity against human EKVX cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay
Cytotoxicity against human EKVX cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay
|
[PMID: 33310545] |
| EL4 | IC50 |
1.34 μg/mL
Compound: (22) taxol
|
In vitro cytotoxicity of compound against EL4, mouse thymoma was defined by microculture tetrazolium assay
In vitro cytotoxicity of compound against EL4, mouse thymoma was defined by microculture tetrazolium assay
|
[PMID: 12620075] |
| EL4 | IC50 |
1.7 μM
Compound: Paclitaxel
|
Cytotoxicity against mouse EL4 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
Cytotoxicity against mouse EL4 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
|
[PMID: 25951057] |
| EL4 | IC50 |
0.0001 μM
Compound: Taxol
|
Antiproliferative activity against mouse EL4 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
Antiproliferative activity against mouse EL4 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
|
[PMID: 27010926] |
| EMT6 | IC50 |
0.009 μM
Compound: Paclitaxel
|
Inhibitory activity of compound against murine mammary adenocarcinoma (EMT-6) cell proliferation
Inhibitory activity of compound against murine mammary adenocarcinoma (EMT-6) cell proliferation
|
[PMID: 9379451] |
| EVSA-T | IC50 |
<3 ng/mL
Compound: 1 (paclitaxel)
|
Cytotoxicity against EVSA-T Tumor cell line in SRB Cell viability test
Cytotoxicity against EVSA-T Tumor cell line in SRB Cell viability test
|
[PMID: 10956217] |
| EVSA-T | IC50 |
<3 ng/mL
Compound: 1
|
Cytotoxicity against human EVSA-T cells
Cytotoxicity against human EVSA-T cells
|
[PMID: 17419065] |
| Fibroblast | IC50 |
0.03 μM
Compound: Taxol
|
Antiproliferative activity against human fibroblast after 72 hrs by imaging analysis
Antiproliferative activity against human fibroblast after 72 hrs by imaging analysis
|
[PMID: 19665384] |
| Fibroblast | IC50 |
>0.25 μM
Compound: Paclitaxel
|
Cytotoxicity against human Fibroblasts assessed as cell growth inhibition
Cytotoxicity against human Fibroblasts assessed as cell growth inhibition
|
[PMID: 26934105] |
| Fibroblast | IC50 |
<0.001 μM
Compound: Taxol
|
Antiproliferative activity against human fibroblast cells after 48 hrs by Hoechst 33342 staining-based assay
Antiproliferative activity against human fibroblast cells after 48 hrs by Hoechst 33342 staining-based assay
|
[PMID: 30655216] |
| Fibroblast | IC50 |
0.1 μM
Compound: Taxol
|
Cytotoxicity against human Fibroblast cells assessed as reduction in cell viability incubated for 48 hrs by Hoechst-33342 staining based cell counting method (Rvb > 25 microM)
Cytotoxicity against human Fibroblast cells assessed as reduction in cell viability incubated for 48 hrs by Hoechst-33342 staining based cell counting method (Rvb > 25 microM)
|
[PMID: 33422908] |
| Flp-In-293 | IC50 |
<40 μM
Compound: Paclitaxel
|
Antiproliferative activity against human Flp-In-293 cells expressing ABCB1 assessed as cell growth inhibition incubated for 72 hrs by SRB assay
Antiproliferative activity against human Flp-In-293 cells expressing ABCB1 assessed as cell growth inhibition incubated for 72 hrs by SRB assay
|
[PMID: 35751979] |
| GES1 | IC50 |
106.2 μM
Compound: Taxol
|
Cytotoxicity against human GES-1 cells incubated for 48 hrs by MTT assay
Cytotoxicity against human GES-1 cells incubated for 48 hrs by MTT assay
|
[PMID: 21664827] |
| GES1 | IC50 |
7.9 nM
Compound: Paclitaxel
|
Cytotoxicity against human GES-1 cells after 72 hrs by CCK8 assay
Cytotoxicity against human GES-1 cells after 72 hrs by CCK8 assay
|
[PMID: 32489099] |
| H22 | IC50 |
0.084 μM
Compound: Taxol
|
Antiproliferative activity against mouse H22 cells assessed as inhibition of cell growth by MTT assay
Antiproliferative activity against mouse H22 cells assessed as inhibition of cell growth by MTT assay
|
[PMID: 32339853] |
| H69AR | IC50 |
2.5 nM
Compound: paclitaxel
|
Antiproliferative activity against drug resistant H69AR cell line expressing MRP1 by Alamar Blue assay
Antiproliferative activity against drug resistant H69AR cell line expressing MRP1 by Alamar Blue assay
|
[PMID: 17286393] |
| HaCaT | IC50 |
0.024 μM
Compound: Paclitaxel
|
Cytotoxicity against human HaCaT cells after 72 hrs by MTS assay
Cytotoxicity against human HaCaT cells after 72 hrs by MTS assay
|
[PMID: 21812410] |
| HaCaT | IC50 |
0.024 μM
Compound: paclitaxel
|
Cytotoxicity against human HaCaT cells assessed as reduction in cell viability by MTS assay
Cytotoxicity against human HaCaT cells assessed as reduction in cell viability by MTS assay
|
[PMID: 25760674] |
| HaCaT | IC50 |
0.002 μM
Compound: Taxol
|
Antiproliferative activity against human HaCaT cells after 48 hrs by Hoechst 33342 staining-based assay
Antiproliferative activity against human HaCaT cells after 48 hrs by Hoechst 33342 staining-based assay
|
[PMID: 30655216] |
| HBL-100 | GI50 |
0.017 nM
Compound: Paclitaxel
|
Growth inhibition of human HBL100 cells
Growth inhibition of human HBL100 cells
|
[PMID: 21986585] |
| HCC 2998 | GI50 |
0.003 μM
Compound: paclitaxel
|
Cytotoxicity against human HCC2998 cells
Cytotoxicity against human HCC2998 cells
|
[PMID: 17696332] |
| HCC 2998 | GI50 |
0.003 μM
Compound: Paclitaxel
|
Cytotoxicity against human HCC2998 cells by sulforhodamine B assay
Cytotoxicity against human HCC2998 cells by sulforhodamine B assay
|
[PMID: 21839640] |
| HCC 2998 | GI50 |
1 nM
Compound: Paclitaxel
|
Growth inhibition of human HCC2998 cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human HCC2998 cells incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 29655610] |
| HCC 2998 | GI50 |
1 nM
Compound: Paclitaxel
|
Cytotoxicity against human HCC 2998 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay
Cytotoxicity against human HCC 2998 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay
|
[PMID: 33310545] |
| HCC1806 | IC50 |
0.001 μM
Compound: Paclitaxel
|
Antiproliferative activity against human HCC1806 cells after 24 hrs by CCK8 assay
Antiproliferative activity against human HCC1806 cells after 24 hrs by CCK8 assay
|
[PMID: 30392953] |
| HCC1806 | IC50 |
0.008 μM
Compound: PTX
|
Cytotoxicity against human HCC1806 cells assessed as growth inhibition measured after 96 hrs by MTT assay
Cytotoxicity against human HCC1806 cells assessed as growth inhibition measured after 96 hrs by MTT assay
|
[PMID: 34600241] |
| HCC1806 | IC50 |
0.009 μM
Compound: PTX
|
Cytotoxicity against human HCC1806 cells assessed as reduction in cell viability measured after 96 hrs by MTT assay
Cytotoxicity against human HCC1806 cells assessed as reduction in cell viability measured after 96 hrs by MTT assay
|
[PMID: 34600241] |
| HCC1806 | GI50 |
0.8 nM
Compound: 1a; PTX
|
Antiproliferative activity against human HCC1806 cells assessed as inhibition of cell growth by SRB assay
Antiproliferative activity against human HCC1806 cells assessed as inhibition of cell growth by SRB assay
|
[PMID: 37490800] |
| HCC1937 | IC50 |
>10 μM
Compound: Paclitaxel
|
Antiproliferative activity against exponentially growing adherent human HCC1937 cells assessed as inhibition of cell proliferation after 72 hrs by luminescence detection based ATPlite assay
Antiproliferative activity against exponentially growing adherent human HCC1937 cells assessed as inhibition of cell proliferation after 72 hrs by luminescence detection based ATPlite assay
|
[PMID: 25872984] |
| HCC1937 | GI50 |
3.3 nM
Compound: 1a; PTX
|
Antiproliferative activity against human HCC1937 cells assessed as inhibition of cell growth by SRB assay
Antiproliferative activity against human HCC1937 cells assessed as inhibition of cell growth by SRB assay
|
[PMID: 37490800] |
| HCC827 | IC50 |
1.254 nM
Compound: Paclitaxel
|
Antiproliferative activity against human HCC827 cells incubated for 48 hrs by CCK8 assay
Antiproliferative activity against human HCC827 cells incubated for 48 hrs by CCK8 assay
|
[PMID: 38972078] |
| HCT-116 | IC50 |
1.6 nM
Compound: 1 (Paclitaxel)
|
In vitro cytotoxicity against human colon cancer cell lines (HCT116); Range 1.6-6.0
In vitro cytotoxicity against human colon cancer cell lines (HCT116); Range 1.6-6.0
|
[PMID: 10890157] |
| HCT-116 | IC50 |
4 nM
Compound: paclitaxel
|
Compound was tested for cytotoxicity against human colon tumor cell line (HCT116)
Compound was tested for cytotoxicity against human colon tumor cell line (HCT116)
|
[PMID: 11277525] |
| HCT-116 | IC50 |
4 nM
Compound: paclitaxel
|
Compound was tested for cytotoxicity against human colon tumor cell line (HCT116)
Compound was tested for cytotoxicity against human colon tumor cell line (HCT116)
|
[PMID: 11277526] |
| HCT-116 | IC50 |
35 nM
Compound: 1
|
Inhibitory activity against human colon tumor cell sensitive to paclitaxel.
Inhibitory activity against human colon tumor cell sensitive to paclitaxel.
|
[PMID: 11741476] |
| HCT-116 | IC50 |
0.0026 μM
Compound: Taxol
|
Concentration required for growth inhibition of human HCT116 colon tumor cell line (CCRF-CEM) was determined
Concentration required for growth inhibition of human HCT116 colon tumor cell line (CCRF-CEM) was determined
|
[PMID: 15324894] |
| HCT-116 | GI50 |
<0.001 μM
Compound: Paclitaxel
|
Compound was tested for growth inhibition of human colon carcinoma HCT116 cell line
Compound was tested for growth inhibition of human colon carcinoma HCT116 cell line
|
[PMID: 15546733] |
| HCT-116 | IC50 |
0.0015 μM
Compound: taxol
|
Antiproliferative activity against human HCT116 cell line
Antiproliferative activity against human HCT116 cell line
|
[PMID: 16759114] |
| HCT-116 | IC50 |
8 ng/mL
Compound: Paclitaxel
|
Cytotoxicity against human HCT 116 cells by MTT assay
Cytotoxicity against human HCT 116 cells by MTT assay
|
[PMID: 16872157] |
| HCT-116 | IC50 |
0.0024 μM
Compound: paclitaxel
|
Antitumor activity against human HCT116 cell line
Antitumor activity against human HCT116 cell line
|
[PMID: 16884301] |
| HCT-116 | IC50 |
0.0006 μM
Compound: paclitaxel
|
Cytotoxicity against human HCT116 cells
Cytotoxicity against human HCT116 cells
|
[PMID: 17113288] |
| HCT-116 | IC50 |
8 ng/mL
Compound: paclitaxel
|
Cytotoxicity against human HCT116 cells by MTT assay
Cytotoxicity against human HCT116 cells by MTT assay
|
[PMID: 17927264] |
| HCT-116 | EC50 |
0.024 μM
Compound: taxol
|
Induction of apoptosis in human HCT116 cells assessed as caspase activation after 24 hrs by HTS assay
Induction of apoptosis in human HCT116 cells assessed as caspase activation after 24 hrs by HTS assay
|
[PMID: 18197614] |
| HCT-116 | IC50 |
1.3 nM
Compound: taxol
|
Cytotoxicity against human HCT116 cells after 72 hrs by SRB assay
Cytotoxicity against human HCT116 cells after 72 hrs by SRB assay
|
[PMID: 18450456] |
| HCT-116 | IC50 |
13.6 nM
Compound: paclitaxel
|
Cytotoxicity against human HCT116 cells
Cytotoxicity against human HCT116 cells
|
[PMID: 18606540] |
| HCT-116 | IC50 |
6.18 μM
Compound: Taxol
|
Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay
Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay
|
[PMID: 18701301] |
| HCT-116 | IC50 |
0.061 μM
Compound: paclitaxel
|
Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay
Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay
|
[PMID: 19053781] |
| HCT-116 | IC50 |
0.0011 μM
Compound: taxol
|
Cytotoxicity against human HCT116 cells after 72 hrs by SRB assay
Cytotoxicity against human HCT116 cells after 72 hrs by SRB assay
|
[PMID: 19124250] |
| HCT-116 | IC50 |
1.1 nM
Compound: paclitaxel
|
Cytotoxicity against human HCT116 cells after 4 days by MTT assay
Cytotoxicity against human HCT116 cells after 4 days by MTT assay
|
[PMID: 19128156] |
| HCT-116 | EC50 |
0.023 μM
Compound: Taxol
|
Induction of apoptosis in human HCT116 cells assessed as caspase activation after 48 hrs
Induction of apoptosis in human HCT116 cells assessed as caspase activation after 48 hrs
|
[PMID: 19282188] |
| HCT-116 | IC50 |
4.37 μM
Compound: Taxol
|
Cytotoxicity against human HCT116 cells after 48 hrs by MTT assay
Cytotoxicity against human HCT116 cells after 48 hrs by MTT assay
|
[PMID: 19359185] |
| HCT-116 | EC50 |
0.018 μM
Compound: paclitaxel
|
Induction of apoptosis in human HCT116 cells measured after 48 hrs by cell and caspase based HTS assay
Induction of apoptosis in human HCT116 cells measured after 48 hrs by cell and caspase based HTS assay
|
[PMID: 19467598] |
| HCT-116 | GI50 |
0.06 μM
Compound: paclitaxel
|
Growth inhibition of human HCT116 cells after 48 hrs
Growth inhibition of human HCT116 cells after 48 hrs
|
[PMID: 19467598] |
| HCT-116 | IC50 |
0.0011 μM
Compound: Taxol
|
Cytotoxicity against human HCT116 cells after 72 hrs by SRB assay
Cytotoxicity against human HCT116 cells after 72 hrs by SRB assay
|
[PMID: 19576785] |
| HCT-116 | IC50 |
<0.0008 μM
Compound: Taxol
|
Antiproliferative activity against human HCT116 cells after 72 hrs by imaging analysis
Antiproliferative activity against human HCT116 cells after 72 hrs by imaging analysis
|
[PMID: 19665384] |
| HCT-116 | IC50 |
0.001 μM
Compound: paclitaxel
|
Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay
Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay
|
[PMID: 19743863] |
| HCT-116 | IC50 |
3.5 nM
Compound: Paclitaxel
|
Cytotoxicity against human HCT116 cells after 1 hr by MTT assay
Cytotoxicity against human HCT116 cells after 1 hr by MTT assay
|
[PMID: 19778067] |
| HCT-116 | IC50 |
4.37 μM
Compound: Taxol
|
Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay
Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay
|
[PMID: 19815316] |
| HCT-116 | EC50 |
0.018 μM
Compound: Paclitaxel
|
Induction of apoptosis in human HCT116 cells assessed as caspase activation after 48 hrs by HTS assay
Induction of apoptosis in human HCT116 cells assessed as caspase activation after 48 hrs by HTS assay
|
[PMID: 20034792] |
| HCT-116 | GI50 |
0.06 μM
Compound: Paclitaxel
|
Growth inhibition of human HCT116 cells after 48 hrs
Growth inhibition of human HCT116 cells after 48 hrs
|
[PMID: 20034792] |
| HCT-116 | IC50 |
0.0013 μM
Compound: Taxol
|
Cytotoxicity against human HCT116 cells after 72 hrs by SRB assay
Cytotoxicity against human HCT116 cells after 72 hrs by SRB assay
|
[PMID: 20181487] |
| HCT-116 | IC50 |
3.21 x 10-3 μM
Compound: Paclitaxel
|
Cytotoxicity against human HCT116 cells by MTT assay
Cytotoxicity against human HCT116 cells by MTT assay
|
[PMID: 20553003] |
| HCT-116 | IC50 |
2 nM
Compound: Paclitaxel
|
Growth inhibition of human HCT116 cells after 96 hrs by sulforhodamine B assay
Growth inhibition of human HCT116 cells after 96 hrs by sulforhodamine B assay
|
[PMID: 20943401] |
| HCT-116 | IC50 |
4.37 μM
Compound: Taxol
|
Cytotoxicity against human HCT116 cells after 48 hrs by MTT assay
Cytotoxicity against human HCT116 cells after 48 hrs by MTT assay
|
[PMID: 21067933] |
| HCT-116 | IC50 |
0.0013 μM
Compound: Taxol
|
Cytotoxicity against human HCT116 cells after 72 hrs by SRB assay
Cytotoxicity against human HCT116 cells after 72 hrs by SRB assay
|
[PMID: 21144756] |
| HCT-116 | IC50 |
4.37 μM
Compound: Taxol
|
Cytotoxicity against human HCT116 cells after 48 hrs by MTT assay
Cytotoxicity against human HCT116 cells after 48 hrs by MTT assay
|
[PMID: 21342735] |
| HCT-116 | IC50 |
0.05 μM
Compound: paclitaxel
|
Cytotoxicity against human HCT116 cells by MTT assay
Cytotoxicity against human HCT116 cells by MTT assay
|
[PMID: 22691179] |
| HCT-116 | IC50 |
4 nM
Compound: PTX
|
Cytotoxicity against human HCT116 assessed as growth inhibition after 72 hrs by Celltiter-Glo luminescent assay
Cytotoxicity against human HCT116 assessed as growth inhibition after 72 hrs by Celltiter-Glo luminescent assay
|
[PMID: 23214452] |
| HCT-116 | GI50 |
0.01 μM
Compound: 1a, PXL, Taxol
|
Cytotoxicity against human HCT116 cells
Cytotoxicity against human HCT116 cells
|
[PMID: 23725535] |
| HCT-116 | IC50 |
0.00613 μM
Compound: Paclitaxel
|
Cytotoxicity against human HCT116 cells after 96 hrs by MTT assay
Cytotoxicity against human HCT116 cells after 96 hrs by MTT assay
|
[PMID: 23746477] |
| HCT-116 | IC50 |
0.045 μg/mL
Compound: Paclitaxel
|
Cytotoxicity against human HCT116 cells after 48 hrs by MTT assay
Cytotoxicity against human HCT116 cells after 48 hrs by MTT assay
|
[PMID: 23755851] |
| HCT-116 | IC50 |
0.38 μg/mL
Compound: Paclitaxel
|
Cytotoxicity against human HCT116 cells after 48 hrs by MTT method
Cytotoxicity against human HCT116 cells after 48 hrs by MTT method
|
[PMID: 24657569] |
| HCT-116 | IC50 |
69 nM
Compound: Paclitaxel
|
Cytotoxicity against human HCT116 cells assessed as growth inhibition after 72 hrs by MTT assay
Cytotoxicity against human HCT116 cells assessed as growth inhibition after 72 hrs by MTT assay
|
[PMID: 24929344] |
| HCT-116 | IC50 |
18 nM
Compound: taxol
|
Antiproliferative activity against human HCT116 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay
Antiproliferative activity against human HCT116 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay
|
[PMID: 25208345] |
| HCT-116 | IC50 |
0.004 μM
Compound: Paclitaxel
|
Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay
Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay
|
[PMID: 25462279] |
| HCT-116 | IC50 |
1.55 μM
Compound: 1
|
Cytotoxicity against human HCT116 cells assessed as inhibition of cell proliferation
Cytotoxicity against human HCT116 cells assessed as inhibition of cell proliferation
|
[PMID: 25466201] |
| HCT-116 | IC50 |
2.7 nM
Compound: Paclitaxel
|
Cytotoxicity against human HCT116 cells after 72 hrs by cell counting Kit-8 assay
Cytotoxicity against human HCT116 cells after 72 hrs by cell counting Kit-8 assay
|
[PMID: 25499433] |
| HCT-116 | IC50 |
6.1 nM
Compound: 28
|
Antiproliferative activity against human HCT116 cells after 72 hrs by WST8 assay
Antiproliferative activity against human HCT116 cells after 72 hrs by WST8 assay
|
[PMID: 25625617] |
| HCT-116 | IC50 |
0.0049 μM
Compound: Taxol
|
Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay
Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay
|
[PMID: 25771484] |
| HCT-116 | IC50 |
0.0028 μM
Compound: 1
|
Cytotoxicity against human HCT116 cells assessed as decrease in cell protein incubated for 48 hrs
Cytotoxicity against human HCT116 cells assessed as decrease in cell protein incubated for 48 hrs
|
[PMID: 26448037] |
| HCT-116 | IC50 |
1.95 x 10-8 mg/mL
Compound: Taxol
|
Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay
Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay
|
[PMID: 26920798] |
| HCT-116 | GI50 |
5.21 μg/mL
Compound: Paclitaxel
|
Cytotoxicity against human HCT116 cells after 48 and 72 hrs by MTT assay
Cytotoxicity against human HCT116 cells after 48 and 72 hrs by MTT assay
|
[PMID: 26927426] |
| HCT-116 | IC50 |
0.003 μM
Compound: Paclitaxel
|
Cytotoxicity against human HCT116 cells assessed as cell growth inhibition
Cytotoxicity against human HCT116 cells assessed as cell growth inhibition
|
[PMID: 26934105] |
| HCT-116 | IC50 |
0.06727 μM
Compound: Paclitaxel
|
Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay
Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay
|
[PMID: 27017265] |
| HCT-116 | CC50 |
1.85 μg/mL
Compound: Paclitaxel
|
Cytotoxicity against human HCT116 cells by MTT assay
Cytotoxicity against human HCT116 cells by MTT assay
|
[PMID: 27301367] |
| HCT-116 | IC50 |
0.9 x 10-3 μM
Compound: Paclitaxel
|
Cytotoxicity against human HCT116 cells by MTT assay
Cytotoxicity against human HCT116 cells by MTT assay
|
[PMID: 27441892] |
| HCT-116 | IC50 |
3.3 μM
Compound: Paclitaxel
|
Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay
Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay
|
[PMID: 27748595] |
| HCT-116 | IC50 |
<0.1 μM
Compound: Taxol
|
Cytotoxicity against human HCT116 cells assessed as cell growth inhibition after 48 hrs by MTT assay
Cytotoxicity against human HCT116 cells assessed as cell growth inhibition after 48 hrs by MTT assay
|
[PMID: 27887843] |
| HCT-116 | GI50 |
0.026 μg/mL
Compound: Paclitaxel
|
Cytotoxicity against human HCT116 cells by MTT assay
Cytotoxicity against human HCT116 cells by MTT assay
|
[PMID: 27914801] |
| HCT-116 | GI50 |
0.1279 μg/mL
Compound: Paclitaxel
|
Cytotoxicity against human HCT116 cells assessed as growth inhibition after 48 hrs by MTT assay
Cytotoxicity against human HCT116 cells assessed as growth inhibition after 48 hrs by MTT assay
|
[PMID: 28110868] |
| HCT-116 | IC50 |
0.03 μM
Compound: Taxol
|
Growth inhibition of human HCT116 cells incubated for 3 days by SRB assay
Growth inhibition of human HCT116 cells incubated for 3 days by SRB assay
|
[PMID: 28625363] |
| HCT-116 | IC50 |
0.0002 μM
Compound: Taxol
|
Growth inhibition of human HCT116 cells after 96 hrs by MTT assay
Growth inhibition of human HCT116 cells after 96 hrs by MTT assay
|
[PMID: 28737396] |
| HCT-116 | IC50 |
4.1 nM
Compound: Taxol
|
Antiproliferative activity against human HCT116 cells after 72 hrs by phosphatase assay
Antiproliferative activity against human HCT116 cells after 72 hrs by phosphatase assay
|
[PMID: 28857558] |
| HCT-116 | IC50 |
1.37 μM
Compound: Taxol
|
Antiproliferative activity against human HCT116 cells after 48 hrs by MTS assay
Antiproliferative activity against human HCT116 cells after 48 hrs by MTS assay
|
[PMID: 29172082] |
| HCT-116 | IC50 |
0.014 μM
Compound: Paclitaxel
|
Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay
Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay
|
[PMID: 29223717] |
| HCT-116 | IC50 |
0.038 μM
Compound: Paclitaxel
|
Cytotoxicity against human HCT116 cells after 96 hrs by MTT assay
Cytotoxicity against human HCT116 cells after 96 hrs by MTT assay
|
[PMID: 29279273] |
| HCT-116 | IC50 |
0.02 μM
Compound: Taxol
|
Cytotoxicity against human HCT116 cells assessed as reduction in cell viability incubated for 24 hrs by CCK8 assay
Cytotoxicity against human HCT116 cells assessed as reduction in cell viability incubated for 24 hrs by CCK8 assay
|
[PMID: 29395979] |
| HCT-116 | IC50 |
4.1 nM
Compound: Taxol
|
Growth inhibition of human HCT116 cells after 72 hrs by phosphatase assay
Growth inhibition of human HCT116 cells after 72 hrs by phosphatase assay
|
[PMID: 29439899] |
| HCT-116 | IC50 |
33.8 nM
Compound: Paclitaxel
|
Cytotoxicity against CD133 positive human HCT116 cells
Cytotoxicity against CD133 positive human HCT116 cells
|
[PMID: 29468872] |
| HCT-116 | GI50 |
4 nM
Compound: Paclitaxel
|
Growth inhibition of human HCT116 cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human HCT116 cells incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 29655610] |
| HCT-116 | IC50 |
0.0023 μM
Compound: PTX
|
Cytotoxicity against human HCT116 cells assessed as cell growth inhibition after 48 hrs by sulforhodamine B assay
Cytotoxicity against human HCT116 cells assessed as cell growth inhibition after 48 hrs by sulforhodamine B assay
|
[PMID: 30633861] |
| HCT-116 | IC50 |
0.0038 μM
Compound: PTX
|
Growth inhibition human HCT116 cells after 72 hrs by MTS assay
Growth inhibition human HCT116 cells after 72 hrs by MTS assay
|
[PMID: 30633861] |
| HCT-116 | IC50 |
<0.001 μM
Compound: Taxol
|
Antiproliferative activity against human HCT116 cells after 48 hrs by Hoechst 33342 staining-based assay
Antiproliferative activity against human HCT116 cells after 48 hrs by Hoechst 33342 staining-based assay
|
[PMID: 30655216] |
| HCT-116 | IC50 |
2.61 nM
Compound: PTX
|
Cytotoxicity against human HCT-116 cells after 72 hrs by SRB assay
Cytotoxicity against human HCT-116 cells after 72 hrs by SRB assay
|
[PMID: 30819618] |
| HCT-116 | IC50 |
1.8 nM
Compound: Taxol
|
Cytotoxicity against human HCT116 cells measured after 48 hrs by MTT assay
Cytotoxicity against human HCT116 cells measured after 48 hrs by MTT assay
|
[PMID: 31050424] |
| HCT-116 | IC50 |
0.11 pM
Compound: Taxol
|
Antiproliferative activity against human HCT116 cells assessed as inhibition of cell viability after 48 hrs by MTS assay
Antiproliferative activity against human HCT116 cells assessed as inhibition of cell viability after 48 hrs by MTS assay
|
[PMID: 31494469] |
| HCT-116 | IC50 |
0.0002 μM
Compound: Taxol
|
Antiproliferation activity against human HCT116 cells assessed as reduction in cell viability incubated for 96 hrs by MTT assay
Antiproliferation activity against human HCT116 cells assessed as reduction in cell viability incubated for 96 hrs by MTT assay
|
[PMID: 32546298] |
| HCT-116 | IC50 |
0.006 μM
Compound: Paclitaxel
|
Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
|
[PMID: 32633512] |
| HCT-116 | IC50 |
0.02 μM
Compound: PTX
|
Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell proliferation measured after 48 hrs by CCK-8 assay
Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell proliferation measured after 48 hrs by CCK-8 assay
|
[PMID: 32650183] |
| HCT-116 | IC50 |
915 ng/mL
Compound: Paclitaxel
|
Cytotoxicity against human HCT-116 cells by MTT assay
Cytotoxicity against human HCT-116 cells by MTT assay
|
[PMID: 32731188] |
| HCT-116 | GI50 |
4 nM
Compound: Paclitaxel
|
Cytotoxicity against human HCT-116 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay
Cytotoxicity against human HCT-116 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay
|
[PMID: 33310545] |
| HCT-116 | IC50 |
0.002 μM
Compound: Taxol
|
Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability incubated for 48 hrs by Hoechst-33342 staining based cell counting method (Rvb > 25 microM)
Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability incubated for 48 hrs by Hoechst-33342 staining based cell counting method (Rvb > 25 microM)
|
[PMID: 33422908] |
| HCT-116 | IC50 |
0.03 μM
Compound: Paclitaxel
|
Cytotoxicity against human HCT-116 cells assessed as cell growth inhibition after 48 hrs by MTT assay
Cytotoxicity against human HCT-116 cells assessed as cell growth inhibition after 48 hrs by MTT assay
|
[PMID: 33459007] |
| HCT-116 | IC50 |
7.7 μM
Compound: Paclitaxel
|
Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability measured after 48 hrs by MTS assay
Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability measured after 48 hrs by MTS assay
|
[PMID: 33529025] |
| HCT-116 | IC50 |
0.021 μM
Compound: Paclitaxel
|
Antiproliferative activity against human HCT-116 assessed as reduction in cell viability measured after 48 hrs by MTT assay
Antiproliferative activity against human HCT-116 assessed as reduction in cell viability measured after 48 hrs by MTT assay
|
[PMID: 34175541] |
| HCT-116 | IC50 |
0.02 μM
Compound: Taxol
|
Anticancer activity against human HCT-116 cells assessed as inhibition of cell proliferation measured after 72 hrs by CCK8 reagent assay
Anticancer activity against human HCT-116 cells assessed as inhibition of cell proliferation measured after 72 hrs by CCK8 reagent assay
|
[PMID: 34399390] |
| HCT-116 | IC50 |
7.48 nM
Compound: PTX
|
Antiproliferative activity against human HCT116 cells incubated for 72 hrs by MTT assay
Antiproliferative activity against human HCT116 cells incubated for 72 hrs by MTT assay
|
[PMID: 34648295] |
| HCT-116 | IC50 |
2.202 μM
Compound: Taxol
|
Cytotoxicity against human HCT-116 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay
Cytotoxicity against human HCT-116 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay
|
[PMID: 34704758] |
| HCT-116 | IC50 |
0.005 μM
Compound: PTX
|
Antiproliferative activity against human HCT-116 cells after 48 hrs by MTT assay
Antiproliferative activity against human HCT-116 cells after 48 hrs by MTT assay
|
[PMID: 35065411] |
| HCT-116 | IC50 |
2.9 μg/mL
Compound: Taxol
|
Cytotoxicity against human HCT-116 cells by MTT assay
Cytotoxicity against human HCT-116 cells by MTT assay
|
[PMID: 36325400] |
| HCT-116 | IC50 |
62.9 nM
Compound: Abraxane
|
Antiproliferative activity against human HCT-116 cells measured after 72 hrs by MTT assay
Antiproliferative activity against human HCT-116 cells measured after 72 hrs by MTT assay
|
[PMID: 36471625] |
| HCT-116 | IC50 |
<0.001 μM
Compound: Paclitaxel
|
Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
|
[PMID: 36511661] |
| HCT-116 | IC50 |
23.97 nM
Compound: PTX
|
Antiproliferative activity against human HCT116 cells assessed as inhibition of proliferation measured after 24 hrs by CCK-8 assay
Antiproliferative activity against human HCT116 cells assessed as inhibition of proliferation measured after 24 hrs by CCK-8 assay
|
[PMID: 37301075] |
| HCT-116 | IC50 |
0.005 μM
Compound: Paclitaxel
|
Cytotoxicity against human HCT-116 cells assessed as reduction in cell growth measured after 72 hrs by MTT assay
Cytotoxicity against human HCT-116 cells assessed as reduction in cell growth measured after 72 hrs by MTT assay
|
[PMID: 37336771] |
| HCT-116 | IC50 |
0.896 nM
Compound: 1
|
Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay
Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay
|
[PMID: 37544183] |
| HCT-116 | IC50 |
27.9 nM
Compound: Paclitaxel
|
Antiproliferative activity against human HCT-116 cells measured after 72 hrs by SRB method
Antiproliferative activity against human HCT-116 cells measured after 72 hrs by SRB method
|
[PMID: 38340509] |
| HCT-116 | IC50 |
0.005 μM
Compound: PTX
|
Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability measured after 72 hrs
Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability measured after 72 hrs
|
[PMID: 38430854] |
| HCT-116 | IC50 |
2.4 nM
Compound: 1 (Paclitaxel)
|
Compound is evaluated for an in vitro cytotoxicity assay against HCT116 tumor cell lines
Compound is evaluated for an in vitro cytotoxicity assay against HCT116 tumor cell lines
|
[PMID: 7783160] |
| HCT-116 | IC50 |
2 nM
Compound: Taxol
|
Compound was tested for inhibition of proliferation of human colon cancer cell line (HCT116)
Compound was tested for inhibition of proliferation of human colon cancer cell line (HCT116)
|
10.1016/0960-894X(94)80020-0 |
| HCT-116 | IC50 |
1 nM
Compound: 1
|
In vitro cytotoxicity determined against HCT116 cell line as the ratio of IC50 to that of paclitaxel
In vitro cytotoxicity determined against HCT116 cell line as the ratio of IC50 to that of paclitaxel
|
10.1016/0960-894X(95)00453-Z |
| HCT-116 | IC50 |
2.4 nM
Compound: 1
|
In vitro cytotoxicity was determined by inhibition against HCT116 cell line proliferation after 72 hours of incubation; value ranges from 2.4-4.0 nM
In vitro cytotoxicity was determined by inhibition against HCT116 cell line proliferation after 72 hours of incubation; value ranges from 2.4-4.0 nM
|
10.1016/0960-894X(95)00453-Z |
| HCT-116 | IC50 |
4 nM
Compound: Paclitaxel
|
In vitro inhibition of proliferation of human colon cancer line 116 after 72 hrs incubation.
In vitro inhibition of proliferation of human colon cancer line 116 after 72 hrs incubation.
|
10.1016/S0960-894X(00)80075-X |
| HCT-116 | IC50 |
0.004 μM
Compound: 1 (Paclitaxel)
|
Compound was tested for its cytotoxicity against human colon cancer cell line HCT116
Compound was tested for its cytotoxicity against human colon cancer cell line HCT116
|
10.1016/S0960-894X(01)80385-1 |
| HCT-116 | IC50 |
0.004 μM
Compound: 1 (Taxol)
|
Compound was evaluated by a cytotoxicity assay in HCT116 human colon carcinoma cell line
Compound was evaluated by a cytotoxicity assay in HCT116 human colon carcinoma cell line
|
10.1016/S0960-894X(01)80980-X |
| HCT-116 | IC50 |
2 nM
Compound: 1
|
The compound was evaluated in vitro for inhibition of human colon cancer cell line HCT116
The compound was evaluated in vitro for inhibition of human colon cancer cell line HCT116
|
10.1016/S0960-894X(97)10142-1 |
| HCT-116 | IC50 |
<0.02 μg/mL
Compound: 1
|
Cytotoxicity against human HCT116 cells
Cytotoxicity against human HCT116 cells
|
10.1021/np50078a018 |
| HCT-116 | GI50 |
0.026 μg/mL
Compound: Paclitaxel
|
Cytotoxicity against human HCT116 cells incubated for 1 to 11 days by MTT assay
Cytotoxicity against human HCT116 cells incubated for 1 to 11 days by MTT assay
|
10.1039/C5MD00404G |
| HCT-116 | GI50 |
6.69 mM
Compound: Paclitaxel
|
Cytotoxicity against human HCT116 cells by MTT assay
Cytotoxicity against human HCT116 cells by MTT assay
|
10.1039/C6MD00278A |
| HCT-116/VM46 | IC50 |
>200 nM
Compound: Taxol
|
Growth inhibition of human HCT116/VM46 cells over-expressing P-gp after 72 hrs by phosphatase assay
Growth inhibition of human HCT116/VM46 cells over-expressing P-gp after 72 hrs by phosphatase assay
|
[PMID: 29439899] |
| HCT-15 | ED50 |
0.54 μM
Compound: Paclitaxel
|
Effective dose against HCT-15 cell line.
Effective dose against HCT-15 cell line.
|
[PMID: 11728187] |
| HCT-15 | IC50 |
438 nM
Compound: Placlitaxel (TAXOL)
|
Inhibitory concentration against HCT-15 cells was evaluated
Inhibitory concentration against HCT-15 cells was evaluated
|
[PMID: 15341492] |
| HCT-15 | GI50 |
0.3 μM
Compound: Paclitaxel
|
Compound was tested for growth inhibition of multidrug resistant tumor HCT-15 cell line
Compound was tested for growth inhibition of multidrug resistant tumor HCT-15 cell line
|
[PMID: 15546733] |
| HCT-15 | IC50 |
79.4 nM
Compound: paclitaxel
|
Antiproliferative activity against drug resistant HCT15 cell line expressing MDR1 by Alamar Blue assay
Antiproliferative activity against drug resistant HCT15 cell line expressing MDR1 by Alamar Blue assay
|
[PMID: 17286393] |
| HCT-15 | GI50 |
0.158 μM
Compound: paclitaxel
|
Cytotoxicity against human HCT15 cells
Cytotoxicity against human HCT15 cells
|
[PMID: 17696332] |
| HCT-15 | GI50 |
0.011 μM
Compound: Paclitaxel
|
Antiproliferative activity against human HCT15 cells by SRB assay
Antiproliferative activity against human HCT15 cells by SRB assay
|
[PMID: 19394218] |
| HCT-15 | GI50 |
0.83 μM
Compound: Paclitaxel
|
Antiproliferative activity against multidrug resistant human HCT15/CLO2 cells by SRB assay
Antiproliferative activity against multidrug resistant human HCT15/CLO2 cells by SRB assay
|
[PMID: 19394218] |
| HCT-15 | IC50 |
140 nM
Compound: Paclitaxel
|
Growth inhibition of human HCT15 cells after 96 hrs by sulforhodamine B assay
Growth inhibition of human HCT15 cells after 96 hrs by sulforhodamine B assay
|
[PMID: 20943401] |
| HCT-15 | GI50 |
0.158 μM
Compound: Paclitaxel
|
Cytotoxicity against human HCT15 cells by sulforhodamine B assay
Cytotoxicity against human HCT15 cells by sulforhodamine B assay
|
[PMID: 21839640] |
| HCT-15 | IC50 |
90 nM
Compound: PTX
|
Cytotoxicity against human HCT15 cells assessed as growth inhibition after 72 hrs by Celltiter-Glo luminescent assay
Cytotoxicity against human HCT15 cells assessed as growth inhibition after 72 hrs by Celltiter-Glo luminescent assay
|
[PMID: 23214452] |
| HCT-15 | IC50 |
0.12 μM
Compound: Taxol
|
Cytotoxicity against human HCT15 cells by MTT assay
Cytotoxicity against human HCT15 cells by MTT assay
|
[PMID: 23425970] |
| HCT-15 | IC50 |
24 nM
Compound: taxol
|
Antiproliferative activity against human HCT15 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay
Antiproliferative activity against human HCT15 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay
|
[PMID: 25208345] |
| HCT-15 | IC50 |
240 nM
Compound: 28
|
Antiproliferative activity against human HCT15 cells after 72 hrs by WST8 assay
Antiproliferative activity against human HCT15 cells after 72 hrs by WST8 assay
|
[PMID: 25625617] |
| HCT-15 | GI50 |
125 nM
Compound: Paclitaxel
|
Growth inhibition of human HCT15 cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human HCT15 cells incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 29655610] |
| HCT-15 | IC50 |
190 μM
Compound: Paclitaxel
|
Antiproliferative activity against taxane-resistant human HCT15 cells after 72 hrs by CellTiter 96 aqueous nonradioactive cell proliferation assay
Antiproliferative activity against taxane-resistant human HCT15 cells after 72 hrs by CellTiter 96 aqueous nonradioactive cell proliferation assay
|
[PMID: 29995409] |
| HCT-15 | GI50 |
125 nM
Compound: Paclitaxel
|
Cytotoxicity against human HCT-15 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay
Cytotoxicity against human HCT-15 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay
|
[PMID: 33310545] |
| HCT-8 | ED50 |
0.011 μg/mL
Compound: Paclitaxel
|
Effective dose required for inhibitory activity against HCT-8 human tumor cell line.
Effective dose required for inhibitory activity against HCT-8 human tumor cell line.
|
[PMID: 12852747] |
| HCT-8 | ED50 |
0.011 μg/mL
Compound: paclitaxel
|
Cytotoxicity against human HCT8 cells after 3 days by SRB assay
Cytotoxicity against human HCT8 cells after 3 days by SRB assay
|
[PMID: 14640511] |
| HCT-8 | IC50 |
0.013 μM
Compound: Paclitaxel
|
Cytotoxicity against human HCT8 cells after 3 days by SRB assay
Cytotoxicity against human HCT8 cells after 3 days by SRB assay
|
[PMID: 16038545] |
| HCT-8 | ED50 |
0.06 μg/mL
Compound: 1
|
Cytotoxicity against human HCT8 cells
Cytotoxicity against human HCT8 cells
|
[PMID: 17643301] |
| HCT-8 | IC50 |
0.037 μM
Compound: paclitaxel
|
Cytotoxicity against human HCT8 cells by MTT assay
Cytotoxicity against human HCT8 cells by MTT assay
|
[PMID: 18001087] |
| HCT-8 | EC50 |
0.21 μg/mL
Compound: Paclitaxel
|
Cytotoxicity against human HCT8 cells
Cytotoxicity against human HCT8 cells
|
[PMID: 18640035] |
| HCT-8 | IC50 |
3.29 μM
Compound: paclitaxel
|
Cytotoxicity against human HCT8 cells
Cytotoxicity against human HCT8 cells
|
[PMID: 18701281] |
| HCT-8 | EC50 |
0.21 μg/mL
Compound: Palitaxel
|
Cytotoxicity against human HCT8 cells after 3 days by sulforhodamine B assay
Cytotoxicity against human HCT8 cells after 3 days by sulforhodamine B assay
|
[PMID: 19193043] |
| HCT-8 | IC50 |
0.037 μM
Compound: paclitaxel
|
Cytotoxicity against human HCT8 cells after 24 hrs by MTT assay
Cytotoxicity against human HCT8 cells after 24 hrs by MTT assay
|
[PMID: 19245261] |
| HCT-8 | IC50 |
3.6 nM
Compound: paclitaxel
|
Cytotoxicity against human HCT8 cells by MTT assay
Cytotoxicity against human HCT8 cells by MTT assay
|
[PMID: 19708679] |
| HCT-8 | IC50 |
3.6 μM
Compound: paclitaxel
|
Cytotoxicity against human HCT8 cells after 96 hrs by MTT assay
Cytotoxicity against human HCT8 cells after 96 hrs by MTT assay
|
[PMID: 20560647] |
| HCT-8 | IC50 |
0.67 μM
Compound: paclitaxel
|
Cytotoxicity against human HCT8 cells after 3 days by MTT assay
Cytotoxicity against human HCT8 cells after 3 days by MTT assay
|
[PMID: 20593839] |
| HCT-8 | IC50 |
5.1 x 10-8 M
Compound: Taxol
|
Cytotoxicity against human HCT8 cells after 72 hrs by MTT assay
Cytotoxicity against human HCT8 cells after 72 hrs by MTT assay
|
[PMID: 20719510] |
| HCT-8 | ED50 |
>100 nM
Compound: Paclitaxel
|
Antiproliferative activity against human HCT8 cells after 3 days by sulforhodamine B assay
Antiproliferative activity against human HCT8 cells after 3 days by sulforhodamine B assay
|
[PMID: 21296579] |
| HCT-8 | GI50 |
>100 nM
Compound: Paclitaxel
|
Cytotoxicity against human HCT8 cells after 3 days
Cytotoxicity against human HCT8 cells after 3 days
|
[PMID: 21377368] |
| HCT-8 | IC50 |
5.1 x 10-8 M
Compound: Taxol
|
Cytotoxicity against human HCT8 cells after 72 hrs by MTT assay
Cytotoxicity against human HCT8 cells after 72 hrs by MTT assay
|
[PMID: 21530251] |
| HCT-8 | IC50 |
0.051 μM
Compound: paclitaxel
|
Cytotoxicity against human HCT8 cells by MTT assay
Cytotoxicity against human HCT8 cells by MTT assay
|
[PMID: 22506620] |
| HCT-8 | IC50 |
0.051 μM
Compound: paclitaxel
|
Cytotoxicity against human HCT8 cells after 72 hrs by MTT assay
Cytotoxicity against human HCT8 cells after 72 hrs by MTT assay
|
[PMID: 22583079] |
| HCT-8 | IC50 |
13.3 μM
Compound: Taxol
|
Cytotoxicity against taxol-resistant human HCT8 cells by MTT assay
Cytotoxicity against taxol-resistant human HCT8 cells by MTT assay
|
[PMID: 23425970] |
| HCT-8 | IC50 |
0.051 μM
Compound: Paclitaxel
|
Cytotoxicity against human HCT8 cells by MTT assay
Cytotoxicity against human HCT8 cells by MTT assay
|
[PMID: 23547884] |
| HCT-8 | IC50 |
0.02 μM
Compound: Taxol
|
Cytotoxicity against human HCT8 cells after 96 hrs by MTT assay
Cytotoxicity against human HCT8 cells after 96 hrs by MTT assay
|
[PMID: 24467317] |
| HCT-8 | IC50 |
0.021 μM
Compound: TAX, Taxol
|
Antiproliferative activity against human HCT8 cells after 48 hrs by SRB method
Antiproliferative activity against human HCT8 cells after 48 hrs by SRB method
|
[PMID: 25061803] |
| HCT-8 | IC50 |
2.6 μM
Compound: TAX, Taxol
|
Antiproliferative activity against vincristine-resistant human HCT8 cells after 48 hrs by SRB method
Antiproliferative activity against vincristine-resistant human HCT8 cells after 48 hrs by SRB method
|
[PMID: 25061803] |
| HCT-8 | IC50 |
266 nM
Compound: taxol
|
Antiproliferative activity against taxol resistant human HCT8 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay
Antiproliferative activity against taxol resistant human HCT8 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay
|
[PMID: 25208345] |
| HCT-8 | IC50 |
5 nM
Compound: taxol
|
Antiproliferative activity against human HCT8 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay
Antiproliferative activity against human HCT8 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay
|
[PMID: 25208345] |
| HCT-8 | IC50 |
0.066 μM
Compound: 6
|
Antiproliferative activity against human HCT8 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
Antiproliferative activity against human HCT8 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
|
[PMID: 25682561] |
| HCT-8 | IC50 |
0.019 μM
Compound: TAX
|
Cytotoxicity against human HCT8 cells assessed as cell viability after 48 hrs by MTT assay
Cytotoxicity against human HCT8 cells assessed as cell viability after 48 hrs by MTT assay
|
[PMID: 27149641] |
| HCT-8 | IC50 |
189.4 nM
Compound: Paclitaxel
|
Cytotoxicity against vinblastine resistant/P-gp overexpressing human HCT8 cells assessed as reduction in cell growth after 24 hrs by MTT assay
Cytotoxicity against vinblastine resistant/P-gp overexpressing human HCT8 cells assessed as reduction in cell growth after 24 hrs by MTT assay
|
[PMID: 27213819] |
| HCT-8 | IC50 |
36.9 nM
Compound: Paclitaxel
|
Antiproliferative activity against human HCT8 cells after 24 hrs by MTT assay
Antiproliferative activity against human HCT8 cells after 24 hrs by MTT assay
|
[PMID: 27213819] |
| HCT-8 | IC50 |
8.7 μM
Compound: PXL
|
Cytotoxicity against human HCT-8 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
Cytotoxicity against human HCT-8 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
|
[PMID: 27707623] |
| HCT-8 | IC50 |
17.4 nM
Compound: Paclitaxel
|
Antiproliferative activity against human HCT8 cells after 48 hrs by MTT assay
Antiproliferative activity against human HCT8 cells after 48 hrs by MTT assay
|
[PMID: 28763646] |
| HCT-8 | IC50 |
0.028 μM
Compound: PTX
|
Antiproliferative activity against human HCT8 cells after 72 hrs by MTT assay
Antiproliferative activity against human HCT8 cells after 72 hrs by MTT assay
|
[PMID: 30530194] |
| HCT-8 | IC50 |
0.17 μM
Compound: Paclitaxel
|
Cytotoxicity against human HCT8 cells assessed as inhibition of cell viability after 48 hrs by SRB assay
Cytotoxicity against human HCT8 cells assessed as inhibition of cell viability after 48 hrs by SRB assay
|
[PMID: 30798081] |
| HCT-8 | IC50 |
0.24 μM
Compound: Taxol
|
Anticancer activity against human HCT-8 cells by MTT assay
Anticancer activity against human HCT-8 cells by MTT assay
|
[PMID: 33316408] |
| HCT-8 | IC50 |
0.028 μM
Compound: Taxol; PTX
|
Antiproliferative activity against human HCT-8 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
Antiproliferative activity against human HCT-8 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
|
[PMID: 33676300] |
| HCT-8 | IC50 |
2.59 μM
Compound: Taxol; PTX
|
Antiproliferative activity against taxol-resistant human HCT-8 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
Antiproliferative activity against taxol-resistant human HCT-8 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
|
[PMID: 33676300] |
| HCT-8 | IC50 |
0.02 μM
Compound: TAX
|
Antiproliferative activity against human HCT-8 cells assessed as cell viability incubated for 48 hrs by MTT assay
Antiproliferative activity against human HCT-8 cells assessed as cell viability incubated for 48 hrs by MTT assay
|
[PMID: 35282680] |
| HCT-8 | IC50 |
0.13 μM
Compound: TAX
|
Antiproliferative activity against human vincristine-resistant HCT-8/VCR cells assessed as cell viability incubated for 48 hrs by MTT assay
Antiproliferative activity against human vincristine-resistant HCT-8/VCR cells assessed as cell viability incubated for 48 hrs by MTT assay
|
[PMID: 35282680] |
| HCT-8 | IC50 |
0.086 μM
Compound: Paclitaxel
|
Antiproliferative activity against human HCT-8 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
Antiproliferative activity against human HCT-8 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
|
[PMID: 36511661] |
| HEK293 | IC50 |
0.01 μM
Compound: 1
|
Cytotoxicity against HEK293 cells
Cytotoxicity against HEK293 cells
|
[PMID: 17485207] |
| HEK293 | IC50 |
43 μM
Compound: taxol
|
Cytotoxicity against HEK293 cells after 18 hrs by MTT assay
Cytotoxicity against HEK293 cells after 18 hrs by MTT assay
|
[PMID: 19446930] |
| HEK293 | IC50 |
0.0039 μM
Compound: Paclitaxel
|
Cytotoxicity against HEK cells after 72 hrs by alamar blue assay
Cytotoxicity against HEK cells after 72 hrs by alamar blue assay
|
[PMID: 20732809] |
| HEK293 | IC50 |
0.008 μg/mL
Compound: Paclitaxel
|
Cytotoxic activity against HEK293 cells after 24 hrs by MTT assay
Cytotoxic activity against HEK293 cells after 24 hrs by MTT assay
|
[PMID: 25305717] |
| HEK293 | IC50 |
0.04 μM
Compound: Paclitaxel
|
Cytotoxicity against HEK293 cells expressing pcDNA3.1 after 72 hrs by MTT assay
Cytotoxicity against HEK293 cells expressing pcDNA3.1 after 72 hrs by MTT assay
|
[PMID: 25842364] |
| HEK293 | IC50 |
0.36 μM
Compound: Paclitaxel
|
Cytotoxicity against HEK293 cells expressing ABCB1 after 72 hrs by MTT assay
Cytotoxicity against HEK293 cells expressing ABCB1 after 72 hrs by MTT assay
|
[PMID: 25842364] |
| HEK293 | IC50 |
16.3 nM
Compound: PTX
|
Cytotoxicity against HEK293 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay
Cytotoxicity against HEK293 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay
|
[PMID: 33280896] |
| HEK293 | IC50 |
5.8 μM
Compound: Paclitaxel
|
Cytotoxicity against human HEK293 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
Cytotoxicity against human HEK293 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
|
[PMID: 34153643] |
| HEK293 | IC50 |
1.5 nM
Compound: Taxol
|
Cytotoxicity against human HEK293 cells incubated for 3 days
Cytotoxicity against human HEK293 cells incubated for 3 days
|
[PMID: 38272190] |
| HEK293 | IC50 |
26.8 nM
Compound: PT
|
Antiproliferative activity against human HEK293 cells assessed as reduction in cell viability incubated for 72 hrs by CelltiterGlo luminescent assay
Antiproliferative activity against human HEK293 cells assessed as reduction in cell viability incubated for 72 hrs by CelltiterGlo luminescent assay
|
[PMID: 38959729] |
| HEK-293T | IC50 |
2.3 nM
Compound: Taxol
|
Cytotoxicity against human 293T cells assessed as reduction in cell viability after 4 days by MTS assay
Cytotoxicity against human 293T cells assessed as reduction in cell viability after 4 days by MTS assay
|
[PMID: 29486949] |
| HEK-293T | CC50 |
<20 nM
Compound: Ptxl; PTX
|
Cytotoxicity against HEK293T cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
Cytotoxicity against HEK293T cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
|
[PMID: 31248772] |
| HEK-293T | IC50 |
0.01 μM
Compound: Taxol
|
Cytotoxicity against human 293T cells assessed as reduction in cell viability after 72 hrs by MTS assay
Cytotoxicity against human 293T cells assessed as reduction in cell viability after 72 hrs by MTS assay
|
[PMID: 33310292] |
| HEK-293T | IC50 |
1.76 nM
Compound: Paclitaxel
|
Cytotoxicity against HEK293T cells assessed as inhibition in cell growth
Cytotoxicity against HEK293T cells assessed as inhibition in cell growth
|
[PMID: 33974423] |
| HEK-293T | IC50 |
36.4 μM
Compound: Paclitaxel
|
Cytotoxicity against human HEK293T cells expressing ABCB1 (unknown origin) measured after 72 hrs by MTT assay
Cytotoxicity against human HEK293T cells expressing ABCB1 (unknown origin) measured after 72 hrs by MTT assay
|
[PMID: 34546748] |
| HEK-293T | IC50 |
6.7 nM
Compound: PTX
|
Antiproliferative activity against ACE-negative human HEK293T cells incubated for 48 hrs by MTT assay
Antiproliferative activity against ACE-negative human HEK293T cells incubated for 48 hrs by MTT assay
|
[PMID: 34699215] |
| HEL | IC50 |
0.2 μM
Compound: PTX
|
Cytotoxicity against human HEL cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
Cytotoxicity against human HEL cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
|
[PMID: 37201429] |
| HeLa | GI50 |
0.007 μM
Compound: Paclitaxel
|
Cytotoxic activity against human cervical adenocarcinoma-derived HeLa cell lines
Cytotoxic activity against human cervical adenocarcinoma-derived HeLa cell lines
|
[PMID: 10406652] |
| HeLa | CC50 |
0.01 μg/mL
Compound: Paclitaxel
|
Cytotoxicity against human HeLa cells
Cytotoxicity against human HeLa cells
|
[PMID: 15387677] |
| HeLa | IC50 |
0.008 μM
Compound: Taxol
|
Cytotoxicity against human HeLa cells by MTT assay
Cytotoxicity against human HeLa cells by MTT assay
|
[PMID: 16539377] |
| HeLa | IC50 |
0.47 μM
Compound: Paclitaxel
|
Antiproliferative activity against human HeLa cell line
Antiproliferative activity against human HeLa cell line
|
[PMID: 16793260] |
| HeLa | CC50 |
0.01 μg/mL
Compound: paclitaxel
|
Cytotoxicity against human HeLa cells
Cytotoxicity against human HeLa cells
|
[PMID: 17500572] |
| HeLa | IC50 |
5.6 nM
Compound: Paclitaxel
|
Cytotoxicity against human HeLa cells by MTT assay
Cytotoxicity against human HeLa cells by MTT assay
|
[PMID: 17764148] |
| HeLa | IC50 |
0.02 μM
Compound: taxol
|
Cytotoxicity against human HeLa cells
Cytotoxicity against human HeLa cells
|
[PMID: 17911017] |
| HeLa | IC50 |
0.008 μM
Compound: taxol
|
Cytotoxicity against human HeLa cells after 72 hrs by MTT assay
Cytotoxicity against human HeLa cells after 72 hrs by MTT assay
|
[PMID: 17915851] |
| HeLa | IC50 |
1.5 nM
Compound: paclitaxel
|
Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay
Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay
|
[PMID: 18461997] |
| HeLa | IC50 |
>3 μg/mL
Compound: paclitaxel
|
Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
|
[PMID: 18553923] |
| HeLa | IC50 |
3.11 μM
Compound: paclitaxel
|
Cytotoxicity against human HeLa cells
Cytotoxicity against human HeLa cells
|
[PMID: 18701281] |
| HeLa | GI50 |
0.02 μM
Compound: taxol
|
Cytotoxicity against human HeLa cells after 72 hrs by MTT colorimetric assay
Cytotoxicity against human HeLa cells after 72 hrs by MTT colorimetric assay
|
[PMID: 19081249] |
| HeLa | IC50 |
0.001 μM
Compound: Paclitaxol
|
Antiproliferative activity against human HeLa cells after 96 hrs by MTT assay
Antiproliferative activity against human HeLa cells after 96 hrs by MTT assay
|
[PMID: 19091579] |
| HeLa | IC50 |
0.61 μg/mL
Compound: paclitaxel
|
Cytotoxicity against human HeLa cells after 44 hrs by MTT assay
Cytotoxicity against human HeLa cells after 44 hrs by MTT assay
|
[PMID: 19928884] |
| HeLa | IC50 |
190 nM
Compound: paclitaxel
|
Cytotoxicity against human HeLa cells after 120 hrs by WST8 assay
Cytotoxicity against human HeLa cells after 120 hrs by WST8 assay
|
[PMID: 20180542] |
| HeLa | IC50 |
30 nM
Compound: paclitaxel
|
Cytotoxicity against human HeLa cells after 48 hrs by WST8 assay
Cytotoxicity against human HeLa cells after 48 hrs by WST8 assay
|
[PMID: 20180542] |
| HeLa | GI50 |
0.02 μM
Compound: Taxol
|
Cytotoxicity against human HeLa cells after 72 hrs by MTT assay
Cytotoxicity against human HeLa cells after 72 hrs by MTT assay
|
[PMID: 20538462] |
| HeLa | IC50 |
0.0089 μM
Compound: Paclitaxel
|
Cytotoxicity against human HeLa cells after 72 hrs by alamar blue assay
Cytotoxicity against human HeLa cells after 72 hrs by alamar blue assay
|
[PMID: 20732809] |
| HeLa | IC50 |
1.6 nM
Compound: Paclitaxel
|
Antiproliferative activity against human HeLa cells by sulforhodamine B assay
Antiproliferative activity against human HeLa cells by sulforhodamine B assay
|
[PMID: 20973488] |
| HeLa | IC50 |
7.7 nM
Compound: Paclitaxel
|
Antiproliferative activity against human HeLa cells expressing tubulin 3beta by sulforhodamine B assay
Antiproliferative activity against human HeLa cells expressing tubulin 3beta by sulforhodamine B assay
|
[PMID: 20973488] |
| HeLa | IC50 |
0.07 μM
Compound: taxol
|
Cytotoxicity against human HeLa after 48 hrs by SRB assay
Cytotoxicity against human HeLa after 48 hrs by SRB assay
|
[PMID: 21044847] |
| HeLa | IC50 |
0.02 μM
Compound: Paclitaxel
|
Cytotoxicity against human HeLa cells after 48 to 72 hrs by WAT-1 assay
Cytotoxicity against human HeLa cells after 48 to 72 hrs by WAT-1 assay
|
[PMID: 21126027] |
| HeLa | IC50 |
100 nM
Compound: Taxol
|
Antiproliferative activity against human HeLa cells after 96 hrs by MTT assay
Antiproliferative activity against human HeLa cells after 96 hrs by MTT assay
|
[PMID: 21296467] |
| HeLa | IC50 |
2.6 nM
Compound: Paclitaxel
|
Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
|
[PMID: 21446699] |
| HeLa | IC50 |
6.62 μM
Compound: Paclitaxel
|
Cytotoxicity against human HeLa cells after 24 hrs by MTT assay
Cytotoxicity against human HeLa cells after 24 hrs by MTT assay
|
[PMID: 21514015] |
| HeLa | IC50 |
1.38 nM
Compound: Paclitaxel
|
Antiproliferative activity against human HeLa cells
Antiproliferative activity against human HeLa cells
|
[PMID: 21786793] |
| HeLa | IC50 |
9.05 nM
Compound: Paclitaxel
|
Antiproliferative activity against beta3-tubulin overexpressing human HeLa cells
Antiproliferative activity against beta3-tubulin overexpressing human HeLa cells
|
[PMID: 21786793] |
| HeLa | IC50 |
1.2 nM
Compound: Paclitaxel
|
Antiproliferative activity against human HeLa cells after 48 hrs by SRB assay
Antiproliferative activity against human HeLa cells after 48 hrs by SRB assay
|
[PMID: 21800839] |
| HeLa | GI50 |
2.82 μM
Compound: Paclitaxel
|
Cytotoxicity against human HeLa cells assessed as growth inhibition after 3 days by MTT assay
Cytotoxicity against human HeLa cells assessed as growth inhibition after 3 days by MTT assay
|
[PMID: 21889341] |
| HeLa | IC50 |
0.6 μM
Compound: paclitaxel
|
Cytotoxicity against human HeLa cells after 48 hrs by SRB assay
Cytotoxicity against human HeLa cells after 48 hrs by SRB assay
|
[PMID: 21973054] |
| HeLa | GI50 |
0.033 nM
Compound: Paclitaxel
|
Growth inhibition of human HeLa cells
Growth inhibition of human HeLa cells
|
[PMID: 21986585] |
| HeLa | IC50 |
0.89 μM
Compound: Taxol
|
Cytotoxicity against human HeLa cells after 72 hrs by MTT assay
Cytotoxicity against human HeLa cells after 72 hrs by MTT assay
|
[PMID: 22483090] |
| HeLa | IC50 |
2.93 nM
Compound: Paclitaxel
|
Cytotoxicity against human HeLa cells after 72 hrs by MTT assay
Cytotoxicity against human HeLa cells after 72 hrs by MTT assay
|
[PMID: 22959518] |
| HeLa | IC50 |
0.38 μg/mL
Compound: Taxol
|
Cytotoxicity against human HeLa cells
Cytotoxicity against human HeLa cells
|
[PMID: 22989532] |
| HeLa | IC50 |
1 μM
Compound: Paclitaxel
|
Cytotoxicity against human HeLa cells assessed as growth inhibition
Cytotoxicity against human HeLa cells assessed as growth inhibition
|
[PMID: 23103097] |
| HeLa | IC50 |
11.2 μM
Compound: Paclitaxel
|
Cytotoxicity against human HeLa cells harboring class 3 beta tubulin mutant assessed as growth inhibition
Cytotoxicity against human HeLa cells harboring class 3 beta tubulin mutant assessed as growth inhibition
|
[PMID: 23103097] |
| HeLa | IC50 |
1 nM
Compound: paclitaxel
|
Cytotoxicity against human HeLa cells after 96 hrs by MTT assay
Cytotoxicity against human HeLa cells after 96 hrs by MTT assay
|
[PMID: 23176628] |
| HeLa | IC50 |
11.2 nM
Compound: paclitaxel
|
Cytotoxicity against human HeLa cells expressing class 3 tubulin after 96 hrs by MTT assay
Cytotoxicity against human HeLa cells expressing class 3 tubulin after 96 hrs by MTT assay
|
[PMID: 23176628] |
| HeLa | IC50 |
5 nM
Compound: PTX
|
Cytotoxicity against human HeLa cells assessed as growth inhibition after 48 hrs by MTT assay
Cytotoxicity against human HeLa cells assessed as growth inhibition after 48 hrs by MTT assay
|
[PMID: 23214452] |
| HeLa | IC50 |
28.45 μM
Compound: Taxol
|
Antitumor activity against human HeLa cells assessed as growth inhibition measured after 48 hrs by MTT assay
Antitumor activity against human HeLa cells assessed as growth inhibition measured after 48 hrs by MTT assay
|
[PMID: 23313635] |
| HeLa | IC50 |
1.6 nM
Compound: Paclitaxel
|
Cytotoxicity against human HeLa cells assessed as growth inhibition after 48 hrs by SRB assay
Cytotoxicity against human HeLa cells assessed as growth inhibition after 48 hrs by SRB assay
|
[PMID: 23332369] |
| HeLa | IC50 |
9.2 nM
Compound: Paclitaxel
|
Inhibition of beta-3 tubulin (unknown origin) transfected in human HeLa cells assessed as growth inhibition after 48 hrs by SRB assay
Inhibition of beta-3 tubulin (unknown origin) transfected in human HeLa cells assessed as growth inhibition after 48 hrs by SRB assay
|
[PMID: 23332369] |
| HeLa | IC50 |
1375 nM
Compound: paclitaxel
|
Cytotoxicity against paclitaxel-resistant human HeLa cells after 48 hrs by MTT assay
Cytotoxicity against paclitaxel-resistant human HeLa cells after 48 hrs by MTT assay
|
[PMID: 23356786] |
| HeLa | IC50 |
6.3 nM
Compound: paclitaxel
|
Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
|
[PMID: 23356786] |
| HeLa | IC50 |
0.0017 μM
Compound: paclitaxel
|
Antiproliferative activity against human HeLa cells after 48 hrs by MTS assay
Antiproliferative activity against human HeLa cells after 48 hrs by MTS assay
|
[PMID: 23855338] |
| HeLa | IC50 |
0.0012 μM
Compound: Paclitaxel
|
Antiproliferative activity against human HeLa cells after 48 hrs by SRB assay
Antiproliferative activity against human HeLa cells after 48 hrs by SRB assay
|
[PMID: 23855953] |
| HeLa | IC50 |
1.6 nM
Compound: paclitaxel
|
Antiproliferative activity against human HeLa cells after 48 hrs by SRB assay
Antiproliferative activity against human HeLa cells after 48 hrs by SRB assay
|
[PMID: 23895532] |
| HeLa | IC50 |
7.7 nM
Compound: paclitaxel
|
Inhibition of beta3 tubulin overexpressed in human HeLa cells after 48 hrs by SRB assay
Inhibition of beta3 tubulin overexpressed in human HeLa cells after 48 hrs by SRB assay
|
[PMID: 23895532] |
| HeLa | IC50 |
1.4 nM
Compound: Paclitaxel
|
Cytotoxicity against human HeLa cells after 72 hrs by MTS assay
Cytotoxicity against human HeLa cells after 72 hrs by MTS assay
|
[PMID: 24087857] |
| HeLa | IC50 |
9.1 nM
Compound: Paclitaxel
|
Cytotoxicity against human HeLa cells expressing beta3-tubulin containing alanine residue at 227 after 72 hrs by MTS assay
Cytotoxicity against human HeLa cells expressing beta3-tubulin containing alanine residue at 227 after 72 hrs by MTS assay
|
[PMID: 24087857] |
| HeLa | IC50 |
12 μM
Compound: Paclitaxel
|
Cytotoxic activity against human HeLa cells
Cytotoxic activity against human HeLa cells
|
[PMID: 24195466] |
| HeLa | IC50 |
8 ng/mL
Compound: Paclitaxel
|
Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay
Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay
|
[PMID: 24387243] |
| HeLa | GI50 |
3.206 nM
Compound: 1, Taxol
|
Growth inhibition of human HeLa cells by MTT assay
Growth inhibition of human HeLa cells by MTT assay
|
[PMID: 24405702] |
| HeLa | IC50 |
2.5 nM
Compound: paclitaxel
|
Cytotoxicity against human HeLa cells by MTT assay
Cytotoxicity against human HeLa cells by MTT assay
|
[PMID: 24422592] |
| HeLa | IC50 |
10.9 μM
Compound: Paclitaxel
|
Antiproliferative activity against human HeLa cells after 24 hrs by MTT assay
Antiproliferative activity against human HeLa cells after 24 hrs by MTT assay
|
[PMID: 24487193] |
| HeLa | IC50 |
0.47 μg/mL
Compound: Paclitaxel
|
Cytotoxicity against human HeLa cells after 48 hrs by MTT method
Cytotoxicity against human HeLa cells after 48 hrs by MTT method
|
[PMID: 24657569] |
| HeLa | IC50 |
1.21 nM
Compound: Taxol
|
Antiproliferative activity against human HeLa cells
Antiproliferative activity against human HeLa cells
|
[PMID: 24890652] |
| HeLa | IC50 |
10 nM
Compound: Taxol
|
Antiproliferative activity against human HeLa cells expressing beta3-tubulin
Antiproliferative activity against human HeLa cells expressing beta3-tubulin
|
[PMID: 24890652] |
| HeLa | IC50 |
16 nM
Compound: paclitaxel
|
Growth inhibition of human HeLa cells overexpressing beta-3 after 96 hrs incubation by sulforhodamine B technique
Growth inhibition of human HeLa cells overexpressing beta-3 after 96 hrs incubation by sulforhodamine B technique
|
[PMID: 24900865] |
| HeLa | IC50 |
5.3 nM
Compound: paclitaxel
|
Growth inhibition of wild type human HeLa cells after 96 hrs incubation by sulforhodamine B technique
Growth inhibition of wild type human HeLa cells after 96 hrs incubation by sulforhodamine B technique
|
[PMID: 24900865] |
| HeLa | IC50 |
96 nM
Compound: Paclitaxel
|
Cytotoxicity against human HeLa cells assessed as growth inhibition after 72 hrs by MTT assay
Cytotoxicity against human HeLa cells assessed as growth inhibition after 72 hrs by MTT assay
|
[PMID: 24929344] |
| HeLa | IC50 |
0.29 μM
Compound: Paclitaxel
|
Antiproliferative activity against human HeLa cells after 24 and 72 hrs by MTT assay
Antiproliferative activity against human HeLa cells after 24 and 72 hrs by MTT assay
|
[PMID: 24941130] |
| HeLa | IC50 |
0.7 nM
Compound: Paclitaxel, Taxol
|
Cytotoxicity against human HeLa cells by MTT assay
Cytotoxicity against human HeLa cells by MTT assay
|
[PMID: 25047938] |
| HeLa | IC50 |
7.7 nM
Compound: Paclitaxel, Taxol
|
Cytotoxicity against human HeLa cells transfected with wild-type tubulin beta3 by MTT assay
Cytotoxicity against human HeLa cells transfected with wild-type tubulin beta3 by MTT assay
|
[PMID: 25047938] |
| HeLa | IC50 |
0.41 μM
Compound: Taxol
|
Cytotoxicity against human HeLa cells assessed as growth inhibition after 72 hrs by CCK-8 assay
Cytotoxicity against human HeLa cells assessed as growth inhibition after 72 hrs by CCK-8 assay
|
[PMID: 25091926] |
| HeLa | IC50 |
5 μM
Compound: Paclitaxel
|
Cytotoxicity against human HeLa cells assessed as reduction in cell viability
Cytotoxicity against human HeLa cells assessed as reduction in cell viability
|
[PMID: 25105722] |
| HeLa | GI50 |
0.025 μM
Compound: Paclitaxel
|
Growth inhibition of human HeLa cells after 48 hrs by SRB assay
Growth inhibition of human HeLa cells after 48 hrs by SRB assay
|
[PMID: 25264072] |
| HeLa | IC50 |
1.18 μg/mL
Compound: Paclitaxel
|
Anticancer activity against human HeLa cells after 24 hrs by MTT assay
Anticancer activity against human HeLa cells after 24 hrs by MTT assay
|
[PMID: 25305717] |
| HeLa | GI50 |
0.025 μM
Compound: Paclitaxel
|
Antiproliferative activity against human HeLa cells assessed as reduction in net protein increase after 48 hrs by SRB assay
Antiproliferative activity against human HeLa cells assessed as reduction in net protein increase after 48 hrs by SRB assay
|
[PMID: 25462234] |
| HeLa | IC50 |
0.008 μM
Compound: Paclitaxel
|
Cytotoxicity against human HeLa cells after 72 hrs by MTT assay
Cytotoxicity against human HeLa cells after 72 hrs by MTT assay
|
[PMID: 25462279] |
| HeLa | IC50 |
1.3 μM
Compound: 1
|
Cytotoxicity against human HeLa cells assessed as inhibition of cell proliferation
Cytotoxicity against human HeLa cells assessed as inhibition of cell proliferation
|
[PMID: 25466201] |
| HeLa | IC50 |
0.01 μM
Compound: Paclitaxel
|
Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
|
[PMID: 25647428] |
| HeLa | IC50 |
0.0035 μM
Compound: paclitaxel
|
Growth inhibition of human HeLa cells by sulforhodamine B assay
Growth inhibition of human HeLa cells by sulforhodamine B assay
|
[PMID: 25685941] |
| HeLa | IC50 |
3.2 nM
Compound: Taxol
|
Cytotoxicity against human HeLa cells assessed as cell viability after 72 hrs by CCK8 assay
Cytotoxicity against human HeLa cells assessed as cell viability after 72 hrs by CCK8 assay
|
[PMID: 25819096] |
| HeLa | GI50 |
0.02 μM
Compound: Paclitaxel
|
Antiproliferative activity against human HeLa cells after 48 hrs by SRB assay
Antiproliferative activity against human HeLa cells after 48 hrs by SRB assay
|
[PMID: 25827522] |
| HeLa | IC50 |
1.9 nM
Compound: Paclitaxel
|
Antiproliferative activity against human HeLa cells after 48 hrs by sulforhodamine B assay
Antiproliferative activity against human HeLa cells after 48 hrs by sulforhodamine B assay
|
[PMID: 25882519] |
| HeLa | IC50 |
32.9 nM
Compound: Paclitaxel
|
Antiproliferative activity against human HeLa cells overexpressing wild type beta3 tubulin after 48 hrs by sulforhodamine B assay
Antiproliferative activity against human HeLa cells overexpressing wild type beta3 tubulin after 48 hrs by sulforhodamine B assay
|
[PMID: 25882519] |
| HeLa | IC50 |
0.38 μM
Compound: Paclitaxel
|
Antiproliferative activity against human HeLa cells assessed as inhibition of cell proliferation incubated for 48 hrs by CCK8 assay
Antiproliferative activity against human HeLa cells assessed as inhibition of cell proliferation incubated for 48 hrs by CCK8 assay
|
[PMID: 25959813] |
| HeLa | IC50 |
2.9 μM
Compound: taxol
|
Cytotoxicity against human HeLa cells after 72 hrs by CCK8 assay
Cytotoxicity against human HeLa cells after 72 hrs by CCK8 assay
|
[PMID: 26316467] |
| HeLa | IC50 |
0.1 μg/mL
Compound: Taxol
|
Cytotoxicity against human HeLa cells after 48 hrs by SRB assay
Cytotoxicity against human HeLa cells after 48 hrs by SRB assay
|
[PMID: 26351042] |
| HeLa | IC50 |
2.29 μM
Compound: Paclitaxel
|
Antiproliferative activity against human HeLa cells after 72 hrs by SRB assay
Antiproliferative activity against human HeLa cells after 72 hrs by SRB assay
|
[PMID: 26602827] |
| HeLa | IC50 |
0.099 μM
Compound: PXT
|
Cytotoxicity against human HeLa cells assessed as cell growth inhibition after 48 hrs by MTT assay
Cytotoxicity against human HeLa cells assessed as cell growth inhibition after 48 hrs by MTT assay
|
[PMID: 26638041] |
| HeLa | GI50 |
0.14 μg/mL
Compound: Paclitaxel
|
Cytotoxicity against human HeLa cells assessed as growth inhibition after 72 hrs by MTT assay
Cytotoxicity against human HeLa cells assessed as growth inhibition after 72 hrs by MTT assay
|
[PMID: 26642768] |
| HeLa | IC50 |
3.01 nM
Compound: Taxol
|
Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 72 hrs by CCK8 assay
Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 72 hrs by CCK8 assay
|
[PMID: 26697718] |
| HeLa | GI50 |
0.005 μg/mL
Compound: Paclitaxel
|
Cytotoxicity against human HeLa cells after 72 hrs by MTT assay
Cytotoxicity against human HeLa cells after 72 hrs by MTT assay
|
[PMID: 26920799] |
| HeLa | IC50 |
18.9 nM
Compound: Paclitaxel
|
Cytotoxicity against human HeLa cells after 48 hrs by Celltiter-Glo luminescent cell viability assay
Cytotoxicity against human HeLa cells after 48 hrs by Celltiter-Glo luminescent cell viability assay
|
[PMID: 26985296] |
| HeLa | GI50 |
0.023 μM
Compound: Paclitaxel
|
Antiproliferative activity against human HeLa cells after 48 hrs by SRB assay
Antiproliferative activity against human HeLa cells after 48 hrs by SRB assay
|
[PMID: 26994690] |
| HeLa | GI50 |
0.0048 μg/mL
Compound: Paclitaxel
|
Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
|
[PMID: 27013391] |
| HeLa | IC50 |
0.018 μM
Compound: PTX
|
Growth inhibition of human HeLa cells incubated for 72 hrs by MTT assay
Growth inhibition of human HeLa cells incubated for 72 hrs by MTT assay
|
[PMID: 27172319] |
| HeLa | GI50 |
0.025 μM
Compound: Paclitaxel
|
Antiproliferative activity against human HeLa cells assessed as growth inhibition after 48 hrs by SRB assay
Antiproliferative activity against human HeLa cells assessed as growth inhibition after 48 hrs by SRB assay
|
[PMID: 27209232] |
| HeLa | IC50 |
2.8 nM
Compound: paclitaxel
|
Antiproliferative activity against human HeLa cells after 48 hrs by SRB assay
Antiproliferative activity against human HeLa cells after 48 hrs by SRB assay
|
[PMID: 27213719] |
| HeLa | IC50 |
24 nM
Compound: paclitaxel
|
Antiproliferative activity against multidrug resistant human HeLa cells expressing wild type beta3 tubulin after 48 hrs by SRB assay
Antiproliferative activity against multidrug resistant human HeLa cells expressing wild type beta3 tubulin after 48 hrs by SRB assay
|
[PMID: 27213719] |
| HeLa | GI50 |
2.34 nM
Compound: Taxol
|
Cytotoxicity against human HeLa cells assessed as cell growth inhibition after 72 hrs by CCK-8 assay
Cytotoxicity against human HeLa cells assessed as cell growth inhibition after 72 hrs by CCK-8 assay
|
[PMID: 27224875] |
| HeLa | CC50 |
0.0048 μg/mL
Compound: Paclitaxel
|
Cytotoxicity against human HeLa cells by MTT assay
Cytotoxicity against human HeLa cells by MTT assay
|
[PMID: 27301367] |
| HeLa | IC50 |
12.62 nM
Compound: PTX
|
Cytotoxicity against human HeLa cells assessed as cell viability measured after 72 hrs by MTS assay
Cytotoxicity against human HeLa cells assessed as cell viability measured after 72 hrs by MTS assay
|
[PMID: 27311893] |
| HeLa | IC50 |
23.29 nM
Compound: PTX
|
Cytotoxicity against human HeLa cells assessed as cell viability measured after 48 hrs by MTS assay
Cytotoxicity against human HeLa cells assessed as cell viability measured after 48 hrs by MTS assay
|
[PMID: 27311893] |
| HeLa | IC50 |
19.87 nM
Compound: Paclitaxel
|
Anti-cancer activity against human HeLa cells assessed as reduction in cell viability after 72 hrs by WST-1 assay
Anti-cancer activity against human HeLa cells assessed as reduction in cell viability after 72 hrs by WST-1 assay
|
[PMID: 27317645] |
| HeLa | IC50 |
6.4 nM
Compound: Paclitaxel
|
Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 96 hrs by MTT assay
Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 96 hrs by MTT assay
|
[PMID: 27434426] |
| HeLa | GI50 |
0.004 μg/mL
Compound: Paclitaxel
|
Cytotoxicity against human HeLa cells assessed as growth inhibition after 72 hrs by MTT assay
Cytotoxicity against human HeLa cells assessed as growth inhibition after 72 hrs by MTT assay
|
[PMID: 27563398] |
| HeLa | GI50 |
0.08 μg/mL
Compound: Paclitaxel
|
Cytotoxicity against human HeLa cells measured after 48 hrs by MTT assay
Cytotoxicity against human HeLa cells measured after 48 hrs by MTT assay
|
[PMID: 27688192] |
| HeLa | IC50 |
<0.008 μM
Compound: Paclitaxel
|
Cytotoxicity against human HeLa cells assessed as decrease in cell viability after 48 hrs by MTS assay
Cytotoxicity against human HeLa cells assessed as decrease in cell viability after 48 hrs by MTS assay
|
[PMID: 27704807] |
| HeLa | IC50 |
1.7 μM
Compound: Paclitaxel
|
Cytotoxicity against human HeLa cells after 72 hrs by MTT assay
Cytotoxicity against human HeLa cells after 72 hrs by MTT assay
|
[PMID: 27748595] |
| HeLa | IC50 |
12.95 μM
Compound: Taxol
|
Cytotoxicity against human HeLa cells assessed as cell growth inhibition after 48 hrs by MTT assay
Cytotoxicity against human HeLa cells assessed as cell growth inhibition after 48 hrs by MTT assay
|
[PMID: 27887843] |
| HeLa | IC50 |
16 μM
Compound: Paclitaxel
|
Growth inhibition of human HeLa cells over expressing beta3-tubulin measured after 96 hrs by sulforhodamine B assay
Growth inhibition of human HeLa cells over expressing beta3-tubulin measured after 96 hrs by sulforhodamine B assay
|
[PMID: 27894589] |
| HeLa | IC50 |
5.3 μM
Compound: Paclitaxel
|
Growth inhibition of human HeLa cells measured after 96 hrs by sulforhodamine B assay
Growth inhibition of human HeLa cells measured after 96 hrs by sulforhodamine B assay
|
[PMID: 27894589] |
| HeLa | GI50 |
0.039 μM
Compound: Paclitaxel
|
Growth inhibition of human HeLa cells after 48 hrs by SRB assay
Growth inhibition of human HeLa cells after 48 hrs by SRB assay
|
[PMID: 27964883] |
| HeLa | IC50 |
0.036 μM
Compound: Taxol
|
Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay
Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay
|
[PMID: 27979593] |
| HeLa | GI50 |
0.0048 μg/mL
Compound: Paclitaxel
|
Cytotoxicity against human HeLa cells assessed as growth inhibition by MTT assay
Cytotoxicity against human HeLa cells assessed as growth inhibition by MTT assay
|
[PMID: 28103537] |
| HeLa | IC50 |
0.0014 μM
Compound: 18; taxol
|
Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 72 hrs by WST-8 dye based assay
Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 72 hrs by WST-8 dye based assay
|
[PMID: 28240909] |
| HeLa | IC50 |
8.21 nM
Compound: Paclitaxel
|
Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
|
[PMID: 28340411] |
| HeLa | GI50 |
0.0048 μg/mL
Compound: Paclitaxel
|
Growth inhibition of human HeLa cells by MTT assay
Growth inhibition of human HeLa cells by MTT assay
|
[PMID: 28411559] |
| HeLa | IC50 |
1.5 nM
Compound: Paclitaxel
|
Antiproliferative activity against human HeLa cells after 48 hrs by SRB assay
Antiproliferative activity against human HeLa cells after 48 hrs by SRB assay
|
[PMID: 28433513] |
| HeLa | IC50 |
21.1 nM
Compound: Paclitaxel
|
Antiproliferative activity against human HeLa cells expressing wild type beta3 tubulin after 48 hrs by SRB assay
Antiproliferative activity against human HeLa cells expressing wild type beta3 tubulin after 48 hrs by SRB assay
|
[PMID: 28433513] |
| HeLa | IC50 |
3 nM
Compound: Paclitaxel
|
Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 72 hrs by CCK-8 assay
Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 72 hrs by CCK-8 assay
|
[PMID: 28598633] |
| HeLa | IC50 |
1.1 nM
Compound: 1
|
Cytotoxicity against human HeLa cells assessed as decrease in cell viability after 48 hrs by MTT assay
Cytotoxicity against human HeLa cells assessed as decrease in cell viability after 48 hrs by MTT assay
|
[PMID: 28624703] |
| HeLa | IC50 |
0.001 μM
Compound: Paclitaxel
|
Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 72 hrs by CCK8 assay
Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 72 hrs by CCK8 assay
|
[PMID: 29043798] |
| HeLa | IC50 |
6.42 μM
Compound: Taxol
|
Antiproliferative activity against human HeLa cells after 48 hrs by MTS assay
Antiproliferative activity against human HeLa cells after 48 hrs by MTS assay
|
[PMID: 29172082] |
| HeLa | IC50 |
0.003 μM
Compound: PTX
|
Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay
Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay
|
[PMID: 29306206] |
| HeLa | IC50 |
4.6 nM
Compound: 1a
|
Cytotoxicity against human HeLa cells assessed as decrease in cell viability after 48 hrs by MTT assay
Cytotoxicity against human HeLa cells assessed as decrease in cell viability after 48 hrs by MTT assay
|
[PMID: 29359935] |
| HeLa | IC50 |
10.9 μM
Compound: Paclitaxel
|
Antiproliferative activity against human HeLa cells after 24 hrs by crystal violet staining-based assay
Antiproliferative activity against human HeLa cells after 24 hrs by crystal violet staining-based assay
|
[PMID: 29407986] |
| HeLa | IC50 |
0.023 μM
Compound: Taxol
|
Antiproliferative activity against human HeLa cells after 48 hrs by CCK8 assay
Antiproliferative activity against human HeLa cells after 48 hrs by CCK8 assay
|
[PMID: 29475587] |
| HeLa | IC50 |
1.6 nM
Compound: Paclitaxel
|
Antiproliferative activity against human HeLa cells by SRB assay
Antiproliferative activity against human HeLa cells by SRB assay
|
[PMID: 29655610] |
| HeLa | IC50 |
7.7 nM
Compound: Paclitaxel
|
Antiproliferative activity against human HeLa cells expressing wild type beta3 tubulin by SRB assay
Antiproliferative activity against human HeLa cells expressing wild type beta3 tubulin by SRB assay
|
[PMID: 29655610] |
| HeLa | IC50 |
2.8 nM
Compound: Paclitaxel
|
Antiproliferative activity against human HeLa cells after 72 hrs by sulforhodamine B assay
Antiproliferative activity against human HeLa cells after 72 hrs by sulforhodamine B assay
|
[PMID: 30098869] |
| HeLa | IC50 |
0.046 μM
Compound: Taxol
|
Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay
Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay
|
[PMID: 30212198] |
| HeLa | IC50 |
2.8 nM
Compound: Paclitaxel
|
Antiproliferative activity against human HeLa cells after 48 hrs by sulforhodamine B assay
Antiproliferative activity against human HeLa cells after 48 hrs by sulforhodamine B assay
|
[PMID: 30297118] |
| HeLa | IC50 |
24 nM
Compound: Paclitaxel
|
Antiproliferative activity against human HeLa cells expressing wild type beta3 tubulin after 48 hrs by sulforhodamine B assay
Antiproliferative activity against human HeLa cells expressing wild type beta3 tubulin after 48 hrs by sulforhodamine B assay
|
[PMID: 30297118] |
| HeLa | IC50 |
45.78 μM
Compound: Paclitaxel
|
Antiproliferative activity against human HeLa after 24 hrs by MTT assay
Antiproliferative activity against human HeLa after 24 hrs by MTT assay
|
[PMID: 30826188] |
| HeLa | GI50 |
0.0048 μg/mL
Compound: Paclitaxel
|
Growth inhibition of human HeLa cells by MTT assay
Growth inhibition of human HeLa cells by MTT assay
|
[PMID: 30910461] |
| HeLa | IC50 |
0.005 μM
Compound: Paclitaxel
|
Cytotoxicity against human HeLa cells assessed as reduction in cell viability measured after 72 hrs by SRB assay
Cytotoxicity against human HeLa cells assessed as reduction in cell viability measured after 72 hrs by SRB assay
|
[PMID: 31120251] |
| HeLa | IC50 |
<0.008 μM
Compound: Paclitaxel
|
Cytotoxicity in human HeLa cells assessed as reduction in cell viability incubated for 3 days by MTT assay
Cytotoxicity in human HeLa cells assessed as reduction in cell viability incubated for 3 days by MTT assay
|
[PMID: 31390200] |
| HeLa | IC50 |
0.0033 μM
Compound: Paclitaxel
|
Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 68 hrs by MTT assay
Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 68 hrs by MTT assay
|
[PMID: 31404864] |
| HeLa | IC50 |
0.001 μM
Compound: Paclitaxel
|
Antiproliferative activity against human HeLa cells measured after 72 hrs by sulforhodamine B assay
Antiproliferative activity against human HeLa cells measured after 72 hrs by sulforhodamine B assay
|
[PMID: 31465222] |
| HeLa | GI50 |
<0.01 μM
Compound: Paciltaxel
|
Antiproliferative activity against human HeLa cells assessed as reduction in cell viability after 48 hrs by SRB assay
Antiproliferative activity against human HeLa cells assessed as reduction in cell viability after 48 hrs by SRB assay
|
[PMID: 31546197] |
| HeLa | GI50 |
<0.016 μM
Compound: Paciltaxel
|
Antiproliferative activity against human HeLa cells by SRB assay
Antiproliferative activity against human HeLa cells by SRB assay
|
[PMID: 31546197] |
| HeLa | IC50 |
>400 μg/mL
Compound: Paclitaxel
|
Antitumour activity against human HeLa cells assessed as reduction in cell viability by MTT assay
Antitumour activity against human HeLa cells assessed as reduction in cell viability by MTT assay
|
[PMID: 31607609] |
| HeLa | GI50 |
0.01 μM
Compound: Paclitaxel
|
Cytotoxicity against human HeLa cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
Cytotoxicity against human HeLa cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
|
[PMID: 31945642] |
| HeLa | IC50 |
0.0014 μM
Compound: Paclitaxel
|
Antiproliferative activity against human HeLa cells assessed as reduction in cell viability after 72 hrs by WST-8 assay
Antiproliferative activity against human HeLa cells assessed as reduction in cell viability after 72 hrs by WST-8 assay
|
[PMID: 31967821] |
| HeLa | IC50 |
3 nM
Compound: Paclitaxel
|
Antiproliferative activity against human HeLa cells assessed as reduction in cell viability measured after 48 hrs by MTT assay
Antiproliferative activity against human HeLa cells assessed as reduction in cell viability measured after 48 hrs by MTT assay
|
[PMID: 32339854] |
| HeLa | IC50 |
0.004 μM
Compound: Paclitaxel
|
Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
|
[PMID: 32633512] |
| HeLa | IC50 |
0.041 μM
Compound: PTX
|
Antiproliferative activity against human HeLa cells assessed as inhibition of cell proliferation measured after 48 hrs by CCK-8 assay
Antiproliferative activity against human HeLa cells assessed as inhibition of cell proliferation measured after 48 hrs by CCK-8 assay
|
[PMID: 32650183] |
| HeLa | IC50 |
28.6 nM
Compound: PTX
|
Cytotoxicity against human HeLa cells assessed as reduction in cell viability measured after 48 hrs by MTT assay
Cytotoxicity against human HeLa cells assessed as reduction in cell viability measured after 48 hrs by MTT assay
|
[PMID: 33280896] |
| HeLa | IC50 |
1.6 nM
Compound: Paclitaxel
|
Antiproliferative activity against human HeLa cells assessed as decrease in cell growth measured after 48 hrs by SRB method
Antiproliferative activity against human HeLa cells assessed as decrease in cell growth measured after 48 hrs by SRB method
|
[PMID: 33310545] |
| HeLa | IC50 |
0.003 μM
Compound: Taxol
|
Anticancer activity against human HeLa cells by MTT assay
Anticancer activity against human HeLa cells by MTT assay
|
[PMID: 33316408] |
| HeLa | IC50 |
0.006 μM
Compound: Paclitaxel
|
Antiproliferative activity against human HeLa cells
Antiproliferative activity against human HeLa cells
|
[PMID: 33421712] |
| HeLa | IC50 |
2.8 nM
Compound: Paclitaxel
|
Cytotoxicity against human HeLa cells assessed as reduction in cell viability by Sulforhodamine B assay
Cytotoxicity against human HeLa cells assessed as reduction in cell viability by Sulforhodamine B assay
|
[PMID: 33647840] |
| HeLa | IC50 |
24 nM
Compound: Paclitaxel
|
Cytotoxicity against human HeLa cells over expressing WT-beta3 assessed as reduction in cell viability by Sulforhodamine B assay
Cytotoxicity against human HeLa cells over expressing WT-beta3 assessed as reduction in cell viability by Sulforhodamine B assay
|
[PMID: 33647840] |
| HeLa | GI50 |
0.0048 μg/mL
Compound: Paclitaxel
|
Cytotoxicity against human HeLa cells assessed as cell growth inhibition
Cytotoxicity against human HeLa cells assessed as cell growth inhibition
|
[PMID: 33826327] |
| HeLa | GI50 |
3.2 nM
Compound: Paclitaxel
|
Growth inhibition of human HeLa cells measured after 48 hrs by SRB assay
Growth inhibition of human HeLa cells measured after 48 hrs by SRB assay
|
[PMID: 34110822] |
| HeLa | IC50 |
0.008 μM
Compound: Paclitaxel
|
Antiproliferative activity against human HeLa assessed as reduction in cell viability measured after 48 hrs by MTT assay
Antiproliferative activity against human HeLa assessed as reduction in cell viability measured after 48 hrs by MTT assay
|
[PMID: 34175541] |
| HeLa | IC50 |
<0.01 μM
Compound: Taxol
|
Anticancer activity against human HeLa cells assessed as inhibition of cell proliferation measured after 72 hrs by CCK8 reagent assay
Anticancer activity against human HeLa cells assessed as inhibition of cell proliferation measured after 72 hrs by CCK8 reagent assay
|
[PMID: 34399390] |
| HeLa | IC50 |
28.6 nM
Compound: PTX
|
Antiproliferative activity against human HeLa cells incubated for 72 hrs by MTT assay
Antiproliferative activity against human HeLa cells incubated for 72 hrs by MTT assay
|
[PMID: 34648295] |
| HeLa | IC50 |
<6.25 x 10-3 μM
Compound: Taxol
|
Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 72 hrs by MTT assay
Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 72 hrs by MTT assay
|
[PMID: 34883453] |
| HeLa | IC50 |
0.23 μM
Compound: Paclitaxel
|
Antiproliferative activity against human HeLa cells by CCK8 assay
Antiproliferative activity against human HeLa cells by CCK8 assay
|
[PMID: 34922028] |
| HeLa | IC50 |
4.3 nM
Compound: Paclitaxel
|
Cytotoxicity against human HeLa cells assessed as growth inhibition
Cytotoxicity against human HeLa cells assessed as growth inhibition
|
[PMID: 34949088] |
| HeLa | IC50 |
0.05 μM
Compound: PTX
|
Cytotoxicity against human HeLa cells assessed as reduction in cell viability by MTT assay
Cytotoxicity against human HeLa cells assessed as reduction in cell viability by MTT assay
|
[PMID: 35213164] |
| HeLa | IC50 |
0.039 μM
Compound: PTX
|
Cytotoxicity against human HeLa cells assessed as reduction in cell viability measured after 24 hrs by MTT assay
Cytotoxicity against human HeLa cells assessed as reduction in cell viability measured after 24 hrs by MTT assay
|
[PMID: 35447432] |
| HeLa | IC50 |
0.006 μM
Compound: Taxol
|
Antiproliferative activity against human HeLa cells assessed as reduction in cell viability after 96 hrs by MTT assay
Antiproliferative activity against human HeLa cells assessed as reduction in cell viability after 96 hrs by MTT assay
|
[PMID: 36270090] |
| HeLa | IC50 |
19.8 nM
Compound: Paclitaxel
|
Antiproliferative activity against human HeLa cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay
Antiproliferative activity against human HeLa cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay
|
[PMID: 36621138] |
| HeLa | IC50 |
2.8 nM
Compound: PTX
|
Antiproliferative activity against wild type human HeLa cells assessed as inhibition of cell growth by SRB assay
Antiproliferative activity against wild type human HeLa cells assessed as inhibition of cell growth by SRB assay
|
[PMID: 36889150] |
| HeLa | IC50 |
24 nM
Compound: PTX
|
Antiproliferative activity against human HeLa cells overexpressing betaIII-tubulin assessed as inhibition of cell growth by SRB assay
Antiproliferative activity against human HeLa cells overexpressing betaIII-tubulin assessed as inhibition of cell growth by SRB assay
|
[PMID: 36889150] |
| HeLa | IC50 |
0.006 μM
Compound: PTX
|
Cytotoxicity against human HeLa cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
Cytotoxicity against human HeLa cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
|
[PMID: 37201429] |
| HeLa | IC50 |
13.2 nM
Compound: PTX
|
Cytotoxicity against human HeLa cells assessed as inhibition of cell growth pre-treated with compound for 3 hrs followed by 620/25 nm red light irradiation for 30 mins measured after 72 hrs by CCK-8 assay
Cytotoxicity against human HeLa cells assessed as inhibition of cell growth pre-treated with compound for 3 hrs followed by 620/25 nm red light irradiation for 30 mins measured after 72 hrs by CCK-8 assay
|
[PMID: 37290494] |
| HeLa | IC50 |
0.034 μM
Compound: Taxol
|
Antiproliferative activity against human HeLa cells assessed as reduction in cell viability incubated for 48 hrs by CCk-8 assay
Antiproliferative activity against human HeLa cells assessed as reduction in cell viability incubated for 48 hrs by CCk-8 assay
|
[PMID: 37329677] |
| HeLa | IC50 |
1 nM
Compound: 1a; PTX
|
Antiproliferative activity against human HeLa cells assessed as inhibition of cell viability by MTT assay
Antiproliferative activity against human HeLa cells assessed as inhibition of cell viability by MTT assay
|
[PMID: 37490800] |
| HeLa | IC50 |
35 nM
Compound: 1a; PTX
|
Antiproliferative activity against human HeLa cells overexpressing betaIII-tubulin assessed as inhibition of cell viability by MTT assay
Antiproliferative activity against human HeLa cells overexpressing betaIII-tubulin assessed as inhibition of cell viability by MTT assay
|
[PMID: 37490800] |
| HeLa | IC50 |
0.007 μM
Compound: 2
|
Antiproliferative activity against human HeLa cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay
Antiproliferative activity against human HeLa cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay
|
[PMID: 37856840] |
| HeLa | IC50 |
0.02 μM
Compound: PTX
|
Antiproliferative activity against human HeLa cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
Antiproliferative activity against human HeLa cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
|
[PMID: 38280356] |
| HeLa | IC50 |
1.1 nM
Compound: Paclitaxel
|
Antiproliferative activity against human HeLa cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
Antiproliferative activity against human HeLa cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
|
[PMID: 38294341] |
| HeLa | IC50 |
20 nM
Compound: Paclitaxel
|
Antiproliferative activity against human HeLa cells expressing tubulin betaIII assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
Antiproliferative activity against human HeLa cells expressing tubulin betaIII assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
|
[PMID: 38294341] |
| HeLa | IC50 |
0.02 μM
Compound: PTX
|
Antiproliferative activity against human HeLa cells assessed as reduction in cell viability measured after 72 hrs
Antiproliferative activity against human HeLa cells assessed as reduction in cell viability measured after 72 hrs
|
[PMID: 38430854] |
| HeLa | IC50 |
0.9 nM
Compound: PT
|
Antiproliferative activity against human HeLa cells assessed as reduction in cell viability incubated for 72 hrs by CelltiterGlo luminescent assay
Antiproliferative activity against human HeLa cells assessed as reduction in cell viability incubated for 72 hrs by CelltiterGlo luminescent assay
|
[PMID: 38959729] |
| HeLa | IC50 |
3 nM
Compound: PT
|
Antiproliferative activity against human HeLa cells assessed as inhibition of cell growth incubated for 72 hrs in presence of verapamil by MTT assay
Antiproliferative activity against human HeLa cells assessed as inhibition of cell growth incubated for 72 hrs in presence of verapamil by MTT assay
|
[PMID: 38959729] |
| HeLa | IC50 |
6.2 nM
Compound: PT
|
Antiproliferative activity against human HeLa cells assessed as inhibition of cell growth incubated for 72 hrs in absence of verapamil by MTT assay
Antiproliferative activity against human HeLa cells assessed as inhibition of cell growth incubated for 72 hrs in absence of verapamil by MTT assay
|
[PMID: 38959729] |
| HeLa | EC50 |
0.008 x 10-3 μM
Compound: Paclitaxel
|
Cytotoxicity against human HeLa cells incubated for 48 to 72 hrs by MTT assay
Cytotoxicity against human HeLa cells incubated for 48 to 72 hrs by MTT assay
|
[PMID: 39038808] |
| HeLa | IC50 |
19.31 μM
Compound: Taxol
|
Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 48 hrs by MTT assay
Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 48 hrs by MTT assay
|
10.1039/C6MD00234J |
| HeLa S3 | IC50 |
0.013 μM
Compound: Paclitaxel
|
Antiproliferative activity against human HeLaS3 cells after 72 hrs by MTT assay
Antiproliferative activity against human HeLaS3 cells after 72 hrs by MTT assay
|
[PMID: 29803003] |
| HeLa S3 | IC50 |
<40 μM
Compound: Paclitaxel
|
Antiproliferative activity against drug-sensitive human HeLaS3 cells assessed as cell growth inhibition incubated for 72 hrs by SRB assay
Antiproliferative activity against drug-sensitive human HeLaS3 cells assessed as cell growth inhibition incubated for 72 hrs by SRB assay
|
[PMID: 35751979] |
| Hep 3B2 | IC50 |
0.031 μM
Compound: Paclitaxel
|
Cytotoxicity against human Hep3B cells after 48 hrs by SRB assay
Cytotoxicity against human Hep3B cells after 48 hrs by SRB assay
|
[PMID: 15043402] |
| Hep 3B2 | IC50 |
0.08 μg/mL
Compound: Taxol
|
Cytotoxicity against human Hep3B cells
Cytotoxicity against human Hep3B cells
|
[PMID: 16038548] |
| Hep 3B2 | IC50 |
0.0054 μM
Compound: paclitaxel
|
Cytotoxicity against human Hep3B cells
Cytotoxicity against human Hep3B cells
|
[PMID: 17113288] |
| Hep 3B2 | IC50 |
0.13 μM
Compound: paclitaxel
|
Cytotoxicity against human Hep3B cells after 3 days by MTT assay
Cytotoxicity against human Hep3B cells after 3 days by MTT assay
|
[PMID: 18419154] |
| Hep 3B2 | IC50 |
7.26 μM
Compound: paclitaxel
|
Cytotoxicity against human Hep3B cells after 72 hrs by MTT assay
Cytotoxicity against human Hep3B cells after 72 hrs by MTT assay
|
[PMID: 19053781] |
| Hep 3B2 | GI50 |
0.0004 μM
Compound: Paclitaxel
|
Anticancer activity against human Hep3B cells after 3 days by SRB assay
Anticancer activity against human Hep3B cells after 3 days by SRB assay
|
[PMID: 20735140] |
| Hep 3B2 | GI50 |
16.17 μM
Compound: Paclitaxel
|
Anticancer activity against vincristine-resistant human Hep3B cells after 3 days by SRB assay
Anticancer activity against vincristine-resistant human Hep3B cells after 3 days by SRB assay
|
[PMID: 20735140] |
| Hep 3B2 | IC50 |
1.6 x 10-5 μM
Compound: Paclitaxel
|
Cytotoxicity against human Hep3B2 cells after 72 hrs by MTS assay
Cytotoxicity against human Hep3B2 cells after 72 hrs by MTS assay
|
[PMID: 21812410] |
| Hep 3B2 | IC50 |
1.6 x 10-5 μM
Compound: paclitaxel
|
Cytotoxicity against human Hep3B2 cells assessed as reduction in cell viability by MTS assay
Cytotoxicity against human Hep3B2 cells assessed as reduction in cell viability by MTS assay
|
[PMID: 25760674] |
| Hep 3B2 | IC50 |
0.02 μM
Compound: Paclitaxel
|
Cytotoxicity activity against human Hep3B cells assessed as growth inhibition measured after 48 hrs by MTT assay
Cytotoxicity activity against human Hep3B cells assessed as growth inhibition measured after 48 hrs by MTT assay
|
[PMID: 27627130] |
| Hep 3B2 | IC50 |
0.73 μM
Compound: Pac
|
Cytotoxicity against human Hep3B cells by MTT assay
Cytotoxicity against human Hep3B cells by MTT assay
|
[PMID: 28262527] |
| Hep 3B2 | IC50 |
16 μg/mL
Compound: Paclitaxel
|
Cytotoxicity against human Hep3B cells assessed as reduction in cell viability incubated for 48 hrs by sulforhodamine B assay
Cytotoxicity against human Hep3B cells assessed as reduction in cell viability incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 39052090] |
| HEp-2 | IC50 |
0.11 μM
Compound: Paclitaxel
|
Cytotoxicity against Homo sapiens (human) Hep2 cells after 48 hr by SRB assay
Cytotoxicity against Homo sapiens (human) Hep2 cells after 48 hr by SRB assay
|
10.1007/s00044-011-9824-9 |
| HepG2 | IC50 |
8.1 μM
Compound: taxol
|
Cytotoxicity against human Hep G2 cells after 48 hrs by WST-8 assay
Cytotoxicity against human Hep G2 cells after 48 hrs by WST-8 assay
|
[PMID: 15730243] |
| HepG2 | IC50 |
0.18 μg/mL
Compound: Taxol
|
Cytotoxicity against human HepG2 cells
Cytotoxicity against human HepG2 cells
|
[PMID: 16038548] |
| HepG2 | IC50 |
6.9 μM
Compound: Taxol
|
Growth inhibition of human HepG2 cells after 48 hrs by WST8 assay
Growth inhibition of human HepG2 cells after 48 hrs by WST8 assay
|
[PMID: 16499322] |
| HepG2 | IC50 |
0.3 μM
Compound: Taxol
|
Cytotoxicity against human HepG2 cells by MTT assay
Cytotoxicity against human HepG2 cells by MTT assay
|
[PMID: 16539377] |
| HepG2 | IC50 |
9.49 μM
Compound: Taxol
|
Cytotoxicity against human HepG2 cells
Cytotoxicity against human HepG2 cells
|
[PMID: 16724842] |
| HepG2 | IC50 |
8.1 μM
Compound: taxol
|
Cytotoxicity against human Hep G2 by WST-8 assay
Cytotoxicity against human Hep G2 by WST-8 assay
|
[PMID: 16933868] |
| HepG2 | IC50 |
8.1 μM
Compound: Taxol
|
Cytotoxicity against human Hep G2 cells
Cytotoxicity against human Hep G2 cells
|
[PMID: 17067155] |
| HepG2 | IC50 |
6.9 μg/mL
Compound: 2
|
Cytotoxicity againt human HepG2 cells
Cytotoxicity againt human HepG2 cells
|
[PMID: 17239597] |
| HepG2 | IC50 |
0.05 μg/mL
Compound: taxol
|
Growth inhibition of human HepG2 cells
Growth inhibition of human HepG2 cells
|
[PMID: 17358082] |
| HepG2 | IC50 |
8.1 μM
Compound: Paclitaxel
|
Growth inhibition of human HepG2 cells
Growth inhibition of human HepG2 cells
|
[PMID: 17490878] |
| HepG2 | IC50 |
0.69 μg/mL
Compound: paclitaxel
|
Growth inhibition of HepG2 cells
Growth inhibition of HepG2 cells
|
[PMID: 17547458] |
| HepG2 | IC50 |
8.1 mM
Compound: taxol
|
Growth inhibition of human HepG2 cells
Growth inhibition of human HepG2 cells
|
[PMID: 17595134] |
| HepG2 | IC50 |
0.82 μM
Compound: taxol
|
Cytotoxicity against human HepG2 cells
Cytotoxicity against human HepG2 cells
|
[PMID: 17911017] |
| HepG2 | IC50 |
0.3 μM
Compound: taxol
|
Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
|
[PMID: 17915851] |
| HepG2 | IC50 |
0.008 μg/mL
Compound: Paclitaxel
|
Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay
Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay
|
[PMID: 17950495] |
| HepG2 | IC50 |
0.007 μM
Compound: paclitaxel
|
Growth inhibition of human HepG2 cells after 72 hrs by MTT assay
Growth inhibition of human HepG2 cells after 72 hrs by MTT assay
|
[PMID: 18313307] |
| HepG2 | IC50 |
4.15 μM
Compound: paclitaxel
|
Growth inhibition of doxorubicin resistant human HepG2 cells after 72 hrs by MTT assay
Growth inhibition of doxorubicin resistant human HepG2 cells after 72 hrs by MTT assay
|
[PMID: 18313307] |
| HepG2 | IC50 |
592 μM
Compound: paclitaxel
|
Resistant ratio, IC50 for multidrug resistant human HepG2 cells to IC50 for human HepG2 cells
Resistant ratio, IC50 for multidrug resistant human HepG2 cells to IC50 for human HepG2 cells
|
[PMID: 18313307] |
| HepG2 | IC50 |
4.68 x 10-2 μM
Compound: paclitaxel
|
Cytotoxicity against human HepG2 cells after 3 days by MTT assay
Cytotoxicity against human HepG2 cells after 3 days by MTT assay
|
[PMID: 18419154] |
| HepG2 | IC50 |
5.9 x 10-3 μM
Compound: paclitaxel
|
Growth inhibition of human HepG2 cells after 72 hrs by SRB assay
Growth inhibition of human HepG2 cells after 72 hrs by SRB assay
|
[PMID: 18512984] |
| HepG2 | IC50 |
0.009 μM
Compound: taxol
|
Cytotoxicity against human HEPG2 cells after 24 hrs by MTT assay
Cytotoxicity against human HEPG2 cells after 24 hrs by MTT assay
|
[PMID: 18586491] |
| HepG2 | IC50 |
0.62 μM
Compound: Taxol
|
Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay
Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay
|
[PMID: 18701301] |
| HepG2 | GI50 |
1 nM
Compound: paclitaxel
|
Cytotoxicity against human HepG2 cells
Cytotoxicity against human HepG2 cells
|
[PMID: 19195901] |
| HepG2 | GI50 |
0.059 μM
Compound: taxol
|
Cytotoxicity against human HepG2 cells by SRB assay
Cytotoxicity against human HepG2 cells by SRB assay
|
[PMID: 19476336] |
| HepG2 | IC50 |
<0.08 μM
Compound: Paclitaxel
|
Cytotoxicity against human HepG2 cells by MTT assay
Cytotoxicity against human HepG2 cells by MTT assay
|
[PMID: 20627721] |
| HepG2 | IC50 |
<0.08 μM
Compound: Paclitaxel
|
Cytotoxicity against human HepG2 cells by MTT assay
Cytotoxicity against human HepG2 cells by MTT assay
|
[PMID: 20716468] |
| HepG2 | IC50 |
0.11 μM
Compound: taxol
|
Cytotoxicity against human HepG2 after 48 hrs by SRB assay
Cytotoxicity against human HepG2 after 48 hrs by SRB assay
|
[PMID: 21044847] |
| HepG2 | ED50 |
>100 nM
Compound: Paclitaxel
|
Antiproliferative activity against human HepG2 cells after 3 days by sulforhodamine B assay
Antiproliferative activity against human HepG2 cells after 3 days by sulforhodamine B assay
|
[PMID: 21296579] |
| HepG2 | IC50 |
10.32 μM
Compound: Paclitaxel
|
Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay
Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay
|
[PMID: 21514015] |
| HepG2 | IC50 |
30.74 μM
Compound: Taxol
|
Cytotoxicity against human HepG2 cells incubated for 48 hrs by MTT assay
Cytotoxicity against human HepG2 cells incubated for 48 hrs by MTT assay
|
[PMID: 21664827] |
| HepG2 | IC50 |
<0.08 μM
Compound: Paclitaxel
|
Cytotoxicity against human HepG2 cells by MTT assay
Cytotoxicity against human HepG2 cells by MTT assay
|
[PMID: 21875764] |
| HepG2 | IC50 |
4.4 x 10-3 μM
Compound: Paclitaxel
|
Cytotoxicity against human HepG2 cells by MTT assay
Cytotoxicity against human HepG2 cells by MTT assay
|
[PMID: 21928797] |
| HepG2 | IC50 |
0.05 μM
Compound: Taxol
|
Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
|
[PMID: 22153338] |
| HepG2 | IC50 |
0.007 μM
Compound: Taxol
|
Cytotoxicity against human HepG2 cells after 24 to 48 hrs by MTT assay
Cytotoxicity against human HepG2 cells after 24 to 48 hrs by MTT assay
|
[PMID: 22222040] |
| HepG2 | IC50 |
30.7 μM
Compound: Taxol
|
Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay
Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay
|
[PMID: 22370266] |
| HepG2 | IC50 |
0.0044 μM
Compound: paclitaxel
|
Cytotoxicity against human HepG2 cells by MTT assay
Cytotoxicity against human HepG2 cells by MTT assay
|
[PMID: 22506620] |
| HepG2 | IC50 |
4.4 x 10-4 μM
Compound: Paclitaxel
|
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay
|
[PMID: 22871217] |
| HepG2 | IC50 |
10.32 μM
Compound: Paclitaxol
|
Cytotoxicity against human HepG2 cells assessed as cell viability after 24 hrs by MTT assay
Cytotoxicity against human HepG2 cells assessed as cell viability after 24 hrs by MTT assay
|
[PMID: 22901410] |
| HepG2 | IC50 |
10.32 μM
Compound: Paclitaxol
|
Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay
Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay
|
[PMID: 22921966] |
| HepG2 | IC50 |
0.054 μM
Compound: Taxol
|
Cytotoxicity against human HepG2 cells after 72 hrs by crystal violet staining based microplate reader analysis
Cytotoxicity against human HepG2 cells after 72 hrs by crystal violet staining based microplate reader analysis
|
[PMID: 23153397] |
| HepG2 | GI50 |
0.18 μM
Compound: paclitaxel
|
Growth inhibition of human HepG2 cells
Growth inhibition of human HepG2 cells
|
[PMID: 23167614] |
| HepG2 | IC50 |
61.8 μM
Compound: Taxol
|
Antitumor activity against human HepG2 cells assessed as growth inhibition measured after 48 hrs by MTT assay
Antitumor activity against human HepG2 cells assessed as growth inhibition measured after 48 hrs by MTT assay
|
[PMID: 23313635] |
| HepG2 | IC50 |
0.006 μM
Compound: Taxol
|
Cytotoxicity against human HepG2 cells after 72 hrs by spectrophotometry
Cytotoxicity against human HepG2 cells after 72 hrs by spectrophotometry
|
[PMID: 23708235] |
| HepG2 | IC50 |
0.59 μg/mL
Compound: Paclitaxel
|
Cytotoxicity against human HepG2 cells after 48 hrs by MTT method
Cytotoxicity against human HepG2 cells after 48 hrs by MTT method
|
[PMID: 24657569] |
| HepG2 | IC50 |
0.0064 μM
Compound: Taxol
|
Cytotoxicity against human HepG2 cells assessed as growth inhibition by MTT assay
Cytotoxicity against human HepG2 cells assessed as growth inhibition by MTT assay
|
[PMID: 24684840] |
| HepG2 | IC50 |
0.19 nM
Compound: Paclitaxel
|
Cytotoxicity against human HepG2 cells assessed as inhibition of cell growth after 3 days by MTT assay
Cytotoxicity against human HepG2 cells assessed as inhibition of cell growth after 3 days by MTT assay
|
[PMID: 24745968] |
| HepG2 | IC50 |
84 nM
Compound: Paclitaxel
|
Cytotoxicity against human HepG2 cells assessed as growth inhibition after 72 hrs by MTT assay
Cytotoxicity against human HepG2 cells assessed as growth inhibition after 72 hrs by MTT assay
|
[PMID: 24929344] |
| HepG2 | IC50 |
4.6 x 10-3 μM
Compound: paclitaxel
|
Cytotoxicity against human HepG2 cells by MTT assay
Cytotoxicity against human HepG2 cells by MTT assay
|
[PMID: 24960143] |
| HepG2 | IC50 |
0.06727 μM
Compound: Paclitaxel
|
Antiproliferative against human HepG2 cells after 48 hrs by MTT assay
Antiproliferative against human HepG2 cells after 48 hrs by MTT assay
|
[PMID: 24996136] |
| HepG2 | IC50 |
2037 nM
Compound: PTX
|
Cytotoxicity against human HepG2 cells assessed as growth inhibition after 48 hrs by MTT method
Cytotoxicity against human HepG2 cells assessed as growth inhibition after 48 hrs by MTT method
|
[PMID: 25025991] |
| HepG2 | IC50 |
0.028 μM
Compound: TAX, Taxol
|
Antiproliferative activity against human HepG2 cells after 48 hrs by SRB method
Antiproliferative activity against human HepG2 cells after 48 hrs by SRB method
|
[PMID: 25061803] |
| HepG2 | IC50 |
0.99 μM
Compound: Taxol
|
Cytotoxicity against human HepG2 cells assessed as growth inhibition after 72 hrs by CCK-8 assay
Cytotoxicity against human HepG2 cells assessed as growth inhibition after 72 hrs by CCK-8 assay
|
[PMID: 25091926] |
| HepG2 | IC50 |
38 nM
Compound: taxol
|
Antiproliferative activity against human HepG2 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay
Antiproliferative activity against human HepG2 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay
|
[PMID: 25208345] |
| HepG2 | IC50 |
2.7 μM
Compound: paclitaxel
|
Cytotoxicity against human HepG2 cells after 48 hrs by trypan blue exclusion method
Cytotoxicity against human HepG2 cells after 48 hrs by trypan blue exclusion method
|
[PMID: 25211032] |
| HepG2 | IC50 |
15.6 μM
Compound: Taxol
|
Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay
Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay
|
[PMID: 25408835] |
| HepG2 | IC50 |
0.19 nM
Compound: Paclitaxel
|
Cytotoxicity against human HepG2 cells assessed as reduction in cell growth after 3 days by MTT assay
Cytotoxicity against human HepG2 cells assessed as reduction in cell growth after 3 days by MTT assay
|
[PMID: 25442315] |
| HepG2 | IC50 |
0.009 μM
Compound: 6
|
Antiproliferative activity against human HepG2 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
Antiproliferative activity against human HepG2 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
|
[PMID: 25682561] |
| HepG2 | IC50 |
0.045 μM
Compound: Taxol
|
Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay
Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay
|
[PMID: 25728023] |
| HepG2 | IC50 |
2600 nM
Compound: PTX
|
Cytotoxicity against human HepG2 cells assessed as growth inhibition after 48 hrs by MTT assay
Cytotoxicity against human HepG2 cells assessed as growth inhibition after 48 hrs by MTT assay
|
[PMID: 26132075] |
| HepG2 | IC50 |
1.217 μM
Compound: 1
|
Cytotoxicity against human HepG2 cells incubated for 48 hrs by CCK-8 assay
Cytotoxicity against human HepG2 cells incubated for 48 hrs by CCK-8 assay
|
[PMID: 26448037] |
| HepG2 | IC50 |
1.06 x 10-8 mg/mL
Compound: Taxol
|
Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
|
[PMID: 26920798] |
| HepG2 | IC50 |
0.02171 μM
Compound: Paclitaxel
|
Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay
Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay
|
[PMID: 27017265] |
| HepG2 | IC50 |
0.0101 μM
Compound: PTX
|
Growth inhibition of human HepG2 cells incubated for 72 hrs by MTT assay
Growth inhibition of human HepG2 cells incubated for 72 hrs by MTT assay
|
[PMID: 27172319] |
| HepG2 | IC50 |
0.2 μM
Compound: Paclitaxel
|
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay
|
[PMID: 27329938] |
| HepG2 | IC50 |
1.2 x 10-2 μM
Compound: Paclitaxel
|
Cytotoxicity against human HepG2 cells by MTT assay
Cytotoxicity against human HepG2 cells by MTT assay
|
[PMID: 27441892] |
| HepG2 | IC50 |
0.006 μM
Compound: Paclitaxel
|
Cytotoxicity activity against human HepG2 cells assessed as growth inhibition measured after 48 hrs by MTT assay
Cytotoxicity activity against human HepG2 cells assessed as growth inhibition measured after 48 hrs by MTT assay
|
[PMID: 27627130] |
| HepG2 | IC50 |
10 μM
Compound: PXL
|
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
|
[PMID: 27707623] |
| HepG2 | IC50 |
6.7 μM
Compound: Paclitaxel
|
Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
|
[PMID: 27748595] |
| HepG2 | IC50 |
10.32 μM
Compound: Paclitaxel
|
Cytotoxicity against human HepG2 cells measured after 24 hrs by MTT assay
Cytotoxicity against human HepG2 cells measured after 24 hrs by MTT assay
|
[PMID: 27769031] |
| HepG2 | IC50 |
15.6 μM
Compound: Taxol
|
Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability by MTT assay
Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability by MTT assay
|
[PMID: 28197320] |
| HepG2 | IC50 |
0.3 μM
Compound: Pac
|
Cytotoxicity against human HepG2 cells by MTT assay
Cytotoxicity against human HepG2 cells by MTT assay
|
[PMID: 28262527] |
| HepG2 | IC50 |
6.3 nM
Compound: Paclitaxel
|
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 96 hrs by MTT assay
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 96 hrs by MTT assay
|
[PMID: 28530828] |
| HepG2 | IC50 |
0.02 μM
Compound: Taxol
|
Growth inhibition of human HepG2 cells incubated for 3 days by SRB assay
Growth inhibition of human HepG2 cells incubated for 3 days by SRB assay
|
[PMID: 28625363] |
| HepG2 | IC50 |
0.0076 μM
Compound: Taxol
|
Growth inhibition of human HepG2 cells after 96 hrs by MTT assay
Growth inhibition of human HepG2 cells after 96 hrs by MTT assay
|
[PMID: 28737396] |
| HepG2 | CC50 |
0.12 μM
Compound: PTX
|
Cytotoxicity against human HepG2 cells by MTS assay
Cytotoxicity against human HepG2 cells by MTS assay
|
[PMID: 29269214] |
| HepG2 | IC50 |
0.0102 μM
Compound: Paclitaxel
|
Cytotoxicity against human HepG2 cells after 96 hrs by MTT assay
Cytotoxicity against human HepG2 cells after 96 hrs by MTT assay
|
[PMID: 29279273] |
| HepG2 | IC50 |
2660 nM
Compound: PTX
|
Growth inhibition of human HepG2 cells after 48 hrs by MTT assay
Growth inhibition of human HepG2 cells after 48 hrs by MTT assay
|
[PMID: 29730191] |
| HepG2 | IC50 |
0.009 μM
Compound: Paclitaxel
|
Antiproliferative activity against human HepG2 cells after 24 hrs by CCK8 assay
Antiproliferative activity against human HepG2 cells after 24 hrs by CCK8 assay
|
[PMID: 30392953] |
| HepG2 | IC50 |
10.3 μM
Compound: Taxol
|
Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
|
[PMID: 30579802] |
| HepG2 | IC50 |
1.9 nM
Compound: Taxol
|
Cytotoxicity against human HepG2 cells measured after 48 hrs by MTT assay
Cytotoxicity against human HepG2 cells measured after 48 hrs by MTT assay
|
[PMID: 31050424] |
| HepG2 | IC50 |
0.18 μM
Compound: PTX
|
Antiproliferative activity against human HepG2 cells incubated for 72 hrs by CCK8 cells
Antiproliferative activity against human HepG2 cells incubated for 72 hrs by CCK8 cells
|
[PMID: 31200238] |
| HepG2 | IC50 |
<0.008 μM
Compound: Paclitaxel
|
Cytotoxicity in human HepG2 cells assessed as reduction in cell viability incubated for 3 days by MTT assay
Cytotoxicity in human HepG2 cells assessed as reduction in cell viability incubated for 3 days by MTT assay
|
[PMID: 31390200] |
| HepG2 | GI50 |
<0.01 μM
Compound: Paciltaxel
|
Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability after 48 hrs by SRB assay
Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability after 48 hrs by SRB assay
|
[PMID: 31546197] |
| HepG2 | GI50 |
<0.016 μM
Compound: Paciltaxel
|
Antiproliferative activity against human HepG2 cells by SRB assay
Antiproliferative activity against human HepG2 cells by SRB assay
|
[PMID: 31546197] |
| HepG2 | IC50 |
101.65 μg/mL
Compound: Paclitaxel
|
Antitumour activity against human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
Antitumour activity against human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
|
[PMID: 31607609] |
| HepG2 | IC50 |
0.009 μM
Compound: Paclitaxel
|
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by sulforhodamine B assay
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by sulforhodamine B assay
|
[PMID: 31901744] |
| HepG2 | IC50 |
0.00076 μM
Compound: Taxol
|
Antiproliferation activity against human HepG2 cells assessed as reduction in cell viability incubated for 96 hrs by MTT assay
Antiproliferation activity against human HepG2 cells assessed as reduction in cell viability incubated for 96 hrs by MTT assay
|
[PMID: 32546298] |
| HepG2 | IC50 |
3.9 μM
Compound: Paclitaxel
|
Antiproliferative activity against human HepG2 cells assessed as reduction in cell proliferation measured after 72 hrs by MTT assay
Antiproliferative activity against human HepG2 cells assessed as reduction in cell proliferation measured after 72 hrs by MTT assay
|
[PMID: 32631535] |
| HepG2 | IC50 |
660 ng/mL
Compound: Paclitaxel
|
Cytotoxicity against human HepG2 cells by MTT assay
Cytotoxicity against human HepG2 cells by MTT assay
|
[PMID: 32731188] |
| HepG2 | IC50 |
12.6 nM
Compound: Paclitaxel
|
Cytotoxicity against human HepG2 cells assessed as growth inhibition
Cytotoxicity against human HepG2 cells assessed as growth inhibition
|
[PMID: 33279291] |
| HepG2 | IC50 |
8.4 μM
Compound: PTX
|
Cytotoxicity against human HepG2 cells assessed as cell growth inhibition measured after 24 hrs by MTT assay
Cytotoxicity against human HepG2 cells assessed as cell growth inhibition measured after 24 hrs by MTT assay
|
[PMID: 33381964] |
| HepG2 | IC50 |
0.2 nM
Compound: PTX
|
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 24 hrs in presence of 10 uM chloramphenicol by MTT assay
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 24 hrs in presence of 10 uM chloramphenicol by MTT assay
|
[PMID: 34097831] |
| HepG2 | IC50 |
1 nM
Compound: PTX
|
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 24 hrs in presence of 1 uM chloramphenicol by MTT assay
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 24 hrs in presence of 1 uM chloramphenicol by MTT assay
|
[PMID: 34097831] |
| HepG2 | IC50 |
220 nM
Compound: PTX
|
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
|
[PMID: 34097831] |
| HepG2 | IC50 |
0.19 μM
Compound: Paclitaxel
|
Anticancer activity against human HepG2 cells assessed as cell growth inhibition measured for 72 hrs by MTT assay
Anticancer activity against human HepG2 cells assessed as cell growth inhibition measured for 72 hrs by MTT assay
|
[PMID: 34303874] |
| HepG2 | IC50 |
10.1 nM
Compound: Taxol
|
Antiproliferative activity against human HepG2 cells assessed as inhibition of cell growth by secondary round CCK8 assay
Antiproliferative activity against human HepG2 cells assessed as inhibition of cell growth by secondary round CCK8 assay
|
[PMID: 34508844] |
| HepG2 | IC50 |
16.6 nM
Compound: PTX
|
Antiproliferative activity against human HepG2 cells incubated for 72 hrs by MTT assay
Antiproliferative activity against human HepG2 cells incubated for 72 hrs by MTT assay
|
[PMID: 34648295] |
| HepG2 | IC50 |
0.06 μM
Compound: PTX
|
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability by MTT assay
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability by MTT assay
|
[PMID: 35213164] |
| HepG2 | IC50 |
0.013 μM
Compound: Taxol
|
Antiproliferative activity against human HepG2 cells assessed as inhibition of cell growth measured after 74 hrs by SRB assay
Antiproliferative activity against human HepG2 cells assessed as inhibition of cell growth measured after 74 hrs by SRB assay
|
[PMID: 35255412] |
| HepG2 | IC50 |
0.22 μM
Compound: Paclitaxel; Taxol
|
Antiproliferative activity against human HepG2 cells measured after 48 hrs by MTT assay
Antiproliferative activity against human HepG2 cells measured after 48 hrs by MTT assay
|
[PMID: 35551039] |
| HepG2 | IC50 |
4.3 μg/mL
Compound: Taxol
|
Cytotoxicity against human HepG2 cells by MTT assay
Cytotoxicity against human HepG2 cells by MTT assay
|
[PMID: 36325400] |
| HepG2 | IC50 |
<0.001 μM
Compound: Paclitaxel
|
Antiproliferative activity against human HepG2 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
Antiproliferative activity against human HepG2 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
|
[PMID: 36511661] |
| HepG2 | IC50 |
2.5 nM
Compound: Paclitaxel
|
Antiproliferative activity against human HepG2 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay
Antiproliferative activity against human HepG2 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay
|
[PMID: 36621138] |
| HepG2 | IC50 |
0.55 μM
Compound: Taxol
|
Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by CCk-8 assay
Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by CCk-8 assay
|
[PMID: 37329677] |
| HepG2 | IC50 |
0.064 μM
Compound: Paclitaxel
|
Cytotoxicity against human HepG2 cells assessed as reduction in cell growth measured after 72 hrs by MTT assay
Cytotoxicity against human HepG2 cells assessed as reduction in cell growth measured after 72 hrs by MTT assay
|
[PMID: 37336771] |
| HepG2 | IC50 |
2600 nM
Compound: Paclitaxel
|
Antiproliferative activity against human HepG2 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay
Antiproliferative activity against human HepG2 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay
|
[PMID: 38107170] |
| HepG2 | IC50 |
7.87 μM
Compound: Paclitaxel
|
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability measured after 48 hrs by MTT colorimetric based assay
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability measured after 48 hrs by MTT colorimetric based assay
|
[PMID: 38107170] |
| HepG2 | IC50 |
0.06 μM
Compound: Paciitaxel
|
Cytotoxicity against human HepG2 cells incubated for 72 hrs by CCK8 assay
Cytotoxicity against human HepG2 cells incubated for 72 hrs by CCK8 assay
|
[PMID: 38493728] |
| HepG2 | IC50 |
0.06 μM
Compound: PTX
|
Cytotoxicity against human HepG2 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay
Cytotoxicity against human HepG2 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay
|
[PMID: 38547648] |
| HepG2 | IC50 |
0.016 μg/mL
Compound: Paclitaxel
|
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by sulforhodamine B assay
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 39052090] |
| HepG2 | IC50 |
0.002 μM
Compound: Paclitaxel
|
Antiproliferative activity against human HepG2 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
Antiproliferative activity against human HepG2 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
|
[PMID: 39163776] |
| HepG2 | IC50 |
>100 μM
Compound: Paclitaxel
|
Antiproliferative activity against human HepG2 cells assessed as cell viability after 48 hrs by MTT assay
Antiproliferative activity against human HepG2 cells assessed as cell viability after 48 hrs by MTT assay
|
10.1039/C4MD00344F |
| HEY | IC50 |
104.1 nM
Compound: Paclitaxel
|
Cytotoxicity against human HEY cells after 48 hrs by MTT assay
Cytotoxicity against human HEY cells after 48 hrs by MTT assay
|
[PMID: 28719204] |
| HEY | IC50 |
2.7 μM
Compound: Taxol
|
Cytotoxicity against human HEY cells after 72 to 120 hrs by sulforhodamine B assay
Cytotoxicity against human HEY cells after 72 to 120 hrs by sulforhodamine B assay
|
[PMID: 29517223] |
| HFF-1 | IC50 |
>10 μM
Compound: Paclitaxel
|
Cytotoxicity against human HFF1 after 24 hrs by MTT assay
Cytotoxicity against human HFF1 after 24 hrs by MTT assay
|
[PMID: 30387611] |
| HFF-1 | IC50 |
>10 μM
Compound: Paclitaxel
|
Cytotoxicity against human HFF1 after 48 hrs by MTT assay
Cytotoxicity against human HFF1 after 48 hrs by MTT assay
|
[PMID: 30387611] |
| HGC-27 | IC50 |
777.8 nM
Compound: Paclitaxel
|
Cytotoxicity against human HGC27 cells by MTT assay
Cytotoxicity against human HGC27 cells by MTT assay
|
[PMID: 17764148] |
| HGC-27 | IC50 |
0.028 μM
Compound: Taxol
|
Antiproliferative activity against human HGC27 cells after 72 hrs by MTT assay
Antiproliferative activity against human HGC27 cells after 72 hrs by MTT assay
|
[PMID: 30212198] |
| HGC-27 | IC50 |
8.4 nM
Compound: Paclitaxel
|
Cytotoxicity against human HGC27 cells after 72 hrs by CCK8 assay
Cytotoxicity against human HGC27 cells after 72 hrs by CCK8 assay
|
[PMID: 32489099] |
| HGC-27 | IC50 |
<0.001 μM
Compound: Paclitaxel
|
Antiproliferative activity against human HGC-27 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
Antiproliferative activity against human HGC-27 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
|
[PMID: 36511661] |
| HGC-27 | IC50 |
0.008 μg/mL
Compound: Paclitaxel
|
Cytotoxicity against human HGC-27 cells assessed as reduction in cell viability incubated for 48 hrs by sulforhodamine B assay
Cytotoxicity against human HGC-27 cells assessed as reduction in cell viability incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 39052090] |
| HL-60 | IC50 |
0.005 μM
Compound: Taxol
|
Cytotoxicity against human HL60 cell line by MTS assay
Cytotoxicity against human HL60 cell line by MTS assay
|
[PMID: 16870446] |
| HL-60 | IC50 |
5 μM
Compound: Taxol
|
Cytotoxicity against human HL60/TX1000 cell line by MTS assay
Cytotoxicity against human HL60/TX1000 cell line by MTS assay
|
[PMID: 16870446] |
| HL-60 | IC50 |
0.93 μM
Compound: paclitaxel
|
Cytotoxicity against human HL60 cells after 72 hrs by MTT assay
Cytotoxicity against human HL60 cells after 72 hrs by MTT assay
|
[PMID: 17896816] |
| HL-60 | IC50 |
0.93 μM
Compound: paclitaxel
|
Cytotoxicity against human HL60 cells after 72 hrs by MTT assay
Cytotoxicity against human HL60 cells after 72 hrs by MTT assay
|
[PMID: 18281952] |
| HL-60 | IC50 |
0.005 μM
Compound: Taxol
|
Cytotoxicity against human HL60 cells after 72 hrs by MTT assay
Cytotoxicity against human HL60 cells after 72 hrs by MTT assay
|
[PMID: 18308566] |
| HL-60 | IC50 |
<2 μg/mL
Compound: paclitaxel
|
Cytotoxicity against human HL60 cells after 48 hrs by MTT assay
Cytotoxicity against human HL60 cells after 48 hrs by MTT assay
|
[PMID: 18553923] |
| HL-60 | IC50 |
4 ng/mL
Compound: Taxol
|
Antiproliferative activity against human HL60 cells after 24 hrs by alamar blue assay
Antiproliferative activity against human HL60 cells after 24 hrs by alamar blue assay
|
[PMID: 19717215] |
| HL-60 | IC50 |
<0.008 μM
Compound: Paclitaxel
|
Cytotoxicity against human HL60 cells after 48 hrs by MTT assay
Cytotoxicity against human HL60 cells after 48 hrs by MTT assay
|
[PMID: 20521771] |
| HL-60 | IC50 |
0.01 μM
Compound: paclitaxel
|
Cytotoxicity against human HL60 cells after 48 hrs by MTT method
Cytotoxicity against human HL60 cells after 48 hrs by MTT method
|
[PMID: 21534539] |
| HL-60 | IC50 |
3.4 nM
Compound: Taxol
|
Cytotoxicity against human HL60 cells after 72 hrs by MTS assay
Cytotoxicity against human HL60 cells after 72 hrs by MTS assay
|
[PMID: 21848268] |
| HL-60 | IC50 |
2.82 nM
Compound: Paclitaxel
|
Cytotoxicity against human HL60 cells after 72 hrs by MTT assay
Cytotoxicity against human HL60 cells after 72 hrs by MTT assay
|
[PMID: 22959518] |
| HL-60 | IC50 |
5.8 nM
Compound: Taxol
|
Cytotoxicity against human HL60 cells expressing BCR-ABL assessed as growth inhibition after 72 hrs by CCK-8 assay
Cytotoxicity against human HL60 cells expressing BCR-ABL assessed as growth inhibition after 72 hrs by CCK-8 assay
|
[PMID: 23301703] |
| HL-60 | IC50 |
<0.008 μM
Compound: Paclitaxel
|
Cytotoxicity against human HL60 cells assessed as inhibition of cell viability after 48 hrs by MTT assay
Cytotoxicity against human HL60 cells assessed as inhibition of cell viability after 48 hrs by MTT assay
|
[PMID: 23327668] |
| HL-60 | IC50 |
<0.008 μM
Compound: paclitaxel
|
Cytotoxicity against human HL60 cells assessed as cell viability measured after 48 hrs by MTT assay
Cytotoxicity against human HL60 cells assessed as cell viability measured after 48 hrs by MTT assay
|
[PMID: 23586920] |
| HL-60 | IC50 |
0.005 μg/mL
Compound: Paclitaxel
|
Cytotoxicity against human HL60 cells after 48 hrs by MTT assay
Cytotoxicity against human HL60 cells after 48 hrs by MTT assay
|
[PMID: 23755851] |
| HL-60 | IC50 |
<0.008 μM
Compound: paclitaxel
|
Cytotoxicity against human HL60 cells after 48 hrs by MTT assay
Cytotoxicity against human HL60 cells after 48 hrs by MTT assay
|
[PMID: 23819871] |
| HL-60 | IC50 |
0.002 μM
Compound: Taxol
|
Cytotoxicity against human HL60 cells
Cytotoxicity against human HL60 cells
|
[PMID: 23937981] |
| HL-60 | IC50 |
5 μM
Compound: Taxol
|
Cytotoxicity against multidrug-resistant human HL60 cells
Cytotoxicity against multidrug-resistant human HL60 cells
|
[PMID: 23937981] |
| HL-60 | IC50 |
<0.008 μM
Compound: paclitaxel
|
Antimicrobial activity against human HL60 cells after 48 hrs by MTT assay
Antimicrobial activity against human HL60 cells after 48 hrs by MTT assay
|
[PMID: 23957453] |
| HL-60 | IC50 |
<0.008 μM
Compound: paclitaxel
|
Cytotoxicity against human HL60 cells after 48 hrs by MTS assay
Cytotoxicity against human HL60 cells after 48 hrs by MTS assay
|
[PMID: 24219809] |
| HL-60 | IC50 |
<0.008 μM
Compound: paclitaxel
|
Cytotoxicity against human HL60 cells after 48 hrs by MTS assay
Cytotoxicity against human HL60 cells after 48 hrs by MTS assay
|
[PMID: 24256484] |
| HL-60 | IC50 |
<0.008 μM
Compound: Paclitaxel
|
Cytotoxicity against human HL60 cells after 48 hrs by MTT assay
Cytotoxicity against human HL60 cells after 48 hrs by MTT assay
|
[PMID: 24417634] |
| HL-60 | IC50 |
<0.008 μM
Compound: paclitaxel
|
Cytotoxicity against human HL60 cells assessed as growth inhibition after 48 hrs by MTS assay
Cytotoxicity against human HL60 cells assessed as growth inhibition after 48 hrs by MTS assay
|
[PMID: 24697496] |
| HL-60 | IC50 |
0.32 μM
Compound: Paclitaxel
|
Antiproliferative activity against human HL60 cells after 24 and 72 hrs by MTT assay
Antiproliferative activity against human HL60 cells after 24 and 72 hrs by MTT assay
|
[PMID: 24941130] |
| HL-60 | IC50 |
1.5 μM
Compound: paclitaxel
|
Cytotoxicity against human HL60 cells after 48 hrs by trypan blue exclusion method
Cytotoxicity against human HL60 cells after 48 hrs by trypan blue exclusion method
|
[PMID: 25211032] |
| HL-60 | IC50 |
<0.008 μM
Compound: paclitaxel
|
Cytotoxicity against human HL60 cells after 48 hrs by MTT assay
Cytotoxicity against human HL60 cells after 48 hrs by MTT assay
|
[PMID: 25375202] |
| HL-60 | IC50 |
0.007 μM
Compound: Taxol, Paclitaxel
|
Cytotoxicity against human HL60 cells after 24 hrs by MTT assay
Cytotoxicity against human HL60 cells after 24 hrs by MTT assay
|
[PMID: 25462222] |
| HL-60 | IC50 |
7.9 nM
Compound: 28
|
Antiproliferative activity against human HL60 cells after 72 hrs by WST8 assay
Antiproliferative activity against human HL60 cells after 72 hrs by WST8 assay
|
[PMID: 25625617] |
| HL-60 | IC50 |
0.0017 μM
Compound: Taxol
|
Antiproliferative activity against human HL60 cells after 72 hrs by MTT assay
Antiproliferative activity against human HL60 cells after 72 hrs by MTT assay
|
[PMID: 25771484] |
| HL-60 | IC50 |
<0.008 μM
Compound: paclitaxel
|
Cytotoxicity against human HL60 cells incubated for 48 hrs by MTT assay
Cytotoxicity against human HL60 cells incubated for 48 hrs by MTT assay
|
[PMID: 25798528] |
| HL-60 | IC50 |
1.8 nM
Compound: Taxol
|
Cytotoxicity against human HL60 cells assessed as cell viability after 72 hrs by CCK8 assay
Cytotoxicity against human HL60 cells assessed as cell viability after 72 hrs by CCK8 assay
|
[PMID: 25819096] |
| HL-60 | IC50 |
<0.008 μM
Compound: Taxol
|
Cytotoxicity against human HL60 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Cytotoxicity against human HL60 cells assessed as reduction in cell viability after 48 hrs by MTT assay
|
[PMID: 25871261] |
| HL-60 | IC50 |
<0.008 μM
Compound: Taxol
|
Cytotoxicity against human HL60 cells assessed as cell viability after 48 hrs by MTS assay
Cytotoxicity against human HL60 cells assessed as cell viability after 48 hrs by MTS assay
|
[PMID: 26068802] |
| HL-60 | IC50 |
3.8 μM
Compound: taxol
|
Cytotoxicity against human HL60 cells after 72 hrs by CCK8 assay
Cytotoxicity against human HL60 cells after 72 hrs by CCK8 assay
|
[PMID: 26316467] |
| HL-60 | IC50 |
1.99 nM
Compound: Taxol
|
Cytotoxicity against human HL60 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay
Cytotoxicity against human HL60 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay
|
[PMID: 26697718] |
| HL-60 | IC50 |
<0.008 μM
Compound: Paclitaxel
|
Cytotoxicity against human HL60 cells assessed as decrease in cell viability after 48 hrs by MTS assay
Cytotoxicity against human HL60 cells assessed as decrease in cell viability after 48 hrs by MTS assay
|
[PMID: 27704807] |
| HL-60 | IC50 |
2 nM
Compound: Paclitaxel
|
Cytotoxicity against human HL60 cells assessed as reduction in cell viability after 72 hrs by CCK-8 assay
Cytotoxicity against human HL60 cells assessed as reduction in cell viability after 72 hrs by CCK-8 assay
|
[PMID: 28598633] |
| HL-60 | IC50 |
<0.008 μM
Compound: Paclitaxel
|
Antiproliferative activity against human HL60 cells after 48 hrs by MTS assay
Antiproliferative activity against human HL60 cells after 48 hrs by MTS assay
|
[PMID: 28654256] |
| HL-60 | IC50 |
<0.008 μM
Compound: Paclitaxel
|
Cytotoxicity against human HL60 cells after 48 hrs by MTS assay
Cytotoxicity against human HL60 cells after 48 hrs by MTS assay
|
[PMID: 29286250] |
| HL-60 | IC50 |
<0.008 μM
Compound: Paclitaxel
|
Cytotoxicity against human HL60 cells after 48 hrs by MTS assay
Cytotoxicity against human HL60 cells after 48 hrs by MTS assay
|
[PMID: 29338226] |
| HL-60 | IC50 |
<0.008 μM
Compound: Paclitaxel
|
Cytotoxicity against human HL60 cells assessed as reduction in cell viability after 48 hrs by MTS assay
Cytotoxicity against human HL60 cells assessed as reduction in cell viability after 48 hrs by MTS assay
|
[PMID: 29338260] |
| HL-60 | IC50 |
2 nM
Compound: Paclitaxel
|
Cytotoxicity against human HL60 cells after 48 hrs by MTT assay
Cytotoxicity against human HL60 cells after 48 hrs by MTT assay
|
[PMID: 29373791] |
| HL-60 | IC50 |
<0.008 μM
Compound: Paclitaxel
|
Growth inhibition of human HL60 cells after 48 hrs by MTS assay
Growth inhibition of human HL60 cells after 48 hrs by MTS assay
|
[PMID: 29412669] |
| HL-60 | IC50 |
0.0026 μM
Compound: Taxol
|
Antiproliferative activity against human HL60 cells after 48 hrs by CCK8 assay
Antiproliferative activity against human HL60 cells after 48 hrs by CCK8 assay
|
[PMID: 29475587] |
| HL-60 | IC50 |
<0.008 μM
Compound: Taxol
|
Cytotoxicity against human HL60 cells assessed as decrease in cell viability after 4 days by MTT assay
Cytotoxicity against human HL60 cells assessed as decrease in cell viability after 4 days by MTT assay
|
[PMID: 29884535] |
| HL-60 | IC50 |
<0.008 μM
Compound: Paclitaxel
|
Antiproliferative activity against human HL60 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay
Antiproliferative activity against human HL60 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay
|
[PMID: 30822712] |
| HL-60 | IC50 |
<0.008 μM
Compound: Paclitaxel
|
Cytotoxicity in human HL60 cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay
Cytotoxicity in human HL60 cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay
|
[PMID: 31310115] |
| HL-60 | IC50 |
2.5 x 10-3 μM
Compound: Taxol
|
Cytotoxicity against human HL60 cells assessed as reduction in cell viability
Cytotoxicity against human HL60 cells assessed as reduction in cell viability
|
[PMID: 32273216] |
| HL-60 | IC50 |
<0.008 μM
Compound: Paclitaxel
|
Cytotoxicity against human HL-60 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Cytotoxicity against human HL-60 cells assessed as reduction in cell viability after 48 hrs by MTT assay
|
[PMID: 32628478] |
| HL-60 | IC50 |
0.08 μM
Compound: PTX
|
Cytotoxicity against human HL-60 cells by MTT assay
Cytotoxicity against human HL-60 cells by MTT assay
|
[PMID: 33915258] |
| HL-60 | IC50 |
<0.008 μM
Compound: Paclitaxel
|
Cytotoxicity against human HL-60 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay
Cytotoxicity against human HL-60 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay
|
[PMID: 34355562] |
| HL-60 | IC50 |
<0.008 μM
Compound: Taxol
|
Cytotoxicity against human HL-60 cells assessed as inhibition of cell growth measured after 48 hrs by MTS assay
Cytotoxicity against human HL-60 cells assessed as inhibition of cell growth measured after 48 hrs by MTS assay
|
[PMID: 34781083] |
| HL-60 | IC50 |
2.2 nM
Compound: Paclitaxel
|
Cytotoxicity against human HL-60 cells assessed as growth inhibition
Cytotoxicity against human HL-60 cells assessed as growth inhibition
|
[PMID: 34949088] |
| HL-60 | IC50 |
<0.008 μM
Compound: Taxol
|
Antiproliferative activity against human HL-60 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
Antiproliferative activity against human HL-60 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
|
[PMID: 36274275] |
| HL-60 | IC50 |
0.012 μM
Compound: PTX
|
Cytotoxicity against human HL-60 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay
Cytotoxicity against human HL-60 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay
|
[PMID: 38547648] |
| HL-60 | IC50 |
0.001 μg/mL
Compound: 1 (Taxol)
|
Tested in vitro for the anticancer activity against HL-60 leukemia cells
Tested in vitro for the anticancer activity against HL-60 leukemia cells
|
10.1016/S0960-894X(97)00058-9 |
| HL-60(TB) | GI50 |
4 nM
Compound: Paclitaxel
|
Growth inhibition of human HL-60(TB) cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human HL-60(TB) cells incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 29655610] |
| HL-60(TB) | GI50 |
4 nM
Compound: Paclitaxel
|
Cytotoxicity against human HL-60(TB) cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay
Cytotoxicity against human HL-60(TB) cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay
|
[PMID: 33310545] |
| HOP-62 | GI50 |
19 nM
Compound: Paclitaxel
|
Growth inhibition of human HOP62 cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human HOP62 cells incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 29655610] |
| HOP-62 | GI50 |
19 nM
Compound: Paclitaxel
|
Cytotoxicity against human HOP-62 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay
Cytotoxicity against human HOP-62 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay
|
[PMID: 33310545] |
| HOP-62 | GI50 |
6.71 x 10-8 M
Compound: 5
|
Cytotoxicity against human HOP62 cells
Cytotoxicity against human HOP62 cells
|
[PMID: 7908950] |
| HOP-92 | GI50 |
25 nM
Compound: Paclitaxel
|
Growth inhibition of human HOP92 cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human HOP92 cells incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 29655610] |
| HOP-92 | GI50 |
25 nM
Compound: Paclitaxel
|
Cytotoxicity against human HOP-92 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay
Cytotoxicity against human HOP-92 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay
|
[PMID: 33310545] |
| Hs-578T | GI50 |
0.003 μM
Compound: paclitaxel
|
Cytotoxicity against human HS578T cells
Cytotoxicity against human HS578T cells
|
[PMID: 17696332] |
| Hs-578T | GI50 |
0.003 μM
Compound: Paclitaxel
|
Cytotoxicity against human Hs578T cells by sulforhodamine B assay
Cytotoxicity against human Hs578T cells by sulforhodamine B assay
|
[PMID: 21839640] |
| Hs-578T | GI50 |
5 nM
Compound: Paclitaxel
|
Growth inhibition of human Hs578T cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human Hs578T cells incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 29655610] |
| Hs-578T | GI50 |
5 nM
Compound: Paclitaxel
|
Cytotoxicity against human Hs-578T cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay
Cytotoxicity against human Hs-578T cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay
|
[PMID: 33310545] |
| Hs-578T | IC50 |
14.8 nM
Compound: Pac
|
Inhibition of human Hs-578T cell spheroids incubated for 7 days by luciferase based assay
Inhibition of human Hs-578T cell spheroids incubated for 7 days by luciferase based assay
|
[PMID: 36780832] |
| HSC-2 | IC50 |
>100 μM
Compound: Paclitaxel
|
Cytotoxicity against human HSC-2 cells
Cytotoxicity against human HSC-2 cells
|
[PMID: 31945642] |
| HSC-T6 | IC50 |
0.75 μg/mL
Compound: paclitaxel
|
Cytotoxicity against rat HSC-T6 cells after 44 hrs by MTT assay
Cytotoxicity against rat HSC-T6 cells after 44 hrs by MTT assay
|
[PMID: 19928884] |
| HT-1080 | IC50 |
1.2 nM
Compound: Taxol
|
Antiproliferative activity against human HT1080 cells after 96 hrs by MTT assay
Antiproliferative activity against human HT1080 cells after 96 hrs by MTT assay
|
[PMID: 21296467] |
| HT-1080 | IC50 |
0.15 nM
Compound: Pac
|
Antiproliferative activity against human HT1080 cells after 48 hrs by sulforhodamine B assay
Antiproliferative activity against human HT1080 cells after 48 hrs by sulforhodamine B assay
|
[PMID: 21604746] |
| HT-1080 | IC50 |
0.15 nM
Compound: Pac
|
Antiproliferative activity against human HT1080 after 48 hrs by SRB assay
Antiproliferative activity against human HT1080 after 48 hrs by SRB assay
|
[PMID: 21920638] |
| HT-1080 | IC50 |
6 μM
Compound: paclitaxel
|
Cytotoxicity against human HT1080 cells assessed as growth inhibition after 24 hrs by MTT assay
Cytotoxicity against human HT1080 cells assessed as growth inhibition after 24 hrs by MTT assay
|
[PMID: 23647462] |
| HT-1080 | GI50 |
3.889 nM
Compound: 1, Taxol
|
Growth inhibition of human HT1080 cells by MTT assay
Growth inhibition of human HT1080 cells by MTT assay
|
[PMID: 24405702] |
| HT-1080 | IC50 |
1.8 nM
Compound: PT
|
Antiproliferative activity against human HT-1080 cells assessed as reduction in cell viability incubated for 72 hrs by CelltiterGlo luminescent assay
Antiproliferative activity against human HT-1080 cells assessed as reduction in cell viability incubated for 72 hrs by CelltiterGlo luminescent assay
|
[PMID: 38959729] |
| HT-29 | IC50 |
0.00016 μM
Compound: paclitaxel
|
In vitro cytotoxic activity against colon adenocarcinoma (HT-29) cells assayed by inhibition of [3H]-labeled thymidine incorporation
In vitro cytotoxic activity against colon adenocarcinoma (HT-29) cells assayed by inhibition of [3H]-labeled thymidine incorporation
|
[PMID: 11728191] |
| HT-29 | IC50 |
0.01 μg/mL
Compound: (22) taxol
|
In vitro cytotoxicity of compound against HT29, human colorectal adenocarcinoma was defined by microculture tetrazolium assay
In vitro cytotoxicity of compound against HT29, human colorectal adenocarcinoma was defined by microculture tetrazolium assay
|
[PMID: 12620075] |
| HT-29 | IC50 |
0.05 μM
Compound: Taxol
|
Cytotoxicity against human HT29 cells by MTT assay
Cytotoxicity against human HT29 cells by MTT assay
|
[PMID: 16539377] |
| HT-29 | EC50 |
0.006 μM
Compound: PXL
|
Cytotoxicity against human HT29 cells
Cytotoxicity against human HT29 cells
|
[PMID: 16870428] |
| HT-29 | IC50 |
5.3 ng/mL
Compound: Paclitaxel
|
Cytotoxicity against human HT-29 cells by MTT assay
Cytotoxicity against human HT-29 cells by MTT assay
|
[PMID: 16872157] |
| HT-29 | IC50 |
0.03 μg/mL
Compound: 1
|
Cytotoxicity against human HT29 cells
Cytotoxicity against human HT29 cells
|
[PMID: 17419065] |
| HT-29 | GI50 |
0.015 μM
Compound: paclitaxel
|
Growth inhibition of human HT29 cells after 48 hrs
Growth inhibition of human HT29 cells after 48 hrs
|
[PMID: 17498960] |
| HT-29 | GI50 |
0.002 μM
Compound: paclitaxel
|
Cytotoxicity against human HT29 cells
Cytotoxicity against human HT29 cells
|
[PMID: 17696332] |
| HT-29 | IC50 |
0.05 μM
Compound: taxol
|
Cytotoxicity against human HT29 cells after 72 hrs by MTT assay
Cytotoxicity against human HT29 cells after 72 hrs by MTT assay
|
[PMID: 17915851] |
| HT-29 | IC50 |
5.3 ng/mL
Compound: paclitaxel
|
Cytotoxicity against human HT29 cells by MTT assay
Cytotoxicity against human HT29 cells by MTT assay
|
[PMID: 17927264] |
| HT-29 | IC50 |
1.9 nM
Compound: paclitaxel
|
Antiproliferative activity against human HT29 cells after 48 hrs by MTT assay
Antiproliferative activity against human HT29 cells after 48 hrs by MTT assay
|
[PMID: 18461997] |
| HT-29 | GI50 |
0.015 μM
Compound: paclitaxel
|
Antiproliferative activity against human HT29 cells
Antiproliferative activity against human HT29 cells
|
[PMID: 18502639] |
| HT-29 | GI50 |
0.015 μM
Compound: Paclitaxel
|
Growth inhibition of human HT29 cells after 48 hrs by sulforhodamine B assay
Growth inhibition of human HT29 cells after 48 hrs by sulforhodamine B assay
|
[PMID: 18579387] |
| HT-29 | GI50 |
0.015 μM
Compound: Pac
|
Antiproliferative activity against human HT29 cells after 48 hrs by sulforhodamine B method
Antiproliferative activity against human HT29 cells after 48 hrs by sulforhodamine B method
|
[PMID: 18617414] |
| HT-29 | IC50 |
3.6 nM
Compound: paclitaxel
|
Cytotoxicity against human HT-29 cells after 4 days by MTT assay
Cytotoxicity against human HT-29 cells after 4 days by MTT assay
|
[PMID: 19128156] |
| HT-29 | IC50 |
3.6 nM
Compound: paclitaxel
|
Cytotoxicity against human HT-29 cells after 72 hrs
Cytotoxicity against human HT-29 cells after 72 hrs
|
[PMID: 19239240] |
| HT-29 | IC50 |
3.4 nM
Compound: Paclitaxel
|
Cytotoxicity against human HT-29 cells after 1 hr by MTT assay
Cytotoxicity against human HT-29 cells after 1 hr by MTT assay
|
[PMID: 19778067] |
| HT-29 | ED50 |
0.1 nM
Compound: paclitaxel
|
Cytotoxicity against human HT-29 cells after 3 days by SRB assay
Cytotoxicity against human HT-29 cells after 3 days by SRB assay
|
[PMID: 20384315] |
| HT-29 | IC50 |
1.4 x 10-3 μM
Compound: Paclitaxel
|
Cytotoxicity against human HT-29 cells by MTT assay
Cytotoxicity against human HT-29 cells by MTT assay
|
[PMID: 20553003] |
| HT-29 | IC50 |
0.38 μM
Compound: Paclitaxel
|
Cytotoxicity against human HT-29 cells by MTT assay
Cytotoxicity against human HT-29 cells by MTT assay
|
[PMID: 20627721] |
| HT-29 | IC50 |
0.38 μM
Compound: Paclitaxel
|
Cytotoxicity against human HT-29 cells by MTT assay
Cytotoxicity against human HT-29 cells by MTT assay
|
[PMID: 20716468] |
| HT-29 | ED50 |
0.0006 μM
Compound: Paclitaxel
|
Cytotoxicity against human HT-29 cells after 3 days by sulforhodamine B assay
Cytotoxicity against human HT-29 cells after 3 days by sulforhodamine B assay
|
[PMID: 20939540] |
| HT-29 | ED50 |
0.1 nM
Compound: paclitaxel
|
Anticancer activity aganist human HT-29 cells
Anticancer activity aganist human HT-29 cells
|
[PMID: 21067206] |
| HT-29 | GI50 |
0.003 μM
Compound: Taxol
|
Cytotoxicity against human HT-29 cells after 72 hrs by MTT assay
Cytotoxicity against human HT-29 cells after 72 hrs by MTT assay
|
[PMID: 21115210] |
| HT-29 | IC50 |
7 nM
Compound: Paclitaxel
|
Cytotoxicity against human HT-29 cells assessed as cell viability after 48 hrs by MTT assay
Cytotoxicity against human HT-29 cells assessed as cell viability after 48 hrs by MTT assay
|
[PMID: 21341718] |
| HT-29 | ED50 |
0.1 nM
Compound: Paclitaxel
|
Cytotoxicity against human HT-29 cells after 3 days by sulforhodamine B assay
Cytotoxicity against human HT-29 cells after 3 days by sulforhodamine B assay
|
[PMID: 21428375] |
| HT-29 | IC50 |
3 nM
Compound: Paclitaxel
|
Cytotoxicity against human HT-29 cells after 48 hrs by MTT assay
Cytotoxicity against human HT-29 cells after 48 hrs by MTT assay
|
[PMID: 21446699] |
| HT-29 | IC50 |
6.1 nM
Compound: Paclitaxel
|
Antiproliferative activity against human HT-29 cells after 72 hrs by sulforhodamine B assay
Antiproliferative activity against human HT-29 cells after 72 hrs by sulforhodamine B assay
|
[PMID: 21480626] |
| HT-29 | GI50 |
0.012 μM
Compound: Paclitaxel
|
Cytotoxicity against human HT-29 cells after 48 hrs by SRB assay
Cytotoxicity against human HT-29 cells after 48 hrs by SRB assay
|
[PMID: 21513294] |
| HT-29 | IC50 |
<10 μM
Compound: Taxol
|
Cytotoxicity against human HT-29 cells incubated for 48 hrs by MTT assay
Cytotoxicity against human HT-29 cells incubated for 48 hrs by MTT assay
|
[PMID: 21664827] |
| HT-29 | GI50 |
0.002 μM
Compound: Paclitaxel
|
Cytotoxicity against human HT-29 cells by sulforhodamine B assay
Cytotoxicity against human HT-29 cells by sulforhodamine B assay
|
[PMID: 21839640] |
| HT-29 | IC50 |
0.38 μM
Compound: Paclitaxel
|
Cytotoxicity against human HT-29 cells by MTT assay
Cytotoxicity against human HT-29 cells by MTT assay
|
[PMID: 21875764] |
| HT-29 | IC50 |
3.94 x 10-3 μM
Compound: Paclitaxel
|
Cytotoxicity against human HT-29 cells by MTT assay
Cytotoxicity against human HT-29 cells by MTT assay
|
[PMID: 21928797] |
| HT-29 | ED50 |
0.006 μM
Compound: Paclitaxel
|
Cytotoxicity against human HT-29 cells after 3 days by sulforhodamine B assay
Cytotoxicity against human HT-29 cells after 3 days by sulforhodamine B assay
|
[PMID: 21973101] |
| HT-29 | IC50 |
0.006 μM
Compound: paclitaxel
|
Cytotoxicity against human HT-29 cells after 3 days by sulforhodamine B assay
Cytotoxicity against human HT-29 cells after 3 days by sulforhodamine B assay
|
[PMID: 22239601] |
| HT-29 | IC50 |
<10 μM
Compound: Taxol
|
Cytotoxicity against human HT-29 cells after 48 hrs by MTT assay
Cytotoxicity against human HT-29 cells after 48 hrs by MTT assay
|
[PMID: 22370266] |
| HT-29 | IC50 |
8 nM
Compound: PTX
|
Cytotoxicity against human HT-29 cells assessed as growth inhibition after 48 hrs by MTT assay
Cytotoxicity against human HT-29 cells assessed as growth inhibition after 48 hrs by MTT assay
|
[PMID: 23214452] |
| HT-29 | ED50 |
0.001 μM
Compound: paclitaxel
|
Cytotoxicity against human HT-29 cells
Cytotoxicity against human HT-29 cells
|
[PMID: 23301897] |
| HT-29 | IC50 |
0.001 μM
Compound: Paclitaxel
|
Cytotoxicity against human HT-29 cells assessed as inhibition of cell proliferation after 3 days by SRB assay
Cytotoxicity against human HT-29 cells assessed as inhibition of cell proliferation after 3 days by SRB assay
|
[PMID: 23327794] |
| HT-29 | IC50 |
0.45 μM
Compound: Taxol
|
Cytotoxicity against human HT-29 cells by MTT assay
Cytotoxicity against human HT-29 cells by MTT assay
|
[PMID: 23425970] |
| HT-29 | IC50 |
0.00198 μM
Compound: Paclitaxel
|
Cytotoxicity against human HT-29 cells after 96 hrs by MTT assay
Cytotoxicity against human HT-29 cells after 96 hrs by MTT assay
|
[PMID: 23746477] |
| HT-29 | GI50 |
0.003 μM
Compound: Taxol
|
Cytotoxicity against human HT-29 cells after 72 hrs by MTT assay
Cytotoxicity against human HT-29 cells after 72 hrs by MTT assay
|
[PMID: 23831811] |
| HT-29 | IC50 |
0.0006 μM
Compound: paclitaxel
|
Cytotoxicity against human HT-29 cells after 72 hrs by SRB assay
Cytotoxicity against human HT-29 cells after 72 hrs by SRB assay
|
[PMID: 23895019] |
| HT-29 | IC50 |
>10 μM
Compound: Paclitaxel
|
Cytotoxicity against human HT-29 cells
Cytotoxicity against human HT-29 cells
|
[PMID: 24344605] |
| HT-29 | GI50 |
0.001 μM
Compound: PCT
|
Growth inhibition of human HT-29 cells after 48 hrs by sulforhodamine B assay
Growth inhibition of human HT-29 cells after 48 hrs by sulforhodamine B assay
|
[PMID: 24727464] |
| HT-29 | IC50 |
0.001 μM
Compound: paclitaxel
|
Cytotoxicity against human HT-29 cells
Cytotoxicity against human HT-29 cells
|
[PMID: 24937209] |
| HT-29 | IC50 |
0.29 μM
Compound: Paclitaxel
|
Antiproliferative activity against human HT-29 cells after 24 and 72 hrs by MTT assay
Antiproliferative activity against human HT-29 cells after 24 and 72 hrs by MTT assay
|
[PMID: 24941130] |
| HT-29 | IC50 |
3.5 μM
Compound: paclitaxel
|
Cytotoxicity against human HT-29 cells after 48 hrs by trypan blue exclusion method
Cytotoxicity against human HT-29 cells after 48 hrs by trypan blue exclusion method
|
[PMID: 25211032] |
| HT-29 | IC50 |
7 nM
Compound: 28
|
Antiproliferative activity against human HT-29 cells after 72 hrs by WST8 assay
Antiproliferative activity against human HT-29 cells after 72 hrs by WST8 assay
|
[PMID: 25625617] |
| HT-29 | IC50 |
0.0008 μM
Compound: Paclitaxel
|
Cytotoxicity against human HT-29 cells assessed as inhibition of cell viability after 3 days by sulforhodamine B assay
Cytotoxicity against human HT-29 cells assessed as inhibition of cell viability after 3 days by sulforhodamine B assay
|
[PMID: 26422131] |
| HT-29 | IC50 |
3.04 nM
Compound: Taxol
|
Cytotoxicity against human HT-29 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay
Cytotoxicity against human HT-29 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay
|
[PMID: 26697718] |
| HT-29 | IC50 |
0.0001 μM
Compound: Taxol
|
Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability after 72 hrs by MTT assay
Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability after 72 hrs by MTT assay
|
[PMID: 27010926] |
| HT-29 | IC50 |
0.02 μM
Compound: Paclitaxel
|
Cytotoxicity against human HT-29 cells assessed as reduction in cell viability after 72 hrs by MTT assay
Cytotoxicity against human HT-29 cells assessed as reduction in cell viability after 72 hrs by MTT assay
|
[PMID: 27329938] |
| HT-29 | IC50 |
0.0008 μM
Compound: Paclitaxel
|
Cytotoxicity against human HT-29 cells incubated for 72 hrs by SRB assay
Cytotoxicity against human HT-29 cells incubated for 72 hrs by SRB assay
|
[PMID: 27983842] |
| HT-29 | IC50 |
0.025 μM
Compound: Taxol
|
Antiproliferative activity against human HT-29 cells expressing NQO1 after 72 hrs by MTT assay
Antiproliferative activity against human HT-29 cells expressing NQO1 after 72 hrs by MTT assay
|
[PMID: 28395199] |
| HT-29 | IC50 |
0.0014 μM
Compound: Paclitaxel
|
Cytotoxicity against human HT-29 cells after 3 days by sulforhodamine B assay
Cytotoxicity against human HT-29 cells after 3 days by sulforhodamine B assay
|
[PMID: 28409637] |
| HT-29 | IC50 |
3 nM
Compound: Paclitaxel
|
Cytotoxicity against human HT-29 cells assessed as reduction in cell viability after 72 hrs by CCK-8 assay
Cytotoxicity against human HT-29 cells assessed as reduction in cell viability after 72 hrs by CCK-8 assay
|
[PMID: 28598633] |
| HT-29 | IC50 |
0.014 μM
Compound: PTX
|
Cytotoxicity against human HT-29 cells assessed as growth reduction under normoxic condition after 72 hrs by MTT assay
Cytotoxicity against human HT-29 cells assessed as growth reduction under normoxic condition after 72 hrs by MTT assay
|
[PMID: 28740613] |
| HT-29 | IC50 |
0.015 μM
Compound: PTX
|
Cytotoxicity against human HT-29 cells assessed as growth reduction under hypoxic condition after 72 hrs by MTT assay
Cytotoxicity against human HT-29 cells assessed as growth reduction under hypoxic condition after 72 hrs by MTT assay
|
[PMID: 28740613] |
| HT-29 | IC50 |
0.0008 μM
Compound: Paclitaxel
|
Cytotoxicity against human HT-29 cells after 72 hrs by MTS assay
Cytotoxicity against human HT-29 cells after 72 hrs by MTS assay
|
[PMID: 29350920] |
| HT-29 | GI50 |
5 nM
Compound: Paclitaxel
|
Growth inhibition of human HT-29 cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human HT-29 cells incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 29655610] |
| HT-29 | IC50 |
0.011 μM
Compound: Taxol
|
Cytotoxicity against human HT-29 cells measured after 24 to 72 hrs by SRB assay
Cytotoxicity against human HT-29 cells measured after 24 to 72 hrs by SRB assay
|
[PMID: 29656990] |
| HT-29 | IC50 |
9 nM
Compound: Paclitaxel
|
Cytotoxicity against human HT-29 cells assessed as reduction in cell viability after 72 hrs by CellTiter 96 aqueous one solution assay
Cytotoxicity against human HT-29 cells assessed as reduction in cell viability after 72 hrs by CellTiter 96 aqueous one solution assay
|
[PMID: 30057155] |
| HT-29 | IC50 |
0.01 μM
Compound: Paclitaxel
|
Cytotoxicity against human HT-29 after 48 hrs by MTT assay
Cytotoxicity against human HT-29 after 48 hrs by MTT assay
|
[PMID: 30387611] |
| HT-29 | IC50 |
0.07 μM
Compound: Paclitaxel
|
Cytotoxicity against human HT-29 after 24 hrs by MTT assay
Cytotoxicity against human HT-29 after 24 hrs by MTT assay
|
[PMID: 30387611] |
| HT-29 | IC50 |
0.008 μM
Compound: Paclitaxel
|
Antiproliferative activity against human HT-29 cells after 24 hrs by CCK8 assay
Antiproliferative activity against human HT-29 cells after 24 hrs by CCK8 assay
|
[PMID: 30392953] |
| HT-29 | IC50 |
0.8 nM
Compound: Taxol
|
Cytotoxicity against human HT-29 cells after 48 hrs by sulforhodamine B assay
Cytotoxicity against human HT-29 cells after 48 hrs by sulforhodamine B assay
|
[PMID: 30528697] |
| HT-29 | IC50 |
14.56 μM
Compound: Paclitaxel
|
Antiproliferative activity against human HT-29 cells after 48 hrs by MTT assay
Antiproliferative activity against human HT-29 cells after 48 hrs by MTT assay
|
[PMID: 30738663] |
| HT-29 | IC50 |
0.002 μM
Compound: Paclitaxel
|
Cytotoxicity against human HT-29 cells assessed as reduction in cell viability measured after 72 hrs by SRB assay
Cytotoxicity against human HT-29 cells assessed as reduction in cell viability measured after 72 hrs by SRB assay
|
[PMID: 31120251] |
| HT-29 | IC50 |
0.001 μM
Compound: Paclitaxel
|
Antiproliferative activity against human HT-29 cells measured after 72 hrs by sulforhodamine B assay
Antiproliferative activity against human HT-29 cells measured after 72 hrs by sulforhodamine B assay
|
[PMID: 31465222] |
| HT-29 | IC50 |
0.0008 μM
Compound: Paclitaxel
|
Cytotoxicity against human HT-29 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay
Cytotoxicity against human HT-29 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay
|
[PMID: 31953129] |
| HT-29 | IC50 |
0.0008 μM
Compound: Paclitaxel
|
Cytotoxicity against human HT-29 cells after 72 hrs by CellTiter 96 Aqueous One Solution reagent based assay
Cytotoxicity against human HT-29 cells after 72 hrs by CellTiter 96 Aqueous One Solution reagent based assay
|
[PMID: 32096998] |
| HT-29 | IC50 |
8.6 nM
Compound: PTX
|
Cytotoxicity against human HT-29 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay
Cytotoxicity against human HT-29 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay
|
[PMID: 33280896] |
| HT-29 | GI50 |
5 nM
Compound: Paclitaxel
|
Cytotoxicity against human HT-29 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay
Cytotoxicity against human HT-29 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay
|
[PMID: 33310545] |
| HT-29 | IC50 |
3.8 nM
Compound: Taxol
|
Antiproliferative activity against human HT-29 cells assessed as inhibition of cell growth by secondary round CCK8 assay
Antiproliferative activity against human HT-29 cells assessed as inhibition of cell growth by secondary round CCK8 assay
|
[PMID: 34508844] |
| HT-29 | IC50 |
7.47 nM
Compound: PTX
|
Antiproliferative activity against human HT-29 cells incubated for 72 hrs by MTT assay
Antiproliferative activity against human HT-29 cells incubated for 72 hrs by MTT assay
|
[PMID: 34648295] |
| HT-29 | IC50 |
0.28 μM
Compound: Paclitaxel
|
Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability after 48 hrs by MTT assay
|
[PMID: 34671737] |
| HT-29 | IC50 |
0.011 μM
Compound: PTX
|
Cytotoxicity against human HT-29 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay
Cytotoxicity against human HT-29 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay
|
[PMID: 35447432] |
| HT-29 | IC50 |
10.8 nM
Compound: Abraxane
|
Antiproliferative activity against human HT-29 cells measured after 72 hrs by MTT assay
Antiproliferative activity against human HT-29 cells measured after 72 hrs by MTT assay
|
[PMID: 36471625] |
| HT-29 | IC50 |
19.94 μM
Compound: Paclitaxel
|
Anticancer activity against human HT-29 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
Anticancer activity against human HT-29 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
|
[PMID: 36481599] |
| HT-29 | IC50 |
3.4 nM
Compound: Paclitaxel
|
Cytotoxicity against human HT-29 cells incubated for 72 hrs by Cell titer blue assay
Cytotoxicity against human HT-29 cells incubated for 72 hrs by Cell titer blue assay
|
[PMID: 37216676] |
| HT-29 | IC50 |
0.07 μM
Compound: PTX
|
Antiproliferative activity against human HT-29 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
Antiproliferative activity against human HT-29 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
|
[PMID: 38280356] |
| HT-29 | IC50 |
5.7 μM
Compound: Paclitaxel
|
Cytotoxicity against human HT-29 cells assessed as inhibition of cell viability incubated for 72 hrs
Cytotoxicity against human HT-29 cells assessed as inhibition of cell viability incubated for 72 hrs
|
[PMID: 38341161] |
| HT-29 | IC50 |
0.03 μM
Compound: PTX
|
Cytotoxicity against human HT-29 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay
Cytotoxicity against human HT-29 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay
|
[PMID: 38547648] |
| HT-29 | IC50 |
3.2 nM
Compound: paclitaxel
|
In vitro cytotoxicity against human colon carcinoma HT-29
In vitro cytotoxicity against human colon carcinoma HT-29
|
[PMID: 8182698] |
| HT-29 | IC50 |
3.6 nM
Compound: paclitaxel
|
Concentration required to inhibit growth of human tumor HT-29 (colon) cell line.
Concentration required to inhibit growth of human tumor HT-29 (colon) cell line.
|
[PMID: 8831755] |
| HT-29 | IC50 |
3.2 nM
Compound: Paclitaxel
|
Growth inhibition of human colon carcinoma (HT-29) cell line
Growth inhibition of human colon carcinoma (HT-29) cell line
|
[PMID: 9022793] |
| HT-29 | IC50 |
3.2 nM
Compound: Paclitaxel
|
Inhibition of the growth against human Colon Carcinoma (HT-29) cell line after 72 hr exposure
Inhibition of the growth against human Colon Carcinoma (HT-29) cell line after 72 hr exposure
|
[PMID: 9022794] |
| HT-29 | IC50 |
0.002 μg/mL
Compound: Paclitaxel
|
Cytotoxicity was evaluated against HT-29 human colon adenocarcinoma cells
Cytotoxicity was evaluated against HT-29 human colon adenocarcinoma cells
|
[PMID: 9871668] |
| HT-29 | IC50 |
3.2 nM
Compound: Paclitaxel
|
Cytotoxicity against human colon HT-29 cell lines
Cytotoxicity against human colon HT-29 cell lines
|
10.1016/S0960-894X(01)80298-5 |
| HT-29 | IC50 |
0.0024 μg/mL
Compound: 3
|
In vitro cytotoxicity against HT29-human colon adenocarcinoma cells.
In vitro cytotoxicity against HT29-human colon adenocarcinoma cells.
|
10.1016/S0960-894X(01)80507-2 |
| HT-29 | IC50 |
3.2 nM
Compound: Paclitaxel
|
Cytotoxicity was evaluated in vitro against HT-29 (colon carcinoma) human tumor cell lines
Cytotoxicity was evaluated in vitro against HT-29 (colon carcinoma) human tumor cell lines
|
10.1016/S0960-894X(01)80568-0 |
| HT-29 | IC50 |
3.6 nM
Compound: Paclitaxel
|
Cytotoxicity was evaluated against HT-29 colon carcinoma human cancer cell line
Cytotoxicity was evaluated against HT-29 colon carcinoma human cancer cell line
|
10.1016/S0960-894X(96)00595-1 |
| HT-29 | IC50 |
<5 nM
Compound: Paclitaxel, Taxol
|
Antiproliferative activity against human HT-29 cells assessed as inhibition of cell proliferation after 3 days by MTS assay
Antiproliferative activity against human HT-29 cells assessed as inhibition of cell proliferation after 3 days by MTS assay
|
10.1039/C1MD00155H |
| HT-29 | GI50 |
5.3 nM
Compound: Taxol
|
Cytotoxicity against human HT-29 cells
Cytotoxicity against human HT-29 cells
|
10.1039/C2MD20089A |
| Huh-7 | IC50 |
0.008 μM
Compound: Taxol
|
Antiproliferative activity against human HuH7 cells after 72 hrs by imaging analysis
Antiproliferative activity against human HuH7 cells after 72 hrs by imaging analysis
|
[PMID: 19665384] |
| Huh-7 | GI50 |
206.7 nM
Compound: 1, Taxol
|
Growth inhibition of human HuH7 cells by MTT assay
Growth inhibition of human HuH7 cells by MTT assay
|
[PMID: 24405702] |
| Huh-7 | IC50 |
6.75 μM
Compound: Taxol
|
Cytotoxicity against human HuH7 cells after 72 hrs by CCK8 assay
Cytotoxicity against human HuH7 cells after 72 hrs by CCK8 assay
|
[PMID: 27623549] |
| Huh-7 | IC50 |
0.012 μM
Compound: Taxol
|
Antiproliferative activity against human HuH7 cells after 48 hrs by Hoechst 33342 staining-based assay
Antiproliferative activity against human HuH7 cells after 48 hrs by Hoechst 33342 staining-based assay
|
[PMID: 30655216] |
| Huh-7 | IC50 |
2 nM
Compound: Paclitaxel
|
Antiproliferative activity against human Huh-7 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay
Antiproliferative activity against human Huh-7 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay
|
[PMID: 32339854] |
| Huh-7 | IC50 |
0.005 μM
Compound: Paclitaxel
|
Cytotoxicity against human Huh-7 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
Cytotoxicity against human Huh-7 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
|
[PMID: 32633512] |
| Huh-7 | GI50 |
7.41 nM
Compound: Taxol
|
Antiproliferative activity against human Huh-7 cells assessed as inhibition of cell growth after 72 hrs by CCK8 assay
Antiproliferative activity against human Huh-7 cells assessed as inhibition of cell growth after 72 hrs by CCK8 assay
|
[PMID: 33239261] |
| Huh-7 | IC50 |
0.013 μM
Compound: Taxol
|
Cytotoxicity against human HuH-7 cells assessed as reduction in cell viability incubated for 48 hrs by Hoechst-33342 staining based cell counting method (Rvb > 25 microM)
Cytotoxicity against human HuH-7 cells assessed as reduction in cell viability incubated for 48 hrs by Hoechst-33342 staining based cell counting method (Rvb > 25 microM)
|
[PMID: 33422908] |
| Huh-7 | IC50 |
7.35 nM
Compound: PTX
|
Antiproliferative activity against human Huh-7 cells incubated for 72 hrs by MTT assay
Antiproliferative activity against human Huh-7 cells incubated for 72 hrs by MTT assay
|
[PMID: 34648295] |
| HUVEC | ED50 |
105 nM
Compound: paclitaxel
|
Cytotoxicity against HUVEC
Cytotoxicity against HUVEC
|
[PMID: 15043407] |
| HUVEC | IC50 |
0.3 μg/mL
Compound: paclitaxel
|
Antiangiogenic activity against HUVEC cells
Antiangiogenic activity against HUVEC cells
|
[PMID: 16384699] |
| HUVEC | IC50 |
0.06 μM
Compound: Paclitaxel
|
Antiproliferative activity against HUVEC cell line
Antiproliferative activity against HUVEC cell line
|
[PMID: 16793260] |
| HUVEC | IC50 |
5.14 μM
Compound: paclitaxel
|
Cytotoxicity against HUVEC cells after 72 hrs by MTT assay
Cytotoxicity against HUVEC cells after 72 hrs by MTT assay
|
[PMID: 19053781] |
| HUVEC | IC50 |
0.05 μM
Compound: Paclitaxel
|
Antiangiogenic activity against HUVEC assessed as inhibition of capillary-like structure formation by NCI antiangiogenesis assay
Antiangiogenic activity against HUVEC assessed as inhibition of capillary-like structure formation by NCI antiangiogenesis assay
|
[PMID: 19084416] |
| HUVEC | IC50 |
0.1 μM
Compound: Paclitaxel
|
Antiangiogenic activity against HUVEC assessed as inhibition of VEGF-induced cell migration by NCI antiangiogenesis assay
Antiangiogenic activity against HUVEC assessed as inhibition of VEGF-induced cell migration by NCI antiangiogenesis assay
|
[PMID: 19084416] |
| HUVEC | IC50 |
1.65 μM
Compound: Paclitaxel
|
Antiangiogenic activity against HUVEC assessed as growth inhibition by NCI antiangiogenesis assay
Antiangiogenic activity against HUVEC assessed as growth inhibition by NCI antiangiogenesis assay
|
[PMID: 19084416] |
| HUVEC | IC50 |
7 nM
Compound: Paclitaxel
|
Growth inhibition of HUVEC
Growth inhibition of HUVEC
|
[PMID: 19601594] |
| HUVEC | IC50 |
0.007 μM
Compound: Paclitaxel, IOUYT
|
Cytotoxicity against HUVEC assessed as cell viability after 48 hrs by MTT assay
Cytotoxicity against HUVEC assessed as cell viability after 48 hrs by MTT assay
|
[PMID: 24012378] |
| HUVEC | GI50 |
0.00148 μM
Compound: Paclitaxel
|
Cytotoxicity against HUVEC cells after 48 hrs by SRB assay
Cytotoxicity against HUVEC cells after 48 hrs by SRB assay
|
[PMID: 26462052] |
| HUVEC | GI50 |
>10 μg/mL
Compound: Paclitaxel
|
Cytotoxicity against primary HUVEC measured after 48 hrs by MTT assay
Cytotoxicity against primary HUVEC measured after 48 hrs by MTT assay
|
[PMID: 27688192] |
| HUVEC | IC50 |
>10 μM
Compound: Paclitaxel
|
Cytotoxicity against HUVEC after 24 hrs by MTT assay
Cytotoxicity against HUVEC after 24 hrs by MTT assay
|
[PMID: 30387611] |
| HUVEC | IC50 |
>10 μM
Compound: Paclitaxel
|
Cytotoxicity against HUVEC after 48 hrs by MTT assay
Cytotoxicity against HUVEC after 48 hrs by MTT assay
|
[PMID: 30387611] |
| HUVEC | IC50 |
9.39 μM
Compound: PTX
|
Cytotoxicity against HUVEC incubated for 48 hrs by MTT assay
Cytotoxicity against HUVEC incubated for 48 hrs by MTT assay
|
[PMID: 30913525] |
| HUVEC | IC50 |
0.0013 μM
Compound: Paclitaxel
|
Cytotoxicity against HUVEC assessed as reduction in cell viability after 72 hrs by sulforhodamine B assay
Cytotoxicity against HUVEC assessed as reduction in cell viability after 72 hrs by sulforhodamine B assay
|
[PMID: 31901744] |
| HUVEC | IC50 |
0.005 μM
Compound: Taxol
|
Cytotoxicity against HUVEC assessed as reduction in cell viability after 72 hrs by MTS assay
Cytotoxicity against HUVEC assessed as reduction in cell viability after 72 hrs by MTS assay
|
[PMID: 33310292] |
| HUVEC | GI50 |
>10 μg/mL
Compound: Paclitaxel
|
Cytotoxicity against HUVEC cells assessed as cell growth inhibition
Cytotoxicity against HUVEC cells assessed as cell growth inhibition
|
[PMID: 33826327] |
| HUVEC | IC50 |
<0.05 μM
Compound: Paclitaxel
|
Antiproliferative activity against human HUVEC cells assessed as cell growth inhibition measured after 48 hrs by MTS assay
Antiproliferative activity against human HUVEC cells assessed as cell growth inhibition measured after 48 hrs by MTS assay
|
[PMID: 35737669] |
| HUVEC | IC50 |
0.071 μM
Compound: Paclitaxel
|
Anti-angiogenesis activity against HUVEC cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
Anti-angiogenesis activity against HUVEC cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
|
[PMID: 36511661] |
| IEC-6 | EC50 |
0.0001 x 10-3 μM
Compound: Paclitaxel
|
Cytotoxicity against rat IEC-6 cells incubated for 48 to 72 hrs by MTT assay
Cytotoxicity against rat IEC-6 cells incubated for 48 to 72 hrs by MTT assay
|
[PMID: 39038808] |
| IGROV-1 | IC50 |
10 ng/mL
Compound: 1 (paclitaxel)
|
Cytotoxicity against IGROV Tumor cell line in SRB Cell viability test
Cytotoxicity against IGROV Tumor cell line in SRB Cell viability test
|
[PMID: 10956217] |
| IGROV-1 | IC50 |
0.06 μM
Compound: 3
|
Antiproliferative activity against human IGROV1 cells assessed as growth inhibition after 72 hrs by Coulter counting analysis
Antiproliferative activity against human IGROV1 cells assessed as growth inhibition after 72 hrs by Coulter counting analysis
|
[PMID: 19833515] |
| IGROV-1 | IC50 |
2.2 nM
Compound: PTX
|
Cytotoxicity against cisplatin-resistant human IGROV1/Pt1 cells after 72 hrs by coulter counter analysis
Cytotoxicity against cisplatin-resistant human IGROV1/Pt1 cells after 72 hrs by coulter counter analysis
|
[PMID: 23140358] |
| IGROV-1 | IC50 |
23 nM
Compound: PTX
|
Cytotoxicity against human IGROV1 cells after 72 hrs by coulter counter analysis
Cytotoxicity against human IGROV1 cells after 72 hrs by coulter counter analysis
|
[PMID: 23140358] |
| IGROV-1 | GI50 |
6.3 nM
Compound: Paclitaxel
|
Growth inhibition of human IGROV1 cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human IGROV1 cells incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 29655610] |
| IGROV-1 | GI50 |
6.3 nM
Compound: Paclitaxel
|
Cytotoxicity against human IGROV-1 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay
Cytotoxicity against human IGROV-1 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay
|
[PMID: 33310545] |
| IMR-32 | GI50 |
0.075 μM
Compound: Paclitaxel
|
Growth inhibition of human IMR32 cells after 48 hrs by SRB assay
Growth inhibition of human IMR32 cells after 48 hrs by SRB assay
|
[PMID: 25264072] |
| IMR-32 | GI50 |
0.075 μM
Compound: Paclitaxel
|
Antiproliferative activity against human IMR32 cells assessed as reduction in net protein increase after 48 hrs by SRB assay
Antiproliferative activity against human IMR32 cells assessed as reduction in net protein increase after 48 hrs by SRB assay
|
[PMID: 25462234] |
| IMR-32 | GI50 |
0.075 μM
Compound: Paclitaxel
|
Antiproliferative activity against human IMR32 cells assessed as growth inhibition after 48 hrs by SRB assay
Antiproliferative activity against human IMR32 cells assessed as growth inhibition after 48 hrs by SRB assay
|
[PMID: 27209232] |
| IMR-32 | GI50 |
0.086 μM
Compound: Paclitaxel
|
Growth inhibition of human IMR32 cells after 48 hrs by SRB assay
Growth inhibition of human IMR32 cells after 48 hrs by SRB assay
|
[PMID: 27964883] |
| IMR-32 | GI50 |
<0.01 μM
Compound: Paciltaxel
|
Antiproliferative activity against human IMR32 cells assessed as reduction in cell viability after 48 hrs by SRB assay
Antiproliferative activity against human IMR32 cells assessed as reduction in cell viability after 48 hrs by SRB assay
|
[PMID: 31546197] |
| IMR-32 | IC50 |
0.03 μM
Compound: Paclitaxel
|
Cytotoxicity against Homo sapiens (human) IMR32 cells after 48 hr by SRB assay
Cytotoxicity against Homo sapiens (human) IMR32 cells after 48 hr by SRB assay
|
10.1007/s00044-011-9824-9 |
| Ishikawa | IC50 |
0.5 nM
Compound: Paclitaxel
|
Antiproliferative activity against human Ishikawa cells assessed as reduction in cell viability
Antiproliferative activity against human Ishikawa cells assessed as reduction in cell viability
|
[PMID: 38911148] |
| J774 | ED50 |
0.09 μM
Compound: Taxol
|
Concentration that inhibits the cell division by 50% after 72 h
Concentration that inhibits the cell division by 50% after 72 h
|
[PMID: 7910216] |
| J774 | IC50 |
0.015 μM
Compound: Paclitaxel
|
Inhibitory activity of compound against murine macrophage-like (J774.2) cell proliferation
Inhibitory activity of compound against murine macrophage-like (J774.2) cell proliferation
|
[PMID: 9379451] |
| J774 | IC50 |
65.6 nM
Compound: Taxol
|
Inhibitory concentration required for cytotoxicity in J774.2 murine macrophage-like cells
Inhibitory concentration required for cytotoxicity in J774.2 murine macrophage-like cells
|
10.1016/0960-894X(95)00300-I |
| J774 | ED50 |
0.09 μM
Compound: 2a (Taxol)
|
In vitro cytotoxicity against J774.2 cells after 72 hr incubation.
In vitro cytotoxicity against J774.2 cells after 72 hr incubation.
|
10.1016/S0960-894X(01)80527-8 |
| J774.2 | ED50 |
0.09 μM
Compound: taxol
|
Concentration that inhibits cell division by 50% after 72 hr for J774.2 cells was determined
Concentration that inhibits cell division by 50% after 72 hr for J774.2 cells was determined
|
[PMID: 1672157] |
| J774.2 | IC50 |
30.9 nM
Compound: Taxol
|
Inhibitory concentration required for cytotoxicity in hydroxyrubicin-resistant (WP159/R) cells
Inhibitory concentration required for cytotoxicity in hydroxyrubicin-resistant (WP159/R) cells
|
10.1016/0960-894X(95)00300-I |
| J774.2 | IC50 |
332.3 nM
Compound: Taxol
|
Inhibitory concentration required for cytotoxicity in DOX-resistant (DOX/R) cells
Inhibitory concentration required for cytotoxicity in DOX-resistant (DOX/R) cells
|
10.1016/0960-894X(95)00300-I |
| J774.2 | ED50 |
0.016 μM
Compound: taxol
|
Cytotoxicity tested against J774.2 cells.
Cytotoxicity tested against J774.2 cells.
|
10.1016/S0960-894X(97)00337-5 |
| Jurkat | GI50 |
<0.01 μM
Compound: paclitaxel
|
Growth inhibition of Jurkat cell
Growth inhibition of Jurkat cell
|
[PMID: 17181155] |
| Jurkat | GI50 |
>10 μM
Compound: paclitaxel
|
Growth inhibition of Jurkat cell overexpressing Bcl2
Growth inhibition of Jurkat cell overexpressing Bcl2
|
[PMID: 17181155] |
| Jurkat | GI50 |
>10 μM
Compound: paclitaxel
|
Growth inhibition of Jurkat cell overexpressing BclXL
Growth inhibition of Jurkat cell overexpressing BclXL
|
[PMID: 17181155] |
| Jurkat | IC50 |
0.01 μM
Compound: Paclitaxel
|
Cell cycle arrest in human Jurkat cells assessed as accumulation at G2/M phase after 24 hrs using propidium iodide staining by FACS analysis
Cell cycle arrest in human Jurkat cells assessed as accumulation at G2/M phase after 24 hrs using propidium iodide staining by FACS analysis
|
[PMID: 21126027] |
| Jurkat | IC50 |
0.0045 μM
Compound: Paclitaxel
|
Antiproliferative activity against human Jurkat cells after 48 to 72 hrs by trypan blue dye exclusion assay and MTT assay
Antiproliferative activity against human Jurkat cells after 48 to 72 hrs by trypan blue dye exclusion assay and MTT assay
|
[PMID: 24852281] |
| Jurkat | IC50 |
0.0005 μM
Compound: PXT
|
Cytotoxicity against human Jurkat cells assessed as cell growth inhibition after 48 hrs by MTT assay
Cytotoxicity against human Jurkat cells assessed as cell growth inhibition after 48 hrs by MTT assay
|
[PMID: 26638041] |
| Jurkat | IC50 |
<0.01 μM
Compound: Taxol
|
Anticancer activity against human Jurkat cells assessed as inhibition of cell proliferation measured after 72 hrs by CCK8 reagent assay
Anticancer activity against human Jurkat cells assessed as inhibition of cell proliferation measured after 72 hrs by CCK8 reagent assay
|
[PMID: 34399390] |
| Jurkat | IC50 |
0.69 μM
Compound: Paclitaxel
|
Cytotoxicity against human Jurkat cells assessed as inhibition of cell proliferation after 96 hrs by MTT assay
Cytotoxicity against human Jurkat cells assessed as inhibition of cell proliferation after 96 hrs by MTT assay
|
10.1039/C4MD00573B |
| K562 | EC50 |
0.054 μM
Compound: Paclitaxel ; Taxol
|
Effective concentration required to arrest propidium iodide stained K562 cells in G2/M phase
Effective concentration required to arrest propidium iodide stained K562 cells in G2/M phase
|
[PMID: 12852768] |
| K562 | GI50 |
0.01 μg/mL
Compound: Paclitaxel
|
Growth inhibition of human K562 cells
Growth inhibition of human K562 cells
|
[PMID: 15387677] |
| K562 | EC50 |
0.014 μM
Compound: PXL
|
Cytotoxicity against human K562 cells
Cytotoxicity against human K562 cells
|
[PMID: 16870428] |
| K562 | GI50 |
0.01 μg/mL
Compound: paclitaxel
|
Antiproliferative activity against human K562 cells
Antiproliferative activity against human K562 cells
|
[PMID: 17500572] |
| K562 | IC50 |
0.6 nM
Compound: paclitaxel
|
Growth inhibition of human K562 cells after 72 hrs by SRB assay
Growth inhibition of human K562 cells after 72 hrs by SRB assay
|
[PMID: 18313307] |
| K562 | IC50 |
4.14 μM
Compound: paclitaxel
|
Growth inhibition of doxorubicin-resistant human K562 cells after 72 hrs by SRB assay
Growth inhibition of doxorubicin-resistant human K562 cells after 72 hrs by SRB assay
|
[PMID: 18313307] |
| K562 | IC50 |
6900 μM
Compound: paclitaxel
|
Resistant ratio, IC50 for multidrug resistant human K562 cells to IC50 for human K562 cells
Resistant ratio, IC50 for multidrug resistant human K562 cells to IC50 for human K562 cells
|
[PMID: 18313307] |
| K562 | IC50 |
3.65 μM
Compound: paclitaxel
|
Cytotoxicity against human K562 cells
Cytotoxicity against human K562 cells
|
[PMID: 18701281] |
| K562 | IC50 |
1.16 μM
Compound: Taxol
|
Cytotoxicity against human K562 cells after 48 hrs by MTT assay
Cytotoxicity against human K562 cells after 48 hrs by MTT assay
|
[PMID: 19359185] |
| K562 | IC50 |
5.63 μM
Compound: Taxol
|
Cytotoxicity against multidrug-resistant human K562 cells after 48 hrs by MTT assay
Cytotoxicity against multidrug-resistant human K562 cells after 48 hrs by MTT assay
|
[PMID: 19359185] |
| K562 | IC50 |
1.16 μM
Compound: Taxol
|
Antiproliferative activity against human K562 cells after 48 hrs by MTT assay
Antiproliferative activity against human K562 cells after 48 hrs by MTT assay
|
[PMID: 19815316] |
| K562 | IC50 |
1.16 μM
Compound: Taxol
|
Cytotoxicity against human K562 cells after 48 hrs by MTT assay
Cytotoxicity against human K562 cells after 48 hrs by MTT assay
|
[PMID: 21067933] |
| K562 | GI50 |
0.004 μM
Compound: Taxol
|
Cytotoxicity against human K562 cells after 72 hrs by MTT assay
Cytotoxicity against human K562 cells after 72 hrs by MTT assay
|
[PMID: 21115210] |
| K562 | IC50 |
1.16 μM
Compound: Taxol
|
Cytotoxicity against human K562 cells after 48 hrs by MTT assay
Cytotoxicity against human K562 cells after 48 hrs by MTT assay
|
[PMID: 21342735] |
| K562 | IC50 |
5.63 μM
Compound: Taxol
|
Cytotoxicity against human multidrug-resistant K562 cells after 48 hrs by MTT assay
Cytotoxicity against human multidrug-resistant K562 cells after 48 hrs by MTT assay
|
[PMID: 21342735] |
| K562 | IC50 |
0.71 nM
Compound: Pac
|
Antiproliferative activity against human K562 cells after 48 hrs by sulforhodamine B assay
Antiproliferative activity against human K562 cells after 48 hrs by sulforhodamine B assay
|
[PMID: 21604746] |
| K562 | IC50 |
0.71 nM
Compound: Pac
|
Antiproliferative activity against human K562 after 48 hrs by SRB assay
Antiproliferative activity against human K562 after 48 hrs by SRB assay
|
[PMID: 21920638] |
| K562 | IC50 |
0.41 μM
Compound: Taxol
|
Cytotoxicity against human K562 cells after 72 hrs by MTT assay
Cytotoxicity against human K562 cells after 72 hrs by MTT assay
|
[PMID: 22483090] |
| K562 | IC50 |
0.41 μM
Compound: Taxol
|
Antiproliferative activity against human K562 cells assessed as growth inhibition by MTT assay
Antiproliferative activity against human K562 cells assessed as growth inhibition by MTT assay
|
[PMID: 23274570] |
| K562 | IC50 |
5.1 nM
Compound: Taxol
|
Cytotoxicity against human K562 cells expressing BCR-ABL assessed as growth inhibition after 72 hrs by CCK-8 assay
Cytotoxicity against human K562 cells expressing BCR-ABL assessed as growth inhibition after 72 hrs by CCK-8 assay
|
[PMID: 23301703] |
| K562 | IC50 |
7 nM
Compound: Taxol
|
Cytotoxicity against imatinib-resistant human K562 cells expressing BCR-ABL Q252H mutant assessed as growth inhibition after 72 hrs by CCK-8 assay
Cytotoxicity against imatinib-resistant human K562 cells expressing BCR-ABL Q252H mutant assessed as growth inhibition after 72 hrs by CCK-8 assay
|
[PMID: 23301703] |
| K562 | IC50 |
15.7 nM
Compound: paclitaxel
|
Cytotoxicity against human K562 cells after 48 hrs by MTT assay
Cytotoxicity against human K562 cells after 48 hrs by MTT assay
|
[PMID: 23356786] |
| K562 | IC50 |
0.41 μM
Compound: Taxol
|
Cytotoxicity against human K562 cells after 72 hrs by MTT assay
Cytotoxicity against human K562 cells after 72 hrs by MTT assay
|
[PMID: 23644204] |
| K562 | IC50 |
4.9 nM
Compound: Taxol
|
Cytotoxicity against human K562 cells by MTT assay
Cytotoxicity against human K562 cells by MTT assay
|
[PMID: 23806112] |
| K562 | GI50 |
7.014 nM
Compound: 1, Taxol
|
Growth inhibition of human K562 cells by MTT assay
Growth inhibition of human K562 cells by MTT assay
|
[PMID: 24405702] |
| K562 | GI50 |
0.1 μM
Compound: PCT
|
Growth inhibition of human K562 cells after 48 hrs by sulforhodamine B assay
Growth inhibition of human K562 cells after 48 hrs by sulforhodamine B assay
|
[PMID: 24727464] |
| K562 | IC50 |
0.0055 μM
Compound: Paclitaxel
|
Antiproliferative activity against human K562 cells after 48 to 72 hrs by trypan blue dye exclusion assay and MTT assay
Antiproliferative activity against human K562 cells after 48 to 72 hrs by trypan blue dye exclusion assay and MTT assay
|
[PMID: 24852281] |
| K562 | IC50 |
0.004 μM
Compound: Taxol
|
Cytotoxicity against human K562 cells assessed as growth inhibition after 72 hrs by CCK-8 assay
Cytotoxicity against human K562 cells assessed as growth inhibition after 72 hrs by CCK-8 assay
|
[PMID: 25091926] |
| K562 | IC50 |
2.4 μM
Compound: paclitaxel
|
Cytotoxicity against human K562 cells after 48 hrs by trypan blue exclusion method
Cytotoxicity against human K562 cells after 48 hrs by trypan blue exclusion method
|
[PMID: 25211032] |
| K562 | IC50 |
0.018 μg/mL
Compound: Paclitaxel
|
Anticancer activity against human K562 cells after 24 hrs by MTT assay
Anticancer activity against human K562 cells after 24 hrs by MTT assay
|
[PMID: 25305717] |
| K562 | IC50 |
5.2 nM
Compound: Taxol
|
Cytotoxicity against human K562 cells assessed as cell viability after 72 hrs by CCK8 assay
Cytotoxicity against human K562 cells assessed as cell viability after 72 hrs by CCK8 assay
|
[PMID: 25819096] |
| K562 | IC50 |
0.9 μM
Compound: paclitaxel
|
Cytotoxicity against human K562 cells by MTT method
Cytotoxicity against human K562 cells by MTT method
|
[PMID: 26287401] |
| K562 | IC50 |
3.8 μM
Compound: taxol
|
Cytotoxicity against human K562 cells after 72 hrs by CCK8 assay
Cytotoxicity against human K562 cells after 72 hrs by CCK8 assay
|
[PMID: 26316467] |
| K562 | IC50 |
7.17 nM
Compound: Taxol
|
Cytotoxicity against human K562 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay
Cytotoxicity against human K562 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay
|
[PMID: 26697718] |
| K562 | IC50 |
0.38 μM
Compound: PTX
|
Antiproliferative activity against human K562 cells after 24 hrs by MTT assay
Antiproliferative activity against human K562 cells after 24 hrs by MTT assay
|
[PMID: 27491707] |
| K562 | IC50 |
3.21 μM
Compound: Taxol
|
Cytotoxicity against human K562 cells after 72 hrs by CCK8 assay
Cytotoxicity against human K562 cells after 72 hrs by CCK8 assay
|
[PMID: 27623549] |
| K562 | IC50 |
2.7 μM
Compound: Paclitaxel
|
Cytotoxicity against human K562 cells after 72 hrs by MTT assay
Cytotoxicity against human K562 cells after 72 hrs by MTT assay
|
[PMID: 27748595] |
| K562 | IC50 |
7.2 nM
Compound: Paclitaxel
|
Cytotoxicity against human K562 cells assessed as reduction in cell viability after 72 hrs by CCK-8 assay
Cytotoxicity against human K562 cells assessed as reduction in cell viability after 72 hrs by CCK-8 assay
|
[PMID: 28598633] |
| K562 | GI50 |
6.3 nM
Compound: Paclitaxel
|
Growth inhibition of human K562 cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human K562 cells incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 29655610] |
| K562 | IC50 |
5.8 μM
Compound: PTX
|
Cytotoxicity against human K562 cells incubated for 48 hrs by MTT assay
Cytotoxicity against human K562 cells incubated for 48 hrs by MTT assay
|
[PMID: 30913525] |
| K562 | IC50 |
0.0033 μM
Compound: Paclitaxel
|
Cytotoxicity against human K562 cells assessed as reduction in cell viability after 68 hrs by MTT assay
Cytotoxicity against human K562 cells assessed as reduction in cell viability after 68 hrs by MTT assay
|
[PMID: 31404864] |
| K562 | IC50 |
3 x 10-3 μM
Compound: Taxol
|
Cytotoxicity against human K562 cells assessed as reduction in cell viability
Cytotoxicity against human K562 cells assessed as reduction in cell viability
|
[PMID: 32273216] |
| K562 | GI50 |
4.85 nM
Compound: Taxol
|
Antiproliferative activity against human K562 cells assessed as inhibition of cell growth after 72 hrs by CCK8 assay
Antiproliferative activity against human K562 cells assessed as inhibition of cell growth after 72 hrs by CCK8 assay
|
[PMID: 33239261] |
| K562 | GI50 |
6.3 nM
Compound: Paclitaxel
|
Cytotoxicity against human K562 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay
Cytotoxicity against human K562 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay
|
[PMID: 33310545] |
| K562 | IC50 |
0.29 μM
Compound: Paclitaxel
|
Antiproliferative activity against human K562 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Antiproliferative activity against human K562 cells assessed as reduction in cell viability after 48 hrs by MTT assay
|
[PMID: 34671737] |
| K562 | IC50 |
29.6 nM
Compound: Abraxane
|
Antiproliferative activity against human K562 cells measured after 72 hrs by MTT assay
Antiproliferative activity against human K562 cells measured after 72 hrs by MTT assay
|
[PMID: 36471625] |
| K562 | IC50 |
0.35 μM
Compound: Paclitaxel
|
Anticancer activity against human K562 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
Anticancer activity against human K562 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
|
[PMID: 36481599] |
| K562 | IC50 |
0.874 μM
Compound: PTX
|
Cytotoxicity against human K562 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
Cytotoxicity against human K562 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
|
[PMID: 37201429] |
| K562 | IC50 |
17.2 nM
Compound: 1
|
Antiproliferative activity against human K562 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay
Antiproliferative activity against human K562 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay
|
[PMID: 37544183] |
| K562 | IC50 |
0.015 μM
Compound: PTX
|
Antiproliferative activity against human K562 cells assessed as reduction in cell viability measured after 72 hrs
Antiproliferative activity against human K562 cells assessed as reduction in cell viability measured after 72 hrs
|
[PMID: 38430854] |
| K562 | IC50 |
0.013 μM
Compound: PTX
|
Cytotoxicity against human K562 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay
Cytotoxicity against human K562 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay
|
[PMID: 38547648] |
| K562 | IC50 |
>100 μM
Compound: Paclitaxel
|
Cytotoxicity against Homo sapiens (human) K562 cells assessed as inhibition of cell proliferation after 24 hr by MTT assay
Cytotoxicity against Homo sapiens (human) K562 cells assessed as inhibition of cell proliferation after 24 hr by MTT assay
|
10.1007/s00044-012-0436-9 |
| K562 | IC50 |
1.26 μM
Compound: Paclitaxel
|
Cytotoxicity against human K562 cells assessed as inhibition of cell proliferation after 96 hrs by MTT assay
Cytotoxicity against human K562 cells assessed as inhibition of cell proliferation after 96 hrs by MTT assay
|
10.1039/C4MD00573B |
| Kasumi 1 | IC50 |
0.01 μM
Compound: Taxol
|
Anticancer activity against human Kasumi 1 cells assessed as inhibition of cell proliferation measured after 72 hrs by CCK8 reagent assay
Anticancer activity against human Kasumi 1 cells assessed as inhibition of cell proliferation measured after 72 hrs by CCK8 reagent assay
|
[PMID: 34399390] |
| Kasumi 1 | IC50 |
0.004 μM
Compound: Taxol
|
Cytotoxicity against human Kasumi 1 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay
Cytotoxicity against human Kasumi 1 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay
|
[PMID: 34704758] |
| KB | IC50 |
0.006 μM
Compound: paclitaxel
|
Cytotoxicity against human KB cells
Cytotoxicity against human KB cells
|
[PMID: 10978200] |
| KB | IC50 |
626 nM
Compound: Paclitaxel
|
Concentration required to inhibit the growth of paclitaxel-resistant human epidermoid carcinoma cells KB-8511 by 50 percent (72 hr exposure)
Concentration required to inhibit the growth of paclitaxel-resistant human epidermoid carcinoma cells KB-8511 by 50 percent (72 hr exposure)
|
[PMID: 11133086] |
| KB | IC50 |
<0.1 μg/mL
Compound: paclitaxel
|
Cytotoxicity against human KB cells after 72 hrs by methylene blue assay
Cytotoxicity against human KB cells after 72 hrs by methylene blue assay
|
[PMID: 11473432] |
| KB | IC50 |
0.0091 μM
Compound: 1a (Paclitaxel)
|
Inhibitory activity against KB nasopharynx cancer cell line
Inhibitory activity against KB nasopharynx cancer cell line
|
[PMID: 12031338] |
| KB | IC50 |
1.7 μM
Compound: 1a (Paclitaxel)
|
Inhibitory activity against Vincristine-resistant KB nasopharynx cancer cell line
Inhibitory activity against Vincristine-resistant KB nasopharynx cancer cell line
|
[PMID: 12031338] |
| KB | IC50 |
0.02 μM
Compound: 1
|
Cytotoxicity against human KB cells after 72 hrs by SRB assay
Cytotoxicity against human KB cells after 72 hrs by SRB assay
|
[PMID: 12088425] |
| KB | IC50 |
0.001 μg/mL
Compound: paclitaxel
|
Cytotoxicity against human KB cells after 72 hrs by methylene blue assay
Cytotoxicity against human KB cells after 72 hrs by methylene blue assay
|
[PMID: 12502326] |
| KB | ED50 |
0.001 μg/mL
Compound: Paclitaxel
|
Effective dose required for inhibitory activity against KB human tumor cell line.
Effective dose required for inhibitory activity against KB human tumor cell line.
|
[PMID: 12852747] |
| KB | IC50 |
0.01 μM
Compound: Paclitaxel ; Taxol
|
Cytotoxic activity against cellular metabolic activity of Cervix KB/HeLa tumor cell line using XTT proliferation assay after incubation with the compound for 48 h
Cytotoxic activity against cellular metabolic activity of Cervix KB/HeLa tumor cell line using XTT proliferation assay after incubation with the compound for 48 h
|
[PMID: 12852768] |
| KB | ED50 |
0.001 μg/mL
Compound: paclitaxel
|
Cytotoxicity against human KB cells after 3 days by SRB assay
Cytotoxicity against human KB cells after 3 days by SRB assay
|
[PMID: 14640511] |
| KB | IC50 |
0.0015 μg/mL
Compound: 53
|
Cytotoxicity against human KB cells
Cytotoxicity against human KB cells
|
[PMID: 14987066] |
| KB | ED50 |
0.4 nM
Compound: paclitaxel
|
Cytotoxicity against human KB cells
Cytotoxicity against human KB cells
|
[PMID: 15043407] |
| KB | IC50 |
80 nM
Compound: Paclitaxel (Taxol)
|
Compound was tested for the cytotoxicity against KB-8-5 cell line expressing P-glycoprotein; value ranges from 30-80 nM
Compound was tested for the cytotoxicity against KB-8-5 cell line expressing P-glycoprotein; value ranges from 30-80 nM
|
[PMID: 15261296] |
| KB | IC50 |
0.001 μM
Compound: Paclitaxel
|
Cytotoxicity against human KB cells after 3 days by SRB assay
Cytotoxicity against human KB cells after 3 days by SRB assay
|
[PMID: 16038545] |
| KB | IC50 |
0.001 μg/mL
Compound: taxol
|
Cytotoxicity against human KB403 cell line by MTT assay
Cytotoxicity against human KB403 cell line by MTT assay
|
[PMID: 16297622] |
| KB | EC50 |
49 nM
Compound: paclitaxel
|
Cell cycle arrest in KB/HeLa cells by accumulation at G2/M phase
Cell cycle arrest in KB/HeLa cells by accumulation at G2/M phase
|
[PMID: 17181164] |
| KB | IC50 |
0.01 μM
Compound: paclitaxel
|
Antiproliferative activity against KB/HeLa cells by XTT assay after 48 hrs
Antiproliferative activity against KB/HeLa cells by XTT assay after 48 hrs
|
[PMID: 17181164] |
| KB | IC50 |
2.45 nM
Compound: Paclitaxel
|
Antiproliferative activity against KB cells expressing MDR1
Antiproliferative activity against KB cells expressing MDR1
|
[PMID: 17228873] |
| KB | ED50 |
1.8 nM
Compound: 1
|
Cytotoxicity against human KB cells by sulforhodamine B assay
Cytotoxicity against human KB cells by sulforhodamine B assay
|
[PMID: 17350834] |
| KB | IC50 |
2.45 nM
Compound: paclitaxel
|
Antiproliferative activity against KB cells
Antiproliferative activity against KB cells
|
[PMID: 17416524] |
| KB | ED50 |
0.002 μg/mL
Compound: 1
|
Cytotoxicity against human KB cells by sulforhodamine B assay
Cytotoxicity against human KB cells by sulforhodamine B assay
|
[PMID: 17643301] |
| KB | IC50 |
0.0013 μg/mL
Compound: Paclitaxel
|
Cytotoxicity against human KB cells after 48 hrs by MTT assay
Cytotoxicity against human KB cells after 48 hrs by MTT assay
|
[PMID: 17950495] |
| KB | EC50 |
49 nM
Compound: paclitaxel
|
Cell cycle arrest in KB/HeLa cells assessed as accumulation at G2/M phase after 24 hrs by flow cytometric analysis
Cell cycle arrest in KB/HeLa cells assessed as accumulation at G2/M phase after 24 hrs by flow cytometric analysis
|
[PMID: 17973361] |
| KB | IC50 |
0.01 μM
Compound: paclitaxel
|
Cytotoxicity against human KB/HeLa cells after 48 hrs by XTT assay
Cytotoxicity against human KB/HeLa cells after 48 hrs by XTT assay
|
[PMID: 17973361] |
| KB | IC50 |
4.2 nM
Compound: paclitaxel
|
Cytotoxicity against human KB cells assessed as cell viability after 48 hrs by MTS assay
Cytotoxicity against human KB cells assessed as cell viability after 48 hrs by MTS assay
|
[PMID: 18295490] |
| KB | EC50 |
<0.005 μg/mL
Compound: Paclitaxel
|
Cytotoxicity against human KB cells
Cytotoxicity against human KB cells
|
[PMID: 18640035] |
| KB | IC50 |
2.54 μM
Compound: paclitaxel
|
Cytotoxicity against human KB cells
Cytotoxicity against human KB cells
|
[PMID: 18701281] |
| KB | IC50 |
2.5 nM
Compound: Paclitaxel
|
Antiproliferative activity against human KB cells after 3 days by SRB assay
Antiproliferative activity against human KB cells after 3 days by SRB assay
|
[PMID: 19041247] |
| KB | IC50 |
16500 nM
Compound: paclitaxel
|
Growth inhibition of human Pgp170 overexpressing multidrug resistant-KB-VIN10 cells after 72 hrs by methylene blue dye assay
Growth inhibition of human Pgp170 overexpressing multidrug resistant-KB-VIN10 cells after 72 hrs by methylene blue dye assay
|
[PMID: 19053773] |
| KB | IC50 |
273 nM
Compound: paclitaxel
|
Growth inhibition of human Pgp170 overexpressing multidrug resistant-KB-TAX50 cells after 72 hrs by methylene blue dye assay
Growth inhibition of human Pgp170 overexpressing multidrug resistant-KB-TAX50 cells after 72 hrs by methylene blue dye assay
|
[PMID: 19053773] |
| KB | IC50 |
3.3 nM
Compound: paclitaxel
|
Growth inhibition of human KB cells after 72 hrs by methylene blue dye assay
Growth inhibition of human KB cells after 72 hrs by methylene blue dye assay
|
[PMID: 19053773] |
| KB | IC50 |
7.9 nM
Compound: paclitaxel
|
Growth inhibition of human KB-7D cells overexpressing multidrug resistant associated protein after 72 hrs by methylene blue dye assay
Growth inhibition of human KB-7D cells overexpressing multidrug resistant associated protein after 72 hrs by methylene blue dye assay
|
[PMID: 19053773] |
| KB | ED50 |
0.023 μM
Compound: 1
|
Growth inhibition of human KB cells xenografted in ip dosed NCr nu/nu mouse administered once daily from day 3 to 6 after implantation measured on day 7 by MTT-based hollow-fiber test
Growth inhibition of human KB cells xenografted in ip dosed NCr nu/nu mouse administered once daily from day 3 to 6 after implantation measured on day 7 by MTT-based hollow-fiber test
|
[PMID: 19161316] |
| KB | EC50 |
<0.005 μg/mL
Compound: Palitaxel
|
Cytotoxicity against human KB cells after 3 days by sulforhodamine B assay
Cytotoxicity against human KB cells after 3 days by sulforhodamine B assay
|
[PMID: 19193043] |
| KB | EC50 |
49 nM
Compound: paclitaxel
|
Cell cycle arrest in human KB/HeLa cells assessed as G2/M phase accumulation after 24 hrs by FACS analysis
Cell cycle arrest in human KB/HeLa cells assessed as G2/M phase accumulation after 24 hrs by FACS analysis
|
[PMID: 19220018] |
| KB | IC50 |
0.03 μM
Compound: paclitaxel
|
Antiproliferative activity against human KB/HeLa cells by XTT assay
Antiproliferative activity against human KB/HeLa cells by XTT assay
|
[PMID: 19220018] |
| KB | IC50 |
0.02 μM
Compound: paclitaxel
|
Cytotoxicity against human KB cells after 48 hrs by neutral red assay
Cytotoxicity against human KB cells after 48 hrs by neutral red assay
|
[PMID: 19879765] |
| KB | IC50 |
1.55 x 10-3 μM
Compound: Paclitaxel
|
Cytotoxicity against human KB cells
Cytotoxicity against human KB cells
|
[PMID: 20036537] |
| KB | IC50 |
0.08 μM
Compound: Paclitaxel
|
Cytotoxicity against human KB cells by MTT assay
Cytotoxicity against human KB cells by MTT assay
|
[PMID: 20122764] |
| KB | IC50 |
>0.085 μg/mL
Compound: paclitaxel
|
Cytotoxicity against human vincristine-resistant KB cells overexpressing p-glycoprotein after 3 days by SRB assay
Cytotoxicity against human vincristine-resistant KB cells overexpressing p-glycoprotein after 3 days by SRB assay
|
[PMID: 20232858] |
| KB | IC50 |
0.002 μg/mL
Compound: paclitaxel
|
Cytotoxicity against human KB cells after 3 days by SRB assay
Cytotoxicity against human KB cells after 3 days by SRB assay
|
[PMID: 20232858] |
| KB | EC50 |
49 nM
Compound: paclitaxel
|
Cell cycle arrest in human KB/HeLa cells assessed as accumulation at G2/M phase after 24 hrs using propidium iodide staining by FACS analysis
Cell cycle arrest in human KB/HeLa cells assessed as accumulation at G2/M phase after 24 hrs using propidium iodide staining by FACS analysis
|
[PMID: 20537765] |
| KB | IC50 |
0.01 μM
Compound: paclitaxel
|
Antiproliferative activity against human KB/HeLa cells after 48 hrs by XTT assay
Antiproliferative activity against human KB/HeLa cells after 48 hrs by XTT assay
|
[PMID: 20537765] |
| KB | IC50 |
0.08 μM
Compound: Paclitaxel
|
Cytotoxicity against human KB cells by MTT assay
Cytotoxicity against human KB cells by MTT assay
|
[PMID: 20627721] |
| KB | IC50 |
0.08 μM
Compound: Paclitaxel
|
Cytotoxicity against human KB cells by MTT assay
Cytotoxicity against human KB cells by MTT assay
|
[PMID: 20716468] |
| KB | ED50 |
0.007 μM
Compound: paclitaxel
|
Cytotoxicity against human KB cells
Cytotoxicity against human KB cells
|
[PMID: 20738103] |
| KB | ED50 |
2.87 nM
Compound: Paclitaxel
|
Antiproliferative activity against human KB cells after 3 days by sulforhodamine B assay
Antiproliferative activity against human KB cells after 3 days by sulforhodamine B assay
|
[PMID: 21296579] |
| KB | GI50 |
0.00487 μM
Compound: Paclitaxel
|
Cytotoxicity activity against human KB cells assessed as growth inhibition at 10 ug/ml after 72 hrs sulforhodamine B assay
Cytotoxicity activity against human KB cells assessed as growth inhibition at 10 ug/ml after 72 hrs sulforhodamine B assay
|
[PMID: 21316977] |
| KB | GI50 |
5.16 nM
Compound: Paclitaxel
|
Cytotoxicity against human KB cells after 3 days
Cytotoxicity against human KB cells after 3 days
|
[PMID: 21377368] |
| KB | EC50 |
2 nM
Compound: Paclitaxel
|
Cell cycle arrest in human KB cells assessed as accumulation of cells at G2/M phase after 24 hrs by propidium iodide-based FACScan
Cell cycle arrest in human KB cells assessed as accumulation of cells at G2/M phase after 24 hrs by propidium iodide-based FACScan
|
[PMID: 21480626] |
| KB | EC50 |
49 nM
Compound: Paclitaxel
|
Cell cycle arrest in human KB/HeLa cells assessed as accumulation of cells at G2/M phase after 24 hrs by flow cytometry
Cell cycle arrest in human KB/HeLa cells assessed as accumulation of cells at G2/M phase after 24 hrs by flow cytometry
|
[PMID: 21705223] |
| KB | IC50 |
0.01 μM
Compound: Paclitaxel
|
Cytotoxicity against human KB/HeLa cells after 48 hrs by XTT assay
Cytotoxicity against human KB/HeLa cells after 48 hrs by XTT assay
|
[PMID: 21705223] |
| KB | IC50 |
6.684 μM
Compound: Paclitaxel
|
Cytotoxicity against human KB cells
Cytotoxicity against human KB cells
|
[PMID: 21784631] |
| KB | IC50 |
0.08 μM
Compound: Paclitaxel
|
Cytotoxicity against human KB cells by MTT assay
Cytotoxicity against human KB cells by MTT assay
|
[PMID: 21875764] |
| KB | IC50 |
3.3 nM
Compound: paclitaxel
|
Growth inhibition of human KB cells after 72 hrs by methylene blue assay
Growth inhibition of human KB cells after 72 hrs by methylene blue assay
|
[PMID: 22060033] |
| KB | IC50 |
4.5 nM
Compound: paclitaxel
|
Cytotoxicity against human KB cells incubated for 48 hrs at 37 degC
Cytotoxicity against human KB cells incubated for 48 hrs at 37 degC
|
[PMID: 22074257] |
| KB | EC50 |
0.006 μM
Compound: Paclitaxel
|
Cytotoxicity against human KB cells by sulforhodamine B assay
Cytotoxicity against human KB cells by sulforhodamine B assay
|
[PMID: 22142543] |
| KB | EC50 |
0.76 μM
Compound: Paclitaxel
|
Cytotoxicity against multi-drug resistant variant vincristine resistant human KB cells expressing P-glycoprotein by sulforhodamine B assay
Cytotoxicity against multi-drug resistant variant vincristine resistant human KB cells expressing P-glycoprotein by sulforhodamine B assay
|
[PMID: 22142543] |
| KB | IC50 |
0.0048 μg/mL
Compound: Paclitaxel
|
Cytotoxicity against human KB cells by SRB assay
Cytotoxicity against human KB cells by SRB assay
|
[PMID: 22204911] |
| KB | GI50 |
4.12 nM
Compound: Paclitaxel
|
Antiproliferative activity against human KB cells after 72 hrs by SRB assay
Antiproliferative activity against human KB cells after 72 hrs by SRB assay
|
[PMID: 22265685] |
| KB | IC50 |
0.0016 μg/mL
Compound: Paclitaxel
|
Cytotoxicity against human KB cells by MTT assay
Cytotoxicity against human KB cells by MTT assay
|
[PMID: 22595179] |
| KB | GI50 |
0.00265 μM
Compound: Paclitaxel
|
Cytotoxicity against human KB cells after 72 hrs by SRB assay
Cytotoxicity against human KB cells after 72 hrs by SRB assay
|
[PMID: 22932313] |
| KB | GI50 |
7.77 nM
Compound: Paclitaxel
|
Growth inhibition of human KB cells by SRB assay
Growth inhibition of human KB cells by SRB assay
|
[PMID: 23274123] |
| KB | GI50 |
0.0064 μM
Compound: Paclitaxel
|
Cytotoxicity against human KB cells by SRB method
Cytotoxicity against human KB cells by SRB method
|
[PMID: 23867604] |
| KB | IC50 |
4.1 nM
Compound: Paclitaxel
|
Cytotoxicity against human KB cells assessed as growth inhibition after 72 hrs by methylene blue staining-based assay
Cytotoxicity against human KB cells assessed as growth inhibition after 72 hrs by methylene blue staining-based assay
|
[PMID: 24106982] |
| KB | GI50 |
0.008 μM
Compound: Paclitaxel
|
Cytotoxicity against human KB cells by SRB assay
Cytotoxicity against human KB cells by SRB assay
|
[PMID: 24315191] |
| KB | GI50 |
0.0064 μM
Compound: paclitaxel
|
Cytotoxicity against human KB cells by SRB assay
Cytotoxicity against human KB cells by SRB assay
|
[PMID: 24502232] |
| KB | IC50 |
5.1 nM
Compound: Paclitaxel
|
Cytotoxicity against human KB cells after 72 hrs by methylene blue assay
Cytotoxicity against human KB cells after 72 hrs by methylene blue assay
|
[PMID: 24657567] |
| KB | IC50 |
3.9 nM
Compound: Paclitaxel
|
Cytotoxicity against human KB cells assessed as inhibition of cell growth after 3 days by MTT assay
Cytotoxicity against human KB cells assessed as inhibition of cell growth after 3 days by MTT assay
|
[PMID: 24745968] |
| KB | IC50 |
0.0039 μM
Compound: Paclitaxel
|
Cytotoxicity against human KB cells after 72 hrs sulforhodamine B colorimetric assay
Cytotoxicity against human KB cells after 72 hrs sulforhodamine B colorimetric assay
|
[PMID: 25008456] |
| KB | IC50 |
3.3 nM
Compound: Paclitaxel
|
Antiproliferative activity against human KB cells
Antiproliferative activity against human KB cells
|
[PMID: 25059503] |
| KB | IC50 |
3.8 μM
Compound: paclitaxel
|
Cytotoxicity against human KB cells after 48 hrs by trypan blue exclusion method
Cytotoxicity against human KB cells after 48 hrs by trypan blue exclusion method
|
[PMID: 25211032] |
| KB | IC50 |
3.7 nM
Compound: PXL
|
Antiproliferative activity against human KB cells after 3 days by SRB assay
Antiproliferative activity against human KB cells after 3 days by SRB assay
|
[PMID: 25241925] |
| KB | IC50 |
3.9 nM
Compound: Paclitaxel
|
Cytotoxicity against human KB cells assessed as reduction in cell growth after 3 days by MTT assay
Cytotoxicity against human KB cells assessed as reduction in cell growth after 3 days by MTT assay
|
[PMID: 25442315] |
| KB | GI50 |
0.0064 μM
Compound: Paclitaxel
|
Antiproliferative activity against human KB cells by sulforhodamine B assay
Antiproliferative activity against human KB cells by sulforhodamine B assay
|
[PMID: 25770782] |
| KB | IC50 |
0.015 μM
Compound: Taxol
|
Antiproliferative activity against human KB cells after 72 hrs by MTT assay
Antiproliferative activity against human KB cells after 72 hrs by MTT assay
|
[PMID: 25771484] |
| KB | IC50 |
5.1 nM
Compound: Paclitaxel
|
Antiproliferative activity against human KB cells after 72 hrs by methylene blue assay
Antiproliferative activity against human KB cells after 72 hrs by methylene blue assay
|
[PMID: 26160020] |
| KB | GI50 |
0.0064 μM
Compound: Paclitaxel
|
Antiproliferative activity against human KB cells assessed as cell growth inhibition by SRB assay
Antiproliferative activity against human KB cells assessed as cell growth inhibition by SRB assay
|
[PMID: 26242242] |
| KB | GI50 |
1 nM
Compound: Paclitaxel
|
Growth inhibition of human KB cells after 72 hrs by MTS assay
Growth inhibition of human KB cells after 72 hrs by MTS assay
|
[PMID: 26778612] |
| KB | IC50 |
0.04 nM
Compound: PXL
|
Antiproliferative activity against human KB cells after 3 days by SRB assay
Antiproliferative activity against human KB cells after 3 days by SRB assay
|
[PMID: 26865176] |
| KB | IC50 |
0.0001 μM
Compound: Taxol
|
Antiproliferative activity against human KB cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
Antiproliferative activity against human KB cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
|
[PMID: 27010926] |
| KB | GI50 |
948 μM
Compound: Paclitaxel
|
Antiproliferative activity against human KB cells after 48 hrs by SRB method
Antiproliferative activity against human KB cells after 48 hrs by SRB method
|
[PMID: 27238842] |
| KB | IC50 |
3.8 μM
Compound: PXL
|
Cytotoxicity against human KB cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
Cytotoxicity against human KB cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
|
[PMID: 27707623] |
| KB | IC50 |
0.8 nM
Compound: Paclitaxel
|
Cytotoxicity against human KB cells assessed as growth inhibition after 48 hrs by SRB assay
Cytotoxicity against human KB cells assessed as growth inhibition after 48 hrs by SRB assay
|
[PMID: 27797192] |
| KB | IC50 |
6.27 nM
Compound: PXL
|
Antiproliferative activity against human KB cells after 72 hrs by SRB assay
Antiproliferative activity against human KB cells after 72 hrs by SRB assay
|
[PMID: 28099003] |
| KB | IC50 |
6.587 μM
Compound: Paclitaxel
|
Cytotoxicity against human KB cells assessed as reduction in cell viability after 48 hrs by MTT assay
Cytotoxicity against human KB cells assessed as reduction in cell viability after 48 hrs by MTT assay
|
[PMID: 28237662] |
| KB | IC50 |
6.3 nM
Compound: Paclitaxel
|
Antiproliferative activity against human KB cells incubated for 72 hrs by SRB assay
Antiproliferative activity against human KB cells incubated for 72 hrs by SRB assay
|
[PMID: 28290698] |
| KB | IC50 |
5.9 nM
Compound: PXL
|
Antiproliferative activity against human KB cells by sulforhodamine B assay
Antiproliferative activity against human KB cells by sulforhodamine B assay
|
[PMID: 28457756] |
| KB | IC50 |
0.0036 μM
Compound: Paclitaxel
|
Cytotoxicity against human KB cells assessed as growth inhibition after 72 hrs by MTT assay
Cytotoxicity against human KB cells assessed as growth inhibition after 72 hrs by MTT assay
|
[PMID: 28590124] |
| KB | IC50 |
1.9 nM
Compound: 1
|
Cytotoxicity against human KB cells assessed as decrease in cell viability after 48 hrs by MTT assay
Cytotoxicity against human KB cells assessed as decrease in cell viability after 48 hrs by MTT assay
|
[PMID: 28624703] |
| KB | GI50 |
5.12 nM
Compound: Paclitaxel
|
Cytotoxicity against human KB cells assessed as growth inhibition after 48 hrs by SRB assay
Cytotoxicity against human KB cells assessed as growth inhibition after 48 hrs by SRB assay
|
[PMID: 28653846] |
| KB | ED50 |
1 x 10-5 μg/mL
Compound: 2
|
Cytotoxicity against human KB cells
Cytotoxicity against human KB cells
|
[PMID: 2878063] |
| KB | ED50 |
1 x 10-5 μg/mL
Compound: 1
|
Cytotoxicity against human KB cells
Cytotoxicity against human KB cells
|
[PMID: 2898009] |
| KB | IC50 |
6.6 nM
Compound: Paclitaxel
|
Cytotoxicity against human KB cells after 72 hrs by sulforhodamine B assay
Cytotoxicity against human KB cells after 72 hrs by sulforhodamine B assay
|
[PMID: 29131631] |
| KB | IC50 |
3.6 nM
Compound: PXL
|
Antiproliferative activity against human KB cells after 72 hrs by sulforhodamine B assay
Antiproliferative activity against human KB cells after 72 hrs by sulforhodamine B assay
|
[PMID: 29319316] |
| KB | IC50 |
7.52 μM
Compound: Paclitaxel
|
Antiproliferative activity against human KB cells after 72 hrs by SRB assay
Antiproliferative activity against human KB cells after 72 hrs by SRB assay
|
[PMID: 29391939] |
| KB | IC50 |
6.8 nM
Compound: PXL
|
Antiproliferative activity against human KB cells after 72 hrs by SRB assay
Antiproliferative activity against human KB cells after 72 hrs by SRB assay
|
[PMID: 30010341] |
| KB | IC50 |
10.3 nM
Compound: Paclitaxol
|
Cytotoxicity against human KB cells after 72 hrs by sulforhodamine B assay
Cytotoxicity against human KB cells after 72 hrs by sulforhodamine B assay
|
[PMID: 30036834] |
| KB | IC50 |
5.71 nM
Compound: PXL
|
Antiproliferative activity against human KB cells after 72 hrs by SRB assay
Antiproliferative activity against human KB cells after 72 hrs by SRB assay
|
[PMID: 30106296] |
| KB | IC50 |
6.69 nM
Compound: PXL
|
Antiproliferative activity against human KB cells after 48 hrs by SRB assay
Antiproliferative activity against human KB cells after 48 hrs by SRB assay
|
[PMID: 30106296] |
| KB | IC50 |
8.21 nM
Compound: PXL
|
Antiproliferative activity against human KB cells after 24 hrs by SRB assay
Antiproliferative activity against human KB cells after 24 hrs by SRB assay
|
[PMID: 30106296] |
| KB | IC50 |
5.9 μM
Compound: Paclitaxel
|
Antiproliferative activity against human KB cells assessed as reduction in cell growth after 72 hrs by sulforhodamine B assay
Antiproliferative activity against human KB cells assessed as reduction in cell growth after 72 hrs by sulforhodamine B assay
|
[PMID: 30189396] |
| KB | IC50 |
6.1 nM
Compound: Paclitaxel
|
Antiproliferative activity against human KB cells assessed as cell growth inhibition after 72 hrs by sulforhodamine B assay
Antiproliferative activity against human KB cells assessed as cell growth inhibition after 72 hrs by sulforhodamine B assay
|
[PMID: 31126820] |
| KB | IC50 |
10 nM
Compound: Paclitaxel
|
Antiproliferative activity against human KB cells assessed as reduction in cell viability after 72 hrs by MTS assay
Antiproliferative activity against human KB cells assessed as reduction in cell viability after 72 hrs by MTS assay
|
[PMID: 31419740] |
| KB | IC50 |
6.72 nM
Compound: PXL
|
Antiproliferative activity against human KB cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
Antiproliferative activity against human KB cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
|
[PMID: 31541869] |
| KB | IC50 |
7.4 nM
Compound: Paclitaxel
|
Antiproliferative activity against human KB cells assessed as reduction in cell viability after 72 hrs by SRB assay
Antiproliferative activity against human KB cells assessed as reduction in cell viability after 72 hrs by SRB assay
|
[PMID: 31550158] |
| KB | IC50 |
6.6 μM
Compound: Paclitaxel
|
Antiproliferative activity against human KB cells incubated for 72 hrs by SRB assay
Antiproliferative activity against human KB cells incubated for 72 hrs by SRB assay
|
[PMID: 31718182] |
| KB | GI50 |
4.1 nM
Compound: Paclitaxel
|
Antiproliferative activity against human KB cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
Antiproliferative activity against human KB cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
|
[PMID: 31938468] |
| KB | IC50 |
7.7 nM
Compound: Paclitaxel
|
Antiproliferative activity against human KB cells assessed as reduction in cell viability after 72 hrs by SRB assay
Antiproliferative activity against human KB cells assessed as reduction in cell viability after 72 hrs by SRB assay
|
[PMID: 32946697] |
| KB | IC50 |
0.00579 μM
Compound: Paclitaxel
|
Antiproliferative activity against human KB cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
Antiproliferative activity against human KB cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
|
[PMID: 34171512] |
| KB | IC50 |
0.008 μM
Compound: Paclitaxel
|
Antiproliferative activity against human KB cells assessed as reduction in cell viability measured after 72 hrs by SRB assay
Antiproliferative activity against human KB cells assessed as reduction in cell viability measured after 72 hrs by SRB assay
|
[PMID: 34403728] |
| KB | GI50 |
4.6 nM
Compound: Paclitaxel
|
Antiproliferative activity against human KB cells assessed as cell growth inhibition measured after 72 hrs by SRB assay
Antiproliferative activity against human KB cells assessed as cell growth inhibition measured after 72 hrs by SRB assay
|
[PMID: 34917259] |
| KB | IC50 |
<0.1 nM
Compound: PXL
|
Antiproliferative activity against human KB cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay
Antiproliferative activity against human KB cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay
|
[PMID: 38251859] |
| KB | IC50 |
6.3 μM
Compound: PXL
|
Antiproliferative activity against human KB cells assessed as cell growth inhibition incubated for 72 hrs by sulforhodamine B assay
Antiproliferative activity against human KB cells assessed as cell growth inhibition incubated for 72 hrs by sulforhodamine B assay
|
[PMID: 38438305] |
| KB | IC50 |
7.1 nM
Compound: PXL
|
Antiproliferative activity against human KB cells assessed as reduction in cell viability by SRB assay
Antiproliferative activity against human KB cells assessed as reduction in cell viability by SRB assay
|
[PMID: 38970504] |
| KB | ED50 |
8.9 μg/mL
Compound: Taxol
|
Cytotoxicity against human KB cells
Cytotoxicity against human KB cells
|
[PMID: 7130986] |
| KB | ED50 |
1.2 x 10-3 μg/mL
Compound: 1
|
Cytotoxicity against human KB cells
Cytotoxicity against human KB cells
|
[PMID: 7264680] |
| KB | ED50 |
2 x 10-2 μg/mL
Compound: paclitaxel
|
Cytotoxicity against human KB cells
Cytotoxicity against human KB cells
|
[PMID: 8778244] |
| KB | IC50 |
0.0088 μg/mL
Compound: 13
|
Cytotoxic activity was evaluated against Epidermoid Carcinoma KB cells
Cytotoxic activity was evaluated against Epidermoid Carcinoma KB cells
|
[PMID: 9873389] |
| KB | ED50 |
2 x 10-2 μg/mL
Compound: palitaxel
|
Cytotoxicity against human KB cells
Cytotoxicity against human KB cells
|
10.1021/np9606660 |
| KB 3-1 | IC50 |
2.92 nM
Compound: Paclitaxel
|
Concentration required to inhibit the growth of paclitaxel-sensitive human epidermoid carcinoma cells KB-31 by 50 percent (72 hr exposure)
Concentration required to inhibit the growth of paclitaxel-sensitive human epidermoid carcinoma cells KB-31 by 50 percent (72 hr exposure)
|
[PMID: 11133086] |
| KB 3-1 | IC50 |
>3000 nM
Compound: Paclitaxel (Taxol)
|
Compound was tested for the cytotoxicity against KB-V1 cell line expressing P-glycoprotein
Compound was tested for the cytotoxicity against KB-V1 cell line expressing P-glycoprotein
|
[PMID: 15261296] |
| KB 3-1 | IC50 |
6 nM
Compound: Paclitaxel (Taxol)
|
Compound was tested for the cytotoxicity against KB-3-1 cell line; value ranges from 2-6 nM
Compound was tested for the cytotoxicity against KB-3-1 cell line; value ranges from 2-6 nM
|
[PMID: 15261296] |
| KB 3-1 | IC50 |
3.9 nM
Compound: Placlitaxel (TAXOL)
|
Inhibitory concentration against KB-3-1 cells was evaluated
Inhibitory concentration against KB-3-1 cells was evaluated
|
[PMID: 15341492] |
| KB 3-1 | IC50 |
>0.0021 μM
Compound: Paclitaxel
|
Inhibitory concentration against human KB-3-1 cells
Inhibitory concentration against human KB-3-1 cells
|
[PMID: 15863325] |
| KB 3-1 | IC50 |
>0.6 μM
Compound: Paclitaxel
|
Inhibitory concentration against KB-G2 cells
Inhibitory concentration against KB-G2 cells
|
[PMID: 15863325] |
| KB 3-1 | IC50 |
23.3 nM
Compound: Paclitaxel
|
Cytotoxicity against KB-3-1 cell line
Cytotoxicity against KB-3-1 cell line
|
[PMID: 17249649] |
| KB 3-1 | IC50 |
0.002 μM
Compound: paclitaxel
|
Growth inhibition of human KB3-1 cells after 72 hrs by MTT assay
Growth inhibition of human KB3-1 cells after 72 hrs by MTT assay
|
[PMID: 18313307] |
| KB 3-1 | IC50 |
400 μM
Compound: paclitaxel
|
Resistant ratio, IC50 for multidrug resistant human KB3-1 cells to IC50 for human KB3-1 cells
Resistant ratio, IC50 for multidrug resistant human KB3-1 cells to IC50 for human KB3-1 cells
|
[PMID: 18313307] |
| KB 3-1 | IC50 |
1.2 nM
Compound: PTX
|
Cytotoxicity against paclitaxel-sensitive human KB3-1 cells assessed as decrease in cell viability after 72 hrs by neutral red dye assay
Cytotoxicity against paclitaxel-sensitive human KB3-1 cells assessed as decrease in cell viability after 72 hrs by neutral red dye assay
|
[PMID: 20302303] |
| KB 3-1 | IC50 |
0.0005 μM
Compound: Paclitaxel
|
Cytotoxicity against human KB-3-1 cells assessed as reduction in cell viability after 72 hrs by MTT assay
Cytotoxicity against human KB-3-1 cells assessed as reduction in cell viability after 72 hrs by MTT assay
|
[PMID: 29501942] |
| KB 3-1 | GI50 |
2.23 nM
Compound: Paclitaxel
|
Cytotoxicity against human KB-3-1 cells assessed as inhibition of cell proliferation
Cytotoxicity against human KB-3-1 cells assessed as inhibition of cell proliferation
|
[PMID: 37849542] |
| KB 3-1 | IC50 |
0.029 μM
Compound: Paclitaxel
|
Antiproliferative activity against human KB-3-1 cells assessed as cell growth inhibition
Antiproliferative activity against human KB-3-1 cells assessed as cell growth inhibition
|
[PMID: 38733884] |
| KB-V1 | IC50 |
>2.3 μM
Compound: 1
|
Cytotoxicity against human KBV1 cells after 72 hrs by SRB assay
Cytotoxicity against human KBV1 cells after 72 hrs by SRB assay
|
[PMID: 12088425] |
| KB-V1 | IC50 |
2013 nM
Compound: Paclitaxel
|
Antiproliferative activity against KBV1 cells expressing MDR1
Antiproliferative activity against KBV1 cells expressing MDR1
|
[PMID: 17228873] |
| KB-V1 | IC50 |
>10000 nM
Compound: Paclitaxel
|
Cytotoxicity against P-glycoprotein-overexpressing KB-V1 cell line
Cytotoxicity against P-glycoprotein-overexpressing KB-V1 cell line
|
[PMID: 17249649] |
| KB-V1 | IC50 |
2013 nM
Compound: paclitaxel
|
Antiproliferative activity against KBV1cells
Antiproliferative activity against KBV1cells
|
[PMID: 17416524] |
| KB-V1 | IC50 |
8 μM
Compound: paclitaxel
|
Growth inhibition of human KB V1 cells after 72 hrs by MTT assay
Growth inhibition of human KB V1 cells after 72 hrs by MTT assay
|
[PMID: 18313307] |
| KB-V1 | IC50 |
2013 nM
Compound: Paclitaxel
|
Antiproliferative activity against human KBV1 cells after 3 days by SRB assay
Antiproliferative activity against human KBV1 cells after 3 days by SRB assay
|
[PMID: 19041247] |
| KB-V1 | IC50 |
9800 nM
Compound: 1
|
Cytotoxicity against human KBV1 cells assessed as decrease in cell viability after 48 hrs by MTT assay
Cytotoxicity against human KBV1 cells assessed as decrease in cell viability after 48 hrs by MTT assay
|
[PMID: 28624703] |
| KB-V1 | GI50 |
431.55 nM
Compound: Paclitaxel
|
Cytotoxicity against multidrug resistant human KB-V1 cells assessed as inhibition of cell proliferation
Cytotoxicity against multidrug resistant human KB-V1 cells assessed as inhibition of cell proliferation
|
[PMID: 37849542] |
| KETR3 | IC50 |
0.05 μM
Compound: Taxol
|
Anticancer activity against human KETR3 cells by MTT assay
Anticancer activity against human KETR3 cells by MTT assay
|
[PMID: 33316408] |
| KG-1 | IC50 |
0.068 μM
Compound: PTX
|
Cytotoxicity against human KG-1 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay
Cytotoxicity against human KG-1 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay
|
[PMID: 38547648] |
| KM12 | GI50 |
0.004 μM
Compound: paclitaxel
|
Cytotoxicity against human KM12 cells
Cytotoxicity against human KM12 cells
|
[PMID: 17696332] |
| KM12 | GI50 |
0.004 μM
Compound: Paclitaxel
|
Cytotoxicity against human KM12 cells by sulforhodamine B assay
Cytotoxicity against human KM12 cells by sulforhodamine B assay
|
[PMID: 21839640] |
| KM12 | GI50 |
5 nM
Compound: Paclitaxel
|
Growth inhibition of human KM12 cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human KM12 cells incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 29655610] |
| KM12 | GI50 |
5 nM
Compound: Paclitaxel
|
Cytotoxicity against human KM12 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay
Cytotoxicity against human KM12 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay
|
[PMID: 33310545] |
| KP-4 | IC50 |
0.007 μM
Compound: 2
|
Antiproliferative activity against human KP-4 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay
Antiproliferative activity against human KP-4 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay
|
[PMID: 37856840] |
| KU812 cell line | IC50 |
5.3 nM
Compound: Taxol
|
Cytotoxicity against human KU812 cells expressing BCR-ABL assessed as growth inhibition after 72 hrs by CCK-8 assay
Cytotoxicity against human KU812 cells expressing BCR-ABL assessed as growth inhibition after 72 hrs by CCK-8 assay
|
[PMID: 23301703] |
| L02 | IC50 |
0.0518 μM
Compound: Taxol
|
Cytotoxicity against human HL-7702 cells assessed as growth inhibition by MTT assay
Cytotoxicity against human HL-7702 cells assessed as growth inhibition by MTT assay
|
[PMID: 24684840] |
| L02 | IC50 |
1.1 μM
Compound: paclitaxel
|
Cytotoxicity against human HL7702 cells by MTT assay
Cytotoxicity against human HL7702 cells by MTT assay
|
[PMID: 24960143] |
| L02 | IC50 |
0.06 μM
Compound: Paclitaxel
|
Cytotoxicity against human HL-7702 cells assessed as reduction in cell viability after 72 hrs by MTT assay
Cytotoxicity against human HL-7702 cells assessed as reduction in cell viability after 72 hrs by MTT assay
|
[PMID: 27329938] |
| L02 | IC50 |
>100 μM
Compound: Taxol
|
Cytotoxicity against human L02 cells assessed as cell growth inhibition after 48 hrs by MTT assay
Cytotoxicity against human L02 cells assessed as cell growth inhibition after 48 hrs by MTT assay
|
[PMID: 27887843] |
| L02 | IC50 |
0.002 μM
Compound: Taxol
|
Cytotoxicity against human LO2 cells after 72 hrs by MTT assay
Cytotoxicity against human LO2 cells after 72 hrs by MTT assay
|
[PMID: 28395199] |
| L02 | IC50 |
5.6 μM
Compound: Taxol
|
Cytotoxicity against NQO1 deficient human L02 cells assessed as reduction in cell viability after 72 hrs by MTT assay
Cytotoxicity against NQO1 deficient human L02 cells assessed as reduction in cell viability after 72 hrs by MTT assay
|
[PMID: 30508483] |
| L02 | GI50 |
30.8 nM
Compound: Paclitaxel
|
Cytotoxicity against human L02 cells assessed as assessed as cell growth inhibition measured after 72 hrs by MTT assay
Cytotoxicity against human L02 cells assessed as assessed as cell growth inhibition measured after 72 hrs by MTT assay
|
[PMID: 33201714] |
| L02 | IC50 |
>100 μM
Compound: PTX
|
Cytotoxicity against human L02 cells assessed as cell growth inhibition measured after 24 hrs by MTT assay
Cytotoxicity against human L02 cells assessed as cell growth inhibition measured after 24 hrs by MTT assay
|
[PMID: 33381964] |
| L02 | IC50 |
<0.1 μM
Compound: Paclitaxel
|
Anticancer activity against human L02 cells assessed as cell growth inhibition measured for 72 hrs by MTT assay
Anticancer activity against human L02 cells assessed as cell growth inhibition measured for 72 hrs by MTT assay
|
[PMID: 34303874] |
| L02 | IC50 |
79.67 μM
Compound: Paclitaxel
|
Cytotoxicity against human L02 cells by CCK8 assay
Cytotoxicity against human L02 cells by CCK8 assay
|
[PMID: 34922028] |
| L02 | IC50 |
0.54 μM
Compound: Paclitaxel; Taxol
|
Antiproliferative activity against human L02 cells measured after 48 hrs by MTT assay
Antiproliferative activity against human L02 cells measured after 48 hrs by MTT assay
|
[PMID: 35551039] |
| L02 | IC50 |
6.1 μM
Compound: Taxol
|
Antiproliferative activity against human L02 cells assessed as inhibition of cell growth measured after 72 hrs by cell titer glo luminescent assay
Antiproliferative activity against human L02 cells assessed as inhibition of cell growth measured after 72 hrs by cell titer glo luminescent assay
|
[PMID: 35640078] |
| L02 | IC50 |
0.13 μM
Compound: Taxol
|
Antiproliferative activity against human L02 cells assessed as reduction in cell viability incubated for 48 hrs by CCk-8 assay
Antiproliferative activity against human L02 cells assessed as reduction in cell viability incubated for 48 hrs by CCk-8 assay
|
[PMID: 37329677] |
| L02 | IC50 |
1.73 μM
Compound: PTX
|
Cytotoxicity against human L02 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
Cytotoxicity against human L02 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
|
[PMID: 38280356] |
| L1210 | IC50 |
0.09 nM
Compound: Paclitaxel
|
Cytotoxicity expressed as concentration required to inhibit cell growth by 50% on continuous exposure time of 96h in L1210 cell line by MTT assay.
Cytotoxicity expressed as concentration required to inhibit cell growth by 50% on continuous exposure time of 96h in L1210 cell line by MTT assay.
|
[PMID: 12392737] |
| L1210 | IC50 |
0.58 nM
Compound: Paclitaxel
|
Cytotoxicity expressed as concentration required to inhibit cell growth by 50% on continuous exposure time of 72 hr in L1210 cell line by MTT assay.
Cytotoxicity expressed as concentration required to inhibit cell growth by 50% on continuous exposure time of 72 hr in L1210 cell line by MTT assay.
|
[PMID: 12392737] |
| L1210 | IC50 |
>5 μM
Compound: Paclitaxel ; Taxol
|
Antiproliferative activity against L1210 phenotype L1210 VCR tumor cell line
Antiproliferative activity against L1210 phenotype L1210 VCR tumor cell line
|
[PMID: 12852768] |
| L1210 | IC50 |
0.06 μM
Compound: Paclitaxel ; Taxol
|
Antiproliferative activity against L1210 tumor cell line
Antiproliferative activity against L1210 tumor cell line
|
[PMID: 12852768] |
| L1210 | IC50 |
>5 μM
Compound: paclitaxel
|
Antiproliferative activity against L1210 VCR cells by XTT assay after 48 hrs
Antiproliferative activity against L1210 VCR cells by XTT assay after 48 hrs
|
[PMID: 17181164] |
| L1210 | IC50 |
0.06 μM
Compound: paclitaxel
|
Antiproliferative activity against L1210 cells by XTT assay after 48 hrs
Antiproliferative activity against L1210 cells by XTT assay after 48 hrs
|
[PMID: 17181164] |
| L1210 | IC50 |
>5 μM
Compound: paclitaxel
|
Antiproliferative activity against mouse vincristine-resistant L1210 cells after 48 hrs by XTT assay
Antiproliferative activity against mouse vincristine-resistant L1210 cells after 48 hrs by XTT assay
|
[PMID: 17973361] |
| L1210 | IC50 |
0.06 μM
Compound: paclitaxel
|
Antiproliferative activity against mouse L1210 cells after 48 hrs by XTT assay
Antiproliferative activity against mouse L1210 cells after 48 hrs by XTT assay
|
[PMID: 17973361] |
| L1210 | IC50 |
0.06 μM
Compound: paclitaxel
|
Antiproliferative activity against mouse L1210 cells after 48 hrs by XTT assay
Antiproliferative activity against mouse L1210 cells after 48 hrs by XTT assay
|
[PMID: 19220018] |
| L1210 | IC50 |
0.07 μM
Compound: paclitaxel
|
Antiproliferative activity against vincristine-resistance MRP1 negative mouse L1210 cells expressing human MDR1 after 48 hrs by XTT assay
Antiproliferative activity against vincristine-resistance MRP1 negative mouse L1210 cells expressing human MDR1 after 48 hrs by XTT assay
|
[PMID: 19220018] |
| L1210 | IC50 |
>5 μM
Compound: paclitaxel
|
Antiproliferative activity against vincristine-resistant mouse L1210 cells after 48 hrs by XTT assay
Antiproliferative activity against vincristine-resistant mouse L1210 cells after 48 hrs by XTT assay
|
[PMID: 20537765] |
| L1210 | IC50 |
0.06 μM
Compound: paclitaxel
|
Antiproliferative activity against mouse L1210 cells after 48 hrs by XTT assay
Antiproliferative activity against mouse L1210 cells after 48 hrs by XTT assay
|
[PMID: 20537765] |
| L1210 | IC50 |
0.4 nM
Compound: Pac
|
Antiproliferative activity against mouse L1210 cells after 48 hrs by sulforhodamine B assay
Antiproliferative activity against mouse L1210 cells after 48 hrs by sulforhodamine B assay
|
[PMID: 21604746] |
| L1210 | IC50 |
>5 μM
Compound: Paclitaxel
|
Antiproliferative activity against mouse VCR-resistant L1210 cells after 48 hrs by XTT assay
Antiproliferative activity against mouse VCR-resistant L1210 cells after 48 hrs by XTT assay
|
[PMID: 21705223] |
| L1210 | IC50 |
0.06 μM
Compound: Paclitaxel
|
Antiproliferative activity against mouse L1210 cells after 48 hrs by XTT assay
Antiproliferative activity against mouse L1210 cells after 48 hrs by XTT assay
|
[PMID: 21705223] |
| L1210 | IC50 |
0.4 nM
Compound: Pac
|
Antiproliferative activity against mouse L1210 after 48 hrs by SRB assay
Antiproliferative activity against mouse L1210 after 48 hrs by SRB assay
|
[PMID: 21920638] |
| L1210 | IC50 |
120 nM
Compound: paclitaxel
|
Cytotoxicity against mouse L1210 cells incubated for 48 hrs at 37 degC
Cytotoxicity against mouse L1210 cells incubated for 48 hrs at 37 degC
|
[PMID: 22074257] |
| L1210 | IC50 |
27.6 nM
Compound: Paclitaxel
|
Cytotoxicity against folate receptor over-expressing mouse L1210 cells after 72 hrs by MTT assay
Cytotoxicity against folate receptor over-expressing mouse L1210 cells after 72 hrs by MTT assay
|
[PMID: 25819334] |
| L1210 | IC50 |
0.024 mM
Compound: 1
|
Tested for cytotoxicity against murine L-1210 cell line
Tested for cytotoxicity against murine L-1210 cell line
|
[PMID: 7650695] |
| L1210 | IC50 |
0.33 μg/mL
Compound: 13
|
Cytotoxic activity was evaluated against murine Leukemia L1210 cells
Cytotoxic activity was evaluated against murine Leukemia L1210 cells
|
[PMID: 9873389] |
| L1210 | IC50 |
6 μM
Compound: Taxol
|
In vitro inhibitory activity of compound against L1210/O murine leukemia cell line
In vitro inhibitory activity of compound against L1210/O murine leukemia cell line
|
10.1016/S0960-894X(01)80411-X |
| L2987 | IC50 |
0.2 μM
Compound: 1
|
Compound was evaluated for its cytotoxicity against L2987 lung carcinoma cells
Compound was evaluated for its cytotoxicity against L2987 lung carcinoma cells
|
[PMID: 12443783] |
| L2987 | IC50 |
0.2 μM
Compound: 1
|
Cytotoxicity against human L2987 cells
Cytotoxicity against human L2987 cells
|
[PMID: 17419065] |
| L929 | GI50 |
0.1 μg/mL
Compound: Paclitaxel
|
Growth inhibition of mouse L929 cells
Growth inhibition of mouse L929 cells
|
[PMID: 15387677] |
| L929 | GI50 |
0.1 μg/mL
Compound: paclitaxel
|
Antiproliferative activity against mouse L929 cells
Antiproliferative activity against mouse L929 cells
|
[PMID: 17500572] |
| L929 | IC50 |
32.95 μg/mL
Compound: Paclitaxel
|
Cytotoxicity against mouse L929 cells assessed as reduction in cell viability measured after 48 hrs
Cytotoxicity against mouse L929 cells assessed as reduction in cell viability measured after 48 hrs
|
[PMID: 31607609] |
| L929 | IC50 |
62.5 nM
Compound: Paclitaxel
|
Cytotoxicity against mouse L929 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
Cytotoxicity against mouse L929 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
|
[PMID: 38283229] |
| LC-2-ad | IC50 |
2.5 nM
Compound: 28
|
Antiproliferative activity against human LC2/ad cells after 72 hrs by WST8 assay
Antiproliferative activity against human LC2/ad cells after 72 hrs by WST8 assay
|
[PMID: 25625617] |
| Lewis lung carcinoma cell line | IC50 |
0.189 μM
Compound: Paclitaxel
|
Cytotoxicity activity against mouse LLC cells assessed as cell growth inhibition after 48 hrs by MTT assay
Cytotoxicity activity against mouse LLC cells assessed as cell growth inhibition after 48 hrs by MTT assay
|
[PMID: 30433783] |
| LNCaP | IC50 |
0.02 μM
Compound: 1
|
Cytotoxicity against human LNCAP cells after 72 hrs by SRB assay
Cytotoxicity against human LNCAP cells after 72 hrs by SRB assay
|
[PMID: 12088425] |
| LNCaP | ED50 |
5 nM
Compound: paclitaxel
|
Cytotoxicity against human LNCAP cells
Cytotoxicity against human LNCAP cells
|
[PMID: 15043407] |
| LNCaP | IC50 |
2 nM
Compound: Paclitaxel
|
Antiproliferative activity against prostate cancer LNCaP Cell line using sulforhodamine B(SRB) assay
Antiproliferative activity against prostate cancer LNCaP Cell line using sulforhodamine B(SRB) assay
|
[PMID: 15801848] |
| LNCaP | ED50 |
2.6 nM
Compound: 1
|
Cytotoxicity against human LNCAP cells by sulforhodamine B assay
Cytotoxicity against human LNCAP cells by sulforhodamine B assay
|
[PMID: 17350834] |
| LNCaP | ED50 |
>10 μM
Compound: Paclitaxel
|
Cytotoxicity against hormone-dependent human LNCAP cells after 2 days by sulforhodamine B assay
Cytotoxicity against hormone-dependent human LNCAP cells after 2 days by sulforhodamine B assay
|
[PMID: 19026551] |
| LNCaP | IC50 |
6.32 μM
Compound: taxol
|
Cytotoxicity against human LNCAP cells after 72 hrs by XTT assay
Cytotoxicity against human LNCAP cells after 72 hrs by XTT assay
|
[PMID: 19754130] |
| LNCaP | IC50 |
22.3 nM
Compound: PTax
|
Cytotoxicity against human LNCAP cells
Cytotoxicity against human LNCAP cells
|
[PMID: 20936874] |
| LNCaP | IC50 |
1.7 μg/mL
Compound: PTX
|
Cytotoxicity against human LNCAP cells assessed as inhibition of cell viability after 48 hrs by MTT assay
Cytotoxicity against human LNCAP cells assessed as inhibition of cell viability after 48 hrs by MTT assay
|
[PMID: 24794748] |
| LNCaP | IC50 |
1.9 nM
Compound: Taxol
|
Antiproliferative activity against human LNCAP cells after 72 hrs by phosphatase assay
Antiproliferative activity against human LNCAP cells after 72 hrs by phosphatase assay
|
[PMID: 28857558] |
| LNCaP | IC50 |
20.96 μM
Compound: Paclitaxel
|
Cytotoxicity against human LNCAP cells assessed as inhibition of cell viability after 48 hrs by SRB assay
Cytotoxicity against human LNCAP cells assessed as inhibition of cell viability after 48 hrs by SRB assay
|
[PMID: 30798081] |
| LNCaP | CC50 |
1.4 nM
Compound: Ptxl; PTX
|
Cytotoxicity against PSMA-positive human LNCAP cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
Cytotoxicity against PSMA-positive human LNCAP cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
|
[PMID: 31248772] |
| LNCaP | IC50 |
0.058 μM
Compound: PTX
|
Cytotoxicity against human LNCaP cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
Cytotoxicity against human LNCaP cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
|
[PMID: 37201429] |
| LoVo | IC50 |
90 nM
Compound: 1
|
Cytotoxicity against human LoVo cells in presence of beta-glucuronidase
Cytotoxicity against human LoVo cells in presence of beta-glucuronidase
|
[PMID: 17419065] |
| LOX IMVI | IC50 |
17.3 nM
Compound: Placlitaxel (TAXOL)
|
Inhibitory concentration against Lox melanoma cells
Inhibitory concentration against Lox melanoma cells
|
[PMID: 15341492] |
| LOX IMVI | GI50 |
0.016 μM
Compound: 1a, PXL, Taxol
|
Cytotoxicity against human LOXIMVI cells
Cytotoxicity against human LOXIMVI cells
|
[PMID: 23725535] |
| LOX IMVI | GI50 |
5 nM
Compound: Paclitaxel
|
Growth inhibition of human LOXIMVI cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human LOXIMVI cells incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 29655610] |
| LOX IMVI | GI50 |
5 nM
Compound: Paclitaxel
|
Cytotoxicity against human LOX IMVI cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay
Cytotoxicity against human LOX IMVI cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay
|
[PMID: 33310545] |
| LS174T | IC50 |
9.5 nM
Compound: Taxol
|
Antiproliferative activity against human LS174T cells after 72 hrs by phosphatase assay
Antiproliferative activity against human LS174T cells after 72 hrs by phosphatase assay
|
[PMID: 28857558] |
| LS180 | IC50 |
2.8 nM
Compound: Paclitaxel
|
Cytotoxicity against human LS180 cells after 48 hrs by MTT assay
Cytotoxicity against human LS180 cells after 48 hrs by MTT assay
|
[PMID: 29373791] |
| LT12 tumor cell line | IC50 |
0.006 μM
Compound: Paclitaxel
|
Antiproliferative activity against rat LT12 cells after 48 hrs by XTT assay
Antiproliferative activity against rat LT12 cells after 48 hrs by XTT assay
|
[PMID: 21705223] |
| Lu1 | IC50 |
0.01 μM
Compound: 1
|
Cytotoxicity against human Lu1 cells after 72 hrs by SRB assay
Cytotoxicity against human Lu1 cells after 72 hrs by SRB assay
|
[PMID: 12088425] |
| Lu1 | ED50 |
2 nM
Compound: paclitaxel
|
Cytotoxicity against human Lu1 cells
Cytotoxicity against human Lu1 cells
|
[PMID: 15043407] |
| Lu1 | ED50 |
>10 μM
Compound: Paclitaxel
|
Cytotoxicity against human Lu1 cells after 2 days by sulforhodamine B assay
Cytotoxicity against human Lu1 cells after 2 days by sulforhodamine B assay
|
[PMID: 19026551] |
| LU-99A | IC50 |
5.2 nM
Compound: 28
|
Antiproliferative activity against human LU99A cells after 72 hrs by WST8 assay
Antiproliferative activity against human LU99A cells after 72 hrs by WST8 assay
|
[PMID: 25625617] |
| M14 | IC50 |
0.007 μM
Compound: Paclitaxel
|
Antiproliferative activity against human M14 cells after 72 hrs by CellTiter96 AQueous nonradioactive cell proliferation assay
Antiproliferative activity against human M14 cells after 72 hrs by CellTiter96 AQueous nonradioactive cell proliferation assay
|
[PMID: 28335606] |
| M14 | GI50 |
5 nM
Compound: Paclitaxel
|
Growth inhibition of human M14 cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human M14 cells incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 29655610] |
| M14 | IC50 |
1.3 nM
Compound: Paclitaxel
|
Antiproliferative activity against human M14 cells measured after 72 hrs by MTS assay
Antiproliferative activity against human M14 cells measured after 72 hrs by MTS assay
|
[PMID: 31860298] |
| M14 | GI50 |
5 nM
Compound: Paclitaxel
|
Cytotoxicity against human M14 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay
Cytotoxicity against human M14 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay
|
[PMID: 33310545] |
| M14 | IC50 |
0.5 nM
Compound: Paclitaxel
|
Cytotoxicity against human M14 cells measured after 72 hrs by western blot
Cytotoxicity against human M14 cells measured after 72 hrs by western blot
|
[PMID: 34378386] |
| M14 | IC50 |
186.3 nM
Compound: Paclitaxel
|
Cytotoxicity against paclitaxel resistant human M14 cells measured after 72 hrs by western blot
Cytotoxicity against paclitaxel resistant human M14 cells measured after 72 hrs by western blot
|
[PMID: 34378386] |
| M14 | IC50 |
1.3 nM
Compound: Paclitaxel
|
Antiproliferative activity against human M14 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTS assay
Antiproliferative activity against human M14 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTS assay
|
[PMID: 34406768] |
| M19-MEL | IC50 |
<3 ng/mL
Compound: 1 (paclitaxel)
|
Cytotoxicity against M19 Tumor cell line in SRB Cell viability test
Cytotoxicity against M19 Tumor cell line in SRB Cell viability test
|
[PMID: 10956217] |
| M21 | GI50 |
0.037 μM
Compound: paclitaxel
|
Growth inhibition of human M21 cells after 48 hrs
Growth inhibition of human M21 cells after 48 hrs
|
[PMID: 17498960] |
| M21 | GI50 |
0.037 μM
Compound: paclitaxel
|
Antiproliferative activity against human M21 cells
Antiproliferative activity against human M21 cells
|
[PMID: 18502639] |
| M21 | GI50 |
0.037 μM
Compound: Paclitaxel
|
Growth inhibition of human M21 cells after 48 hrs by sulforhodamine B assay
Growth inhibition of human M21 cells after 48 hrs by sulforhodamine B assay
|
[PMID: 18579387] |
| M21 | GI50 |
0.037 μM
Compound: Pac
|
Antiproliferative activity against human M21 cells after 48 hrs by sulforhodamine B method
Antiproliferative activity against human M21 cells after 48 hrs by sulforhodamine B method
|
[PMID: 18617414] |
| Malme-3M | GI50 |
50 nM
Compound: Paclitaxel
|
Growth inhibition of human MALME-3M cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human MALME-3M cells incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 29655610] |
| Malme-3M | GI50 |
50 nM
Compound: Paclitaxel
|
Cytotoxicity against human Malme-3M cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay
Cytotoxicity against human Malme-3M cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay
|
[PMID: 33310545] |
| MCF-10A | IC50 |
427 μM
Compound: Paclitaxel
|
Cytotoxicity against human MCF10A cells assessed as growth inhibition after 72 hrs by MTT assay
Cytotoxicity against human MCF10A cells assessed as growth inhibition after 72 hrs by MTT assay
|
[PMID: 24044895] |
| MCF-10A | IC50 |
14.3 μM
Compound: 1
|
Cytotoxicity against human MCF10A cells assessed as inhibition of cell proliferation
Cytotoxicity against human MCF10A cells assessed as inhibition of cell proliferation
|
[PMID: 25466201] |
| MCF-10A | IC50 |
38 μM
Compound: Pacli
|
Cytotoxicity against human MCF10A cells after 48 hrs by MTT assay
Cytotoxicity against human MCF10A cells after 48 hrs by MTT assay
|
[PMID: 25563891] |
| MCF-10A | IC50 |
0.0058 μM
Compound: Paclitaxel
|
Cytotoxicity against human MCF10A cells assessed as decrease in cell viability after 72 hrs by CellTiter-Glo luminescence assay
Cytotoxicity against human MCF10A cells assessed as decrease in cell viability after 72 hrs by CellTiter-Glo luminescence assay
|
[PMID: 28926237] |
| MCF-10A | IC50 |
>10 μM
Compound: Paclitaxel
|
Antiproliferative activity against human MCF-10A cells assessed as cell growth inhibition measured after 48 hrs by MTS assay
Antiproliferative activity against human MCF-10A cells assessed as cell growth inhibition measured after 48 hrs by MTS assay
|
[PMID: 35737669] |
| MCF-10A | IC50 |
7.82 μM
Compound: Taxol
|
Cytotoxicity against human MCF-10A cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
Cytotoxicity against human MCF-10A cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
|
[PMID: 39044437] |
| MCF7 | GI50 |
0.0011 μM
Compound: Paclitaxel
|
Cytotoxic activity against human breast tumor-derived MCF-7 cell lines
Cytotoxic activity against human breast tumor-derived MCF-7 cell lines
|
[PMID: 10406652] |
| MCF7 | IC50 |
1.7 nM
Compound: Paclitaxel
|
Inhibitory activity against the growth of MCF-7 (human breast carcinoma) cell line after 72 hours of drug exposure
Inhibitory activity against the growth of MCF-7 (human breast carcinoma) cell line after 72 hours of drug exposure
|
[PMID: 10617084] |
| MCF7 | IC50 |
300 nM
Compound: Paclitaxel
|
Inhibitory activity against the growth of MCF-7R ( multi drug resistant human breast carcinoma) cell line after 72 hours of drug exposure
Inhibitory activity against the growth of MCF-7R ( multi drug resistant human breast carcinoma) cell line after 72 hours of drug exposure
|
[PMID: 10617084] |
| MCF7 | IC50 |
<3 ng/mL
Compound: 1 (paclitaxel)
|
Cytotoxicity against MCF-7 Tumor cell line in SRB Cell viability test
Cytotoxicity against MCF-7 Tumor cell line in SRB Cell viability test
|
[PMID: 10956217] |
| MCF7 | IC50 |
2 nM
Compound: Taxol
|
Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay
Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay
|
[PMID: 11325226] |
| MCF7 | ED50 |
4 nM
Compound: 1a (Taxol)
|
Cytotoxicity against MCF-7 cells with reference to taxol
Cytotoxicity against MCF-7 cells with reference to taxol
|
[PMID: 11334567] |
| MCF7 | IC50 |
>6 μM
Compound: 1a (Paclitaxel)
|
Inhibitory activity against Adriamycin-resistant MCF-7 breast cancer cell line
Inhibitory activity against Adriamycin-resistant MCF-7 breast cancer cell line
|
[PMID: 12031338] |
| MCF7 | IC50 |
0.0055 μM
Compound: 1a (Paclitaxel)
|
Inhibitory activity against MCF-7 breast cancer cell line
Inhibitory activity against MCF-7 breast cancer cell line
|
[PMID: 12031338] |
| MCF7 | IC50 |
0.02 μM
Compound: 1
|
Cytotoxicity against human MCF7 cells after 72 hrs by SRB assay
Cytotoxicity against human MCF7 cells after 72 hrs by SRB assay
|
[PMID: 12088425] |
| MCF7 | IC50 |
0.5 nM
Compound: Paclitaxel
|
Cytotoxicity expressed as concentration required to inhibit cell growth by 50% on continuous exposure time of 96h in MCF-7 cell line by MTT assay.
Cytotoxicity expressed as concentration required to inhibit cell growth by 50% on continuous exposure time of 96h in MCF-7 cell line by MTT assay.
|
[PMID: 12392737] |
| MCF7 | IC50 |
2.87 nM
Compound: Paclitaxel
|
Cytotoxicity expressed as concentration required to inhibit cell growth by 50% on continuous exposure time of 72 hr in MCF-7 cell line by MTT assay.
Cytotoxicity expressed as concentration required to inhibit cell growth by 50% on continuous exposure time of 72 hr in MCF-7 cell line by MTT assay.
|
[PMID: 12392737] |
| MCF7 | IC50 |
1.7 nM
Compound: Paclitaxel
|
In vitro cytotoxicity of compound against human MCF-7 (breast) cancer cell line after 72 hr of drug exposure
In vitro cytotoxicity of compound against human MCF-7 (breast) cancer cell line after 72 hr of drug exposure
|
[PMID: 12477344] |
| MCF7 | IC50 |
0.0001 μg/mL
Compound: (22) taxol
|
In vitro cytotoxicity of compound against MCF7, human breast cancer was defined by microculture tetrazolium assay
In vitro cytotoxicity of compound against MCF7, human breast cancer was defined by microculture tetrazolium assay
|
[PMID: 12620075] |
| MCF7 | IC50 |
0.04 μM
Compound: Paclitaxel
|
In vitro inhibitory concentration of compound against human cancer MACL MCF-7 cell line was determined
In vitro inhibitory concentration of compound against human cancer MACL MCF-7 cell line was determined
|
[PMID: 12882225] |
| MCF7 | IC50 |
1.7 nM
Compound: Taxol
|
In vitro cytotoxicity against MCF-7 cell line
In vitro cytotoxicity against MCF-7 cell line
|
[PMID: 14584931] |
| MCF7 | IC50 |
11.2 nM
Compound: Taxol
|
Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
|
[PMID: 14695798] |
| MCF7 | IC50 |
4.9 nM
Compound: 1
|
Cytotoxicity against human MCF7 cells after 48 hrs by MTS method
Cytotoxicity against human MCF7 cells after 48 hrs by MTS method
|
[PMID: 14987051] |
| MCF7 | IC50 |
1.4 nM
Compound: 1
|
Cytotoxicity against human MCF7 cells after 72 hrs by SRB assay
Cytotoxicity against human MCF7 cells after 72 hrs by SRB assay
|
[PMID: 14987056] |
| MCF7 | IC50 |
354 nM
Compound: 1
|
Cytotoxicity against human multidrug-resistant MCF7 cells after 72 hrs by SRB assay
Cytotoxicity against human multidrug-resistant MCF7 cells after 72 hrs by SRB assay
|
[PMID: 14987056] |
| MCF7 | IC50 |
11.2 nM
Compound: taxol
|
Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
|
[PMID: 15043404] |
| MCF7 | IC50 |
1.7 nM
Compound: 1a Paclitaxel
|
Compound was tested for its cytotoxicity by inhibiting the growth of MCF-7 cell line after 72 h
Compound was tested for its cytotoxicity by inhibiting the growth of MCF-7 cell line after 72 h
|
[PMID: 15225730] |
| MCF7 | IC50 |
0.8 μM
Compound: 1
|
inhibitory concentration against the growth of breast cancer MCF-7 cell line after 72 hr of exposure
inhibitory concentration against the growth of breast cancer MCF-7 cell line after 72 hr of exposure
|
[PMID: 15501062] |
| MCF7 | GI50 |
0.01 μM
Compound: Paclitaxel
|
Compound was tested for growth inhibition of MCF-7 cell line (non multidrug resistant)
Compound was tested for growth inhibition of MCF-7 cell line (non multidrug resistant)
|
[PMID: 15546733] |
| MCF7 | IC50 |
0.00125 μg/mL
Compound: Paclitaxel
|
Inhibitory concentration required to inhibit MCF-7 Cell line growth on continuous exposure time of 72 h
Inhibitory concentration required to inhibit MCF-7 Cell line growth on continuous exposure time of 72 h
|
[PMID: 15664868] |
| MCF7 | IC50 |
0.14 μg/mL
Compound: Taxol
|
Cytotoxicity against human MCF7 cells
Cytotoxicity against human MCF7 cells
|
[PMID: 16038548] |
| MCF7 | IC50 |
0.6 nM
Compound: 1
|
Cytotoxic potency in MCF7 human mammary carcinoma cell line after 72 hr exposure by SRB test
Cytotoxic potency in MCF7 human mammary carcinoma cell line after 72 hr exposure by SRB test
|
[PMID: 16183281] |
| MCF7 | ED50 |
3.23 nM
Compound: 1
|
Cytotoxicity against human breast cancer MCF7 cell line
Cytotoxicity against human breast cancer MCF7 cell line
|
[PMID: 16289636] |
| MCF7 | IC50 |
0.005 μg/mL
Compound: taxol
|
Cytotoxicity against MCF7 cell line by MTT assay
Cytotoxicity against MCF7 cell line by MTT assay
|
[PMID: 16297622] |
| MCF7 | IC50 |
0.019 μM
Compound: paclitaxel
|
Cytotoxicity against human MCF7 cell line
Cytotoxicity against human MCF7 cell line
|
[PMID: 16420032] |
| MCF7 | IC50 |
<0.015 μM
Compound: 1
|
Antiproliferative activity against human MCF7 cell line by MTT assay after 72 hrs
Antiproliferative activity against human MCF7 cell line by MTT assay after 72 hrs
|
[PMID: 16513344] |
| MCF7 | IC50 |
0.043 μM
Compound: 1
|
Antiproliferative activity against human MCF7 cell line by MTT assay after 1 hr
Antiproliferative activity against human MCF7 cell line by MTT assay after 1 hr
|
[PMID: 16513344] |
| MCF7 | IC50 |
0.007 μM
Compound: Taxol
|
Cytotoxicity against human MCF7 cells by MTT assay
Cytotoxicity against human MCF7 cells by MTT assay
|
[PMID: 16539377] |
| MCF7 | EC50 |
0.036 μM
Compound: PXL
|
Cytotoxicity against human MCF7 cells
Cytotoxicity against human MCF7 cells
|
[PMID: 16870428] |
| MCF7 | IC50 |
0.0019 μM
Compound: paclitaxel
|
Antitumor activity against human MCF7 cell line
Antitumor activity against human MCF7 cell line
|
[PMID: 16884301] |
| MCF7 | IC50 |
0.0005 μM
Compound: paclitaxel
|
Cytotoxicity against human MCF7 cells
Cytotoxicity against human MCF7 cells
|
[PMID: 17113288] |
| MCF7 | ED50 |
1.1 nM
Compound: 1
|
Cytotoxicity against human MCF7 cells by sulforhodamine B assay
Cytotoxicity against human MCF7 cells by sulforhodamine B assay
|
[PMID: 17350834] |
| MCF7 | ED50 |
0.05 μg/mL
Compound: 1
|
Cytotoxicity against ERalpha positive human MCF7 cells
Cytotoxicity against ERalpha positive human MCF7 cells
|
[PMID: 17419065] |
| MCF7 | IC50 |
<3 ng/mL
Compound: 1
|
Cytotoxicity against human MCF7 cells
Cytotoxicity against human MCF7 cells
|
[PMID: 17419065] |
| MCF7 | IC50 |
4.9 nM
Compound: 1
|
Cytotoxicity against ERalpha positive human MCF7 cells
Cytotoxicity against ERalpha positive human MCF7 cells
|
[PMID: 17419065] |
| MCF7 | GI50 |
0.054 μM
Compound: paclitaxel
|
Growth inhibition of human MCF7 cells after 48 hrs
Growth inhibition of human MCF7 cells after 48 hrs
|
[PMID: 17498960] |
| MCF7 | IC50 |
2.5 nM
Compound: paclitaxel
|
Growth inhibition of Pgp deficient MCF7 cells expressing MRP1
Growth inhibition of Pgp deficient MCF7 cells expressing MRP1
|
[PMID: 17567121] |
| MCF7 | IC50 |
0.0018 μM
Compound: Paclitaxel
|
Inhibition of serum-induced proliferation of human MCF7 cells
Inhibition of serum-induced proliferation of human MCF7 cells
|
[PMID: 17601739] |
| MCF7 | IC50 |
8.2 μM
Compound: Paclitaxel
|
Inhibition of serum-induced proliferation of human adriamycin-resistant MCF7 cells
Inhibition of serum-induced proliferation of human adriamycin-resistant MCF7 cells
|
[PMID: 17601739] |
| MCF7 | IC50 |
12.4 nM
Compound: Paclitaxel
|
Cytotoxicity against human MCF7 cells by MTT assay
Cytotoxicity against human MCF7 cells by MTT assay
|
[PMID: 17764148] |
| MCF7 | IC50 |
0.007 μM
Compound: taxol
|
Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay
Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay
|
[PMID: 17915851] |
| MCF7 | IC50 |
0.008 μg/mL
Compound: Paclitaxel
|
Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
|
[PMID: 17950495] |
| MCF7 | IC50 |
1.17 x 10-2 μM
Compound: paclitaxel
|
Cytotoxicity against human MCF7 cells after 3 days by MTT assay
Cytotoxicity against human MCF7 cells after 3 days by MTT assay
|
[PMID: 18419154] |
| MCF7 | IC50 |
1.7 nM
Compound: paclitaxel
|
Cytotoxicity against Pgp deficient human MCF7 cells after 72 hrs by sulforhodamine B test
Cytotoxicity against Pgp deficient human MCF7 cells after 72 hrs by sulforhodamine B test
|
[PMID: 18465846] |
| MCF7 | GI50 |
0.054 μM
Compound: paclitaxel
|
Antiproliferative activity against human MCF7 cells
Antiproliferative activity against human MCF7 cells
|
[PMID: 18502639] |
| MCF7 | GI50 |
0.054 μM
Compound: Paclitaxel
|
Growth inhibition of human MCF7 cells after 48 hrs by sulforhodamine B assay
Growth inhibition of human MCF7 cells after 48 hrs by sulforhodamine B assay
|
[PMID: 18579387] |
| MCF7 | IC50 |
0.006 μM
Compound: taxol
|
Cytotoxicity against human MCF7 cells after 24 hrs by MTT assay
Cytotoxicity against human MCF7 cells after 24 hrs by MTT assay
|
[PMID: 18586491] |
| MCF7 | GI50 |
0.054 μM
Compound: Pac
|
Antiproliferative activity against human MCF7 cells after 48 hrs by sulforhodamine B method
Antiproliferative activity against human MCF7 cells after 48 hrs by sulforhodamine B method
|
[PMID: 18617414] |
| MCF7 | EC50 |
0.0072 μg/mL
Compound: Paclitaxel
|
Cytotoxicity against human MCF7 cells
Cytotoxicity against human MCF7 cells
|
[PMID: 18640035] |
| MCF7 | IC50 |
2.98 μM
Compound: paclitaxel
|
Cytotoxicity against human MCF7 cells
Cytotoxicity against human MCF7 cells
|
[PMID: 18701281] |
| MCF7 | ED50 |
3.2 nM
Compound: 1
|
Cytotoxicity against human MCF7 cells
Cytotoxicity against human MCF7 cells
|
[PMID: 18926701] |
| MCF7 | ED50 |
2.1 nM
Compound: paclitaxel
|
Cytotoxicity against human MCF7 cells
Cytotoxicity against human MCF7 cells
|
[PMID: 18977659] |
| MCF7 | IC50 |
39 nM
Compound: Paclitaxel
|
Cytotoxicity against human MCF7 cells after 72 hrs by SRB method
Cytotoxicity against human MCF7 cells after 72 hrs by SRB method
|
[PMID: 18990574] |
| MCF7 | ED50 |
>10 μM
Compound: Paclitaxel
|
Cytotoxicity against human MCF7 cells after 2 days by sulforhodamine B assay
Cytotoxicity against human MCF7 cells after 2 days by sulforhodamine B assay
|
[PMID: 19026551] |
| MCF7 | IC50 |
0.1 μM
Compound: Paclitaxel
|
Cytotoxicity against human MCF7 cells after 48 hrs by WST-8 assay
Cytotoxicity against human MCF7 cells after 48 hrs by WST-8 assay
|
[PMID: 19072209] |
| MCF7 | EC50 |
0.0072 μg/mL
Compound: Palitaxel
|
Cytotoxicity against human MCF7 cells after 3 days by sulforhodamine B assay
Cytotoxicity against human MCF7 cells after 3 days by sulforhodamine B assay
|
[PMID: 19193043] |
| MCF7 | IC50 |
1.2 nM
Compound: paclitaxel
|
Cytotoxicity against P-glycoprotein deficient wild type human MCF7 cells after 72 hrs
Cytotoxicity against P-glycoprotein deficient wild type human MCF7 cells after 72 hrs
|
[PMID: 19239240] |
| MCF7 | IC50 |
300 nM
Compound: paclitaxel
|
Cytotoxicity against human MCF7 cells expressing P-glycoprotein after 72 hrs
Cytotoxicity against human MCF7 cells expressing P-glycoprotein after 72 hrs
|
[PMID: 19239240] |
| MCF7 | IC50 |
2.11 μM
Compound: Taxol
|
Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
|
[PMID: 19359185] |
| MCF7 | IC50 |
0.1 μM
Compound: paclitaxel
|
Cytotoxicity against human MCF7 cells after 48 hrs by SRB method
Cytotoxicity against human MCF7 cells after 48 hrs by SRB method
|
[PMID: 19425589] |
| MCF7 | IC50 |
0.08 μM
Compound: Taxol
|
Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay
Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay
|
[PMID: 19467877] |
| MCF7 | IC50 |
3 nM
Compound: Paclitaxel
|
Growth inhibition of human MCF7 cells after 48 hrs by sulforhodamine B assay
Growth inhibition of human MCF7 cells after 48 hrs by sulforhodamine B assay
|
[PMID: 19601594] |
| MCF7 | IC50 |
0.003 μM
Compound: paclitaxel
|
Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay
Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay
|
[PMID: 19743863] |
| MCF7 | IC50 |
0.002 μM
Compound: paclitaxel
|
Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay
Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay
|
[PMID: 19860383] |
| MCF7 | IC50 |
0.021 μM
Compound: Taxol
|
Antiproliferative activity human MCF7 cells after 20 hrs by MTT assay
Antiproliferative activity human MCF7 cells after 20 hrs by MTT assay
|
[PMID: 20149494] |
| MCF7 | IC50 |
29 μM
Compound: 1, paclitaxel
|
Cytotoxicity against human MCF7 cells
Cytotoxicity against human MCF7 cells
|
[PMID: 20302348] |
| MCF7 | IC50 |
1.3 μM
Compound: Paclitaxel
|
Cytotoxicity against human MCF7 cells by MTT assay
Cytotoxicity against human MCF7 cells by MTT assay
|
[PMID: 20627721] |
| MCF7 | IC50 |
1.3 μM
Compound: Paclitaxel
|
Cytotoxicity against human MCF7 cells by MTT assay
Cytotoxicity against human MCF7 cells by MTT assay
|
[PMID: 20716468] |
| MCF7 | IC50 |
0.0044 μM
Compound: Paclitaxel
|
Cytotoxicity against human MCF7 cells after 72 hrs by alamar blue assay
Cytotoxicity against human MCF7 cells after 72 hrs by alamar blue assay
|
[PMID: 20732809] |
| MCF7 | IC50 |
0.002 μM
Compound: Paclitaxel
|
Cytotoxicity against human MCF7 cells after 72 hrs by SRB assay
Cytotoxicity against human MCF7 cells after 72 hrs by SRB assay
|
[PMID: 20800500] |
| MCF7 | IC50 |
0.021 μM
Compound: Taxol
|
Antiproliferative activity against human MCF7 cells after 96 hrs by MTT assay
Antiproliferative activity against human MCF7 cells after 96 hrs by MTT assay
|
[PMID: 20974505] |
| MCF7 | IC50 |
2.11 μM
Compound: Taxol
|
Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
|
[PMID: 21067933] |
| MCF7 | GI50 |
0.003 μM
Compound: Taxol
|
Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay
Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay
|
[PMID: 21115210] |
| MCF7 | IC50 |
0.63 μM
Compound: Taxol
|
Cytotoxicity against human MCF7 cells after 24 hrs by MTT assay
Cytotoxicity against human MCF7 cells after 24 hrs by MTT assay
|
[PMID: 21115212] |
| MCF7 | IC50 |
20.5 nM
Compound: Taxol
|
Antiproliferative activity against human MCF7 cells after 96 hrs by MTT assay
Antiproliferative activity against human MCF7 cells after 96 hrs by MTT assay
|
[PMID: 21296467] |
| MCF7 | ED50 |
>100 nM
Compound: Paclitaxel
|
Antiproliferative activity against human MCF7 cells after 3 days by sulforhodamine B assay
Antiproliferative activity against human MCF7 cells after 3 days by sulforhodamine B assay
|
[PMID: 21296579] |
| MCF7 | IC50 |
6 nM
Compound: Paclitaxel
|
Cytotoxicity against human MCF7 cells assessed as cell viability after 48 hrs by MTT assay
Cytotoxicity against human MCF7 cells assessed as cell viability after 48 hrs by MTT assay
|
[PMID: 21341718] |
| MCF7 | IC50 |
2.11 μM
Compound: Taxol
|
Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
|
[PMID: 21342735] |
| MCF7 | IC50 |
0.002 μM
Compound: Paclitaxel
|
Antiproliferative activity against human MCF7 cells expressing estrogen receptor after 72 hrs by WST-1 assay
Antiproliferative activity against human MCF7 cells expressing estrogen receptor after 72 hrs by WST-1 assay
|
[PMID: 21440449] |
| MCF7 | GI50 |
0.012 μM
Compound: Paclitaxel
|
Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay
Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay
|
[PMID: 21513294] |
| MCF7 | IC50 |
<0.008 μM
Compound: paclitaxel
|
Cytotoxicity against human MCF7 cells after 48 hrs by MTT method
Cytotoxicity against human MCF7 cells after 48 hrs by MTT method
|
[PMID: 21534539] |
| MCF7 | IC50 |
0.0025 μM
Compound: paclitaxel, Taxol
|
Cytotoxic activity against drug-sensitive Pgp-, MRP1-deficient human MCF7 cells after 48 hrs by sulforhodamine B assay in presence of 50 nM vinblastin
Cytotoxic activity against drug-sensitive Pgp-, MRP1-deficient human MCF7 cells after 48 hrs by sulforhodamine B assay in presence of 50 nM vinblastin
|
[PMID: 21680190] |
| MCF7 | IC50 |
1.62 nM
Compound: Paclitaxel
|
Cytotoxicity against human MCF7 cells after 48 hrs by Alamar blue assay
Cytotoxicity against human MCF7 cells after 48 hrs by Alamar blue assay
|
[PMID: 21779519] |
| MCF7 | IC50 |
1.4 x 10-2 μM
Compound: Paclitaxel
|
Cytotoxicity against human MCF7 cells after 72 hrs by MTS assay
Cytotoxicity against human MCF7 cells after 72 hrs by MTS assay
|
[PMID: 21812410] |
| MCF7 | IC50 |
0.91 nM
Compound: (+)-2, 2, taxol
|
Antiproliferative activity against human MCF7 cells after 96 hrs by SRB method
Antiproliferative activity against human MCF7 cells after 96 hrs by SRB method
|
[PMID: 21870795] |
| MCF7 | IC50 |
1.3 μM
Compound: Paclitaxel
|
Cytotoxicity against human MCF7 cells by MTT assay
Cytotoxicity against human MCF7 cells by MTT assay
|
[PMID: 21875764] |
| MCF7 | GI50 |
1.07 μM
Compound: Paclitaxel
|
Cytotoxicity against human MCF7 cells assessed as growth inhibition after 3 days by MTT assay
Cytotoxicity against human MCF7 cells assessed as growth inhibition after 3 days by MTT assay
|
[PMID: 21889341] |
| MCF7 | IC50 |
0.003 μM
Compound: Taxol
|
Cytotoxicity against human MCF7 cells after 24 to 48 hrs by MTT assay
Cytotoxicity against human MCF7 cells after 24 to 48 hrs by MTT assay
|
[PMID: 22222040] |
| MCF7 | IC50 |
0.1 μM
Compound: paclitaxel
|
Cytotoxicity against human MCF7 cells after 96 hrs by MTT assay
Cytotoxicity against human MCF7 cells after 96 hrs by MTT assay
|
[PMID: 22360613] |
| MCF7 | IC50 |
0.006 μM
Compound: taxol
|
Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay
Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay
|
[PMID: 22472045] |
| MCF7 | IC50 |
4.77 μM
Compound: Taxol
|
Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay
Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay
|
[PMID: 22483090] |
| MCF7 | IC50 |
0.9 μM
Compound: paclitaxel
|
Cytotoxicity against human MCF7 cells by MTT assay
Cytotoxicity against human MCF7 cells by MTT assay
|
[PMID: 22691179] |
| MCF7 | IC50 |
15 nM
Compound: Taxol
|
Cytotoxicity against estrogen receptor-positive human MCF7 cells assessed as inhibition of cell proliferation after 24 hrs by MTT assay
Cytotoxicity against estrogen receptor-positive human MCF7 cells assessed as inhibition of cell proliferation after 24 hrs by MTT assay
|
[PMID: 22818081] |
| MCF7 | IC50 |
3 x 10-3 μM
Compound: Paclitaxel
|
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay
|
[PMID: 22871217] |
| MCF7 | GI50 |
0.03 μM
Compound: paclitaxel
|
Growth inhibition of human MCF7 cells
Growth inhibition of human MCF7 cells
|
[PMID: 23167614] |
| MCF7 | IC50 |
77.2 μM
Compound: Taxol
|
Antitumor activity against human MCF7 cells assessed as growth inhibition measured after 48 hrs by MTT assay
Antitumor activity against human MCF7 cells assessed as growth inhibition measured after 48 hrs by MTT assay
|
[PMID: 23313635] |
| MCF7 | IC50 |
<0.008 μM
Compound: Paclitaxel
|
Cytotoxicity against human MCF7 cells assessed as inhibition of cell viability after 48 hrs by MTT assay
Cytotoxicity against human MCF7 cells assessed as inhibition of cell viability after 48 hrs by MTT assay
|
[PMID: 23327668] |
| MCF7 | IC50 |
0.66 μM
Compound: Taxol
|
Cytotoxicity against human MCF7 cells by MTT assay
Cytotoxicity against human MCF7 cells by MTT assay
|
[PMID: 23425970] |
| MCF7 | IC50 |
0.005 μM
Compound: Taxol
|
Cytotoxicity against human MCF7 cells compound treated for 6 hrs measured 48 hrs post washout by MTT assay
Cytotoxicity against human MCF7 cells compound treated for 6 hrs measured 48 hrs post washout by MTT assay
|
[PMID: 23584542] |
| MCF7 | IC50 |
<0.008 μM
Compound: paclitaxel
|
Cytotoxicity against human MCF7 assessed as cell viability measured after 48 hrs by MTT assay
Cytotoxicity against human MCF7 assessed as cell viability measured after 48 hrs by MTT assay
|
[PMID: 23586920] |
| MCF7 | IC50 |
0.1 μM
Compound: Paclitaxel
|
Cytotoxicity against human MCF7 cells after 3 days by MTT assay
Cytotoxicity against human MCF7 cells after 3 days by MTT assay
|
[PMID: 23738539] |
| MCF7 | IC50 |
5 nM
Compound: Taxol
|
Cytotoxicity against human MCF7 cells by MTT assay
Cytotoxicity against human MCF7 cells by MTT assay
|
[PMID: 23806112] |
| MCF7 | IC50 |
<0.008 μM
Compound: paclitaxel
|
Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
|
[PMID: 23819871] |
| MCF7 | GI50 |
0.003 μM
Compound: Taxol
|
Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay
Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay
|
[PMID: 23831811] |
| MCF7 | IC50 |
<0.008 μM
Compound: paclitaxel
|
Antimicrobial activity against human MCF7 cells after 48 hrs by MTT assay
Antimicrobial activity against human MCF7 cells after 48 hrs by MTT assay
|
[PMID: 23957453] |
| MCF7 | IC50 |
0.003 μM
Compound: Paclitaxel, IOUYT
|
Antiproliferative activity against human MCF7 cells assessed as cell viability after 72 hrs by MTT assay
Antiproliferative activity against human MCF7 cells assessed as cell viability after 72 hrs by MTT assay
|
[PMID: 24012378] |
| MCF7 | IC50 |
75.2 μM
Compound: Paclitaxel
|
Cytotoxicity against human MCF7 cells assessed as growth inhibition after 72 hrs by MTT assay
Cytotoxicity against human MCF7 cells assessed as growth inhibition after 72 hrs by MTT assay
|
[PMID: 24044895] |
| MCF7 | IC50 |
0.5 μM
Compound: Paclitaxel
|
Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay
Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay
|
[PMID: 24056146] |
| MCF7 | IC50 |
0.1 μM
Compound: paclitaxel
|
Cytotoxicity against human MCF7 cells assessed as growth inhibition after 72 hrs by MTT assay
Cytotoxicity against human MCF7 cells assessed as growth inhibition after 72 hrs by MTT assay
|
[PMID: 24063567] |
| MCF7 | IC50 |
0.1 μM
Compound: Paclitaxel
|
Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
|
[PMID: 24063582] |
| MCF7 | IC50 |
3.1 μM
Compound: Paclitaxel
|
Cytotoxic activity against human MCF7 cells
Cytotoxic activity against human MCF7 cells
|
[PMID: 24195466] |
| MCF7 | IC50 |
20.5 nM
Compound: Taxol
|
Antiproliferative against human MCF7 cells assessed as cell viability after 96 hrs by MTT assay
Antiproliferative against human MCF7 cells assessed as cell viability after 96 hrs by MTT assay
|
[PMID: 24211639] |
| MCF7 | IC50 |
<0.008 μM
Compound: paclitaxel
|
Cytotoxicity against human MCF7 cells after 48 hrs by MTS assay
Cytotoxicity against human MCF7 cells after 48 hrs by MTS assay
|
[PMID: 24219809] |
| MCF7 | IC50 |
<0.008 μM
Compound: paclitaxel
|
Cytotoxicity against human MCF7 cells after 48 hrs by MTS assay
Cytotoxicity against human MCF7 cells after 48 hrs by MTS assay
|
[PMID: 24256484] |
| MCF7 | IC50 |
7.05 nM
Compound: Paclitaxel
|
Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay
Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay
|
[PMID: 24332858] |
| MCF7 | GI50 |
1.29 nM
Compound: 1, Taxol
|
Growth inhibition of human MCF7 cells by MTT assay
Growth inhibition of human MCF7 cells by MTT assay
|
[PMID: 24405702] |
| MCF7 | IC50 |
<0.008 μM
Compound: Paclitaxel
|
Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
|
[PMID: 24417634] |
| MCF7 | IC50 |
0.61 μg/mL
Compound: Paclitaxel
|
Cytotoxicity against human MCF7 cells after 48 hrs by MTT method
Cytotoxicity against human MCF7 cells after 48 hrs by MTT method
|
[PMID: 24657569] |
| MCF7 | IC50 |
<0.008 μM
Compound: paclitaxel
|
Cytotoxicity against human MCF7 cells assessed as growth inhibition after 48 hrs by MTS assay
Cytotoxicity against human MCF7 cells assessed as growth inhibition after 48 hrs by MTS assay
|
[PMID: 24697496] |
| MCF7 | GI50 |
0.005 μM
Compound: PCT
|
Growth inhibition of human MCF7 cells after 48 hrs by sulforhodamine B assay
Growth inhibition of human MCF7 cells after 48 hrs by sulforhodamine B assay
|
[PMID: 24727464] |
| MCF7 | IC50 |
45 nM
Compound: Paclitaxel
|
Cytotoxicity against human MCF7 cells assessed as growth inhibition after 72 hrs by MTT assay
Cytotoxicity against human MCF7 cells assessed as growth inhibition after 72 hrs by MTT assay
|
[PMID: 24929344] |
| MCF7 | IC50 |
0.33 μM
Compound: Paclitaxel
|
Antiproliferative activity against human MCF7 cells after 24 and 72 hrs by MTT assay
Antiproliferative activity against human MCF7 cells after 24 and 72 hrs by MTT assay
|
[PMID: 24941130] |
| MCF7 | IC50 |
1.5 x 10-3 μM
Compound: paclitaxel
|
Cytotoxicity against human MCF7 cells by MTT assay
Cytotoxicity against human MCF7 cells by MTT assay
|
[PMID: 24960143] |
| MCF7 | IC50 |
0.02581 μM
Compound: Paclitaxel
|
Antiproliferative against human MCF7 cells after 48 hrs by MTT assay
Antiproliferative against human MCF7 cells after 48 hrs by MTT assay
|
[PMID: 24996136] |
| MCF7 | IC50 |
1.7 nM
Compound: Paclitaxel, Taxol
|
Cytotoxicity against human MCF7 cells by MTT assay
Cytotoxicity against human MCF7 cells by MTT assay
|
[PMID: 25047938] |
| MCF7 | IC50 |
0.023 μM
Compound: TAX, Taxol
|
Antiproliferative activity against human MCF7 cells after 48 hrs by SRB method
Antiproliferative activity against human MCF7 cells after 48 hrs by SRB method
|
[PMID: 25061803] |
| MCF7 | IC50 |
7.6 μM
Compound: TAX, Taxol
|
Antiproliferative activity against doxorubicin-resistant human MCF7 cells after 48 hrs by SRB method
Antiproliferative activity against doxorubicin-resistant human MCF7 cells after 48 hrs by SRB method
|
[PMID: 25061803] |
| MCF7 | IC50 |
0.004 μM
Compound: 1, TAX
|
Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay
Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay
|
[PMID: 25084144] |
| MCF7 | IC50 |
0.005 μM
Compound: 1, TAX
|
Cytotoxicity against human MCF7 cells in presence of 10 mM DTT after 48 hrs by SRB assay
Cytotoxicity against human MCF7 cells in presence of 10 mM DTT after 48 hrs by SRB assay
|
[PMID: 25084144] |
| MCF7 | IC50 |
1.8 μM
Compound: Paclitaxel
|
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability
|
[PMID: 25105722] |
| MCF7 | IC50 |
0.2 μM
Compound: Paclitaxel
|
Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay
Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay
|
[PMID: 25176329] |
| MCF7 | IC50 |
132 nM
Compound: taxol
|
Antiproliferative activity against human MCF7 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay
Antiproliferative activity against human MCF7 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay
|
[PMID: 25208345] |
| MCF7 | IC50 |
3.2 μM
Compound: paclitaxel
|
Cytotoxicity against human MCF7 cells after 48 hrs by trypan blue exclusion method
Cytotoxicity against human MCF7 cells after 48 hrs by trypan blue exclusion method
|
[PMID: 25211032] |
| MCF7 | IC50 |
>100 nM
Compound: PXL
|
Antiproliferative activity against human MCF7 cells after 3 days by SRB assay
Antiproliferative activity against human MCF7 cells after 3 days by SRB assay
|
[PMID: 25241925] |
| MCF7 | IC50 |
0.01 μg/mL
Compound: Paclitaxel
|
Anticancer activity against human MCF7 cells after 24 hrs by MTT assay
Anticancer activity against human MCF7 cells after 24 hrs by MTT assay
|
[PMID: 25305717] |
| MCF7 | IC50 |
<0.008 μM
Compound: paclitaxel
|
Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
|
[PMID: 25375202] |
| MCF7 | IC50 |
2.58 μM
Compound: Pacli
|
Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
|
[PMID: 25563891] |
| MCF7 | IC50 |
0.003 μM
Compound: 6
|
Antiproliferative activity against human MCF7 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
Antiproliferative activity against human MCF7 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
|
[PMID: 25682561] |
| MCF7 | IC50 |
0.032 μM
Compound: Taxol
|
Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
|
[PMID: 25728023] |
| MCF7 | IC50 |
1.4 x 10-2 μM
Compound: paclitaxel
|
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability by MTS assay
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability by MTS assay
|
[PMID: 25760674] |
| MCF7 | IC50 |
<0.008 μM
Compound: paclitaxel
|
Cytotoxicity against human MCF7 cells incubated for 48 hrs by MTT assay
Cytotoxicity against human MCF7 cells incubated for 48 hrs by MTT assay
|
[PMID: 25798528] |
| MCF7 | IC50 |
6.2 nM
Compound: Taxol
|
Cytotoxicity against human MCF7 cells assessed as cell viability after 72 hrs by CCK8 assay
Cytotoxicity against human MCF7 cells assessed as cell viability after 72 hrs by CCK8 assay
|
[PMID: 25819096] |
| MCF7 | IC50 |
4.42 mM
Compound: paclitaxel
|
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by SRB colorimetric assay
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by SRB colorimetric assay
|
[PMID: 25856545] |
| MCF7 | IC50 |
<0.008 μM
Compound: Taxol
|
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTT assay
|
[PMID: 25871261] |
| MCF7 | IC50 |
<0.008 μM
Compound: Taxol
|
Cytotoxicity against human MCF7 cells assessed as cell viability after 48 hrs by MTS assay
Cytotoxicity against human MCF7 cells assessed as cell viability after 48 hrs by MTS assay
|
[PMID: 26068802] |
| MCF7 | IC50 |
2.3 μM
Compound: taxol
|
Cytotoxicity against human MCF7 cells after 72 hrs by CCK8 assay
Cytotoxicity against human MCF7 cells after 72 hrs by CCK8 assay
|
[PMID: 26316467] |
| MCF7 | IC50 |
3.99 μM
Compound: Paclitaxel
|
Antiproliferative activity against human MCF7 cells after 72 hrs by SRB assay
Antiproliferative activity against human MCF7 cells after 72 hrs by SRB assay
|
[PMID: 26602827] |
| MCF7 | IC50 |
7.4 nM
Compound: Paclitaxel
|
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay
|
[PMID: 26690274] |
| MCF7 | IC50 |
7.32 nM
Compound: Taxol
|
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay
|
[PMID: 26697718] |
| MCF7 | IC50 |
3.9 nM
Compound: PXL
|
Antiproliferative activity against human MCF7 cells after 3 days by SRB assay
Antiproliferative activity against human MCF7 cells after 3 days by SRB assay
|
[PMID: 26865176] |
| MCF7 | GI50 |
0.075 μg/mL
Compound: Paclitaxel
|
Cytotoxicity against human MCF7 cells after 48 and 72 hrs by MTT assay
Cytotoxicity against human MCF7 cells after 48 and 72 hrs by MTT assay
|
[PMID: 26927426] |
| MCF7 | IC50 |
0.0001 μM
Compound: Taxol
|
Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability measured after 48 hrs by SRB assay
Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability measured after 48 hrs by SRB assay
|
[PMID: 27010926] |
| MCF7 | IC50 |
0.02581 μM
Compound: Paclitaxel
|
Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay
Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay
|
[PMID: 27017265] |
| MCF7 | IC50 |
0.012 μM
Compound: TAX
|
Cytotoxicity against human MCF7 cells assessed as cell viability after 48 hrs by MTT assay
Cytotoxicity against human MCF7 cells assessed as cell viability after 48 hrs by MTT assay
|
[PMID: 27149641] |
| MCF7 | IC50 |
0.0124 μM
Compound: PTX
|
Growth inhibition of human MCF7 cells incubated for 72 hrs by MTT assay
Growth inhibition of human MCF7 cells incubated for 72 hrs by MTT assay
|
[PMID: 27172319] |
| MCF7 | IC50 |
32.3 nM
Compound: Paclitaxel
|
Antiproliferative activity against human MCF7 cells after 24 hrs by MTT assay
Antiproliferative activity against human MCF7 cells after 24 hrs by MTT assay
|
[PMID: 27213819] |
| MCF7 | GI50 |
4.38 nM
Compound: Taxol
|
Cytotoxicity against human MCF7 cells assessed as cell growth inhibition after 72 hrs by CCK-8 assay
Cytotoxicity against human MCF7 cells assessed as cell growth inhibition after 72 hrs by CCK-8 assay
|
[PMID: 27224875] |
| MCF7 | IC50 |
1.25 nM
Compound: PTX
|
Cytotoxicity against human MCF7 cells assessed as cell viability measured after 72 hrs by MTS assay
Cytotoxicity against human MCF7 cells assessed as cell viability measured after 72 hrs by MTS assay
|
[PMID: 27311893] |
| MCF7 | IC50 |
3.1 nM
Compound: PTX
|
Cytotoxicity against human MCF7 cells assessed as cell viability measured after 48 hrs by MTS assay
Cytotoxicity against human MCF7 cells assessed as cell viability measured after 48 hrs by MTS assay
|
[PMID: 27311893] |
| MCF7 | IC50 |
0.2 nM
Compound: Paclitaxel
|
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 96 hrs by MTT assay
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 96 hrs by MTT assay
|
[PMID: 27434426] |
| MCF7 | IC50 |
0.6 x 10-3 μM
Compound: Paclitaxel
|
Cytotoxicity against human MCF7 cells by MTT assay
Cytotoxicity against human MCF7 cells by MTT assay
|
[PMID: 27441892] |
| MCF7 | IC50 |
0.1 μM
Compound: Paclitaxel
|
Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability measured after 72 hrs by MTS assay
Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability measured after 72 hrs by MTS assay
|
[PMID: 27449957] |
| MCF7 | IC50 |
0.06 μM
Compound: Paclitaxel
|
Cytotoxicity activity against human MCF7 cells assessed as growth inhibition measured after 48 hrs by MTT assay
Cytotoxicity activity against human MCF7 cells assessed as growth inhibition measured after 48 hrs by MTT assay
|
[PMID: 27627130] |
| MCF7 | IC50 |
<0.008 μM
Compound: Paclitaxel
|
Cytotoxicity against human MCF7 cells assessed as decrease in cell viability after 48 hrs by MTS assay
Cytotoxicity against human MCF7 cells assessed as decrease in cell viability after 48 hrs by MTS assay
|
[PMID: 27704807] |
| MCF7 | IC50 |
0.1 μM
Compound: Paclitaxel
|
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTT assay
|
[PMID: 27704822] |
| MCF7 | IC50 |
22.75 nM
Compound: Paclitaxel
|
Cytotoxicity against human MCF7 cells assessed as growth inhibition after 48 hrs by SRB assay
Cytotoxicity against human MCF7 cells assessed as growth inhibition after 48 hrs by SRB assay
|
[PMID: 27797192] |
| MCF7 | GI50 |
0.0048 μg/mL
Compound: Paclitaxel
|
Cytotoxicity against human MCF7 cells by MTT assay
Cytotoxicity against human MCF7 cells by MTT assay
|
[PMID: 27914801] |
| MCF7 | IC50 |
0.63 μM
Compound: Taxol
|
Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay
Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay
|
[PMID: 27979593] |
| MCF7 | IC50 |
10.4 nM
Compound: PXL
|
Antiproliferative activity against human MCF7 cells after 72 hrs by SRB assay
Antiproliferative activity against human MCF7 cells after 72 hrs by SRB assay
|
[PMID: 28099003] |
| MCF7 | GI50 |
0.0048 μg/mL
Compound: Paclitaxel
|
Cytotoxicity against human MCF7 cells assessed as growth inhibition after 48 hrs by MTT assay
Cytotoxicity against human MCF7 cells assessed as growth inhibition after 48 hrs by MTT assay
|
[PMID: 28110868] |
| MCF7 | IC50 |
11.4 μM
Compound: Paclitaxel
|
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTT assay
|
[PMID: 28237662] |
| MCF7 | IC50 |
10.4 nM
Compound: Paclitaxel
|
Antiproliferative activity against human MCF7 cells incubated for 72 hrs by SRB assay
Antiproliferative activity against human MCF7 cells incubated for 72 hrs by SRB assay
|
[PMID: 28290698] |
| MCF7 | IC50 |
11.46 nM
Compound: PXL
|
Antiproliferative activity against human MCF7 cells by sulforhodamine B assay
Antiproliferative activity against human MCF7 cells by sulforhodamine B assay
|
[PMID: 28457756] |
| MCF7 | IC50 |
7.3 nM
Compound: Paclitaxel
|
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by CCK-8 assay
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by CCK-8 assay
|
[PMID: 28598633] |
| MCF7 | GI50 |
11.9 nM
Compound: Paclitaxel
|
Cytotoxicity against human MCF7 cells assessed as growth inhibition after 48 hrs by SRB assay
Cytotoxicity against human MCF7 cells assessed as growth inhibition after 48 hrs by SRB assay
|
[PMID: 28653846] |
| MCF7 | IC50 |
<0.008 μM
Compound: Paclitaxel
|
Antiproliferative activity against human MCF7 cells after 48 hrs by MTS assay
Antiproliferative activity against human MCF7 cells after 48 hrs by MTS assay
|
[PMID: 28654256] |
| MCF7 | IC50 |
0.0088 μM
Compound: Paclitaxel
|
Cytotoxicity against human MCF7 cells assessed as decrease in cell viability after 72 hrs by CellTiter-Glo luminescence assay
Cytotoxicity against human MCF7 cells assessed as decrease in cell viability after 72 hrs by CellTiter-Glo luminescence assay
|
[PMID: 28926237] |
| MCF7 | IC50 |
11.4 nM
Compound: Paclitaxel
|
Cytotoxicity against human MCF7 cells after 72 hrs by sulforhodamine B assay
Cytotoxicity against human MCF7 cells after 72 hrs by sulforhodamine B assay
|
[PMID: 29131631] |
| MCF7 | IC50 |
1.428 μM
Compound: Paclitaxel
|
Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay
Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay
|
[PMID: 29223717] |
| MCF7 | IC50 |
<0.008 μM
Compound: Paclitaxel
|
Cytotoxicity against human MCF7 cells after 48 hrs by MTS assay
Cytotoxicity against human MCF7 cells after 48 hrs by MTS assay
|
[PMID: 29286250] |
| MCF7 | IC50 |
8.8 nM
Compound: PXL
|
Antiproliferative activity against human MCF7 cells after 72 hrs by sulforhodamine B assay
Antiproliferative activity against human MCF7 cells after 72 hrs by sulforhodamine B assay
|
[PMID: 29319316] |
| MCF7 | IC50 |
<0.008 μM
Compound: Paclitaxel
|
Cytotoxicity against human MCF7 cells after 48 hrs by MTS assay
Cytotoxicity against human MCF7 cells after 48 hrs by MTS assay
|
[PMID: 29338226] |
| MCF7 | IC50 |
<0.008 μM
Compound: Paclitaxel
|
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTS assay
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTS assay
|
[PMID: 29338260] |
| MCF7 | IC50 |
<0.008 μM
Compound: Paclitaxel
|
Growth inhibition of human MCF7 cells after 48 hrs by MTS assay
Growth inhibition of human MCF7 cells after 48 hrs by MTS assay
|
[PMID: 29412669] |
| MCF7 | IC50 |
2290.87 nM
Compound: Paclitaxel
|
Cytotoxicity against human paclitaxel-resistant MCF7 cells after 72 hrs by MTT assay
Cytotoxicity against human paclitaxel-resistant MCF7 cells after 72 hrs by MTT assay
|
[PMID: 29468872] |
| MCF7 | IC50 |
2.4 x 10-3 μM
Compound: Paclitaxel
|
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by CCK-8 assay
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by CCK-8 assay
|
[PMID: 29648818] |
| MCF7 | IC50 |
6.5 x 10-3 μM
Compound: Paclitaxel
|
Cytotoxicity against human MCF7 cells expressing Oct4-GFP assessed as reduction in cell viability after 72 hrs by CCK-8 assay
Cytotoxicity against human MCF7 cells expressing Oct4-GFP assessed as reduction in cell viability after 72 hrs by CCK-8 assay
|
[PMID: 29648818] |
| MCF7 | GI50 |
4 nM
Compound: Paclitaxel
|
Growth inhibition of human MCF7 cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human MCF7 cells incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 29655610] |
| MCF7 | IC50 |
5.5 nM
Compound: PTX
|
Growth inhibition of human MCF7 cells after 96 hrs by trypan blue exclusion assay
Growth inhibition of human MCF7 cells after 96 hrs by trypan blue exclusion assay
|
[PMID: 29730191] |
| MCF7 | IC50 |
5 nM
Compound: Paclitaxel
|
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTT assay
|
[PMID: 29759727] |
| MCF7 | IC50 |
<0.008 μM
Compound: Taxol
|
Cytotoxicity against human MCF7 cells assessed as decrease in cell viability after 4 days by MTT assay
Cytotoxicity against human MCF7 cells assessed as decrease in cell viability after 4 days by MTT assay
|
[PMID: 29884535] |
| MCF7 | IC50 |
11.2 nM
Compound: PXL
|
Antiproliferative activity against human MCF7 cells after 72 hrs by SRB assay
Antiproliferative activity against human MCF7 cells after 72 hrs by SRB assay
|
[PMID: 30010341] |
| MCF7 | IC50 |
9.6 nM
Compound: Paclitaxol
|
Cytotoxicity against human MCF7 cells after 72 hrs by sulforhodamine B assay
Cytotoxicity against human MCF7 cells after 72 hrs by sulforhodamine B assay
|
[PMID: 30036834] |
| MCF7 | IC50 |
7.52 nM
Compound: PXL
|
Antiproliferative activity against human MCF7 cells after 72 hrs by SRB assay
Antiproliferative activity against human MCF7 cells after 72 hrs by SRB assay
|
[PMID: 30106296] |
| MCF7 | IC50 |
8.37 nM
Compound: PXL
|
Antiproliferative activity against human MCF7 cells after 24 hrs by SRB assay
Antiproliferative activity against human MCF7 cells after 24 hrs by SRB assay
|
[PMID: 30106296] |
| MCF7 | IC50 |
8.54 nM
Compound: PXL
|
Antiproliferative activity against human MCF7 cells after 48 hrs by SRB assay
Antiproliferative activity against human MCF7 cells after 48 hrs by SRB assay
|
[PMID: 30106296] |
| MCF7 | IC50 |
11.5 μM
Compound: Paclitaxel
|
Antiproliferative activity against human MCF7 cells assessed as reduction in cell growth after 72 hrs by sulforhodamine B assay
Antiproliferative activity against human MCF7 cells assessed as reduction in cell growth after 72 hrs by sulforhodamine B assay
|
[PMID: 30189396] |
| MCF7 | IC50 |
0.47 μM
Compound: TAX
|
Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay
Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay
|
[PMID: 30677614] |
| MCF7 | IC50 |
<15 nM
Compound: PTX
|
Cytotoxicity against human MCF7 cells after 72 hrs by SRB assay
Cytotoxicity against human MCF7 cells after 72 hrs by SRB assay
|
[PMID: 30819618] |
| MCF7 | IC50 |
<0.008 μM
Compound: Paclitaxel
|
Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay
Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay
|
[PMID: 30822712] |
| MCF7 | IC50 |
40.37 μM
Compound: Paclitaxel
|
Antiproliferative activity against human MCF7 after 24 hrs by MTT assay
Antiproliferative activity against human MCF7 after 24 hrs by MTT assay
|
[PMID: 30826188] |
| MCF7 | IC50 |
1.17 μM
Compound: PTX
|
Cytotoxicity against human MCF7 cells incubated for 48 hrs by MTT assay
Cytotoxicity against human MCF7 cells incubated for 48 hrs by MTT assay
|
[PMID: 30913525] |
| MCF7 | IC50 |
0.05 μM
Compound: Paclitaxel
|
Cytotoxicity against human MCF7 cells measured after 72 hrs by sulforhodamine B assay
Cytotoxicity against human MCF7 cells measured after 72 hrs by sulforhodamine B assay
|
[PMID: 30920216] |
| MCF7 | IC50 |
0.2 nM
Compound: Taxol
|
Cytotoxicity against human MCF7 cells measured after 48 hrs by MTT assay
Cytotoxicity against human MCF7 cells measured after 48 hrs by MTT assay
|
[PMID: 31050424] |
| MCF7 | IC50 |
11.2 nM
Compound: Paclitaxel
|
Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition after 72 hrs by sulforhodamine B assay
Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition after 72 hrs by sulforhodamine B assay
|
[PMID: 31126820] |
| MCF7 | CC50 |
<20 nM
Compound: Ptxl; PTX
|
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
|
[PMID: 31248772] |
| MCF7 | IC50 |
<0.008 μM
Compound: Paclitaxel
|
Cytotoxicity in human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay
Cytotoxicity in human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay
|
[PMID: 31310115] |
| MCF7 | IC50 |
<0.008 μM
Compound: Paclitaxel
|
Cytotoxicity in human MCF7 cells assessed as reduction in cell viability incubated for 3 days by MTT assay
Cytotoxicity in human MCF7 cells assessed as reduction in cell viability incubated for 3 days by MTT assay
|
[PMID: 31390200] |
| MCF7 | IC50 |
0.0033 μM
Compound: Paclitaxel
|
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 68 hrs by MTT assay
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 68 hrs by MTT assay
|
[PMID: 31404864] |
| MCF7 | IC50 |
12.06 nM
Compound: PXL
|
Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
|
[PMID: 31541869] |
| MCF7 | GI50 |
<0.01 μM
Compound: Paciltaxel
|
Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by SRB assay
Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by SRB assay
|
[PMID: 31546197] |
| MCF7 | IC50 |
>10 μM
Compound: Paclitaxel
|
Antiproliferative activity against human MCF7 cells incubated for 72 hrs by SRB assay
Antiproliferative activity against human MCF7 cells incubated for 72 hrs by SRB assay
|
[PMID: 31718182] |
| MCF7 | GI50 |
8.3 nM
Compound: Paclitaxel
|
Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
|
[PMID: 31938468] |
| MCF7 | IC50 |
>40 μM
Compound: Paclitaxel
|
Anticancer activity against human MCF7 cells
Anticancer activity against human MCF7 cells
|
[PMID: 31945642] |
| MCF7 | IC50 |
3 x 10-3 μM
Compound: Taxol
|
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability
|
[PMID: 32273216] |
| MCF7 | IC50 |
<0.008 μM
Compound: Paclitaxel
|
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTT assay
|
[PMID: 32628478] |
| MCF7 | IC50 |
0.004 μM
Compound: PTX
|
Antiproliferative activity against human MCF7 cells assessed as inhibition of cell proliferation measured after 48 hrs by CCK-8 assay
Antiproliferative activity against human MCF7 cells assessed as inhibition of cell proliferation measured after 48 hrs by CCK-8 assay
|
[PMID: 32650183] |
| MCF7 | IC50 |
0.0025 μM
Compound: Paclitaxel
|
Anticancer activity against human MCF7 cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay
Anticancer activity against human MCF7 cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay
|
[PMID: 32731188] |
| MCF7 | IC50 |
13.5 nM
Compound: Paclitaxel
|
Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by SRB assay
Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by SRB assay
|
[PMID: 32946697] |
| MCF7 | GI50 |
2.76 nM
Compound: Taxol
|
Antiproliferative activity against human MCF-7 cells assessed as inhibition of cell growth after 72 hrs by CCK8 assay
Antiproliferative activity against human MCF-7 cells assessed as inhibition of cell growth after 72 hrs by CCK8 assay
|
[PMID: 33239261] |
| MCF7 | IC50 |
6.6 nM
Compound: PTX
|
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay
|
[PMID: 33280896] |
| MCF7 | GI50 |
4 nM
Compound: Paclitaxel
|
Cytotoxicity against human MCF7 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay
Cytotoxicity against human MCF7 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay
|
[PMID: 33310545] |
| MCF7 | IC50 |
0.09 μM
Compound: Taxol
|
Anticancer activity against human MCF7 cells by MTT assay
Anticancer activity against human MCF7 cells by MTT assay
|
[PMID: 33316408] |
| MCF7 | IC50 |
5.1 μM
Compound: PTX
|
Cytotoxicity against human MCF7 cells assessed as cell growth inhibition measured after 24 hrs by MTT assay
Cytotoxicity against human MCF7 cells assessed as cell growth inhibition measured after 24 hrs by MTT assay
|
[PMID: 33381964] |
| MCF7 | IC50 |
0.003 μM
Compound: Taxol
|
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by Hoechst-33342 staining based cell counting method (Rvb > 25 microM)
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by Hoechst-33342 staining based cell counting method (Rvb > 25 microM)
|
[PMID: 33422908] |
| MCF7 | IC50 |
2.1 μM
Compound: Paclitaxel
|
Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay
Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay
|
[PMID: 33587631] |
| MCF7 | EC50 |
194.2 nM
Compound: Paclitaxel
|
Antiproliferative activity against human MCF7 cells
Antiproliferative activity against human MCF7 cells
|
[PMID: 33705908] |
| MCF7 | EC50 |
2065.8 nM
Compound: Paclitaxel
|
Antiproliferative activity against human MCF7 cells expressing TUBB3
Antiproliferative activity against human MCF7 cells expressing TUBB3
|
[PMID: 33705908] |
| MCF7 | GI50 |
0.0021 μg/mL
Compound: Paclitaxel
|
Cytotoxicity against human MCF7 cells assessed as cell growth inhibition
Cytotoxicity against human MCF7 cells assessed as cell growth inhibition
|
[PMID: 33826327] |
| MCF7 | IC50 |
0.015 μg/mL
Compound: Taxol
|
Cytotoxicity against human MCF7 cells assessed as cell growth inhibition by MTT assay
Cytotoxicity against human MCF7 cells assessed as cell growth inhibition by MTT assay
|
[PMID: 34000484] |
| MCF7 | IC50 |
0.42 μM
Compound: PTX
|
Cytotoxicity activity against human MCF7 cells assessed as reduction in cell viability incubated for 24 hrs in presence of 100 uM photoCORM delivered CO by MTT assay
Cytotoxicity activity against human MCF7 cells assessed as reduction in cell viability incubated for 24 hrs in presence of 100 uM photoCORM delivered CO by MTT assay
|
[PMID: 34097831] |
| MCF7 | IC50 |
0.56 μM
Compound: PTX
|
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 24 hrs in presence of 20 uM chloramphenicol by MTT assay
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 24 hrs in presence of 20 uM chloramphenicol by MTT assay
|
[PMID: 34097831] |
| MCF7 | IC50 |
0.57 μM
Compound: PTX
|
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 24 hrs in presence of 10 uM chloramphenicol by MTT assay
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 24 hrs in presence of 10 uM chloramphenicol by MTT assay
|
[PMID: 34097831] |
| MCF7 | IC50 |
0.63 μM
Compound: PTX
|
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 24 hrs in presence of 50 uM photoCORM delivered CO by MTT assay
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 24 hrs in presence of 50 uM photoCORM delivered CO by MTT assay
|
[PMID: 34097831] |
| MCF7 | IC50 |
71 μM
Compound: PTX
|
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 24 hrs in absence of chloramphenicol by MTT assay
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 24 hrs in absence of chloramphenicol by MTT assay
|
[PMID: 34097831] |
| MCF7 | IC50 |
90 μM
Compound: PTX
|
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 24 hrs in absence of photoCORM delivered CO by MTT assay
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 24 hrs in absence of photoCORM delivered CO by MTT assay
|
[PMID: 34097831] |
| MCF7 | IC50 |
0.48 μM
Compound: Paclitaxel
|
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
|
[PMID: 34153643] |
| MCF7 | IC50 |
0.0633 μM
Compound: Paclitaxel
|
Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
|
[PMID: 34171512] |
| MCF7 | IC50 |
0.008 μM
Compound: Paclitaxel
|
Antiproliferative activity against human MCF7 assessed as reduction in cell viability measured after 48 hrs by MTT assay
Antiproliferative activity against human MCF7 assessed as reduction in cell viability measured after 48 hrs by MTT assay
|
[PMID: 34175541] |
| MCF7 | IC50 |
<0.008 μM
Compound: Paclitaxel
|
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay
|
[PMID: 34355562] |
| MCF7 | IC50 |
<0.01 μM
Compound: Taxol
|
Anticancer activity against human MCF7 cells assessed as inhibition of cell proliferation measured after 72 hrs by CCK8 reagent assay
Anticancer activity against human MCF7 cells assessed as inhibition of cell proliferation measured after 72 hrs by CCK8 reagent assay
|
[PMID: 34399390] |
| MCF7 | IC50 |
0.015 μM
Compound: Paclitaxel
|
Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability measured after 72 hrs by SRB assay
Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability measured after 72 hrs by SRB assay
|
[PMID: 34403728] |
| MCF7 | IC50 |
0.03 μM
Compound: PTX
|
Cytotoxicity against human MCF7 cells expressing TLR4 assessed as reduction in cell viability measured after 96 hrs by MTT assay
Cytotoxicity against human MCF7 cells expressing TLR4 assessed as reduction in cell viability measured after 96 hrs by MTT assay
|
[PMID: 34600241] |
| MCF7 | IC50 |
0.35 μM
Compound: Paclitaxel
|
Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTT assay
|
[PMID: 34671737] |
| MCF7 | IC50 |
>81.1 x 10-3 μM
Compound: Taxol
|
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay
|
[PMID: 34883453] |
| MCF7 | GI50 |
7.1 nM
Compound: Paclitaxel
|
Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition measured after 72 hrs by SRB assay
Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition measured after 72 hrs by SRB assay
|
[PMID: 34917259] |
| MCF7 | IC50 |
0.032 μM
Compound: Paclitaxel
|
Antiproliferative activity against human MCF7 cells by CCK8 assay
Antiproliferative activity against human MCF7 cells by CCK8 assay
|
[PMID: 34922028] |
| MCF7 | IC50 |
32.3 nM
Compound: PTX
|
Cytotoxicity in human MCF7 assessed as inhibition in cell growth measured after 24 hrs by MTT assay
Cytotoxicity in human MCF7 assessed as inhibition in cell growth measured after 24 hrs by MTT assay
|
[PMID: 35084853] |
| MCF7 | EC50 |
44.72 μM
Compound: Taxol
|
Antiproliferative activity against cisplatin-resistant human MCF7-CR cells assessed as reduction in cell viability after 24 hrs by MTT assay
Antiproliferative activity against cisplatin-resistant human MCF7-CR cells assessed as reduction in cell viability after 24 hrs by MTT assay
|
[PMID: 35421577] |
| MCF7 | IC50 |
0.012 μM
Compound: PTX
|
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay
|
[PMID: 35447432] |
| MCF7 | IC50 |
0.64 μM
Compound: Paclitaxel; Taxol
|
Antiproliferative activity against human MCF7 cells measured after 48 hrs by MTT assay
Antiproliferative activity against human MCF7 cells measured after 48 hrs by MTT assay
|
[PMID: 35551039] |
| MCF7 | IC50 |
35.7 nM
Compound: Paclitaxel
|
Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition measured after 48 hrs by MTS assay
Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition measured after 48 hrs by MTS assay
|
[PMID: 35737669] |
| MCF7 | IC50 |
6.1 nM
Compound: Paclitaxel
|
Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition incubated for 48 hr by MTT assay
Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition incubated for 48 hr by MTT assay
|
[PMID: 36092142] |
| MCF7 | IC50 |
0.002 μM
Compound: Taxol
|
Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay
Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay
|
[PMID: 36162214] |
| MCF7 | IC50 |
<0.008 μM
Compound: Taxol
|
Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
|
[PMID: 36274275] |
| MCF7 | IC50 |
4.7 μg/mL
Compound: Taxol
|
Cytotoxicity against human MCF7 cells by MTT assay
Cytotoxicity against human MCF7 cells by MTT assay
|
[PMID: 36325400] |
| MCF7 | IC50 |
19.7 nM
Compound: Abraxane
|
Antiproliferative activity against human MCF7 cells measured after 72 hrs by MTT assay
Antiproliferative activity against human MCF7 cells measured after 72 hrs by MTT assay
|
[PMID: 36471625] |
| MCF7 | IC50 |
47.25 μM
Compound: Paclitaxel
|
Anticancer activity against human MCF7 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
Anticancer activity against human MCF7 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
|
[PMID: 36481599] |
| MCF7 | IC50 |
<0.001 μM
Compound: Paclitaxel
|
Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
|
[PMID: 36511661] |
| MCF7 | IC50 |
0.48 μM
Compound: Paclitaxel
|
Antitumor activity against human MCF7 cells assessed as cell viability incubated for 48 hrs by CCK8 assay
Antitumor activity against human MCF7 cells assessed as cell viability incubated for 48 hrs by CCK8 assay
|
[PMID: 36753987] |
| MCF7 | IC50 |
15 nM
Compound: Paclitaxel
|
Anticancer activity against human MCF7 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
Anticancer activity against human MCF7 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
|
[PMID: 37146221] |
| MCF7 | IC50 |
0.55 μM
Compound: Paclitaxel
|
Antitumor activity against human MCF7 cells incubated for 48 hrs by CCK8 assay
Antitumor activity against human MCF7 cells incubated for 48 hrs by CCK8 assay
|
[PMID: 37229830] |
| MCF7 | IC50 |
0.01 μM
Compound: PTX
|
Antiproliferative activity against human MCF7 cells assessed as inhibition of cell proliferation measured after 48 hrs by CCK-8 assay
Antiproliferative activity against human MCF7 cells assessed as inhibition of cell proliferation measured after 48 hrs by CCK-8 assay
|
[PMID: 37395092] |
| MCF7 | IC50 |
0.007 μM
Compound: 2
|
Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay
Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay
|
[PMID: 37856840] |
| MCF7 | IC50 |
0.002 μM
Compound: Taxol
|
Inhibition of cell growth in human MCF7 cells incubated for 72 hrs by SRB method
Inhibition of cell growth in human MCF7 cells incubated for 72 hrs by SRB method
|
[PMID: 38171146] |
| MCF7 | IC50 |
13.4 nM
Compound: PXL
|
Antiproliferative activity against HER2-negative human MCF7 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay
Antiproliferative activity against HER2-negative human MCF7 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay
|
[PMID: 38251859] |
| MCF7 | IC50 |
0.22 μM
Compound: PTX
|
Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
|
[PMID: 38280356] |
| MCF7 | IC50 |
31.5 nM
Compound: PTX
|
Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability measured after 72 hrs
Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability measured after 72 hrs
|
[PMID: 38430854] |
| MCF7 | IC50 |
11 μM
Compound: PXL
|
Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition incubated for 72 hrs by sulforhodamine B assay
Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition incubated for 72 hrs by sulforhodamine B assay
|
[PMID: 38438305] |
| MCF7 | IC50 |
0.02 μM
Compound: PTX
|
Cytotoxicity against human MCF7 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay
Cytotoxicity against human MCF7 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay
|
[PMID: 38547648] |
| MCF7 | IC50 |
28.74 nM
Compound: TAX; PTX
|
Antiproliferation activity against human MCF7 cells measured after 72 hrs incubation by MTT assay
Antiproliferation activity against human MCF7 cells measured after 72 hrs incubation by MTT assay
|
[PMID: 38781920] |
| MCF7 | IC50 |
2.2 nM
Compound: PT
|
Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by CelltiterGlo luminescent assay
Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by CelltiterGlo luminescent assay
|
[PMID: 38959729] |
| MCF7 | IC50 |
12.1 nM
Compound: PXL
|
Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability by SRB assay
Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability by SRB assay
|
[PMID: 38970504] |
| MCF7 | EC50 |
0.005 x 10-3 μM
Compound: Paclitaxel
|
Cytotoxicity against human MCF7 cells incubated for 48 to 72 hrs by MTT assay
Cytotoxicity against human MCF7 cells incubated for 48 to 72 hrs by MTT assay
|
[PMID: 39038808] |
| MCF7 | IC50 |
1.7 nM
Compound: 59
|
Cytotoxicity against human MCF7 cells
Cytotoxicity against human MCF7 cells
|
[PMID: 39068862] |
| MCF7 | IC50 |
1.7 nM
Compound: paclitaxel
|
In vitro cytotoxicity against human mammary carcinoma MCF-7
In vitro cytotoxicity against human mammary carcinoma MCF-7
|
[PMID: 8182698] |
| MCF7 | IC50 |
299 nM
Compound: paclitaxel
|
In vitro cytotoxicity against human mammary carcinoma cells 180 fold resistant to adriamycin MCF7-R
In vitro cytotoxicity against human mammary carcinoma cells 180 fold resistant to adriamycin MCF7-R
|
[PMID: 8182698] |
| MCF7 | IC50 |
1.7 nM
Compound: paclitaxel
|
Concentration required to inhibit growth of human tumor MCF-7 (breast) cell line.
Concentration required to inhibit growth of human tumor MCF-7 (breast) cell line.
|
[PMID: 8831755] |
| MCF7 | IC50 |
299 nM
Compound: paclitaxel
|
Concentration required to inhibit growth of human tumor MFC7-R (breast) cell line.
Concentration required to inhibit growth of human tumor MFC7-R (breast) cell line.
|
[PMID: 8831755] |
| MCF7 | IC50 |
1.7 nM
Compound: Paclitaxel
|
Growth inhibition of human mammary carcinoma (MCF-7) cell line
Growth inhibition of human mammary carcinoma (MCF-7) cell line
|
[PMID: 9022793] |
| MCF7 | IC50 |
1.7 nM
Compound: Paclitaxel
|
Inhibition of the growth against human mammary carcinoma (MCF-7) cell line after 72 hr exposure
Inhibition of the growth against human mammary carcinoma (MCF-7) cell line after 72 hr exposure
|
[PMID: 9022794] |
| MCF7 | GI50 |
1.1 nM
Compound: Paclitaxel
|
Compound was tested in vitro for growth inhibition of MCF-7 cells derived from human breast tumor.
Compound was tested in vitro for growth inhibition of MCF-7 cells derived from human breast tumor.
|
[PMID: 9873597] |
| MCF7 | IC50 |
1.86 μM
Compound: Paclitaxel
|
Cytotoxicity against Homo sapiens (human) MCF7 cells assessed as inhibition of cell proliferation after 24 hr by MTT assay
Cytotoxicity against Homo sapiens (human) MCF7 cells assessed as inhibition of cell proliferation after 24 hr by MTT assay
|
10.1007/s00044-012-0436-9 |
| MCF7 | IC50 |
1.7 nM
Compound: Paclitaxel
|
Cytotoxicity against human breast MCF-7 cancer cell lines
Cytotoxicity against human breast MCF-7 cancer cell lines
|
10.1016/S0960-894X(01)80298-5 |
| MCF7 | IC50 |
300 nM
Compound: Paclitaxel
|
Cytotoxicity against adriamycin resistant human breast MCF-7 cancer cell lines
Cytotoxicity against adriamycin resistant human breast MCF-7 cancer cell lines
|
10.1016/S0960-894X(01)80298-5 |
| MCF7 | IC50 |
1.7 nM
Compound: Paclitaxel
|
Cytotoxicity was evaluated in vitro against MCF-7 (mammary carcinoma) human tumor cell lines
Cytotoxicity was evaluated in vitro against MCF-7 (mammary carcinoma) human tumor cell lines
|
10.1016/S0960-894X(01)80568-0 |
| MCF7 | IC50 |
1.7 nM
Compound: Paclitaxel
|
Cytotoxicity was evaluated against MCF-7 mammary carcinoma human breast cancer cell line
Cytotoxicity was evaluated against MCF-7 mammary carcinoma human breast cancer cell line
|
10.1016/S0960-894X(96)00595-1 |
| MCF7 | IC50 |
4.9 nM
Compound: Paclitaxel
|
Evaluated in vitro for antiproliferative activity against MCF-7 cell lines model of hormone dependent breast cancer
Evaluated in vitro for antiproliferative activity against MCF-7 cell lines model of hormone dependent breast cancer
|
10.1016/S0960-894X(97)10152-4 |
| MCF7 | IC50 |
9.66 μM
Compound: Paclitaxel
|
Cytotoxicity against human MCF7 cells assessed as inhibition of cell proliferation after 96 hrs by MTT assay
Cytotoxicity against human MCF7 cells assessed as inhibition of cell proliferation after 96 hrs by MTT assay
|
10.1039/C4MD00573B |
| MCF7 | GI50 |
0.0048 μg/mL
Compound: Paclitaxel
|
Cytotoxicity against human MCF7 cells incubated for 1 to 11 days by MTT assay
Cytotoxicity against human MCF7 cells incubated for 1 to 11 days by MTT assay
|
10.1039/C5MD00404G |
| MCF7 | IC50 |
13.99 μM
Compound: Taxol
|
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTT assay
|
10.1039/C6MD00234J |
| MCF7 | GI50 |
0.087 mM
Compound: Paclitaxel
|
Cytotoxicity against human MCF7 cells by MTT assay
Cytotoxicity against human MCF7 cells by MTT assay
|
10.1039/C6MD00278A |
| MCF7/PTX | IC50 |
54.8 μM
Compound: PTX
|
Cytotoxicity against human MCF7/PTX cells incubated for 48 hrs by MTT assay
Cytotoxicity against human MCF7/PTX cells incubated for 48 hrs by MTT assay
|
[PMID: 30913525] |
| MCF7-DOX | IC50 |
585 nM
Compound: 1
|
Cytotoxic potency in doxorubicin resistant MCF7 cell line after 72 hr exposure by SRB test
Cytotoxic potency in doxorubicin resistant MCF7 cell line after 72 hr exposure by SRB test
|
[PMID: 16183281] |
| MCF7R | IC50 |
299 nM
Compound: Taxol
|
In vitro cytotoxicity against MCF7-R cell line
In vitro cytotoxicity against MCF7-R cell line
|
[PMID: 14584931] |
| MCF7R | IC50 |
1.185 μM
Compound: Paclitaxel
|
In vitro cytotoxic activity against growth of MDR phenotype human breast carcinoma cell line (MCF-7-R) after 72 hr
In vitro cytotoxic activity against growth of MDR phenotype human breast carcinoma cell line (MCF-7-R) after 72 hr
|
[PMID: 15177459] |
| MCF7R | IC50 |
550 nM
Compound: Paclitaxel
|
Cytotoxicity against human mammary tumor cell line MCF7-R
Cytotoxicity against human mammary tumor cell line MCF7-R
|
[PMID: 16298526] |
| MCF7R | IC50 |
299 nM
Compound: Paclitaxel, Taxol
|
Cytotoxicity against human MCF7/R cells by MTT assay
Cytotoxicity against human MCF7/R cells by MTT assay
|
[PMID: 25047938] |
| MCF7R | IC50 |
0.19 μM
Compound: Paclitaxel
|
Antiproliferative activity against paclitaxel-resistant human MCF7R cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
Antiproliferative activity against paclitaxel-resistant human MCF7R cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
|
[PMID: 36511661] |
| MCF7R | IC50 |
299 nM
Compound: Paclitaxel
|
Growth inhibition of human mammary carcinoma 180 fold resistant to doxorubicin (MCF-7-R) cell line
Growth inhibition of human mammary carcinoma 180 fold resistant to doxorubicin (MCF-7-R) cell line
|
[PMID: 9022793] |
| MCF7R | IC50 |
299 nM
Compound: Paclitaxel
|
Inhibition of the growth against human mammary carcinoma 180 fold resistant to doxorubicin (MCF-7-R) cell line after 72 hr exposure
Inhibition of the growth against human mammary carcinoma 180 fold resistant to doxorubicin (MCF-7-R) cell line after 72 hr exposure
|
[PMID: 9022794] |
| MCF7R | IC50 |
860 nM
Compound: Paclitaxel
|
Cytotoxicity was evaluated in MCF7-R cell line
Cytotoxicity was evaluated in MCF7-R cell line
|
[PMID: 9871652] |
| MCF7R | IC50 |
299 nM
Compound: Paclitaxel
|
Cytotoxicity was evaluated against MCF7-R (mammary carcinoma 180-fold resistant to doxorubicin, expressing MDR phenotype) human breast cancer cell line
Cytotoxicity was evaluated against MCF7-R (mammary carcinoma 180-fold resistant to doxorubicin, expressing MDR phenotype) human breast cancer cell line
|
10.1016/S0960-894X(96)00595-1 |
| MCF7S | IC50 |
0.002 μM
Compound: Paclitaxel
|
In vitro cytotoxic activity against growth of human breast carcinoma cell line (MCF-7-S) after 72 hr
In vitro cytotoxic activity against growth of human breast carcinoma cell line (MCF-7-S) after 72 hr
|
[PMID: 15177459] |
| MCF7S | IC50 |
1.7 nM
Compound: Paclitaxel
|
Cytotoxicity against human mammary tumor cell line MCF7-S
Cytotoxicity against human mammary tumor cell line MCF7-S
|
[PMID: 16298526] |
| MCF7-VP | IC50 |
2.8 nM
Compound: paclitaxel
|
Growth inhibition of Pgp deficient MCF7/VP cells expressing MRP1
Growth inhibition of Pgp deficient MCF7/VP cells expressing MRP1
|
[PMID: 17567121] |
| MCF7-VP | IC50 |
0.0028 μM
Compound: paclitaxel, Taxol
|
Cytotoxic activity against Pgp-deficient human MCF7/VP cells expressing MRP1 after 48 hrs by sulforhodamine B assay
Cytotoxic activity against Pgp-deficient human MCF7/VP cells expressing MRP1 after 48 hrs by sulforhodamine B assay
|
[PMID: 21680190] |
| MDA-MB-231 | IC50 |
4.5 nM
Compound: 1
|
Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTS method
Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTS method
|
[PMID: 14987051] |
| MDA-MB-231 | IC50 |
0.12 μg/mL
Compound: Taxol
|
Cytotoxicity against human MDA-MB-231 cells
Cytotoxicity against human MDA-MB-231 cells
|
[PMID: 16038548] |
| MDA-MB-231 | IC50 |
4.5 nM
Compound: 1
|
Cytotoxicity against ERalpha negative human MDA-MB-231 cells
Cytotoxicity against ERalpha negative human MDA-MB-231 cells
|
[PMID: 17419065] |
| MDA-MB-231 | IC50 |
7.03 x 10-2 μM
Compound: paclitaxel
|
Cytotoxicity against human MDA-MB-231 cells after 3 days by MTT assay
Cytotoxicity against human MDA-MB-231 cells after 3 days by MTT assay
|
[PMID: 18419154] |
| MDA-MB-231 | IC50 |
40.5 nM
Compound: paclitaxel
|
Cytotoxicity against human MDA-MB-231 cells
Cytotoxicity against human MDA-MB-231 cells
|
[PMID: 18606540] |
| MDA-MB-231 | IC50 |
3.9 μg/mL
Compound: PTX
|
Anticancer activity against human MDA-MB-231 cells by MTT assay
Anticancer activity against human MDA-MB-231 cells by MTT assay
|
[PMID: 18826299] |
| MDA-MB-231 | IC50 |
47.1 nM
Compound: Paclitaxel
|
Cytotoxicity against human MDA-MB-231 cells after 72 hrs by SRB method
Cytotoxicity against human MDA-MB-231 cells after 72 hrs by SRB method
|
[PMID: 18990574] |
| MDA-MB-231 | IC50 |
25 μM
Compound: 1, paclitaxel
|
Cytotoxicity against human MDA-MB-231 cells
Cytotoxicity against human MDA-MB-231 cells
|
[PMID: 20302348] |
| MDA-MB-231 | IC50 |
>50 μM
Compound: taxol
|
Cytotoxicity against human MDA-MB-231 after 48 hrs by SRB assay
Cytotoxicity against human MDA-MB-231 after 48 hrs by SRB assay
|
[PMID: 21044847] |
| MDA-MB-231 | IC50 |
9.1 nM
Compound: Pac
|
Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by sulforhodamine B assay
Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by sulforhodamine B assay
|
[PMID: 21604746] |
| MDA-MB-231 | IC50 |
9.1 nM
Compound: Pac
|
Antiproliferative activity against human MDA-MB-231 after 48 hrs by SRB assay
Antiproliferative activity against human MDA-MB-231 after 48 hrs by SRB assay
|
[PMID: 21920638] |
| MDA-MB-231 | IC50 |
5 μM
Compound: Paclitaxel
|
Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by MTT assay
Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by MTT assay
|
[PMID: 22871217] |
| MDA-MB-231 | IC50 |
0.052 μM
Compound: Taxol
|
Cytotoxicity against human MDA-MB-231 cells after 72 hrs by crystal violet staining based microplate reader analysis
Cytotoxicity against human MDA-MB-231 cells after 72 hrs by crystal violet staining based microplate reader analysis
|
[PMID: 23153397] |
| MDA-MB-231 | IC50 |
<1 μM
Compound: Paclitaxel
|
Cytotoxicity against human MDA-MB-231 cells after 72 hrs by SRB assay
Cytotoxicity against human MDA-MB-231 cells after 72 hrs by SRB assay
|
[PMID: 23848163] |
| MDA-MB-231 | IC50 |
87 μM
Compound: Paclitaxel
|
Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 72 hrs by MTT assay
Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 72 hrs by MTT assay
|
[PMID: 24044895] |
| MDA-MB-231 | IC50 |
5.6 nM
Compound: PTX
|
Cytotoxicity against human MDA-MB-231 cells after 72 hrs by MTT assay
Cytotoxicity against human MDA-MB-231 cells after 72 hrs by MTT assay
|
[PMID: 24564494] |
| MDA-MB-231 | IC50 |
8.2 x 10-3 μM
Compound: paclitaxel
|
Cytotoxicity against human MDA-MB-231 cells by MTT assay
Cytotoxicity against human MDA-MB-231 cells by MTT assay
|
[PMID: 24960143] |
| MDA-MB-231 | IC50 |
0.0066 μM
Compound: Paclitaxel
|
Cytotoxicity against human MDA-MB-231 cells after 72 hrs sulforhodamine B colorimetric assay
Cytotoxicity against human MDA-MB-231 cells after 72 hrs sulforhodamine B colorimetric assay
|
[PMID: 25008456] |
| MDA-MB-231 | IC50 |
>7.8 nM
Compound: PXL
|
Antiproliferative activity against human MDA-MB-231 cells after 3 days by SRB assay
Antiproliferative activity against human MDA-MB-231 cells after 3 days by SRB assay
|
[PMID: 25241925] |
| MDA-MB-231 | GI50 |
0.091 μM
Compound: Paclitaxel
|
Growth inhibition of human MDA-MB-231 cells after 48 hrs by SRB assay
Growth inhibition of human MDA-MB-231 cells after 48 hrs by SRB assay
|
[PMID: 25264072] |
| MDA-MB-231 | IC50 |
6.2 μM
Compound: Taxol
|
Antiproliferative activity against human MDA-MB-231 cells after 4 hrs by MTT assay
Antiproliferative activity against human MDA-MB-231 cells after 4 hrs by MTT assay
|
[PMID: 25453798] |
| MDA-MB-231 | IC50 |
0.457 μM
Compound: Taxol, Paclitaxel
|
Cytotoxicity against paclitaxel-resistant human MDA-MB-231 cells after 24 hrs by MTT assay
Cytotoxicity against paclitaxel-resistant human MDA-MB-231 cells after 24 hrs by MTT assay
|
[PMID: 25462222] |
| MDA-MB-231 | GI50 |
0.091 μM
Compound: Paclitaxel
|
Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in net protein increase after 48 hrs by SRB assay
Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in net protein increase after 48 hrs by SRB assay
|
[PMID: 25462234] |
| MDA-MB-231 | GI50 |
<0.01 μM
Compound: Paclitaxel
|
Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by SRB assay
Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by SRB assay
|
[PMID: 25827522] |
| MDA-MB-231 | IC50 |
7 nM
Compound: PTX
|
Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 72 hrs by MTT assay
Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 72 hrs by MTT assay
|
[PMID: 26132075] |
| MDA-MB-231 | IC50 |
<0.001 μM
Compound: 1
|
Cytotoxicity against human MDA-MB-231 cells incubated for 72 hrs by MTT assay
Cytotoxicity against human MDA-MB-231 cells incubated for 72 hrs by MTT assay
|
[PMID: 26448037] |
| MDA-MB-231 | IC50 |
2.56 μM
Compound: Paclitaxel
|
Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by SRB assay
Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by SRB assay
|
[PMID: 26602827] |
| MDA-MB-231 | IC50 |
3.9 nM
Compound: Paclitaxel
|
Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by MTT assay
Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by MTT assay
|
[PMID: 26690274] |
| MDA-MB-231 | IC50 |
18 nM
Compound: PXL
|
Antiproliferative activity against human MDA-MB-231 cells after 3 days by SRB assay
Antiproliferative activity against human MDA-MB-231 cells after 3 days by SRB assay
|
[PMID: 26865176] |
| MDA-MB-231 | IC50 |
0.021 μM
Compound: Paclitaxel
|
Cytotoxicity against human MDA-MB-231 cells assessed as cell growth inhibition
Cytotoxicity against human MDA-MB-231 cells assessed as cell growth inhibition
|
[PMID: 26934105] |
| MDA-MB-231 | GI50 |
<0.01 μM
Compound: Paclitaxel
|
Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by SRB assay
Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by SRB assay
|
[PMID: 26994690] |
| MDA-MB-231 | GI50 |
0.091 μM
Compound: Paclitaxel
|
Antiproliferative activity against human MDA-MB-231 cells assessed as growth inhibition after 48 hrs by SRB assay
Antiproliferative activity against human MDA-MB-231 cells assessed as growth inhibition after 48 hrs by SRB assay
|
[PMID: 27209232] |
| MDA-MB-231 | GI50 |
8.67 nM
Compound: Taxol
|
Cytotoxicity against human MDA-MB-231 cells assessed as cell growth inhibition after 72 hrs by CCK-8 assay
Cytotoxicity against human MDA-MB-231 cells assessed as cell growth inhibition after 72 hrs by CCK-8 assay
|
[PMID: 27224875] |
| MDA-MB-231 | IC50 |
3.388 nM
Compound: Paclitaxel
|
Anti-cancer activity against human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by WST-1 assay
Anti-cancer activity against human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by WST-1 assay
|
[PMID: 27317645] |
| MDA-MB-231 | IC50 |
0.1 μM
Compound: Paclitaxel
|
Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability measured after 72 hrs by MTS assay
Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability measured after 72 hrs by MTS assay
|
[PMID: 27449957] |
| MDA-MB-231 | IC50 |
3.05 nM
Compound: Paclitaxel
|
Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 48 hrs by SRB assay
Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 48 hrs by SRB assay
|
[PMID: 27797192] |
| MDA-MB-231 | GI50 |
0.092 μM
Compound: Paclitaxel
|
Growth inhibition of human MDA-MB-231 cells after 48 hrs by SRB assay
Growth inhibition of human MDA-MB-231 cells after 48 hrs by SRB assay
|
[PMID: 27964883] |
| MDA-MB-231 | IC50 |
2.7 nM
Compound: Paclitaxel
|
Cytotoxicity against human MDA-MB-231 cells incubated for 72 hrs by CellTiter 96 aqueous one solution cell proliferation assay
Cytotoxicity against human MDA-MB-231 cells incubated for 72 hrs by CellTiter 96 aqueous one solution cell proliferation assay
|
[PMID: 27983842] |
| MDA-MB-231 | IC50 |
8.82 nM
Compound: PXL
|
Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by SRB assay
Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by SRB assay
|
[PMID: 28099003] |
| MDA-MB-231 | IC50 |
9.384 μM
Compound: Paclitaxel
|
Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 48 hrs by MTT assay
|
[PMID: 28237662] |
| MDA-MB-231 | IC50 |
0.0026 μM
Compound: Paclitaxel
|
Cytotoxicity in human MDA-MB-231 cells assessed as reduction in cell viability incubated for for 72 hrs by cell-titer-96 aqueous one solution cell proliferation assay
Cytotoxicity in human MDA-MB-231 cells assessed as reduction in cell viability incubated for for 72 hrs by cell-titer-96 aqueous one solution cell proliferation assay
|
[PMID: 28252962] |
| MDA-MB-231 | IC50 |
0.08 μM
Compound: Taxol
|
Cytotoxicity against human MDA-MB-231 cells assessed as decrease in cell proliferation after 48 hrs by MTT assay
Cytotoxicity against human MDA-MB-231 cells assessed as decrease in cell proliferation after 48 hrs by MTT assay
|
[PMID: 28262526] |
| MDA-MB-231 | IC50 |
8.8 nM
Compound: Paclitaxel
|
Antiproliferative activity against human MDA-MB-231 cells incubated for 72 hrs by SRB assay
Antiproliferative activity against human MDA-MB-231 cells incubated for 72 hrs by SRB assay
|
[PMID: 28290698] |
| MDA-MB-231 | IC50 |
9.63 nM
Compound: PXL
|
Antiproliferative activity against human MDA-MB-231 cells by sulforhodamine B assay
Antiproliferative activity against human MDA-MB-231 cells by sulforhodamine B assay
|
[PMID: 28457756] |
| MDA-MB-231 | IC50 |
0.009 μM
Compound: taxol
|
Cytotoxicity against human MDA-MB-231 cells assessed as decrease in cell viability after 72 hrs by CellTiter 96 AQueous one solution cell proliferation assay
Cytotoxicity against human MDA-MB-231 cells assessed as decrease in cell viability after 72 hrs by CellTiter 96 AQueous one solution cell proliferation assay
|
[PMID: 28594169] |
| MDA-MB-231 | GI50 |
10 nM
Compound: Paclitaxel
|
Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 48 hrs by SRB assay
Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 48 hrs by SRB assay
|
[PMID: 28653846] |
| MDA-MB-231 | IC50 |
0.059 μM
Compound: Paclitaxel
|
Cytotoxicity against human MDA-MB-231 cells assessed as decrease in cell viability after 72 hrs by CellTiter-Glo luminescence assay
Cytotoxicity against human MDA-MB-231 cells assessed as decrease in cell viability after 72 hrs by CellTiter-Glo luminescence assay
|
[PMID: 28926237] |
| MDA-MB-231 | IC50 |
9.4 nM
Compound: Paclitaxel
|
Cytotoxicity against human MDA-MB-231 cells after 72 hrs by sulforhodamine B assay
Cytotoxicity against human MDA-MB-231 cells after 72 hrs by sulforhodamine B assay
|
[PMID: 29131631] |
| MDA-MB-231 | IC50 |
0.003 μM
Compound: PTX
|
Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay
Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay
|
[PMID: 29306206] |
| MDA-MB-231 | IC50 |
7 nM
Compound: PXL
|
Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by sulforhodamine B assay
Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by sulforhodamine B assay
|
[PMID: 29319316] |
| MDA-MB-231 | IC50 |
3 nM
Compound: Paclitaxel
|
Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay
Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay
|
[PMID: 29373791] |
| MDA-MB-231 | IC50 |
5.34 μM
Compound: Paclitaxel
|
Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by SRB assay
Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by SRB assay
|
[PMID: 29391939] |
| MDA-MB-231 | GI50 |
12.5 nM
Compound: Paclitaxel
|
Growth inhibition of human MDA-MB-231 cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human MDA-MB-231 cells incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 29655610] |
| MDA-MB-231 | IC50 |
8.1 nM
Compound: PXL
|
Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by SRB assay
Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by SRB assay
|
[PMID: 30010341] |
| MDA-MB-231 | IC50 |
17 nM
Compound: Paclitaxel
|
Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by CellTiter 96 aqueous one solution assay
Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by CellTiter 96 aqueous one solution assay
|
[PMID: 30057155] |
| MDA-MB-231 | IC50 |
>10 nM
Compound: PXL
|
Antiproliferative activity against human MDA-MB-231 cells after 24 hrs by SRB assay
Antiproliferative activity against human MDA-MB-231 cells after 24 hrs by SRB assay
|
[PMID: 30106296] |
| MDA-MB-231 | IC50 |
12.1 nM
Compound: PXL
|
Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by SRB assay
Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by SRB assay
|
[PMID: 30106296] |
| MDA-MB-231 | IC50 |
8.51 nM
Compound: PXL
|
Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by SRB assay
Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by SRB assay
|
[PMID: 30106296] |
| MDA-MB-231 | IC50 |
9.6 μM
Compound: Paclitaxel
|
Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell growth after 72 hrs by sulforhodamine B assay
Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell growth after 72 hrs by sulforhodamine B assay
|
[PMID: 30189396] |
| MDA-MB-231 | IC50 |
2.6 nM
Compound: Taxol
|
Cytotoxicity against human MDA-MB-231 cells after 72 hrs by CellTiter 96 AQueous One Solution Cell Proliferation Assay
Cytotoxicity against human MDA-MB-231 cells after 72 hrs by CellTiter 96 AQueous One Solution Cell Proliferation Assay
|
[PMID: 30192537] |
| MDA-MB-231 | IC50 |
0.001 μM
Compound: Paclitaxel
|
Cytotoxicity against human MDA-MB-231 after 48 hrs by MTT assay
Cytotoxicity against human MDA-MB-231 after 48 hrs by MTT assay
|
[PMID: 30387611] |
| MDA-MB-231 | IC50 |
0.2 μM
Compound: Paclitaxel
|
Cytotoxicity against human MDA-MB-231 after 24 hrs by MTT assay
Cytotoxicity against human MDA-MB-231 after 24 hrs by MTT assay
|
[PMID: 30387611] |
| MDA-MB-231 | IC50 |
0.004 μM
Compound: Paclitaxel
|
Cytotoxicity activity against human MDA-MB-231 cells assessed as cell growth inhibition after 48 hrs by MTT assay
Cytotoxicity activity against human MDA-MB-231 cells assessed as cell growth inhibition after 48 hrs by MTT assay
|
[PMID: 30433783] |
| MDA-MB-231 | IC50 |
0.06 μM
Compound: Taxol
|
Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by Hoechst 33342 staining-based assay
Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by Hoechst 33342 staining-based assay
|
[PMID: 30655216] |
| MDA-MB-231 | IC50 |
13.23 μM
Compound: Paclitaxel
|
Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay
Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay
|
[PMID: 30738663] |
| MDA-MB-231 | IC50 |
0.1 μM
Compound: Paclitaxel
|
Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability measured after 72 hrs by SRB assay
Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability measured after 72 hrs by SRB assay
|
[PMID: 31120251] |
| MDA-MB-231 | IC50 |
9.1 nM
Compound: Paclitaxel
|
Antiproliferative activity against human MDA-MB-231 cells assessed as cell growth inhibition after 72 hrs by sulforhodamine B assay
Antiproliferative activity against human MDA-MB-231 cells assessed as cell growth inhibition after 72 hrs by sulforhodamine B assay
|
[PMID: 31126820] |
| MDA-MB-231 | IC50 |
9.74 nM
Compound: PXL
|
Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
|
[PMID: 31541869] |
| MDA-MB-231 | GI50 |
<0.016 μM
Compound: Paciltaxel
|
Antiproliferative activity against human MDA-MB-231 cells by SRB assay
Antiproliferative activity against human MDA-MB-231 cells by SRB assay
|
[PMID: 31546197] |
| MDA-MB-231 | IC50 |
10.7 nM
Compound: Paclitaxel
|
Antiproliferative activity against triple-negative human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by SRB assay
Antiproliferative activity against triple-negative human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by SRB assay
|
[PMID: 31550158] |
| MDA-MB-231 | IC50 |
170 nM
Compound: Taxol
|
Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 72 hrs by CellTiter 96 aqueous one solution assay
Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 72 hrs by CellTiter 96 aqueous one solution assay
|
[PMID: 31633350] |
| MDA-MB-231 | IC50 |
9.4 μM
Compound: Paclitaxel
|
Antiproliferative activity against human MDA-MB-231 cells incubated for 72 hrs by SRB assay
Antiproliferative activity against human MDA-MB-231 cells incubated for 72 hrs by SRB assay
|
[PMID: 31718182] |
| MDA-MB-231 | IC50 |
2.01 μM
Compound: Paclitaxel
|
Antimigratory activity in human MDA-MB-231 cells assessed as inhibition of cell motility after 24 hrs by microscopic analysis
Antimigratory activity in human MDA-MB-231 cells assessed as inhibition of cell motility after 24 hrs by microscopic analysis
|
[PMID: 31838326] |
| MDA-MB-231 | GI50 |
5.2 nM
Compound: Paclitaxel
|
Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
|
[PMID: 31938468] |
| MDA-MB-231 | IC50 |
0.0027 μM
Compound: Paclitaxel
|
Cytotoxicity against human MDA-MB-231 cells after 72 hrs by CellTiter 96 Aqueous One Solution reagent based assay
Cytotoxicity against human MDA-MB-231 cells after 72 hrs by CellTiter 96 Aqueous One Solution reagent based assay
|
[PMID: 32096998] |
| MDA-MB-231 | IC50 |
3 nM
Compound: Paclitaxel
|
Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay
Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay
|
[PMID: 32339854] |
| MDA-MB-231 | IC50 |
0.003 μM
Compound: Paclitaxel
|
Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
|
[PMID: 32633512] |
| MDA-MB-231 | IC50 |
8.6 nM
Compound: Paclitaxel
|
Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by SRB assay
Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by SRB assay
|
[PMID: 32946697] |
| MDA-MB-231 | IC50 |
<0.025 μM
Compound: Taxol
|
Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell growth by MTT assay
Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell growth by MTT assay
|
[PMID: 32949719] |
| MDA-MB-231 | IC50 |
0.2 nM
Compound: Paclitaxel
|
Cytotoxicity against human MDA-MB-231 cells after 72 hrs by Cell Titer-Blue cell viability assay
Cytotoxicity against human MDA-MB-231 cells after 72 hrs by Cell Titer-Blue cell viability assay
|
[PMID: 33006889] |
| MDA-MB-231 | IC50 |
0.02 μM
Compound: 1; PTX
|
Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay
Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay
|
[PMID: 33065439] |
| MDA-MB-231 | IC50 |
0.9 μM
Compound: Paclitaxel
|
Antiproliferative activity against human MDA-MB-231 cells assessed as cell viability after 24 hrs
Antiproliferative activity against human MDA-MB-231 cells assessed as cell viability after 24 hrs
|
[PMID: 33139111] |
| MDA-MB-231 | GI50 |
12.5 nM
Compound: Paclitaxel
|
Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay
Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay
|
[PMID: 33310545] |
| MDA-MB-231 | IC50 |
0.1 μM
Compound: Paclitaxel
|
Antiproliferative activity against human MDA-MB-231 cells
Antiproliferative activity against human MDA-MB-231 cells
|
[PMID: 33421712] |
| MDA-MB-231 | IC50 |
0.03 μM
Compound: Taxol
|
Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 48 hrs by Hoechst-33342 staining based cell counting method (Rvb > 25 microM)
Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 48 hrs by Hoechst-33342 staining based cell counting method (Rvb > 25 microM)
|
[PMID: 33422908] |
| MDA-MB-231 | IC50 |
<0.001 μM
Compound: Taxol
|
Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 96 hrs by MTT assay
Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 96 hrs by MTT assay
|
[PMID: 33713977] |
| MDA-MB-231 | IC50 |
0.6 nM
Compound: Taxol
|
Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell proliferation measured after 72 hrs by CellTiter 96 AQueous One Solution Cell Proliferation assay
Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell proliferation measured after 72 hrs by CellTiter 96 AQueous One Solution Cell Proliferation assay
|
[PMID: 33859802] |
| MDA-MB-231 | IC50 |
1.6 μM
Compound: Paclitaxel
|
Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
|
[PMID: 34153643] |
| MDA-MB-231 | IC50 |
0.00917 μM
Compound: Paclitaxel
|
Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
|
[PMID: 34171512] |
| MDA-MB-231 | IC50 |
0.8 nM
Compound: Paclitaxel
|
Cytotoxicity against human MDA-MB-231 cells measured after 72 hrs by western blot
Cytotoxicity against human MDA-MB-231 cells measured after 72 hrs by western blot
|
[PMID: 34378386] |
| MDA-MB-231 | IC50 |
0.008 μM
Compound: Paclitaxel
|
Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability measured after 72 hrs by SRB assay
Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability measured after 72 hrs by SRB assay
|
[PMID: 34403728] |
| MDA-MB-231 | IC50 |
2.8 nM
Compound: Paclitaxel
|
Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTS assay
Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTS assay
|
[PMID: 34406768] |
| MDA-MB-231 | IC50 |
0.027 μM
Compound: PTX
|
Cytotoxicity against human MDA-MB-231 cells expressing TLR4 assessed as growth inhibition measured after 96 hrs by MTT assay
Cytotoxicity against human MDA-MB-231 cells expressing TLR4 assessed as growth inhibition measured after 96 hrs by MTT assay
|
[PMID: 34600241] |
| MDA-MB-231 | IC50 |
0.04 μM
Compound: PTX
|
Cytotoxicity against human MDA-MB-231 cells expressing TLR4 assessed as reduction in cell viability measured after 96 hrs by MTT assay
Cytotoxicity against human MDA-MB-231 cells expressing TLR4 assessed as reduction in cell viability measured after 96 hrs by MTT assay
|
[PMID: 34600241] |
| MDA-MB-231 | IC50 |
3.42 nM
Compound: PTX
|
Antiproliferative activity against human MDA-MB-231 cells incubated for 72 hrs by MTT assay
Antiproliferative activity against human MDA-MB-231 cells incubated for 72 hrs by MTT assay
|
[PMID: 34648295] |
| MDA-MB-231 | IC50 |
3.1 nM
Compound: PTX
|
Antiproliferative activity against ACE-positive human MDA-MB-231 cells incubated for 48 hrs by MTT assay
Antiproliferative activity against ACE-positive human MDA-MB-231 cells incubated for 48 hrs by MTT assay
|
[PMID: 34699215] |
| MDA-MB-231 | IC50 |
3.77 μM
Compound: Paclitaxel
|
Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay
Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay
|
[PMID: 34726897] |
| MDA-MB-231 | GI50 |
7.4 nM
Compound: Paclitaxel
|
Antiproliferative activity against human MDA-MB-231 cells assessed as cell growth inhibition measured after 72 hrs by SRB assay
Antiproliferative activity against human MDA-MB-231 cells assessed as cell growth inhibition measured after 72 hrs by SRB assay
|
[PMID: 34917259] |
| MDA-MB-231 | IC50 |
56.12 μM
Compound: Paclitaxel
|
Antiproliferative activity against human MDA-MB-231 cells by CCK8 assay
Antiproliferative activity against human MDA-MB-231 cells by CCK8 assay
|
[PMID: 34922028] |
| MDA-MB-231 | IC50 |
0.003 μM
Compound: PTX
|
Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay
Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay
|
[PMID: 35065411] |
| MDA-MB-231 | IC50 |
0.007 μM
Compound: PTX
|
Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay
Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay
|
[PMID: 35447432] |
| MDA-MB-231 | GI50 |
0.22 μM
Compound: PTX
|
Antiproliferative activity against human MDA-MB-231 cells measured after 6 days by MTT assay
Antiproliferative activity against human MDA-MB-231 cells measured after 6 days by MTT assay
|
[PMID: 35617854] |
| MDA-MB-231 | GI50 |
0.3 μM
Compound: PTX
|
Antiproliferative activity against human MDA-MB-231 cells measured after 24 hrs by MTT assay
Antiproliferative activity against human MDA-MB-231 cells measured after 24 hrs by MTT assay
|
[PMID: 35617854] |
| MDA-MB-231 | IC50 |
<0.001 μM
Compound: Taxol
|
Cytotoxicity against human MDA-MB-231 cells by MTT assay
Cytotoxicity against human MDA-MB-231 cells by MTT assay
|
[PMID: 36057236] |
| MDA-MB-231 | IC50 |
19.3 nM
Compound: Paclitaxel
|
Antiproliferative activity against human MDA-MB-231 cells assessed as cell growth inhibition incubated for 48 hr by MTT assay
Antiproliferative activity against human MDA-MB-231 cells assessed as cell growth inhibition incubated for 48 hr by MTT assay
|
[PMID: 36092142] |
| MDA-MB-231 | IC50 |
0.05 μM
Compound: Taxol
|
Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability after 96 hrs by MTT assay
Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability after 96 hrs by MTT assay
|
[PMID: 36270090] |
| MDA-MB-231 | IC50 |
<0.001 μM
Compound: Paclitaxel
|
Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
|
[PMID: 36511661] |
| MDA-MB-231 | IC50 |
1.1 nM
Compound: Paclitaxel
|
Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay
Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay
|
[PMID: 36621138] |
| MDA-MB-231 | IC50 |
0.7 nM
Compound: Pac
|
Inhibition of human MDA-MB-231 cell spheroids incubated for 7 days by luciferase based assay
Inhibition of human MDA-MB-231 cell spheroids incubated for 7 days by luciferase based assay
|
[PMID: 36780832] |
| MDA-MB-231 | IC50 |
0.07 μM
Compound: Paclitaxel
|
Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
|
[PMID: 36786551] |
| MDA-MB-231 | IC50 |
0.6 x 10-3 μM
Compound: Taxol
|
Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
|
[PMID: 36884371] |
| MDA-MB-231 | IC50 |
30 nM
Compound: Paclitaxel
|
Anticancer activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
Anticancer activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
|
[PMID: 37146221] |
| MDA-MB-231 | IC50 |
3.8 nM
Compound: Paclitaxel
|
Cytotoxicity against human MDA-MB-231 cells incubated for 72 hrs by Cell titer blue assay
Cytotoxicity against human MDA-MB-231 cells incubated for 72 hrs by Cell titer blue assay
|
[PMID: 37216676] |
| MDA-MB-231 | IC50 |
0.33 μM
Compound: Taxol
|
Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 48 hrs by CCk-8 assay
Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 48 hrs by CCk-8 assay
|
[PMID: 37329677] |
| MDA-MB-231 | IC50 |
>100 μM
Compound: PTX
|
Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell proliferation measured after 48 hrs by CCK-8 assay
Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell proliferation measured after 48 hrs by CCK-8 assay
|
[PMID: 37395092] |
| MDA-MB-231 | GI50 |
1.6 nM
Compound: 1a; PTX
|
Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth by SRB assay
Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth by SRB assay
|
[PMID: 37490800] |
| MDA-MB-231 | IC50 |
<0.005 μM
Compound: Taxol
|
Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
|
[PMID: 37837671] |
| MDA-MB-231 | IC50 |
0.9 nM
Compound: PXL
|
Antiproliferative activity against triple negative human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay
Antiproliferative activity against triple negative human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay
|
[PMID: 38251859] |
| MDA-MB-231 | IC50 |
0.19 μM
Compound: PTX
|
Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
|
[PMID: 38280356] |
| MDA-MB-231 | IC50 |
6.9 μM
Compound: Paclitaxel
|
Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell viability incubated for 72 hrs
Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell viability incubated for 72 hrs
|
[PMID: 38341161] |
| MDA-MB-231 | IC50 |
8.7 μM
Compound: PXL
|
Antiproliferative activity against human MDA-MB-231 cells assessed as cell growth inhibition incubated for 72 hrs by sulforhodamine B assay
Antiproliferative activity against human MDA-MB-231 cells assessed as cell growth inhibition incubated for 72 hrs by sulforhodamine B assay
|
[PMID: 38438305] |
| MDA-MB-231 | IC50 |
0.11 μM
Compound: Paciitaxel
|
Cytotoxicity against human MDA-MB-231 cells incubated for 72 hrs by CCK8 assay
Cytotoxicity against human MDA-MB-231 cells incubated for 72 hrs by CCK8 assay
|
[PMID: 38493728] |
| MDA-MB-231 | IC50 |
0.003 μM
Compound: PTX
|
Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay
Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay
|
[PMID: 38547648] |
| MDA-MB-231 | IC50 |
8.4 nM
Compound: PXL
|
Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability by SRB assay
Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability by SRB assay
|
[PMID: 38970504] |
| MDA-MB-231 | IC50 |
4.55 μM
Compound: Taxol
|
Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
|
[PMID: 39044437] |
| MDA-MB-231 | IC50 |
38.31 nM
Compound: PTX
|
Antitumor activity against human MDA-MB-231 cells assessed as inhibition of cell viability by measuring inhibition rate measured after 72 hrs by CCK-8 assay relative to control
Antitumor activity against human MDA-MB-231 cells assessed as inhibition of cell viability by measuring inhibition rate measured after 72 hrs by CCK-8 assay relative to control
|
[PMID: 39208364] |
| MDA-MB-361 | IC50 |
>150 ng/mL
Compound: Paclitaxel
|
Antiproliferative activity against human MDA-MB-361 cells assessed as cell growth inhibition incubated for 1 days by MTS assay
Antiproliferative activity against human MDA-MB-361 cells assessed as cell growth inhibition incubated for 1 days by MTS assay
|
[PMID: 20068177] |
| MDA-MB-361 | IC50 |
>150 ng/mL
Compound: Paclitaxel
|
Antiproliferative activity against human MDA-MB-361 cells assessed as cell growth inhibition incubated for 2 days by MTS assay
Antiproliferative activity against human MDA-MB-361 cells assessed as cell growth inhibition incubated for 2 days by MTS assay
|
[PMID: 20068177] |
| MDA-MB-361 | IC50 |
4 ng/mL
Compound: Paclitaxel
|
Antiproliferative activity against human MDA-MB-361 cells assessed as cell growth inhibition incubated for 3 days by MTS assay
Antiproliferative activity against human MDA-MB-361 cells assessed as cell growth inhibition incubated for 3 days by MTS assay
|
[PMID: 20068177] |
| MDA-MB-435 | IC50 |
0.0008 μM
Compound: 1 (Paclitaxel)
|
Cytotoxicity against paclitaxel sensitive LCC6-WT-human breast carcinoma cell line
Cytotoxicity against paclitaxel sensitive LCC6-WT-human breast carcinoma cell line
|
[PMID: 11549446] |
| MDA-MB-435 | IC50 |
0.612 μM
Compound: 1 (Paclitaxel)
|
Cytotoxicity against paclitaxel resistant LCC6-MDR-MDR1 transfected cell line
Cytotoxicity against paclitaxel resistant LCC6-MDR-MDR1 transfected cell line
|
[PMID: 11549446] |
| MDA-MB-435 | IC50 |
490 nM
Compound: 1 (Paclitaxel)
|
Inhibitory concentration against LCC6-MDR human breast cancer cell line
Inhibitory concentration against LCC6-MDR human breast cancer cell line
|
[PMID: 11549446] |
| MDA-MB-435 | IC50 |
0.004 μM
Compound: Paclitaxel
|
In vitro cytotoxic activity against growth of human breast carcinoma cell line (LCC6-WT) after 72 hr
In vitro cytotoxic activity against growth of human breast carcinoma cell line (LCC6-WT) after 72 hr
|
[PMID: 15177459] |
| MDA-MB-435 | IC50 |
0.379 μM
Compound: Paclitaxel
|
In vitro cytotoxic activity against growth of MDR1 transduced line (LCC6-MDR) after 72 hr
In vitro cytotoxic activity against growth of MDR1 transduced line (LCC6-MDR) after 72 hr
|
[PMID: 15177459] |
| MDA-MB-435 | IC50 |
0.005 μM
Compound: Taxol
|
Cytotoxicity against human MDA435 cell line by MTS assay
Cytotoxicity against human MDA435 cell line by MTS assay
|
[PMID: 16870446] |
| MDA-MB-435 | IC50 |
105 nM
Compound: paclitaxel
|
Antiproliferative activity against multidrug resistant MDA435/LCC6 cells by ELISA
Antiproliferative activity against multidrug resistant MDA435/LCC6 cells by ELISA
|
[PMID: 17154505] |
| MDA-MB-435 | IC50 |
2.9 nM
Compound: paclitaxel
|
Antiproliferative activity against MDA435/LCC6 cells by ELISA
Antiproliferative activity against MDA435/LCC6 cells by ELISA
|
[PMID: 17154505] |
| MDA-MB-435 | IC50 |
4.8 nM
Compound: paclitaxel
|
Antiproliferative activity against multidrug resistant MDA435/LCC6 cells in presence of 5 uM 1,13-bis[4'-((5,7-dihydroxy)-4H-chromen-4-on-2-yl)phenyl]-1,4,7,10,13-pentaoxatridecane by ELISA
Antiproliferative activity against multidrug resistant MDA435/LCC6 cells in presence of 5 uM 1,13-bis[4'-((5,7-dihydroxy)-4H-chromen-4-on-2-yl)phenyl]-1,4,7,10,13-pentaoxatridecane by ELISA
|
[PMID: 17154505] |
| MDA-MB-435 | IC50 |
5.2 nM
Compound: paclitaxel
|
Antiproliferative activity against multidrug resistant MDA435/LCC6 cells in presence of 5 uM verapamil by ELISA
Antiproliferative activity against multidrug resistant MDA435/LCC6 cells in presence of 5 uM verapamil by ELISA
|
[PMID: 17154505] |
| MDA-MB-435 | IC50 |
0.005 μM
Compound: Taxol
|
Cytotoxicity against human MDA435 cells after 72 hrs by MTT assay
Cytotoxicity against human MDA435 cells after 72 hrs by MTT assay
|
[PMID: 18308566] |
| MDA-MB-435 | GI50 |
4 nM
Compound: paclitaxel
|
Antiproliferative activity against human MDA-MB-435 cells after 72 hrs
Antiproliferative activity against human MDA-MB-435 cells after 72 hrs
|
[PMID: 18610995] |
| MDA-MB-435 | IC50 |
277 nM
Compound: paclitaxel
|
Cytotoxicity against human MDA-MB-435 cells after 48 hrs by sulforhodamine B assay
Cytotoxicity against human MDA-MB-435 cells after 48 hrs by sulforhodamine B assay
|
[PMID: 20919720] |
| MDA-MB-435 | IC50 |
69.3 nM
Compound: paclitaxel
|
Resistance index, ratio of IC50 for human multidrug-resistant MDA-MB-435/LCCMDR1 cells to IC50 for human MDA-MB-435 cells
Resistance index, ratio of IC50 for human multidrug-resistant MDA-MB-435/LCCMDR1 cells to IC50 for human MDA-MB-435 cells
|
[PMID: 20919720] |
| MDA-MB-435 | IC50 |
16 nM
Compound: Paclitaxel
|
Antiproliferative activity against human MDA-MB-435 cells by sulforhodamine B assay
Antiproliferative activity against human MDA-MB-435 cells by sulforhodamine B assay
|
[PMID: 21775150] |
| MDA-MB-435 | IC50 |
465 nM
Compound: Paclitaxel
|
Antiproliferative activity against human MDA-MB-435 cells expressing LCC6MDR1 by sulforhodamine B assay
Antiproliferative activity against human MDA-MB-435 cells expressing LCC6MDR1 by sulforhodamine B assay
|
[PMID: 21775150] |
| MDA-MB-435 | IC50 |
4 nM
Compound: Paclitaxel
|
Cytotoxicity against human MDA-MB-435 cells assessed as growth inhibition after 48 hrs by SRB assay
Cytotoxicity against human MDA-MB-435 cells assessed as growth inhibition after 48 hrs by SRB assay
|
[PMID: 23547728] |
| MDA-MB-435 | IC50 |
0.005 μM
Compound: Taxol
|
Cytotoxicity against human MDA435 cells
Cytotoxicity against human MDA435 cells
|
[PMID: 23937981] |
| MDA-MB-435 | IC50 |
1.93 nM
Compound: Taxol
|
Antiproliferative activity against human MDA-MB-435 cells
Antiproliferative activity against human MDA-MB-435 cells
|
[PMID: 24890652] |
| MDA-MB-435 | IC50 |
0.005 μM
Compound: Taxol, Paclitaxel
|
Cytotoxicity against human MDA435 cells after 24 hrs by MTT assay
Cytotoxicity against human MDA435 cells after 24 hrs by MTT assay
|
[PMID: 25462222] |
| MDA-MB-435 | IC50 |
3.3 nM
Compound: Paclitaxel
|
Antiproliferative activity against human MDA-MB-435 cells after 48 hrs by sulforhodamine B assay
Antiproliferative activity against human MDA-MB-435 cells after 48 hrs by sulforhodamine B assay
|
[PMID: 25882519] |
| MDA-MB-435 | EC50 |
4.5 nM
Compound: paclitaxel
|
Cytotoxicity against human MDA-MB-435 cells assessed as growth inhibition after 48 hrs by SRB assay
Cytotoxicity against human MDA-MB-435 cells assessed as growth inhibition after 48 hrs by SRB assay
|
[PMID: 27213719] |
| MDA-MB-435 | IC50 |
0.2 nM
Compound: Paclitaxel
|
Cytotoxicity against human MDA-MB-435 cells incubated for 72 hrs by CellTiter 96 aqueous one solution cell proliferation assay
Cytotoxicity against human MDA-MB-435 cells incubated for 72 hrs by CellTiter 96 aqueous one solution cell proliferation assay
|
[PMID: 27983842] |
| MDA-MB-435 | GI50 |
1 nM
Compound: Paclitaxel
|
Antiproliferative activity against human MDA-MB-435 cells assessed as cell growth inhibition in presence of 0.1% FBS by sulforhodamine B assay
Antiproliferative activity against human MDA-MB-435 cells assessed as cell growth inhibition in presence of 0.1% FBS by sulforhodamine B assay
|
[PMID: 28112516] |
| MDA-MB-435 | GI50 |
1.9 nM
Compound: Paclitaxel
|
Antiproliferative activity against human MDA-MB-435 cells assessed as cell growth inhibition in presence of 1% FBS by sulforhodamine B assay
Antiproliferative activity against human MDA-MB-435 cells assessed as cell growth inhibition in presence of 1% FBS by sulforhodamine B assay
|
[PMID: 28112516] |
| MDA-MB-435 | GI50 |
3.4 nM
Compound: Paclitaxel
|
Antiproliferative activity against human MDA-MB-435 cells assessed as cell growth inhibition in presence of 10% FBS by sulforhodamine B assay
Antiproliferative activity against human MDA-MB-435 cells assessed as cell growth inhibition in presence of 10% FBS by sulforhodamine B assay
|
[PMID: 28112516] |
| MDA-MB-435 | IC50 |
0.0031 μM
Compound: Paclitaxel
|
Cytotoxicity in human MDA-MB-435 cells assessed as reduction in cell viability incubated for for 72 hrs by cell-titer-96 aqueous one solution cell proliferation assay
Cytotoxicity in human MDA-MB-435 cells assessed as reduction in cell viability incubated for for 72 hrs by cell-titer-96 aqueous one solution cell proliferation assay
|
[PMID: 28252962] |
| MDA-MB-435 | IC50 |
2 nM
Compound: Paclitaxel
|
Antiproliferative activity against human MDA-MB-435 cells after 48 hrs by SRB assay
Antiproliferative activity against human MDA-MB-435 cells after 48 hrs by SRB assay
|
[PMID: 28433513] |
| MDA-MB-435 | IC50 |
0.0005 μM
Compound: taxol
|
Cytotoxicity against human MDA-MB-435 cells assessed as decrease in cell viability after 72 hrs by CellTiter 96 AQueous one solution cell proliferation assay
Cytotoxicity against human MDA-MB-435 cells assessed as decrease in cell viability after 72 hrs by CellTiter 96 AQueous one solution cell proliferation assay
|
[PMID: 28594169] |
| MDA-MB-435 | GI50 |
4 nM
Compound: Paclitaxel
|
Growth inhibition of human MDA-MB-435 cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human MDA-MB-435 cells incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 29655610] |
| MDA-MB-435 | IC50 |
13 nM
Compound: Paclitaxel
|
Cytotoxicity against human MDA-MB-435 cells assessed as reduction in cell viability after 72 hrs by CellTiter 96 aqueous one solution assay
Cytotoxicity against human MDA-MB-435 cells assessed as reduction in cell viability after 72 hrs by CellTiter 96 aqueous one solution assay
|
[PMID: 30057155] |
| MDA-MB-435 | IC50 |
4.5 nM
Compound: Paclitaxel
|
Antiproliferative activity against human MDA-MB-435 cells after 72 hrs by sulforhodamine B assay
Antiproliferative activity against human MDA-MB-435 cells after 72 hrs by sulforhodamine B assay
|
[PMID: 30098869] |
| MDA-MB-435 | IC50 |
3.1 nM
Compound: Taxol
|
Cytotoxicity against human MDA-MB-435 cells after 72 hrs by CellTiter 96 AQueous One Solution Cell Proliferation Assay
Cytotoxicity against human MDA-MB-435 cells after 72 hrs by CellTiter 96 AQueous One Solution Cell Proliferation Assay
|
[PMID: 30192537] |
| MDA-MB-435 | IC50 |
0.4 nM
Compound: Taxol
|
Antiproliferative activity against human MDA-MB-435 cells assessed as inhibition of cell growth incubated for 72 hrs by CellTiter 96 aqueous one solution assay
Antiproliferative activity against human MDA-MB-435 cells assessed as inhibition of cell growth incubated for 72 hrs by CellTiter 96 aqueous one solution assay
|
[PMID: 31633350] |
| MDA-MB-435 | IC50 |
0.0002 μM
Compound: Paclitaxel
|
Cytotoxicity against human MDA-MB-435 cells after 72 hrs by CellTiter 96 Aqueous One Solution reagent based assay
Cytotoxicity against human MDA-MB-435 cells after 72 hrs by CellTiter 96 Aqueous One Solution reagent based assay
|
[PMID: 32096998] |
| MDA-MB-435 | IC50 |
0.4 nM
Compound: Paclitaxel
|
Cytotoxicity against human MDA-MB-435 cells after 72 hrs by Cell Titer-Blue cell viability assay
Cytotoxicity against human MDA-MB-435 cells after 72 hrs by Cell Titer-Blue cell viability assay
|
[PMID: 33006889] |
| MDA-MB-435 | GI50 |
4 nM
Compound: Paclitaxel
|
Cytotoxicity against human MDA-MB-435 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay
Cytotoxicity against human MDA-MB-435 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay
|
[PMID: 33310545] |
| MDA-MB-435 | IC50 |
4.5 nM
Compound: Paclitaxel
|
Antiproliferative activity against human MDA-MB-435 cells assessed as reduction in cell viability by Sulforhodamine B assay
Antiproliferative activity against human MDA-MB-435 cells assessed as reduction in cell viability by Sulforhodamine B assay
|
[PMID: 33647840] |
| MDA-MB-435 | IC50 |
0.3 nM
Compound: Taxol
|
Cytotoxicity against human MDA-MB-435 cells assessed as inhibition of cell proliferation measured after 72 hrs by CellTiter 96 AQueous One Solution Cell Proliferation assay
Cytotoxicity against human MDA-MB-435 cells assessed as inhibition of cell proliferation measured after 72 hrs by CellTiter 96 AQueous One Solution Cell Proliferation assay
|
[PMID: 33859802] |
| MDA-MB-435 | IC50 |
0.3 x 10-3 μM
Compound: Taxol
|
Cytotoxicity against human MDA-MB-435 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
Cytotoxicity against human MDA-MB-435 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
|
[PMID: 36884371] |
| MDA-MB-435 | IC50 |
4.5 nM
Compound: PTX
|
Antiproliferative activity against human MDA-MB-435 cells assessed as inhibition of cell growth by SRB assay
Antiproliferative activity against human MDA-MB-435 cells assessed as inhibition of cell growth by SRB assay
|
[PMID: 36889150] |
| MDA-MB-435 | IC50 |
1.9 nM
Compound: Paclitaxel
|
Cytotoxicity against human MDA-MB-435 cells incubated for 72 hrs by Cell titer blue assay
Cytotoxicity against human MDA-MB-435 cells incubated for 72 hrs by Cell titer blue assay
|
[PMID: 37216676] |
| MDA-MB-435 | IC50 |
2.6 nM
Compound: Paclitaxel
|
Cytotoxicity against human MDAMB-435 cells assessed as reduction in cell viability measured after 72 hrs by MTS assay
Cytotoxicity against human MDAMB-435 cells assessed as reduction in cell viability measured after 72 hrs by MTS assay
|
[PMID: 38237151] |
| MDA-MB-435 | IC50 |
2.3 μM
Compound: Paclitaxel
|
Cytotoxicity against human MDA-MB-435 cells assessed as inhibition of cell viability incubated for 72 hrs
Cytotoxicity against human MDA-MB-435 cells assessed as inhibition of cell viability incubated for 72 hrs
|
[PMID: 38341161] |
| MDA-MB-435 | IC50 |
0.2 nM
Compound: P
|
Cytotoxicity against human MDA-MB-435 cells treated for 72 hrs
Cytotoxicity against human MDA-MB-435 cells treated for 72 hrs
|
[PMID: 38964520] |
| MDA-MB-435 | IC50 |
860 nM
Compound: Paclitaxel
|
Cytotoxicity was evaluated in MDA 435/LCC6-MDR cell line
Cytotoxicity was evaluated in MDA 435/LCC6-MDR cell line
|
[PMID: 9871652] |
| MDA-MB-435S | IC50 |
0.009 μM
Compound: Taxol
|
Cytotoxicity against human MDA-MB-435S cells assessed as growth inhibition after 72 hrs by CCK-8 assay
Cytotoxicity against human MDA-MB-435S cells assessed as growth inhibition after 72 hrs by CCK-8 assay
|
[PMID: 25091926] |
| MDA-MB-436 | IC50 |
8 nM
Compound: PTX
|
Cytotoxicity against human MDA-MB-436 cells assessed as growth inhibition after 72 hrs by MTT assay
Cytotoxicity against human MDA-MB-436 cells assessed as growth inhibition after 72 hrs by MTT assay
|
[PMID: 26132075] |
| MDA-MB-453 | IC50 |
0.7 nM
Compound: Paclitaxel
|
Antiproliferative activity against human MDA-MB-453 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTS assay
Antiproliferative activity against human MDA-MB-453 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTS assay
|
[PMID: 34406768] |
| MDA-MB-468 | IC50 |
7.17 nM
Compound: Paclitaxel
|
Cytotoxicity against human MDA-MB-468 cells after 4 days by MTS/cell proliferation assay
Cytotoxicity against human MDA-MB-468 cells after 4 days by MTS/cell proliferation assay
|
[PMID: 25098528] |
| MDA-MB-468 | IC50 |
5 nM
Compound: PTX
|
Cytotoxicity against human MDA-MB-468 cells assessed as growth inhibition after 72 hrs by MTT assay
Cytotoxicity against human MDA-MB-468 cells assessed as growth inhibition after 72 hrs by MTT assay
|
[PMID: 26132075] |
| MDA-MB-468 | IC50 |
3.87 μM
Compound: Paclitaxel
|
Antiproliferative activity against human MDA-MB-468 cells after 72 hrs by SRB assay
Antiproliferative activity against human MDA-MB-468 cells after 72 hrs by SRB assay
|
[PMID: 26602827] |
| MDA-MB-468 | IC50 |
0.2 μM
Compound: Paclitaxel
|
Antiproliferative activity against human MDA-MB-468 cells assessed as reduction in cell viability measured after 72 hrs by MTS assay
Antiproliferative activity against human MDA-MB-468 cells assessed as reduction in cell viability measured after 72 hrs by MTS assay
|
[PMID: 27449957] |
| MDA-MB-468 | IC50 |
5.4 nM
Compound: Taxol
|
Antiproliferative activity against human MDA-MB-468 cells after 72 hrs by phosphatase assay
Antiproliferative activity against human MDA-MB-468 cells after 72 hrs by phosphatase assay
|
[PMID: 28857558] |
| MDA-MB-468 | IC50 |
0.0061 μM
Compound: Paclitaxel
|
Cytotoxicity against human MDA-MB-468 cells assessed as decrease in cell viability after 72 hrs by CellTiter-Glo luminescence assay
Cytotoxicity against human MDA-MB-468 cells assessed as decrease in cell viability after 72 hrs by CellTiter-Glo luminescence assay
|
[PMID: 28926237] |
| MDA-MB-468 | GI50 |
12.5 nM
Compound: Paclitaxel
|
Growth inhibition of human MDA-MB-468 cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human MDA-MB-468 cells incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 29655610] |
| MDA-MB-468 | IC50 |
1 nM
Compound: Paclitaxel
|
Antiproliferative activity against human MDA-MB-468 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTS assay
Antiproliferative activity against human MDA-MB-468 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTS assay
|
[PMID: 34406768] |
| MDA-MB-468 | IC50 |
3 nM
Compound: PTX
|
Antiproliferative activity against ACE-positive human MDA-MB-468 cells incubated for 48 hrs by MTT assay
Antiproliferative activity against ACE-positive human MDA-MB-468 cells incubated for 48 hrs by MTT assay
|
[PMID: 34699215] |
| MDA-MB-468 | GI50 |
0.1 μM
Compound: PTX
|
Antiproliferative activity against human MDA-MB-468 cells measured after 6 days by MTT assay
Antiproliferative activity against human MDA-MB-468 cells measured after 6 days by MTT assay
|
[PMID: 35617854] |
| MDA-MB-468 | IC50 |
3.5 nM
Compound: PT
|
Antiproliferative activity against human MDA-MB-468 cells assessed as reduction in cell viability incubated for 72 hrs by CelltiterGlo luminescent assay
Antiproliferative activity against human MDA-MB-468 cells assessed as reduction in cell viability incubated for 72 hrs by CelltiterGlo luminescent assay
|
[PMID: 38959729] |
| MDA-MB-468 | IC50 |
0.31 μM
Compound: Paclitaxel
|
Cytotoxicity against human MDA-MB-468 cells assessed as inhibition of cell proliferation after 96 hrs by MTT assay
Cytotoxicity against human MDA-MB-468 cells assessed as inhibition of cell proliferation after 96 hrs by MTT assay
|
10.1039/C4MD00573B |
| MDR | IC50 |
0.4 μM
Compound: paclitaxel
|
Antiproliferative activity against LT12 MDR cells by XTT assay after 48 hrs
Antiproliferative activity against LT12 MDR cells by XTT assay after 48 hrs
|
[PMID: 17181164] |
| MES-SA | IC50 |
0.0006 μM
Compound: PTX
|
The compound was evaluated for the growth inhibition of MES-SA uterine tumor cell lines using MTT assay.
The compound was evaluated for the growth inhibition of MES-SA uterine tumor cell lines using MTT assay.
|
[PMID: 10698449] |
| MES-SA | IC50 |
0.005 μM
Compound: Taxol
|
Cytotoxicity against human MES-SA cell line by MTS assay
Cytotoxicity against human MES-SA cell line by MTS assay
|
[PMID: 16870446] |
| MES-SA | IC50 |
0.0005 μM
Compound: paclitaxel
|
Cytotoxicity against human MES-SA cells
Cytotoxicity against human MES-SA cells
|
[PMID: 17113288] |
| MES-SA | IC50 |
1.6 nM
Compound: paclitaxel
|
Antiproliferative activity against drug sensitive Messa cell line by Alamar Blue assay
Antiproliferative activity against drug sensitive Messa cell line by Alamar Blue assay
|
[PMID: 17286393] |
| MES-SA | IC50 |
0.005 μM
Compound: Taxol
|
Cytotoxicity against human MESSA cells after 72 hrs by MTT assay
Cytotoxicity against human MESSA cells after 72 hrs by MTT assay
|
[PMID: 18308566] |
| MES-SA | IC50 |
0.008 μM
Compound: paclitaxel
|
Cytotoxicity against human MES-SA cells after 72 hrs by MTT assay
Cytotoxicity against human MES-SA cells after 72 hrs by MTT assay
|
[PMID: 19053781] |
| MES-SA | GI50 |
<0.00001 μM
Compound: Paclitaxel
|
Antiproliferative activity against human MESSA cells by SRB assay
Antiproliferative activity against human MESSA cells by SRB assay
|
[PMID: 19394218] |
| MES-SA | IC50 |
<0.001 μM
Compound: paclitaxel
|
Antiproliferative activity against human MES-SA cells after 72 hrs by MTT assay
Antiproliferative activity against human MES-SA cells after 72 hrs by MTT assay
|
[PMID: 19743863] |
| MES-SA | IC50 |
2.96 nM
Compound: paclitaxel
|
Antiproliferative activity against human MES-SA cells assessed as growth inhibition
Antiproliferative activity against human MES-SA cells assessed as growth inhibition
|
[PMID: 21324686] |
| MES-SA | IC50 |
2.96 nM
Compound: Paclitaxel
|
Antiproliferative activity against human MES-SA cells
Antiproliferative activity against human MES-SA cells
|
[PMID: 21324687] |
| MES-SA | IC50 |
2.96 nM
Compound: paclitaxel
|
Cytotoxicity against human MES-SA cells
Cytotoxicity against human MES-SA cells
|
[PMID: 21324692] |
| MES-SA | IC50 |
4 nM
Compound: PTX
|
Cytotoxicity against human MES-SA cells assessed as cell viability after 96 hrs by trypan blue exclusion
Cytotoxicity against human MES-SA cells assessed as cell viability after 96 hrs by trypan blue exclusion
|
[PMID: 21812421] |
| MES-SA | IC50 |
4 nM
Compound: A, paclitaxel, taxol
|
Cytotoxicity against human MES-SA cells after 96 hrs by trypan blue exclusion assay
Cytotoxicity against human MES-SA cells after 96 hrs by trypan blue exclusion assay
|
[PMID: 22587519] |
| MES-SA | IC50 |
3 nM
Compound: Paclitaxel
|
Cytotoxicity against human MES-SA cells
Cytotoxicity against human MES-SA cells
|
[PMID: 23141916] |
| MES-SA | IC50 |
4 nM
Compound: PTX
|
Cytotoxicity against human MESSA cells assessed as growth inhibition after 72 hrs by Celltiter-Glo luminescent assay
Cytotoxicity against human MESSA cells assessed as growth inhibition after 72 hrs by Celltiter-Glo luminescent assay
|
[PMID: 23214452] |
| MES-SA | GI50 |
4 nM
Compound: PTX, Taxol
|
Growth inhibition of human MES-SA cells
Growth inhibition of human MES-SA cells
|
[PMID: 23750455] |
| MES-SA | GI50 |
7 nM
Compound: Taxol
|
Growth inhibition of human MES-SA cells after 48 hrs by MTT assay
Growth inhibition of human MES-SA cells after 48 hrs by MTT assay
|
[PMID: 23927793] |
| MES-SA | IC50 |
0.005 μM
Compound: Taxol
|
Cytotoxicity against human MES-SA cells
Cytotoxicity against human MES-SA cells
|
[PMID: 23937981] |
| MES-SA | IC50 |
5 μM
Compound: Taxol
|
Cytotoxicity against multidrug-resistant human MES-SA cells
Cytotoxicity against multidrug-resistant human MES-SA cells
|
[PMID: 23937981] |
| MES-SA | IC50 |
4 nM
Compound: PTX
|
Cytotoxicity against human MESSA cells assessed as growth inhibition after 72 hrs by CellTitre-Glo assay
Cytotoxicity against human MESSA cells assessed as growth inhibition after 72 hrs by CellTitre-Glo assay
|
[PMID: 25025991] |
| MES-SA | IC50 |
0.008 μM
Compound: Taxol, Paclitaxel
|
Cytotoxicity against human MES-SA cells after 24 hrs by MTT assay
Cytotoxicity against human MES-SA cells after 24 hrs by MTT assay
|
[PMID: 25462222] |
| MES-SA | GI50 |
0.007 μM
Compound: taxol
|
Antiproliferative activity against human MES-SA cells assessed as reduction in cell viability after 48 hrs by MTT assay
Antiproliferative activity against human MES-SA cells assessed as reduction in cell viability after 48 hrs by MTT assay
|
[PMID: 25671501] |
| MES-SA | IC50 |
4 nM
Compound: PTX
|
Cytotoxicity against human MESSA cells assessed as growth inhibition after 72 hrs by CellTiter-Glo assay
Cytotoxicity against human MESSA cells assessed as growth inhibition after 72 hrs by CellTiter-Glo assay
|
[PMID: 26132075] |
| MES-SA | GI50 |
0.007 μM
Compound: paclitaxel
|
Cytotoxicity against human MES-SA cells assessed as growth inhibition incubated for 48 hrs by MTT assay
Cytotoxicity against human MES-SA cells assessed as growth inhibition incubated for 48 hrs by MTT assay
|
[PMID: 26360047] |
| MES-SA | GI50 |
0.007 μM
Compound: Paclitaxel
|
Antiproliferative activity against human MES-SA cells after 48 to 96 hrs by MTT assay
Antiproliferative activity against human MES-SA cells after 48 to 96 hrs by MTT assay
|
[PMID: 27218860] |
| MES-SA | IC50 |
2.47 nM
Compound: Paclitaxel
|
Cytotoxicity against human MES-SA cells assessed as inhibition in cell growth
Cytotoxicity against human MES-SA cells assessed as inhibition in cell growth
|
[PMID: 33974423] |
| MES-SA | IC50 |
1.1 nM
Compound: PT
|
Antiproliferative activity against human MES-SA cells assessed as reduction in cell viability incubated for 72 hrs by CelltiterGlo luminescent assay
Antiproliferative activity against human MES-SA cells assessed as reduction in cell viability incubated for 72 hrs by CelltiterGlo luminescent assay
|
[PMID: 38959729] |
| MES-SA/Dx5 | IC50 |
0.0003 μM
Compound: PTX
|
The compound was evaluated for the growth inhibition of Dx5 w/PSC cell lines using MTT assay.
The compound was evaluated for the growth inhibition of Dx5 w/PSC cell lines using MTT assay.
|
[PMID: 10698449] |
| MES-SA/Dx5 | IC50 |
2.7 μM
Compound: PTX
|
The compound was evaluated for the growth inhibition of Dx5 cell lines using MTT assay.
The compound was evaluated for the growth inhibition of Dx5 cell lines using MTT assay.
|
[PMID: 10698449] |
| MES-SA/Dx5 | IC50 |
uM μM
Compound: paclitaxel
|
In vitro cytotoxic activity against uterine sarcoma (MES-SA) cells assayed by inhibition of [3H]-labeled thymidine incorporation
In vitro cytotoxic activity against uterine sarcoma (MES-SA) cells assayed by inhibition of [3H]-labeled thymidine incorporation
|
[PMID: 11728191] |
| MES-SA/Dx5 | GI50 |
>10 μM
Compound: paclitaxel
|
Tested for inhibition of cell proliferation activity in doxorubicin resistant human uterus sarcoma MES-SA/DX5 cell
Tested for inhibition of cell proliferation activity in doxorubicin resistant human uterus sarcoma MES-SA/DX5 cell
|
[PMID: 12773051] |
| MES-SA/Dx5 | GI50 |
0.063 μM
Compound: paclitaxel
|
Tested for inhibition of cell proliferation activity in human uterus sarcoma MES-SA cell
Tested for inhibition of cell proliferation activity in human uterus sarcoma MES-SA cell
|
[PMID: 12773051] |
| MES-SA/Dx5 | IC50 |
5 μM
Compound: Taxol
|
Cytotoxicity against human MES-SA/DX5 cell line by MTS assay
Cytotoxicity against human MES-SA/DX5 cell line by MTS assay
|
[PMID: 16870446] |
| MES-SA/Dx5 | IC50 |
>1000 nM
Compound: paclitaxel
|
Antiproliferative activity against drug resistant Messa/DX5 cell line expressing MDR1 by Alamar Blue assay
Antiproliferative activity against drug resistant Messa/DX5 cell line expressing MDR1 by Alamar Blue assay
|
[PMID: 17286393] |
| MES-SA/Dx5 | IC50 |
5 μM
Compound: Taxol
|
Cytotoxicity against human MESSA/DX5 cells after 72 hrs by MTT assay
Cytotoxicity against human MESSA/DX5 cells after 72 hrs by MTT assay
|
[PMID: 18308566] |
| MES-SA/Dx5 | GI50 |
0.16 μM
Compound: Paclitaxel
|
Antiproliferative activity against multidrug resistant human MES-SA/Dx5 cells by SRB assay
Antiproliferative activity against multidrug resistant human MES-SA/Dx5 cells by SRB assay
|
[PMID: 19394218] |
| MES-SA/Dx5 | GI50 |
7.54 μM
Compound: Taxol
|
Intrinsic cytotoxicity against human MES-SA/Dx5 cells
Intrinsic cytotoxicity against human MES-SA/Dx5 cells
|
[PMID: 19679475] |
| MES-SA/Dx5 | IC50 |
7538 nM
Compound: Taxol
|
Cytotoxicity against human MES-SA/Dx5 cells
Cytotoxicity against human MES-SA/Dx5 cells
|
[PMID: 19679475] |
| MES-SA/Dx5 | IC50 |
750 nM
Compound: PTX
|
Cytotoxicity against multidrug-resistant human MES-SA/Dx5 cells assessed as cell viability after 96 hrs by trypan blue exclusion
Cytotoxicity against multidrug-resistant human MES-SA/Dx5 cells assessed as cell viability after 96 hrs by trypan blue exclusion
|
[PMID: 21812421] |
| MES-SA/Dx5 | IC50 |
750 nM
Compound: A, paclitaxel, taxol
|
Cytotoxicity against human MESSA/DX5 cells after 96 hrs by trypan blue exclusion assay
Cytotoxicity against human MESSA/DX5 cells after 96 hrs by trypan blue exclusion assay
|
[PMID: 22587519] |
| MES-SA/Dx5 | IC50 |
1764 nM
Compound: PTX
|
Cytotoxicity against human MESSA/DX5 cells assessed as growth inhibition after 72 hrs by Celltiter-Glo luminescent assay
Cytotoxicity against human MESSA/DX5 cells assessed as growth inhibition after 72 hrs by Celltiter-Glo luminescent assay
|
[PMID: 23214452] |
| MES-SA/Dx5 | GI50 |
750 nM
Compound: PTX, Taxol
|
Growth inhibition of multidrug-resistant human MES-SA/Dx5 cells
Growth inhibition of multidrug-resistant human MES-SA/Dx5 cells
|
[PMID: 23750455] |
| MES-SA/Dx5 | GI50 |
9800 nM
Compound: Taxol
|
Growth inhibition of human doxorubicin-resistant MES-SA/Dx5 cells after 48 hrs by MTT assay
Growth inhibition of human doxorubicin-resistant MES-SA/Dx5 cells after 48 hrs by MTT assay
|
[PMID: 23927793] |
| MES-SA/Dx5 | IC50 |
10 μM
Compound: Taxol
|
Cytotoxicity against human MES-SA/Dx5 cells
Cytotoxicity against human MES-SA/Dx5 cells
|
[PMID: 23937981] |
| MES-SA/Dx5 | IC50 |
1764 nM
Compound: PTX
|
Cytotoxicity against human MESSA/DX5 cells assessed as growth inhibition after 72 hrs by CellTitre-Glo assay
Cytotoxicity against human MESSA/DX5 cells assessed as growth inhibition after 72 hrs by CellTitre-Glo assay
|
[PMID: 25025991] |
| MES-SA/Dx5 | IC50 |
5.1 μM
Compound: Taxol, Paclitaxel
|
Cytotoxicity against human MES-SA/Dx5 cells after 24 hrs by MTT assay
Cytotoxicity against human MES-SA/Dx5 cells after 24 hrs by MTT assay
|
[PMID: 25462222] |
| MES-SA/Dx5 | GI50 |
9.8 μM
Compound: taxol
|
Antiproliferative activity against human MES-SA/Dx5 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Antiproliferative activity against human MES-SA/Dx5 cells assessed as reduction in cell viability after 48 hrs by MTT assay
|
[PMID: 25671501] |
| MES-SA/Dx5 | IC50 |
1764 nM
Compound: PTX
|
Cytotoxicity against human MESSA/DX5 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo assay
Cytotoxicity against human MESSA/DX5 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo assay
|
[PMID: 26132075] |
| MES-SA/Dx5 | GI50 |
10 μM
Compound: paclitaxel
|
Cytotoxicity against human MES-SA/Dx5 cells assessed as growth inhibition incubated for 48 hrs by MTT assay
Cytotoxicity against human MES-SA/Dx5 cells assessed as growth inhibition incubated for 48 hrs by MTT assay
|
[PMID: 26360047] |
| MES-SA/Dx5 | GI50 |
10 μM
Compound: Paclitaxel
|
Antiproliferative activity against human MES-SA/Dx5 cells after 48 to 96 hrs by MTT assay
Antiproliferative activity against human MES-SA/Dx5 cells after 48 to 96 hrs by MTT assay
|
[PMID: 27218860] |
| MES-SA/Dx5 | IC50 |
210 nM
Compound: Paclitaxel
|
Growth inhibition of human MES-SA/Dx5 cells after 72 hrs by SRB assay
Growth inhibition of human MES-SA/Dx5 cells after 72 hrs by SRB assay
|
[PMID: 29251920] |
| MES-SA/Dx5 | GI50 |
1800 nM
Compound: Paclitaxel
|
Antiproliferative activity against human MES-SA/Dx5 cells
Antiproliferative activity against human MES-SA/Dx5 cells
|
[PMID: 29617135] |
| MES-SA/Dx5 | IC50 |
>400 nM
Compound: Paclitaxel
|
Cytotoxicity against human MES-SA/Dx5 cells assessed as inhibition in cell growth
Cytotoxicity against human MES-SA/Dx5 cells assessed as inhibition in cell growth
|
[PMID: 33974423] |
| MEXF514 | IC50 |
1.03 μM
Compound: Paclitaxel
|
In vitro inhibitory concentration of compound against human cancer MEXF 514 cell line was determined
In vitro inhibitory concentration of compound against human cancer MEXF 514 cell line was determined
|
[PMID: 12882225] |
| MGC-803 | IC50 |
0.85 μM
Compound: Taxol
|
Cytotoxicity against human MGC803 cells after 72 hrs by MTT assay
Cytotoxicity against human MGC803 cells after 72 hrs by MTT assay
|
[PMID: 22483090] |
| MGC-803 | IC50 |
0.85 μM
Compound: Taxol
|
Antiproliferative activity against human MGC803 cells assessed as growth inhibition by MTT assay
Antiproliferative activity against human MGC803 cells assessed as growth inhibition by MTT assay
|
[PMID: 23274570] |
| MGC-803 | IC50 |
0.85 μM
Compound: Taxol
|
Cytotoxicity against human MGC803 cells after 72 hrs by MTT assay
Cytotoxicity against human MGC803 cells after 72 hrs by MTT assay
|
[PMID: 23644204] |
| MGC-803 | IC50 |
0.83 μM
Compound: PTX
|
Antiproliferative activity against human MGC803 cells after 24 hrs by MTT assay
Antiproliferative activity against human MGC803 cells after 24 hrs by MTT assay
|
[PMID: 27491707] |
| MGC-803 | IC50 |
3.8 μM
Compound: Paclitaxel
|
Cytotoxicity against human MGC803 cells assessed as reduction in cell viability measured after 72 hrs by CCK8 assay
Cytotoxicity against human MGC803 cells assessed as reduction in cell viability measured after 72 hrs by CCK8 assay
|
[PMID: 32193933] |
| MGC-803 | IC50 |
3.8 nM
Compound: Paclitaxel
|
Cytotoxicity against human MGC803 cells after 72 hrs by CCK8 assay
Cytotoxicity against human MGC803 cells after 72 hrs by CCK8 assay
|
[PMID: 32489099] |
| MGC-803 | IC50 |
45.22 nM
Compound: Paclitaxel
|
Potentiation of paclitaxel-induced cytotoxicity against PTX-resistant human MGC-803 cells assessed as paclitaxel IC50 incubated for 24 hrs by MTT assay (Rvb = 88.68 nM)
Potentiation of paclitaxel-induced cytotoxicity against PTX-resistant human MGC-803 cells assessed as paclitaxel IC50 incubated for 24 hrs by MTT assay (Rvb = 88.68 nM)
|
[PMID: 32682200] |
| MIA PaCa-2 | IC50 |
7.2 nM
Compound: PTX
|
Cytotoxicity against human MIAPaCa2 cells after 72 hrs by coulter counter analysis
Cytotoxicity against human MIAPaCa2 cells after 72 hrs by coulter counter analysis
|
[PMID: 23140358] |
| MIA PaCa-2 | IC50 |
6.1 nM
Compound: 28
|
Antiproliferative activity against human MIAPaCa2 cells after 72 hrs by WST8 assay
Antiproliferative activity against human MIAPaCa2 cells after 72 hrs by WST8 assay
|
[PMID: 25625617] |
| MIA PaCa-2 | IC50 |
2.5 μM
Compound: Paclitaxel
|
Antiproliferative activity against human MIAPaCa2 cells after 48 hrs by MTT assay
Antiproliferative activity against human MIAPaCa2 cells after 48 hrs by MTT assay
|
[PMID: 28667872] |
| MIA PaCa-2 | IC50 |
6 nM
Compound: Paclitaxel
|
Cytotoxicity against human MIAPaCa2 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Cytotoxicity against human MIAPaCa2 cells assessed as reduction in cell viability after 48 hrs by MTT assay
|
[PMID: 29759727] |
| MIA PaCa-2 | IC50 |
0.003 μM
Compound: PTX
|
Cytotoxicity against human MIA PaCa-2 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay
Cytotoxicity against human MIA PaCa-2 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay
|
[PMID: 38547648] |
| MIA PaCa-2 | EC50 |
0.002 x 10-3 μM
Compound: Paclitaxel
|
Cytotoxicity against human MIA PaCa-2 cells incubated for 48 to 72 hrs by MTT assay
Cytotoxicity against human MIA PaCa-2 cells incubated for 48 to 72 hrs by MTT assay
|
[PMID: 39038808] |
| MIA PaCa-2 | IC50 |
0.1 μM
Compound: Paclitaxel
|
Antiproliferative activity against human MIAPaCa2 cells assessed as cell viability after 48 hrs by MTT assay
Antiproliferative activity against human MIAPaCa2 cells assessed as cell viability after 48 hrs by MTT assay
|
10.1039/C4MD00344F |
| MIA PaCa-2 | IC50 |
2.5 μM
Compound: Paclitaxel
|
Antiproliferative activity against human MIAPaCa2 cells after 48 hrs by MTT assay
Antiproliferative activity against human MIAPaCa2 cells after 48 hrs by MTT assay
|
10.1039/C6MD00256K |
| MKN-45 | IC50 |
0.0026 μM
Compound: paclitaxel
|
Antitumor activity against human MKN45 cell line
Antitumor activity against human MKN45 cell line
|
[PMID: 16884301] |
| MKN-45 | IC50 |
0.0005 μM
Compound: paclitaxel
|
Cytotoxicity against human MKN45 cells
Cytotoxicity against human MKN45 cells
|
[PMID: 17113288] |
| MKN-45 | IC50 |
89.06 μM
Compound: paclitaxel
|
Cytotoxicity against human MKN45 cells after 72 hrs by MTT assay
Cytotoxicity against human MKN45 cells after 72 hrs by MTT assay
|
[PMID: 19053781] |
| MKN-45 | IC50 |
4 nM
Compound: 28
|
Antiproliferative activity against human MKN45 cells after 72 hrs by WST8 assay
Antiproliferative activity against human MKN45 cells after 72 hrs by WST8 assay
|
[PMID: 25625617] |
| MKN-45 | EC50 |
0.003 μM
Compound: Taxol
|
Antitumor activity against human MKN-45 cells assessed as inhibition of cell growth measured after 48 hrs by CCK-8 assay
Antitumor activity against human MKN-45 cells assessed as inhibition of cell growth measured after 48 hrs by CCK-8 assay
|
[PMID: 38878517] |
| MM96L | IC50 |
>10 μM
Compound: Paclitaxel
|
Cytotoxicity against human MM96L after 24 hrs by MTT assay
Cytotoxicity against human MM96L after 24 hrs by MTT assay
|
[PMID: 30387611] |
| MM96L | IC50 |
>10 μM
Compound: Paclitaxel
|
Cytotoxicity against human MM96L after 48 hrs by MTT assay
Cytotoxicity against human MM96L after 48 hrs by MTT assay
|
[PMID: 30387611] |
| MOLM-13 | IC50 |
3.45 nM
Compound: PTX
|
Antiproliferative activity against human MOLM-13 cells incubated for 72 hrs by MTT assay
Antiproliferative activity against human MOLM-13 cells incubated for 72 hrs by MTT assay
|
[PMID: 34648295] |
| MOLM-13 | IC50 |
0.004 μM
Compound: PTX
|
Antiproliferative activity against human MOLM-13 cells assessed as reduction in cell viability measured after 72 hrs
Antiproliferative activity against human MOLM-13 cells assessed as reduction in cell viability measured after 72 hrs
|
[PMID: 38430854] |
| MOLT-4 | IC50 |
2.7 nM
Compound: Taxol
|
Cytotoxicity against human MOLT4 cells expressing BCR-ABL assessed as growth inhibition after 72 hrs by CCK-8 assay
Cytotoxicity against human MOLT4 cells expressing BCR-ABL assessed as growth inhibition after 72 hrs by CCK-8 assay
|
[PMID: 23301703] |
| MOLT-4 | GI50 |
0.032 μM
Compound: 1a, PXL, Taxol
|
Cytotoxicity against human MOLT4 cells
Cytotoxicity against human MOLT4 cells
|
[PMID: 23725535] |
| MOLT-4 | IC50 |
1.8 nM
Compound: Taxol
|
Cytotoxicity against human MOLT4 cells by MTT assay
Cytotoxicity against human MOLT4 cells by MTT assay
|
[PMID: 23806112] |
| MOLT-4 | GI50 |
2.232 nM
Compound: 1, Taxol
|
Growth inhibition of human MOLT4 cells by MTT assay
Growth inhibition of human MOLT4 cells by MTT assay
|
[PMID: 24405702] |
| MOLT-4 | IC50 |
2.2 nM
Compound: Taxol
|
Cytotoxicity against human MOLT4 cells assessed as cell viability after 72 hrs by CCK8 assay
Cytotoxicity against human MOLT4 cells assessed as cell viability after 72 hrs by CCK8 assay
|
[PMID: 25819096] |
| MOLT-4 | IC50 |
2.7 μM
Compound: taxol
|
Cytotoxicity against human MOLT4 cells after 72 hrs by CCK8 assay
Cytotoxicity against human MOLT4 cells after 72 hrs by CCK8 assay
|
[PMID: 26316467] |
| MOLT-4 | GI50 |
5 nM
Compound: Paclitaxel
|
Growth inhibition of human MOLT4 cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human MOLT4 cells incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 29655610] |
| MOLT-4 | GI50 |
5 nM
Compound: Paclitaxel
|
Cytotoxicity against human MOLT-4 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay
Cytotoxicity against human MOLT-4 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay
|
[PMID: 33310545] |
| MOLT-4 | IC50 |
0.004 μM
Compound: PTX
|
Cytotoxicity against human MOLT-4 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay
Cytotoxicity against human MOLT-4 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay
|
[PMID: 38547648] |
| MOLT-4 | IC50 |
1.6 nM
Compound: taxol
|
The compound was tested for inhibition concentration against MOLT-4 cell line
The compound was tested for inhibition concentration against MOLT-4 cell line
|
[PMID: 7907372] |
| MRC5 | IC50 |
80 nM
Compound: 28
|
Antiproliferative activity against human MRC5 cells after 72 hrs by WST8 assay
Antiproliferative activity against human MRC5 cells after 72 hrs by WST8 assay
|
[PMID: 25625617] |
| MRC5 | IC50 |
0.00052 μM
Compound: Paclitaxel
|
Cytotoxic activity against human MRC5 cells incubated for 72 hrs by resazurin dye based spectrophotometry
Cytotoxic activity against human MRC5 cells incubated for 72 hrs by resazurin dye based spectrophotometry
|
[PMID: 28282127] |
| MRC5 | IC50 |
>200 μM
Compound: Paclitaxel
|
Cytotoxicity against human MRC5 cells assessed as inhibition of cell viability after 48 hrs by SRB assay
Cytotoxicity against human MRC5 cells assessed as inhibition of cell viability after 48 hrs by SRB assay
|
[PMID: 30798081] |
| MRC5 | IC50 |
0.00052 μM
Compound: Paclitaxel
|
Growth inhibition of human MRC5 cells after 72 hrs by resazurin dye based spectrophotometric method assay
Growth inhibition of human MRC5 cells after 72 hrs by resazurin dye based spectrophotometric method assay
|
[PMID: 32091210] |
| MRC5 | IC50 |
25 μM
Compound: 31
|
Cytotoxicity against human MRC5 cells assessed as reduction in cell viability by Almar Blue stained fluorescence-based assay
Cytotoxicity against human MRC5 cells assessed as reduction in cell viability by Almar Blue stained fluorescence-based assay
|
[PMID: 32858470] |
| MRC5 | IC50 |
0.00052 μM
Compound: Paclitaxel
|
Cytotoxicity against human MRC5 cells assessed as growth inhibition measured after 72 hrs by MTS assay
Cytotoxicity against human MRC5 cells assessed as growth inhibition measured after 72 hrs by MTS assay
|
[PMID: 33825474] |
| MRC5 | IC50 |
0.523 μM
Compound: Paclitaxel
|
Cytotoxicity against human MRC-5 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
Cytotoxicity against human MRC-5 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
|
[PMID: 35450348] |
| MV4-11 | IC50 |
0.017 μM
Compound: Taxol
|
Antiproliferative activity against human MV411 cells after 72 hrs by MTT assay
Antiproliferative activity against human MV411 cells after 72 hrs by MTT assay
|
[PMID: 30212198] |
| MV4-11 | IC50 |
1.62 nM
Compound: PTX
|
Antiproliferative activity against human MV4-11 cells incubated for 72 hrs by MTT assay
Antiproliferative activity against human MV4-11 cells incubated for 72 hrs by MTT assay
|
[PMID: 34648295] |
| MV4-11 | IC50 |
3.4 nM
Compound: 1
|
Antiproliferative activity against human MV4-11 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay
Antiproliferative activity against human MV4-11 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay
|
[PMID: 37544183] |
| MV4-11 | IC50 |
3.4 nM
Compound: 1
|
Antiproliferative activity against human MV4-11 cells transfected with FLT3-ITD mutant assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay
Antiproliferative activity against human MV4-11 cells transfected with FLT3-ITD mutant assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay
|
[PMID: 37544183] |
| MV4-11 | IC50 |
0.75 μM
Compound: Paclitaxel
|
Cytotoxicity against human MV411 cells assessed as inhibition of cell proliferation after 96 hrs by MTT assay
Cytotoxicity against human MV411 cells assessed as inhibition of cell proliferation after 96 hrs by MTT assay
|
10.1039/C4MD00573B |
| MX1 | IC50 |
0.0225 μM
Compound: taxol
|
Antiproliferative activity against human MX1 cell line
Antiproliferative activity against human MX1 cell line
|
[PMID: 16759114] |
| MX1 | IC50 |
35 nM
Compound: taxol
|
Cytotoxicity against human MX1 cells after 72 hrs by SRB assay
Cytotoxicity against human MX1 cells after 72 hrs by SRB assay
|
[PMID: 18450456] |
| MX1 | IC50 |
0.046 μM
Compound: taxol
|
Cytotoxicity against human MX1 cells after 72 hrs by SRB assay
Cytotoxicity against human MX1 cells after 72 hrs by SRB assay
|
[PMID: 19124250] |
| MX1 | IC50 |
0.046 μM
Compound: Taxol
|
Cytotoxicity against human MX1 cells after 72 hrs by SRB assay
Cytotoxicity against human MX1 cells after 72 hrs by SRB assay
|
[PMID: 19576785] |
| MX1 | IC50 |
0.035 μM
Compound: Taxol
|
Cytotoxicity against human MX1 cells after 72 hrs by SRB assay
Cytotoxicity against human MX1 cells after 72 hrs by SRB assay
|
[PMID: 20181487] |
| MX1 | IC50 |
0.035 μM
Compound: Taxol
|
Cytotoxicity against human MX1 cells after 72 hrs by SRB assay
Cytotoxicity against human MX1 cells after 72 hrs by SRB assay
|
[PMID: 21144756] |
| MX1 | IC50 |
5.59 nM
Compound: Paclitaxel
|
Cytotoxicity against folate receptor over-expressing human MX1 cells after 72 hrs by MTT assay
Cytotoxicity against folate receptor over-expressing human MX1 cells after 72 hrs by MTT assay
|
[PMID: 25819334] |
| NALM-6 | IC50 |
0.0041 μM
Compound: Paclitaxel
|
Antiproliferative activity against human NALM6 cells after 48 to 72 hrs by trypan blue dye exclusion assay and MTT assay
Antiproliferative activity against human NALM6 cells after 48 to 72 hrs by trypan blue dye exclusion assay and MTT assay
|
[PMID: 24852281] |
| NB-4 | IC50 |
0.1 μM
Compound: Paclitaxel
|
Cytotoxicity against human NB4 cells after 48 hrs by WST-8 assay
Cytotoxicity against human NB4 cells after 48 hrs by WST-8 assay
|
[PMID: 19072209] |
| NB-4 | IC50 |
0.1 μM
Compound: paclitaxel
|
Cytotoxicity against human NB4 cells after 48 hrs by SRB method
Cytotoxicity against human NB4 cells after 48 hrs by SRB method
|
[PMID: 19425589] |
| NB-4 | IC50 |
0.03 μM
Compound: Paclitaxel
|
Cytotoxicity against human NB4 cells after 3 days by MTT assay
Cytotoxicity against human NB4 cells after 3 days by MTT assay
|
[PMID: 23738539] |
| NB-4 | IC50 |
0.03 μM
Compound: paclitaxel
|
Cytotoxicity against human NB4 cells assessed as growth inhibition after 72 hrs by MTT assay
Cytotoxicity against human NB4 cells assessed as growth inhibition after 72 hrs by MTT assay
|
[PMID: 24063567] |
| NB-4 | IC50 |
0.03 μM
Compound: Paclitaxel
|
Cytotoxicity against human NB4 cells after 48 hrs by MTT assay
Cytotoxicity against human NB4 cells after 48 hrs by MTT assay
|
[PMID: 24063582] |
| NB-4 | IC50 |
2.3 nM
Compound: PTX
|
Cytotoxicity against human NB4 cells assessed as growth inhibition after 48 hrs by CellTiter-Fluor assay
Cytotoxicity against human NB4 cells assessed as growth inhibition after 48 hrs by CellTiter-Fluor assay
|
[PMID: 26132075] |
| NCI/ADR-RES | GI50 |
>50 μM
Compound: Paclitaxel
|
Cytotoxic activity against MCF-7/ADR cell lines
Cytotoxic activity against MCF-7/ADR cell lines
|
[PMID: 10406652] |
| NCI/ADR-RES | IC50 |
299 nM
Compound: Paclitaxel
|
In vitro cytotoxicity of compound against human MCF-7-MDR (breast) cancer cell line after 72 hr of drug exposure
In vitro cytotoxicity of compound against human MCF-7-MDR (breast) cancer cell line after 72 hr of drug exposure
|
[PMID: 12477344] |
| NCI/ADR-RES | GI50 |
8 μM
Compound: Paclitaxel
|
Compound was tested for growth inhibition of multidrug resistant tumor MCF-7/ADR cell line
Compound was tested for growth inhibition of multidrug resistant tumor MCF-7/ADR cell line
|
[PMID: 15546733] |
| NCI/ADR-RES | ED50 |
1.53 nM
Compound: 1
|
Cytotoxicity against multidrug resistant breast cancer MCF7/ADR cell line
Cytotoxicity against multidrug resistant breast cancer MCF7/ADR cell line
|
[PMID: 16289636] |
| NCI/ADR-RES | EC50 |
>10 μM
Compound: Taxol
|
Cell cycle arrest in NCI/ADR (MDR) cells by accumulation at G2/M phase
Cell cycle arrest in NCI/ADR (MDR) cells by accumulation at G2/M phase
|
[PMID: 16377187] |
| NCI/ADR-RES | ED50 |
1.5 μM
Compound: 1
|
Cytotoxicity against human NCI/ADR-RES cells
Cytotoxicity against human NCI/ADR-RES cells
|
[PMID: 18926701] |
| NCI/ADR-RES | IC50 |
1300 nM
Compound: 1,paclitaxel
|
Cytotoxicity against taxol-resistant human NCI/ADR-RES cells after 72 hrs by MTT assay
Cytotoxicity against taxol-resistant human NCI/ADR-RES cells after 72 hrs by MTT assay
|
[PMID: 18951787] |
| NCI/ADR-RES | ED50 |
2 μM
Compound: paclitaxel
|
Cytotoxicity against human NCI/ADR-RES cells
Cytotoxicity against human NCI/ADR-RES cells
|
[PMID: 18977659] |
| NCI/ADR-RES | IC50 |
13 μM
Compound: Paclitaxel
|
Cytotoxicity against human NCI-ADR-RES expressing MDR1 cells after 48 to 72 hrs by WAT-1 assay
Cytotoxicity against human NCI-ADR-RES expressing MDR1 cells after 48 to 72 hrs by WAT-1 assay
|
[PMID: 21126027] |
| NCI/ADR-RES | IC50 |
6263 nM
Compound: Paclitaxel
|
Anticancer activity against P-gp overexpressing human NCI/ADR-RES cells after 96 hrs by SRB assay
Anticancer activity against P-gp overexpressing human NCI/ADR-RES cells after 96 hrs by SRB assay
|
[PMID: 21557538] |
| NCI/ADR-RES | IC50 |
>6400 nM
Compound: Paclitaxel
|
Cytotoxicity against human NCI-ADR-RES cells after 48 hrs by Alamar blue assay
Cytotoxicity against human NCI-ADR-RES cells after 48 hrs by Alamar blue assay
|
[PMID: 21779519] |
| NCI/ADR-RES | IC50 |
1500 nM
Compound: PTX
|
Growth inhibition of doxorubicin-resistant human NCI-ADR-RES cells overexpressing P-glycoprotein after 96 hrs
Growth inhibition of doxorubicin-resistant human NCI-ADR-RES cells overexpressing P-glycoprotein after 96 hrs
|
[PMID: 22044164] |
| NCI/ADR-RES | IC50 |
3300 nM
Compound: PTX
|
Cytotoxicity against human NCI/ADR-RES cells assessed as growth inhibition by trypan blue exclusion assay
Cytotoxicity against human NCI/ADR-RES cells assessed as growth inhibition by trypan blue exclusion assay
|
[PMID: 23214452] |
| NCI/ADR-RES | IC50 |
6.9 μM
Compound: Taxol
|
Cytotoxicity against human MCF7/ADR cells by MTT assay
Cytotoxicity against human MCF7/ADR cells by MTT assay
|
[PMID: 23425970] |
| NCI/ADR-RES | GI50 |
0.04 μM
Compound: PCT
|
Growth inhibition of human NCI-ADR-RES cells after 48 hrs by sulforhodamine B assay
Growth inhibition of human NCI-ADR-RES cells after 48 hrs by sulforhodamine B assay
|
[PMID: 24727464] |
| NCI/ADR-RES | EC50 |
13 nM
Compound: paclitaxel
|
Cytotoxicity against human NCI-ADR-RES cells assessed as inhibition of cell proliferation by SRB assay
Cytotoxicity against human NCI-ADR-RES cells assessed as inhibition of cell proliferation by SRB assay
|
[PMID: 24801610] |
| NCI/ADR-RES | IC50 |
5000 nM
Compound: paclitaxel
|
Growth inhibition of human NCI/ADR-RES cells overexpressing P-gp after 96 hrs incubation by sulforhodamine B technique
Growth inhibition of human NCI/ADR-RES cells overexpressing P-gp after 96 hrs incubation by sulforhodamine B technique
|
[PMID: 24900865] |
| NCI/ADR-RES | IC50 |
3300 nM
Compound: PTX
|
Cytotoxicity against human NCI/ADR-RES cells assessed as growth inhibition after 96 hrs by Giemsa staining-based light microscopy
Cytotoxicity against human NCI/ADR-RES cells assessed as growth inhibition after 96 hrs by Giemsa staining-based light microscopy
|
[PMID: 25025991] |
| NCI/ADR-RES | IC50 |
4.36 x 10-2 M
Compound: paclitaxel
|
Cytotoxicity against human MCF7/ADR cells assessed as reduction in cell viability after 48 hrs by SRB colorimetric assay
Cytotoxicity against human MCF7/ADR cells assessed as reduction in cell viability after 48 hrs by SRB colorimetric assay
|
[PMID: 25856545] |
| NCI/ADR-RES | IC50 |
6000 nM
Compound: PTX
|
Cytotoxicity against Pgp overexpressing human NCI-ADR-RES cells assessed as growth inhibition after 48 hrs by SRB assay
Cytotoxicity against Pgp overexpressing human NCI-ADR-RES cells assessed as growth inhibition after 48 hrs by SRB assay
|
[PMID: 26132075] |
| NCI/ADR-RES | IC50 |
9153 nM
Compound: Paclitaxel
|
Cytotoxicity against P-gp overexpressing human MCF7/ADR cells assessed as reduction in cell growth after 24 hrs by MTT assay
Cytotoxicity against P-gp overexpressing human MCF7/ADR cells assessed as reduction in cell growth after 24 hrs by MTT assay
|
[PMID: 27213819] |
| NCI/ADR-RES | IC50 |
2500 μM
Compound: Paclitaxel
|
Growth inhibition of human NCI/ADR-RES cells over expressing Pgp measured after 96 hrs by sulforhodamine B assay
Growth inhibition of human NCI/ADR-RES cells over expressing Pgp measured after 96 hrs by sulforhodamine B assay
|
[PMID: 27894589] |
| NCI/ADR-RES | IC50 |
>10 μM
Compound: Paclitaxel
|
Antiproliferative activity against human NCI-ADR-RES cells after 48 hrs by SRB assay
Antiproliferative activity against human NCI-ADR-RES cells after 48 hrs by SRB assay
|
[PMID: 28335606] |
| NCI/ADR-RES | GI50 |
5943 nM
Compound: Paclitaxel
|
Antiproliferative activity against human NCI/ADR-RES cells
Antiproliferative activity against human NCI/ADR-RES cells
|
[PMID: 29617135] |
| NCI/ADR-RES | GI50 |
630 nM
Compound: Paclitaxel
|
Growth inhibition of human NCI/ADR-RES cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human NCI/ADR-RES cells incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 29655610] |
| NCI/ADR-RES | IC50 |
3100 nM
Compound: PTX
|
Growth inhibition of human NCI/ADR-RES cells after 96 hrs by trypan blue exclusion assay
Growth inhibition of human NCI/ADR-RES cells after 96 hrs by trypan blue exclusion assay
|
[PMID: 29730191] |
| NCI/ADR-RES | IC50 |
>9000 μM
Compound: Paclitaxel
|
Antiproliferative activity against taxane-resistant human NCI/ADR-RES cells after 72 hrs by CellTiter 96 aqueous nonradioactive cell proliferation assay
Antiproliferative activity against taxane-resistant human NCI/ADR-RES cells after 72 hrs by CellTiter 96 aqueous nonradioactive cell proliferation assay
|
[PMID: 29995409] |
| NCI/ADR-RES | IC50 |
>100000 nM
Compound: Paclitaxol
|
Cytotoxicity against human MCF7/ADR cells after 72 hrs by sulforhodamine B assay
Cytotoxicity against human MCF7/ADR cells after 72 hrs by sulforhodamine B assay
|
[PMID: 30036834] |
| NCI/ADR-RES | IC50 |
17.68 μM
Compound: TAX
|
Cytotoxicity against human MCF7/ADR cells after 72 hrs by MTT assay
Cytotoxicity against human MCF7/ADR cells after 72 hrs by MTT assay
|
[PMID: 30677614] |
| NCI/ADR-RES | IC50 |
>10000 nM
Compound: PTX
|
Cytotoxicity against human MCF7/ADR cells after 72 hrs by SRB assay
Cytotoxicity against human MCF7/ADR cells after 72 hrs by SRB assay
|
[PMID: 30819618] |
| NCI/ADR-RES | GI50 |
630 nM
Compound: Paclitaxel
|
Cytotoxicity against human NCI/ADR-RES cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay
Cytotoxicity against human NCI/ADR-RES cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay
|
[PMID: 33310545] |
| NCI/ADR-RES | IC50 |
0.181 μM
Compound: Paclitaxel
|
Anticancer activity against Multi drug resistant human NCI-ADR-RES cells assessed as inhibition of cell growth
Anticancer activity against Multi drug resistant human NCI-ADR-RES cells assessed as inhibition of cell growth
|
[PMID: 33328099] |
| NCI/ADR-RES | IC50 |
800 nM
Compound: Paclitaxel
|
Antiproliferative activity against human NCI/ADR-RES cells overexpressing Pgp
Antiproliferative activity against human NCI/ADR-RES cells overexpressing Pgp
|
[PMID: 33705908] |
| NCI/ADR-RES | IC50 |
58.7 μM
Compound: Paclitaxel
|
Antiproliferative activity against human MCF7/ADR cells incubated for 48 hrs by CCK-8 assay
Antiproliferative activity against human MCF7/ADR cells incubated for 48 hrs by CCK-8 assay
|
[PMID: 33725657] |
| NCI/ADR-RES | IC50 |
9335 nM
Compound: PTX
|
Cytotoxicity in human NCI-ADR-RES assessed as inhibition in cell growth measured after 24 hrs by MTT assay
Cytotoxicity in human NCI-ADR-RES assessed as inhibition in cell growth measured after 24 hrs by MTT assay
|
[PMID: 35084853] |
| NCI/ADR-RES | IC50 |
58.7 μM
Compound: Paclitaxel
|
Antitumor activity against human MCF7ADR cells incubated for 48 hrs by CCK8 assay
Antitumor activity against human MCF7ADR cells incubated for 48 hrs by CCK8 assay
|
[PMID: 37229830] |
| NCI/ADR-RES | IC50 |
1.5 μM
Compound: Paclitaxel
|
Antiproliferative activity against human NCI/ADR-RES cells assessed as inhibition of cell growth measured after 48 hrs by sulforhodamine B assay
Antiproliferative activity against human NCI/ADR-RES cells assessed as inhibition of cell growth measured after 48 hrs by sulforhodamine B assay
|
[PMID: 37902628] |
| NCI/ADR-RES | IC50 |
9326 nM
Compound: PTX
|
Antiproliferative activity against human MCF7ADR cells assessed as reduction in cell viability measured after 72 hrs
Antiproliferative activity against human MCF7ADR cells assessed as reduction in cell viability measured after 72 hrs
|
[PMID: 38430854] |
| NCI/ADR-RES | IC50 |
9100 nM
Compound: PTX
|
Reversal effect on P-gp-mediated multidrug resistance in human NCI/ADR-RES cells assessed as inhibition of cell proliferation incubated for 72 hrs by SRB assay
Reversal effect on P-gp-mediated multidrug resistance in human NCI/ADR-RES cells assessed as inhibition of cell proliferation incubated for 72 hrs by SRB assay
|
[PMID: 38502936] |
| NCI/ADR-RES | IC50 |
463.86 nM
Compound: TAX; PTX
|
Antiproliferation activity against human MCF7/ADR cells measured after 72 hrs incubation by MTT assay
Antiproliferation activity against human MCF7/ADR cells measured after 72 hrs incubation by MTT assay
|
[PMID: 38781920] |
| NCI/ADR-RES | GI50 |
>15000 nM
Compound: Paclitaxel
|
Compound was tested in vitro for growth inhibition of MCF-7/ADR cells that exhibit MDR phenotype.
Compound was tested in vitro for growth inhibition of MCF-7/ADR cells that exhibit MDR phenotype.
|
[PMID: 9873597] |
| NCI-H1299 | IC50 |
15 nM
Compound: PTX
|
Inhibitory concentration against NCI-H1299 Human Nonsmall cell lung cancer cells after 96h exposure to the compound.
Inhibitory concentration against NCI-H1299 Human Nonsmall cell lung cancer cells after 96h exposure to the compound.
|
[PMID: 10579854] |
| NCI-H1299 | IC50 |
35 nM
Compound: PTX
|
Inhibitory concentration against NCI-H1299 Human Nonsmall cell lung cancer cells after 24 hr exposure to the compound.
Inhibitory concentration against NCI-H1299 Human Nonsmall cell lung cancer cells after 24 hr exposure to the compound.
|
[PMID: 10579854] |
| NCI-H1299 | IC50 |
37.7 nM
Compound: Placlitaxel (TAXOL)
|
Inhibitory concentration against NCI-H1299 cells was evaluated
Inhibitory concentration against NCI-H1299 cells was evaluated
|
[PMID: 15341492] |
| NCI-H1299 | EC50 |
0.163 μM
Compound: paclitaxel
|
Induction of apoptosis in human H1299 cells assessed as caspase activation after 24 hrs
Induction of apoptosis in human H1299 cells assessed as caspase activation after 24 hrs
|
[PMID: 15566300] |
| NCI-H1299 | IC50 |
15 nM
Compound: 1
|
Cytotoxicity against human NCI-H1299 cells after 96 hrs
Cytotoxicity against human NCI-H1299 cells after 96 hrs
|
[PMID: 17419065] |
| NCI-H1299 | IC50 |
35 nM
Compound: 1
|
Cytotoxicity against human NCI-H1299 cells after 12 hrs
Cytotoxicity against human NCI-H1299 cells after 12 hrs
|
[PMID: 17419065] |
| NCI-H1299 | EC50 |
0.098 μM
Compound: Taxol
|
Induction of apoptosis in human H1299 cells assessed as caspase activation after 48 hrs
Induction of apoptosis in human H1299 cells assessed as caspase activation after 48 hrs
|
[PMID: 19500976] |
| NCI-H1299 | GI50 |
0.023 μM
Compound: Taxol
|
Growth inhibition of human H1299 cells after 48 hrs
Growth inhibition of human H1299 cells after 48 hrs
|
[PMID: 19500976] |
| NCI-H1299 | IC50 |
1500 nM
Compound: Paclitaxel
|
Cytotoxicity against human H1299 cells incubated for 24 hrs by MTT assay
Cytotoxicity against human H1299 cells incubated for 24 hrs by MTT assay
|
[PMID: 27983842] |
| NCI-H1299 | IC50 |
7.83 μM
Compound: Taxol
|
Antiproliferative activity against human H1299 cells after 48 hrs by MTS assay
Antiproliferative activity against human H1299 cells after 48 hrs by MTS assay
|
[PMID: 29172082] |
| NCI-H1299 | IC50 |
0.005 μM
Compound: Taxol
|
Antiproliferative activity against human NCI-H1299 cells assessed as reduction in cell growth by MTT assay
Antiproliferative activity against human NCI-H1299 cells assessed as reduction in cell growth by MTT assay
|
[PMID: 32949719] |
| NCI-H1299 | IC50 |
0.009 μM
Compound: Paclitaxel
|
Antiproliferative activity against human NCI-H1299 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
Antiproliferative activity against human NCI-H1299 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
|
[PMID: 36511661] |
| NCI-H1437 | IC50 |
<0.001 μM
Compound: Paclitaxel
|
Antiproliferative activity against human NCI-H1437 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
Antiproliferative activity against human NCI-H1437 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
|
[PMID: 36511661] |
| NCI-H1650 | IC50 |
3.17 x 10-8 mg/mL
Compound: Taxol
|
Cytotoxicity against human NCI-H1650 cells after 72 hrs by MTT assay
Cytotoxicity against human NCI-H1650 cells after 72 hrs by MTT assay
|
[PMID: 26920798] |
| NCI-H1650 | IC50 |
6.8 x 10-2 μM
Compound: Paclitaxel
|
Cytotoxicity against human NCI-H1650 cells by MTT assay
Cytotoxicity against human NCI-H1650 cells by MTT assay
|
[PMID: 27441892] |
| NCI-H1650 | IC50 |
0.07 μM
Compound: Taxol
|
Growth inhibition of human NCI-H1650 cells incubated for 3 days by SRB assay
Growth inhibition of human NCI-H1650 cells incubated for 3 days by SRB assay
|
[PMID: 28625363] |
| NCI-H1650 | IC50 |
>1 μM
Compound: Taxol
|
Growth inhibition of human NCI-H1650 cells after 96 hrs by MTT assay
Growth inhibition of human NCI-H1650 cells after 96 hrs by MTT assay
|
[PMID: 28737396] |
| NCI-H1975 | IC50 |
7.94 nM
Compound: Paclitaxel
|
Cytotoxicity against human NCI-H1975 cells after 4 days by MTS/cell proliferation assay
Cytotoxicity against human NCI-H1975 cells after 4 days by MTS/cell proliferation assay
|
[PMID: 25098528] |
| NCI-H1975 | IC50 |
7.7 nM
Compound: Taxol
|
Cytotoxicity against human NCI-H1975 cells assessed as cell viability after 72 hrs by CCK8 assay
Cytotoxicity against human NCI-H1975 cells assessed as cell viability after 72 hrs by CCK8 assay
|
[PMID: 25819096] |
| NCI-H1975 | IC50 |
2.5 nM
Compound: PTX
|
Cytotoxicity against human NCI-H1975 cells assessed as growth inhibition after 72 hrs by CellTiter-Fluor assay
Cytotoxicity against human NCI-H1975 cells assessed as growth inhibition after 72 hrs by CellTiter-Fluor assay
|
[PMID: 26132075] |
| NCI-H1975 | IC50 |
2.8 μM
Compound: taxol
|
Cytotoxicity against human NCI-H1975 cells after 72 hrs by CCK8 assay
Cytotoxicity against human NCI-H1975 cells after 72 hrs by CCK8 assay
|
[PMID: 26316467] |
| NCI-H1975 | GI50 |
5.77 nM
Compound: Taxol
|
Cytotoxicity against human NCI-H1975 cells assessed as cell growth inhibition after 72 hrs by CCK-8 assay
Cytotoxicity against human NCI-H1975 cells assessed as cell growth inhibition after 72 hrs by CCK-8 assay
|
[PMID: 27224875] |
| NCI-H1975 | IC50 |
3.9 μM
Compound: Taxol
|
Cytotoxicity against human NCI-H1975 cells after 72 hrs by MTT assay
Cytotoxicity against human NCI-H1975 cells after 72 hrs by MTT assay
|
[PMID: 30579802] |
| NCI-H1975 | IC50 |
28 nM
Compound: Paclitaxel
|
Anticancer activity against human NCI-H1975 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
Anticancer activity against human NCI-H1975 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
|
[PMID: 37146221] |
| NCI-H1975 | IC50 |
75 μM
Compound: PTX
|
Cytotoxicity against human NCI-H1975 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay
Cytotoxicity against human NCI-H1975 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay
|
[PMID: 38547648] |
| NCI-H1993 | GI50 |
0.004 μM
Compound: Paclitaxel
|
Antiproliferative activity against patient-derived paclitaxel-sensitive NCI-H1993 cells after 48 to 96 hrs by MTT assay
Antiproliferative activity against patient-derived paclitaxel-sensitive NCI-H1993 cells after 48 to 96 hrs by MTT assay
|
[PMID: 27218860] |
| NCI-H2126 | IC50 |
2.5 μM
Compound: Paclitaxel
|
Cytotoxicity against human NCI-H2126 cells assessed as reduction in cell viability after 72 hrs by MTT assay
Cytotoxicity against human NCI-H2126 cells assessed as reduction in cell viability after 72 hrs by MTT assay
|
[PMID: 22871217] |
| NCI-H226 | IC50 |
<3 ng/mL
Compound: 1 (paclitaxel)
|
Cytotoxicity against H226 Tumor cell line in SRB Cell viability test
Cytotoxicity against H226 Tumor cell line in SRB Cell viability test
|
[PMID: 10956217] |
| NCI-H226 | GI50 |
20 μM
Compound: Paclitaxel
|
Compound was tested for growth inhibition of multidrug resistant tumor NCI-H226 cell line
Compound was tested for growth inhibition of multidrug resistant tumor NCI-H226 cell line
|
[PMID: 15546733] |
| NCI-H226 | IC50 |
0.0068 μM
Compound: paclitaxel
|
Cytotoxicity against human NCI-H226 cells
Cytotoxicity against human NCI-H226 cells
|
[PMID: 17113288] |
| NCI-H226 | GI50 |
3.9 nM
Compound: Paclitaxel
|
Growth inhibition of human NCI-H226 cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human NCI-H226 cells incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 29655610] |
| NCI-H226 | GI50 |
3.9 nM
Compound: Paclitaxel
|
Cytotoxicity against human NCI-H226 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay
Cytotoxicity against human NCI-H226 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay
|
[PMID: 33310545] |
| NCI-H23 | GI50 |
6.3 nM
Compound: Paclitaxel
|
Growth inhibition of human NCI-H23 cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human NCI-H23 cells incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 29655610] |
| NCI-H23 | GI50 |
6.3 nM
Compound: Paclitaxel
|
Cytotoxicity against human NCI-H23 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay
Cytotoxicity against human NCI-H23 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay
|
[PMID: 33310545] |
| NCI-H292 | IC50 |
0.006 μM
Compound: Taxol
|
Cytotoxicity against human NCI-H292 cells after 72 hrs by MTT assay
Cytotoxicity against human NCI-H292 cells after 72 hrs by MTT assay
|
[PMID: 26712098] |
| NCI-H295R | IC50 |
0.08 μM
Compound: Taxol
|
Cytotoxicity against human H295R cells by MTT assay
Cytotoxicity against human H295R cells by MTT assay
|
[PMID: 16539377] |
| NCI-H322M | GI50 |
0.013 μM
Compound: paclitaxel
|
Cytotoxicity against human NCI-H322M cells
Cytotoxicity against human NCI-H322M cells
|
[PMID: 17696332] |
| NCI-H322M | GI50 |
0.013 μM
Compound: Paclitaxel
|
Cytotoxicity against human NCI-H322M cells by sulforhodamine B assay
Cytotoxicity against human NCI-H322M cells by sulforhodamine B assay
|
[PMID: 21839640] |
| NCI-H322M | GI50 |
0.05 μM
Compound: 1a, PXL, Taxol
|
Cytotoxicity against human NCI-H322M cells
Cytotoxicity against human NCI-H322M cells
|
[PMID: 23725535] |
| NCI-H322M | GI50 |
12.5 nM
Compound: Paclitaxel
|
Growth inhibition of human NCI-H322M cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human NCI-H322M cells incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 29655610] |
| NCI-H322M | GI50 |
12.5 nM
Compound: Paclitaxel
|
Cytotoxicity against human NCI-H322M cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay
Cytotoxicity against human NCI-H322M cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay
|
[PMID: 33310545] |
| NCI-H358 | IC50 |
3.8 μg/mL
Compound: PTX
|
Anticancer activity against human NCI-H358 cells by MTT assay
Anticancer activity against human NCI-H358 cells by MTT assay
|
[PMID: 18826299] |
| NCI-H358 | IC50 |
0.01 μM
Compound: Taxol
|
Cytotoxicity against human NCI-H358 cells by MTT assay
Cytotoxicity against human NCI-H358 cells by MTT assay
|
[PMID: 23425970] |
| NCI-H358 | IC50 |
2 nM
Compound: taxol
|
Antiproliferative activity against human NCI-H358 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay
Antiproliferative activity against human NCI-H358 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay
|
[PMID: 25208345] |
| NCI-H358 | IC50 |
7.9 nM
Compound: 28
|
Antiproliferative activity against human NCI-H358 cells after 72 hrs by WST8 assay
Antiproliferative activity against human NCI-H358 cells after 72 hrs by WST8 assay
|
[PMID: 25625617] |
| NCI-H441 | IC50 |
0.15 μM
Compound: Taxol
|
Anticancer activity against human NCI-H441 cells assessed as inhibition of cell proliferation measured after 72 hrs by CCK8 reagent assay
Anticancer activity against human NCI-H441 cells assessed as inhibition of cell proliferation measured after 72 hrs by CCK8 reagent assay
|
[PMID: 34399390] |
| NCI-H460 | ED50 |
0.015 μM
Compound: Paclitaxel
|
Effective dose against NCI-H460 cell line.
Effective dose against NCI-H460 cell line.
|
[PMID: 11728187] |
| NCI-H460 | IC50 |
0.00014 μM
Compound: paclitaxel
|
In vitro cytotoxic activity against nonsmall cell lung carcinoma (NCI-H460) cells assayed by inhibition of [3H]-labeled thymidine incorporation
In vitro cytotoxic activity against nonsmall cell lung carcinoma (NCI-H460) cells assayed by inhibition of [3H]-labeled thymidine incorporation
|
[PMID: 11728191] |
| NCI-H460 | IC50 |
>10 nM
Compound: Paclitaxel
|
Antiproliferative activity against the human non small cell lung carcinoma cell line NCI-H460
Antiproliferative activity against the human non small cell lung carcinoma cell line NCI-H460
|
[PMID: 11814821] |
| NCI-H460 | IC50 |
0.01 μM
Compound: Paclitaxel ; Taxol
|
Cytotoxic activity against cellular metabolic activity of Lung NCI-H460 tumor cell line using XTT proliferation assay after incubation with the compound for 48 h
Cytotoxic activity against cellular metabolic activity of Lung NCI-H460 tumor cell line using XTT proliferation assay after incubation with the compound for 48 h
|
[PMID: 12852768] |
| NCI-H460 | IC50 |
9.5 nM
Compound: Taxol
|
Cytotoxicity against human NCI-H460 cells after 48 hrs by MTT assay
Cytotoxicity against human NCI-H460 cells after 48 hrs by MTT assay
|
[PMID: 14695798] |
| NCI-H460 | IC50 |
9.5 nM
Compound: taxol
|
Cytotoxicity against human NCI-H460 cells after 48 hrs by MTT assay
Cytotoxicity against human NCI-H460 cells after 48 hrs by MTT assay
|
[PMID: 15043404] |
| NCI-H460 | GI50 |
0.007 μM
Compound: Paclitaxel
|
Compound was tested for growth inhibition of human non-small cell lung cancer NCI-H460 cell line
Compound was tested for growth inhibition of human non-small cell lung cancer NCI-H460 cell line
|
[PMID: 15546733] |
| NCI-H460 | IC50 |
0.012 μM
Compound: Taxol
|
Antiproliferative activity against NCI-H460 cell line by MTS assay
Antiproliferative activity against NCI-H460 cell line by MTS assay
|
[PMID: 16257201] |
| NCI-H460 | IC50 |
0.01 μM
Compound: paclitaxel
|
Antiproliferative activity against NCI-H460 cells by XTT assay after 48 hrs
Antiproliferative activity against NCI-H460 cells by XTT assay after 48 hrs
|
[PMID: 17181164] |
| NCI-H460 | IC50 |
0.01 μM
Compound: paclitaxel
|
Cytotoxicity against human NCI-H460 cells after 48 hrs by XTT assay
Cytotoxicity against human NCI-H460 cells after 48 hrs by XTT assay
|
[PMID: 17973361] |
| NCI-H460 | IC50 |
0.07 μM
Compound: paclitaxel
|
Antiproliferative activity against human NCI-H460 cells by XTT assay
Antiproliferative activity against human NCI-H460 cells by XTT assay
|
[PMID: 19220018] |
| NCI-H460 | IC50 |
4.9 nM
Compound: paclitaxel
|
Cytotoxicity against human H460 cells after 72 hrs
Cytotoxicity against human H460 cells after 72 hrs
|
[PMID: 19239240] |
| NCI-H460 | IC50 |
0.01 μM
Compound: paclitaxel
|
Antiproliferative activity against human NCI-H460 cells after 48 hrs by XTT assay
Antiproliferative activity against human NCI-H460 cells after 48 hrs by XTT assay
|
[PMID: 20537765] |
| NCI-H460 | IC50 |
14.6 nM
Compound: Paclitaxel
|
Antiproliferative activity against human NCI-H460 cells after 72 hrs by sulforhodamine B assay
Antiproliferative activity against human NCI-H460 cells after 72 hrs by sulforhodamine B assay
|
[PMID: 21480626] |
| NCI-H460 | GI50 |
0.024 μM
Compound: Paclitaxel
|
Cytotoxicity against human H460 cells after 48 hrs by SRB assay
Cytotoxicity against human H460 cells after 48 hrs by SRB assay
|
[PMID: 21513294] |
| NCI-H460 | IC50 |
0.004 μM
Compound: paclitaxel
|
Antiproliferative activity against human NCI-H460 cells after 48 hrs by alamar blue assay
Antiproliferative activity against human NCI-H460 cells after 48 hrs by alamar blue assay
|
[PMID: 21563750] |
| NCI-H460 | IC50 |
0.01 μM
Compound: Paclitaxel
|
Cytotoxicity against human NCI-H460 cells after 48 hrs by XTT assay
Cytotoxicity against human NCI-H460 cells after 48 hrs by XTT assay
|
[PMID: 21705223] |
| NCI-H460 | IC50 |
2078 μM
Compound: Paclitaxel
|
Anticancer activity against multidrug resistant human NCI-H460 cells after 72 hrs by SRB assay
Anticancer activity against multidrug resistant human NCI-H460 cells after 72 hrs by SRB assay
|
[PMID: 21707046] |
| NCI-H460 | IC50 |
9.4 μM
Compound: Paclitaxel
|
Anticancer activity against human NCI-H460 cells after 72 hrs by SRB assay
Anticancer activity against human NCI-H460 cells after 72 hrs by SRB assay
|
[PMID: 21707046] |
| NCI-H460 | IC50 |
8 μM
Compound: Taxol
|
Cytotoxicity against human NCI-H460 cells after overnight incubation by MTT assay
Cytotoxicity against human NCI-H460 cells after overnight incubation by MTT assay
|
[PMID: 21942765] |
| NCI-H460 | IC50 |
0.008 μM
Compound: Taxol
|
Cytotoxicity against human H460 cells after 24 to 48 hrs by MTT assay
Cytotoxicity against human H460 cells after 24 to 48 hrs by MTT assay
|
[PMID: 22222040] |
| NCI-H460 | GI50 |
0.03 μM
Compound: paclitaxel
|
Growth inhibition of human NCI-H460 cells
Growth inhibition of human NCI-H460 cells
|
[PMID: 23167614] |
| NCI-H460 | IC50 |
24 μM
Compound: Taxol
|
Cytotoxicity against human H460 cells by MTT assay
Cytotoxicity against human H460 cells by MTT assay
|
[PMID: 23425970] |
| NCI-H460 | GI50 |
0.1 μM
Compound: PCT
|
Growth inhibition of human NCI-H460 cells after 48 hrs by sulforhodamine B assay
Growth inhibition of human NCI-H460 cells after 48 hrs by sulforhodamine B assay
|
[PMID: 24727464] |
| NCI-H460 | IC50 |
0.01 μM
Compound: Taxol
|
Cytotoxicity against human NCI-H460 cells assessed as growth inhibition by MTT assay
Cytotoxicity against human NCI-H460 cells assessed as growth inhibition by MTT assay
|
[PMID: 25091926] |
| NCI-H460 | IC50 |
1.43 μM
Compound: 1
|
Cytotoxicity against human H460 cells assessed as inhibition of cell proliferation
Cytotoxicity against human H460 cells assessed as inhibition of cell proliferation
|
[PMID: 25466201] |
| NCI-H460 | IC50 |
10 nM
Compound: 28
|
Antiproliferative activity against human NCI-H460 cells after 72 hrs by WST8 assay
Antiproliferative activity against human NCI-H460 cells after 72 hrs by WST8 assay
|
[PMID: 25625617] |
| NCI-H460 | IC50 |
4.287 μM
Compound: 1
|
Cytotoxicity against human H460 cells incubated for 48 hrs by CCK-8 assay
Cytotoxicity against human H460 cells incubated for 48 hrs by CCK-8 assay
|
[PMID: 26448037] |
| NCI-H460 | IC50 |
0.01 μM
Compound: Paclitaxel
|
Antiproliferative activity against human NCI-H460 cells after 72 hrs by CellTiter96 AQueous nonradioactive cell proliferation assay
Antiproliferative activity against human NCI-H460 cells after 72 hrs by CellTiter96 AQueous nonradioactive cell proliferation assay
|
[PMID: 28335606] |
| NCI-H460 | IC50 |
1 nM
Compound: Paclitaxel
|
Cytotoxicity against human NCI-H460 cells assessed as reduction in cell viability after 96 hrs by MTT assay
Cytotoxicity against human NCI-H460 cells assessed as reduction in cell viability after 96 hrs by MTT assay
|
[PMID: 28530828] |
| NCI-H460 | IC50 |
0.006 μM
Compound: PTX
|
Cytotoxicity against human NCI-H460 cells assessed as growth reduction under normoxic condition after 72 hrs by MTT assay
Cytotoxicity against human NCI-H460 cells assessed as growth reduction under normoxic condition after 72 hrs by MTT assay
|
[PMID: 28740613] |
| NCI-H460 | IC50 |
0.007 μM
Compound: PTX
|
Cytotoxicity against human NCI-H460 cells assessed as growth reduction under hypoxic condition after 72 hrs by MTT assay
Cytotoxicity against human NCI-H460 cells assessed as growth reduction under hypoxic condition after 72 hrs by MTT assay
|
[PMID: 28740613] |
| NCI-H460 | IC50 |
0.004 μM
Compound: Paclitaxel
|
Cytotoxicity against human NCI-H460 cells after 96 hrs by MTT assay
Cytotoxicity against human NCI-H460 cells after 96 hrs by MTT assay
|
[PMID: 29279273] |
| NCI-H460 | GI50 |
6.3 nM
Compound: Paclitaxel
|
Growth inhibition of human NCI-H460 cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human NCI-H460 cells incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 29655610] |
| NCI-H460 | IC50 |
0.08 μM
Compound: Paclitaxel
|
Cytotoxicity against human H460 cells assessed as inhibition of cell viability after 48 hrs by SRB assay
Cytotoxicity against human H460 cells assessed as inhibition of cell viability after 48 hrs by SRB assay
|
[PMID: 30798081] |
| NCI-H460 | GI50 |
0.00176 μM
Compound: Paclitaxel
|
Cytotoxicity against human NCI-H460 cells assessed as growth inhibition measured after 48 hrs by SRB assay
Cytotoxicity against human NCI-H460 cells assessed as growth inhibition measured after 48 hrs by SRB assay
|
[PMID: 31059248] |
| NCI-H460 | GI50 |
0.00165 μM
Compound: Paclitaxel
|
Cytotoxicity against human NCI-H460 cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay
Cytotoxicity against human NCI-H460 cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay
|
[PMID: 31534659] |
| NCI-H460 | IC50 |
<0.001 μM
Compound: Taxol
|
Antiproliferative activity against human NCI-H460 cells assessed as reduction in cell growth by MTT assay
Antiproliferative activity against human NCI-H460 cells assessed as reduction in cell growth by MTT assay
|
[PMID: 32949719] |
| NCI-H460 | GI50 |
6.3 nM
Compound: Paclitaxel
|
Cytotoxicity against human NCI-H460 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay
Cytotoxicity against human NCI-H460 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay
|
[PMID: 33310545] |
| NCI-H460 | IC50 |
0.005 μM
Compound: Taxol
|
Anticancer activity against human H460 cells by MTT assay
Anticancer activity against human H460 cells by MTT assay
|
[PMID: 33316408] |
| NCI-H460 | IC50 |
6.01 nM
Compound: PTX
|
Antiproliferative activity against human NCI-H460 cells incubated for 72 hrs by MTT assay
Antiproliferative activity against human NCI-H460 cells incubated for 72 hrs by MTT assay
|
[PMID: 34648295] |
| NCI-H460 | IC50 |
0.0006 μM
Compound: Paclitaxel
|
Anticancer activity against human NCI-H460 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
Anticancer activity against human NCI-H460 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
|
[PMID: 35450348] |
| NCI-H460 | IC50 |
0.117 μM
Compound: Paclitaxel
|
Anticancer activity against against human multi-drug resistant NCI-H460/R cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
Anticancer activity against against human multi-drug resistant NCI-H460/R cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
|
[PMID: 35450348] |
| NCI-H460 | IC50 |
0.005 μM
Compound: Taxol
|
Antiproliferative activity against human H460 cells assessed as reduction in cell viability after 96 hrs by MTT assay
Antiproliferative activity against human H460 cells assessed as reduction in cell viability after 96 hrs by MTT assay
|
[PMID: 36270090] |
| NCI-H460 | IC50 |
<0.001 μM
Compound: Paclitaxel
|
Antiproliferative activity against human NCI-H460 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
Antiproliferative activity against human NCI-H460 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
|
[PMID: 36511661] |
| NCI-H460 | IC50 |
632.6 nM
Compound: Paclitaxel
|
Anti-cancer activity of human PTX-resistant NCI-H460 cells incubated for 48 hrs by CCK8 assay
Anti-cancer activity of human PTX-resistant NCI-H460 cells incubated for 48 hrs by CCK8 assay
|
[PMID: 38692523] |
| NCI-H460 | GI50 |
2.19 x 10-8 M
Compound: 5
|
Cytotoxicity against human NCI-H460 cells
Cytotoxicity against human NCI-H460 cells
|
[PMID: 7908950] |
| NCI-H460 | IC50 |
7 nM
Compound: Paclitaxel
|
Evaluated in vitro for antiproliferative activity against NIC-H460 cell lines derived from large cell carcinoma of the lung
Evaluated in vitro for antiproliferative activity against NIC-H460 cell lines derived from large cell carcinoma of the lung
|
10.1016/S0960-894X(97)10152-4 |
| NCI-H520 | IC50 |
8.2 nM
Compound: Taxol
|
Antiproliferative activity against human NCI-H520 cells after 72 hrs by phosphatase assay
Antiproliferative activity against human NCI-H520 cells after 72 hrs by phosphatase assay
|
[PMID: 28857558] |
| NCI-H522 | GI50 |
15.8 nM
Compound: Paclitaxel
|
Growth inhibition of human NCI-H522 cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human NCI-H522 cells incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 29655610] |
| NCI-H522 | GI50 |
15.8 nM
Compound: Paclitaxel
|
Cytotoxicity against human NCI-H522 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay
Cytotoxicity against human NCI-H522 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay
|
[PMID: 33310545] |
| NCI-H596 | IC50 |
0.035 μM
Compound: Taxol
|
Antiproliferative activity against NQO1 deficient human NCI-H596 cells after 72 hrs by MTT assay
Antiproliferative activity against NQO1 deficient human NCI-H596 cells after 72 hrs by MTT assay
|
[PMID: 28395199] |
| NCI-H630 | IC50 |
0.024 μM
Compound: paclitaxel
|
Antitumor activity against human NCI-H630 cell line
Antitumor activity against human NCI-H630 cell line
|
[PMID: 16884301] |
| NCI-H69 | IC50 |
1.9 nM
Compound: paclitaxel
|
Antiproliferative activity against drug sensitive NCI-H69 cell line by Alamar Blue assay
Antiproliferative activity against drug sensitive NCI-H69 cell line by Alamar Blue assay
|
[PMID: 17286393] |
| NCI-H727 | IC50 |
0.01 μM
Compound: Taxol
|
Cytotoxicity against human NCI-H727 cells assessed as reduction in cell viability incubated for 48 hrs by Hoechst-33342 staining based cell counting method (Rvb > 25 microM)
Cytotoxicity against human NCI-H727 cells assessed as reduction in cell viability incubated for 48 hrs by Hoechst-33342 staining based cell counting method (Rvb > 25 microM)
|
[PMID: 33422908] |
| NCI-H838 | IC50 |
0.026 μM
Compound: paclitaxel
|
Cytotoxicity against human NCI-H838 cells after 72 hrs by MTT assay
Cytotoxicity against human NCI-H838 cells after 72 hrs by MTT assay
|
[PMID: 19053781] |
| NCI-N87 | IC50 |
5.9 nM
Compound: Taxol
|
Antiproliferative activity against human NCI-N87 cells after 96 hrs by MTT assay
Antiproliferative activity against human NCI-N87 cells after 96 hrs by MTT assay
|
[PMID: 21296467] |
| NCI-N87 | IC50 |
7.53 nM
Compound: Paclitaxel
|
Cytotoxicity against human NCI-N87 cells after 4 days by MTS/cell proliferation assay
Cytotoxicity against human NCI-N87 cells after 4 days by MTS/cell proliferation assay
|
[PMID: 25098528] |
| NCM460 | IC50 |
<0.008 μM
Compound: Paclitaxel
|
Cytotoxicity in human NCM460 cells assessed as reduction in cell viability incubated for 3 days by MTT assay
Cytotoxicity in human NCM460 cells assessed as reduction in cell viability incubated for 3 days by MTT assay
|
[PMID: 31390200] |
| NCM460 | IC50 |
<0.008 μM
Compound: Paclitaxel
|
Cytotoxicity against human NCM460 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Cytotoxicity against human NCM460 cells assessed as reduction in cell viability after 48 hrs by MTT assay
|
[PMID: 32628478] |
| NCM460 | IC50 |
9.2 nM
Compound: PTX
|
Cytotoxicity against human NCM460 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay
Cytotoxicity against human NCM460 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay
|
[PMID: 33280896] |
| NFF | IC50 |
0.0047 μM
Compound: Paclitaxel
|
Cytotoxicity against human NFF after 72 hrs by alamar blue assay
Cytotoxicity against human NFF after 72 hrs by alamar blue assay
|
[PMID: 20732809] |
| NIH3T3 | IC50 |
1.29 μM
Compound: Paclitaxel
|
Antiproliferative activity against mouse NIH3T3 cell line
Antiproliferative activity against mouse NIH3T3 cell line
|
[PMID: 16793260] |
| NIH3T3 | IC50 |
0.58 μM
Compound: 6
|
Antiproliferative activity against mouse NIH/3T3 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
Antiproliferative activity against mouse NIH/3T3 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
|
[PMID: 25682561] |
| NIH3T3 | IC50 |
4.2 μM
Compound: paclitaxel
|
Cytotoxicity against mouse NIH/3T3 cells assessed as reduction in cell viability by MTS assay
Cytotoxicity against mouse NIH/3T3 cells assessed as reduction in cell viability by MTS assay
|
[PMID: 25760674] |
| NIH3T3 | IC50 |
20.01 μM
Compound: Paclitaxel
|
Antiproliferative activity against mouse NIH/3T3 cells assessed as inhibition of cell proliferation incubated for 48 hrs by CCK8 assay
Antiproliferative activity against mouse NIH/3T3 cells assessed as inhibition of cell proliferation incubated for 48 hrs by CCK8 assay
|
[PMID: 25959813] |
| NIH3T3 | IC50 |
25 nM
Compound: 1
|
Cytotoxicity against mouse NIH/3T3 cells after 48 hrs by MTT assay
Cytotoxicity against mouse NIH/3T3 cells after 48 hrs by MTT assay
|
[PMID: 30448418] |
| NIH3T3 | IC50 |
4875 nM
Compound: 1
|
Cytotoxicity against mouse NIH/3T3 cells harboring MDR G185 after 48 hrs by MTT assay
Cytotoxicity against mouse NIH/3T3 cells harboring MDR G185 after 48 hrs by MTT assay
|
[PMID: 30448418] |
| NIH-3T3-G185 | IC50 |
53.9 μM
Compound: Taxol (Paclitaxel)
|
TP_TRANSPORTER: inhibition of LDS-751 efflux in NIH-3T3-G185 cells
TP_TRANSPORTER: inhibition of LDS-751 efflux in NIH-3T3-G185 cells
|
[PMID: 11716514] |
| NIH-3T3-G185 | IC50 |
54 μM
Compound: Taxol (Paclitaxel)
|
TP_TRANSPORTER: inhibition of Daunorubicin efflux in NIH-3T3-G185 cells
TP_TRANSPORTER: inhibition of Daunorubicin efflux in NIH-3T3-G185 cells
|
[PMID: 11716514] |
| NIH-3T3-G185 | IC50 |
70.2 μM
Compound: Taxol (Paclitaxel)
|
TP_TRANSPORTER: inhibition of Rhodamine 123 efflux in NIH-3T3-G185 cells
TP_TRANSPORTER: inhibition of Rhodamine 123 efflux in NIH-3T3-G185 cells
|
[PMID: 11716514] |
| NSCLC | IC50 |
4.3 nM
Compound: Paclitaxel
|
Evaluated in vitro for antiproliferative activity against NYH cell lines derived from small cell lung cancer
Evaluated in vitro for antiproliferative activity against NYH cell lines derived from small cell lung cancer
|
10.1016/S0960-894X(97)10152-4 |
| NUGC-3 | GI50 |
0.02 μM
Compound: paclitaxel
|
Growth inhibition of human NUGC3 cells
Growth inhibition of human NUGC3 cells
|
[PMID: 23167614] |
| OCI-Ly1 | IC50 |
0.18 μM
Compound: Paclitaxel
|
Cytotoxicity against human OCI-LY1 cells assessed as inhibition of cell proliferation after 96 hrs by MTT assay
Cytotoxicity against human OCI-LY1 cells assessed as inhibition of cell proliferation after 96 hrs by MTT assay
|
10.1039/C4MD00573B |
| OE19 | IC50 |
0.4 μM
Compound: taxol
|
Cytotoxicity against human OE19 cells after 72 hrs by MTT assay
Cytotoxicity against human OE19 cells after 72 hrs by MTT assay
|
[PMID: 17915851] |
| OE33 | IC50 |
0.2 μM
Compound: taxol
|
Cytotoxicity against human OE33 cells after 72 hrs by MTT assay
Cytotoxicity against human OE33 cells after 72 hrs by MTT assay
|
[PMID: 17915851] |
| OS-RC-2 | IC50 |
<0.08 μM
Compound: Paclitaxel
|
Cytotoxicity against human OS-RC2 cells by MTT assay
Cytotoxicity against human OS-RC2 cells by MTT assay
|
[PMID: 20627721] |
| OS-RC-2 | IC50 |
<0.08 μM
Compound: Paclitaxel
|
Cytotoxicity against human OS-RC2 cells by MTT assay
Cytotoxicity against human OS-RC2 cells by MTT assay
|
[PMID: 20716468] |
| OS-RC-2 | IC50 |
<0.08 μM
Compound: Paclitaxel
|
Cytotoxicity against human OS-RC2 cells by MTT assay
Cytotoxicity against human OS-RC2 cells by MTT assay
|
[PMID: 21875764] |
| OV-1063 | IC50 |
0.015 μM
Compound: Paclitaxel
|
Inhibitory activity of compound against human ovarian carcinoma (OV-1063) Cell proliferation
Inhibitory activity of compound against human ovarian carcinoma (OV-1063) Cell proliferation
|
[PMID: 9379451] |
| OV-90 | IC50 |
5.19 μM
Compound: Taxol
|
Anticancer activity against human OV-90 cells assessed as inhibition of cell proliferation measured after 72 hrs by CCK8 reagent assay
Anticancer activity against human OV-90 cells assessed as inhibition of cell proliferation measured after 72 hrs by CCK8 reagent assay
|
[PMID: 34399390] |
| OVCAR | IC50 |
0.06 μM
Compound: Paclitaxel
|
Cytotoxicity against Homo sapiens (human) OVCAR cells after 48 hr by SRB assay
Cytotoxicity against Homo sapiens (human) OVCAR cells after 48 hr by SRB assay
|
10.1007/s00044-011-9824-9 |
| OVCAR-3 | IC50 |
0.01 μM
Compound: Taxol
|
Cytotoxicity against human Ovcar3 cells by MTT assay
Cytotoxicity against human Ovcar3 cells by MTT assay
|
[PMID: 16539377] |
| OVCAR-3 | IC50 |
0.2 nM
Compound: 1
|
Cytotoxicity against human OVCAR-3 cells
Cytotoxicity against human OVCAR-3 cells
|
[PMID: 17419065] |
| OVCAR-3 | IC50 |
0.01 μM
Compound: taxol
|
Cytotoxicity against human Ovcar3 cells after 72 hrs by MTT assay
Cytotoxicity against human Ovcar3 cells after 72 hrs by MTT assay
|
[PMID: 17915851] |
| OVCAR-3 | IC50 |
2.7 μM
Compound: paclitaxel
|
Growth inhibition of human OVCAR-3 cells after 48 hrs by sulforhodamine B assay
Growth inhibition of human OVCAR-3 cells after 48 hrs by sulforhodamine B assay
|
[PMID: 19939522] |
| OVCAR-3 | GI50 |
0.02 μM
Compound: 1a, PXL, Taxol
|
Cytotoxicity against human OVCAR3 cells
Cytotoxicity against human OVCAR3 cells
|
[PMID: 23725535] |
| OVCAR-3 | GI50 |
0.2 μM
Compound: PCT
|
Growth inhibition of human OVCAR3 cells after 48 hrs by sulforhodamine B assay
Growth inhibition of human OVCAR3 cells after 48 hrs by sulforhodamine B assay
|
[PMID: 24727464] |
| OVCAR-3 | IC50 |
3.3 nM
Compound: Paclitaxel
|
Cytotoxicity against human OVCAR3 cells incubated for 72 hrs by CellTiter 96 aqueous one solution cell proliferation assay
Cytotoxicity against human OVCAR3 cells incubated for 72 hrs by CellTiter 96 aqueous one solution cell proliferation assay
|
[PMID: 27983842] |
| OVCAR-3 | IC50 |
0.0075 μM
Compound: Paclitaxel
|
Cytotoxicity in human OVCAR3 cells assessed as reduction in cell viability incubated for for 72 hrs by cell-titer-96 aqueous one solution cell proliferation assay
Cytotoxicity in human OVCAR3 cells assessed as reduction in cell viability incubated for for 72 hrs by cell-titer-96 aqueous one solution cell proliferation assay
|
[PMID: 28252962] |
| OVCAR-3 | IC50 |
0.002 μM
Compound: taxol
|
Cytotoxicity against human OVCAR3 cells assessed as decrease in cell viability after 72 hrs by CellTiter 96 AQueous one solution cell proliferation assay
Cytotoxicity against human OVCAR3 cells assessed as decrease in cell viability after 72 hrs by CellTiter 96 AQueous one solution cell proliferation assay
|
[PMID: 28594169] |
| OVCAR-3 | GI50 |
4 nM
Compound: Paclitaxel
|
Growth inhibition of human OVCAR3 cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human OVCAR3 cells incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 29655610] |
| OVCAR-3 | IC50 |
0.011 μM
Compound: Taxol
|
Cytotoxicity against human OVCAR3 cells measured after 24 to 72 hrs by SRB assay
Cytotoxicity against human OVCAR3 cells measured after 24 to 72 hrs by SRB assay
|
[PMID: 29656990] |
| OVCAR-3 | IC50 |
13 nM
Compound: Paclitaxel
|
Cytotoxicity against human OVCAR3 cells assessed as reduction in cell viability after 72 hrs by CellTiter 96 aqueous one solution assay
Cytotoxicity against human OVCAR3 cells assessed as reduction in cell viability after 72 hrs by CellTiter 96 aqueous one solution assay
|
[PMID: 30057155] |
| OVCAR-3 | IC50 |
7.5 nM
Compound: Taxol
|
Cytotoxicity against human OVCAR3 cells after 72 hrs by CellTiter 96 AQueous One Solution Cell Proliferation Assay
Cytotoxicity against human OVCAR3 cells after 72 hrs by CellTiter 96 AQueous One Solution Cell Proliferation Assay
|
[PMID: 30192537] |
| OVCAR-3 | IC50 |
0.38 μM
Compound: Paclitaxel
|
Antiproliferative activity against human OVCAR3 cells incubated for 48 hrs by MTT assay
Antiproliferative activity against human OVCAR3 cells incubated for 48 hrs by MTT assay
|
[PMID: 31279299] |
| OVCAR-3 | IC50 |
5 nM
Compound: Taxol
|
Antiproliferative activity against human OVCAR3 cells assessed as inhibition of cell growth incubated for 72 hrs by CellTiter 96 aqueous one solution assay
Antiproliferative activity against human OVCAR3 cells assessed as inhibition of cell growth incubated for 72 hrs by CellTiter 96 aqueous one solution assay
|
[PMID: 31633350] |
| OVCAR-3 | IC50 |
0.0015 μM
Compound: Paclitaxel
|
Cytotoxicity against human OVCAR3 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay
Cytotoxicity against human OVCAR3 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay
|
[PMID: 31953129] |
| OVCAR-3 | IC50 |
0.0033 μM
Compound: Paclitaxel
|
Cytotoxicity against human OVCAR3 cells after 72 hrs by CellTiter 96 Aqueous One Solution reagent based assay
Cytotoxicity against human OVCAR3 cells after 72 hrs by CellTiter 96 Aqueous One Solution reagent based assay
|
[PMID: 32096998] |
| OVCAR-3 | IC50 |
5.1 nM
Compound: Paclitaxel
|
Cytotoxicity against human OVCAR-3 cells after 72 hrs by Cell Titer-Blue cell viability assay
Cytotoxicity against human OVCAR-3 cells after 72 hrs by Cell Titer-Blue cell viability assay
|
[PMID: 33006889] |
| OVCAR-3 | GI50 |
4 nM
Compound: Paclitaxel
|
Cytotoxicity against human OVCAR-3 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay
Cytotoxicity against human OVCAR-3 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay
|
[PMID: 33310545] |
| OVCAR-3 | IC50 |
1.8 nM
Compound: Taxol
|
Cytotoxicity against human OVCAR-3 cells assessed as inhibition of cell proliferation measured after 72 hrs by CellTiter 96 AQueous One Solution Cell Proliferation assay
Cytotoxicity against human OVCAR-3 cells assessed as inhibition of cell proliferation measured after 72 hrs by CellTiter 96 AQueous One Solution Cell Proliferation assay
|
[PMID: 33859802] |
| OVCAR-3 | IC50 |
1.8 x 10-3 μM
Compound: Taxol
|
Cytotoxicity against human OVCAR-3 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
Cytotoxicity against human OVCAR-3 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
|
[PMID: 36884371] |
| OVCAR-3 | IC50 |
4.9 nM
Compound: Paclitaxel
|
Cytotoxicity against human OVCAR-3 cells incubated for 72 hrs by Cell titer blue assay
Cytotoxicity against human OVCAR-3 cells incubated for 72 hrs by Cell titer blue assay
|
[PMID: 37216676] |
| OVCAR-3 | IC50 |
2.6 nM
Compound: Taxol
|
Cytotoxicity against human OVCAR-3 cells assessed as inhibition of cell growth for 72 hrs by CellTiter-Blue cell viability assay
Cytotoxicity against human OVCAR-3 cells assessed as inhibition of cell growth for 72 hrs by CellTiter-Blue cell viability assay
|
[PMID: 37643353] |
| OVCAR-3 | IC50 |
5.6 nM
Compound: Paclitaxel
|
Cytotoxicity against human OVCAR-3 cells assessed as reduction in cell viability measured after 72 hrs by MTS assay
Cytotoxicity against human OVCAR-3 cells assessed as reduction in cell viability measured after 72 hrs by MTS assay
|
[PMID: 38237151] |
| OVCAR-3 | IC50 |
5.9 μM
Compound: Paclitaxel
|
Cytotoxicity against human OVCAR-3 cells assessed as inhibition of cell viability incubated for 72 hrs
Cytotoxicity against human OVCAR-3 cells assessed as inhibition of cell viability incubated for 72 hrs
|
[PMID: 38341161] |
| OVCAR-3 | IC50 |
0.004 μM
Compound: PTX
|
Cytotoxicity against human OVCAR-3 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay
Cytotoxicity against human OVCAR-3 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay
|
[PMID: 38547648] |
| OVCAR-3 | IC50 |
0.1 nM
Compound: P
|
Cytotoxicity against human OVCAR-3 cells treated for 72 hrs
Cytotoxicity against human OVCAR-3 cells treated for 72 hrs
|
[PMID: 38964520] |
| OVCAR-3 | GI50 |
1.97 x 10-8 M
Compound: 5
|
Cytotoxicity against human OVCAR-3 cells
Cytotoxicity against human OVCAR-3 cells
|
[PMID: 7908950] |
| OVCAR-4 | GI50 |
630 nM
Compound: Paclitaxel
|
Growth inhibition of human OVCAR4 cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human OVCAR4 cells incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 29655610] |
| OVCAR-4 | IC50 |
>600 μM
Compound: Paclitaxel
|
Antiproliferative activity against taxane-resistant human OVCAR4 cells after 72 hrs by CellTiter 96 aqueous nonradioactive cell proliferation assay
Antiproliferative activity against taxane-resistant human OVCAR4 cells after 72 hrs by CellTiter 96 aqueous nonradioactive cell proliferation assay
|
[PMID: 29995409] |
| OVCAR-4 | GI50 |
630 nM
Compound: Paclitaxel
|
Cytotoxicity against human OVCAR-4 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay
Cytotoxicity against human OVCAR-4 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay
|
[PMID: 33310545] |
| OVCAR-5 | GI50 |
7.9 nM
Compound: Paclitaxel
|
Growth inhibition of human OVCAR5 cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human OVCAR5 cells incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 29655610] |
| OVCAR-5 | GI50 |
7.9 nM
Compound: Paclitaxel
|
Cytotoxicity against human OVCAR-5 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay
Cytotoxicity against human OVCAR-5 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay
|
[PMID: 33310545] |
| OVCAR-5 | IC50 |
7.3 nM
Compound: Paclitaxel
|
Cytotoxicity against human OVCAR-5 cells incubated for 72 hrs by Cell titer blue assay
Cytotoxicity against human OVCAR-5 cells incubated for 72 hrs by Cell titer blue assay
|
[PMID: 37216676] |
| OVCAR-5 | IC50 |
3.6 nM
Compound: Taxol
|
Cytotoxicity against human OVCAR-5 cells assessed as inhibition of cell growth for 72 hrs by CellTiter-Blue cell viability assay
Cytotoxicity against human OVCAR-5 cells assessed as inhibition of cell growth for 72 hrs by CellTiter-Blue cell viability assay
|
[PMID: 37643353] |
| OVCAR-8 | IC50 |
4.7 nM
Compound: Paclitaxel
|
Anticancer activity against human OVCAR8 cells after 96 hrs by SRB assay
Anticancer activity against human OVCAR8 cells after 96 hrs by SRB assay
|
[PMID: 21557538] |
| OVCAR-8 | IC50 |
2 nM
Compound: PTX
|
Growth inhibition of human OVCAR8 cells overexpressing P-glycoprotein after 96 hrs
Growth inhibition of human OVCAR8 cells overexpressing P-glycoprotein after 96 hrs
|
[PMID: 22044164] |
| OVCAR-8 | IC50 |
5 nM
Compound: PTX
|
Cytotoxicity against human OVCAR8 cells assessed as growth inhibition by trypan blue exclusion assay
Cytotoxicity against human OVCAR8 cells assessed as growth inhibition by trypan blue exclusion assay
|
[PMID: 23214452] |
| OVCAR-8 | EC50 |
18 nM
Compound: paclitaxel
|
Cytotoxicity against human OVCAR8 cells assessed as inhibition of cell proliferation by SRB assay
Cytotoxicity against human OVCAR8 cells assessed as inhibition of cell proliferation by SRB assay
|
[PMID: 24801610] |
| OVCAR-8 | IC50 |
10 nM
Compound: paclitaxel
|
Growth inhibition of human OVCAR8 cells after 96 hrs incubation by sulforhodamine B technique
Growth inhibition of human OVCAR8 cells after 96 hrs incubation by sulforhodamine B technique
|
[PMID: 24900865] |
| OVCAR-8 | IC50 |
5 nM
Compound: PTX
|
Cytotoxicity against human OVCAR8 cells assessed as growth inhibition after 96 hrs by Giemsa staining-based light microscopy
Cytotoxicity against human OVCAR8 cells assessed as growth inhibition after 96 hrs by Giemsa staining-based light microscopy
|
[PMID: 25025991] |
| OVCAR-8 | IC50 |
3.7 nM
Compound: PTX
|
Cytotoxicity against human OVCAR8 cells assessed as growth inhibition after 48 hrs by SRB assay
Cytotoxicity against human OVCAR8 cells assessed as growth inhibition after 48 hrs by SRB assay
|
[PMID: 26132075] |
| OVCAR-8 | IC50 |
5 μM
Compound: Paclitaxel
|
Growth inhibition of human OVCAR8 cells measured after 96 hrs by sulforhodamine B assay
Growth inhibition of human OVCAR8 cells measured after 96 hrs by sulforhodamine B assay
|
[PMID: 27894589] |
| OVCAR-8 | IC50 |
0.01 μM
Compound: Paclitaxel
|
Growth inhibition of human OVCAR8 cells after 72 hrs by SRB assay
Growth inhibition of human OVCAR8 cells after 72 hrs by SRB assay
|
[PMID: 29519737] |
| OVCAR-8 | GI50 |
7.9 nM
Compound: Paclitaxel
|
Growth inhibition of human OVCAR8 cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human OVCAR8 cells incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 29655610] |
| OVCAR-8 | IC50 |
4 nM
Compound: PTX
|
Growth inhibition of human OVCAR8 cells after 96 hrs by trypan blue exclusion assay
Growth inhibition of human OVCAR8 cells after 96 hrs by trypan blue exclusion assay
|
[PMID: 29730191] |
| OVCAR-8 | GI50 |
7.9 nM
Compound: Paclitaxel
|
Cytotoxicity against human OVCAR-8 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay
Cytotoxicity against human OVCAR-8 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay
|
[PMID: 33310545] |
| OVCAR-8 | IC50 |
5.3 nM
Compound: Paclitaxel
|
Antiproliferative activity against human OVCAR-8 cells
Antiproliferative activity against human OVCAR-8 cells
|
[PMID: 33705908] |
| OVCAR-8 | IC50 |
6.5 nM
Compound: Taxol
|
Cytotoxicity against human OVCAR-8 cells assessed as inhibition of cell growth for 72 hrs by CellTiter-Blue cell viability assay
Cytotoxicity against human OVCAR-8 cells assessed as inhibition of cell growth for 72 hrs by CellTiter-Blue cell viability assay
|
[PMID: 37643353] |
| P388 | IC50 |
16 nM
Compound: Paclitaxel
|
The compound was tested for susceptibility to a multidrug resistant(MDR) subline of murine P388/S leukemia cells under continuous exposure conditions for 3-4 days
The compound was tested for susceptibility to a multidrug resistant(MDR) subline of murine P388/S leukemia cells under continuous exposure conditions for 3-4 days
|
[PMID: 10843209] |
| P388 | IC50 |
170 nM
Compound: Paclitaxel
|
The compound was tested for susceptibility to P-glycoprotein (PgP) mediated drug efflux using murine P388/VMDRC.04 cells under continuous exposure conditions for 3-4 days
The compound was tested for susceptibility to P-glycoprotein (PgP) mediated drug efflux using murine P388/VMDRC.04 cells under continuous exposure conditions for 3-4 days
|
[PMID: 10843209] |
| P388 | IC50 |
0.02 μM
Compound: 1
|
Cytotoxicity against mouse P388 cells after 72 hrs by SRB assay
Cytotoxicity against mouse P388 cells after 72 hrs by SRB assay
|
[PMID: 12088425] |
| P388 | GI50 |
2.93 ng/mL
Compound: Paclitaxel
|
Cytotoxic activity against mouse leukemia P388 cell line
Cytotoxic activity against mouse leukemia P388 cell line
|
[PMID: 12482420] |
| P388 | IC50 |
2.27 μg/mL
Compound: (22) taxol
|
In vitro cytotoxicity of compound against P388, mouse fibroblast leukemia was defined by microculture tetrazolium assay
In vitro cytotoxicity of compound against P388, mouse fibroblast leukemia was defined by microculture tetrazolium assay
|
[PMID: 12620075] |
| P388 | IC50 |
0.27 μg/mL
Compound: Taxol
|
The concentration required to 50% inhibition of the P388 leukemic cell proliferation
The concentration required to 50% inhibition of the P388 leukemic cell proliferation
|
[PMID: 1672159] |
| P388 | IC50 |
0.01 μM
Compound: Taxol
|
Cytotoxicity against murine P388 cell line by MTS assay
Cytotoxicity against murine P388 cell line by MTS assay
|
[PMID: 16870446] |
| P388 | IC50 |
22 nM
Compound: paclitaxel
|
Antiproliferative activity against P388 cells by ELISA
Antiproliferative activity against P388 cells by ELISA
|
[PMID: 17154505] |
| P388 | IC50 |
>5 μM
Compound: paclitaxel
|
Antiproliferative activity against P388 ADR cells by XTT assay after 48 hrs
Antiproliferative activity against P388 ADR cells by XTT assay after 48 hrs
|
[PMID: 17181164] |
| P388 | IC50 |
0.04 μM
Compound: paclitaxel
|
Antiproliferative activity against P388 cells by XTT assay after 48 hrs
Antiproliferative activity against P388 cells by XTT assay after 48 hrs
|
[PMID: 17181164] |
| P388 | IC50 |
0.93 μM
Compound: paclitaxel
|
Cytotoxicity against mouse P388 cells after 72 hrs by MTT assay
Cytotoxicity against mouse P388 cells after 72 hrs by MTT assay
|
[PMID: 17896816] |
| P388 | IC50 |
>5 μM
Compound: paclitaxel
|
Antiproliferative activity against mouse adriamycin-resistant P388 cells after 48 hrs by XTT assay
Antiproliferative activity against mouse adriamycin-resistant P388 cells after 48 hrs by XTT assay
|
[PMID: 17973361] |
| P388 | IC50 |
0.04 μM
Compound: paclitaxel
|
Antiproliferative activity against mouse P388 cells after 48 hrs by XTT assay
Antiproliferative activity against mouse P388 cells after 48 hrs by XTT assay
|
[PMID: 17973361] |
| P388 | IC50 |
0.93 μM
Compound: paclitaxel
|
Cytotoxicity against mouse P388 cells after 72 hrs by MTT assay
Cytotoxicity against mouse P388 cells after 72 hrs by MTT assay
|
[PMID: 18281952] |
| P388 | IC50 |
0.01 μM
Compound: Taxol
|
Cytotoxicity against mouse P388 cells after 72 hrs by MTT assay
Cytotoxicity against mouse P388 cells after 72 hrs by MTT assay
|
[PMID: 18308566] |
| P388 | IC50 |
0.05 μM
Compound: paclitaxel
|
Antiproliferative activity against doxorubicin-resistant mouse P388 cells expressing MDR1 protein after 48 hrs by XTT assay
Antiproliferative activity against doxorubicin-resistant mouse P388 cells expressing MDR1 protein after 48 hrs by XTT assay
|
[PMID: 19220018] |
| P388 | IC50 |
0.07 μM
Compound: paclitaxel
|
Antiproliferative activity against mouse P388 cells after 48 hrs by XTT assay
Antiproliferative activity against mouse P388 cells after 48 hrs by XTT assay
|
[PMID: 19220018] |
| P388 | IC50 |
>5 μM
Compound: paclitaxel
|
Antiproliferative activity against adriamycin-resistant mouse P388 cells after 48 hrs by XTT assay
Antiproliferative activity against adriamycin-resistant mouse P388 cells after 48 hrs by XTT assay
|
[PMID: 20537765] |
| P388 | IC50 |
0.04 μM
Compound: paclitaxel
|
Antiproliferative activity against mouse P388 cells after 48 hrs by XTT assay
Antiproliferative activity against mouse P388 cells after 48 hrs by XTT assay
|
[PMID: 20537765] |
| P388 | IC50 |
>5 μM
Compound: Paclitaxel
|
Antiproliferative activity against ADR-resistant mouse P388 cells after 48 hrs by XTT assay
Antiproliferative activity against ADR-resistant mouse P388 cells after 48 hrs by XTT assay
|
[PMID: 21705223] |
| P388 | IC50 |
0.04 μM
Compound: Paclitaxel
|
Antiproliferative activity against mouse P388 cells after 48 hrs by XTT proliferation assay
Antiproliferative activity against mouse P388 cells after 48 hrs by XTT proliferation assay
|
[PMID: 21705223] |
| P388 | IC50 |
0.2 μg/mL
Compound: Paclitaxel
|
Cytotoxicity against mouse P388 cells after 48 hrs by MTT assay
Cytotoxicity against mouse P388 cells after 48 hrs by MTT assay
|
[PMID: 23755851] |
| P388 | IC50 |
0.0001 μM
Compound: Taxol
|
Antiproliferative activity against mouse P388 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
Antiproliferative activity against mouse P388 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
|
[PMID: 27010926] |
| P388 | IC50 |
45 μg/mL
Compound: 1
|
Cytotoxicity against mouse P388 cells by MTT assay
Cytotoxicity against mouse P388 cells by MTT assay
|
[PMID: 7561894] |
| P388 | IC50 |
0.03 μg/mL
Compound: paclitaxel
|
Cytotoxicity against mouse P388 cells after 48 hrs by MTT assay
Cytotoxicity against mouse P388 cells after 48 hrs by MTT assay
|
[PMID: 9134747] |
| P388 | IC50 |
0.2 μg/mL
Compound: Paclitaxel
|
Cytotoxicity was evaluated against P388 mouse lymphoma cells
Cytotoxicity was evaluated against P388 mouse lymphoma cells
|
[PMID: 9871668] |
| P388 | GI50 |
16 nM
Compound: Paclitaxel
|
Compound was tested in vitro for growth inhibition of murine leukemic P388 cells
Compound was tested in vitro for growth inhibition of murine leukemic P388 cells
|
[PMID: 9873597] |
| P388 | IC50 |
6 μM
Compound: Taxol
|
In vitro inhibitory activity of compound against P388/O murine leukemia cell line
In vitro inhibitory activity of compound against P388/O murine leukemia cell line
|
10.1016/S0960-894X(01)80411-X |
| P388 | IC50 |
0.046 μg/mL
Compound: 3
|
In vitro cytotoxicity against P388-mouse leukemia cells.
In vitro cytotoxicity against P388-mouse leukemia cells.
|
10.1016/S0960-894X(01)80507-2 |
| P388 | IC50 |
0.01 μg/mL
Compound: Taxol (TAX)
|
Tested for the cytostatic activity as inhibitory concentration against P-388 mouse leukemia cells
Tested for the cytostatic activity as inhibitory concentration against P-388 mouse leukemia cells
|
10.1016/S0960-894X(97)00071-1 |
| P388 | IC50 |
0.05 μg/mL
Compound: 2
|
Antiproliferative activity against mouse P388 cells by MTT assay
Antiproliferative activity against mouse P388 cells by MTT assay
|
10.1021/np50089a022 |
| P388/ADR | IC50 |
>5 μM
Compound: Paclitaxel ; Taxol
|
Antiproliferative activity against P388 phenotype P388 ADR tumor cell line
Antiproliferative activity against P388 phenotype P388 ADR tumor cell line
|
[PMID: 12852768] |
| P388/ADR | IC50 |
0.04 μM
Compound: Paclitaxel ; Taxol
|
Antiproliferative activity against P388 tumor cell line
Antiproliferative activity against P388 tumor cell line
|
[PMID: 12852768] |
| P388/ADR | IC50 |
1636 nM
Compound: paclitaxel
|
Antiproliferative activity against adriamycin resistant P388 cells by ELISA
Antiproliferative activity against adriamycin resistant P388 cells by ELISA
|
[PMID: 17154505] |
| P388/ADR | IC50 |
30 nM
Compound: paclitaxel
|
Antiproliferative activity against adriamycin resistant P388 cells in presence of 5 uM 1,13-bis[4'-((5,7-dihydroxy)-4H-chromen-4-on-2-yl)phenyl]-1,4,7,10,13-pentaoxatridecane by ELISA
Antiproliferative activity against adriamycin resistant P388 cells in presence of 5 uM 1,13-bis[4'-((5,7-dihydroxy)-4H-chromen-4-on-2-yl)phenyl]-1,4,7,10,13-pentaoxatridecane by ELISA
|
[PMID: 17154505] |
| P388/ADR | GI50 |
>15000 nM
Compound: Paclitaxel
|
Compound was tested in vitro for growth inhibition of murine leukemic P388/ADR cells that exhibit MDR phenotype.
Compound was tested in vitro for growth inhibition of murine leukemic P388/ADR cells that exhibit MDR phenotype.
|
[PMID: 9873597] |
| P388D1 | IC50 |
35 nM
Compound: Pac
|
Antiproliferative activity against mouse P388D1 cells after 48 hrs by sulforhodamine B assay
Antiproliferative activity against mouse P388D1 cells after 48 hrs by sulforhodamine B assay
|
[PMID: 21604746] |
| P388D1 | IC50 |
35 nM
Compound: Pac
|
Antiproliferative activity against human P388D1 after 48 hrs by SRB assay
Antiproliferative activity against human P388D1 after 48 hrs by SRB assay
|
[PMID: 21920638] |
| PA-1 | IC50 |
0.006 μg/mL
Compound: taxol
|
Cytotoxicity against human PA1 cell line by MTT assay
Cytotoxicity against human PA1 cell line by MTT assay
|
[PMID: 16297622] |
| PA-1 | IC50 |
0.008 μM
Compound: Taxol
|
Cytotoxicity against human PA1 cells compound treated for 6 hrs measured 48 hrs post washout by MTT assay
Cytotoxicity against human PA1 cells compound treated for 6 hrs measured 48 hrs post washout by MTT assay
|
[PMID: 23584542] |
| PA-1 | IC50 |
3 nM
Compound: Taxol
|
Antiproliferative activity against human PA1 cells after 72 hrs by phosphatase assay
Antiproliferative activity against human PA1 cells after 72 hrs by phosphatase assay
|
[PMID: 28857558] |
| PANC-1 | IC50 |
7 nM
Compound: 2
|
Cytotoxicity against human PANC1 cells after 72 hrs by MTT assay
Cytotoxicity against human PANC1 cells after 72 hrs by MTT assay
|
[PMID: 18081257] |
| PANC-1 | IC50 |
9.9 nM
Compound: 1,paclitaxel
|
Cytotoxicity against taxol-sensitive human PANC1 cells after 72 hrs by MTT assay
Cytotoxicity against taxol-sensitive human PANC1 cells after 72 hrs by MTT assay
|
[PMID: 18951787] |
| PANC-1 | IC50 |
9.9 nM
Compound: 1
|
Growth inhibition of human PANC1 cells after 72 hrs by MTT assay
Growth inhibition of human PANC1 cells after 72 hrs by MTT assay
|
[PMID: 19022679] |
| PANC-1 | IC50 |
25.7 nM
Compound: paclitaxel
|
Cytotoxicity against human PANC1 cells expressing mdr1, mrp1, mrp2, lrp genes after 72 hrs
Cytotoxicity against human PANC1 cells expressing mdr1, mrp1, mrp2, lrp genes after 72 hrs
|
[PMID: 19239240] |
| PANC-1 | IC50 |
<0.008 μM
Compound: Paclitaxel
|
Growth inhibition of human PANC1 cells after 48 hrs by SRB assay
Growth inhibition of human PANC1 cells after 48 hrs by SRB assay
|
[PMID: 20521771] |
| PANC-1 | IC50 |
384.1 nM
Compound: Taxol
|
Antiproliferative activity against human PANC1 cells after 96 hrs by MTT assay
Antiproliferative activity against human PANC1 cells after 96 hrs by MTT assay
|
[PMID: 21296467] |
| PANC-1 | IC50 |
1.1 x 10-3 μM
Compound: Paclitaxel
|
Cytotoxicity against human PANC1 cells after 72 hrs by MTS assay
Cytotoxicity against human PANC1 cells after 72 hrs by MTS assay
|
[PMID: 21812410] |
| PANC-1 | IC50 |
0.26 μM
Compound: Paclitaxel
|
Cytotoxicity against human PANC1 cells assessed as reduction in cell viability after 72 hrs by MTT assay
Cytotoxicity against human PANC1 cells assessed as reduction in cell viability after 72 hrs by MTT assay
|
[PMID: 22871217] |
| PANC-1 | IC50 |
5.2 nM
Compound: PTX
|
Cytotoxicity against human PANC1 cells after 72 hrs by coulter counter analysis
Cytotoxicity against human PANC1 cells after 72 hrs by coulter counter analysis
|
[PMID: 23140358] |
| PANC-1 | IC50 |
<1 μM
Compound: Paclitaxel
|
Cytotoxicity against human PANC1 cells after 72 hrs by SRB assay
Cytotoxicity against human PANC1 cells after 72 hrs by SRB assay
|
[PMID: 23848163] |
| PANC-1 | GI50 |
2.409 nM
Compound: 1, Taxol
|
Growth inhibition of human PANC1 cells by MTT assay
Growth inhibition of human PANC1 cells by MTT assay
|
[PMID: 24405702] |
| PANC-1 | IC50 |
1.18 μM
Compound: 1
|
Cytotoxicity against human PANC1 cells assessed as inhibition of cell proliferation
Cytotoxicity against human PANC1 cells assessed as inhibition of cell proliferation
|
[PMID: 25466201] |
| PANC-1 | IC50 |
1.1 x 10-3 μM
Compound: paclitaxel
|
Cytotoxicity against human PANC1 cells assessed as reduction in cell viability by MTS assay
Cytotoxicity against human PANC1 cells assessed as reduction in cell viability by MTS assay
|
[PMID: 25760674] |
| PANC-1 | GI50 |
0.012 μM
Compound: Paclitaxel
|
Antiproliferative activity against human PANC1 cells after 48 hrs by SRB assay
Antiproliferative activity against human PANC1 cells after 48 hrs by SRB assay
|
[PMID: 25827522] |
| PANC-1 | GI50 |
0.1279 μg/mL
Compound: Paclitaxel
|
Cytotoxicity against human PANC1 cells after 48 hrs by MTT assay
Cytotoxicity against human PANC1 cells after 48 hrs by MTT assay
|
[PMID: 26299346] |
| PANC-1 | GI50 |
0.0038 μg/mL
Compound: Paclitaxel
|
Cytotoxicity against human PANC1 cells after 48 hrs by MTT assay
Cytotoxicity against human PANC1 cells after 48 hrs by MTT assay
|
[PMID: 26920799] |
| PANC-1 | GI50 |
0.1279 μg/mL
Compound: Paclitaxel
|
Cytotoxicity against human PANC1 cells after 48 hrs by MTT assay
Cytotoxicity against human PANC1 cells after 48 hrs by MTT assay
|
[PMID: 27013391] |
| PANC-1 | CC50 |
0.1279 μg/mL
Compound: Paclitaxel
|
Cytotoxicity against human PANC1 cells by MTT assay
Cytotoxicity against human PANC1 cells by MTT assay
|
[PMID: 27301367] |
| PANC-1 | GI50 |
0.127 μg/mL
Compound: Paclitaxel
|
Cytotoxicity against human PANC1 cells assessed as growth inhibition after 90 hrs by MTT assay
Cytotoxicity against human PANC1 cells assessed as growth inhibition after 90 hrs by MTT assay
|
[PMID: 27563398] |
| PANC-1 | GI50 |
5.8 μg/mL
Compound: Paclitaxel
|
Cytotoxicity against human PANC1 cells measured after 48 hrs by MTT assay
Cytotoxicity against human PANC1 cells measured after 48 hrs by MTT assay
|
[PMID: 27688192] |
| PANC-1 | GI50 |
0.1279 μg/mL
Compound: Paclitaxel
|
Cytotoxicity against human PANC1 cells assessed as growth inhibition by MTT assay
Cytotoxicity against human PANC1 cells assessed as growth inhibition by MTT assay
|
[PMID: 28103537] |
| PANC-1 | GI50 |
0.1279 μg/mL
Compound: Paclitaxel
|
Growth inhibition of human PANC1 cells by MTT assay
Growth inhibition of human PANC1 cells by MTT assay
|
[PMID: 28411559] |
| PANC-1 | IC50 |
0.04 μM
Compound: Paclitaxel
|
Antiproliferative activity against human PANC1 cells after 24 hrs by CCK8 assay
Antiproliferative activity against human PANC1 cells after 24 hrs by CCK8 assay
|
[PMID: 30392953] |
| PANC-1 | IC50 |
0.06 μM
Compound: Paclitaxel
|
Cytotoxicity activity against human PANC1 cells assessed as cell growth inhibition after 48 hrs by MTT assay
Cytotoxicity activity against human PANC1 cells assessed as cell growth inhibition after 48 hrs by MTT assay
|
[PMID: 30433783] |
| PANC-1 | GI50 |
0.1279 μg/mL
Compound: Paclitaxel
|
Growth inhibition of human PANC1 cells by MTT assay
Growth inhibition of human PANC1 cells by MTT assay
|
[PMID: 30910461] |
| PANC-1 | IC50 |
3.5 μM
Compound: Taxol
|
Cytotoxicity against human PANC1 cells incubated for 48 hrs by MTT assay
Cytotoxicity against human PANC1 cells incubated for 48 hrs by MTT assay
|
[PMID: 31042380] |
| PANC-1 | IC50 |
0.004 μM
Compound: Paclitaxel
|
Cytotoxicity against human PANC-1 cells assessed as reduction in cell growth measured after 72 hrs by MTT assay
Cytotoxicity against human PANC-1 cells assessed as reduction in cell growth measured after 72 hrs by MTT assay
|
[PMID: 37336771] |
| PANC-1 | IC50 |
0.003 μM
Compound: PTX
|
Cytotoxicity against human PANC-1 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay
Cytotoxicity against human PANC-1 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay
|
[PMID: 38547648] |
| PANC-1 | IC50 |
0.021 μM
Compound: Paclitaxel
|
Antiproliferative activity against human PANC-1 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
Antiproliferative activity against human PANC-1 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
|
[PMID: 39163776] |
| PANC-1 | GI50 |
0.004 μg/mL
Compound: Paclitaxel
|
Cytotoxicity against human PANC1 cells assessed as growth inhibition after 48 hrs by MTT assay
Cytotoxicity against human PANC1 cells assessed as growth inhibition after 48 hrs by MTT assay
|
10.1039/C5MD00057B |
| Panel NCI-60 (60 carcinoma cell lines) | GI50 |
0.1 nM
Compound: Taxol
|
Growth inhibitory activity against human cancer cell line in the NCI's anticancer drug screening program
Growth inhibitory activity against human cancer cell line in the NCI's anticancer drug screening program
|
[PMID: 15743190] |
| PBMC | IC50 |
5 μM
Compound: Taxol
|
Cytotoxicity against human PBMC cells
Cytotoxicity against human PBMC cells
|
[PMID: 23937981] |
| PC-12 | GI50 |
539 ng/mL
Compound: Paclitaxel
|
Cytotoxic activity against human lung cancer PC-12 cell line
Cytotoxic activity against human lung cancer PC-12 cell line
|
[PMID: 12482420] |
| PC-14 | IC50 |
4.4 nM
Compound: 28
|
Antiproliferative activity against human PC14 cells after 72 hrs by WST8 assay
Antiproliferative activity against human PC14 cells after 72 hrs by WST8 assay
|
[PMID: 25625617] |
| PC-3 | GI50 |
0.015 nM
Compound: Paclitaxel
|
Inhibitory concentration against PC3 (prostate) cells
Inhibitory concentration against PC3 (prostate) cells
|
[PMID: 12825928] |
| PC-3 | IC50 |
77 nM
Compound: 1
|
Cytotoxicity against human PC3 cells after 48 hrs by MTS method
Cytotoxicity against human PC3 cells after 48 hrs by MTS method
|
[PMID: 14987051] |
| PC-3 | IC50 |
0.016 μM
Compound: Paclitaxel
|
Cytotoxicity against human PC3 cells after 48 hrs by SRB assay
Cytotoxicity against human PC3 cells after 48 hrs by SRB assay
|
[PMID: 15043402] |
| PC-3 | IC50 |
3.4 nM
Compound: Paclitaxel
|
Antiproliferative activity against prostate cancer PC-3 cell line using sulforhodamine B(SRB) assay
Antiproliferative activity against prostate cancer PC-3 cell line using sulforhodamine B(SRB) assay
|
[PMID: 15801848] |
| PC-3 | IC50 |
0.017 μM
Compound: paclitaxel
|
Antitumor activity against human PC3 cell line
Antitumor activity against human PC3 cell line
|
[PMID: 16884301] |
| PC-3 | IC50 |
5 nM
Compound: 1a, PTX
|
Cytotoxicity against PC3 cell line by MTT assay
Cytotoxicity against PC3 cell line by MTT assay
|
[PMID: 17263521] |
| PC-3 | ED50 |
55.5 nM
Compound: 1
|
Cytotoxicity against human PC3 cells by sulforhodamine B assay
Cytotoxicity against human PC3 cells by sulforhodamine B assay
|
[PMID: 17350834] |
| PC-3 | IC50 |
77 nM
Compound: 1
|
Cytotoxicity against ERbeta positive human PC3 cells
Cytotoxicity against ERbeta positive human PC3 cells
|
[PMID: 17419065] |
| PC-3 | GI50 |
0.004 μM
Compound: paclitaxel
|
Cytotoxicity against human PC3 cells
Cytotoxicity against human PC3 cells
|
[PMID: 17696332] |
| PC-3 | EC50 |
0.0097 μg/mL
Compound: Paclitaxel
|
Cytotoxicity against human PC3 cells
Cytotoxicity against human PC3 cells
|
[PMID: 18640035] |
| PC-3 | IC50 |
2.85 μM
Compound: paclitaxel
|
Cytotoxicity against human PC3 cells
Cytotoxicity against human PC3 cells
|
[PMID: 18701281] |
| PC-3 | IC50 |
2.73 μM
Compound: Taxol
|
Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay
Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay
|
[PMID: 18701301] |
| PC-3 | IC50 |
0.2 μM
Compound: Paclitaxel
|
Cytotoxicity against human PC3 cells after 48 hrs by WST-8 assay
Cytotoxicity against human PC3 cells after 48 hrs by WST-8 assay
|
[PMID: 19072209] |
| PC-3 | EC50 |
0.0097 μg/mL
Compound: Palitaxel
|
Cytotoxicity against human PC3 cells after 3 days by sulforhodamine B assay
Cytotoxicity against human PC3 cells after 3 days by sulforhodamine B assay
|
[PMID: 19193043] |
| PC-3 | IC50 |
1.4 nM
Compound: 1,PTX
|
Cytotoxicity against human PC3 cells after 4 days by sulforhodamine B assay
Cytotoxicity against human PC3 cells after 4 days by sulforhodamine B assay
|
[PMID: 19359169] |
| PC-3 | IC50 |
0.2 μM
Compound: paclitaxel
|
Cytotoxicity against human PC3 cells after 48 hrs by SRB method
Cytotoxicity against human PC3 cells after 48 hrs by SRB method
|
[PMID: 19425589] |
| PC-3 | IC50 |
<0.0008 μM
Compound: Taxol
|
Antiproliferative activity against human PC3 cells after 72 hrs by imaging analysis
Antiproliferative activity against human PC3 cells after 72 hrs by imaging analysis
|
[PMID: 19665384] |
| PC-3 | IC50 |
>50 μM
Compound: taxol
|
Cytotoxicity against human PC3 after 48 hrs by SRB assay
Cytotoxicity against human PC3 after 48 hrs by SRB assay
|
[PMID: 21044847] |
| PC-3 | GI50 |
0.004 μM
Compound: Taxol
|
Cytotoxicity against human PC3 cells after 72 hrs by MTT assay
Cytotoxicity against human PC3 cells after 72 hrs by MTT assay
|
[PMID: 21115210] |
| PC-3 | ED50 |
8.87 nM
Compound: Paclitaxel
|
Antiproliferative activity against human PC3 cells after 3 days by sulforhodamine B assay
Antiproliferative activity against human PC3 cells after 3 days by sulforhodamine B assay
|
[PMID: 21296579] |
| PC-3 | IC50 |
0.43 nM
Compound: Paclitaxel
|
Antiproliferative activity against human PC3 cells by sulforhodamine B assay
Antiproliferative activity against human PC3 cells by sulforhodamine B assay
|
[PMID: 21775150] |
| PC-3 | IC50 |
188 nM
Compound: Paclitaxel
|
Antiproliferative activity against human paclitaxel-resistant PC3 cells by sulforhodamine B assay
Antiproliferative activity against human paclitaxel-resistant PC3 cells by sulforhodamine B assay
|
[PMID: 21775150] |
| PC-3 | GI50 |
0.004 μM
Compound: Paclitaxel
|
Cytotoxicity against human PC3 cells by sulforhodamine B assay
Cytotoxicity against human PC3 cells by sulforhodamine B assay
|
[PMID: 21839640] |
| PC-3 | GI50 |
1.46 μM
Compound: Paclitaxel
|
Cytotoxicity against human PC3 cells assessed as growth inhibition after 3 days by MTT assay
Cytotoxicity against human PC3 cells assessed as growth inhibition after 3 days by MTT assay
|
[PMID: 21889341] |
| PC-3 | IC50 |
57.2 μM
Compound: Taxol
|
Cytotoxicity against human PC3 cells after 48 hrs by MTT assay
Cytotoxicity against human PC3 cells after 48 hrs by MTT assay
|
[PMID: 22370266] |
| PC-3 | IC50 |
0.4 nM
Compound: paclitaxel
|
Antiproliferative activity against human PC3 cells after 48 hrs by SRB assay
Antiproliferative activity against human PC3 cells after 48 hrs by SRB assay
|
[PMID: 22783954] |
| PC-3 | IC50 |
0.14 μM
Compound: Taxol
|
Cytotoxicity against human PC3 cells by MTT assay
Cytotoxicity against human PC3 cells by MTT assay
|
[PMID: 23425970] |
| PC-3 | IC50 |
0.2 μM
Compound: Paclitaxel
|
Cytotoxicity against human PC3 cells after 3 days by MTT assay
Cytotoxicity against human PC3 cells after 3 days by MTT assay
|
[PMID: 23738539] |
| PC-3 | IC50 |
0.02 μM
Compound: paclitaxel
|
Cytotoxicity against human PC3 cells after 72 hrs by MTT assay
Cytotoxicity against human PC3 cells after 72 hrs by MTT assay
|
[PMID: 24033131] |
| PC-3 | IC50 |
1.5 μM
Compound: Paclitaxel
|
Cytotoxicity against human PC3 cells after 48 hrs by SRB assay
Cytotoxicity against human PC3 cells after 48 hrs by SRB assay
|
[PMID: 24056146] |
| PC-3 | IC50 |
0.2 μM
Compound: paclitaxel
|
Cytotoxicity against human PC3 cells assessed as growth inhibition after 72 hrs by MTT assay
Cytotoxicity against human PC3 cells assessed as growth inhibition after 72 hrs by MTT assay
|
[PMID: 24063567] |
| PC-3 | IC50 |
0.2 μM
Compound: Paclitaxel
|
Cytotoxicity against human PC3 cells after 48 hrs by MTT assay
Cytotoxicity against human PC3 cells after 48 hrs by MTT assay
|
[PMID: 24063582] |
| PC-3 | GI50 |
<0.1 μM
Compound: PCT
|
Growth inhibition of human PC3 cells after 48 hrs by sulforhodamine B assay
Growth inhibition of human PC3 cells after 48 hrs by sulforhodamine B assay
|
[PMID: 24727464] |
| PC-3 | IC50 |
2.9 μg/mL
Compound: PTX
|
Cytotoxicity against human PC3 cells assessed as inhibition of cell viability after 48 hrs by MTT assay
Cytotoxicity against human PC3 cells assessed as inhibition of cell viability after 48 hrs by MTT assay
|
[PMID: 24794748] |
| PC-3 | IC50 |
2.5 nM
Compound: paclitaxel
|
Cytotoxicity against human PC3 cells assessed as viability after 96 hrs
Cytotoxicity against human PC3 cells assessed as viability after 96 hrs
|
[PMID: 24900437] |
| PC-3 | IC50 |
3990 nM
Compound: PTX
|
Cytotoxicity against human PC3 cells assessed as growth inhibition after 48 hrs by MTT method
Cytotoxicity against human PC3 cells assessed as growth inhibition after 48 hrs by MTT method
|
[PMID: 25025991] |
| PC-3 | IC50 |
0.94 μM
Compound: Taxol
|
Cytotoxicity against human PC3 cells after 24 hrs by MTT assay
Cytotoxicity against human PC3 cells after 24 hrs by MTT assay
|
[PMID: 25226363] |
| PC-3 | IC50 |
0.012 μM
Compound: Paclitaxel
|
Cytotoxicity against human PC3 cells after 48 hrs by MTT assay
Cytotoxicity against human PC3 cells after 48 hrs by MTT assay
|
[PMID: 25647428] |
| PC-3 | IC50 |
0.04 μM
Compound: paclitaxel
|
Growth inhibition of human PC3 cells by sulforhodamine B assay
Growth inhibition of human PC3 cells by sulforhodamine B assay
|
[PMID: 25685941] |
| PC-3 | IC50 |
4900 nM
Compound: PTX
|
Cytotoxicity against human PC3 cells assessed as growth inhibition after 48 hrs by MTT assay
Cytotoxicity against human PC3 cells assessed as growth inhibition after 48 hrs by MTT assay
|
[PMID: 26132075] |
| PC-3 | IC50 |
<0.001 μM
Compound: 1
|
Cytotoxicity against human PC3 cells incubated for 72 hrs by MTT assay
Cytotoxicity against human PC3 cells incubated for 72 hrs by MTT assay
|
[PMID: 26448037] |
| PC-3 | IC50 |
0.02 μM
Compound: Paclitaxel
|
Antiproliferative activity against human PC3 cells after 48 hrs by sulforhodamine B assay
Antiproliferative activity against human PC3 cells after 48 hrs by sulforhodamine B assay
|
[PMID: 26785306] |
| PC-3 | IC50 |
0.002 μM
Compound: Taxol
|
Cytotoxicity against human PC3 cells assessed as growth inhibition after 72 hrs by Alamar blue assay
Cytotoxicity against human PC3 cells assessed as growth inhibition after 72 hrs by Alamar blue assay
|
[PMID: 26904921] |
| PC-3 | IC50 |
0.004 μM
Compound: Paclitaxel
|
Cytotoxicity against human PC3 cells assessed as cell growth inhibition
Cytotoxicity against human PC3 cells assessed as cell growth inhibition
|
[PMID: 26934105] |
| PC-3 | IC50 |
0.021 μM
Compound: PTX
|
Growth inhibition of human PC3 cells incubated for 72 hrs by MTT assay
Growth inhibition of human PC3 cells incubated for 72 hrs by MTT assay
|
[PMID: 27172319] |
| PC-3 | IC50 |
0.002 μM
Compound: taxol
|
Antiproliferative activity against human PC3 cells after 72 hrs by MTT assay
Antiproliferative activity against human PC3 cells after 72 hrs by MTT assay
|
[PMID: 27214307] |
| PC-3 | IC50 |
0.03 μM
Compound: Paclitaxel
|
Cytotoxicity against human PC3 cells assessed as reduction in cell viability after 72 hrs by MTT assay
Cytotoxicity against human PC3 cells assessed as reduction in cell viability after 72 hrs by MTT assay
|
[PMID: 27329938] |
| PC-3 | IC50 |
14.5 μM
Compound: PXL
|
Cytotoxicity against human PC-3 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
Cytotoxicity against human PC-3 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
|
[PMID: 27707623] |
| PC-3 | IC50 |
0.004 μM
Compound: Paclitaxel
|
Antiproliferative activity against human PC3 cells after 72 hrs by CellTiter96 AQueous nonradioactive cell proliferation assay
Antiproliferative activity against human PC3 cells after 72 hrs by CellTiter96 AQueous nonradioactive cell proliferation assay
|
[PMID: 28335606] |
| PC-3 | GI50 |
5.8 nM
Compound: Paclitaxel
|
Growth inhibition of human PC3 cells after 4 days by SRB assay
Growth inhibition of human PC3 cells after 4 days by SRB assay
|
[PMID: 28740601] |
| PC-3 | IC50 |
4.57 μM
Compound: Taxol
|
Antiproliferative activity against human PC3 cells after 48 hrs by MTS assay
Antiproliferative activity against human PC3 cells after 48 hrs by MTS assay
|
[PMID: 29172082] |
| PC-3 | IC50 |
3.7 nM
Compound: Paclitaxel
|
Cytotoxicity against human PC3 cells after 72 hrs by MTS assay
Cytotoxicity against human PC3 cells after 72 hrs by MTS assay
|
[PMID: 29406710] |
| PC-3 | GI50 |
6.3 nM
Compound: Paclitaxel
|
Growth inhibition of human PC3 cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human PC3 cells incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 29655610] |
| PC-3 | GI50 |
0.013 μM
Compound: Paclitaxel
|
Growth inhibition of human PC3 cells after 48 hrs by SRB assay
Growth inhibition of human PC3 cells after 48 hrs by SRB assay
|
[PMID: 29655982] |
| PC-3 | IC50 |
7 nM
Compound: Paclitaxel
|
Cytotoxicity against human PC3 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Cytotoxicity against human PC3 cells assessed as reduction in cell viability after 48 hrs by MTT assay
|
[PMID: 29759727] |
| PC-3 | IC50 |
7 μM
Compound: Taxol
|
Growth inhibition of human PC3 cells after 48 hrs by MTT assay
Growth inhibition of human PC3 cells after 48 hrs by MTT assay
|
[PMID: 30108837] |
| PC-3 | IC50 |
1.1 nM
Compound: Paclitaxel
|
Cytotoxicity in human PC3 cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay
Cytotoxicity in human PC3 cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay
|
[PMID: 30122035] |
| PC-3 | IC50 |
<0.001 μM
Compound: Taxol
|
Antiproliferative activity against human PC3 cells after 48 hrs by Hoechst 33342 staining-based assay
Antiproliferative activity against human PC3 cells after 48 hrs by Hoechst 33342 staining-based assay
|
[PMID: 30655216] |
| PC-3 | IC50 |
0.67 μM
Compound: Paclitaxel
|
Cytotoxicity against human PC3 cells assessed as inhibition of cell viability after 48 hrs by SRB assay
Cytotoxicity against human PC3 cells assessed as inhibition of cell viability after 48 hrs by SRB assay
|
[PMID: 30798081] |
| PC-3 | IC50 |
0.15 μM
Compound: Paclitaxel
|
Cytotoxicity against human PC3 cells measured after 72 hrs by sulforhodamine B assay
Cytotoxicity against human PC3 cells measured after 72 hrs by sulforhodamine B assay
|
[PMID: 30920216] |
| PC-3 | IC50 |
0.17 μM
Compound: Paclitaxel
|
Cytotoxicity against human PC3 cells assessed as reduction in cell viability measured after 72 hrs by SRB assay
Cytotoxicity against human PC3 cells assessed as reduction in cell viability measured after 72 hrs by SRB assay
|
[PMID: 31120251] |
| PC-3 | CC50 |
2.7 nM
Compound: Ptxl; PTX
|
Cytotoxicity against PSMA-deficient human PC3 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
Cytotoxicity against PSMA-deficient human PC3 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
|
[PMID: 31248772] |
| PC-3 | IC50 |
1.1 nM
Compound: Paclitaxel
|
Antiproliferative activity against human PC3 cells
Antiproliferative activity against human PC3 cells
|
[PMID: 31251599] |
| PC-3 | IC50 |
1.9 nM
Compound: Paclitaxel
|
Antiproliferative activity against human PC3 cells measured after 72 hrs by MTS assay
Antiproliferative activity against human PC3 cells measured after 72 hrs by MTS assay
|
[PMID: 31860298] |
| PC-3 | GI50 |
0.03 μM
Compound: Taxol
|
Antiproliferative activity against human PC3 cells assessed as inhibition of cell growth after 72 hrs by MTT assay
Antiproliferative activity against human PC3 cells assessed as inhibition of cell growth after 72 hrs by MTT assay
|
[PMID: 32199690] |
| PC-3 | GI50 |
6.3 nM
Compound: Paclitaxel
|
Cytotoxicity against human PC-3 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay
Cytotoxicity against human PC-3 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay
|
[PMID: 33310545] |
| PC-3 | IC50 |
0.002 μM
Compound: Taxol
|
Cytotoxicity against human PC-3 cells assessed as reduction in cell viability incubated for 48 hrs by Hoechst-33342 staining based cell counting method (Rvb > 25 microM)
Cytotoxicity against human PC-3 cells assessed as reduction in cell viability incubated for 48 hrs by Hoechst-33342 staining based cell counting method (Rvb > 25 microM)
|
[PMID: 33422908] |
| PC-3 | IC50 |
0.04 μM
Compound: Paclitaxel
|
Cytotoxicity against human PC-3 cells assessed as cell growth inhibition after 48 hrs by MTT assay
Cytotoxicity against human PC-3 cells assessed as cell growth inhibition after 48 hrs by MTT assay
|
[PMID: 33459007] |
| PC-3 | IC50 |
<0.025 μM
Compound: Taxol
|
Cytotoxicity against human PC3 cells assessed as reduction in cell viability incubated for 96 hrs by MTT assay
Cytotoxicity against human PC3 cells assessed as reduction in cell viability incubated for 96 hrs by MTT assay
|
[PMID: 33713977] |
| PC-3 | IC50 |
2.6 μM
Compound: Paclitaxel
|
Cytotoxicity against human PC-3 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
Cytotoxicity against human PC-3 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
|
[PMID: 34153643] |
| PC-3 | IC50 |
<0.01 μM
Compound: Taxol
|
Anticancer activity against human PC-3 cells assessed as inhibition of cell proliferation measured after 72 hrs by CCK8 reagent assay
Anticancer activity against human PC-3 cells assessed as inhibition of cell proliferation measured after 72 hrs by CCK8 reagent assay
|
[PMID: 34399390] |
| PC-3 | IC50 |
<0.025 μM
Compound: Taxol
|
Cytotoxicity against human PC-3 cells by MTT assay
Cytotoxicity against human PC-3 cells by MTT assay
|
[PMID: 36057236] |
| PC-3 | IC50 |
4900 μM
Compound: Paclitaxel
|
Cytotoxicity against human PC-3 cells assessed as reduction in cell viability
Cytotoxicity against human PC-3 cells assessed as reduction in cell viability
|
[PMID: 38107170] |
| PC-3 | IC50 |
0.01 μM
Compound: PTX
|
Cytotoxicity against human PC-3 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay
Cytotoxicity against human PC-3 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay
|
[PMID: 38547648] |
| PC-3 | IC50 |
0.12 μM
Compound: Paclitaxel
|
Cytotoxicity against Homo sapiens (human) PC3 cells after 48 hr by SRB assay
Cytotoxicity against Homo sapiens (human) PC3 cells after 48 hr by SRB assay
|
10.1007/s00044-011-9824-9 |
| PC-3 | GI50 |
7.2 nM
Compound: Taxol
|
Cytotoxicity against human PC3 cells
Cytotoxicity against human PC3 cells
|
10.1039/C2MD20089A |
| PC-3 | IC50 |
0.012 μM
Compound: Paclitaxel
|
Antiproliferative activity against human PC3 cells assessed as cell viability after 48 hrs by MTT assay
Antiproliferative activity against human PC3 cells assessed as cell viability after 48 hrs by MTT assay
|
10.1039/C4MD00344F |
| PC-3 | IC50 |
1.9 μM
Compound: Paclitaxel
|
Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay
Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay
|
10.1039/C6MD00256K |
| PC-3M | IC50 |
0.027 μM
Compound: paclitaxel
|
Cytotoxicity against human PC3M cells after 24 hrs by MTT assay
Cytotoxicity against human PC3M cells after 24 hrs by MTT assay
|
[PMID: 19245261] |
| PC-6 | GI50 |
1.27 ng/mL
Compound: Paclitaxel
|
Cytotoxic activity against human lung cancer PC-6 cell line
Cytotoxic activity against human lung cancer PC-6 cell line
|
[PMID: 12482420] |
| PC-6 | GI50 |
1.27 ng/mL
Compound: 161
|
Growth inhibition of human PC-6 cells
Growth inhibition of human PC-6 cells
|
[PMID: 34213340] |
| PC-9 | IC50 |
2.7 x 10-3 μM
Compound: Paclitaxel
|
Cytotoxicity against human PC9 cells assessed as reduction in cell viability after 72 hrs by CCK-8 assay
Cytotoxicity against human PC9 cells assessed as reduction in cell viability after 72 hrs by CCK-8 assay
|
[PMID: 29648818] |
| PC-9 | IC50 |
3.7 μM
Compound: Taxol
|
Cytotoxicity against human PC9 cells after 72 hrs by MTT assay
Cytotoxicity against human PC9 cells after 72 hrs by MTT assay
|
[PMID: 30579802] |
| PG-49 cell line | IC50 |
0.31 nM
Compound: Paclitaxel
|
Cytotoxicity expressed as concentration required to inhibit cell growth by 50% on continuous exposure time of 96h in PG-49 cell line by MTT assay.
Cytotoxicity expressed as concentration required to inhibit cell growth by 50% on continuous exposure time of 96h in PG-49 cell line by MTT assay.
|
[PMID: 12392737] |
| PPC-1 | IC50 |
3.4 nM
Compound: Paclitaxel
|
Antiproliferative activity against prostate cancer PPC-1 cell line using sulforhodamine B(SRB) assay
Antiproliferative activity against prostate cancer PPC-1 cell line using sulforhodamine B(SRB) assay
|
[PMID: 15801848] |
| PT-45 | IC50 |
0.005 μM
Compound: Taxol
|
Cytotoxicity against human PT45 cells by MTT assay
Cytotoxicity against human PT45 cells by MTT assay
|
[PMID: 16539377] |
| PT-45 | IC50 |
0.005 μM
Compound: taxol
|
Cytotoxicity against human PT45 cells after 72 hrs by MTT assay
Cytotoxicity against human PT45 cells after 72 hrs by MTT assay
|
[PMID: 17915851] |
| Raji | EC50 |
0.008 x 10-3 μM
Compound: Paclitaxel
|
Cytotoxicity against human Raji cells incubated for 48 to 72 hrs by MTT assay
Cytotoxicity against human Raji cells incubated for 48 to 72 hrs by MTT assay
|
[PMID: 39038808] |
| Ramos | IC50 |
3.35 nM
Compound: PTX
|
Antiproliferative activity against human Ramos cells incubated for 72 hrs by MTT assay
Antiproliferative activity against human Ramos cells incubated for 72 hrs by MTT assay
|
[PMID: 34648295] |
| RAW264.7 | IC50 |
>5 μM
Compound: Paclitaxel
|
Antiproliferative activity against mouse RAW264.7 cells after 18 hrs by CellTiter96 AQueous nonradioactive cell proliferation assay
Antiproliferative activity against mouse RAW264.7 cells after 18 hrs by CellTiter96 AQueous nonradioactive cell proliferation assay
|
[PMID: 28335606] |
| RCC4 | IC50 |
0.1 μM
Compound: Taxol
|
Anticancer activity against human RCC4 cells assessed as inhibition of cell proliferation measured after 72 hrs by CCK8 reagent assay
Anticancer activity against human RCC4 cells assessed as inhibition of cell proliferation measured after 72 hrs by CCK8 reagent assay
|
[PMID: 34399390] |
| RCC4/VHL | IC50 |
0.06 μM
Compound: Taxol
|
Anticancer activity against human RCC4/VHL cells assessed as inhibition of cell proliferation measured after 72 hrs by CCK8 reagent assay
Anticancer activity against human RCC4/VHL cells assessed as inhibition of cell proliferation measured after 72 hrs by CCK8 reagent assay
|
[PMID: 34399390] |
| RD | IC50 |
14200 nM
Compound: PTX
|
Cytotoxicity against human RD cells assessed as growth inhibition after 48 hrs by MTT method
Cytotoxicity against human RD cells assessed as growth inhibition after 48 hrs by MTT method
|
[PMID: 25025991] |
| RD | IC50 |
>10000 nM
Compound: PTX
|
Cytotoxicity against human RD cells assessed as growth inhibition after 48 hrs by MTT assay
Cytotoxicity against human RD cells assessed as growth inhibition after 48 hrs by MTT assay
|
[PMID: 26132075] |
| RD | IC50 |
>10000 nM
Compound: Paclitaxel
|
Antiproliferative activity against human RD cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
Antiproliferative activity against human RD cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
|
[PMID: 38107170] |
| Rhabdomyosarcoma cell | IC50 |
8.4 nM
Compound: Paclitaxel
|
Antiproliferative activity against human Rhabdomyosarcoma cells after 96 hrs by MTS assay
Antiproliferative activity against human Rhabdomyosarcoma cells after 96 hrs by MTS assay
|
[PMID: 26386818] |
| RKO | IC50 |
>3 μM
Compound: Paclitaxel ; Taxol
|
Cytotoxic activity against human colon adenocarcinoma RKO cells with ectopic inducible expression of cyclin-dependent kinase inhibitor p27kip1
Cytotoxic activity against human colon adenocarcinoma RKO cells with ectopic inducible expression of cyclin-dependent kinase inhibitor p27kip1
|
[PMID: 12852768] |
| RKO | IC50 |
0.01 μM
Compound: Paclitaxel ; Taxol
|
Cytotoxic activity against human colon adenocarcinoma RKO cells without ectopic inducible expression of cyclin-dependent kinase inhibitor p27kip1
Cytotoxic activity against human colon adenocarcinoma RKO cells without ectopic inducible expression of cyclin-dependent kinase inhibitor p27kip1
|
[PMID: 12852768] |
| RKO | IC50 |
>3 μM
Compound: paclitaxel
|
Antiproliferative activity against RKO cells with ectopic-induced p27kip1-expression by XTT assay after 48 hrs
Antiproliferative activity against RKO cells with ectopic-induced p27kip1-expression by XTT assay after 48 hrs
|
[PMID: 17181164] |
| RKO | IC50 |
0.01 μM
Compound: paclitaxel
|
Antiproliferative activity against RKO cells by XTT assay after 48 hrs
Antiproliferative activity against RKO cells by XTT assay after 48 hrs
|
[PMID: 17181164] |
| RKO | IC50 |
>3 μM
Compound: paclitaxel
|
Cytotoxicity against human RKO cells with ectopic-inducible expression of p27kip1 after 48 hrs by XTT assay
Cytotoxicity against human RKO cells with ectopic-inducible expression of p27kip1 after 48 hrs by XTT assay
|
[PMID: 17973361] |
| RKO | IC50 |
0.01 μM
Compound: paclitaxel
|
Cytotoxicity against human RKO cells after 48 hrs by XTT assay
Cytotoxicity against human RKO cells after 48 hrs by XTT assay
|
[PMID: 17973361] |
| RKO | IC50 |
>10 μM
Compound: paclitaxel
|
Antiproliferative activity against human RKO cells containing ecdysone-inducible expression vector of p27kipl by XTT assay
Antiproliferative activity against human RKO cells containing ecdysone-inducible expression vector of p27kipl by XTT assay
|
[PMID: 19220018] |
| RKO | IC50 |
0.02 μM
Compound: paclitaxel
|
Antiproliferative activity against human RKO cells by XTT assay
Antiproliferative activity against human RKO cells by XTT assay
|
[PMID: 19220018] |
| RKO | IC50 |
>3 μM
Compound: paclitaxel
|
Antiproliferative activity against human RKO cells expressing p27Kip1 after 48 hrs by XTT assay
Antiproliferative activity against human RKO cells expressing p27Kip1 after 48 hrs by XTT assay
|
[PMID: 20537765] |
| RKO | IC50 |
0.01 μM
Compound: paclitaxel
|
Antiproliferative activity against human RKO cells after 48 hrs by XTT assay
Antiproliferative activity against human RKO cells after 48 hrs by XTT assay
|
[PMID: 20537765] |
| RL | IC50 |
0.003 μM
Compound: paclitaxel
|
Antiproliferative activity against human RL cells after 72 hrs by MTT assay
Antiproliferative activity against human RL cells after 72 hrs by MTT assay
|
[PMID: 19743863] |
| RL | IC50 |
0.007 μM
Compound: PTX
|
Cytotoxicity against human RL cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay
Cytotoxicity against human RL cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay
|
[PMID: 38547648] |
| RPMI-7951 | IC50 |
0.013 μM
Compound: Paclitaxel
|
Cytotoxicity against human RPMI7951 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay
Cytotoxicity against human RPMI7951 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay
|
[PMID: 32435422] |
| RPMI-8226 | GI50 |
0.002 μM
Compound: paclitaxel
|
Cytotoxicity against human RPMI8226 cells
Cytotoxicity against human RPMI8226 cells
|
[PMID: 17696332] |
| RPMI-8226 | GI50 |
0.002 μM
Compound: Paclitaxel
|
Cytotoxicity against human RPMI8226 cells by sulforhodamine B assay
Cytotoxicity against human RPMI8226 cells by sulforhodamine B assay
|
[PMID: 21839640] |
| RPMI-8226 | GI50 |
19.9 nM
Compound: Paclitaxel
|
Growth inhibition of human RPMI8226 cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human RPMI8226 cells incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 29655610] |
| RPMI-8226 | IC50 |
1.53 μM
Compound: PTX
|
Antiproliferative activity against human RPMI8226 cells incubated for 72 hrs by CCK8 cells
Antiproliferative activity against human RPMI8226 cells incubated for 72 hrs by CCK8 cells
|
[PMID: 31200238] |
| RPMI-8226 | GI50 |
19.9 nM
Compound: Paclitaxel
|
Cytotoxicity against human RPMI-8226 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay
Cytotoxicity against human RPMI-8226 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay
|
[PMID: 33310545] |
| RPMI-8226 | IC50 |
0.002 μM
Compound: PTX
|
Cytotoxicity against human RPMI-8226 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay
Cytotoxicity against human RPMI-8226 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay
|
[PMID: 38547648] |
| RPTEC | IC50 |
0.0009 μM
Compound: paclitaxel
|
Cytotoxicity against human RPTEC cells
Cytotoxicity against human RPTEC cells
|
[PMID: 17113288] |
| RT-112 | IC50 |
0.07 μM
Compound: Paclitaxel
|
Cytotoxicity against human RT-112 cells assessed as cell growth inhibition after 48 hrs by MTT assay
Cytotoxicity against human RT-112 cells assessed as cell growth inhibition after 48 hrs by MTT assay
|
[PMID: 33459007] |
| RWPE-1 | IC50 |
0.7 μg/mL
Compound: PTX
|
Cytotoxicity against human RWPE1 cells assessed as inhibition of cell viability after 48 hrs by MTT assay
Cytotoxicity against human RWPE1 cells assessed as inhibition of cell viability after 48 hrs by MTT assay
|
[PMID: 24794748] |
| RXF 393 | GI50 |
0.05 μM
Compound: 1a, PXL, Taxol
|
Cytotoxicity against human RXF393 cells
Cytotoxicity against human RXF393 cells
|
[PMID: 23725535] |
| RXF 393 | GI50 |
15.8 nM
Compound: Paclitaxel
|
Growth inhibition of human RXF393 cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human RXF393 cells incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 29655610] |
| RXF 393 | GI50 |
15.8 nM
Compound: Paclitaxel
|
Cytotoxicity against human RXF 393 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay
Cytotoxicity against human RXF 393 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay
|
[PMID: 33310545] |
| RXF 944 | IC50 |
0.05 μM
Compound: Paclitaxel
|
In vitro inhibitory concentration of compound against human cancer RXF 944 cell line was determined
In vitro inhibitory concentration of compound against human cancer RXF 944 cell line was determined
|
[PMID: 12882225] |
| SAOS-2 | IC50 |
0.35 μM
Compound: Paclitaxel
|
Antiproliferative activity against human Saos2 cells after 24 and 72 hrs by MTT assay
Antiproliferative activity against human Saos2 cells after 24 and 72 hrs by MTT assay
|
[PMID: 24941130] |
| SF-268 | IC50 |
0.01 μM
Compound: Paclitaxel ; Taxol
|
Cytotoxic activity against cellular metabolic activity of Glioma SF-268 tumor cell line using XTT proliferation assay after incubation with the compound for 48 h
Cytotoxic activity against cellular metabolic activity of Glioma SF-268 tumor cell line using XTT proliferation assay after incubation with the compound for 48 h
|
[PMID: 12852768] |
| SF-268 | IC50 |
21.7 nM
Compound: Taxol
|
Cytotoxicity against human SF268 cells after 48 hrs by MTT assay
Cytotoxicity against human SF268 cells after 48 hrs by MTT assay
|
[PMID: 14695798] |
| SF-268 | IC50 |
21.7 nM
Compound: taxol
|
Cytotoxicity against human SF268 cells after 48 hrs by MTT assay
Cytotoxicity against human SF268 cells after 48 hrs by MTT assay
|
[PMID: 15043404] |
| SF-268 | IC50 |
0.01 μM
Compound: paclitaxel
|
Antiproliferative activity against SF268 cells by XTT assay after 48 hrs
Antiproliferative activity against SF268 cells by XTT assay after 48 hrs
|
[PMID: 17181164] |
| SF-268 | IC50 |
0.01 μM
Compound: paclitaxel
|
Cytotoxicity against human SF268 cells after 48 hrs by XTT assay
Cytotoxicity against human SF268 cells after 48 hrs by XTT assay
|
[PMID: 17973361] |
| SF-268 | IC50 |
15.3 nM
Compound: paclitaxel
|
Cytotoxicity against human SF268 cells
Cytotoxicity against human SF268 cells
|
[PMID: 18606540] |
| SF-268 | IC50 |
0.05 μM
Compound: paclitaxel
|
Antiproliferative activity against human SF268 cells by XTT assay
Antiproliferative activity against human SF268 cells by XTT assay
|
[PMID: 19220018] |
| SF-268 | IC50 |
0.01 μM
Compound: paclitaxel
|
Antiproliferative activity against human SF268 cells after 48 hrs by XTT assay
Antiproliferative activity against human SF268 cells after 48 hrs by XTT assay
|
[PMID: 20537765] |
| SF-268 | GI50 |
0.012 μM
Compound: Paclitaxel
|
Cytotoxicity against human SF268 cells after 48 hrs by SRB assay
Cytotoxicity against human SF268 cells after 48 hrs by SRB assay
|
[PMID: 21513294] |
| SF-268 | IC50 |
0.01 μM
Compound: Paclitaxel
|
Cytotoxicity against human SF268 cells after 48 hrs by XTT assay
Cytotoxicity against human SF268 cells after 48 hrs by XTT assay
|
[PMID: 21705223] |
| SF-268 | GI50 |
5 nM
Compound: Paclitaxel
|
Growth inhibition of human SF268 cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human SF268 cells incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 29655610] |
| SF-268 | GI50 |
5 nM
Compound: Paclitaxel
|
Cytotoxicity against human SF-268 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay
Cytotoxicity against human SF-268 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay
|
[PMID: 33310545] |
| SF-295 | IC50 |
290 nM
Compound: paclitaxel
|
Cytotoxicity against human SF295 cells
Cytotoxicity against human SF295 cells
|
[PMID: 18606540] |
| SF-295 | IC50 |
24.55 nM
Compound: Paclitaxel
|
Antiproliferative activity against human SF295 cells
Antiproliferative activity against human SF295 cells
|
[PMID: 21324687] |
| SF-295 | IC50 |
0.056 μM
Compound: Paclitaxel
|
Antiproliferative activity against human SF295 cells after 72 hrs by CellTiter96 AQueous nonradioactive cell proliferation assay
Antiproliferative activity against human SF295 cells after 72 hrs by CellTiter96 AQueous nonradioactive cell proliferation assay
|
[PMID: 28335606] |
| SF-295 | GI50 |
25 nM
Compound: Paclitaxel
|
Growth inhibition of human SF295 cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human SF295 cells incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 29655610] |
| SF-295 | IC50 |
56 μM
Compound: Paclitaxel
|
Antiproliferative activity against taxane-resistant human SF295 cells after 72 hrs by CellTiter 96 aqueous nonradioactive cell proliferation assay
Antiproliferative activity against taxane-resistant human SF295 cells after 72 hrs by CellTiter 96 aqueous nonradioactive cell proliferation assay
|
[PMID: 29995409] |
| SF-295 | GI50 |
25 nM
Compound: Paclitaxel
|
Cytotoxicity against human SF-295 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay
Cytotoxicity against human SF-295 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay
|
[PMID: 33310545] |
| SF-539 | GI50 |
5 nM
Compound: Paclitaxel
|
Growth inhibition of human SF539 cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human SF539 cells incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 29655610] |
| SF-539 | GI50 |
5 nM
Compound: Paclitaxel
|
Cytotoxicity against human SF-539 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay
Cytotoxicity against human SF-539 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay
|
[PMID: 33310545] |
| SF-539 | GI50 |
3.66 x 10-9 M
Compound: 5
|
Cytotoxicity against human SF539 cells
Cytotoxicity against human SF539 cells
|
[PMID: 7908950] |
| SGC-7901 | IC50 |
3.34 μM
Compound: Taxol
|
Antiproliferative activity against human SGC7901 cells after 48 hrs by MTT assay
Antiproliferative activity against human SGC7901 cells after 48 hrs by MTT assay
|
[PMID: 19815316] |
| SGC-7901 | GI50 |
3.088 nM
Compound: 1, Taxol
|
Growth inhibition of human SGC7901 cells by MTT assay
Growth inhibition of human SGC7901 cells by MTT assay
|
[PMID: 24405702] |
| SGC-7901 | IC50 |
5.1 nM
Compound: Taxol
|
Cytotoxicity against human SGC7901 cells assessed as cell viability after 72 hrs by CCK8 assay
Cytotoxicity against human SGC7901 cells assessed as cell viability after 72 hrs by CCK8 assay
|
[PMID: 25819096] |
| SGC-7901 | IC50 |
9.8 μM
Compound: taxol
|
Cytotoxicity against human SGC7901 cells after 72 hrs by CCK8 assay
Cytotoxicity against human SGC7901 cells after 72 hrs by CCK8 assay
|
[PMID: 26316467] |
| SGC-7901 | IC50 |
0.2 μg/mL
Compound: Taxol
|
Cytotoxicity against human SGC7901 cells after 48 hrs by SRB assay
Cytotoxicity against human SGC7901 cells after 48 hrs by SRB assay
|
[PMID: 26351042] |
| SGC-7901 | IC50 |
0.15 μM
Compound: Taxol
|
Cytotoxicity against human SGC-7901 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
Cytotoxicity against human SGC-7901 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
|
[PMID: 37856864] |
| SGC-7901 | IC50 |
14.35 μM
Compound: Paclitaxel
|
Cytotoxicity against human SGC-7901 cells assessed as reduction in cell viability measured after 48 hrs by MTT colorimetric assay
Cytotoxicity against human SGC-7901 cells assessed as reduction in cell viability measured after 48 hrs by MTT colorimetric assay
|
[PMID: 38107170] |
| SH-SY5Y | IC50 |
0.2 μM
Compound: Paclitaxel
|
Cytotoxicity against human SH-SY5Y cells after 48 hrs by WST-8 assay
Cytotoxicity against human SH-SY5Y cells after 48 hrs by WST-8 assay
|
[PMID: 19072209] |
| SH-SY5Y | IC50 |
0.2 μM
Compound: paclitaxel
|
Cytotoxicity against human SH-SY5Y cells after 48 hrs by SRB method
Cytotoxicity against human SH-SY5Y cells after 48 hrs by SRB method
|
[PMID: 19425589] |
| SH-SY5Y | IC50 |
8.56 μM
Compound: Paclitaxel
|
Cytotoxicity against human SH-SY5Y cells after 24 hrs by MTT assay
Cytotoxicity against human SH-SY5Y cells after 24 hrs by MTT assay
|
[PMID: 21514015] |
| SH-SY5Y | IC50 |
0.004 μM
Compound: Taxol
|
Cytotoxicity against human SH-SY5Y cells after 24 to 48 hrs by MTT assay
Cytotoxicity against human SH-SY5Y cells after 24 to 48 hrs by MTT assay
|
[PMID: 22222040] |
| SH-SY5Y | IC50 |
0.2 μM
Compound: Paclitaxel
|
Cytotoxicity against human SH-SY5Y cells after 3 days by MTT assay
Cytotoxicity against human SH-SY5Y cells after 3 days by MTT assay
|
[PMID: 23738539] |
| SH-SY5Y | IC50 |
0.2 μM
Compound: paclitaxel
|
Cytotoxicity against human SH-SY5Y cells assessed as growth inhibition after 72 hrs by MTT assay
Cytotoxicity against human SH-SY5Y cells assessed as growth inhibition after 72 hrs by MTT assay
|
[PMID: 24063567] |
| SH-SY5Y | IC50 |
0.2 μM
Compound: Paclitaxel
|
Cytotoxicity against human SH-SY5Y cells after 48 hrs by MTT assay
Cytotoxicity against human SH-SY5Y cells after 48 hrs by MTT assay
|
[PMID: 24063582] |
| SH-SY5Y | IC50 |
7.3 μg/mL
Compound: Paclitaxel
|
Anticancer activity against human SH-SY5Y cells after 24 hrs by MTT assay
Anticancer activity against human SH-SY5Y cells after 24 hrs by MTT assay
|
[PMID: 25305717] |
| SiHa | IC50 |
1.3 μg/mL
Compound: paclitaxel
|
Cytotoxicity against SiHa cancer cell line
Cytotoxicity against SiHa cancer cell line
|
[PMID: 16384699] |
| SiHa | IC50 |
3.5 μM
Compound: Paclitaxel
|
Antiproliferative activity against human SiHa cell line
Antiproliferative activity against human SiHa cell line
|
[PMID: 16793260] |
| SiHa | GI50 |
0.03 μM
Compound: taxol
|
Cytotoxicity against human SiHa cells after 72 hrs by MTT colorimetric assay
Cytotoxicity against human SiHa cells after 72 hrs by MTT colorimetric assay
|
[PMID: 19081249] |
| SiHa | GI50 |
0.03 μM
Compound: Taxol
|
Cytotoxicity against human SiHa cells after 72 hrs by MTT assay
Cytotoxicity against human SiHa cells after 72 hrs by MTT assay
|
[PMID: 20538462] |
| SiHa | IC50 |
1.4 μM
Compound: Paclitaxel
|
Cytotoxicity against human SiHa cells measured after 72 hrs by sulforhodamine B assay
Cytotoxicity against human SiHa cells measured after 72 hrs by sulforhodamine B assay
|
[PMID: 30920216] |
| SiHa | GI50 |
0.01 μM
Compound: Paclitaxel
|
Cytotoxicity against human SiHa cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
Cytotoxicity against human SiHa cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
|
[PMID: 31945642] |
| SJSA-1 | IC50 |
3.2 nM
Compound: taxol
|
Cytotoxicity against human SJSA1 cells expressing GRP78 after 6 hrs by MTT assay
Cytotoxicity against human SJSA1 cells expressing GRP78 after 6 hrs by MTT assay
|
[PMID: 18243696] |
| SK-BR-3 | GI50 |
6.1 μM
Compound: PTX
|
Antiproliferative activity against human SK-BR3 cells after 96 hrs by MTS assay
Antiproliferative activity against human SK-BR3 cells after 96 hrs by MTS assay
|
[PMID: 18164205] |
| SK-BR-3 | IC50 |
0.11 μM
Compound: Paclitaxel
|
Cytotoxicity against human SK-BR-3 cells after 48 hrs by MTT assay
Cytotoxicity against human SK-BR-3 cells after 48 hrs by MTT assay
|
[PMID: 20521771] |
| SK-BR-3 | IC50 |
0.11 μM
Compound: paclitaxel
|
Cytotoxicity against human SKBR3 cells by MTT assay
Cytotoxicity against human SKBR3 cells by MTT assay
|
[PMID: 22691179] |
| SK-BR-3 | IC50 |
0.0019 μM
Compound: Paclitaxel
|
Growth inhibition of human SKBR3 cells after 48 hrs by MTT assay
Growth inhibition of human SKBR3 cells after 48 hrs by MTT assay
|
[PMID: 22850214] |
| SK-BR-3 | IC50 |
>100 nM
Compound: PXL
|
Antiproliferative activity against human SK-BR-3 cells after 3 days by SRB assay
Antiproliferative activity against human SK-BR-3 cells after 3 days by SRB assay
|
[PMID: 25241925] |
| SK-BR-3 | IC50 |
12.7 μM
Compound: PXL
|
Cytotoxicity against human SK-BR-3 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
Cytotoxicity against human SK-BR-3 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
|
[PMID: 27707623] |
| SK-HEP1 | IC50 |
0.24 μM
Compound: Taxol
|
Cytotoxicity against human SKHEP1 cells by MTT assay
Cytotoxicity against human SKHEP1 cells by MTT assay
|
[PMID: 23425970] |
| SK-HEP1 | GI50 |
0.011 μM
Compound: Paclitaxel
|
Growth inhibition of human SKHEP1 cells after 48 hrs by SRB assay
Growth inhibition of human SKHEP1 cells after 48 hrs by SRB assay
|
[PMID: 29655982] |
| SK-MEL | IC50 |
4.1 μM
Compound: paclitaxel
|
Cytotoxicity against human SK-MEL cells after 48 hrs by neutral red assay
Cytotoxicity against human SK-MEL cells after 48 hrs by neutral red assay
|
[PMID: 19879765] |
| SK-MEL | IC50 |
0.0001 μM
Compound: Taxol
|
Antiproliferative activity against human SK-MEL cells assessed as reduction in cell growth inhibition
Antiproliferative activity against human SK-MEL cells assessed as reduction in cell growth inhibition
|
[PMID: 27010926] |
| SK-MEL-2 | IC50 |
0.07 μM
Compound: 1
|
Cytotoxicity against human SK-MEL-2 cells after 72 hrs by SRB assay
Cytotoxicity against human SK-MEL-2 cells after 72 hrs by SRB assay
|
[PMID: 12088425] |
| SK-MEL-2 | IC50 |
0.0072 μM
Compound: paclitaxel
|
Antitumor activity against human SK-MEL-2 cell line
Antitumor activity against human SK-MEL-2 cell line
|
[PMID: 16884301] |
| SK-MEL-2 | IC50 |
0.009 μM
Compound: Paclitaxel
|
Antiproliferative activity against human SK-MEL-2 cells after 72 hrs by CellTiter96 AQueous nonradioactive cell proliferation assay
Antiproliferative activity against human SK-MEL-2 cells after 72 hrs by CellTiter96 AQueous nonradioactive cell proliferation assay
|
[PMID: 28335606] |
| SK-MEL-2 | GI50 |
400 nM
Compound: Paclitaxel
|
Growth inhibition of human SK-MEL-2 cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human SK-MEL-2 cells incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 29655610] |
| SK-MEL-2 | GI50 |
400 nM
Compound: Paclitaxel
|
Cytotoxicity against human SK-MEL-2 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay
Cytotoxicity against human SK-MEL-2 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay
|
[PMID: 33310545] |
| SK-MEL-24 | IC50 |
4.73 μM
Compound: Paclitaxel
|
Cytotoxicity against human SK-MEL-24 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay
Cytotoxicity against human SK-MEL-24 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay
|
[PMID: 32435422] |
| SK-MEL-28 | GI50 |
400 nM
Compound: Paclitaxel
|
Growth inhibition of human SK-MEL-28 cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human SK-MEL-28 cells incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 29655610] |
| SK-MEL-28 | GI50 |
400 nM
Compound: Paclitaxel
|
Cytotoxicity against human SK-MEL-28 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay
Cytotoxicity against human SK-MEL-28 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay
|
[PMID: 33310545] |
| SK-MEL-28 | IC50 |
1.07 μM
Compound: PTX
|
Anticancer activity against human SK-MEL-28 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
Anticancer activity against human SK-MEL-28 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
|
[PMID: 37197457] |
| SK-MEL3 | IC50 |
4.73 μM
Compound: PTX
|
Anticancer activity against human SK-MEL3 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
Anticancer activity against human SK-MEL3 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
|
[PMID: 37197457] |
| SK-MEL-5 | IC50 |
0.15 μM
Compound: paclitaxel
|
Cytotoxicity against human SK-MEL-5 cells by MTT assay
Cytotoxicity against human SK-MEL-5 cells by MTT assay
|
[PMID: 22691179] |
| SK-MEL-5 | GI50 |
5 nM
Compound: Paclitaxel
|
Growth inhibition of human SK-MEL-5 cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human SK-MEL-5 cells incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 29655610] |
| SK-MES-1 | IC50 |
13.5 nM
Compound: Paclitaxel
|
Cytotoxicity against human SKMES1 cells after 48 hrs by Celltiter-Glo luminescent cell viability assay
Cytotoxicity against human SKMES1 cells after 48 hrs by Celltiter-Glo luminescent cell viability assay
|
[PMID: 26985296] |
| SK-MES-1 | IC50 |
0.01 μM
Compound: PTX
|
Cytotoxicity against human SK-MES-1 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay
Cytotoxicity against human SK-MES-1 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay
|
[PMID: 38547648] |
| SK-N-SH | GI50 |
2.19 μM
Compound: Paclitaxel
|
Cytotoxicity against human SK-N-SH cells assessed as growth inhibition after 3 days by MTT assay
Cytotoxicity against human SK-N-SH cells assessed as growth inhibition after 3 days by MTT assay
|
[PMID: 21889341] |
| SK-OV-3 | IC50 |
0.01 μM
Compound: Paclitaxel ; Taxol
|
Cytotoxic activity against cellular metabolic activity of Ovary SKOV3 tumor cell line using XTT proliferation assay after incubation with the compound for 48 h
Cytotoxic activity against cellular metabolic activity of Ovary SKOV3 tumor cell line using XTT proliferation assay after incubation with the compound for 48 h
|
[PMID: 12852768] |
| SK-OV-3 | IC50 |
1.35 μM
Compound: taxol
|
Cytotoxicity against human SKOV3 cells after 48 hrs by SRB assay
Cytotoxicity against human SKOV3 cells after 48 hrs by SRB assay
|
[PMID: 15787460] |
| SK-OV-3 | IC50 |
8.7 μg/mL
Compound: paclitaxel
|
Cytotoxicity against sk-ov-3 cancer cell line
Cytotoxicity against sk-ov-3 cancer cell line
|
[PMID: 16384699] |
| SK-OV-3 | IC50 |
0.005 μM
Compound: paclitaxel
|
Antitumor activity against human SKOV3 cell line
Antitumor activity against human SKOV3 cell line
|
[PMID: 16884301] |
| SK-OV-3 | IC50 |
0.01 μM
Compound: paclitaxel
|
Antiproliferative activity against SKOV3 cells by XTT assay after 48 hrs
Antiproliferative activity against SKOV3 cells by XTT assay after 48 hrs
|
[PMID: 17181164] |
| SK-OV-3 | GI50 |
0.008 μM
Compound: paclitaxel
|
Cytotoxicity against human SK-OV3 cells
Cytotoxicity against human SK-OV3 cells
|
[PMID: 17696332] |
| SK-OV-3 | IC50 |
0.01 μM
Compound: paclitaxel
|
Cytotoxicity against human SKOV3 cells after 48 hrs by XTT assay
Cytotoxicity against human SKOV3 cells after 48 hrs by XTT assay
|
[PMID: 17973361] |
| SK-OV-3 | IC50 |
2.43 μM
Compound: paclitaxel
|
Cytotoxicity against human SKOV3 cells
Cytotoxicity against human SKOV3 cells
|
[PMID: 18701281] |
| SK-OV-3 | IC50 |
0.00134 μM
Compound: Taxol
|
Antitumor activity against human SKOV3 cells after 72 hrs by MTT assay
Antitumor activity against human SKOV3 cells after 72 hrs by MTT assay
|
[PMID: 18762358] |
| SK-OV-3 | IC50 |
4 μg/mL
Compound: PTX
|
Anticancer activity against human SKOV3 cells by MTT assay
Anticancer activity against human SKOV3 cells by MTT assay
|
[PMID: 18826299] |
| SK-OV-3 | IC50 |
65.8 nM
Compound: Paclitaxel
|
Cytotoxicity against human SKOV3 cells after 72 hrs by SRB method
Cytotoxicity against human SKOV3 cells after 72 hrs by SRB method
|
[PMID: 18990574] |
| SK-OV-3 | IC50 |
0.016 μM
Compound: Paclitaxol
|
Antiproliferative activity against human SKOV3 cells after 96 hrs by MTT assay
Antiproliferative activity against human SKOV3 cells after 96 hrs by MTT assay
|
[PMID: 19091579] |
| SK-OV-3 | IC50 |
0.05 μM
Compound: paclitaxel
|
Antiproliferative activity against human SKOV3 cells by XTT assay
Antiproliferative activity against human SKOV3 cells by XTT assay
|
[PMID: 19220018] |
| SK-OV-3 | IC50 |
0.53 μM
Compound: paclitaxel
|
Cytotoxicity against human SKOV3 cells after 48 hrs by neutral red assay
Cytotoxicity against human SKOV3 cells after 48 hrs by neutral red assay
|
[PMID: 19879765] |
| SK-OV-3 | IC50 |
0.01 μM
Compound: paclitaxel
|
Antiproliferative activity against human SKOV3 cells after 48 hrs by XTT assay
Antiproliferative activity against human SKOV3 cells after 48 hrs by XTT assay
|
[PMID: 20537765] |
| SK-OV-3 | IC50 |
2600 nM
Compound: Paclitaxel
|
Antiproliferative activity against human SKOV3 cells expressing MDR1-6/6 by sulforhodamine B assay
Antiproliferative activity against human SKOV3 cells expressing MDR1-6/6 by sulforhodamine B assay
|
[PMID: 20973488] |
| SK-OV-3 | IC50 |
3 nM
Compound: Paclitaxel
|
Antiproliferative activity against human SKOV3 cells by sulforhodamine B assay
Antiproliferative activity against human SKOV3 cells by sulforhodamine B assay
|
[PMID: 20973488] |
| SK-OV-3 | IC50 |
14.5 nM
Compound: Paclitaxel
|
Antiproliferative activity against human SKOV3 cells after 72 hrs by sulforhodamine B assay
Antiproliferative activity against human SKOV3 cells after 72 hrs by sulforhodamine B assay
|
[PMID: 21480626] |
| SK-OV-3 | IC50 |
0.006 μM
Compound: paclitaxel
|
Antiproliferative activity against human SKOV3 cells after 48 hrs by alamar blue assay
Antiproliferative activity against human SKOV3 cells after 48 hrs by alamar blue assay
|
[PMID: 21563750] |
| SK-OV-3 | IC50 |
2.6 nM
Compound: Pac
|
Antiproliferative activity against human SKOV3 cells after 48 hrs by sulforhodamine B assay
Antiproliferative activity against human SKOV3 cells after 48 hrs by sulforhodamine B assay
|
[PMID: 21604746] |
| SK-OV-3 | IC50 |
0.01 μM
Compound: Paclitaxel
|
Cytotoxicity against human SKOV3 cells after 48 hrs by XTT assay
Cytotoxicity against human SKOV3 cells after 48 hrs by XTT assay
|
[PMID: 21705223] |
| SK-OV-3 | IC50 |
2.95 nM
Compound: Paclitaxel
|
Antiproliferative activity against human SKOV3 cells
Antiproliferative activity against human SKOV3 cells
|
[PMID: 21786793] |
| SK-OV-3 | IC50 |
4875 nM
Compound: Paclitaxel
|
Antiproliferative activity against MDR-1-6/6 overexpressing human SKOV3 cells
Antiproliferative activity against MDR-1-6/6 overexpressing human SKOV3 cells
|
[PMID: 21786793] |
| SK-OV-3 | GI50 |
0.008 μM
Compound: Paclitaxel
|
Cytotoxicity against human SKOV3 cells by sulforhodamine B assay
Cytotoxicity against human SKOV3 cells by sulforhodamine B assay
|
[PMID: 21839640] |
| SK-OV-3 | IC50 |
2.6 nM
Compound: Pac
|
Antiproliferative activity against human SKOV3 after 48 hrs by SRB assay
Antiproliferative activity against human SKOV3 after 48 hrs by SRB assay
|
[PMID: 21920638] |
| SK-OV-3 | IC50 |
<0.0001 μM
Compound: paclitaxel
|
Cytotoxicity against human SKOV3 cells by MTT assay
Cytotoxicity against human SKOV3 cells by MTT assay
|
[PMID: 22506620] |
| SK-OV-3 | IC50 |
0.4 μM
Compound: paclitaxel
|
Cytotoxicity against human SKOV3 cells by MTT assay
Cytotoxicity against human SKOV3 cells by MTT assay
|
[PMID: 22691179] |
| SK-OV-3 | IC50 |
2.7 nM
Compound: PTX
|
Cytotoxicity against human SKOV3 cells after 72 hrs by coulter counter analysis
Cytotoxicity against human SKOV3 cells after 72 hrs by coulter counter analysis
|
[PMID: 23140358] |
| SK-OV-3 | IC50 |
2596 nM
Compound: Paclitaxel
|
Inhibition of MDR1 (unknown origin) transfected in human SKOV3 cells assessed as growth inhibition after 48 hrs by SRB assay
Inhibition of MDR1 (unknown origin) transfected in human SKOV3 cells assessed as growth inhibition after 48 hrs by SRB assay
|
[PMID: 23332369] |
| SK-OV-3 | IC50 |
4.4 nM
Compound: Paclitaxel
|
Cytotoxicity against human SKOV3 cells assessed as growth inhibition after 48 hrs by SRB assay
Cytotoxicity against human SKOV3 cells assessed as growth inhibition after 48 hrs by SRB assay
|
[PMID: 23332369] |
| SK-OV-3 | IC50 |
0.1 μM
Compound: Taxol
|
Cytotoxicity against human SKOV3 cells by MTT assay
Cytotoxicity against human SKOV3 cells by MTT assay
|
[PMID: 23425970] |
| SK-OV-3 | IC50 |
0.012 μM
Compound: Taxol
|
Cytotoxicity against human SKOV3 cells after 72 hrs by spectrophotometry
Cytotoxicity against human SKOV3 cells after 72 hrs by spectrophotometry
|
[PMID: 23708235] |
| SK-OV-3 | IC50 |
3 nM
Compound: paclitaxel
|
Antiproliferative activity against human SKOV3 cells after 48 hrs by SRB assay
Antiproliferative activity against human SKOV3 cells after 48 hrs by SRB assay
|
[PMID: 23895532] |
| SK-OV-3 | IC50 |
3 nM
Compound: Paclitaxel
|
Cytotoxicity against human SKOV3 cells after 72 hrs by MTS assay
Cytotoxicity against human SKOV3 cells after 72 hrs by MTS assay
|
[PMID: 24087857] |
| SK-OV-3 | IC50 |
4875 nM
Compound: Paclitaxel
|
Cytotoxicity against human SKOV3 cells expressing MDR1 after 72 hrs by MTS assay
Cytotoxicity against human SKOV3 cells expressing MDR1 after 72 hrs by MTS assay
|
[PMID: 24087857] |
| SK-OV-3 | IC50 |
35 nM
Compound: 1, Taxol
|
Cytotoxicity against human SKOV3 cells after 48 hrs by MTT assay
Cytotoxicity against human SKOV3 cells after 48 hrs by MTT assay
|
[PMID: 24269481] |
| SK-OV-3 | IC50 |
2655 nM
Compound: Taxol
|
Antiproliferative activity against human SKOV3 cells expressing MDR1/M-6-6
Antiproliferative activity against human SKOV3 cells expressing MDR1/M-6-6
|
[PMID: 24890652] |
| SK-OV-3 | IC50 |
3 nM
Compound: Taxol
|
Antiproliferative activity against human SKOV3 cells
Antiproliferative activity against human SKOV3 cells
|
[PMID: 24890652] |
| SK-OV-3 | GI50 |
4.7 nM
Compound: Paclitaxel
|
Cytotoxicity against human SKOV3 cells by SRB method
Cytotoxicity against human SKOV3 cells by SRB method
|
[PMID: 24893224] |
| SK-OV-3 | IC50 |
<1 μM
Compound: Paclitaxel
|
Anticancer against human SKOV3 cells overexpressing P-gp assessed as cell viability after 48 hrs by SRB assay
Anticancer against human SKOV3 cells overexpressing P-gp assessed as cell viability after 48 hrs by SRB assay
|
[PMID: 24946145] |
| SK-OV-3 | IC50 |
<1 nM
Compound: Paclitaxel
|
Cytotoxicity against human SKOV3 cells assessed as reduction in cell viability after 48 hrs by sulforhodamine B colorimetric assay
Cytotoxicity against human SKOV3 cells assessed as reduction in cell viability after 48 hrs by sulforhodamine B colorimetric assay
|
[PMID: 25462285] |
| SK-OV-3 | IC50 |
6.2 μM
Compound: paclitaxel
|
Growth inhibition of human SKOV3 cells by sulforhodamine B assay
Growth inhibition of human SKOV3 cells by sulforhodamine B assay
|
[PMID: 25685941] |
| SK-OV-3 | IC50 |
6.3 nM
Compound: Paclitaxel
|
Antiproliferative activity against human SKOV3 cells overexpressing wild type beta3 tubulin after 48 hrs by sulforhodamine B assay
Antiproliferative activity against human SKOV3 cells overexpressing wild type beta3 tubulin after 48 hrs by sulforhodamine B assay
|
[PMID: 25882519] |
| SK-OV-3 | IC50 |
4.7 nM
Compound: PTX
|
Dark cytotoxicity against human SKOV3 cells assessed as cell viability after 72 hrs by MTT assay
Dark cytotoxicity against human SKOV3 cells assessed as cell viability after 72 hrs by MTT assay
|
[PMID: 26974508] |
| SK-OV-3 | IC50 |
0.0001 μM
Compound: Taxol
|
Antiproliferative activity against human SK-OV-3 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
Antiproliferative activity against human SK-OV-3 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
|
[PMID: 27010926] |
| SK-OV-3 | IC50 |
1200 nM
Compound: paclitaxel
|
Antiproliferative activity against multidrug resistant human SKOV3 cells expressing MDR1-M6/6 after 48 hrs by SRB assay
Antiproliferative activity against multidrug resistant human SKOV3 cells expressing MDR1-M6/6 after 48 hrs by SRB assay
|
[PMID: 27213719] |
| SK-OV-3 | IC50 |
5 nM
Compound: paclitaxel
|
Cytotoxicity against human SKOV3 cells assessed as growth inhibition after 48 hrs by SRB assay
Cytotoxicity against human SKOV3 cells assessed as growth inhibition after 48 hrs by SRB assay
|
[PMID: 27213719] |
| SK-OV-3 | IC50 |
3 nM
Compound: Paclitaxel
|
Antiproliferative activity against human SKOV3 cells after 48 hrs by SRB assay
Antiproliferative activity against human SKOV3 cells after 48 hrs by SRB assay
|
[PMID: 28433513] |
| SK-OV-3 | IC50 |
0.002 μM
Compound: PTX
|
Antiproliferative activity against human SKOV3 cells after 48 hrs by MTT assay
Antiproliferative activity against human SKOV3 cells after 48 hrs by MTT assay
|
[PMID: 29306206] |
| SK-OV-3 | IC50 |
2.39 nM
Compound: Taxol
|
Cytotoxicity against human SKOV3 cells after 72 to 120 hrs by sulforhodamine B assay
Cytotoxicity against human SKOV3 cells after 72 to 120 hrs by sulforhodamine B assay
|
[PMID: 29517223] |
| SK-OV-3 | IC50 |
3.99 nM
Compound: Taxol
|
Cytotoxicity against human SKOV3 cells after 72 to 120 hrs in presence of verapamil by sulforhodamine B assay
Cytotoxicity against human SKOV3 cells after 72 to 120 hrs in presence of verapamil by sulforhodamine B assay
|
[PMID: 29517223] |
| SK-OV-3 | GI50 |
6.3 nM
Compound: Paclitaxel
|
Growth inhibition of human SKOV3 cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human SKOV3 cells incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 29655610] |
| SK-OV-3 | IC50 |
3 nM
Compound: Paclitaxel
|
Antiproliferative activity against human SKOV3 cells by SRB assay
Antiproliferative activity against human SKOV3 cells by SRB assay
|
[PMID: 29655610] |
| SK-OV-3 | IC50 |
5 nM
Compound: Paclitaxel
|
Antiproliferative activity against human SKOV3 cells after 72 hrs by sulforhodamine B assay
Antiproliferative activity against human SKOV3 cells after 72 hrs by sulforhodamine B assay
|
[PMID: 30098869] |
| SK-OV-3 | IC50 |
5 nM
Compound: Paclitaxel
|
Antiproliferative activity against human SKOV3 cells after 48 hrs by sulforhodamine B assay
Antiproliferative activity against human SKOV3 cells after 48 hrs by sulforhodamine B assay
|
[PMID: 30297118] |
| SK-OV-3 | IC50 |
6.29 μM
Compound: PTX
|
Cytotoxicity against human SKOV3 cells incubated for 48 hrs by MTT assay
Cytotoxicity against human SKOV3 cells incubated for 48 hrs by MTT assay
|
[PMID: 30913525] |
| SK-OV-3 | IC50 |
0.02 fmol
Compound: PTX; 1
|
Photocytotoxicity against human SKOV3 cells assessed as reduction in cell viability per cell incubated for 24 hrs followed by 10 J/cm2 laser light irradiation and measured after 72 hrs by MTT assay
Photocytotoxicity against human SKOV3 cells assessed as reduction in cell viability per cell incubated for 24 hrs followed by 10 J/cm2 laser light irradiation and measured after 72 hrs by MTT assay
|
[PMID: 30987891] |
| SK-OV-3 | GI50 |
0.00134 μM
Compound: Paclitaxel
|
Cytotoxicity against human SKOV3 cells assessed as growth inhibition measured after 48 hrs by SRB assay
Cytotoxicity against human SKOV3 cells assessed as growth inhibition measured after 48 hrs by SRB assay
|
[PMID: 31059248] |
| SK-OV-3 | IC50 |
0.43 μM
Compound: Paclitaxel
|
Antiproliferative activity against human SKOV3 cells incubated for 48 hrs by MTT assay
Antiproliferative activity against human SKOV3 cells incubated for 48 hrs by MTT assay
|
[PMID: 31279299] |
| SK-OV-3 | GI50 |
0.00136 μM
Compound: Paclitaxel
|
Cytotoxicity against human SKOV3 cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay
Cytotoxicity against human SKOV3 cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay
|
[PMID: 31534659] |
| SK-OV-3 | IC50 |
0.002 μM
Compound: Paclitaxel
|
Cytotoxicity against human SK-OV-3 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
Cytotoxicity against human SK-OV-3 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
|
[PMID: 32633512] |
| SK-OV-3 | IC50 |
31.3 nM
Compound: Taxol
|
Antiproliferative activity against human SK-OV-3 cells assessed as cell growth inhibition measured for 72 hrs
Antiproliferative activity against human SK-OV-3 cells assessed as cell growth inhibition measured for 72 hrs
|
[PMID: 33038665] |
| SK-OV-3 | GI50 |
6.3 nM
Compound: Paclitaxel
|
Cytotoxicity against human SK-OV-3 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay
Cytotoxicity against human SK-OV-3 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay
|
[PMID: 33310545] |
| SK-OV-3 | IC50 |
3 nM
Compound: Paclitaxel
|
Antiproliferative activity against human SK-OV-3 cells assessed as decrease in cell growth measured after 48 hrs by SRB method
Antiproliferative activity against human SK-OV-3 cells assessed as decrease in cell growth measured after 48 hrs by SRB method
|
[PMID: 33310545] |
| SK-OV-3 | IC50 |
1200 nM
Compound: Paclitaxel
|
Cytotoxicity against human SK-OV-3 cells over expressing MDR1-6/6 assessed as reduction in cell viability by Sulforhodamine B assay
Cytotoxicity against human SK-OV-3 cells over expressing MDR1-6/6 assessed as reduction in cell viability by Sulforhodamine B assay
|
[PMID: 33647840] |
| SK-OV-3 | IC50 |
5 nM
Compound: Paclitaxel
|
Cytotoxicity against human SK-OV-3 cells assessed as reduction in cell viability by Sulforhodamine B assay
Cytotoxicity against human SK-OV-3 cells assessed as reduction in cell viability by Sulforhodamine B assay
|
[PMID: 33647840] |
| SK-OV-3 | IC50 |
34.5 nM
Compound: Paclitaxel
|
Antiproliferative activity against human SK-OV-3 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay
Antiproliferative activity against human SK-OV-3 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay
|
[PMID: 36621138] |
| SK-OV-3 | IC50 |
1200 nM
Compound: PTX
|
Antiproliferative activity against human SK-OV-3 cells overexpressing MDR-1-M6/6 assessed as inhibition of cell growth by SRB assay
Antiproliferative activity against human SK-OV-3 cells overexpressing MDR-1-M6/6 assessed as inhibition of cell growth by SRB assay
|
[PMID: 36889150] |
| SK-OV-3 | IC50 |
5 nM
Compound: PTX
|
Antiproliferative activity against wild type human SK-OV-3 cells assessed as inhibition of cell growth by SRB assay
Antiproliferative activity against wild type human SK-OV-3 cells assessed as inhibition of cell growth by SRB assay
|
[PMID: 36889150] |
| SK-OV-3 | IC50 |
1.19 nM
Compound: Paclitaxel
|
Antiproliferative activity against human SK-OV-3 cells incubated for 48 hrs by CCK8 assay
Antiproliferative activity against human SK-OV-3 cells incubated for 48 hrs by CCK8 assay
|
[PMID: 38972078] |
| SMMC-7721 | IC50 |
2.86 μM
Compound: paclitaxel
|
Cytotoxicity against human SMMC7721 cells
Cytotoxicity against human SMMC7721 cells
|
[PMID: 18701281] |
| SMMC-7721 | IC50 |
<0.008 μM
Compound: Paclitaxel
|
Cytotoxicity against human SMMC7721 cells after 48 hrs by MTT assay
Cytotoxicity against human SMMC7721 cells after 48 hrs by MTT assay
|
[PMID: 20521771] |
| SMMC-7721 | IC50 |
>50 μM
Compound: taxol
|
Cytotoxicity against human SMMC7721 after 48 hrs by SRB assay
Cytotoxicity against human SMMC7721 after 48 hrs by SRB assay
|
[PMID: 21044847] |
| SMMC-7721 | IC50 |
1.42 μM
Compound: Taxol
|
Cytotoxicity against human SMMC7721 cells after 24 hrs by MTT assay
Cytotoxicity against human SMMC7721 cells after 24 hrs by MTT assay
|
[PMID: 21115212] |
| SMMC-7721 | IC50 |
<0.008 μM
Compound: paclitaxel
|
Cytotoxicity against human SMMC7721 cells after 48 hrs by MTT method
Cytotoxicity against human SMMC7721 cells after 48 hrs by MTT method
|
[PMID: 21534539] |
| SMMC-7721 | IC50 |
0.88 μM
Compound: Taxol
|
Cytotoxicity against human SMMC7721 cells after 72 hrs by MTT assay
Cytotoxicity against human SMMC7721 cells after 72 hrs by MTT assay
|
[PMID: 22153338] |
| SMMC-7721 | IC50 |
0.15 μM
Compound: Paclitaxel
|
Cytotoxicity against human SMMC7721 cells assessed as reduction in cell viability after 72 hrs by MTT assay
Cytotoxicity against human SMMC7721 cells assessed as reduction in cell viability after 72 hrs by MTT assay
|
[PMID: 22871217] |
| SMMC-7721 | IC50 |
<0.008 μM
Compound: Paclitaxel
|
Cytotoxicity against human SMMC7721 cells assessed as inhibition of cell viability after 48 hrs by MTT assay
Cytotoxicity against human SMMC7721 cells assessed as inhibition of cell viability after 48 hrs by MTT assay
|
[PMID: 23327668] |
| SMMC-7721 | IC50 |
<0.008 μM
Compound: paclitaxel
|
Cytotoxicity against human SMMC7721 assessed as cell viability measured after 48 hrs by MTT assay
Cytotoxicity against human SMMC7721 assessed as cell viability measured after 48 hrs by MTT assay
|
[PMID: 23586920] |
| SMMC-7721 | IC50 |
<0.008 μM
Compound: paclitaxel
|
Cytotoxicity against human SMMC7721 cells after 48 hrs by MTT assay
Cytotoxicity against human SMMC7721 cells after 48 hrs by MTT assay
|
[PMID: 23819871] |
| SMMC-7721 | IC50 |
<0.008 μM
Compound: paclitaxel
|
Antimicrobial activity against human SMMC7721 cells after 48 hrs by MTT assay
Antimicrobial activity against human SMMC7721 cells after 48 hrs by MTT assay
|
[PMID: 23957453] |
| SMMC-7721 | IC50 |
<0.008 μM
Compound: paclitaxel
|
Cytotoxicity against human SMMC7721 cells after 48 hrs by MTS assay
Cytotoxicity against human SMMC7721 cells after 48 hrs by MTS assay
|
[PMID: 24219809] |
| SMMC-7721 | IC50 |
<0.008 μM
Compound: paclitaxel
|
Cytotoxicity against human SMMC7721 cells after 48 hrs by MTS assay
Cytotoxicity against human SMMC7721 cells after 48 hrs by MTS assay
|
[PMID: 24256484] |
| SMMC-7721 | IC50 |
<0.008 μM
Compound: Paclitaxel
|
Cytotoxicity against human SMMC7721 cells after 48 hrs by MTT assay
Cytotoxicity against human SMMC7721 cells after 48 hrs by MTT assay
|
[PMID: 24417634] |
| SMMC-7721 | IC50 |
<0.008 μM
Compound: paclitaxel
|
Cytotoxicity against human SMMC7721 cells assessed as growth inhibition after 48 hrs by MTS assay
Cytotoxicity against human SMMC7721 cells assessed as growth inhibition after 48 hrs by MTS assay
|
[PMID: 24697496] |
| SMMC-7721 | IC50 |
<0.008 μM
Compound: paclitaxel
|
Cytotoxicity against human SMMC7721 cells after 48 hrs by MTT assay
Cytotoxicity against human SMMC7721 cells after 48 hrs by MTT assay
|
[PMID: 25375202] |
| SMMC-7721 | IC50 |
0.12 μM
Compound: Taxol
|
Antiproliferative activity against human SMMC7721 cells after 72 hrs by MTT assay
Antiproliferative activity against human SMMC7721 cells after 72 hrs by MTT assay
|
[PMID: 25771484] |
| SMMC-7721 | IC50 |
<0.008 μM
Compound: paclitaxel
|
Cytotoxicity against human SMMC7721 cells incubated for 48 hrs by MTT assay
Cytotoxicity against human SMMC7721 cells incubated for 48 hrs by MTT assay
|
[PMID: 25798528] |
| SMMC-7721 | IC50 |
<0.008 μM
Compound: Taxol
|
Cytotoxicity against human SMMC7721 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Cytotoxicity against human SMMC7721 cells assessed as reduction in cell viability after 48 hrs by MTT assay
|
[PMID: 25871261] |
| SMMC-7721 | IC50 |
<0.008 μM
Compound: Taxol
|
Cytotoxicity against human SMMC7721 cells assessed as cell viability after 48 hrs by MTS assay
Cytotoxicity against human SMMC7721 cells assessed as cell viability after 48 hrs by MTS assay
|
[PMID: 26068802] |
| SMMC-7721 | IC50 |
<0.008 μM
Compound: Paclitaxel
|
Cytotoxicity against human SMMC7721 cells assessed as decrease in cell viability after 48 hrs by MTS assay
Cytotoxicity against human SMMC7721 cells assessed as decrease in cell viability after 48 hrs by MTS assay
|
[PMID: 27704807] |
| SMMC-7721 | IC50 |
<0.008 μM
Compound: Paclitaxel
|
Antiproliferative activity against human SMMC7721 cells after 48 hrs by MTS assay
Antiproliferative activity against human SMMC7721 cells after 48 hrs by MTS assay
|
[PMID: 28654256] |
| SMMC-7721 | IC50 |
<0.008 μM
Compound: Paclitaxel
|
Cytotoxicity against human SMMC7721 cells after 48 hrs by MTS assay
Cytotoxicity against human SMMC7721 cells after 48 hrs by MTS assay
|
[PMID: 29286250] |
| SMMC-7721 | IC50 |
<0.008 μM
Compound: Paclitaxel
|
Cytotoxicity against human SMMC7721 cells after 48 hrs by MTS assay
Cytotoxicity against human SMMC7721 cells after 48 hrs by MTS assay
|
[PMID: 29338226] |
| SMMC-7721 | IC50 |
<0.008 μM
Compound: Paclitaxel
|
Cytotoxicity against human SMMC7721 cells assessed as reduction in cell viability after 48 hrs by MTS assay
Cytotoxicity against human SMMC7721 cells assessed as reduction in cell viability after 48 hrs by MTS assay
|
[PMID: 29338260] |
| SMMC-7721 | IC50 |
<0.008 μM
Compound: Paclitaxel
|
Growth inhibition of human SMMC7721 cells after 48 hrs by MTS assay
Growth inhibition of human SMMC7721 cells after 48 hrs by MTS assay
|
[PMID: 29412669] |
| SMMC-7721 | IC50 |
<0.008 μM
Compound: Taxol
|
Cytotoxicity against human SMMC7721 cells assessed as decrease in cell viability after 4 days by MTT assay
Cytotoxicity against human SMMC7721 cells assessed as decrease in cell viability after 4 days by MTT assay
|
[PMID: 29884535] |
| SMMC-7721 | IC50 |
<0.008 μM
Compound: Paclitaxel
|
Antiproliferative activity against human SMMC7721 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay
Antiproliferative activity against human SMMC7721 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay
|
[PMID: 30822712] |
| SMMC-7721 | IC50 |
<0.008 μM
Compound: Paclitaxel
|
Cytotoxicity against human SMMC-7721 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Cytotoxicity against human SMMC-7721 cells assessed as reduction in cell viability after 48 hrs by MTT assay
|
[PMID: 32628478] |
| SMMC-7721 | IC50 |
0.143 μM
Compound: Taxol
|
Cytotoxicity against human SMMC-7721 cells assessed as inhibition of cell growth measured after 48 hrs by MTS assay
Cytotoxicity against human SMMC-7721 cells assessed as inhibition of cell growth measured after 48 hrs by MTS assay
|
[PMID: 34781083] |
| SMMC-7721 | IC50 |
0.07 μM
Compound: PTX
|
Cytotoxicity against human SMMC-7721 cells assessed as reduction in cell viability by MTT assay
Cytotoxicity against human SMMC-7721 cells assessed as reduction in cell viability by MTT assay
|
[PMID: 35213164] |
| SMMC-7721 | IC50 |
0.097 μM
Compound: Taxol
|
Antiproliferative activity against human SMMC-7721 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
Antiproliferative activity against human SMMC-7721 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
|
[PMID: 36274275] |
| SN12C | GI50 |
6.3 nM
Compound: Paclitaxel
|
Growth inhibition of human SN12C cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human SN12C cells incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 29655610] |
| SN12C | GI50 |
6.3 nM
Compound: Paclitaxel
|
Cytotoxicity against human SN12C cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay
Cytotoxicity against human SN12C cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay
|
[PMID: 33310545] |
| SNB-19 | GI50 |
0.04 μM
Compound: 1a, PXL, Taxol
|
Cytotoxicity against human SNB19 cells
Cytotoxicity against human SNB19 cells
|
[PMID: 23725535] |
| SNB-19 | GI50 |
10 nM
Compound: Paclitaxel
|
Growth inhibition of human SNB19 cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human SNB19 cells incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 29655610] |
| SNB-19 | GI50 |
10 nM
Compound: Paclitaxel
|
Cytotoxicity against human SNB-19 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay
Cytotoxicity against human SNB-19 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay
|
[PMID: 33310545] |
| SNB-75 | GI50 |
0.004 μM
Compound: paclitaxel
|
Cytotoxicity against human SNB75 cells
Cytotoxicity against human SNB75 cells
|
[PMID: 17696332] |
| SNB-75 | GI50 |
0.004 μM
Compound: Paclitaxel
|
Cytotoxicity against human SNB75 cells by sulforhodamine B assay
Cytotoxicity against human SNB75 cells by sulforhodamine B assay
|
[PMID: 21839640] |
| SNB-75 | GI50 |
7.9 nM
Compound: Paclitaxel
|
Growth inhibition of human SNB75 cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human SNB75 cells incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 29655610] |
| SNB-75 | GI50 |
7.9 nM
Compound: Paclitaxel
|
Cytotoxicity against human SNB-75 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay
Cytotoxicity against human SNB-75 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay
|
[PMID: 33310545] |
| SNB-75 | GI50 |
8.08 x 10-9 M
Compound: 5
|
Cytotoxicity against human SNB75 cells
Cytotoxicity against human SNB75 cells
|
[PMID: 7908950] |
| SNU-387 | IC50 |
0.27 μM
Compound: Paclitaxel
|
Cytotoxicity against human SNU387 cells after 48 hrs by MTT assay
Cytotoxicity against human SNU387 cells after 48 hrs by MTT assay
|
[PMID: 23701597] |
| SNU-398 | EC50 |
0.011 μM
Compound: taxol
|
Induction of apoptosis in human SNU398 cells assessed as caspase activation after 24 hrs by HTS assay
Induction of apoptosis in human SNU398 cells assessed as caspase activation after 24 hrs by HTS assay
|
[PMID: 18197614] |
| SNU-398 | GI50 |
0.01 μM
Compound: Taxol
|
Induction of apoptosis in human SNU398 cells assessed as caspase activation after 48 hrs
Induction of apoptosis in human SNU398 cells assessed as caspase activation after 48 hrs
|
[PMID: 19282188] |
| SNU-398 | EC50 |
0.009 μM
Compound: paclitaxel
|
Induction of apoptosis in human SNU398 cells measured after 48 hrs by cell and caspase based HTS assay
Induction of apoptosis in human SNU398 cells measured after 48 hrs by cell and caspase based HTS assay
|
[PMID: 19467598] |
| SNU-398 | GI50 |
0.061 μM
Compound: paclitaxel
|
Growth inhibition of human SNU398 cells after 48 hrs
Growth inhibition of human SNU398 cells after 48 hrs
|
[PMID: 19467598] |
| SNU-398 | EC50 |
0.009 μM
Compound: Paclitaxel
|
Induction of apoptosis in human SNU398 cells assessed as caspase activation after 48 hrs by HTS assay
Induction of apoptosis in human SNU398 cells assessed as caspase activation after 48 hrs by HTS assay
|
[PMID: 20034792] |
| SNU-398 | GI50 |
0.061 μM
Compound: Paclitaxel
|
Growth inhibition of human SNU398 cells after 48 hrs
Growth inhibition of human SNU398 cells after 48 hrs
|
[PMID: 20034792] |
| SNU-398 | IC50 |
0.6 nM
Compound: Taxol
|
Cytotoxicity against human SNU398 cells after 48 hrs by sulforhodamine B assay
Cytotoxicity against human SNU398 cells after 48 hrs by sulforhodamine B assay
|
[PMID: 30528697] |
| SR | GI50 |
6.3 nM
Compound: Paclitaxel
|
Growth inhibition of human SR cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human SR cells incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 29655610] |
| SR | GI50 |
6.3 nM
Compound: Paclitaxel
|
Cytotoxicity against human SR cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay
Cytotoxicity against human SR cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay
|
[PMID: 33310545] |
| SU-DHL-6 | GI50 |
7.9 nM
Compound: Paclitaxel
|
Growth inhibition of human SU-DHL6 cells incubated for 72 hrs by CellTiter-Glo assay
Growth inhibition of human SU-DHL6 cells incubated for 72 hrs by CellTiter-Glo assay
|
[PMID: 30878826] |
| SUP-B15 | IC50 |
8 nM
Compound: Taxol
|
Cytotoxicity against human SUP-B15 cells expressing BCR-ABL assessed as growth inhibition after 72 hrs by CCK-8 assay
Cytotoxicity against human SUP-B15 cells expressing BCR-ABL assessed as growth inhibition after 72 hrs by CCK-8 assay
|
[PMID: 23301703] |
| SW1573 | GI50 |
5 nM
Compound: Paclitaxel
|
Growth inhibition of human SW1573 cells
Growth inhibition of human SW1573 cells
|
[PMID: 21986585] |
| SW1573 | GI50 |
1.5 μM
Compound: PTX
|
Antiproliferative activity against human SW1573 cells incubated for 48 hrs in absence of P-gp and CYP3A4/5 inhibitor verapamil by SRB assay
Antiproliferative activity against human SW1573 cells incubated for 48 hrs in absence of P-gp and CYP3A4/5 inhibitor verapamil by SRB assay
|
[PMID: 31070367] |
| SW1573 | GI50 |
1.6 μM
Compound: PTX
|
Antiproliferative activity against human SW1573 cells incubated for 48 hrs in presence of P-gp and CYP3A4/5 inhibitor verapamil by SRB assay
Antiproliferative activity against human SW1573 cells incubated for 48 hrs in presence of P-gp and CYP3A4/5 inhibitor verapamil by SRB assay
|
[PMID: 31070367] |
| SW1573 | GI50 |
196 μM
Compound: PTX
|
Antiproliferative activity against human SW1573 cells over-expressing P-gp incubated for 48 hrs in absence of P-gp and CYP3A4/5 inhibitor verapamil by SRB assay
Antiproliferative activity against human SW1573 cells over-expressing P-gp incubated for 48 hrs in absence of P-gp and CYP3A4/5 inhibitor verapamil by SRB assay
|
[PMID: 31070367] |
| SW1573 | GI50 |
4.2 μM
Compound: PTX
|
Antiproliferative activity against human SW1573 cells over-expressing P-gp incubated for 48 hrs in presence of P-gp and CYP3A4/5 inhibitor verapamil by SRB assay
Antiproliferative activity against human SW1573 cells over-expressing P-gp incubated for 48 hrs in presence of P-gp and CYP3A4/5 inhibitor verapamil by SRB assay
|
[PMID: 31070367] |
| SW1573 | GI50 |
1.5 nM
Compound: PTX
|
Antiproliferative activity against human SW1573 cells incubated for 48 hrs in absence of P-gp and CYP3A4/5 inhibitor verapamil by sulforhodamine B assay
Antiproliferative activity against human SW1573 cells incubated for 48 hrs in absence of P-gp and CYP3A4/5 inhibitor verapamil by sulforhodamine B assay
|
[PMID: 31271961] |
| SW1573 | GI50 |
1.6 nM
Compound: PTX
|
Antiproliferative activity against human SW1573 cells incubated for 48 hrs in presence of P-gp and CYP3A4/5 inhibitor verapamil by sulforhodamine B assay
Antiproliferative activity against human SW1573 cells incubated for 48 hrs in presence of P-gp and CYP3A4/5 inhibitor verapamil by sulforhodamine B assay
|
[PMID: 31271961] |
| SW1573 | GI50 |
196 nM
Compound: PTX
|
Antiproliferative activity against human SW1573 cells over-expressing P-gp incubated for 48 hrs in absence of P-gp and CYP3A4/5 inhibitor verapamil by sulforhodamine B assay
Antiproliferative activity against human SW1573 cells over-expressing P-gp incubated for 48 hrs in absence of P-gp and CYP3A4/5 inhibitor verapamil by sulforhodamine B assay
|
[PMID: 31271961] |
| SW1573 | GI50 |
4.2 nM
Compound: PTX
|
Antiproliferative activity against human SW1573 cells over-expressing P-gp incubated for 48 hrs in presence of P-gp and CYP3A4/5 inhibitor verapamil by sulforhodamine B assay
Antiproliferative activity against human SW1573 cells over-expressing P-gp incubated for 48 hrs in presence of P-gp and CYP3A4/5 inhibitor verapamil by sulforhodamine B assay
|
[PMID: 31271961] |
| SW1573 | GI50 |
0.3 μM
Compound: PTX
|
Growth inhibition of human SW1573 cells overexpressing P-glycoprotein measured after 48 hrs in absence of verapamil by SRB colorimetric assay
Growth inhibition of human SW1573 cells overexpressing P-glycoprotein measured after 48 hrs in absence of verapamil by SRB colorimetric assay
|
[PMID: 37137247] |
| SW1573 | GI50 |
0.31 nM
Compound: PTX
|
Growth inhibition of human SW1573 cells overexpressing P-glycoprotein measured after 48 hrs in presence of verapamil by SRB colorimetric assay
Growth inhibition of human SW1573 cells overexpressing P-glycoprotein measured after 48 hrs in presence of verapamil by SRB colorimetric assay
|
[PMID: 37137247] |
| SW1573 | GI50 |
0.46 nM
Compound: PTX
|
Growth inhibition of human SW1573 cells measured after 48 hrs in presence of verapamil by SRB colorimetric assay
Growth inhibition of human SW1573 cells measured after 48 hrs in presence of verapamil by SRB colorimetric assay
|
[PMID: 37137247] |
| SW1573 | GI50 |
0.53 nM
Compound: PTX
|
Growth inhibition of human SW1573 cells measured after 48 hrs in absence of verapamil by SRB colorimetric assay
Growth inhibition of human SW1573 cells measured after 48 hrs in absence of verapamil by SRB colorimetric assay
|
[PMID: 37137247] |
| SW1990 | IC50 |
0.18 μM
Compound: Taxol
|
Anticancer activity against human SW1990 cells by MTT assay
Anticancer activity against human SW1990 cells by MTT assay
|
[PMID: 33316408] |
| SW1990 | IC50 |
0.01 μM
Compound: Paclitaxel
|
Antiproliferative activity against human SW1990 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
Antiproliferative activity against human SW1990 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
|
[PMID: 36511661] |
| SW48 | IC50 |
0.001 μM
Compound: paclitaxel
|
Antiproliferative activity against human SW48 cells after 72 hrs by MTT assay
Antiproliferative activity against human SW48 cells after 72 hrs by MTT assay
|
[PMID: 19743863] |
| SW480 | IC50 |
0.312 μM
Compound: Taxol
|
In vitro anti-cancer activity against the colon cancer cell line SW480 was determined
In vitro anti-cancer activity against the colon cancer cell line SW480 was determined
|
[PMID: 12873496] |
| SW480 | IC50 |
0.002 μM
Compound: paclitaxel
|
Antiproliferative activity against human SW480 cells after 72 hrs by MTT assay
Antiproliferative activity against human SW480 cells after 72 hrs by MTT assay
|
[PMID: 19743863] |
| SW480 | IC50 |
<0.008 μM
Compound: paclitaxel
|
Cytotoxicity against human SW480 cells after 48 hrs by MTT method
Cytotoxicity against human SW480 cells after 48 hrs by MTT method
|
[PMID: 21534539] |
| SW480 | IC50 |
0.011 μM
Compound: paclitaxel
|
Antiproliferative activity against human SW480 cells after 48 hrs by alamar blue assay
Antiproliferative activity against human SW480 cells after 48 hrs by alamar blue assay
|
[PMID: 21563750] |
| SW480 | IC50 |
0.15 μM
Compound: Paclitaxel
|
Cytotoxicity against human SW480 cells assessed as inhibition of cell viability after 48 hrs by MTT assay
Cytotoxicity against human SW480 cells assessed as inhibition of cell viability after 48 hrs by MTT assay
|
[PMID: 23327668] |
| SW480 | IC50 |
12.1 nM
Compound: paclitaxel
|
Cytotoxicity against human SW480 cells after 48 hrs by MTT assay
Cytotoxicity against human SW480 cells after 48 hrs by MTT assay
|
[PMID: 23356786] |
| SW480 | IC50 |
<0.008 μM
Compound: paclitaxel
|
Cytotoxicity against human SW480 assessed as cell viability measured after 48 hrs by MTT assay
Cytotoxicity against human SW480 assessed as cell viability measured after 48 hrs by MTT assay
|
[PMID: 23586920] |
| SW480 | IC50 |
0.04 μM
Compound: paclitaxel
|
Cytotoxicity against human SW480 cells after 48 hrs by MTT assay
Cytotoxicity against human SW480 cells after 48 hrs by MTT assay
|
[PMID: 23819871] |
| SW480 | IC50 |
0.04 μM
Compound: paclitaxel
|
Antimicrobial activity against human SW480 cells after 48 hrs by MTT assay
Antimicrobial activity against human SW480 cells after 48 hrs by MTT assay
|
[PMID: 23957453] |
| SW480 | IC50 |
<0.008 μM
Compound: paclitaxel
|
Cytotoxicity against human SW480 cells after 48 hrs by MTS assay
Cytotoxicity against human SW480 cells after 48 hrs by MTS assay
|
[PMID: 24219809] |
| SW480 | IC50 |
<0.008 μM
Compound: paclitaxel
|
Cytotoxicity against human SW480 cells after 48 hrs by MTS assay
Cytotoxicity against human SW480 cells after 48 hrs by MTS assay
|
[PMID: 24256484] |
| SW480 | IC50 |
<0.008 μM
Compound: Paclitaxel
|
Cytotoxicity against human SW480 cells after 48 hrs by MTT assay
Cytotoxicity against human SW480 cells after 48 hrs by MTT assay
|
[PMID: 24417634] |
| SW480 | IC50 |
<0.008 μM
Compound: paclitaxel
|
Cytotoxicity against human SW480 cells assessed as growth inhibition after 48 hrs by MTS assay
Cytotoxicity against human SW480 cells assessed as growth inhibition after 48 hrs by MTS assay
|
[PMID: 24697496] |
| SW480 | IC50 |
0.007 μM
Compound: TAX, Taxol
|
Antiproliferative activity against human SW480 cells after 48 hrs by SRB method
Antiproliferative activity against human SW480 cells after 48 hrs by SRB method
|
[PMID: 25061803] |
| SW480 | IC50 |
0.15 μM
Compound: paclitaxel
|
Cytotoxicity against human SW480 cells after 48 hrs by MTT assay
Cytotoxicity against human SW480 cells after 48 hrs by MTT assay
|
[PMID: 25375202] |
| SW480 | IC50 |
0.021 μM
Compound: 6
|
Antiproliferative activity against human SW480 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
Antiproliferative activity against human SW480 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay
|
[PMID: 25682561] |
| SW480 | IC50 |
<0.008 μM
Compound: paclitaxel
|
Cytotoxicity against human SW480 cells incubated for 48 hrs by MTT assay
Cytotoxicity against human SW480 cells incubated for 48 hrs by MTT assay
|
[PMID: 25798528] |
| SW480 | IC50 |
<0.008 μM
Compound: Taxol
|
Cytotoxicity against human SW480 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Cytotoxicity against human SW480 cells assessed as reduction in cell viability after 48 hrs by MTT assay
|
[PMID: 25871261] |
| SW480 | IC50 |
<0.008 μM
Compound: Taxol
|
Cytotoxicity against human SW480 cells assessed as cell viability after 48 hrs by MTS assay
Cytotoxicity against human SW480 cells assessed as cell viability after 48 hrs by MTS assay
|
[PMID: 26068802] |
| SW480 | IC50 |
<0.008 μM
Compound: Paclitaxel
|
Cytotoxicity against human SW480 cells assessed as decrease in cell viability after 48 hrs by MTS assay
Cytotoxicity against human SW480 cells assessed as decrease in cell viability after 48 hrs by MTS assay
|
[PMID: 27704807] |
| SW480 | IC50 |
<0.008 μM
Compound: Paclitaxel
|
Antiproliferative activity against human SW480 cells after 48 hrs by MTS assay
Antiproliferative activity against human SW480 cells after 48 hrs by MTS assay
|
[PMID: 28654256] |
| SW480 | IC50 |
<0.008 μM
Compound: Paclitaxel
|
Cytotoxicity against human SW480 cells after 48 hrs by MTS assay
Cytotoxicity against human SW480 cells after 48 hrs by MTS assay
|
[PMID: 29286250] |
| SW480 | IC50 |
<0.008 μM
Compound: Paclitaxel
|
Cytotoxicity against human SW480 cells after 48 hrs by MTS assay
Cytotoxicity against human SW480 cells after 48 hrs by MTS assay
|
[PMID: 29338226] |
| SW480 | IC50 |
<0.008 μM
Compound: Paclitaxel
|
Cytotoxicity against human SW480 cells assessed as reduction in cell viability after 48 hrs by MTS assay
Cytotoxicity against human SW480 cells assessed as reduction in cell viability after 48 hrs by MTS assay
|
[PMID: 29338260] |
| SW480 | IC50 |
0.19 μM
Compound: Taxol
|
Cytotoxicity against human SW480 cells assessed as reduction in cell viability incubated for 24 hrs by CCK8 assay
Cytotoxicity against human SW480 cells assessed as reduction in cell viability incubated for 24 hrs by CCK8 assay
|
[PMID: 29395979] |
| SW480 | IC50 |
<0.008 μM
Compound: Paclitaxel
|
Growth inhibition of human SW480 cells after 48 hrs by MTS assay
Growth inhibition of human SW480 cells after 48 hrs by MTS assay
|
[PMID: 29412669] |
| SW480 | IC50 |
<0.008 μM
Compound: Taxol
|
Cytotoxicity against human SW480 cells assessed as decrease in cell viability after 4 days by MTT assay
Cytotoxicity against human SW480 cells assessed as decrease in cell viability after 4 days by MTT assay
|
[PMID: 29884535] |
| SW480 | IC50 |
<0.008 μM
Compound: Paclitaxel
|
Antiproliferative activity against human SW480 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay
Antiproliferative activity against human SW480 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay
|
[PMID: 30822712] |
| SW480 | IC50 |
<0.008 μM
Compound: Paclitaxel
|
Cytotoxicity against human SW480 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Cytotoxicity against human SW480 cells assessed as reduction in cell viability after 48 hrs by MTT assay
|
[PMID: 32628478] |
| SW480 | IC50 |
<0.008 μM
Compound: Paclitaxel
|
Cytotoxicity against human SW480 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay
Cytotoxicity against human SW480 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay
|
[PMID: 34355562] |
| SW480 | IC50 |
<0.008 μM
Compound: Taxol
|
Antiproliferative activity against human SW480 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
Antiproliferative activity against human SW480 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
|
[PMID: 36274275] |
| SW-620 | IC50 |
0.03 μM
Compound: Paclitaxel
|
Cytotoxicity against human SW620 cells after 48 to 72 hrs by WAT-1 assay
Cytotoxicity against human SW620 cells after 48 to 72 hrs by WAT-1 assay
|
[PMID: 21126027] |
| SW-620 | IC50 |
0.03 μM
Compound: Paclitaxel
|
Cytotoxicity against human SW620 cells assessed as reduction in cell viability after 72 hrs by MTT assay
Cytotoxicity against human SW620 cells assessed as reduction in cell viability after 72 hrs by MTT assay
|
[PMID: 29501942] |
| SW-620 | GI50 |
4 nM
Compound: Paclitaxel
|
Growth inhibition of human SW620 cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human SW620 cells incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 29655610] |
| SW-620 | GI50 |
4 nM
Compound: Paclitaxel
|
Cytotoxicity against human SW-620 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay
Cytotoxicity against human SW-620 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay
|
[PMID: 33310545] |
| SW620/AD300 | IC50 |
1.97 μM
Compound: Paclitaxel
|
Cytotoxicity against human SW620/AD300 cells assessed as reduction in cell viability after 72 hrs by MTT assay
Cytotoxicity against human SW620/AD300 cells assessed as reduction in cell viability after 72 hrs by MTT assay
|
[PMID: 29501942] |
| SW626 | ED50 |
12 pM
Compound: 1
|
Growth inhibition of human SW626 cells xenografted in ip dosed NCr nu/nu mouse administered once daily from day 3 to 6 after implantation measured on day 7 by MTT-based hollow-fiber test
Growth inhibition of human SW626 cells xenografted in ip dosed NCr nu/nu mouse administered once daily from day 3 to 6 after implantation measured on day 7 by MTT-based hollow-fiber test
|
[PMID: 19161316] |
| SW780 | IC50 |
1.1 nM
Compound: paclitaxel
|
Cytotoxicity against human SW780 cells after 96 hrs by MTT assay
Cytotoxicity against human SW780 cells after 96 hrs by MTT assay
|
[PMID: 23176628] |
| T47D | EC50 |
0.03 μM
Compound: paclitaxel
|
Induction of apoptosis in human T47D cells assessed as caspase activation after 24 hrs
Induction of apoptosis in human T47D cells assessed as caspase activation after 24 hrs
|
[PMID: 15566300] |
| T47D | EC50 |
0.036 μM
Compound: taxol
|
Induction of apoptosis in human T47D cells assessed as caspase activation after 24 hrs by HTS assay
Induction of apoptosis in human T47D cells assessed as caspase activation after 24 hrs by HTS assay
|
[PMID: 18197614] |
| T47D | EC50 |
0.035 μM
Compound: Taxol
|
Induction of apoptosis in human T47D cells assessed as caspase activation after 48 hrs
Induction of apoptosis in human T47D cells assessed as caspase activation after 48 hrs
|
[PMID: 19282188] |
| T47D | EC50 |
0.037 μM
Compound: paclitaxel
|
Induction of apoptosis in human T47D cells measured after 48 hrs by cell and caspase based HTS assay
Induction of apoptosis in human T47D cells measured after 48 hrs by cell and caspase based HTS assay
|
[PMID: 19467598] |
| T47D | GI50 |
0.026 μM
Compound: paclitaxel
|
Growth inhibition of human T47D cells after 48 hrs
Growth inhibition of human T47D cells after 48 hrs
|
[PMID: 19467598] |
| T47D | EC50 |
0.037 μM
Compound: Taxol
|
Induction of apoptosis in human T47D cells assessed as caspase activation after 48 hrs
Induction of apoptosis in human T47D cells assessed as caspase activation after 48 hrs
|
[PMID: 19500976] |
| T47D | GI50 |
0.026 μM
Compound: Taxol
|
Growth inhibition of human T47D cells after 48 hrs
Growth inhibition of human T47D cells after 48 hrs
|
[PMID: 19500976] |
| T47D | IC50 |
0.004 μM
Compound: paclitaxel
|
Antiproliferative activity against human T47D cells after 72 hrs by MTT assay
Antiproliferative activity against human T47D cells after 72 hrs by MTT assay
|
[PMID: 19743863] |
| T47D | EC50 |
0.037 μM
Compound: Paclitaxel
|
Induction of apoptosis in human T47D cells assessed as caspase activation after 48 hrs by HTS assay
Induction of apoptosis in human T47D cells assessed as caspase activation after 48 hrs by HTS assay
|
[PMID: 20034792] |
| T47D | GI50 |
0.026 μM
Compound: Paclitaxel
|
Growth inhibition of human T47D cells after 48 hrs
Growth inhibition of human T47D cells after 48 hrs
|
[PMID: 20034792] |
| T47D | GI50 |
0.15 nM
Compound: Paclitaxel
|
Growth inhibition of human T47D cells
Growth inhibition of human T47D cells
|
[PMID: 21986585] |
| T47D | IC50 |
4 nM
Compound: Paclitaxel
|
Cytotoxicity against human T47D cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay
Cytotoxicity against human T47D cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay
|
[PMID: 23468529] |
| T47D | GI50 |
0.01 μM
Compound: 1a, PXL, Taxol
|
Cytotoxicity against human T47D cells
Cytotoxicity against human T47D cells
|
[PMID: 23725535] |
| T47D | IC50 |
0.2 μM
Compound: Paclitaxel
|
Antiproliferative activity against human T47D cells assessed as reduction in cell viability measured after 72 hrs by MTS assay
Antiproliferative activity against human T47D cells assessed as reduction in cell viability measured after 72 hrs by MTS assay
|
[PMID: 27449957] |
| T47D | GI50 |
12.5 nM
Compound: Paclitaxel
|
Cytotoxicity against human T47D cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay
Cytotoxicity against human T47D cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay
|
[PMID: 33310545] |
| T98G | IC50 |
0.74 μM
Compound: Taxol
|
Cytotoxicity against human T98G cells assessed as reduction in cell viability incubated for 24 hrs by CCK8 assay
Cytotoxicity against human T98G cells assessed as reduction in cell viability incubated for 24 hrs by CCK8 assay
|
[PMID: 29395979] |
| T98G | IC50 |
0.012 μM
Compound: Taxol
|
Cytotoxicity against human T98G assessed as reduction in cell viability after 72 hrs by MTS assay
Cytotoxicity against human T98G assessed as reduction in cell viability after 72 hrs by MTS assay
|
[PMID: 33310292] |
| T98G | IC50 |
8.7 μM
Compound: Paclitaxel
|
Cytotoxicity against human T98G cells assessed as growth inhibition
Cytotoxicity against human T98G cells assessed as growth inhibition
|
[PMID: 34949088] |
| TERT-RPE1 | ED50 |
23 nM
Compound: paclitaxel
|
Cytotoxicity against human telomerase reverse transcriptase expressing human RPE1 cells
Cytotoxicity against human telomerase reverse transcriptase expressing human RPE1 cells
|
[PMID: 15043407] |
| TERT-RPE1 | IC50 |
5.1 nM
Compound: PT
|
Antiproliferative activity against human RPE-1 cells assessed as reduction in cell viability incubated for 72 hrs by CelltiterGlo luminescent assay
Antiproliferative activity against human RPE-1 cells assessed as reduction in cell viability incubated for 72 hrs by CelltiterGlo luminescent assay
|
[PMID: 38959729] |
| THP-1 | GI50 |
0.1374 μg/mL
Compound: Paclitaxel
|
Cytotoxicity against human THP1 cells after 48 hrs by MTT assay
Cytotoxicity against human THP1 cells after 48 hrs by MTT assay
|
[PMID: 26299346] |
| THP-1 | GI50 |
0.1374 μg/mL
Compound: Paclitaxel
|
Cytotoxicity against human THP1 cells after 48 hrs by MTT assay
Cytotoxicity against human THP1 cells after 48 hrs by MTT assay
|
[PMID: 27013391] |
| THP-1 | CC50 |
0.1374 μg/mL
Compound: Paclitaxel
|
Cytotoxicity against human THP1 cells by MTT assay
Cytotoxicity against human THP1 cells by MTT assay
|
[PMID: 27301367] |
| THP-1 | GI50 |
0.133 μg/mL
Compound: Paclitaxel
|
Cytotoxicity against human THP1 cells assessed as growth inhibition after 72 hrs by MTT assay
Cytotoxicity against human THP1 cells assessed as growth inhibition after 72 hrs by MTT assay
|
[PMID: 27563398] |
| THP-1 | GI50 |
>100 μg/mL
Compound: Paclitaxel
|
Cytotoxicity against PMP-differentiated human THP1 cells measured after 48 hrs by MTT assay
Cytotoxicity against PMP-differentiated human THP1 cells measured after 48 hrs by MTT assay
|
[PMID: 27688192] |
| THP-1 | GI50 |
5.7 μg/mL
Compound: Paclitaxel
|
Cytotoxicity against human THP1 cells measured after 48 hrs by MTT assay
Cytotoxicity against human THP1 cells measured after 48 hrs by MTT assay
|
[PMID: 27688192] |
| THP-1 | GI50 |
0.1374 μg/mL
Compound: Paclitaxel
|
Cytotoxicity against human THP1 cells by MTT assay
Cytotoxicity against human THP1 cells by MTT assay
|
[PMID: 27914801] |
| THP-1 | IC50 |
3.01 nM
Compound: PTX
|
Antiproliferative activity against human THP-1 cells incubated for 72 hrs by MTT assay
Antiproliferative activity against human THP-1 cells incubated for 72 hrs by MTT assay
|
[PMID: 34648295] |
| THP-1 | IC50 |
<1.5 nM
Compound: 1
|
Antiproliferative activity against human THP-1 cells transfected with wild type FLT3 assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay
Antiproliferative activity against human THP-1 cells transfected with wild type FLT3 assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay
|
[PMID: 37544183] |
| THP-1 | GI50 |
0.14 μg/mL
Compound: Paclitaxel
|
Cytotoxicity against human THP1 cells assessed as growth inhibition after 48 hrs by MTT assay
Cytotoxicity against human THP1 cells assessed as growth inhibition after 48 hrs by MTT assay
|
10.1039/C5MD00057B |
| THP-1 | GI50 |
0.1374 μg/mL
Compound: Paclitaxel
|
Cytotoxicity against human THP1 cells incubated for 1 to 11 days by MTT assay
Cytotoxicity against human THP1 cells incubated for 1 to 11 days by MTT assay
|
10.1039/C5MD00404G |
| TK-10 | GI50 |
19.9 nM
Compound: Paclitaxel
|
Growth inhibition of human TK10 cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human TK10 cells incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 29655610] |
| TK-10 | GI50 |
19.9 nM
Compound: Paclitaxel
|
Cytotoxicity against human TK-10 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay
Cytotoxicity against human TK-10 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay
|
[PMID: 33310545] |
| TOV21G | IC50 |
0.264 μM
Compound: Paclitaxel
|
Anticancer activity against human TOV-21G-RT cells assessed as inhibition of cell growth
Anticancer activity against human TOV-21G-RT cells assessed as inhibition of cell growth
|
[PMID: 33328099] |
| U-251 | IC50 |
0.03 μM
Compound: taxol
|
Cytotoxicity against human U251 after 48 hrs by SRB assay
Cytotoxicity against human U251 after 48 hrs by SRB assay
|
[PMID: 21044847] |
| U-251 | GI50 |
0.003 μM
Compound: PCT
|
Growth inhibition of human U251 cells after 48 hrs by sulforhodamine B assay
Growth inhibition of human U251 cells after 48 hrs by sulforhodamine B assay
|
[PMID: 24727464] |
| U-251 | IC50 |
128 nM
Compound: Paclitaxel
|
Cytotoxicity against human U251 cells assessed as growth inhibition after 72 hrs by MTT assay
Cytotoxicity against human U251 cells assessed as growth inhibition after 72 hrs by MTT assay
|
[PMID: 24929344] |
| U-251 | IC50 |
23 nM
Compound: taxol
|
Antiproliferative activity against human U251 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay
Antiproliferative activity against human U251 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay
|
[PMID: 25208345] |
| U-251 | GI50 |
6.3 nM
Compound: Paclitaxel
|
Growth inhibition of human U251 cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human U251 cells incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 29655610] |
| U-251 | GI50 |
6.3 nM
Compound: Paclitaxel
|
Cytotoxicity against human U-251 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay
Cytotoxicity against human U-251 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay
|
[PMID: 33310545] |
| U-251 | IC50 |
0.323 μM
Compound: Paclitaxel
|
Antiproliferative activity against human U-251 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
Antiproliferative activity against human U-251 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
|
[PMID: 39163776] |
| U2OS | IC50 |
24 nM
Compound: paclitaxel
|
Antiproliferative activity against human U2OS cells after 48 hrs by MTT assay
Antiproliferative activity against human U2OS cells after 48 hrs by MTT assay
|
[PMID: 18461997] |
| U2OS | IC50 |
3.4 nM
Compound: PTX
|
Cytotoxicity against human U2OS cells after 72 hrs by coulter counter analysis
Cytotoxicity against human U2OS cells after 72 hrs by coulter counter analysis
|
[PMID: 23140358] |
| U2OS | IC50 |
0.03 μM
Compound: Taxol
|
Anticancer activity against human U2OS cells assessed as inhibition of cell proliferation measured after 72 hrs by CCK8 reagent assay
Anticancer activity against human U2OS cells assessed as inhibition of cell proliferation measured after 72 hrs by CCK8 reagent assay
|
[PMID: 34399390] |
| U-87MG ATCC | IC50 |
3.2 μg/mL
Compound: paclitaxel
|
Cytotoxicity against U87 cancer cell line
Cytotoxicity against U87 cancer cell line
|
[PMID: 16384699] |
| U-87MG ATCC | IC50 |
0.08 μM
Compound: Paclitaxel
|
Antiproliferative activity against human U87 MG cell line
Antiproliferative activity against human U87 MG cell line
|
[PMID: 16793260] |
| U-87MG ATCC | GI50 |
0.02 μM
Compound: taxol
|
Cytotoxicity against human U87 cells after 72 hrs by MTT colorimetric assay
Cytotoxicity against human U87 cells after 72 hrs by MTT colorimetric assay
|
[PMID: 19081249] |
| U-87MG ATCC | GI50 |
0.02 μM
Compound: Taxol
|
Cytotoxicity against human U87 cells after 72 hrs by MTT assay
Cytotoxicity against human U87 cells after 72 hrs by MTT assay
|
[PMID: 20538462] |
| U-87MG ATCC | IC50 |
90 μM
Compound: Paclitaxel
|
Anticancer activity against human U87MG cells after 72 hrs by SRB assay
Anticancer activity against human U87MG cells after 72 hrs by SRB assay
|
[PMID: 21707046] |
| U-87MG ATCC | IC50 |
8.1 μM
Compound: Paclitaxel
|
Cytotoxicity against human U87 cells assessed as reduction in cell viability after 72 hrs by MTT assay
Cytotoxicity against human U87 cells assessed as reduction in cell viability after 72 hrs by MTT assay
|
[PMID: 22871217] |
| U-87MG ATCC | IC50 |
4.67 μM
Compound: Taxol
|
Cytotoxicity against human U87 cells assessed as reduction in cell viability incubated for 24 hrs by CCK8 assay
Cytotoxicity against human U87 cells assessed as reduction in cell viability incubated for 24 hrs by CCK8 assay
|
[PMID: 29395979] |
| U-87MG ATCC | GI50 |
0.01 μM
Compound: Paclitaxel
|
Cytotoxicity against human U87 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
Cytotoxicity against human U87 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
|
[PMID: 31945642] |
| U-87MG ATCC | IC50 |
0.00038 μM
Compound: Taxol
|
Antiproliferation activity against human U87MG cells assessed as reduction in cell viability incubated for 96 hrs by MTT assay
Antiproliferation activity against human U87MG cells assessed as reduction in cell viability incubated for 96 hrs by MTT assay
|
[PMID: 32546298] |
| U-87MG ATCC | IC50 |
0.008 μM
Compound: Taxol
|
Cytotoxicity against human U-87 MG cells assessed as reduction in cell viability after 72 hrs by MTS assay
Cytotoxicity against human U-87 MG cells assessed as reduction in cell viability after 72 hrs by MTS assay
|
[PMID: 33310292] |
| U-87MG ATCC | IC50 |
0.01 μM
Compound: Taxol
|
Anticancer activity against human U-87 MG cells assessed as inhibition of cell proliferation measured after 72 hrs by CCK8 reagent assay
Anticancer activity against human U-87 MG cells assessed as inhibition of cell proliferation measured after 72 hrs by CCK8 reagent assay
|
[PMID: 34399390] |
| U-937 | IC50 |
3.37 nM
Compound: Paclitaxel
|
Cytotoxicity against human U937 cells after 72 hrs by MTT assay
Cytotoxicity against human U937 cells after 72 hrs by MTT assay
|
[PMID: 22959518] |
| U-937 | IC50 |
2.3 nM
Compound: Taxol
|
Cytotoxicity against human U937 cells expressing BCR-ABL assessed as growth inhibition after 72 hrs by CCK-8 assay
Cytotoxicity against human U937 cells expressing BCR-ABL assessed as growth inhibition after 72 hrs by CCK-8 assay
|
[PMID: 23301703] |
| U-937 | IC50 |
1.9 nM
Compound: Taxol
|
Cytotoxicity against human U937 cells by MTT assay
Cytotoxicity against human U937 cells by MTT assay
|
[PMID: 23806112] |
| U-937 | GI50 |
2.392 nM
Compound: 1, Taxol
|
Growth inhibition of human U937 cells by MTT assay
Growth inhibition of human U937 cells by MTT assay
|
[PMID: 24405702] |
| U-937 | IC50 |
2.5 nM
Compound: Taxol
|
Cytotoxicity against human U937 cells assessed as cell viability after 72 hrs by CCK8 assay
Cytotoxicity against human U937 cells assessed as cell viability after 72 hrs by CCK8 assay
|
[PMID: 25819096] |
| U-937 | IC50 |
2.1 μM
Compound: taxol
|
Cytotoxicity against human U937 cells after 72 hrs by CCK8 assay
Cytotoxicity against human U937 cells after 72 hrs by CCK8 assay
|
[PMID: 26316467] |
| U-937 | IC50 |
0.006 μM
Compound: PXT
|
Cytotoxicity against human U937 cells assessed as cell growth inhibition after 48 hrs by MTT assay
Cytotoxicity against human U937 cells assessed as cell growth inhibition after 48 hrs by MTT assay
|
[PMID: 26638041] |
| U-937 | IC50 |
1.66 nM
Compound: Taxol
|
Cytotoxicity against human U937 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay
Cytotoxicity against human U937 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay
|
[PMID: 26697718] |
| U-937 | GI50 |
2.12 nM
Compound: Taxol
|
Cytotoxicity against human U937 cells assessed as cell growth inhibition after 72 hrs by CCK-8 assay
Cytotoxicity against human U937 cells assessed as cell growth inhibition after 72 hrs by CCK-8 assay
|
[PMID: 27224875] |
| U-937 | IC50 |
1.7 nM
Compound: Paclitaxel
|
Cytotoxicity against human U937 cells assessed as reduction in cell viability after 72 hrs by CCK-8 assay
Cytotoxicity against human U937 cells assessed as reduction in cell viability after 72 hrs by CCK-8 assay
|
[PMID: 28598633] |
| U-937 | IC50 |
1 nM
Compound: taxol
|
The compound was tested for inhibition concentration against U-937 cell line
The compound was tested for inhibition concentration against U-937 cell line
|
[PMID: 7907372] |
| U-937/GTB | IC50 |
0.0059 μM
Compound: Paclitaxel
|
Cytotoxicity against human U937 GTB cells after 72 hrs by fluorometric microculture cytotoxicity assay
Cytotoxicity against human U937 GTB cells after 72 hrs by fluorometric microculture cytotoxicity assay
|
[PMID: 16562840] |
| U-937/GTB | IC50 |
0.0059 μM
Compound: paclitaxel
|
Cytotoxicity against U937 GTB cells
Cytotoxicity against U937 GTB cells
|
[PMID: 17442577] |
| UACC-257 | GI50 |
0.04 μM
Compound: paclitaxel
|
Cytotoxicity against human UACC257 cells
Cytotoxicity against human UACC257 cells
|
[PMID: 17696332] |
| UACC-257 | GI50 |
0.04 μM
Compound: Paclitaxel
|
Cytotoxicity against human UACC257 cells by sulforhodamine B assay
Cytotoxicity against human UACC257 cells by sulforhodamine B assay
|
[PMID: 21839640] |
| UACC-62 | GI50 |
0.01 μM
Compound: PCT
|
Growth inhibition of human UACC62 cells after 48 hrs by sulforhodamine B assay
Growth inhibition of human UACC62 cells after 48 hrs by sulforhodamine B assay
|
[PMID: 24727464] |
| UACC-62 | IC50 |
0.006 μM
Compound: Paclitaxel
|
Antiproliferative activity against human UACC62 cells after 72 hrs by CellTiter96 AQueous nonradioactive cell proliferation assay
Antiproliferative activity against human UACC62 cells after 72 hrs by CellTiter96 AQueous nonradioactive cell proliferation assay
|
[PMID: 28335606] |
| UACC-62 | GI50 |
5 nM
Compound: Paclitaxel
|
Growth inhibition of human UACC62 cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human UACC62 cells incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 29655610] |
| UACC-62 | GI50 |
5 nM
Compound: Paclitaxel
|
Cytotoxicity against human UACC-62 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay
Cytotoxicity against human UACC-62 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay
|
[PMID: 33310545] |
| UACC-812 | IC50 |
0.7 μM
Compound: paclitaxel
|
Antiproliferative activity against human UACC-812 cells after 72 hrs by MTT assay
Antiproliferative activity against human UACC-812 cells after 72 hrs by MTT assay
|
[PMID: 19743863] |
| UO-31 | GI50 |
125 nM
Compound: Paclitaxel
|
Growth inhibition of human UO31 cells incubated for 48 hrs by sulforhodamine B assay
Growth inhibition of human UO31 cells incubated for 48 hrs by sulforhodamine B assay
|
[PMID: 29655610] |
| UO-31 | IC50 |
240 μM
Compound: Paclitaxel
|
Antiproliferative activity against taxane-resistant human UO31 cells after 72 hrs by CellTiter 96 aqueous nonradioactive cell proliferation assay
Antiproliferative activity against taxane-resistant human UO31 cells after 72 hrs by CellTiter 96 aqueous nonradioactive cell proliferation assay
|
[PMID: 29995409] |
| UO-31 | GI50 |
125 nM
Compound: Paclitaxel
|
Cytotoxicity against human UO-31 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay
Cytotoxicity against human UO-31 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay
|
[PMID: 33310545] |
| Vero | GI50 |
0.03 μM
Compound: PCT
|
Growth inhibition of African green monkey Vero cells after 48 hrs by sulforhodamine B assay
Growth inhibition of African green monkey Vero cells after 48 hrs by sulforhodamine B assay
|
[PMID: 24727464] |
| Vero | IC50 |
0.65 μM
Compound: PXT
|
Cytotoxicity against African green monkey Vero cells assessed as cell growth inhibition after 48 hrs by MTT assay
Cytotoxicity against African green monkey Vero cells assessed as cell growth inhibition after 48 hrs by MTT assay
|
[PMID: 26638041] |
| Vero | IC50 |
>100 μg/mL
Compound: Paclitaxel
|
Cytotoxicity against African green monkey Vero cells assessed as cell growth inhibition after 24 hrs by MTT assay
Cytotoxicity against African green monkey Vero cells assessed as cell growth inhibition after 24 hrs by MTT assay
|
[PMID: 27105027] |
| Vero | ED50 |
>0.3 μg/mL
Compound: paclitaxel
|
Cytotoxicity against african green monkey Vero cells
Cytotoxicity against african green monkey Vero cells
|
[PMID: 8778244] |
| WALKER | IC50 |
150 nM
Compound: Paclitaxel
|
In vitro antiproliferative activity against Walker cell line
In vitro antiproliferative activity against Walker cell line
|
10.1016/S0960-894X(97)10152-4 |
| WI-38 | IC50 |
0.04 μM
Compound: taxol
|
Cytotoxicity against human WI 38 cells after 48 hrs by WST-8 assay
Cytotoxicity against human WI 38 cells after 48 hrs by WST-8 assay
|
[PMID: 15730243] |
| WI-38 | IC50 |
0.034 μM
Compound: Taxol
|
Growth inhibition of human WI38 cells after 48 hrs by WST8 assay
Growth inhibition of human WI38 cells after 48 hrs by WST8 assay
|
[PMID: 16499322] |
| WI-38 | IC50 |
0.0468 μM
Compound: Taxol
|
Cytotoxicity against human WI38 cells
Cytotoxicity against human WI38 cells
|
[PMID: 16724842] |
| WI-38 | IC50 |
0.04 μM
Compound: taxol
|
Cytotoxicity against human WI38 cells by WST-8 assay
Cytotoxicity against human WI38 cells by WST-8 assay
|
[PMID: 16933868] |
| WI-38 | IC50 |
0.04 μM
Compound: Taxol
|
Cytotoxicity against human WI38 cells
Cytotoxicity against human WI38 cells
|
[PMID: 17067155] |
| WI-38 | IC50 |
0.034 μg/mL
Compound: 2
|
Cytotoxicity againt human WI38 cells
Cytotoxicity againt human WI38 cells
|
[PMID: 17239597] |
| WI-38 | IC50 |
0.02 μg/mL
Compound: taxol
|
Growth inhibition of human WI38 cells
Growth inhibition of human WI38 cells
|
[PMID: 17358082] |
| WI-38 | IC50 |
0.04 μM
Compound: Paclitaxel
|
Growth inhibition of human WI38 cells
Growth inhibition of human WI38 cells
|
[PMID: 17490878] |
| WI-38 | IC50 |
0.05 μg/mL
Compound: paclitaxel
|
Growth inhibition of WI38 cells
Growth inhibition of WI38 cells
|
[PMID: 17547458] |
| WI-38 | IC50 |
0.04 mM
Compound: taxol
|
Growth inhibition of human WI38 cells
Growth inhibition of human WI38 cells
|
[PMID: 17595134] |
| WI-38 | GI50 |
13.7 nM
Compound: paclitaxel
|
Cytotoxicity against human WI38 cells
Cytotoxicity against human WI38 cells
|
[PMID: 19195901] |
| WI-38 | IC50 |
0.05 μM
Compound: paclitaxel
|
Cytotoxicity against human WI38 cells after 72 hrs by MTT assay
Cytotoxicity against human WI38 cells after 72 hrs by MTT assay
|
[PMID: 24033131] |
| WI-38 | IC50 |
55.7 nM
Compound: Paclitaxel
|
Cytotoxicity against folate receptor deficient human WI38 cells after 72 hrs by MTT assay
Cytotoxicity against folate receptor deficient human WI38 cells after 72 hrs by MTT assay
|
[PMID: 25819334] |
| WI-38 | IC50 |
>10 μM
Compound: Paclitaxel
|
Antiproliferative activity against human WI-38 cells assessed as cell growth inhibition measured after 48 hrs by MTS assay
Antiproliferative activity against human WI-38 cells assessed as cell growth inhibition measured after 48 hrs by MTS assay
|
[PMID: 35737669] |
| WI-38 VA13 | IC50 |
0.005 μM
Compound: taxol
|
Cytotoxicity against human VA13 cells after 48 hrs by WST-8 assay
Cytotoxicity against human VA13 cells after 48 hrs by WST-8 assay
|
[PMID: 15730243] |
| WI-38 VA13 | IC50 |
0.0043 μM
Compound: Taxol
|
Growth inhibition of human VA13 cells after 48 hrs by WST8 assay
Growth inhibition of human VA13 cells after 48 hrs by WST8 assay
|
[PMID: 16499322] |
| WI-38 VA13 | IC50 |
0.0059 μM
Compound: Taxol
|
Cytotoxicity against human VA13 cells
Cytotoxicity against human VA13 cells
|
[PMID: 16724842] |
| WI-38 VA13 | IC50 |
0.005 μM
Compound: taxol
|
Cytotoxicity against human VA-13 cells by by WST-8 assay
Cytotoxicity against human VA-13 cells by by WST-8 assay
|
[PMID: 16933868] |
| WI-38 VA13 | IC50 |
0.005 μM
Compound: Taxol
|
Cytotoxicity against human VA13 cells
Cytotoxicity against human VA13 cells
|
[PMID: 17067155] |
| WI-38 VA13 | IC50 |
0.0043 μg/mL
Compound: 2
|
Cytotoxicity againt human VA13 cells
Cytotoxicity againt human VA13 cells
|
[PMID: 17239597] |
| WI-38 VA13 | IC50 |
0.01 μg/mL
Compound: taxol
|
Growth inhibition of human VA13 cells
Growth inhibition of human VA13 cells
|
[PMID: 17358082] |
| WI-38 VA13 | IC50 |
0.005 μM
Compound: Paclitaxel
|
Growth inhibition of human VA13 cells
Growth inhibition of human VA13 cells
|
[PMID: 17490878] |
| WI-38 VA13 | IC50 |
0.01 μg/mL
Compound: paclitaxel
|
Growth inhibition of VA13 cells
Growth inhibition of VA13 cells
|
[PMID: 17547458] |
| WI-38 VA13 | IC50 |
0.005 mM
Compound: taxol
|
Growth inhibition of human VA13 cells
Growth inhibition of human VA13 cells
|
[PMID: 17595134] |
| WI-38 VA13 | CC50 |
<20 nM
Compound: Ptxl; PTX
|
Cytotoxicity against human VA13 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
Cytotoxicity against human VA13 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
|
[PMID: 31248772] |
| WiDr | IC50 |
<3 ng/mL
Compound: 1 (paclitaxel)
|
Cytotoxicity against WIDR Tumor cell line in SRB Cell viability test
Cytotoxicity against WIDR Tumor cell line in SRB Cell viability test
|
[PMID: 10956217] |
| WiDr | IC50 |
<3 ng/mL
Compound: 1
|
Cytotoxicity against human WIDR cells
Cytotoxicity against human WIDR cells
|
[PMID: 17419065] |
| WiDr | GI50 |
0.22 nM
Compound: Paclitaxel
|
Growth inhibition of human WiDr cells
Growth inhibition of human WiDr cells
|
[PMID: 21986585] |
| WM 266-4 | IC50 |
0.32 nM
Compound: Taxol
|
Antiproliferative activity against human WM266.4 cells assessed as inhibition of cell viability after 48 hrs by MTS assay
Antiproliferative activity against human WM266.4 cells assessed as inhibition of cell viability after 48 hrs by MTS assay
|
[PMID: 31494469] |
| WRL68 | IC50 |
0.0035 μg/mL
Compound: taxol
|
Cytotoxicity against human WRL68 cell line by MTT assay
Cytotoxicity against human WRL68 cell line by MTT assay
|
[PMID: 16297622] |
| WRL68 | IC50 |
0.004 μM
Compound: taxol
|
Cytotoxicity against human WRL68 cells after 24 hrs by MTT assay
Cytotoxicity against human WRL68 cells after 24 hrs by MTT assay
|
[PMID: 18586491] |
| WRL68 | IC50 |
0.004 μM
Compound: Taxol
|
Cytotoxicity against human WRL68 cells compound treated for 6 hrs measured 48 hrs post washout by MTT assay
Cytotoxicity against human WRL68 cells compound treated for 6 hrs measured 48 hrs post washout by MTT assay
|
[PMID: 23584542] |
| WRL68 | IC50 |
0.004 μg/mL
Compound: Paclitaxel
|
Anticancer activity against human WRL68 cells after 24 hrs by MTT assay
Anticancer activity against human WRL68 cells after 24 hrs by MTT assay
|
[PMID: 25305717] |
| YOSHIDA | IC50 |
7.9 nM
Compound: Paclitaxel
|
In vitro antiproliferative activity against Yoshida cell lines
In vitro antiproliferative activity against Yoshida cell lines
|
10.1016/S0960-894X(97)10152-4 |
| ZR-75-1 | IC50 |
308 nM
Compound: Paclitaxel
|
Cytotoxicity against ZR-75-1 cell line
Cytotoxicity against ZR-75-1 cell line
|
[PMID: 17249649] |
| ZR-75-1 | IC50 |
6.2 nM
Compound: Paclitaxel
|
Cytotoxicity against human ZR-75-1 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay
Cytotoxicity against human ZR-75-1 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay
|
[PMID: 23468529] |
| ZR-75-1 | IC50 |
>100 nM
Compound: PXL
|
Antiproliferative activity against human ZR-75-1 cells after 3 days by SRB assay
Antiproliferative activity against human ZR-75-1 cells after 3 days by SRB assay
|
[PMID: 25241925] |
Paclitaxel (20 nM; 48 hours) induces programmed cell death and exists a block at the G2/M phase of the cell cycle[1].
Paclitaxel (20 nM; 48 hours) induces a consistent increase in the level of p53[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:MCF-7, MDA-MB-231 cells
-
Concentration:20 nM
-
Incubation Time:48 hours
-
Result:Induced programmed cell death.
-
Cell Line:MCF-7, MDA-MB-231 cells
-
Concentration:20 nM
-
Incubation Time:48 hours
-
Result:>60% of MCF-7 cells and 50% of MDA-MB-231 cells were in the G2/M phase following 24 h treament.
-
Cell Line:MCF-7 cells (harboring wild-type p53)
-
Concentration:20 nM
-
Incubation Time:48 hours
-
Result:Induced a consistent increase in the level of p53.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:MDA-231 xenograft-bearing mice[3]
-
Dosage:1, 20 mg/kg
-
Administration:Intraperitoneal injection; five cycles (1 time/2 days)
-
Result:Liver metastases were obviously induced in the low-PTX (1 mg/kg) group with little influence on primary tumor growth compared with high-PTX group.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 33069-62-4
-
Appearance Solid
-
Molecular Weight 853.91
-
Formula C47H51NO14
-
Color White to off-white
-
SMILES
O=C(C1=CC=CC=C1)N[C@@H](C2=CC=CC=C2)[C@H](C(O[C@@H]3C(C)=C([C@@H](OC(C)=O)C([C@@]4(C)[C@]([C@@](CO5)(OC(C)=O)[C@@]5([H])C[C@@H]4O)([H])[C@@H]6OC(C7=CC=CC=C7)=O)=O)C(C)(C)[C@@]6(O)C3)=O)O
-
Structure Classification
-
Initial Source
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Publications (365)
-
Journal Impact Factor
-
Most Recent
-
Signal Transduct Target Ther
Selective depletion of tumor-associated SAMHD1 enhances chemotherapeutic efficacy and antitumor immune responses. [Abstract]2025 Dec 15;10(1):406. PMID: 41392286 -
Signal Transduct Target Ther
Elaiophylin triggers paraptosis and preferentially kills ovarian cancer drug-resistant cells by inducing MAPK hyperactivation. [Abstract]2022 Sep 12;7(1):317. PMID: 36097006 -
Nat Med
Prospective observational study on biomarkers of response in pancreatic ductal adenocarcinoma. [Abstract]2024 Mar;30(3):749-761. PMID: 38287168
Paclitaxel purchased from MedChemExpress. Usage Cited in: Nat Med. 2024 Mar;30(3):749-761. [Abstract]
The relative cell viability of shCtl-, shNDUFB8-, and shCEMIP2-transfected cells was detected by XTT assay after paclitaxel (50 nM) plus gemcitabine treatment (A+G), single-agent 5-Fu (5-FU), and the FOLFIRINOX chemotherapy cocktail [FU+IRI+OXA: 5-FU+Irinotecan (SN-38) +Oxaliplatin] for 48h.
-
Cell
2022 Sep 1;185(18):3356-3374.e22. PMID: 36055199 -
Cell
Targeting Pin1 renders pancreatic cancer eradicable by synergizing with immunochemotherapy. [Abstract]2021 Sep 2;184(18):4753-4771.e27. PMID: 34388391 -
Nat Nanotechnol
Intrinsic bioactivity of black phosphorus nanomaterials on mitotic centrosome destabilization through suppression of PLK1 kinase. [Abstract]2021 Oct;16(10):1150-1160. PMID: 34354264 -
Mol Cancer
LINC00115 promotes chemoresistant breast cancer stem-like cell stemness and metastasis through SETDB1/PLK3/HIF1α signaling. [Abstract]2024 Mar 22;23(1):60. PMID: 38520019 -
Cell Res
Targeting ATAD3A-PINK1-mitophagy axis overcomes chemoimmunotherapy resistance by redirecting PD-L1 to mitochondria. [Abstract]2023 Mar;33(3):215-228. PMID: 36627348 -
Gastroenterology
AGR2-Dependent Nuclear Import of RNA Polymerase II Constitutes a Specific Target of Pancreatic Ductal Adenocarcinoma in the Context of Wild-Type p53. [Abstract]2021 Nov;161(5):1601-1614.e23. PMID: 34303658
Paclitaxel purchased from MedChemExpress. Usage Cited in: Gastroenterology. 2021 Nov;161(5):1601-1614.e23. [Abstract]
Bar graphs show the GI50 of 5-fluoruracil (48 h), irinotecan (48 h), gemcitabine (48 h), paclitaxel (48 h), and oxaliplatin (48 h) in PDAC cells in combination with bioactive hexapeptides (NTAIYY and PTTIYY) or controls (saline and NTAIYA).
-
-
Drug Resist Updat
Replacing the tropolonic methoxyl group of colchicine with methylamino increases tubulin binding affinity with improved therapeutic index and overcomes paclitaxel cross-resistance. [Abstract]2023 Feb 13;68:100951. PMID: 36841134 -
Bioact Mater
Concerting magnesium implant degradation facilitates local chemotherapy in tumor-associated bone defect. [Abstract]2024 Jun 24:40:445-459. PMID: 39027327 -
Bioact Mater
Biomimetic hydrogels with mesoscale collagen architecture for patient-derived tumor organoids culture. [Abstract]2024 May 11:38:384-398. PMID: 38764448
Paclitaxel purchased from MedChemExpress. Usage Cited in: Bioact Mater. 2024 May 11:38:384-398. [Abstract]
Paclitaxel (10 μM; 3–5 days) reduced the activity of lung cancer organoid-3 (LCO-3) with no significant effect on the activity of LCO-1 and LCO-2.
-
Cell Mol Immunol
2020 May;17(5):496-506. PMID: 31160756 -
-
Mol Cell
The RNA-stability-independent role of the RNA m6A reader YTHDF2 in promoting protein translation to confer tumor chemotherapy resistance. [Abstract]2025 Jun 19;85(12):2320-2336.e9. PMID: 40480228 -
ACS Nano
Celecoxib Augments Paclitaxel-Induced Immunogenic Cell Death in Triple-Negative Breast Cancer. [Abstract]2024 Jun 18;18(24):15864-15877. PMID: 38829727
Paclitaxel purchased from MedChemExpress. Usage Cited in: ACS Nano. 2024 Jun 18;18(24):15864-15877. [Abstract]
Paclitaxel (PTX, 0.1-1 μM; 24 h) increases COX-2 mRNA expression in 4T1 cells in a dose-dependent manner and induces elevated PGE2 release in the culture medium.
-
ACS Nano
Coassembly Nanomedicine Mediated by Intermolecular Interactions Between Methotrexate and Baricitinib for Improved Rheumatoid Arthritis Treatment. [Abstract]2024 Mar 19;18(11):8337-8349. PMID: 38437640 -
ACS Nano
A Side-Effect-Free Interventional Therapy for Precisely Eliminating Unresectable Cancer Pain. [Abstract]2023 Dec 12;17(23):23535-23544. PMID: 38084419 -
-
Nat Commun
Enhancing tandem mass spectrometry-based metabolite annotation with online chemical labeling. [Abstract]2025 Jul 26;16(1):6911. PMID: 40715063 -
Nat Commun
Oral ENPP1 inhibitor designed using generative AI as next generation STING modulator for solid tumors. [Abstract]2025 May 23;16(1):4793. PMID: 40410143 -
Nat Commun
2025 Mar 14;16(1):2526. PMID: 40087304 -
Nat Commun
Redox-responsive polymer micelles co-encapsulating immune checkpoint inhibitors and chemotherapeutic agents for glioblastoma therapy. [Abstract]2024 Feb 6;15(1):1118. PMID: 38320994 -
Nat Commun
Nuclear membrane protein SUN2 promotes replication of flaviviruses through modulating cytoskeleton reorganization mediated by NS1. [Abstract]2024 Jan 5;15(1):296. PMID: 38177122 -
-
Autophagy
2021 Dec;17(12):3976-3991. PMID: 33752561 -
Adv Sci (Weinh)
2026 Feb 3:e16660. PMID: 41632021 -
Adv Sci (Weinh)
Efferocytosis-Driven Polyamine Metabolism in Macrophages Enhances Cancer Stem Cell Enrichment after Chemotherapy in Ovarian Cancer. [Abstract]2025 Nov 21:e12508. PMID: 41271556 -
Adv Sci (Weinh)
The Crosstalk Between CRL5 and APC/C E3 Ligases Regulates Metastasis and Chemosensitivity of Cancer Cells. [Abstract]2025 Oct 29:e12652. PMID: 41159544 -
Adv Sci (Weinh)
Mesenchymal Stromal Cells Play an Analgesic Role Through a Npy2r Sensory Neuron-Mediated Lung-to-Brain Axis. [Abstract]2025 Aug 28:e04922. PMID: 40874463 -
Adv Sci (Weinh)
Pia Mater-Penetrable Lipopolymer Nanoparticles for Gliocyte-Targeted IL-10 mRNA Therapy Alleviate Paclitaxel-Induced Peripheral Neuropathy. [Abstract]2025 May 13:e2500362. PMID: 40364590 -
Adv Sci (Weinh)
EccDNA-Driven VPS41 Amplification Alleviates Genotoxic Stress via Lysosomal KAI1 Degradation. [Abstract]2025 Apr 24:e2501934. PMID: 40271553 -
Adv Sci (Weinh)
Pyruvate Kinase M2-Responsive Release of Paclitaxel and Indoleamine 2,3-Dioxygenase Inhibitor for Immuno-Chemotherapy of Nonsmall Cell Lung Cancer. [Abstract]2024 Dec 24:e2409790. PMID: 39716923 -
Adv Sci (Weinh)
DNMT3a Downregulation Ttriggered Upregulation of GABAA Receptor in the mPFC Promotes Paclitaxel-Induced Pain and Anxiety in Male Mice. [Abstract]2024 Dec 16:e2407387. PMID: 39679872 -
Adv Sci (Weinh)
The Tumor Suppressor TPD52-Governed Endoplasmic Reticulum Stress is Modulated by APCCdc20. [Abstract]2024 Dec;11(45):e2405441. PMID: 39401430 -
Adv Sci (Weinh)
Overcoming the On-Target Toxicity in Antibody-Mediated Therapies via an Indirect Active Targeting Strategy. [Abstract]2023 Mar;10(9):e2206912. PMID: 36683161 -
J Clin Invest
DNA topoisomerase II inhibition potentiates osimertinib's therapeutic efficacy in EGFR-mutant non-small cell lung cancer models. [Abstract]2024 Mar 7;134(10):e172716. PMID: 38451729
Paclitaxel purchased from MedChemExpress. Usage Cited in: J Clin Invest. 2024 Mar 7;134(10):e172716. [Abstract]
The given cell lines were treated with 250 nM osimertinib (Osim), 1.25 μM Etoposide (VP-16), 125 nM Doxorubicin (DXR), 5 nM Paclitaxel, 10 μM Cisplatin, 25 μM Carboplatin, 25 nM Gemcitabine, 20 nM 5-Fluorouracil (5-FU), 25 μM Cyclophosphamide, 25 μM Capecitabine, or 10 nM Vincristine alone or in combination for 3 days. Cell numbers were then measured using the SRB assay.
-
Theranostics
Caspase-mediated AURKA cleavage at Asp132 is essential for paclitaxel to elicit cell apoptosis. [Abstract]2024 Jun 17;14(10):3909-3926. PMID: 38994036 -
Theranostics
Endogenous glutamate determines ferroptosis sensitivity via ADCY10-dependent YAP suppression in lung adenocarcinoma. [Abstract]2021 Mar 24;11(12):5650-5674. PMID: 33897873 -
-
Nucleic Acids Res
HDAC8 cooperates with SMAD3/4 complex to suppress SIRT7 and promote cell survival and migration. [Abstract]2020 Apr 6;48(6):2912-2923. PMID: 31970414 -
J Adv Res
Mitochondrial fatty acid oxidation as the target for blocking therapy-resistance and inhibiting tumor recurrence: The proof-of-principle model demonstrated for ovarian cancer cells. [Abstract]2025 Mar 17:S2090-1232(25)00186-9. PMID: 40107354 -
Biomaterials
2022 Oct:289:121800. PMID: 36166893 -
J Exp Clin Cancer Res
Neddylation activated TRIM25 desensitizes triple-negative breast cancer to paclitaxel via TFEB-mediated autophagy. [Abstract]2024 Jun 26;43(1):177. PMID: 38926803 -
J Exp Clin Cancer Res
CCAAT enhancer binding protein delta activates vesicle associated membrane protein 3 transcription to enhance chemoresistance and extracellular PD-L1 expression in triple-negative breast cancer. [Abstract]2024 Apr 16;43(1):115. PMID: 38627816 -
J Exp Clin Cancer Res
Deubiquitylase YOD1 regulates CDK1 stability and drives triple-negative breast cancer tumorigenesis. [Abstract]2023 Sep 4;42(1):228. PMID: 37667382 -
J Exp Clin Cancer Res
ZBTB28 induces autophagy by regulation of FIP200 and Bcl-XL facilitating cervical cancer cell apoptosis. [Abstract]2021 Apr 30;40(1):150. PMID: 33931087 -
Carbohydr Polym
Chitosan/dextran-based organohydrogel delivers EZH2 inhibitor to epigenetically reprogram chemo/immuno-resistance in unresectable metastatic melanoma. [Abstract]2024 Dec 15:346:122645. PMID: 39245506 -
Small
Self-Assembled Carrier-Free Nanomedicines Potentiate Chemo-Photothermal Immunotherapy by Overcoming Prostaglandin E2-Mediated Immunosuppression. [Abstract]2026 Apr;22(20):e12540. PMID: 41665479 -
J Control Release
Design and tuning of a cell-penetrating albumin derivative as a versatile nanovehicle for intracellular drug delivery. [Abstract]2018 May 10;277:23-34. PMID: 29530390 -
MedComm (2020)
KSQ-4279, an Inhibitor of Ubiquitin Specific Peptidase 1, Enhanced the Chemotherapeutic Efficacy in ABCB1/ABCG2/ABCC1-Mediated Multidrug Resistant Cancers. [Abstract]2025 Nov 29;6(12):e70517. PMID: 41328326 -
Research (Wash D C)
Engineered Endometrial Clear Cell Cancer-on-a-Chip Reveals Early Invasion-Metastasis Cascade of Cancer Cells. [Abstract]2025 Apr 14:29:0177. PMID: 40231208 -
Cell Rep Med
Sex-biased intratumoral microbiome influences tumor molecular and immune landscape and disease outcomes. [Abstract]2026 May 19;7(5):102757. PMID: 42013847 -
Cell Rep Med
HE4 drives PD-L1 expression in myeloid cells via IFN-γR-JAK-STAT3 signaling to promote tumor immune evasion. [Abstract]2026 Apr 21;7(4):102691. PMID: 41861828 -
Cell Rep Med
CAN-Scan: A multi-omic phenotype-driven precision oncology platform identifies prognostic biomarkers of therapy response for colorectal cancer. [Abstract]2025 Apr 2:102053. PMID: 40187357 -
Cell Rep Med
Using patient-derived organoids to predict locally advanced or metastatic lung cancer tumor response: A real-world study. [Abstract]2023 Feb 21;4(2):100911. PMID: 36657446 -
J Immunother Cancer
ATM/NEMO signaling modulates the expression of PD-L1 following docetaxel chemotherapy in prostate cancer. [Abstract]2021 Jul;9(7):e001758. PMID: 34301812 -
Pharmacol Res
Depletion of regulatory T cells enhancing the anti-tumor effect of in situ vaccination in solid tumors. [Abstract]2024 May:203:107174. PMID: 38580185 -
Mater Today Bio
Nanocomposite hydrogel acupoint therapy for sustained pregabalin delivery and long-term neuropathic pain relief. [Abstract]2026 Feb 24:37:102967. PMID: 41809379 -
Mater Today Bio
Nanotube topography inhibits NLRP3 inflammasome activation by reducing microtubule glutamylation. [Abstract]2025 May 10:32:101838. PMID: 40487178 -
Clin Cancer Res
CD24hiCD27+ Bregs within Metastatic Lymph Nodes Promote Multidrug Resistance in Breast Cancer. [Abstract]2023 Dec 15;29(24):5227-5243. PMID: 37831062 -
Cancer Lett
The deubiquitinase OTUD5 stabilizes SLC7A11 to promote progression and reduce paclitaxel sensitivity in triple-negative breast cancer. [Abstract]2024 Sep 12:217232. PMID: 39276913 -
Int J Biol Sci
Nuclear Softness Promotes the Metastatic Potential of Large-Nucleated Colorectal Cancer Cells via the ErbB4-Akt1-Lamin A/C Signaling Pathway. [Abstract]2024 Apr 29;20(7):2748-2762. PMID: 38725859 -
Adv Healthc Mater
Novel Drug-Testing Platform for Vascular Injury-induced Intimal Hyperplasia Using a Microphysiological System. [Abstract]2025 Aug 11:e00602. PMID: 40787716 -
Acta Biomater
Redox-responsive dendritic copolymer-drug conjugates enhance therapeutic mitophagy through coordinated microtubule destabilization for synergistic triple-negative breast cancer therapy. [Abstract]2025 Aug:202:248-261. PMID: 40555336 -
Cell Death Dis
Both direct and indirect suppression of MCL1 synergizes with BCLXL inhibition in preclinical models of gastric cancer. [Abstract]2025 Mar 12;16(1):170. PMID: 40075071 -
Cell Death Dis
Inhibition of KLF5 promotes ferroptosis via the ZEB1/HMOX1 axis to enhance sensitivity to oxaliplatin in cancer cells. [Abstract]2025 Jan 18;16(1):28. PMID: 39827156 -
Cell Death Dis
2021 Apr 1;12(4):338. PMID: 33795638 -
Sci China Life Sci
2025 Aug;68(8):2348-2362. PMID: 40410652 -
-
Cell Commun Signal
Phosphorylated IRF3 promotes GSDME-mediated pyroptosis through RIPK1/FADD/caspase-8 complex formation during mitotic arrest in ovarian cancer. [Abstract]2025 Jul 1;23(1):306. PMID: 40597187 -
Cell Commun Signal
2025 Jun 4;23(1):263. PMID: 40462136 -
Cell Commun Signal
Targeting the ERK1/2 and p38 MAPK pathways attenuates Golgi tethering factor golgin-97 depletion-induced cancer progression in breast cancer. [Abstract]2025 Jan 13;23(1):22. PMID: 39800687 -
Cell Commun Signal
BI-2865, a pan-KRAS inhibitor, reverses the P-glycoprotein induced multidrug resistance in vitro and in vivo. [Abstract]2024 Jun 13;22(1):325. PMID: 38872211 -
Dev Cell
Gene copy-number changes and chromosomal instability induced by aneuploidy confer resistance to chemotherapy. [Abstract]2021 Sep 13;56(17):2440-2454.e6. PMID: 34352223 -
Acta Pharmacol Sin
Nobiletin and polydatin synergistically alleviate triple-negative breast cancer liver metastasis via suppressing ECM1a-mediated fatty acid biosynthesis. [Abstract]2025 Oct 13. PMID: 41083594 -
Acta Pharmacol Sin
Desloratadine ameliorates paclitaxel-induced peripheral neuropathy and hypersensitivity reactions in mice. [Abstract]2024 Oct;45(10):2061-2076. PMID: 38789495 -
Acta Pharmacol Sin
Ras inhibitor farnesylthiosalicylic acid conjugated with IR783 dye exhibits improved tumor-targeting and altered anti-breast cancer mechanisms in mice. [Abstract]2022 Jul;43(7):1843-1856. PMID: 34845369 -
EMBO Mol Med
Activated glucocorticoid receptor is an estrogen receptor silencer in ER+ metastatic breast cancer. [Abstract]2025 Nov 19. PMID: 41261233 -
Phytomedicine
Fangchinoline suppresses hepatocellular carcinoma by regulating ROS accumulation via the TRIM7/Nrf2 signaling pathway. [Abstract]2024 Dec:135:156143. PMID: 39461200 -
Phytomedicine
Artemisitene induces apoptosis of breast cancer cells by targeting FDFT1 and inhibits the growth of breast cancer patient-derived organoids. [Abstract]2024 Dec:135:156155. PMID: 39461203 -
Phytomedicine
Ginsenoside Rh2 enhances immune surveillance of natural killer (NK) cells via inhibition of ERp5 in breast cancer. [Abstract]2024 Jan:123:155180. PMID: 38043385 -
Phytomedicine
Sophflarine A, a novel matrine-derived alkaloid from Sophora flavescens with therapeutic potential for non-small cell lung cancer through ROS-mediated pyroptosis and autophagy. [Abstract]2023 Jul 25:116:154909. PMID: 37269775 -
Phytomedicine
Khellin as a selective monoamine oxidase B inhibitor ameliorated paclitaxel-induced peripheral neuropathy in mice. [Abstract]2023 Mar:111:154673. PMID: 36716674 -
-
Phytomedicine
Crystal structure of tubulin-barbigerone complex enables rational design of potent anticancer agents with isoflavone skeleton. [Abstract]2023 Jan:109:154550. PMID: 36610121 -
EMBO J
Pharmacological CDK4/6 inhibition reveals a p53-dependent senescent state with restricted toxicity. [Abstract]2022 Mar 15;41(6):e108946. PMID: 34985783 -
ACS Appl Mater Interfaces
Calcium-Overloaded Multifunctional Nanoparticles for Synergistically Enhanced Photothermal and Chemotherapy and Immune Activation in Triple-Negative Breast Cancer. [Abstract]2026 Mar 11;18(9):13670-13689. PMID: 41769838 -
ACS Appl Mater Interfaces
Hypoxia Alleviation-Potentiated Chemotherapy Enhances Anti-PD-L1 Treatment for Triple-Negative Breast Cancer via Improving Tumor Immunogenicity and Inhibiting STAT3 Activation. [Abstract]2026 Feb 11;18(5):7845-7862. PMID: 41618887 -
ACS Appl Mater Interfaces
2026 Jan 25. PMID: 41582522 -
Free Radic Biol Med
Cavidine alleviates paclitaxel-induced peripheral neuropathy by promoting mitochondrial autophagy through inhibiting PKM2-mediated histone lactylation. [Abstract]2025 Sep 24:241:367-383. PMID: 41005738 -
Cancer Immunol Res
Discovery of podofilox as a potent cGAMP-STING signaling enhancer with antitumor activity. [Abstract]2023 May 3;11(5):583-599. PMID: 36921097 -
ACS Appl Mater Interfaces
Peptide-Targeted High-Density Lipoprotein Nanoparticles for Combinatorial Treatment against Metastatic Breast Cancer. [Abstract]2021 Aug 4;13(30):35248-35265. PMID: 34284582 -
Food Res Int
Glycyrrhiza uralensis Fisch: A novel source of analgesic activity through NaV1.8 sodium channel modulation. [Abstract]2025 Dec;222(Pt 1):117620. PMID: 41267240 -
NPJ Precis Oncol
Targeting the DYRK1A kinase prevents cancer progression and metastasis and promotes cancer cells response to G1/S targeting chemotherapy drugs. [Abstract]2024 Jun 5;8(1):128. PMID: 38839871 -
NPJ Precis Oncol
Single-organoid analysis reveals clinically relevant treatment-resistant and invasive subclones in pancreatic cancer. [Abstract]2023 Dec 8;7(1):128. PMID: 38066116 -
Br J Pharmacol
Contributions of synaptic energetic dysfunction by microtubule dynamics and microtubule-based mitochondrial transport disorder to morphine tolerance. [Abstract]2025 May 13. PMID: 40361281 -
Br J Pharmacol
Targeted disruption of mitochondria potently reverses multidrug resistance in cancer therapy. [Abstract]2022 Jul;179(13):3346-3362. PMID: 35040123 -
Cell Syst
A Multi-center Study on the Reproducibility of Drug-Response Assays in Mammalian Cell Lines. [Abstract]2019 Jul 24;9(1):35-48.e5. PMID: 31302153 -
Biomed Pharmacother
Gilteritinib reverses ABCB1-mediated multidrug resistance: Preclinical in vitro and animal investigations. [Abstract]2024 Oct 28:180:117603. PMID: 39471652 -
J Transl Med
Vascular restenosis following paclitaxel-coated balloon therapy is attributable to NLRP3 activation and LIN9 upregulation. [Abstract]2024 Sep 27;22(1):871. PMID: 39334121 -
Biomed Pharmacother
Paclitaxel-resistance facilitates glycolytic metabolism via Hexokinase-2-regulated ABC and SLC transporter genes in ovarian clear cell carcinoma. [Abstract]2024 Nov:180:117452. PMID: 39341074 -
Biomed Pharmacother
Liensinine diperchlorate and artemisitene synergistically attenuate breast cancer progression through suppressing PI3K-AKT signaling and their efficiency in breast cancer patient-derived organoids. [Abstract]2024 Jun 10:176:116871. PMID: 38861856 -
Biomed Pharmacother
Patient-derived organoid culture of gastric cancer for disease modeling and drug sensitivity testing. [Abstract]2023 Jul:163:114751. PMID: 37105073 -
J Transl Med
CDK1 serves as a therapeutic target of adrenocortical carcinoma via regulating epithelial-mesenchymal transition, G2/M phase transition, and PANoptosis. [Abstract]2022 Oct 2;20(1):444. PMID: 36184616 -
Biomed Pharmacother
β2-adrenoreceptor agonist ameliorates mechanical allodynia in paclitaxel-induced neuropathic pain via induction of mitochondrial biogenesis. [Abstract]2021 Dec:144:112331. PMID: 34673421 -
Biomed Pharmacother
PPARγ activation mitigates mechanical allodynia in paclitaxel-induced neuropathic pain via induction of Nrf2/HO-1 signaling pathway. [Abstract]2020 Sep;129:110356. PMID: 32535388 -
J Transl Int Med
Anti-SIA-cIgG enhances chemotherapy effectiveness through PTPN13-regulated tumor stemness in head and neck squamous cell carcinoma. [Abstract]2026 Mar 26;14(2):237-258. PMID: 42046805 -
Chin Med J (Engl)
Inhibitory effect of blestriarene C on triple-negative breast cancer: Inducing ferroptosis and mitophagy via SESN2/AKT/FOXO4 axis. [Abstract]2026 Mar 5;139(5):699-709. PMID: 41527177 -
Stem Cell Res Ther
Epiregulin increases stemness-associated genes expression and promotes chemoresistance of non-small cell lung cancer via ERK signaling. [Abstract]2022 May 12;13(1):197. PMID: 35551652 -
Oncogene
Disrupted mitochondrial homeostasis coupled with mitotic arrest generates antineoplastic oxidative stress. [Abstract]2022 Jan;41(3):427-443. PMID: 34773075 -
Oncogene
TTPAL promotes gastric tumorigenesis by directly targeting NNMT to activate PI3K/AKT signaling. [Abstract]2021 Dec;40(49):6666-6679. PMID: 34642500 -
Cell Chem Biol
Suppression of pain transmission and behavior by inhibition of peripheral diacylglycerol metabolism. [Abstract]2026 Jan 15;33(1):74-90.e19. PMID: 41544618 -
Cell Chem Biol
A highly potent bi-thiazole inhibitor of LOX rewires collagen architecture and enhances chemoresponse in triple-negative breast cancer. [Abstract]2024 Jul 9:S2451-9456(24)00273-3. PMID: 39043186 -
Cell Chem Biol
Pharmacological Targeting of Vacuolar H+-ATPase via Subunit V1G Combats Multidrug-Resistant Cancer. [Abstract]2020 Nov 19;27(11):1359-1370.e8. PMID: 32649904 -
Cell Death Discov
MSLN-mediated activation of EGFR-ERK1/2 signaling drives liver metastasis in breast cancer. [Abstract]2026 Jan 9;12(1):11. PMID: 41513618 -
Cell Death Discov
NRG1/PDGFC loop between fibroblasts and cancer cells drives paclitaxel resistance via ferroptosis suppression in breast cancer. [Abstract]2025 Nov 10;11(1):520. PMID: 41213930 -
Cell Rep
Targeting the DSTYK-ULK1 axis rewires TNFR1 signaling to overcome treatment resistance in lung cancer. [Abstract]2026 Mar 12;45(3):117087. PMID: 41824459 -
Cell Rep
Incorporation of human iPSC-derived stromal cells creates a pancreatic cancer organoid with heterogeneous cancer-associated fibroblasts. [Abstract]2023 Nov 12;42(11):113420. PMID: 37955987 -
Cell Rep
The deubiquitinase OTUD1 noncanonically suppresses Akt activation through its N-terminal intrinsically disordered region. [Abstract]2023 Jan 31;42(1):111916. PMID: 36640312 -
Clin Transl Med
Pathogenic variants of TUBB8 cause oocyte spindle defects by disrupting with EB1/CAKP5 interactions and potential treatment targeting microtubule acetylation through HDAC6 inhibition. [Abstract]2025 Jan;15(1):e70193. PMID: 39834092 -
Neural Regen Res
Fidgetin interacting with microtubule end binding protein EB3 affects axonal regrowth in spinal cord injury. [Abstract]2023 Dec;18(12):2727-2732. PMID: 37449637 -
Anal Chem
Label-Free Isolation of Low-Adhesion Cells with Stem Properties for Cancer Stem Cell-Specific Drug Evaluation. [Abstract]2023 Apr 11;95(14):6191. PMID: 36122350 -
Thyroid
Targeting Super-Enhancer-Driven Oncogenic Transcription by CDK7 Inhibition in Anaplastic Thyroid Carcinoma. [Abstract]2019 Jun;29(6):809-823. PMID: 30924726 -
J Cell Biol
2026 Jan 5;225(1):e202503083. PMID: 41236476 -
J Cell Biol
Adapting plasma membrane for mitotic cell rounding through Aurora A phosphorylation of numb. [Abstract]2025 Dec 1;224(12):e202412005. PMID: 41212116 -
Mol Med
Paclitaxel alleviates spinal cord injury via activation of the Wnt/β-catenin signaling pathway. [Abstract]2025 May 6;31(1):172. PMID: 40329167 -
Elife
2022 May 3;11:e69255. PMID: 35503721 -
-
Phytother Res
Higher efficacy of resveratrol against advanced breast cancer organoids: A comparison with that of clinically relevant drugs. [Abstract]2022 Aug;36(8):3313-3324. PMID: 35649509 -
Cell Mol Life Sci
Glycocalyx hyaluronan removal-induced increasing of cell stiffness delays breast cancer cells progression. [Abstract]2025 Feb 27;82(1):96. PMID: 40011237 -
Cell Biosci
Anti-tumor effects of dual PI3K-HDAC inhibitor CUDC-907 on activation of ROS-IRE1α-JNK-mediated cytotoxic autophagy in esophageal cancer. [Abstract]2022 Aug 21;12(1):135. PMID: 35989326 -
J Agric Food Chem
Discovery of Myricetin as a Potent Inhibitor of Human Flap Endonuclease 1, Which Potentially Can Be Used as Sensitizing Agent against HT-29 Human Colon Cancer Cells. [Abstract]2019 Feb 13;67(6):1656-1665. PMID: 30694659
Paclitaxel purchased from MedChemExpress. Usage Cited in: J Agric Food Chem. 2019 Feb 13;67(6):1656-1665. [Abstract]
Western blot image and statistical analysis of phosphorylated γH2AX levels in HT-29 cells with different treatments after 48 h. Myricetin and PTX used are 32 μM and 100 nM, respectively.
-
Ecotoxicol Environ Saf
PPARγ-responsive luciferase reporter system for high-throughput screening of chemical toxins with potential pulmonary fibrosis effects. [Abstract]2025 Nov 15:307:119433. PMID: 41273832 -
Cancer Cell Int
Establishment and characteristic analysis of a novel patient derived cell line of intrahepatic cholangiocarcinoma. [Abstract]2025 Oct 15;25(1):357. PMID: 41094661 -
Cancer Cell Int
A novel STAT3/ NFκB p50 axis regulates stromal-KDM2A to promote M2 macrophage-mediated chemoresistance in breast cancer. [Abstract]2023 Oct 11;23(1):237. PMID: 37821959 -
Eur J Med Chem
Design, synthesis and biological evaluation of plant-derived miliusol derivatives achieve TNBC profound regression in vivo. [Abstract]2024 Sep 18:279:116882. PMID: 39305634 -
Int J Mol Med
Proteasome inhibitors decrease paclitaxel‑induced cell death in nasopharyngeal carcinoma with the accumulation of CDK1/cyclin B1. [Abstract]2021 Oct;48(4):193. PMID: 34435645 -
Biochem Pharmacol
Ticagrelor reverses multidrug resistance in breast cancer by inhibiting PI3K/AKT/mTOR pathway and suppressing ABCB1 expression and function. [Abstract]2026 Mar 15:249:117903. PMID: 41846011 -
Breast Cancer Res
Multi-receptor targeted therapy of breast cancer and brain metastases with a novel QUAD-drug conjugate. [Abstract]2025 Oct 27;27(1):189. PMID: 41146202 -
Biochem Pharmacol
Discovery of a potent BRD4 PROTAC and evaluation of its bioactivity in breast cancer cell lines. [Abstract]2025 Jul 12:241:117159. PMID: 40659131 -
Breast Cancer Res
THEM6 modulates carboplatin sensitivity by regulating ferroptosis through FDFT1 in triple-negative breast cancer. [Abstract]2025 Jul 6;27(1):124. PMID: 40619388 -
Biochem Pharmacol
VPS34-IN1 induces apoptosis of ER + breast cancer cells via activating PERK/ATF4/CHOP pathway. [Abstract]2023 Aug:214:115634. PMID: 37290596 -
Biochem Pharmacol
A PARP1 PROTAC as a novel strategy against PARP inhibitor resistance via promotion of ferroptosis in p53-positive breast cancer. [Abstract]2022 Dec:206:115329. PMID: 36309080 -
Cell Prolif
2021 May;54(5):e13038. PMID: 33793020 -
Breast Cancer Res
First in class dual MDM2/MDMX inhibitor ALRN-6924 enhances antitumor efficacy of chemotherapy in TP53 wild-type hormone receptor-positive breast cancer models. [Abstract]2021 Mar 4;23(1):29. PMID: 33663585 -
Biochem Pharmacol
Appraising the "entourage effect": Antitumor action of a pure cannabinoid versus a botanical drug preparation in preclinical models of breast cancer. [Abstract]2018 Nov:157:285-293. PMID: 29940172 -
J Gastroenterol
Chemotherapy-induced cell cycle arrest is associated with increased claudin-18 isoform 2 expression and enhanced zolbetuximab-mediated cytotoxicity in gastric cancer. [Abstract]2026 May 14. PMID: 42133042 -
Mol Cancer Ther
DHX9 inhibition enhances paclitaxel sensitivity by inducing mitotic failure in ovarian and endometrial cancers. [Abstract]2026 Mar 24. PMID: 41873535 -
Mol Cancer Ther
Multimeric Anti-DR5 IgM Agonist Antibody IGM-8444 Is a Potent Inducer of Cancer Cell Apoptosis and Synergizes with Chemotherapy and BCL-2 Inhibitor ABT-199. [Abstract]2021 Dec;20(12):2483-2494. PMID: 34711645 -
J Enzyme Inhib Med Chem
PD-L1 dimerisation induced by biphenyl derivatives mediates anti-breast cancer activity via the non-immune PD-L1-AKT-mTOR/Bcl2 pathway. [Abstract]2023 Dec;38(1):2230388. PMID: 37439326 -
Mar Drugs
Marine Sulfated Polysaccharide PMGS Synergizes with Paclitaxel in Inhibiting Cervical Cancer In Vitro. [Abstract]2023 Apr 23;21(5):259. PMID: 37233453
Paclitaxel purchased from MedChemExpress. Usage Cited in: Mar Drugs. 2023 Apr 23;21(5):259. [Abstract]
Paclitaxel (PTX; 3.125, 6.25, 12.5, 25, 50, 100 nM; 48 h) reduces the viability of Hela, SiHa, and C33A cells in a dose-dependent manner.(3.125 nM for Hela cells, 100 nM for SiHa and C33A cells)
Paclitaxel purchased from MedChemExpress. Usage Cited in: Mar Drugs. 2023 Apr 23;21(5):259. [Abstract]
Paclitaxel (PTX; 50 nM; 48 h) increases the expression of Cleaved-caspase-9 and Cleaved-caspase-3 in Hela cells.
-
Biomacromolecules
2023 Feb 13;24(2):849-857. PMID: 36639133 -
-
Cells
A Comprehensive Adenoid Cystic Carcinoma-Derived Organoid Platform for Disease Modeling and Drug Screening Captures Interpatient Heterogeneity. [Abstract]2026 Feb 23;15(4):383. PMID: 41744826 -
Int J Pharm
Mesenchymal stem cell-delivered paclitaxel nanoparticles exhibit enhanced efficacy against a syngeneic orthotopic mouse model of pancreatic cancer. [Abstract]2024 Sep 23:124753. PMID: 39321899 -
J Funct Biomater
A Potential Effect of Circadian Rhythm in the Delivery/Therapeutic Performance of Paclitaxel-Dendrimer Nanosystems. [Abstract]2023 Jul 11;14(7):362. PMID: 37504857 -
Int J Pharm
Surface-modified nanoparticles of docetaxel for chemotherapy of lung cancer: an intravenous to oral switch. [Abstract]2023 Apr 5:636:122846. PMID: 36921744 -
-
Commun Biol
2025 Jul 3;8(1):989. PMID: 40610677 -
-
Commun Biol
Development and validation of the Normalized Organoid Growth Rate (NOGR) metric in brightfield imaging-based assays. [Abstract]2024 Dec 3;7(1):1612. PMID: 39627437 -
Cancer Immunol Immunother
GSDME-mediated pyroptosis promotes anti-tumor immunity of neoadjuvant chemotherapy in breast cancer. [Abstract]2024 Jul 2;73(9):177. PMID: 38954046 -
Gastric Cancer
Anthracycline chemicals with anthracyclinone structure exert antitumor effects by inhibiting angiogenesis and lymphangiogenesis in a xenografted gastric tumor model. [Abstract]2023 Nov;26(6):863-877. PMID: 37344705 -
Commun Biol
A pipeline for malignancy and therapy agnostic assessment of cancer drug response using cell mass measurements. [Abstract]2022 Nov 26;5(1):1295. PMID: 36435843 -
Drug Des Devel Ther
Effects of Quercetin on the Efficacy of Various Chemotherapeutic Drugs in Cervical Cancer Cells. [Abstract]2021 Feb 15:15:577-588. PMID: 33623367 -
Int J Mol Sci
ABCG2 Contributes to Multidrug Resistance and Aggressive Phenotypes Associated with ERK Signaling in Gastric Cancer. [Abstract]2026 Jun 2;27(11):5039. PMID: 42278563 -
Int J Mol Sci
2025 Nov 28;26(23):11540. PMID: 41373692 -
Int J Oncol
Discovery of the late autophagy inhibitor FZU‑0045‑053 and its anti‑breast cancer and immunomodulatory effects. [Abstract]2026 Jan;68(1):10. PMID: 41312734 -
Biol Direct
Integrative genomics unveils basement membrane-related diagnostic markers and therapeutic targets in esophageal squamous cell carcinoma. [Abstract]2024 Sep 11;19(1):79. PMID: 39256753 -
Int J Mol Sci
CRISPR/Cas9-Mediated CtBP1 Gene Editing Enhances Chemosensitivity and Inhibits Metastatic Potential in Esophageal Squamous Cell Carcinoma Cells. [Abstract]2023 Sep 13;24(18):14030. PMID: 37762332 -
Eng Comput
A global sensitivity analysis of a mechanistic model of neoadjuvant chemotherapy for triple negative breast cancer constrained by in vitro and in vivo imaging data. [Abstract]2024;40(3):1469-1499. PMID: 39620056 -
Int J Oncol
Ipatasertib exhibits anti‑tumorigenic effects and enhances sensitivity to paclitaxel in endometrial cancer in vitro and in vivo. [Abstract]2023 Sep;63(3):103. PMID: 37503790 -
Int J Oncol
A novel ferroptosis‑related gene signature for overall survival prediction and immune infiltration in patients with breast cancer. [Abstract]2022 Dec;61(6):148. PMID: 36222299 -
Int J Mol Sci
(+)-Usnic Acid Induces ROS-dependent Apoptosis via Inhibition of Mitochondria Respiratory Chain Complexes and Nrf2 Expression in Lung Squamous Cell Carcinoma. [Abstract]2020 Jan 29;21(3):876. PMID: 32013250 -
Biomolecules
Mesenchymal Stem Cell Exosome-Mediated Delivery of Paclitaxel for Pancreatic Cancer Therapy. [Abstract]2026 Feb 9;16(2):269. PMID: 41750339 -
Cell Oncol (Dordr)
Inhibition of EREG/ErbB/ERK by Astragaloside IV reversed taxol-resistance of non-small cell lung cancer through attenuation of stemness via TGFβ and Hedgehog signal pathway. [Abstract]2024 Dec;47(6):2201-2215. PMID: 39373858 -
Pharmaceuticals (Basel)
2022 Sep 6;15(9):1111. PMID: 36145332 -
Cell Oncol (Dordr)
AZD4547 targets the FGFR/Akt/SOX2 axis to overcome paclitaxel resistance in head and neck cancer. [Abstract]2022 Feb;45(1):41-56. PMID: 34837170 -
Front Pharmacol
Guaiazulene Triggers ROS-Induced Apoptosis and Protective Autophagy in Non-small Cell Lung Cancer. [Abstract]2021 Apr 15:12:621181. PMID: 33935713 -
ACS Appl Bio Mater
Amphiphilic Glycopolymer Nanoparticles for pH-Responsive Paclitaxel Delivery and Enhanced Efficacy in Pancreatic Ductal Adenocarcinoma Therapy. [Abstract]2026 Jun 1;9(11):4723-4739. PMID: 42138136 -
Eur J Pharmacol
DNMT3A-regulated medial prefrontal cortex circuits modulate paclitaxel-induced neuropathic pain. [Abstract]2026 Mar 28:1019:178674. PMID: 41740780 -
Int Immunopharmacol
2025 Jul 30:163:115273. PMID: 40743622 -
Int J Cancer
Establishment of patient-derived organoids for guiding personalized therapies in breast cancer patients. [Abstract]2024 Jul 15;155(2):324-338. PMID: 38533706 -
Bioorg Chem
The cytotoxic natural compound erianin binds to colchicine site of β-tubulin and overcomes taxane resistance. [Abstract]2024 Jun 17:150:107569. PMID: 38905886 -
Eur J Pharmacol
IP3R1 dysregulation via mir-200c-3p/SSFA2 axis contributes to taxol resistance in head and neck cancer. [Abstract]2024 Jun 15:973:176592. PMID: 38642666 -
J Mol Cell Cardiol
Defective autophagy triggered by arterial cyclic stretch promotes neointimal hyperplasia in vein grafts via the p62/nrf2/slc7a11 signaling pathway. [Abstract]2022 Dec:173:101-114. PMID: 36308866 -
Eur J Pharmacol
Notch signaling activation contributes to paclitaxel-induced neuropathic pain via activation of A1 astrocytes. [Abstract]2022 Aug 5:928:175130. PMID: 35777441 -
Eur J Pharmacol
Screening of and mechanism underlying the action of serum- and glucocorticoid-regulated kinase 3-targeted drugs against estrogen receptor-positive breast cancer. [Abstract]2022 May 12;174982. PMID: 35569550 -
Eur J Pharmacol
MiR-375 inhibits the stemness of breast cancer cells by blocking the JAK2/STAT3 signaling. [Abstract]2020 Oct 5;884:173359. PMID: 32738343 -
Microbiologyopen
Fungal Colonization by Malassezia globosa Promotes Breast Cancer Progression and M2 Macrophage Polarization Through the MBL-C3a-C3aR Signaling Pathway. [Abstract]2025 Dec;14(6):e70193. PMID: 41381403 -
RSC Adv
A novel label-free electrochemical immunosensor for the detection of heat shock protein 70 of lung adenocarcinoma cell line following paclitaxel treatment using l-cysteine-functionalized Au@MnO2/MoO3 nanocomposites. [Abstract]2023 Oct 12;13(43):29847-29861. PMID: 37842680 -
Molecules
A Carabrane-Type Sesquiterpenolide Carabrone from Carpesium cernuum Inhibits SW1990 Pancreatic Cancer Cells by Inducing Ferroptosis. [Abstract]2022 Sep 9;27(18):5841. PMID: 36144577 -
Molecules
Design, Synthesis, and Biological Evaluation of Aromatic Amide-Substituted Benzimidazole-Derived Chalcones. The Effect of Upregulating TP53 Protein Expression. [Abstract]2020 Mar 5;25(5):1162. PMID: 32150865 -
Cell Rep Methods
Tumor immune microenvironment reconstitution in patient-derived organoids enables therapy modeling for NSCLC. [Abstract]2026 Jun 15;6(6):101339. PMID: 42134319 -
Cell Rep Methods
RECOVER identifies synergistic drug combinations in vitro through sequential model optimization. [Abstract]2023 Oct 23;3(10):100599. PMID: 37797618 -
J Biomed Inform
2023 Jun:142:104383. PMID: 37196989 -
Gene Ther
Exosomal PD-L1 confers chemoresistance and promotes tumorigenic properties in esophageal cancer cells via upregulating STAT3/miR-21. [Abstract]2023 Feb;30(1-2):88-100. PMID: 35440807 -
Mol Pharm
Synthesis and Characterization of PDMS-PMOXA-Based Polymersomes Sensitive to MMP-9 for Application in Breast Cancer. [Abstract]2018 Nov 5;15(11):4884-4897. PMID: 30274515 -
BJU Int
Drug-releasing intravesical floating technology for sequential gemcitabine and docetaxel in non-muscle-invasive bladder cancer. [Abstract]2025 Nov 3. PMID: 41178321 -
Cancers (Basel)
USP53 Exerts Tumor-Promoting Effects in Triple-Negative Breast Cancer by Deubiquitinating CRKL. [Abstract]2023 Oct 18;15(20):5033. PMID: 37894400 -
Cancers
Identification of Cardiac Glycosides as Novel Inhibitors of eIF4A1-Mediated Translation in Triple-Negative Breast Cancer Cells. [Abstract]2020 Aug 4;12(8):2169. PMID: 32759815 -
Cancer Sci
MASTL Promotes Hepatocellular Carcinoma Progression and Paclitaxel Resistance Through Mitotic Catastrophe. [Abstract]2025 Dec 5. PMID: 41347427 -
ACS Omega
Piceatannol and Pumpkin Seed Oil Synergistically Promote Apoptosis of PC3 Prostate Cancer Cells via Intrinsic Mitochondrial Pathway. [Abstract]2025 Nov 3;10(44):52202-52214. PMID: 41244467 -
ACS Omega
Association Study of OATP1B3 Polymorphisms on Hepatic Uptake and Drug-Drug Interaction In Vitro. [Abstract]2025 Oct 29;10(44):52562-52575. PMID: 41244417 -
Biol Proced Online
Establishment of a mouse lung cancer organoid model and its applications for therapeutic screening. [Abstract]2025 Jun 16;27(1):21. PMID: 40524168 -
Mol Neurobiol
Functional Investigation of TUBB4A Variants Associated with Different Clinical Phenotypes. [Abstract]2022 Aug;59(8):5056-5069. PMID: 35668344 -
Front Cell Dev Biol
HIF1α Regulates IL17 Signaling Pathway Influencing Sensitivity of Taxane-Based Chemotherapy for Breast Cancer. [Abstract]2021 Sep 14:9:729965. PMID: 34595177 -
Biochim Biophys Acta Mol Basis Dis
Anticancer and chemo-sensitizing effects of annonacin via p53-mediated DNA damage in ovarian cancer. [Abstract]2025 Jul 4;1871(7):167971. PMID: 40618909 -
FASEB J
FGF13 enhances the function of TRPV1 by stabilizing microtubules and regulates acute and chronic itch. [Abstract]2024 May 31;38(10):e23661. PMID: 38733310 -
J Cell Mol Med
Integrated analysis identifies RAC3 as an immune-related prognostic biomarker associated with chemotherapy sensitivity in endometrial cancer. [Abstract]2023 Aug;27(16):2385-2397. PMID: 37386813 -
Exp Neurol
2023 Mar:361:114315. PMID: 36586551 -
J Cell Mol Med
Toll-like receptor 4 regulates spontaneous intestinal tumorigenesis by up-regulating IL-6 and GM-CSF. [Abstract]2020 Jan;24(1):385-397. PMID: 31650683 -
FASEB J
2019 Apr;33(4):5520-5534. PMID: 30668917 -
iScience
Utidelone suppresses PDAC growth and enhances gemcitabine therapy by inducing immunogenic cell death. [Abstract]2025 Apr 23;28(6):112509. PMID: 40530421 -
iScience
Amitriptyline revitalizes ICB response via dually inhibiting Kyn/Indole and 5-HT pathways of tryptophan metabolism in ovarian cancer. [Abstract]2024 Nov 28;27(12):111488. PMID: 39759009 -
iScience
2024 Jul 1;27(8):110434. PMID: 39108714 -
iScience
PBRM1 presents a potential ctDNA marker to monitor response to neoadjuvant chemotherapy in cervical cancer. [Abstract]2024 Feb 9;27(3):109160. PMID: 38414861 -
Transl Oncol
CircSLC39A8 attenuates paclitaxel resistance in ovarian cancer by regulating the miR‑185‑5p/BMF axis. [Abstract]2023 Oct:36:101746. PMID: 37499410 -
Transl Oncol
2022 Dec:26:101540. PMID: 36115073 -
iScience
Multiomic characterization and drug testing establish circulating tumor cells as an ex vivo tool for personalized medicine. [Abstract]2022 Sep 6;25(10):105081. PMID: 36204272 -
-
Sci Rep
Deploying the high-throughput virtual screening (HTVS) approach for the identification of new lactate dehydrogenase (LDH) inhibitors with anticancer assets. [Abstract]2026 Jan 21;16(1):5921. PMID: 41565942 -
Sci Rep
The hydroxamate based HDAC inhibitor WMJ-J-09 induces colorectal cancer cell death by targeting tubulin and downregulating survivin. [Abstract]2025 Jun 4;15(1):19590. PMID: 40467895 -
Sci Rep
Biological and genetic characterization of a newly established human primary multidrug-resistant distal cholangiocarcinoma cell line, CBC3T-6. [Abstract]2024 Nov 29;14(1):29661. PMID: 39613883 -
Oncol Rep
Ursolic acid inhibits the proliferation of triple‑negative breast cancer stem‑like cells through NRF2‑mediated ferroptosis. [Abstract]2024 Jul;52(1):94. PMID: 38847277 -
J Biol Chem
Cell adhesion molecule CD44v10 promotes stem-like properties in triple-negative breast cancer cells via glucose transporter GLUT1-mediated glycolysis. [Abstract]2022 Nov;298(11):102588. PMID: 36243113 -
Biomedicines
An Orthotopic Model of Uveal Melanoma in Zebrafish Embryo: A Novel Platform for Drug Evaluation. [Abstract]2021 Dec 10;9(12):1873. PMID: 34944689 -
Aging
Overexpressed ITGA2 contributes to paclitaxel resistance by ovarian cancer cells through the activation of the AKT/FoxO1 pathway. [Abstract]2020 Mar 22;12(6):5336-5351. PMID: 32202508 -
Bioconjug Chem
Design, Synthesis, and Characterization of a Paclitaxel Formulation Activated by Extracellular MMP9. [Abstract]2020 Mar 18;31(3):781-793. PMID: 31894970 -
Sci Rep
Drug-induced PD-L1 expression and cell stress response in breast cancer cells can be balanced by drug combination. [Abstract]2019 Oct 22;9(1):15099. PMID: 31641154 -
Sci Rep
2019 Sep 24;9(1):13786. PMID: 31551480 -
Sci Rep
Matrix Metalloproteinase Expressions Play Important role in Prediction of Ovarian Cancer Outcome. [Abstract]2019 Aug 12;9(1):11677. PMID: 31406154 -
Sci Rep
Unveiling novel targets of paclitaxel resistance by single molecule long-read RNA sequencing in breast cancer. [Abstract]2019 Apr 15;9(1):6032. PMID: 30988345 -
J Pharmacol Exp Ther
Morusin reverses paclitaxel resistance by inhibiting the stem cell-like properties of non-small cell lung cancer in a β-catenin-dependent manner. [Abstract]2025 Sep 3;392(10):103692. PMID: 40997566 -
J Pharm Sci
α1-Acid Glycoprotein Has the Potential to Serve as a Biomimetic Drug Delivery Carrier for Anticancer Agents. [Abstract]2019 Nov;108(11):3592-3598. PMID: 31288036 -
PLoS Genet
Barrier-to-autointegration factor protects against the cGAS-STING response to chromatin bridges. [Abstract]2026 Jun 3;22(6):e1012191. PMID: 42234713 -
ACS Pharmacol Transl Sci
Antineuroblastoma Activity Evaluation and Mechanism of Novel PD-L1 Small Molecule Inhibitors through Immune and Non-Immune Pathways. [Abstract]2025 Jul 7;8(8):2612-2629. PMID: 40810160 -
Cell Signal
Inhibition of XIST restrains paclitaxel resistance in breast cancer cells by targeting hsa-let-7d-5p/ATG16L1 through regulation of autophagy. [Abstract]2024 Dec 3:111534. PMID: 39638138 -
Cell Signal
An integrative pan-cancer analysis of WWC family genes and functional validation in lung cancer. [Abstract]2024 Mar:115:111034. PMID: 38190957 -
Brain Res Bull
Lysine-specific Demethylase 1 in Primary Sensory Neurons Participates in Chronic Compression of Dorsal Root Ganglion-induced Neuropathic Pain. [Abstract]2022 Dec:191:30-39. PMID: 36240908 -
Biochim Biophys Acta
2018 May;1862(5):1134-1147. PMID: 29410075
Paclitaxel purchased from MedChemExpress. Usage Cited in: Biochim Biophys Acta. 2018 May;1862(5):1134-1147. [Abstract]
The effects of CS1 on polymerized microtubules are also investigated using a cellular tubulin polymer assay. Nocodazole (1 μM) and Paclitaxel (1.5 μM) are used as depolymerization and polymerization controls, respectively.
-
Heliyon
HMGA2 promotes resistance against paclitaxel by targeting the p53 signaling pathway in colorectal cancer cells. [Abstract]2024 May 20;10(11):e31431. PMID: 38845972 -
Exp Cell Res
2026 Aug 1;461(1):115103. PMID: 42276196 -
Transl Lung Cancer Res
Development of a 3D-3 co-culture microbead consisting of cancer-associated fibroblasts and human umbilical vein endothelial cells for the anti-tumor drug assessment of lung cancer. [Abstract]2025 Jun 30;14(6):2159-2179. PMID: 40673102 -
Transl Lung Cancer Res
Construction of a lung cancer 3D culture model based on alginate/gelatin micro-beads for drug evaluation. [Abstract]2024 Oct 31;13(10):2698-2712. PMID: 39507032 -
Exp Cell Res
Angelicin inhibits cell growth and promotes apoptosis in oral squamous cell carcinoma by negatively regulating DUSP6/cMYC signaling pathway. [Abstract]2023 Nov 15;432(2):113793. PMID: 37741490 -
Exp Cell Res
Network-based analysis with primary cells reveals drug response landscape of acute myeloid leukemia. [Abstract]2020 Aug 1;393(1):112054. PMID: 32376287 -
Food Chem Toxicol
Scandenolone from Cudrania tricuspidata fruit extract suppresses the viability of breast cancer cells (MCF-7) in vitro and in vivo. [Abstract]2019 Apr:126:56-66. PMID: 30753858 -
Phytochemistry
Phytochemical study of Fissistigma fulgens (Hook.f. & Thomson) Merr. leaves: Previously undescribed dihydrochalcone derivatives and their biological activities. [Abstract]2025 Dec 2:243:114735. PMID: 41344390 -
Eur J Med Res
Long non-coding RNA NORAD serves as a promoter of oncogenesis and inhibits ferroptosis via miR-144-3p-mTOR-ferritinophagy axis in cancer. [Abstract]2025 Aug 4;30(1):704. PMID: 40760677 -
BMC Cancer
Preclinical studies of the falnidamol as a highly potent and specific active ABCB1 transporter inhibitor. [Abstract]2025 Jan 7;25(1):24. PMID: 39773145 -
Toxicol Appl Pharmacol
Nicotinamide riboside activates SIRT3 to prevent paclitaxel-induced peripheral neuropathy. [Abstract]2024 Aug 9:117066. PMID: 39128506
Paclitaxel purchased from MedChemExpress. Usage Cited in: Toxicol Appl Pharmacol. 2024 Aug 9:117066. [Abstract]
WB images of SIRT3, AcK68-MnSOD and AcK122-MnSOD expressions in DRG tissues. Quantification of SIRT3, AcK68-MnSOD and AcK122-MnSOD expressions normalized with β-actin expressions and the Saline+Saline treated samples was set to 1 (NR (Nicotinamide riboside chloride); PTX (4 mg/kg, i. p.) Group, PTX (4 mg/kg, i.p.) + NR (400 mg/kg, i.g.) Group, PTX (4 mg/kg, I.P.) + NR (400 mg/kg, i.g.) +3-TYP (50 mg/kg, i.p.) group, NR (400 mg/kg, i.p.) group, 3-TYP (50 mg/kg, i.p.) group in SIRT3 WT mice)
Paclitaxel purchased from MedChemExpress. Usage Cited in: Toxicol Appl Pharmacol. 2024 Aug 9:117066. [Abstract]
The representative images depicting the expression of AcK68-MnSOD in each group were utilized for immunohistochemical detection (NR (Nicotinamide riboside chloride); PTX (4 mg/kg, i. p.) Group, PTX (4 mg/kg, i.p.) + NR (400 mg/kg, i.g.) Group, PTX (4 mg/kg, I.P.) + NR (400 mg/kg, i.g.) +3-TYP (50 mg/kg, i.p.) group, NR(400 mg/kg, i.p.) group, 3-TYP (50 mg/kg, i.p.) group in SIRT3 WT mice)
-
Toxicol Appl Pharmacol
2024 Feb:483:116807. PMID: 38199493 -
Cell Cycle
Ultrasound-targeted microbubble destruction-mediated miR-144-5p overexpression enhances the anti-tumor effect of paclitaxel on thyroid carcinoma by targeting STON2. [Abstract]2022 May;21(10):1058-1076. PMID: 35184686 -
Int J Med Sci
Integrative analysis identifies PIGK as an oncogenic glycosylphosphatidylinositol transamidase subunit with prognostic, immunological, and therapeutic relevance in head and neck cancer. [Abstract]2026 Jan 1;23(1):161-176. PMID: 41399371 -
Mol Carcinog
Curcuminoid PBPD induces cuproptosis and endoplasmic reticulum stress in cervical cancer via the Notch1/RBP-J/NRF2/FDX1 pathway. [Abstract]2024 Aug;63(8):1449-1466. PMID: 38801356 -
Mol Carcinog
2020 May;59(5):512-519. PMID: 32124501 -
Environ Toxicol
The miRNA-149-5p/MyD88 axis is responsible for ursolic acid-mediated attenuation of the stemness and chemoresistance of non-small cell lung cancer cells. [Abstract]2020 May;35(5):561-569. PMID: 31855318 -
Hum Cell
Establishment and comparison of three sublines from a human uterine carcinosarcoma cell line, ESCA. [Abstract]2025 Jun 2;38(4):115. PMID: 40455147 -
Hum Cell
TIPE2 sensitizes breast cancer cells to paclitaxel by suppressing drug-induced autophagy and cancer stem cell properties. [Abstract]2023 Jul;36(4):1485-1500. PMID: 36964413 -
Hum Cell
Long non-coding RNA TPT1-AS1 sensitizes breast cancer cell to paclitaxel and inhibits cell proliferation by miR-3156-5p/caspase 2 axis. [Abstract]2021 Jul;34(4):1244-1254. PMID: 33999360 -
Cancer Med
Zinc cooperates with p53 to inhibit the activity of mitochondrial aconitase through reactive oxygen species accumulation. [Abstract]2019 May;8(5):2462-2473. PMID: 30972978 -
Curr Issues Mol Biol
Transcriptomic Profiling of Carboplatin- and Paclitaxel-Resistant Lung Adenocarcinoma Cells Reveals CSF3 as a Potential Biomarker for the Carboplatin Plus Paclitaxel Doublet Regimens. [Abstract]2024 Dec 11;46(12):13951-13969. PMID: 39727962 -
Mol Immunol
LINC00337 induces tumor development and chemoresistance to paclitaxel of breast cancer by recruiting M2 tumor-associated macrophages. [Abstract]2021 Oct:138:1-9. PMID: 34314939 -
Micromachines
2021 Jun 10;12(6):681. PMID: 34200752 -
3 Biotech
POU4F1 enhances lung cancer gemcitabine resistance by regulating METTL3-dependent TWF1 mRNA N6 adenosine methylation. [Abstract]2025 Jan;15(1):7. PMID: 39676891 -
-
Am J Cancer Res
The resistance of esophageal cancer cells to paclitaxel can be reduced by the knockdown of long noncoding RNA DDX11-AS1 through TAF1/TOP2A inhibition. [Abstract]2019 Oct 1;9(10):2233-2248. PMID: 31720085 -
Am J Cancer Res
2017 Apr 1;7(4):903-912. PMID: 28469962
Paclitaxel purchased from MedChemExpress. Usage Cited in: Am J Cancer Res. 2017 Apr 1;7(4):903-912. [Abstract]
Synergistic inhibition of colony formation of ATC cells by E7080 and Paclitaxel. Representative images of colony formation in C643 cells treated with vehicle control (DMSO) or E7080 and Paclitaxel at the indicated concentrations, individually or in combination, are shown in left panel. Quantitative analysis of colony numbers is shown in right panel.
-
J Biochem Mol Toxicol
MIAT shuttled by tumor-secreted exosomes promotes paclitaxel resistance in esophageal cancer cells by activating the TAF1/SREBF1 axis. [Abstract]2023 Aug;37(8):e23380. PMID: 37132394 -
Onco Targets Ther
2020 May 4;13:3777-3788. PMID: 32440146 -
Neuroscience
Paclitaxel Induces Sex-biased Behavioral Deficits and Changes in Gene Expression in Mouse Prefrontal Cortex. [Abstract]2020 Feb 1;426:168-178. PMID: 31846751 -
Onco Targets Ther
Expression Of BMP7 In Ovarian Cancer And Biological Effect Of BMP7 Knockdown On Ovarian Cancer Cells. [Abstract]2019 Sep 26;12:7897-7909. PMID: 31576147 -
-
BMC Pregnancy Childbirth
2024 Oct 28;24(1):705. PMID: 39468487 -
Invest New Drugs
Ad-VT enhances the sensitivity of chemotherapy-resistant lung adenocarcinoma cells to gemcitabine and paclitaxel in vitro and in vivo. [Abstract]2022 Apr;40(2):274-289. PMID: 34981275 -
Invest New Drugs
Autophagy promotes oncolysis of an adenovirus expressing apoptin in human bladder cancer models. [Abstract]2021 Aug;39(4):949-960. PMID: 33534026 -
SLAS Discov
A Multiplexed Screening Assay to Evaluate Chemotherapy-Induced Myelosuppression Using Healthy Peripheral Blood and Bone Marrow. [Abstract]2018 Aug;23(7):687-696. PMID: 29865911 -
Cancer Manag Res
miR-613 Suppresses Chemoresistance and Stemness in Triple-Negative Breast Cancer by Targeting FAM83A. [Abstract]2020 Dec 8:12:12623-12633. PMID: 33324107 -
J Nat Med
Tenacissoside G reverses paclitaxel resistance by inhibiting Src/PTN/P-gp signaling axis activation in ovarian cancer cells. [Abstract]2025 Apr 8. PMID: 40195205 -
Mol Biotechnol
Verteporfin Exerts Anticancer Effects and Reverses Resistance to Paclitaxel via Inducing Ferroptosis in Esophageal Squamous Cell Cancer Cells. [Abstract]2024 Sep;66(9):2558-2568. PMID: 37751128 -
Clin Transl Oncol
Establishment of an acquired lorlatinib-resistant cell line of non-small cell lung cancer and its mediated resistance mechanism. [Abstract]2022 Nov;24(11):2231-2240. PMID: 35852680 -
Tissue Cell
Vitamin D enhances the sensitivity of breast cancer cells to the combination therapy of photodynamic therapy and paclitaxel. [Abstract]2022 Aug:77:101815. PMID: 35623307 -
Clin Exp Pharmacol Physiol
Cathelicidin deficiency exacerbates cardiac dysfunction in lipopolysaccharide-induced endotoxaemic mice. [Abstract]2020 Apr;47(4):677-686. PMID: 31868940 -
Eur J Neurosci
Ketogenic diet prevents paclitaxel-induced neuropathic nociception through activation of PPARγ signalling pathway and inhibition of neuroinflammation in rat dorsal root ganglion. [Abstract]2021 Aug;54(4):5341-5356. PMID: 34318540 -
Behav Brain Res
Astroglial morphological changes in periaqueductal grey in different pain and itch mice models. [Abstract]2024 May 28:115075. PMID: 38815698 -
Thorac Cancer
Potential monoamine oxidase A inhibitor suppressing paclitaxel-resistant non-small cell lung cancer metastasis and growth. [Abstract]2020 Oct;11(10):2858-2866. PMID: 32875729 -
FEBS Open Bio
2020 Aug;10(8):1655-1667. PMID: 32594651 -
Cancer Chemother Pharmacol
Downregulation of SRSF3 by antisense oligonucleotides sensitizes oral squamous cell carcinoma and breast cancer cells to paclitaxel treatment. [Abstract]2019 Nov;84(5):1133-1143. PMID: 31515668 -
Anticancer Drugs
APG-1252 enhances the anticancer role of paclitaxel in non-small-cell lung cancer cells by suppressing the extracellular regulated protein kinases/myeloid cell leukemia 1 pathway. [Abstract]2026 Jan 14. PMID: 41608859 -
Oncol Lett
SBEM confers paclitaxel resistance in breast cancer via DUSP16-mediated MAPK/AMPK pathway activation. [Abstract]2025 Oct 21;30(6):607. PMID: 41181635 -
J Gene Med
Oncogenic tRNA-derived fragment tRF-Leu-CAG promotes tumorigenesis of lung cancer via targeting TCEA3 and increasing autophagy. [Abstract]2024 Sep;26(9):e3737. PMID: 39198937 -
Biochem Biophys Res Commun
Pemigatinib, a selective FGFR inhibitor overcomes ABCB1-mediated multidrug resistance in cancer cells. [Abstract]2024 Jan 8:691:149314. PMID: 38039831 -
Biochem Biophys Res Commun
Cloning, expression of porcine GSDME and identification of its site cleaved by caspase-3. [Abstract]2023 Aug 20:669:61-67. PMID: 37267861
Paclitaxel purchased from MedChemExpress. Usage Cited in: Biochem Biophys Res Commun. 2023 Aug 20:669:61-67. [Abstract]
Paclitaxel (25, 50 μM; 24 h) significantly increases the expression of caspase-3 in PK-15 cells.
-
Oncol Lett
LPCAT1 is transcriptionally regulated by FOXA1 to promote breast cancer progression and paclitaxel resistance. [Abstract]2023 Feb 15;25(4):134. PMID: 36909375
Paclitaxel purchased from MedChemExpress. Usage Cited in: Oncol Lett. 2023 Feb 15;25(4):134. [Abstract]
Paclitaxel (PTX; 0‑100 nM; 72 h) inhibits the viability of MDA‑MB‑231cells.
-
Bioorg Med Chem Lett
New synthetic phenylquinazoline derivatives induce apoptosis by targeting the pro-survival members of the BCL-2 family. [Abstract]2022 Jul 1;67:128731. PMID: 35421577 -
Biochem Biophys Res Commun
2020 Jan 15;521(3):596-602. PMID: 31679697 -
Biochem Biophys Res Commun
PMN inhibits colorectal cancer cells through inducing mitotic arrest and p53-dependent apoptosis via the inhibition of tubulin polymerization. [Abstract]2018 May 23;499(4):927-933. PMID: 29626471 -
Mol Cell Oncol
SNX1 inhibits human ovarian cancer progression via regulation of the cell cycle, apoptosis and migration. [Abstract]2025 Dec 31;13(1):2604899. PMID: 41487280 -
Biomed Chromatogr
P-glycoprotein-mediated herb-drug interaction evaluation between Tenacissoside G and paclitaxel. [Abstract]2024 Aug 17:e5984. PMID: 39152775 -
Anticancer Res
Establishment of Patient-derived Preclinical Models for Invasive Papillary Cholangiocarcinoma. [Abstract]2022 Jan;42(1):599-608. PMID: 34969769 -
Biochem Genet
2025 Nov 22. PMID: 41273664 -
Am J Transl Res
RACGAP1 knockdown synergizes and enhances the effects of chemotherapeutics on ovarian cancer. [Abstract]2024 May 15;16(5):2132-2146. PMID: 38883382 -
Curr Med Sci
Salidroside Enhances the Sensitivity of Lung Cancer Cells to Paclitaxel by Regulating the Wnt/β-catenin Signaling Pathway. [Abstract]2025 Feb;45(1):104-113. PMID: 40014194 -
Braz J Med Biol Res
FRAX486, a PAK inhibitor, overcomes ABCB1-mediated multidrug resistance in breast cancer cells. [Abstract]2024 Jul 1:57:e13357. PMID: 38958364 -
J Asian Nat Prod Res
Design, synthesis, and biological evaluation of bergapten derivatives as potent anti-pancreatic cancer agents. [Abstract]2025 Jun 18:1-17. PMID: 40531172 -
STAR Protoc
Protocol for generating a pancreatic cancer organoid associated with heterogeneous tumor microenvironment. [Abstract]2025 Jan 7;6(1):103539. PMID: 39772386 -
J Asthma
Paclitaxel Inhibits Proliferation by Negatively Regulating Cdk1-Cell Cycle Axis in Rat Airway Smooth Muscle Cells. [Abstract]2024 Oct;61(10):1328-1336. PMID: 38696283 -
-
-
-
-
-
-
-
-
-
bioRxiv
Radiation synergizes with BET inhibition to stimulate durable, systemic anti-tumor immunity in murine cancer models. [Abstract]2026 Feb 18:2026.02.16.706212. PMID: 41757027 -
-
-
-
-
-
-
-
-
-
bioRxiv
2025 Aug 27:2025.08.22.671824. PMID: 40909578 -
bioRxiv
2025 Jul 12:2025.07.08.663754. PMID: 40672312 -
-
-
-
-
-
-
-
-
bioRxiv
RBN-2397, a PARP7 Inhibitor, Synergizes with Paclitaxel to Inhibit Proliferation and Migration of Ovarian Cancer Cells. [Abstract]2024 Aug 21:2024.08.20.608802. PMID: 39229139 -
-
-
-
-
-
-
-
-
-
-
Paclitaxel purchased from MedChemExpress. Usage Cited in: Arch Cancer Res. 2023 Jan 30.
Paclitaxel (CPT; 10-6 -12-10 M; 72 h) demonstrates a strong antitumor activity and an inhibitory of proliferation (IC50 = 6.28 nM) in U937 cells.
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Solvent & Solubility
DMSO : 100 mg/mL (117.11 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
H2O : < 0.1 mg/mL (insoluble)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: Corn Oil
Solubility: 10 mg/mL (11.71 mM); Suspended solution; Need ultrasonic
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (286 KB)
-
SDS (781 KB)
- English - EN (781 KB)
- Français - FR (781 KB)
- Deutsch - DE (781 KB)
- Norwegian - NO (781 KB)
- Español - ES (781 KB)
- Swedish - SV (781 KB)
- Italian - IT (781 KB)
- Portuguese - PT (781 KB)
-
Handling Instructions (2659 KB)
References
[1]. Choi YH, et al. Paclitaxel-induced growth arrest and apoptosis is associated with the upregulation of the Cdk inhibitor, p21WAF1/CIP1, in human breast cancer cells. Oncol Rep. 2012 Dec;28(6):2163-9. [Content Brief]
[2]. Dziadyk JM, et al. Paclitaxel-induced apoptosis may occur without a prior G2/M-phase arrest. Anticancer Res. 2004 Jan-Feb;24(1):27-36. [Content Brief]
[3]. Li Q, et al. Low doses of paclitaxel enhance liver metastasis of breast cancer cells in the mouse model. FEBS J. 2016 Aug;283(15):2836-52. [Content Brief]
[4]. Pan Z, et al. Paclitaxel attenuates Bcl-2 resistance to apoptosis in breast cancer cells through an endoplasmic reticulum-mediated calciumrelease in a dosage dependent manner. Biochem Biophys Res Commun. 2013 Feb 13. pii: S0006-291X(13)00259-3. [Content Brief]
[5]. Cadamuro M, et al. Low dose paclitaxel reduces S100A4 nuclear import to inhibit invasion and hematogenous metastasis of cholangiocarcinoma. Cancer Res. 2016 Jun 21. [Content Brief]
[6]. Li Q, et al. Low doses of paclitaxel enhance liver metastasis of breast cancer cells in the mouse model. FEBS J. 2016 Jun 16. [Content Brief]
[7]. Yilmaz E, et al. Sensory neuron subpopulation-specific dysregulation of intracellular calcium in a rat model of chemotherapy-induced peripheral neuropathy. Neuroscience. 2015 Aug 6;300:210-8. [Content Brief]
[8]. Jing C, et al. E7080 enhances the antitumor effects of paclitaxel in anaplastic thyroid cancer. Am J Cancer Res. 2017 Apr 1;7(4):903-912. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.1711 mL | 5.8554 mL | 11.7108 mL | 29.2771 mL |
| 5 mM | 0.2342 mL | 1.1711 mL | 2.3422 mL | 5.8554 mL | |
| 10 mM | 0.1171 mL | 0.5855 mL | 1.1711 mL | 2.9277 mL | |
| 15 mM | 0.0781 mL | 0.3904 mL | 0.7807 mL | 1.9518 mL | |
| 20 mM | 0.0586 mL | 0.2928 mL | 0.5855 mL | 1.4639 mL | |
| 25 mM | 0.0468 mL | 0.2342 mL | 0.4684 mL | 1.1711 mL | |
| 30 mM | 0.0390 mL | 0.1952 mL | 0.3904 mL | 0.9759 mL | |
| 40 mM | 0.0293 mL | 0.1464 mL | 0.2928 mL | 0.7319 mL | |
| 50 mM | 0.0234 mL | 0.1171 mL | 0.2342 mL | 0.5855 mL | |
| 60 mM | 0.0195 mL | 0.0976 mL | 0.1952 mL | 0.4880 mL | |
| 80 mM | 0.0146 mL | 0.0732 mL | 0.1464 mL | 0.3660 mL | |
| 100 mM | 0.0117 mL | 0.0586 mL | 0.1171 mL | 0.2928 mL |